cluster,concept,cuis
1607,glyburide ( n = $nmbr$ ),C0017628
1607,glyburide,C0017628
1607,glipizide ( n = $nmbr$ ),C0017642
1607,glipizide,C0017642
1606,good / moderate response,C0205170;C4085643
1606,good,C0205170
1605,glycosylated hemoglobin  %,C0017853
1605,glycohemoglobin  %,C0202054;C0696092
1605,glycated hemoglobin — % -,C0017853
1605,glycated hemoglobin — %,C0017853
1605,glycated hemoglobin | |,C0017853
1605,glycated hemoglobin level,C0202054
1605,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
1605,glycated hemoglobin - % ’,C0017853
1605,glycated hemoglobin ( % ),C0017853
1605,glycated hemoglobin  standardized level — %,C0017853
1605,glycated hemoglobin  nonstandardized level — %,C0202054
1605,glycated hemoglobin  n ( % ),C0062408;C3666909
1605,glycated hemoglobin  median ( iqr ),C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
1605,glycated hemoglobin  %,C0017853
1605,glycated hemoglobin,C0017853
1605,glycated haemoglobin ( % ),C0017853
1605,glycated haemoglobin  %,C0017853
1605,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
1604,glucose test,C0337438;C0595310
1604,glucose metabolism,C0596620
1604,glucose in urine    ≥ $nmbr$ +,C0004076
1604,glucosamine ( n = $nmbr$ ),C0017718
1604,glucosamine,C0017718
1603,uacr  mgg $nmbr$ ( gm ),C0017480;C3854019
1603,triglycerides  mmolt $nmbr$ ( gm * ),C0017480;C0041004;C3854019
1603,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
1603,gm,C0017480;C3854019
1603,germany,C0017480
1603,de ( n = $nmbr$ ),C0011198;C0017480;C3541240
1603,de $nmbr$ n = $nmbr$,C0011198;C0017480;C3541240
1603,de,C0011198;C0017480;C3541240
1603,( gm ),C0017480;C3854019
1602,who / idf ifg,C1334085;C1708411
1602,igt / ifg,C1334085;C1708411
1602,ifg and igt,C1334085;C1708411
1602,ifg / igt,C1334085;C1708411
1602,ifg,C1334085;C1708411
1602,ada ifg,C1060325;C1334085;C1708411;C3811629
1601,ipf - related,C0034069;C1800706
1601,ipf,C0034069;C1800706
1600,immunologic,C0152036;C0205470
1600,imm only,C0205171;C0205470;C1720467
1600,imm,C0205470
1599,natalizumab ( n = $nmbr$ ) f,C0016327;C1172734
1599,la grade b  n ( % ) f,C0016327;C1881342
1599,f emale,C0016327
1599,f - plasma glucose  mmol / l,C0016327;C0202042;C0455280;C1532563
1599,f * >,C0016327
1599,f $nmbr$ vs placebo,C0016327
1599,f,C0016327
1599,ancestry ( % ) f,C0016327
1599,? f ? n,C0016327
1599,$nmbr$ f $nmbr$ q % ),C0016327
1599,$nmbr$ f $nmbr$ l % $nmbr$,C0016327
1599,$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
1599,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f,C0016327
1598,lvh by echocardiography,C0013516;C0149721
1598,lvh by echocardiogram,C0013516;C0149721;C2243117
1598,lvh by echo or ecg,C0058928;C0149721;C1655045
1598,lvh - n = $nmbr$,C0149721
1598,lvh + n = $nmbr$,C0149721
1598,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
1598,lvh,C0149721
1598,lv hypertrophy  n ( % ),C0149721
1598,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
1598,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
1598,left ventricular hypertrophy * *,C0149721;C3484363
1598,left ventricular hypertrophy ( % ),C0149721;C3484363
1598,left ventricular hypertrophy  n ( % ),C0149721;C3484363
1598,left ventricular hypertrophy,C0149721;C3484363
1597,l vs . c,C0439394;C1706495;C3642217
1597,l compared wit,C0439394;C1706495;C3642217
1597,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
1597,l / ll,C0439394;C1706495;C3642217
1597,l / c,C0439394;C1706495;C3642217
1597,l . i ( $nmbr$ . $nmbr$ ),C0021966;C0221138;C0439394;C1706495;C3642217
1597,l ( % ),C0439394;C1706495;C3642217
1597,l $nmbr$ - $nmbr$ vs placebo,C0439394;C1706495;C3642217
1597,l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$,C0439394;C1706495;C3642217
1597,l $nmbr$,C0439394;C1706495;C3642217
1597,l,C0439394;C1706495;C3642217
1597,( l ) t,C0439394;C1706495;C3642217
1597,$nmbr$ . $nmbr$ ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
1596,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
1596,mdi,C0993596;C1839839;C4049613
1596,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
1596,gff mdi,C0993596;C1839839;C4049613
1596,ff mdi,C0993596;C1839839;C4049613;C4554348
1595,id ( n = $nmbr$ ),C0009450;C0600091;C1441613
1595,id,C0009450;C0600091;C1441613
1595,( id,C0009450;C0600091;C1441613
1594,omeprazole,C0028978
1594,mestizos,C0682082
1594,meddra smq,C1140263
1593,mexico,C0025885
1593,mexican,C0240339
1592,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
1592,copd exacerbation : no,C0740304
1592,asthma exacerbations,C0349790
1592,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
1591,complex lesions ^,C0221198;C0439855;C1704241
1591,anatomic complexity characteristics,C0439855;C0502371;C1704241
1590,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1590,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1590,depression ^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1590,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
1590,depressed only,C0344315;C0549249
1590,depressed and low perceived social support,C0344315;C0549249
1589,documented symptomatic chdb,C0231220;C1301725;C1609436
1589,documented mi,C1301725;C1609436;C3810814
1589,documented hypoglycaemiac,C1301725;C1609436
1589,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
1588,qd,C0332173
1588,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1588,daily exercise ( % ),C0332173
1588,daily,C0332173
1588,d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .,C0073187;C0332173;C4484261
1588,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
1588,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
1588,d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value ),C0073187;C0332173;C4484261
1588,d $nmbr$ vs warfarin,C0073187;C0332173;C4484261
1588,d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
1588,d $nmbr$ % ( n / n ),C0073187;C0332173;C4484261
1588,d  mitral stenosis vhd ( n = $nmbr$ ),C0026269;C0073187;C0264766;C0332173;C4484261
1588,d,C0073187;C0332173;C4484261
1587,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1587,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
1587,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1587,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1587,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1587,minimum  maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
1587,minimum,C1524031;C1552614;C2826545
1587,median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
1587,( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
1586,maximum cimt a med an,C0806909;C1552615;C2826546
1586,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
1586,maximum,C0806909;C1552615;C2826546
1586,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
1586,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
1586,average maximum common and bifurcation cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546
1586,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
1585,infliximab monotherapy,C0666743
1585,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
1585,infliximab - naive ( n = $nmbr$ ),C0666743
1585,infliximab - experienced ( n = $nmbr$ ),C0666743
1585,infliximab ( n = $nmbr$ ),C0666743
1585,infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % ),C0205195;C0439272;C0666743
1585,infliximab $nmbr$ mg / kg,C0439272;C0666743
1585,infliximab,C0666743
1585,inflix  yes,C0666743;C1549445;C1705108;C1710701
1585,inflix  no,C0666743
1585,combined infliximab,C0205195;C0666743
1584,tocilizumab ( n = $nmbr$ ),C1609165
1584,tocilizumab,C1609165
1584,mra use,C0243032;C1609165;C3891069
1584,mra regimen ( n - $nmbr$ ),C0040808;C0243032;C1609165;C2945654;C3891069
1584,mra  ( % ),C0243032;C1609165;C3891069
1584,mra,C0243032;C1609165;C3891069
1583,other chd,C0280604;C3542407
1583,no family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
1583,no chd simva ( „ = $nmbr$ ),C0280604;C3542407
1583,no chd simva ( n = $nmbr$ ],C0280604;C3542407
1583,no chd simva,C0280604;C3542407
1583,no chd eze / simva ( n = $nmbr$ ),C0280604;C3542407
1583,no chd eze / simva $nmbr$ = $nmbr$ },C0280604;C3542407
1583,no chd eze / simva,C0280604;C3542407
1583,no chd,C0280604;C3542407
1583,known chd,C0205309;C0280604;C3542407
1583,family history ot chd  n ( % ),C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
1583,family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
1583,chd status §,C0280604;C0449438;C3542407
1583,chd status,C0280604;C0449438;C3542407
1583,chd simva ( „ = $nmbr$ ),C0280604;C3542407
1583,chd simva $nmbr$ = $nmbr$ ],C0280604;C3542407
1583,chd simva,C0280604;C3542407
1583,chd risk - no . ( % ),C0280604;C3542407
1583,chd eze / simva ( „ = $nmbr$ ),C0280604;C3542407
1583,chd eze / simva ( n = $nmbr$ ],C0280604;C3542407
1583,chd eze / simva,C0280604;C3542407
1583,chd deaths,C0011065;C0280604;C1306577;C3542407
1583,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
1583,chd + cl all,C0280604;C0596019;C3542407
1583,chd *  n ( % ),C0280604;C3542407
1583,chd  n ( % ),C0280604;C3542407
1583,chd,C0280604;C3542407
1582,total diuretic dose ( iv + oral ) on day $nmbr$  mg,C0012798;C0022326;C2986497;C4265176
1582,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
1582,nyha iv  n ( % ),C0022326;C1275491;C4265176
1582,nyha iv  %,C0022326;C1275491;C4265176
1582,lll / iv,C0022326;C1261077;C4265176
1582,lll - iv,C0022326;C1261077;C4265176
1582,iv nitrates,C0022326;C4265176
1582,iv ( n z $nmbr$ ),C0022326;C4265176
1582,iv ( $nmbr$ ),C0022326;C4265176
1582,iv,C0022326;C4265176
1582,dyspnea at rest ( nyha iv )  ( % ),C0022326;C0743330;C1275491;C4265176
1582,dual iv,C0022326;C0205173;C1554184;C4265176
1582,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
1581,ng ( n = $nmbr$  $nmbr$ ),C0017887;C0028074
1581,ng,C0017887;C0028074
1581,need for $nmbr$ ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
1581,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
1580,tg ’,C0337445
1580,tg §,C0337445
1580,tg > $nmbr$ . $nmbr$,C0337445
1580,tg < = $nmbr$ . $nmbr$,C0337445
1580,tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ ),C0337445;C3715113
1580,tg +,C0337445
1580,tg *,C0337445
1580,tg ( mmol / l ) c,C0337445;C1532563
1580,tg ( mmol / l ),C0337445;C1532563
1580,tg ( mmol / l  median ),C0337445;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1580,tg,C0337445
1579,tiotropium $nmbr$ gg qd,C0017454;C0018370;C0213771;C0332173
1579,olodaterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C2934193
1579,indacaterol $nmbr$ gg qd,C0017454;C0018370;C0332173;C1722260
1579,ind $nmbr$ gg q . d . n / n ( % ),C0017454;C0018370;C4049864
1579,gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
1579,gg,C0017454;C0018370
1579,formoterol $nmbr$ gg bid,C0017454;C0018370;C0060657
1579,formoterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C0060657
1579,ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C0205999;C4554348
1579,ff $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C4554348
1579,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
1578,om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0028971;C1319635;C1705272
1578,om $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0028971;C1319635;C1705272
1578,om $nmbr$ /,C0028971;C1705272
1578,new om,C0028971;C0205314;C1705272
1577,overweight ( bmi £ $nmbr$ to < $nmbr$ ),C0497406;C0578022
1577,overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ ),C0497406;C0578022
1577,overweight,C0497406
1577,bmi $nmbr$ – $nmbr$ overweight,C0497406;C0578022
1577,$nmbr$ - $nmbr$ . $nmbr$ : overweight,C0497406
1577,$nmbr$ - $nmbr$ - $nmbr$  overweight,C0497406
1576,vte at day $nmbr$ +,C0332173;C0439228;C0439505;C0630906
1576,use of rescue albuterol  puffs / day *,C0001927;C0332173;C0439228;C0439505;C1524063;C1533107
1576,subacute ( $nmbr$ - $nmbr$ days ),C0205365;C0439228
1576,slo days,C0439228;C1416602;C3539661
1576,saba puffs per day at baseline,C0332173;C0439228;C0439505;C1533107
1576,patient status after wake - up  % of days patient woke :,C0439228;C0449437;C1170730
1576,no . of days to randomization — median ( iqr ),C0439228
1576,no . of days to homa - ir testing — median ( iqr ),C0439228
1576,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1576,lmwh within $nmbr$ days before randomization — no . / total no . ( % ),C0019139;C0439228;C3536766
1576,hospital stay ( days ),C0439228;C3489408
1576,hospital stay  days,C0439228;C3489408
1576,every day,C0332173;C0439228;C0439505
1576,days without albuterol use  * %,C0001927;C0042153;C0439228;C0457083;C1947944
1576,days with heartburna ( days ),C0439228
1576,day $nmbr$ oral glucocorticoid use — no . { % ),C0017710;C0332173;C0439228;C0439505;C0442027;C4521986
1576,current smoker ( > $nmbr$ cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
1576,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
1576,albuterol use ( sd )  puffs / day,C0001927;C0042153;C0332173;C0439228;C0439505;C0457083;C1533107;C1947944;C2699239
1576,a ngina > $nmbr$ day s previously *,C0332173;C0439228;C0439505
1576,^ $nmbr$ days,C0439228
1576,> = medion ( $nmbr$ days ),C0439228
1576,> = median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1576,> = $nmbr$ days,C0439228
1576,> $nmbr$ days ( % ),C0439228
1576,> $nmbr$ days,C0439228
1576,> $nmbr$ / day,C0332173;C0439228;C0439505
1576,< median { $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1576,< median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
1576,< $nmbr$ days ( n = $nmbr$ ),C0439228
1576,< $nmbr$ days ( % ),C0439228
1576,< $nmbr$ days,C0439228
1576,( iqr ) — days,C0439228
1576,$nmbr$ — $nmbr$ days,C0439228
1576,$nmbr$ days stroke ( ischemic ),C0439228
1576,$nmbr$ days new mi or definite acute st,C0205314;C0439228;C3810814
1576,$nmbr$ days new mi,C0205314;C0439228;C3810814
1576,$nmbr$ days,C0439228
1576,$nmbr$ day l,C0332173;C0439228;C0439505
1576,$nmbr$ / day,C0332173;C0439228;C0439505
1576,$nmbr$ - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
1576,$nmbr$ - day cce,C0332173;C0439228;C0439505
1576,$nmbr$ - $nmbr$ days ( % ),C0439228
1576,$nmbr$ - $nmbr$ days,C0439228
1576,$nmbr$ - $nmbr$ / day,C0332173;C0439228;C0439505
1575,lv systolic dysfunction  n ( % ),C0023128;C0731033;C0749225;C1881413
1575,lv heart structure,C0018787;C0023128;C0731033;C1881413
1575,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
1575,lv diastolic dysfunction  n ( % ),C0023128;C0520863;C0731033;C1881413
1575,latvia,C0023128
1574,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
1574,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
1574,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
1574,location of disease  n ( % ),C0012634;C0450429;C1515974;C4284930;C4284931
1574,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
1574,location  n ( % ),C0450429;C1515974;C4284930;C4284931
1574,location,C0450429;C1515974;C4284930;C4284931
1574,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
1574,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
1574,infarct location — no . / total no . ( % ),C0021308;C0450429;C1515974;C4284930;C4284931
1574,infarct location anterior,C0021308;C0450429;C1515974;C4284930;C4284931
1574,infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ ),C0021308;C0450429;C1515974;C4284930;C4284931
1574,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
1574,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
1574,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
1574,disease location  %,C0012634;C0450429;C1515974;C4284930;C4284931
1574,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
1573,lower dose,C0445550;C1708745
1573,lower - dose,C0445550;C1708745
1573,low dose,C0445550;C1708745
1573,low - dose statin,C0360714;C0445550;C1708745
1573,low - dose edoxaban vs warfarin,C0445550;C1708745;C2975435
1573,low - dose edoxaban ( n = $nmbr$ ),C0445550;C1708745;C2975435
1573,low - dose edoxaban,C0445550;C1708745;C2975435
1573,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
1572,lower risk ( n = $nmbr$ ),C3272281;C3538919
1572,lower risk,C3272281;C3538919
1572,low risk and more symptoms ( group b ),C3272281;C3538919
1572,low risk and fewer symptoms ( group a ),C3272281;C3538919
1572,low risk ( n $nmbr$ $nmbr$ ),C3272281;C3538919
1572,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
1572,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
1572,low risk ( $nmbr$ - $nmbr$ ),C3272281;C3538919
1572,low risk,C3272281;C3538919
1572,$nmbr$ - $nmbr$ ( low risk ),C3272281;C3538919
1571,lm bifurcation treated,C0184906;C1261082;C1551056;C3146289
1571,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
1571,lm $nmbr$ bid ( n = $nmbr$ ),C1261082;C1551056
1571,lm $nmbr$ $nmbr$,C1261082;C1551056
1571,left main coronary artery  n ( % ),C1261082
1571,left main coronary artery,C1261082
1570,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
1570,left sided colitis,C2887821
1570,left side only,C3842976
1570,left side of colon,C0227388
1570,left - sided disease only,C0012634;C3842976
1570,left - sided colitis,C2887821
1569,lvh by minnesota code  no . ( % ),C0009219;C0026183;C0149721;C0805701;C3889831
1569,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
1569,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
1568,lev status,C0023556;C0449438
1568,lev - naive,C0023556
1568,lev - exposed,C0023556
1568,lev ( n   =   $nmbr$ ),C0023556
1567,leisure,C0086542
1567,left shoulder,C0524469
1567,leflunomide,C0063041
1566,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
1566,left side  n ( % ),C0205091
1566,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
1566,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
1566,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
1566,left main,C0205091;C0205225;C0443246;C1542147;C1552822
1566,left circumflex  n ( % ),C0205091;C0443246;C1552822;C1880089
1566,left - sided colitisz,C0205091;C0443246
1566,left,C0205091;C0443246;C1552822
1565,patients with low ( < $nmbr$ mg / dl ) c $nmbr$,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low { < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
1565,low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low to medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1565,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
1565,low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low c $nmbr$ / c $nmbr$ and anti - dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low c $nmbr$ ( < $nmbr$ mg / dl )  %,C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
1565,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low - medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
1565,low - ceiling diuretic,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( > $nmbr$ . $nmbr$ and < $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( < $nmbr$ % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( < $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
1565,low ( < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( $nmbr$ - $nmbr$ )  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low ( $nmbr$ - $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1565,$nmbr$ low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
1564,total score on the sgrq - c  i,C0021966;C0221138;C2964552;C3826872
1564,stratum i,C0021966;C0221138
1564,period i,C0021966;C0221138;C0439531;C1948053
1564,pde - $nmbr$ i monotherapy,C0021966;C0221138
1564,pde - $nmbr$ i,C0021966;C0221138
1564,other ' i ',C0021966;C0221138
1564,infliiimab i,C0021966;C0221138
1564,ii $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138;C1710602;C4082587
1564,i u - uj,C0021966;C0221138;C0439148
1564,i or ii,C0021966;C0221138
1564,i no . of events,C0021966;C0221138
1564,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
1564,i / ii,C0021966;C0221138;C1710602;C4082587
1564,i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
1564,i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
1564,i - ^ w « - i - $nmbr$,C0021966;C0221138
1564,i ( $nmbr$ . i ),C0021966;C0221138
1564,i & ii : fev $nmbr$ > $nmbr$ % predicted,C0021966;C0221138;C1710602;C3714541;C4082587
1564,i % $nmbr$,C0021966;C0221138
1564,i $nmbr$ ± i $nmbr$,C0021966;C0221138
1564,i $nmbr$ ± $nmbr$ ii,C0021966;C0221138;C1710602;C4082587
1564,i $nmbr$ ± $nmbr$ i,C0021966;C0221138
1564,i $nmbr$ i ± i $nmbr$,C0021966;C0221138
1564,i $nmbr$ i ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
1564,i $nmbr$ i $nmbr$ ± $nmbr$,C0021966;C0221138
1564,i $nmbr$ i,C0021966;C0221138
1564,i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,C0021966;C0221138
1564,i $nmbr$ ( i $nmbr$ . i ),C0021966;C0221138
1564,i $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
1564,i,C0021966;C0221138
1564,ffa / i,C0015688;C0021966;C0221138
1564,ciass i,C0021966;C0221138
1564,bm i < $nmbr$,C0006416;C0021966;C0221138
1564,aqe i $nmbr$,C0021966;C0221138
1564,antithrombotic ! i,C0021966;C0221138
1564,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
1564,> o - $nmbr$ - i - i,C0021966;C0221138;C0483204
1564,> i,C0021966;C0221138
1564,< $nmbr$ kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
1564,- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ ),C0016327;C0021966;C0221138
1564,- b - i —,C0021966;C0221138
1564,- b - i -,C0021966;C0221138
1564,( i - blocker,C0021966;C0221138
1564,$nmbr$ — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
1564,$nmbr$ t i,C0021966;C0221138;C2603360
1564,$nmbr$ i - $nmbr$ - $nmbr$ ai,C0003504;C0021966;C0221138;C4551710
1564,$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ ),C0021966;C0221138
1564,$nmbr$ . i ± ii . $nmbr$,C0021966;C0221138;C1710602;C4082587
1564,$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ ),C0021966;C0221138
1564,$nmbr$ . $nmbr$ to . $nmbr$ . i . iot,C0006196;C0021966;C0221138
1564,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a,C0021966;C0221138
1564,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0021966;C0221138
1564,$nmbr$ . $nmbr$ ( io . i ),C0021966;C0221138;C1046794;C3146236
1564,$nmbr$ . $nmbr$ ( i $nmbr$ . s ),C0021966;C0221138
1564,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i ),C0021966;C0221138
1564,$nmbr$ - i,C0021966;C0221138
1564,$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i,C0021966;C0221138
1564,$nmbr$ ( $nmbr$ i . i ),C0021966;C0221138
1563,lvh on ecg,C0232306
1563,lvh by ecg or echocardiographyd,C0232306
1563,lvh by ecg or echocardiography  no ( % ),C0232306
1563,lvh by ecg or echo . n ( % ),C0232306
1563,lvh by ecg / echo,C0058928;C0232306;C1655045
1563,lvh by ecg,C0232306
1563,lv hypertrophy per ecg,C0232306
1563,ecg - lvh ( sokolow - lyon ),C0232306
1563,ecg - lvh ( cornell ),C0232306
1563,baseline ecg with lvh  n ( % ),C0168634;C0232306;C1442488
1562,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
1562,post - bronchodilator fevi $nmbr$ % predicted,C0849974;C1561566;C2599594;C4528367
1562,post - bronchodilator fevi  n ( % ),C0429706;C0849974;C1561566;C2599594;C4528367
1562,fevi percent predicted ( % ),C0429706;C0439165;C0849974;C1561566;C4528367
1562,fevi auc $nmbr$ - $nmbr$ l,C0376690;C0429706;C0849974;C1561566;C4528367
1562,fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
1562,fevi  l *,C0429706;C0849974;C1561566;C4528367
1562,fevi  l,C0429706;C0849974;C1561566;C4528367
1562,fevi  % predicted *,C0849974;C1561566;C4528367
1562,fevi  % predicted  mean ( sd ) $nmbr$,C0849974;C1561566;C4528367
1562,$nmbr$ ( fevi ^ $nmbr$ % pred ),C0849974;C1561566;C4528367
1562,$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred ),C0849974;C1561566;C4528367
1561,qrs interval > $nmbr$ msec — no . ( % ),C0439223;C0520880
1561,qrs > $nmbr$ msec $nmbr$ - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
1561,qrs < $nmbr$ msec,C0439223
1560,predose fvc ( l ) *,C0439565;C3714541;C3812758
1560,predose fvc ( l ),C0439565;C3714541;C3812758
1560,predose fev / fvc,C0439565;C3714541;C3812758
1560,predose fev -  at randomization,C0034656;C0439565;C3714541;C3812758
1560,predose fev $nmbr$ ( l ) *,C0439565;C3714541;C3812758
1560,pre - dose,C0439565;C3812758
1559,brv overalla ( n = $nmbr$ ),C0155502
1559,brv overall ( n = $nmbr$ ),C0155502;C0282416;C1561607
1559,brv overall,C0155502
1559,brv dosage  mg / d,C0155502;C0178602;C0439422;C2986497
1559,brv > $nmbr$ mg / day,C0155502;C0439422
1559,brv $nmbr$   mg / day,C0155502;C0439422
1559,brv $nmbr$ mg / day ( n = $nmbr$ ),C0155502;C0439422
1559,brv $nmbr$ mg / day ( n =,C0155502;C0439422
1558,prior smoker,C0337671
1558,previous smokers,C0337671
1558,previous smoker,C0337671
1558,former smokers,C0337671
1558,former smoker — no . { % ),C0337671
1558,former smoker — no . ( % ),C0337671
1558,former smoker ( n = $nmbr$ ),C0337671
1558,former smoker ( n = $nmbr$  $nmbr$ ),C0337671
1558,former smoker  n ( % ),C0337671
1558,former smoker,C0337671
1558,exsmoker,C0337671;C4555205
1558,ex - smokers : qvai $nmbr$ - sfc,C0337671;C4521536;C4555205
1558,ex - smokers ( n = $nmbr$ ),C0337671;C4555205
1558,ex - smokers ( itt ) ( n = $nmbr$ ),C0337671;C4555205
1558,ex - smokers $nmbr$,C0337671;C4555205
1558,ex - smokers,C0337671;C4555205
1558,ex - smoker / smoker  %,C0337671;C4555205
1558,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
1558,ex - smoker ( n z $nmbr$ ),C0337671;C4555205
1558,ex - smoker,C0337671;C4555205
1557,nonsmoker  n ( % ),C0337672;C0425293;C4554605
1557,nonsmoker,C0337672;C0425293;C4554605
1557,non - smoker ( n = $nmbr$  $nmbr$ ),C0337672;C0425293;C4554605
1557,non - smoker,C0337672;C0425293;C4554605
1557,never smoker,C0425293
1556,patients with only mrf hr ( $nmbr$ % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
1556,mrf subjects,C0312443;C1412879
1556,mrf,C0312443;C1412879
1555,less than $nmbr$ year,C0439092;C0439234;C0439508
1555,less than $nmbr$ mm hg,C0439092;C0439475
1555,less than $nmbr$ kg / m $nmbr$,C0439092;C1532718
1555,less than $nmbr$ . $nmbr$ %,C0439092
1555,less than $nmbr$ %,C0439092
1555,less than $nmbr$,C0439092
1554,bosentan use :,C0042153;C0252643;C0457083;C1947944
1554,bosentan ( n = $nmbr$ ),C0252643
1554,bosentan,C0252643
1553,post - mi,C0856742
1553,post - dose,C0439568
1553,lost bmd,C0745777;C3815882
1552,losartan plus lisinopril ( n = $nmbr$ ),C0065374;C0126174;C0332287
1552,losartan n = $nmbr$,C0126174
1552,losartan + placebo,C0032042;C0126174;C1696465;C1706408
1552,losartan + lisinopril,C0065374;C0126174
1552,losartan ( n = $nmbr$ ),C0126174
1552,losartan ( n = $nmbr$  $nmbr$ ),C0126174
1552,losartan  n / n ( % ),C0126174
1552,losartan,C0126174
1552,chf on losartan ( % ),C0018802;C0126174
1551,psa ‐ modified shs of hands and feet,C0018563;C0392747;C1552914;C3810537;C3813209;C3889737
1551,psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale ),C0392747;C3810537;C3813209;C3889737
1551,psa subtypes  n ( % ),C0449560;C3810537;C3813209
1551,psa reported  n ( % ),C3810537;C3813209
1551,psa - modified total shs,C3810537;C3813209
1551,psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
1551,psa - modified shs ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
1551,psa - modified mases score ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
1551,psa ( ng / ml ),C0439275;C3810537;C3813209
1551,psa ( n = $nmbr$ ),C3810537;C3813209
1551,psa,C3810537;C3813209
1551,no psa ( n = $nmbr$ ),C3810537;C3813209
1551,no psa,C3810537;C3813209
1550,pt . years = $nmbr$,C0032743;C0439234;C0699718
1550,pt,C0032743;C0699718
1549,pts,C1419129;C2698747
1549,no . pts,C1419129;C2698747
1549,# pts,C1419129;C2698747
1548,regular ppi use,C0205272;C0358591;C0871125;C3811894
1548,proton pump inhibitors,C0358591;C1384478;C3540020
1548,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
1548,proton pump inhibitor ( n  % ),C0358591;C3536754;C4521480
1548,proton pump inhibitor,C0358591;C3536754;C4521480
1548,proton - pump inhibitors,C0358591;C1384478;C3540020
1548,proton - pump inhibitor,C0358591;C3536754;C4521480
1548,ppi use within $nmbr$ months of randomization,C0358591;C0871125;C3811894
1548,ppi use at baseline,C0358591;C0871125;C3811894
1548,ppi use ( p = $nmbr$ . $nmbr$ t ),C0358591;C0871125;C3811894
1548,ppi use ( p = $nmbr$ - $nmbr$ t ),C0358591;C0871125;C3811894
1548,ppi use,C0358591;C0871125;C3811894
1548,ppi or h $nmbr$ receptor antagonist  n ( % ),C0358591;C0871125;C3811894
1548,ppi but no aspirin,C0358591;C0871125;C3811894
1548,ppi,C0358591;C0871125;C3811894
1548,nontrial ppi,C0358591;C0871125;C3811894
1548,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
1548,no regular ppi use,C0205272;C0358591;C0871125;C3811894
1548,no ppi,C0358591;C0871125;C3811894
1547,pump,C0182537
1547,on pump,C3842462
1547,on - pump,C3842462
1547,off pump,C0182537;C1518543
1547,off - pump,C0182537;C1518543
1546,uvb,C0454530;C0564461
1546,puva,C0853073;C1704892
1545,result,C1274040;C1546471;C2825142
1545,outcomes,C1274040
1545,outcome type,C0332307;C1274040;C1547052
1545,outcome severity,C0439793;C0522510;C1274040
1545,outcome and metabolizer phenotype,C1274040
1545,outcome - variant,C0205419;C1274040
1545,outcome ( n  % },C1274040
1545,outcome,C1274040
1545,other outcomes,C1274040
1545,ischemic outcomes,C0475224;C1274040
1545,baseline outcomes,C0168634;C1274040;C1442488
1545,ancova result,C0814908;C1274040;C1546471;C2825142
1545,adverse outcome,C1274040
1544,trend / het . test,C1521798;C4554533
1544,pvaluefor trend,C1521798;C4554533
1544,p value for trend across tertiles,C1521798;C1709380;C4554533
1544,p value for trend *,C1521798;C1709380;C4554533
1544,p value for trend,C1521798;C1709380;C4554533
1544,p trend,C0369773;C1521798;C2603361;C4554533
1544,p j $nmbr$ * trend,C1518835;C1521798;C4554533
1544,p for trend -,C0369773;C1521798;C2603361;C4554533
1544,p for trend,C0369773;C1521798;C2603361;C4554533
1544,p - value for trend across categories,C1521798;C1709380;C4554533
1544,p - value for trend *,C1521798;C1709380;C4554533
1544,p - value ( trend ),C1521798;C1709380;C4554533
1543,with laba  n ( % ) pretreatment,C1550147;C2709094;C3539075;C3539076
1543,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
1543,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
1543,pre - treatment [ n ( % ) ] c,C1550147;C2709094;C3539075;C3539076
1543,no pretreatment,C1550147;C2709094;C3539075;C3539076
1543,high - dose statin pretreatment ( n = $nmbr$ ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
1543,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1543,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1543,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
1543,$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ ),C0439590;C1550147;C2709094;C3539075;C3539076
1542,persistent wrf ( n = $nmbr$ ),C0205322;C0332996
1542,persistent or permanent immobilization,C0205322;C0332996
1542,persistent or paroxysmal,C0205322;C0332996
1542,persistent faol ( n [ $nmbr$ ),C0205322;C0332996
1542,persistent faod ( n [ $nmbr$ ),C0205322;C0332996
1542,persistent af  n ( % ),C0205322;C0332996;C0344434;C4049859
1542,persistent af,C0205322;C0332996;C0344434;C4049859
1542,persistent / permanent,C0205322;C0205355;C0332996
1542,persistent *,C0205322;C0332996
1542,persistent ( n  % ),C0205322;C0332996
1542,persistent  n ( % ),C0205322;C0332996
1542,persistent,C0205322;C0332996
1542,no persistent wrf ( n = $nmbr$  $nmbr$ ),C0205322;C0332996
1542,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
1541,penetrating no . of resections  n ( % ),C0205321
1541,penetrating disease  %,C0012634;C0205321
1541,penetrating,C0205321
1540,pef !,C0030771;C1518922;C1542834
1540,pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834
1539,emphysema ( n = $nmbr$ ),C0013990;C0034067
1539,emphysema ( itt ) ( n = $nmbr$ ),C0013990;C0034067
1539,emphysema ( % ),C0013990;C0034067
1539,emphysema,C0013990;C0034067
1538,qmax category  n ( % ) :,C0683312;C3889287
1538,mace category  n ( % ) [ ir ],C0022065;C0022071;C0349381;C0683312;C0949745;C1445339;C1448132;C3889287
1538,hemoglobin category,C0019046;C0683312;C3889287
1538,glycatedhemoglobin category  %,C0683312;C3889287
1538,egfr category  n ( % ),C0683312;C1739039;C3811844;C3812682;C3889287
1538,category — no . / total no . ( % ),C0683312;C3889287
1538,category $nmbr$ and $nmbr$,C0683312;C3889287
1538,category $nmbr$,C0683312;C3889287
1538,category,C0683312;C3889287
1538,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
1538,categorical variables,C0439828;C0683312;C3889287
1538,cardiovascular disease risk category,C0683312;C1113685;C3889287
1538,bmi category,C0578022;C0683312;C3889287
1538,background csdmard category,C0683312;C1706907;C3889287
1538,age category >,C0001779;C0683312;C3889287
1538,age category ( years )  n ( % ),C0683312;C1510829;C3889287
1538,age category ( % ),C0001779;C0683312;C3889287
1538,age category  n ( % ) < $nmbr$ years,C0683312;C1510829;C3889287
1538,age category  n ( % ) :,C0001779;C0683312;C3889287
1538,age category  n ( % ),C0001779;C0683312;C3889287
1538,age category,C0001779;C0683312;C3889287
1538,/ \ge category,C0683312;C1292300;C3538705;C3889287
1537,eo severity by la classification at baseline ( baseline of the healing study )  n ( % ),C0332120;C0439793;C0522510;C1881447
1537,eo,C0332120
1536,nationality,C0027473
1536,minority,C0026192
1536,abdominal obesity *,C0311277
1536,abdominal obesity,C0311277
1535,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
1535,abnormal,C0205161;C2347472;C2699333
1534,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
1534,anemia ( % ),C0002871;C1000483;C4554633
1534,anemia  no . / total ( % ) ”,C0002871;C1000483;C4554633
1534,anemia  %,C0002871;C1000483;C4554633
1534,anemia,C0002871;C1000483;C4554633
1533,medal,C0524670
1533,dermal,C0221928;C1522447
1532,n america,C0002454;C0369718;C0441922
1532,americas * *,C0002454;C0596070
1532,americas ( n = $nmbr$ ),C0002454;C0596070
1532,americas  excluding us,C0002454;C0596070
1532,americas,C0002454;C0596070
1532,american,C0596070
1532,america,C0002454
1531,range race  n ( % ),C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
1531,racial group  n ( % ),C0034510;C0441848;C1706779;C3669213;C3853635
1531,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
1531,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
1531,race_white  %,C0034510;C1706779;C3853635
1531,race — no . { % ) - i -,C0034510;C1706779;C3853635
1531,race — no . { % ) ' i ',C0034510;C1706779;C3853635
1531,race — no . / total no . ( % ) f,C0034510;C1706779;C3853635
1531,race — no . ( % ) 卞,C0034510;C1706779;C3853635
1531,race — no . ( % ) |,C0034510;C1706779;C3853635
1531,race — no . ( % ) f,C0034510;C1706779;C3853635
1531,race — no . ( % ) : t,C0034510;C1706779;C3853635
1531,race — no . ( % ) : c,C0034510;C1706779;C3853635
1531,race — no . ( % ) ' (,C0034510;C1706779;C3853635
1531,race — no . ( % ),C0034510;C1706779;C3853635
1531,race §,C0034510;C1706779;C3853635
1531,race white,C0034510;C1706779;C3853635
1531,race or ethnicity  n ( % ),C0034510;C1706779;C3853635
1531,race or ethnicity,C0034510;C1706779;C3853635
1531,race or ethnic origin,C0034510;C1706779;C3853635
1531,race or ethnic group — no . { % ) ■ ' ( white,C0034510;C1706779;C3853635
1531,race or ethnic group — no . f,C0034510;C1706779;C3853635
1531,race or ethnic group — no . / total no . ( % ) f,C0034510;C1706779;C3853635
1531,race or ethnic group — no . ( % ) f,C0034510;C1706779;C3853635
1531,race or ethnic group — no . ( % ) : t,C0034510;C1706779;C3853635
1531,race or ethnic group ( % ) f,C0034510;C1706779;C3853635
1531,race or ethnic group ( % ),C0034510;C1706779;C3853635
1531,race or ethnic group  no . ( % ),C0034510;C1706779;C3853635
1531,race or ethnic group  n ( % ) *,C0034510;C1706779;C3853635
1531,race or ethnic group,C0034510;C1706779;C3853635
1531,race or ethnic background — no . ( % ) f,C0034510;C1706779;C3853635
1531,race nonwhitet,C0034510;C1706779;C3853635
1531,race n ( % ),C0034510;C1706779;C3853635
1531,race and ss at baseline,C0034510;C1706779;C3853635
1531,race : white,C0034510;C1706779;C3853635
1531,race : non - white,C0034510;C1706779;C3853635
1531,race :,C0034510;C1706779;C3853635
1531,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
1531,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
1531,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
1531,race / ethnicity  zz ( % ),C0015031;C0034510;C0243103;C1706779;C2347310;C3853635
1531,race / ethnicity  no . ( % ) *,C0015031;C0034510;C0243103;C1706779;C3853635
1531,race / ethnicity  no . ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
1531,race / ethnicity  n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
1531,race / ethnicity  % white non - hispanic,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1518422;C1518424;C1533020;C1533021;C1706779;C3853635
1531,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
1531,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
1531,race - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
1531,race - nonwhite,C0034510;C1706779;C3853635
1531,race - non - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
1531,race - non - white,C0034510;C1706779;C3853635
1531,race - no . ( % ),C0034510;C1706779;C3853635
1531,race - n ( % ),C0034510;C1706779;C3853635
1531,race *,C0034510;C1706779;C3853635
1531,race ( white  n [ % ] ),C0034510;C1706779;C3853635
1531,race ( p = o - $nmbr$ ),C0034510;C1706779;C3853635
1531,race ( non - white ) ( % ),C0034510;C1706779;C3853635
1531,race ( % white ),C0034510;C1706779;C3853635
1531,race ( % ) white,C0034510;C1706779;C3853635
1531,race ( % ) *,C0034510;C1706779;C3853635
1531,race ( % ) ) ',C0034510;C1706779;C3853635
1531,race ( % ) $,C0034510;C1706779;C3853635
1531,race ( % ),C0034510;C1706779;C3853635
1531,race $nmbr$,C0034510;C1706779;C3853635
1531,race    n   ( % ),C0034510;C1706779;C3853635
1531,race  zz ( % ),C0034510;C1706779;C3853635
1531,race  white ( % ),C0034510;C1706779;C3853635
1531,race  white    n   ( % ),C0034510;C1706779;C3853635
1531,race  white  n ( % of patients ),C0034510;C1706779;C3853635
1531,race  white  n ( % ),C0034510;C1706779;C3853635
1531,race  while,C0034510;C1706779;C3853635
1531,race  nonwhite,C0034510;C1706779;C3853635
1531,race  non - white,C0034510;C1706779;C3853635
1531,race  no . / total ( % ),C0034510;C1706779;C3853635
1531,race  no . ( % ) white,C0034510;C1706779;C3853635
1531,race  no . ( % ) c,C0034510;C1706779;C3853635
1531,race  no . ( % ) b,C0034510;C1706779;C3853635
1531,race  no . ( % ) *,C0034510;C1706779;C3853635
1531,race  no . ( % ),C0034510;C1706779;C3853635
1531,race  n ( % ],C0034510;C1706779;C3853635
1531,race  n ( % ) ’,C0034510;C1706779;C3853635
1531,race  n ( % ) y,C0034510;C1706779;C3853635
1531,race  n ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
1531,race  n ( % ) t,C0034510;C1706779;C3853635
1531,race  n ( % ) b,C0034510;C1706779;C3853635
1531,race  n ( % ) a,C0034510;C1706779;C3853635
1531,race  n ( % ) :,C0034510;C1706779;C3853635
1531,race  n ( % ) +,C0034510;C1706779;C3853635
1531,race  n ( % ) *,C0034510;C1706779;C3853635
1531,race  n ( % ),C0034510;C1706779;C3853635
1531,race  black or african - american  n ( % ),C0034510;C1706779;C3853635
1531,race  asian  n ( % ),C0034510;C1706779;C3853635
1531,race  * ’ n ( % ),C0034510;C1706779;C3853635
1531,race  % white,C0034510;C1706779;C3853635
1531,race  % nonwhite,C0034510;C1706779;C3853635
1531,race  % caucasian,C0034510;C1706779;C3853635
1531,race  %,C0034510;C1706779;C3853635
1531,race,C0034510;C1706779;C3853635
1531,other race  n ( % ),C0034510;C1706779;C3853635
1531,other race,C0034510;C1706779;C3853635
1531,nonwhite race !,C0034510;C1706779;C3853635
1531,nonwhite race,C0034510;C1706779;C3853635
1531,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
1531,$ race was determined by the investigator during the patient ' s interview .,C0034510;C1706779;C3853635
1530,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
1530,magnetic resonance angiography,C0243032
1529,duration of prior alendronate use  months,C0102118;C0332152;C0439231;C1881378;C2826257;C2826775
1529,alendronate ( n = $nmbr$ ),C0102118
1529,alendronate,C0102118
1528,ranolazine vs . placebo km failure rate,C0073633
1528,ranolazine n = $nmbr$,C0073633
1528,ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ ),C0032042;C0073633;C1696465;C1706408
1528,ranolazine ( n = $nmbr$ ),C0073633
1528,ranolazine ( n = $nmbr$  $nmbr$ ),C0073633
1528,ranolazine ( n $nmbr$ $nmbr$ ),C0073633
1528,ranolazine  n   =   $nmbr$,C0073633
1528,ranolazine  n = i $nmbr$ i $nmbr$,C0021966;C0073633;C0221138
1528,ranolazine,C0073633
1527,cangrelor n / n ( % ),C1121991
1527,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
1527,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C1121991
1527,cangrelor ( n = $nmbr$ ) n / n ( % ),C1121991
1527,cangrelor ( n = $nmbr$ ),C1121991
1527,cangrelor  %,C1121991
1527,cangrelor,C1121991
1526,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C2826257
1526,prior angina pectoris,C0002962;C0332152;C2826257
1526,prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
1526,prior angina  n / n ( % ),C0002962;C0332152;C2826257
1526,prior angina,C0002962;C0332152;C2826257
1526,no prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
1526,hospitalized angina,C0002962;C0701159
1526,hospitaiization for angina,C0002962
1526,current angina ( % ),C0002962;C0521116;C1705970
1526,current angina,C0002962;C0521116;C1705970
1526,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
1526,angina status — no . ( % ),C0002962;C0449438
1526,angina pectorisf,C0002962
1526,angina pectoris 本,C0002962
1526,angina pectoris — no . ( % ),C0002962
1526,angina pectoris *,C0002962
1526,angina pectoris  ( % ),C0002962
1526,angina pectoris,C0002962
1526,angina or positive stress test,C0002962
1526,angina or acute mi,C0002962
1526,angina .,C0002962
1526,angina ( past $nmbr$ weeks ),C0002962;C2987125
1526,angina  n ( % ),C0002962
1526,angina,C0002962
1525,canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
1525,canakinumab,C2718773
1525,anakinra,C0245109
1525,all canakinumab,C2718773
1524,noncomplex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0700276;C1384516
1524,complex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0439855;C0700276;C1384516;C1704241
1524,anatomy,C0002808;C0700276;C1384516
1523,or for cana vs pbo ( $nmbr$ % ci ) §,C1418845
1523,or for cana vs pbo ( $nmbr$ % ci ) | |,C1418845
1523,cana $nmbr$ / met ( n = $nmbr$ ),C1418845
1523,cana $nmbr$ ( n = $nmbr$ ),C1418845
1523,cana,C1418845
1523,all cana,C1418845
1522,vents / patients,C0030705
1522,subset of patients on metformin,C0030705;C1515021
1522,subset of patients not on metformin,C0030705;C1515021
1522,remaining patients,C0030705;C1527428
1522,randomized patients,C0030705;C0034656;C3815594
1522,randomised patients with spondylitis at baseline  n,C0030705;C0038012
1522,randomised patients with enthesitis at baselinet,C0030705;C1282952
1522,randomised patients with dactylitis at baseline,C0030705;C0239161
1522,randomised patients ( n ),C0030705
1522,race  % of patients,C0030705;C0034510;C1706779;C3853635
1522,percentages of patients with event,C0030705;C0439165;C1549488;C1561533
1522,percentage patients reaching target,C0030705;C0439165;C1549488;C1561533
1522,percentage of patients with event,C0030705;C0439165;C1549488;C1561533
1522,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C1549488;C1561533
1522,percentage of patients receiving dose adjustment,C0030705;C0439165;C1549488;C1561533
1522,percent of patients,C0030705;C0439165
1522,patients without syndesmophytes at baseline,C0030705;C0221690
1522,patients without ra  as  or psa ( n = $nmbr$  $nmbr$ ),C0030705;C3538806;C4048756
1522,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
1522,patients without draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
1522,patients without diabetesb,C0030705
1522,patients without diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
1522,patients without diabetes,C0011847;C0011849;C0030705
1522,patients without chronic,C0030705;C0205191
1522,patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
1522,patients without,C0030705
1522,patients with syndesmophytes at baseline,C0030705;C0221690
1522,patients with radiographic erosion  n / n ( % ),C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
1522,patients with ra  as  or psa ( n = $nmbr$ ),C0030705;C3538806;C4048756
1522,patients with pulmonary embolism,C0030705;C0034065
1522,patients with prior ml hr ( $nmbr$ % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
1522,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
1522,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
1522,patients with pneumonia resulting in death  n ( % ),C0030705;C0032285
1522,patients with pneumonia events  n ( % ) #,C0030705;C0032285;C0441471;C3541888
1522,patients with pneumonia event  n ( % ) #,C0030705;C0032285;C0441471;C4019010
1522,patients with perianal fistulae  n [ % ],C0030705;C0267561
1522,patients with normoalbuminuria at baseline,C0030705
1522,patients with no prior cvd ( primary,C0007222;C0030705;C0332152;C2826257
1522,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
1522,patients with nail psoriasis ( mnapsi > $nmbr$ ),C0030705;C0406322
1522,patients with microalbuminuria at baseline,C0030705;C0730345
1522,patients with measurement,C0030705;C0242485
1522,patients with macroalbuminuria at baseline,C0030705
1522,patients with improvement $ $nmbr$ . $nmbr$,C0030705;C2986411
1522,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *,C0017853;C0030705
1522,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *,C0017853;C0030705
1522,patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis,C0017853;C0030705
1522,patients with fistulas at baseline,C0016169;C0030705
1522,patients with fingernail involvement,C0030705;C0222001;C1314939
1522,patients with event / patients analyzed,C0030705;C0441471;C4019010
1522,patients with event / patients analysed,C0030705;C0441471;C4019010
1522,patients with event / analyzed,C0030705;C0441471;C4019010
1522,patients with event ( n  % ),C0030705;C0441471;C4019010
1522,patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score,C0030705;C1282952
1522,patients with enthesitis at week $nmbr$  n ( % ),C0030705;C1282952
1522,patients with enthesitis at baseline  no .,C0030705;C1282952
1522,patients with enthesitis ( lei > $nmbr$ ),C0023401;C0030705;C0428209;C1282952
1522,patients with enthesitis  no . ( % ),C0030705;C1282952
1522,patients with enthesitis  n ( % ),C0030705;C1282952
1522,patients with enthesitis,C0030705;C1282952
1522,patients with endpoin t  n ( % ),C0030705
1522,patients with end point,C0030705;C2349179;C2826544
1522,patients with draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
1522,patients with digits with dactylitis  n ( % ),C0030705;C0582802
1522,patients with diabetesb,C0030705
1522,patients with diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
1522,patients with diabetes mellitus,C0011849;C0030705
1522,patients with diabetes,C0011847;C0011849;C0030705
1522,patients with dactylitisa,C0030705
1522,patients with dactylitis at week $nmbr$  n ( % ),C0030705;C0239161
1522,patients with dactylitis at baseline  no .,C0030705;C0239161
1522,patients with dactylitis  no . ( % ),C0030705;C0239161
1522,patients with dactylitis,C0030705;C0239161
1522,patients with chronic,C0030705;C0205191
1522,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
1522,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
1522,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
1522,patients with any clinical,C0030705;C0205210
1522,patients with an event per $nmbr$ patient - years,C0030705;C0441471;C4019010
1522,patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
1522,patients with > $nmbr$ co - aeds,C0030705;C0180309;C3245499
1522,patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C3887665
1522,patients with > $nmbr$ % bsa,C0030705
1522,patients with $nmbr$ co - aeds,C0030705;C0180309;C3245499
1522,patients with $nmbr$ co - aed,C0030705;C0887457;C3245499
1522,patients with $ $nmbr$ % bsa at baseline  no .,C0030705
1522,patients who used insulin pump,C0030705
1522,patients who received positive results on test for antibodies to infliximabt,C0030705
1522,patients who received negative results on test for antibodies to infliximabt,C0030705
1522,patients who received indeterminate results on test for antibodies to infliximabt,C0030705
1522,patients who received $nmbr$ or $nmbr$ drugs,C0030705
1522,patients who received $nmbr$ drug,C0030705
1522,patients who had ulcerations at,C0030705
1522,patients who did not use insulin pump,C0030705
1522,patients using concurrent tiotropium,C0030705
1522,patients treated with statins ( n = $nmbr$ ),C0030705
1522,patients treated with losartan ( n = $nmbr$ ),C0030705
1522,patients treated with insulin,C0030705
1522,patients treated with atenoloi ( n = $nmbr$ ),C0030705
1522,patients treated for > $nmbr$ weeks ( % ),C0030705
1522,patients treated and operated  n ( % ),C0030705
1522,patients treated,C0030705
1522,patients total no .,C0030705
1522,patients taking oral corticosteroids at baseline  n ( % ),C0030705
1522,patients taking mtx  no . ( % ),C0030705
1522,patients taking mtx  n ( % ),C0030705
1522,patients receiving statin,C0030705
1522,patients receiving mtx  n =,C0030705
1522,patients receiving mtx,C0030705
1522,patients receiving lcz  no . ( % ),C0030705
1522,patients receiving immunotherapy  no . ( % ),C0030705
1522,patients receiving immunosuppressive agents at baseline,C0030705
1522,patients receiving enl  no . ( % ),C0030705
1522,patients receiving corticosteroids at baseline,C0030705
1522,patients receiving any uc medication  n ( % ),C0030705
1522,patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f,C0030705
1522,patients randomly assigned,C0030705
1522,patients randomized  no .,C0030705
1522,patients randomized  n,C0030705
1522,patients randomized,C0030705
1522,patients randomised  n,C0030705
1522,patients on atorvastatin  rosuvastatin  or simvastatin at,C0030705;C0286651;C0965129
1522,patients not treated with statins ( n = $nmbr$ ),C0030705
1522,patients not receiving statin,C0030705
1522,patients not receiving mtx  n =,C0030705
1522,patients not receiving immunosuppressive agents at baseline,C0030705
1522,patients not receiving corticosteroids at baseline,C0030705
1522,patients n,C0030705
1522,patients meeting the criteria to receive $nmbr$ mg of,C0030705
1522,patients included in analysis,C0030705
1522,patients in analysis  n,C0002778;C0030705;C0936012;C1524024
1522,patients having exacerbation,C0030705
1522,patients entering pt period n = $nmbr$,C0030705
1522,patients assessed,C0030705
1522,patients analyzed  n,C0030705
1522,patients aged > $nmbr$ y  no  ( ss ),C0030705
1522,patients > $nmbr$ y *,C0030705
1522,patients > $nmbr$ y,C0030705
1522,patients > $nmbr$ %,C0030705
1522,patients < $nmbr$ y *,C0030705
1522,patients < $nmbr$ y,C0030705
1522,patients < $nmbr$ %,C0030705
1522,patients ( treated set * )  n,C0030705
1522,patients ( n ),C0030705
1522,patients ( ft ),C0030705
1522,patients    n   ( % ),C0030705
1522,patients  no . / total no . ( % ),C0030705
1522,patients  no .,C0030705
1522,patients  n / n ( % ) a,C0030705
1522,patients  n ( % ),C0030705
1522,patients  n,C0030705
1522,patients,C0030705
1522,patient years,C0030705;C0439234
1522,patient presentation,C0030705;C0449450
1522,patient population,C0030705;C0032659;C1257890
1522,patient classification,C0008902;C0008903;C0030705;C0678229
1522,patient characteristic,C0030705
1522,patient - reported hypertension — no . { % ),C0030705
1522,patient,C0030705
1522,of patients meeting criterion / total no . of patients,C0030705
1522,of patients,C0030705
1522,obese patients  ! n ( % ),C0028754;C0030705
1522,number ol ( % ) patients > $nmbr$ years,C0030705;C0237753;C0439234;C0449788
1522,no . patients with,C0030705
1522,no . patients ( % ),C0030705
1522,no . of patients with ra,C0030705
1522,no . of patients with psa,C0030705
1522,no . of patients with events ( % ),C0030705
1522,no . of patients with as,C0030705
1522,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
1522,no . of patients / total no . ( % ),C0030705
1522,no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ ),C0030705
1522,no . of patients / no . of events,C0030705
1522,no . of patients ( % ),C0030705
1522,no . of patients,C0030705
1522,no . of hospitalised patients,C0030705
1522,no . ( % ) with event [ incidence rate per $nmbr$ patient - y ],C0030705;C0441471;C1708485;C4019010
1522,no . ( % ) of patients with ≥ $nmbr$ % bsa affected,C0030705
1522,no . ( % ) of patients with stroke,C0030705
1522,no . ( % ) of patients with fingernail involvement,C0030705
1522,no . ( % ) of patients with atrial tachyarrhythmia,C0030705
1522,n ( % ) patients with risk faetors for cv disease aged > $nmbr$,C0030705;C0035647;C0369718;C0441922;C4552904
1522,itt patients  n ( % ),C0030705
1522,for patients using personal cgm,C0030705
1522,for patients not using personal cgm,C0030705
1522,ard ( $nmbr$ % cl ) per $nmbr$ patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
1522,anti - tnf - naive patients $nmbr$,C0030705;C1448177
1522,anti - tnf - naive patients,C0030705;C1448177
1522,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
1522,anti - tnf - experienced patients,C0030705;C1448177
1522,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
1522,all randomized patients,C0030705;C0034656;C3815594
1522,all patients with opg n - $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
1522,all patients with fistulas ( n = $nmbr$ ),C0016169;C0030705
1522,all patients n = $nmbr$ $nmbr$,C0030705
1522,all patients n = $nmbr$,C0030705
1522,all patients ( « = $nmbr$ $nmbr$ ),C0030705
1522,all patients ( p = $nmbr$ . $nmbr$ ),C0030705
1522,all patients ( p < $nmbr$ . $nmbr$ ),C0030705
1522,all patients ( n   =   $nmbr$ ) b,C0030705
1522,all patients ( n = $nmbr$ ),C0030705
1522,all patients ( n = $nmbr$  $nmbr$ ),C0030705
1522,all patients ( n $nmbr$ $nmbr$ ),C0030705
1522,all patients  n =,C0030705
1522,all patients,C0030705
1522,aii patients ( n = $nmbr$ ),C0030705;C1424250;C2698414
1522,( $nmbr$ patients ),C0030705
1522,% patients,C0030705
1522,% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$,C0030705
1521,other / missing,C1551393;C1705492;C3272743
1521,missing hb at yr $nmbr$,C0019046;C0439234;C1551393;C1705492;C3272743
1521,missing *,C1551393;C1705492;C3272743
1521,missing  n ( % ) a,C1551393;C1705492;C3272743
1521,missing,C1551393;C1705492;C3272743
1521,hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .,C0001779;C0005767;C0005768;C0012000;C0020261;C0030705;C0229664;C1551393;C1705492;C3272743
1520,premenopausal  %,C0279752
1520,premenopausal,C0279752
1520,poslmenopausal  ht,C0018510;C0677607
1520,menopause and ht,C0025320;C0567312
1520,menopause and hrt,C0025320;C0567312
1519,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
1519,postmenopausal and no ht,C0232970
1519,postmenopausal and no hrt,C0232970
1519,postmenopausal and current ht,C0232970
1519,postmenopausal and current hrt,C0232970
1519,postmenopausal ( % ),C0232970
1519,postmenopausal  no hrt,C0232970
1519,postmenopausal  never or past hormone therapy use,C0232970;C2003901
1519,postmenopausal  current hrt,C0232970;C0282402;C0521116;C1705970
1519,postmenopausal,C0232970
1519,post - menopausal ( a ),C0232970
1519,history of postmenopausal fracture *,C0232970;C1272071
1518,retinopathy — no . ( % ),C0035309;C1962966
1518,retinopathy — %,C0035309;C1962966
1518,retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0035309;C0205390;C1300072;C1306673;C1962966
1518,retinopathy,C0035309;C1962966
1517,neuropathy — no . ( % ),C0442874
1517,neuropathy,C0442874
1516,mar imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C3829202;C4255469
1516,imputed,C2699638
1516,cr imputation ( random . ) ( n = $nmbr$ ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
1516,bocf - iike imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C2984917
1515,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
1515,amputations  n ( % ),C0002688
1515,amputation — no . ( % ),C0002688;C0332840;C1546539
1515,amputation,C0002688;C0332840;C1546539
1514,pi,C0122626;C0429863;C3537219;C3539772
1514,pb,C1415801;C3819255
1514,nph,C0020258;C0027442
1513,north ameriea,C1709269
1513,north,C1709269
1513,nordic countries,C0036273
1513,nordic,C0331873
1512,korean,C1556095
1512,korea,C0022771
1512,forearm,C0016536
1511,row §,C1552840;C1552846
1511,row * n = $nmbr$,C1552840;C1552846
1511,row,C1552840;C1552846
1510,o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
1510,o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0029118;C0029434;C0483204
1510,o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o ),C0483204
1510,o $nmbr$,C0483204
1510,o,C0483204
1510,> o - $nmbr$ - ii,C0483204;C1710602;C4082587
1510,- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
1510,- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ ),C0483204
1510,$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % ),C0483204
1510,$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o ),C0483204
1510,$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ ),C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ ),C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ ),C0021966;C0221138;C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ ),C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ ),C0021966;C0221138;C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o ),C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ ),C0021966;C0221138;C0483204
1510,$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo ),C0483204
1510,$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ ),C0021966;C0221138;C0483204
1510,$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ ),C0483204
1510,$nmbr$ ( o - o $nmbr$ - o - $nmbr$ ),C0483204
1510,$nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
1510,$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
1509,korea  republic of,C0022773
1509,czech repumc,C0337799
1508,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
1508,> $nmbr$ % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
1507,kccq score,C3476798
1507,kccq ( $nmbr$ months ),C0439231;C3476798
1506,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
1506,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
1506,nste acs,C0742343;C4318612
1506,nste - acs,C0742343;C4318612
1506,no acs,C0742343;C4318612
1506,days from acs to randomization,C0439228;C0742343;C4318612
1506,days between acs and rand,C0439228;C0742343;C4318612
1506,acs type,C0332307;C0742343;C1547052;C4318612
1506,acs ( n = $nmbr$  $nmbr$ ),C0742343;C4318612
1506,acs ( n - $nmbr$  $nmbr$ ),C0742343;C4318612
1506,acs,C0742343;C4318612
1505,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
1505,csf a ( $nmbr$ ( pm ),C3540512;C3889436
1505,csf $nmbr$ s - hydroxy -,C3540512;C3889436
1505,csf,C3540512;C3889436
1504,sacral and / or lumbar,C0036037
1504,overall quality of life,C3641830
1503,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
1503,favors ff / vi favors placebo,C0205999;C0309049;C4554348
1503,favors favors lisinopril chlorthalidone,C0309049
1503,favors favors amlodipine chlorthalidone,C0309049
1502,no nasal polyps,C0027430
1502,nasal polyps  n ( % ),C0027430
1502,nasal polyps,C0027430
1502,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430
1502,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
1501,native hawaiian or other pacific islander,C0337920
1501,native hawaiian or other pacific,C0337920
1501,native hawaiian or,C0337920
1501,native hawaiian / pacific islander,C0242191;C0337920
1501,native hawaiian / other,C0337920
1501,hawaiian pacific islander,C0242191;C0337920
1501,hawaiian / pacific islander,C0242191;C0337920
1501,hawaiian / pacific,C0337920
1500,daily activities / social functioning,C0037395;C0871707
1500,daily activities,C0871707
1499,nyha_class,C1882083
1499,nyha class — no . ( % ) $,C1882083
1499,nyha class — no . ( % ),C1882083
1499,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
1499,nyha class not reported,C1882083
1499,nyha class ( when patient was last in stable condition before admission )  %,C1882083
1499,nyha class ( when patient was last in stable condition,C1882083
1499,nyha class $nmbr$ or higher,C1882083
1499,nyha class $nmbr$ - $nmbr$ : no { n = llll ),C1882083
1499,nyha class  n ( % ) i,C1882083
1499,nyha class  n ( % ),C1882083
1499,nyha class  ( % ),C1882083
1499,nyha class,C1882083
1499,nyha chf class,C0018802;C1882083
1499,new york heart association congestive heart failure class,C0018802;C1882083
1499,new york heart association class,C1882083
1498,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
1498,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
1498,nyha class iii or iv ( n = $nmbr$ ),C1882086
1498,nyha class iii or iv  n ( % ),C1882086
1498,nyha class iii  % ( n ),C1882086
1498,nyha class iii,C1882086
1497,residence in asia  n ( % ),C0003980;C0237096
1497,region  asia / paafic,C0003980;C0017446;C0205147
1497,getgoal - l - asia,C0003980
1497,asia pacific or other,C0003980
1497,asia pacific and south africa,C0003980
1497,asia pacific and other,C0003980
1497,asia pacific and africa,C0003980
1497,asia pacific ( n = $nmbr$ ),C0003980
1497,asia pacific,C0003980
1497,asia and pacific islands,C0003980
1497,asia / pacific / other,C0003980
1497,asia / pacific ( % ),C0003980
1497,asia / pacific,C0003980
1497,asia - pacific region and south africa,C0003980;C0017446;C0205147
1497,asia - pacific hr ( $nmbr$ % cl ),C0003980;C0596019
1497,asia - pacific and south africa,C0003980
1497,asia - pacific,C0003980
1497,asia ( n = $nmbr$ ),C0003980
1497,asia ( n = $nmbr$  $nmbr$ ),C0003980
1497,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
1497,asia #,C0003980
1497,asia  pacific and other,C0003980
1497,asia,C0003980
1496,p - value for east asian versus non - east asian *,C0078988;C1707877;C1709380
1496,other asian,C0078988
1496,oriental,C0078988;C0699027
1496,non - asian ( n = $nmbr$ $nmbr$ ),C0078988;C1518422
1496,non - asian,C0078988;C1518422
1496,east asian,C0078988;C1707877
1496,asians ( n = $nmbr$ ),C0078988
1496,asian or pacific islander,C0078988
1496,asian or oriental,C0078988
1496,asian / pacific islander  n ( % ),C0078988;C0242191
1496,asian / oriental,C0078988;C0699027
1496,asian *,C0078988
1496,asian ( n — $nmbr$ ),C0078988
1496,asian ( n   = $nmbr$ ),C0078988
1496,asian ( n = $nmbr$ ),C0078988
1496,asian ( n = $nmbr$  $nmbr$ ),C0078988
1496,asian ( $nmbr$ . $nmbr$ % ),C0078988
1496,asian  n ( % ),C0078988
1496,asian,C0078988
1495,eczema,C0013595;C4553957
1495,ankle edema,C0235439
1494,edge ii,C0205154;C1710602;C2697523;C4082587
1494,edge,C0205154;C2697523
1493,ne,C0027608;C0028219;C3538705
1493,( ne  ne ),C0027608;C0028219;C3538705
1493,$nmbr$ . $nmbr$ ( ne  ne ),C0027608;C0028219;C3538705
1492,se,C0036919
1492,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
1492,mean ± se,C0036919;C0444504;C2347634;C2348143
1492,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
1492,mean ( se ) trough  l,C0036919;C0444504;C0444506;C2347634;C2348143
1492,mean ( se ) auc ^ p l,C0036919;C0376690;C0444504;C2347634;C2348143
1492,mean ( se ) auc $nmbr$ - $nmbr$  l,C0036919;C0376690;C0444504;C2347634;C2348143
1492,mean ( se ),C0036919;C0444504;C2347634;C2348143
1492,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
1492,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
1492,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
1492,hscrp ( post - baseline / baseline ratio )  ls mean   ±   se,C0023668;C0036919;C0168634;C0444504;C0456603;C0687676;C1442488;C1547037;C1704687;C2347634;C2348143;C3469826
1492,calculated annual decline  mean ± se,C0036919;C0332181;C0444504;C0444686;C1441506;C2347634;C2348143
1492,( se ] tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
1492,( se ] tf hdl - c,C0036919;C3715113;C4048299;C4048587
1492,( se ] tf,C0036919;C4048299;C4048587
1492,( se ] t *,C0036919
1492,( se ] t,C0036919
1492,( se ] +,C0036919
1492,( se ) t *,C0036919
1492,( se ),C0036919
1492,% ( se ),C0036919
1491,« s $nmbr$ - $nmbr$,C0565930;C2603362
1491,| : s blocker,C0565930;C2603362
1491,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
1491,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
1491,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
1491,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
1491,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
1491,second co - primary,C0205436;C0457385;C0565930;C1561503;C1705190;C3245499
1491,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
1491,second ( n = $nmbr$ ),C0205436;C0457385;C0565930;C1561503;C1705190
1491,s £ $nmbr$,C0565930;C2603362
1491,s fs $nmbr$,C0565930;C1517317;C2603362;C3814419
1491,s . e .,C0565930;C2603362
1491,s ( s $nmbr$,C0565930;C2603362
1491,s $nmbr$ yrs,C0565930;C2603362
1491,s $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
1491,s $nmbr$ - $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
1491,s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %,C0565930;C2603362
1491,s $nmbr$ ( $nmbr$ . s ),C0565930;C2603362
1491,s $nmbr$ %,C0565930;C2603362
1491,s $nmbr$,C0565930;C2603362
1491,s,C0565930;C2603362
1491,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
1491,= s $nmbr$,C0565930;C2603362
1491,$nmbr$ s f $nmbr$ ),C0016327;C0565930;C2603362
1491,$nmbr$ s . $nmbr$ ± s . $nmbr$,C0565930;C2603362
1491,$nmbr$ ( $nmbr$ s . s ),C0565930;C2603362
1490,metabolism and nutrition,C0025519;C0025520
1490,metabolic syndromeb,C0311400;C1524026;C2707259
1489,mental status ( baseline spmsq scores )  n ( % ),C0168634;C0278060;C1442488
1489,mental status,C0278060
1488,patients with established cv disease aged > $nmbr$ years .,C0007222;C0030705;C0443211;C1272684;C1510829
1488,established cvd ( age > $nmbr$ ),C0001779;C0007222;C0443211;C1272684
1488,established cardiovascular disease,C0007222;C0443211;C1272684
1488,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
1488,established atherosclerotic disease  n ( % ),C0012634;C0333482;C0443211;C1272684
1488,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
1488,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
1488,established atherosclerotic,C0333482;C0443211;C1272684
1488,established ascvd or > $nmbr$ cv risk factors,C0443211;C1272684;C3665365
1488,established ascvd,C0443211;C1272684;C3665365
1488,established ( n = $nmbr$ ),C0443211;C1272684
1488,established,C0443211;C1272684
1487,stemi ( % ),C1536220;C3538872
1487,stemi,C1536220;C3538872
1487,st - segment — elevation myocardial infarction,C1536220
1487,st - segment elevation myocardial infarction,C1536220
1487,st - segment - elevation myocardial infarction — no . ( % ),C1536220
1487,st - elevation myocardial infarction,C1536220;C3538872
1487,prior stemi,C0332152;C1536220;C2826257;C3538872
1487,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
1487,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
1487,no prior stemi,C0332152;C1536220;C2826257;C3538872
1487,myocardial infarction without st - segment elevation — no . ( % ),C1536220
1486,selena - sledai activity  n ( % ),C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
1486,ease activity ],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
1486,disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s,C0205177;C0439167;C0439234;C0441655;C0449238;C0872146;C1292728;C1561536;C2926735;C3668946;C4049938;C4049939
1486,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
1486,activity ( $nmbr$ - $nmbr$ vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
1486,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
1486,active   versus   placebo,C0205177;C3853793;C3888249
1486,active vs placebo,C0205177;C3853793;C3888249
1486,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
1486,active smokers,C0205177;C0337664;C3853793;C3888249
1486,active smoker,C0205177;C0337664;C3853793;C3888249
1486,active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y,C0043193;C0205177;C1520135;C3853793;C3888249
1486,active or previous cancer,C0205177;C3853793;C3888249
1486,active comparatorb,C0205177;C3853793;C3888249
1486,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1486,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1486,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1486,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
1486,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
1486,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
1486,active canakinumab ( n   =   $nmbr$  $nmbr$ ),C0205177;C2718773;C3853793;C3888249
1486,active a,C0205177;C3853793;C3888249
1486,active ( n = $nmbr$ ),C0205177;C3853793;C3888249
1486,active,C0205177;C3853793;C3888249
1485,lda  %,C4553195
1485,hder *,C3898895
1485,eda  %,C0162359;C1539327;C3539920;C3887494
1484,dd ( n = $nmbr$ ),C3538867;C3814791
1484,dd,C3538867;C3814791
1483,cdai §,C0683448;C1413248;C3273706
1483,cdai score §,C0683448;C1413248;C3273706
1483,cdai score < $nmbr$,C0683448;C1413248;C3273706
1483,cdai score  median ( min  max ),C0683448;C1413248;C3273706
1483,cdai score  mean ± sda,C0683448;C1413248;C3273706
1483,cdai score  mean ( s . d . ),C0683448;C1413248;C3273706
1483,cdai score,C0683448;C1413248;C3273706
1483,cdai > $nmbr$  n [ % ],C0683448;C1413248;C3273706
1483,cdai < $nmbr$ t,C0683448;C1413248;C3273706
1483,cdai < $nmbr$ . $nmbr$ *,C0683448;C1413248;C3273706
1483,cdai ( $nmbr$ - $nmbr$ ),C0683448;C1413248;C3273706
1483,cdai,C0683448;C1413248;C3273706
1482,± sd .,C2699239
1482,symptom score ( sd ),C2699239;C3476546
1482,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
1482,sd or %,C2699239
1482,sd of sbp,C0085805;C2699239
1482,sd,C2699239
1482,sbp ( sd )  mm   hg,C0085805;C0439475;C2699239
1482,sbp  mm   hg ( sd ),C0085805;C0439475;C2699239
1482,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
1482,mssbp ± sd  mmhg,C0439475;C2699239
1482,mssbp  mmhg ( sd ),C0439475;C2699239
1482,msdbp ± sd  mmhg,C0439475;C2699239
1482,msdbp  mmhg ( sd ),C0439475;C2699239
1482,mean ucsd - sobq score * ( sd ),C2699239;C3533236
1482,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
1482,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
1482,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
1482,limb ( sd ),C0015385;C2699239
1482,hr  bpm ( sd ),C2699239
1482,dbp ( sd )  mm   hg,C0439475;C0536221;C2699239;C3813197;C4281799
1482,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
1482,blood pressure in mm hg  mean ( sd ),C0428886;C0439475;C0488053;C2699239
1482,blood pressure  mmhg  mean ( sd ),C0428886;C0439475;C2699239
1482,blood pressure  mm hg  mean ( sd ),C0428886;C0439475;C2699239
1482,blood pressure  mean ± sd mm hg,C0428886;C0439475;C2699239
1482,blood pressure  mean ( sd ) [ range ]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
1482,blood pressure  mean ( sd )  mm hg systolic,C0428886;C0439475;C2699239
1482,blood pressure  mean ( sd )  mm hg,C0428886;C0439475;C2699239
1482,[ sd ],C2699239
1482,( sd ),C2699239
1481,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
1481,gene,C0017337
1480,gemfibrozil ( n = $nmbr$,C0017245
1480,gemfibrozil,C0017245
1479,gmr,C1522544;C1704695
1478,serms,C0732611
1478,grs,C1412761;C3539564
1477,> $nmbr$ drinks / wk,C0452428
1477,> $nmbr$ drinks / week,C0452428
1477,> $nmbr$ drinks / dav,C0452428
1477,> $nmbr$ drinks,C0452428
1477,> $nmbr$ ( $nmbr$ ) drinks / day if male ( female ),C0452428
1477,$nmbr$ drinks / wk,C0452428
1477,$nmbr$ drinks,C0452428
1477,$nmbr$ - $nmbr$ drinks / wk,C0452428
1477,$nmbr$ - $nmbr$ drinks / dav,C0452428
1477,$nmbr$ - $nmbr$ drinks,C0452428
1477,$nmbr$ + drinks / wk,C0452428
1476,ref §,C1425988
1476,ref .,C1425988
1476,( ref ),C1425988
1476,$nmbr$ . $nmbr$ ( ref . ),C1425988
1476,$nmbr$ ( ref ),C1425988
1475,serum uric acid  difference vs placebo ( $nmbr$ % cl ),C0455272;C0700634;C1705241;C1705242
1475,sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C1705241;C1705242
1475,sbp  difference,C0085805;C1705241;C1705242
1475,risk difference,C0035647;C1705241;C1705242;C4552904
1475,percentage difference ( $nmbr$ % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
1475,mean arterial pressure  difference,C0428886;C1705241;C1705242
1475,lsms difference ( $nmbr$ % ci ) $nmbr$,C0008107;C1705241;C1705242;C3259781
1475,lsm difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
1475,lsm difference,C1705241;C1705242
1475,ls means difference ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,ls means difference ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,ls mean difference vs placebo ( $nmbr$ % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
1475,ls - mean difference between treatment groups ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1475,ls - mean between - group difference ( $nmbr$ % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
1475,least squares mean between - treatment difference ( $nmbr$ % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
1475,incidence rate difference  linagliptin - placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1708485;C2746078
1475,hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl ),C0019016;C1705241;C1705242;C1825777;C3538758
1475,estimated difference ( $nmbr$ % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
1475,estimated difference %,C0750572;C1705241;C1705242
1475,estimated difference,C0750572;C1705241;C1705242
1475,difference vs placebo * *,C1705241;C1705242
1475,difference vs placebo ( $nmbr$ % ci ),C1705241;C1705242
1475,difference vs placebo ',C1705241;C1705242
1475,difference vs placebo  % [ $nmbr$ % cl ]  p,C1705241;C1705242
1475,difference vs placebo,C1705241;C1705242
1475,difference vs pbo ( $nmbr$ % ci ),C1705241;C1705242
1475,difference vs pbo,C1705241;C1705242
1475,difference vs ff $nmbr$ pg ( $nmbr$ % ci ),C1705241;C1705242
1475,difference vs . placebo  kg ( $nmbr$ % cl ),C1705241;C1705242
1475,difference vs . placebo  % ( $nmbr$ % cl ),C1705241;C1705242
1475,difference vs . placebo,C1705241;C1705242
1475,difference vs . pbof mean ( s . e . ) t,C1705241;C1705242
1475,difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
1475,difference in sbp between treatment,C0085805;C1705241;C1705242
1475,difference in means ( $nmbr$ % cl ),C0596019;C1704970;C1705241;C1705242
1475,difference in means,C1704970;C1705241;C1705242
1475,difference in ls means ( $nmbr$ % ci ) versus placebo,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,difference in ls means ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,difference in ls means ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,difference in ls means ( $nmbr$ % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
1475,difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
1475,difference in ls mean vs placebo ( $nmbr$ % ci )  %,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
1475,difference in ls mean $nmbr$ ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
1475,difference from placeboa,C1705241;C1705242
1475,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
1475,difference from placebo * ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
1475,difference from placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
1475,difference from placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
1475,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
1475,difference from baselinea,C1705241;C1705242
1475,difference ff / vi versus uc  %,C0205999;C1705241;C1705242;C4554348
1475,difference ( tiotropium - placebo ) ml ( $nmbr$ % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
1475,difference ( se ),C0036919;C1705241;C1705242
1475,difference ( a ) vs placebo ( $nmbr$ % cl ),C1705241;C1705242
1475,difference ( % ),C1705241;C1705242
1475,difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
1475,difference ( $nmbr$ % ci ) *,C0008107;C1705241;C1705242;C3259781
1475,difference ( $nmbr$ % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
1475,difference $nmbr$ years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
1475,difference $nmbr$ years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
1475,difference $nmbr$,C1705241;C1705242
1475,difference,C1705241;C1705242
1475,ambulatory sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C0439841;C1705241;C1705242
1475,% difference  $nmbr$ % ci ),C0008107;C1705241;C1705242;C3259781
1475,% - point difference ( $nmbr$ % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
1474,secukinumab pooled †   ( n   = $nmbr$ ),C1709595;C2349200;C3179547;C4522255
1474,secukinumab $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1474,secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1474,secukinumab,C3179547
1474,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
1474,any secukinumab ( n   = $nmbr$ ),C3179547
1473,selexipag vs placebo hazard ratio ( $nmbr$ % cl ),C2000145
1473,selexipag ( n = $nmbr$ ),C2000145
1473,selexipag,C2000145
1472,sex : female,C0086287
1472,sex ( female ),C0086287
1472,sex  female    n   ( % ),C0086287
1472,sex  female  n ( % ),C0086287
1472,sex  female  %,C0086287
1472,sex  female,C0086287
1472,sex  % female,C0086287
1472,number of females n ( % ),C0086287;C0237753;C0449788
1472,male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1472,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1472,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
1472,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
1472,females only,C0086287;C0205171;C1720467
1472,females ( n = $nmbr$ ),C0086287
1472,females ( itt ) ( n = $nmbr$ ),C0086287
1472,females  n ( % ),C0086287
1472,females  > $nmbr$ . $nmbr$,C0086287
1472,females  > $nmbr$,C0086287
1472,females  < $nmbr$ . $nmbr$,C0086287
1472,females  < $nmbr$,C0086287
1472,females  %,C0086287
1472,females,C0086287
1472,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
1472,female subjects ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
1472,female simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
1472,female simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female simva,C0043210;C0086287;C1705497;C1705498
1472,female sex — number ( % ),C0086287;C0237753;C0449788
1472,female sex — no . { % ),C0086287
1472,female sex — no . ( % ) race — no . ( % ) f,C0086287
1472,female sex — no . ( % ),C0086287
1472,female sex — %,C0086287
1472,female sex ( % ),C0086287
1472,female sex  no . / total ( % ),C0086287
1472,female sex  no . ( % ),C0086287
1472,female sex  n ( % ) race  n ( % ),C0034510;C0086287;C1706779;C3853635
1472,female sex  n ( % ),C0086287
1472,female sex  %,C0086287
1472,female sex,C0086287
1472,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
1472,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
1472,female participants who are ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0679646;C1705497;C1705498
1472,female n ( % ),C0043210;C0086287;C1705497;C1705498
1472,female gender n ( % ),C0086287
1472,female gender ( % ),C0086287
1472,female gender,C0086287
1472,female eze / simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
1472,female eze / simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female eze / simva,C0043210;C0086287;C1705497;C1705498
1472,female : ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0439234;C1705497;C1705498
1472,female : premenopausal,C0043210;C0086287;C1705497;C1705498
1472,female : perimenopausal or < $nmbr$ years postmenopausal,C0043210;C0086287;C1705497;C1705498
1472,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
1472,female - n ( % ),C0043210;C0086287;C1705497;C1705498
1472,female ( n — $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female ( n   = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female ( n z $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female ( n = lll $nmbr$ ),C0043210;C0086287;C1261077;C1705497;C1705498
1472,female ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female ( n = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
1472,female ( % ),C0043210;C0086287;C1705497;C1705498
1472,female $nmbr$,C0043210;C0086287;C1705497;C1705498
1472,female  no . ( % ),C0043210;C0086287;C1705497;C1705498
1472,female  no ( % ),C0043210;C0086287;C1705497;C1705498
1472,female  n ( % ) race  n ( % ),C0034510;C0043210;C0086287;C1705497;C1705498;C1706779;C3853635
1472,female  n ( % ),C0043210;C0086287;C1705497;C1705498
1472,female  %,C0043210;C0086287;C1705497;C1705498
1472,female,C0043210;C0086287;C1705497;C1705498
1472,$nmbr$ ( except for female alone ),C0043210;C0086287;C1705497;C1705498
1471,smokers : qva $nmbr$ - $nmbr$ fc,C0337664;C2983605
1471,smokers  no . ( % ),C0337664
1471,smokers  n ( % ),C0337664
1471,smokers  %,C0337664
1471,smokers,C0337664
1471,smoker or ex - smoker  n ( % ),C0337664
1471,smoker ( % ) a,C0337664
1471,smoker ( % ),C0337664
1471,smoker  n ( % ),C0337664
1471,smoker  %,C0337664
1471,smoker  ! n ( % ),C0337664
1471,smoker,C0337664
1471,past smoker  n ( % ),C0337664;C1444637;C4284302
1471,noncurrent smoker,C0337664
1471,ever - smoker,C0337664;C3887636
1470,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex ( women  n [ % ] ),C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
1470,sex ( women  men ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
1470,sex ( p = $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
1470,sex ( interaction : p = $nmbr$ . $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
1470,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  no . ( % ) male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  no  ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  n ( % ) b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  n ( % ) *,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  men / women  %,C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
1470,sex  men ( % ),C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,intercourse satisfac -,C0009253
1470,> $nmbr$ yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1470,> $nmbr$ yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
1469,positive family history of type $nmbr$ diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
1469,family history ol diabetes ?,C1313937
1469,family history of vte,C0241889;C0630906
1469,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
1469,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
1469,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
1469,family history of premature,C0151526;C0205252;C0241889;C4018905
1469,family history of diabetes — no . ( % ),C1313937
1469,family history of diabetes mellitus — no . { % ),C0260526;C1313937
1469,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
1469,family history of diabetes ( - ),C1313937
1469,family history of diabetes ( + ),C1313937
1469,family history of diabetes ( % ) *,C1313937
1469,family history of cancerf,C0241889
1469,family history of cancera,C0241889
1469,family history ^,C0241889
1469,family history  n ( % ),C0241889
1468,smoking history — no . ( % ),C1519384
1468,smoking history : ex - smoker,C0337664;C1519384
1468,smoking history ( ever ),C1519384;C3887636
1468,smoking history    n   ( % ),C1519384
1468,smoking history  r ( % ),C0205090;C0684010;C1519384;C2603358
1468,smoking history  n ( % ),C1519384
1468,smoking history,C1519384
1468,history of smoking,C1519384
1467,stricturing,C1261287
1467,stenosis > $nmbr$ %,C0678234;C1261287;C2632116
1467,percent stenosis [ investigator ],C0035173;C0439165;C0678234;C1261287;C2632116
1467,percent stenosis [ core lab ],C0439165;C0678234;C1261287;C2632116;C4684837
1467,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
1467,ica stenosis $nmbr$ % - $nmbr$ % f,C0016327;C0201519;C0678234;C1261287;C2632116
1467,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
1467,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
1467,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
1467,% stenosis  as assessed by investigator,C0678234;C1261287;C2632116
1467,% stenosis  as assessed by core laboratory,C0678234;C1261287;C2632116
1466,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
1466,fasting triglycerides > $nmbr$ mg / dl *,C0015663;C0041004;C0439269
1466,fasting triglycerides  mg / dl,C0015663;C0041004;C0439269
1466,fasting triglycerides,C0015663;C0041004
1466,fasting tgs §,C0015663;C1156212;C1537574
1466,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
1466,fasting lipids ( mmol / $nmbr$ ),C0015663;C0023779;C0439190
1466,fasting lipid levels  mmol / l,C0015663;C0428460;C1532563
1466,fasting glucose — mg / dl,C0015663;C0017725;C0439269
1466,fasting glucose > $nmbr$ mg / dl *,C0015663;C0017725;C0439269
1466,fasting glucose > $nmbr$ mg / dl  n ( % ),C0015663;C0017725;C0439269
1466,fasting glucose *,C0015663;C0017725
1466,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
1466,fasting glucose  mg / dl ',C0015663;C0017725;C0439269
1466,fasting glucose  mg / dl,C0015663;C0017725;C0439269
1466,fasting glucose,C0015663;C0017725
1466,fasting free fatty acids ( ^ mol / liter ),C0015663
1466,fasting,C0015663
1466,fastest third,C0015663;C0205437;C0456962;C2985769
1466,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
1466,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
1466,faster aspart,C0015663;C0123677;C0456962;C2985769
1465,risk factor for venous thromboembolism  no . ( % ),C1521761;C2827422;C3495424;C3496592
1465,factors that confer a,C1521761;C2827422
1465,factor present,C0150312;C0449450;C1521761;C2827422
1465,factor at baseline,C0168634;C1442488;C1521761;C2827422
1465,factor absent,C1521761;C2827422
1465,factor *,C1521761;C2827422
1465,factor,C1521761;C2827422
1465,baseline factor,C0168634;C1442488;C1521761;C2827422
1464,post - menopausal without hormone replacement,C0019930
1464,post - menopausal with hormone replacement,C0019930
1464,aortic - valve replacement,C0003506
1463,distal forearm,C0588203
1463,diltiazem or verapamil,C0012373
1462,hospitalized without airway compromise,C0701159;C4055482
1462,airway compromise,C4055482
1461,high - school graduate or ged,C0870649;C1549971
1461,high - school graduate,C0870649;C1549971
1460,on step - $nmbr$ drug  %,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
1460,. $nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463
1460,$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
1459,spine *,C0037949;C2752558
1459,spine,C0037949;C2752558
1459,spinal,C0521329
1459,pint,C0560012;C3811619;C3890014;C3890556
1459,pin /,C0175718;C1168556;C1704584
1458,dpp ‐ $nmbr$ inhibitors,C0243077;C1414174
1458,dpp - $nmbr$ inhibitors,C0243077;C1414174
1458,dpp - $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
1458,dpp - $nmbr$ inhibitor,C1414174;C1999216
1458,dpp - $nmbr$,C1414174
1457,nesiritide ( n = $nmbr$ ),C0054015
1457,nesiritide  % z,C0054015
1457,bnp — pg / ml  i,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
1457,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
1457,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0054015;C1095989;C1417808;C2982014
1457,bnp / ntbnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
1457,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
1457,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
1457,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
1457,bnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
1457,bnp  pg / mlt,C0030827;C0054015;C0072225;C1095989;C1266240;C1417808;C2982014;C4553833
1457,bnp  pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
1457,bnp,C0054015;C1095989;C1417808;C2982014
1456,lama +,C0999593;C1416775
1456,lama ( tiotropium )  b   n ( % ),C0213771;C0999593;C1416775
1456,lama,C0999593;C1416775
1456,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
1456,laba / lama,C0999593;C1416775
1455,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
1455,la grade a  n ( % ) f,C0023031;C0023749;C0230347;C2346906;C4553351
1455,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
1455,fpg  mmol / la,C0023031;C0023749;C0230347;C0439190;C2346906;C4553351
1454,stage iii,C0441771
1454,stage ii,C0441767
1454,q wave mi,C0861151
1454,q - wave mi,C0861151
1454,gold stage iii,C0018026;C0441771;C1304897
1454,gold stage ii,C0018026;C0441767;C1304897
1453,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
1453,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
1453,agi,C1299007
1452,sdai < $nmbr$ t,C3871128
1452,sdai < $nmbr$ . $nmbr$ *,C3871128
1452,sdai ( $nmbr$ - $nmbr$ ),C3871128
1452,sdai,C3871128
1451,spain ( n = $nmbr$ ),C0037747
1451,spain,C0037747
1450,saudi arabia,C0036243
1450,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
1449,sama $nmbr$,C1075468
1449,sama  b   n ( % ),C1075468
1449,sama,C1075468
1448,stomach,C0038351;C3714551
1448,source,C0449416;C1705919;C4521696
1448,so $nmbr$ %,C0037640
1448,so,C0037640
1447,snp,C0752046;C1527094
1447,sleep,C0037313
1446,st / t wave,C0036056;C0429103;C3272372
1446,st - t wavett,C0036056;C3272372
1446,st - t waveft,C0036056;C3272372
1446,st - t wave changes,C0036056;C0429103;C3272372
1446,st - t wave abnormality d,C0036056;C1839341;C3272372
1446,st - t wave  no . ( % ),C0036056;C0429103;C3272372
1446,st - t wave  n ( % ),C0036056;C0429103;C3272372
1446,st - t wave,C0036056;C0429103;C3272372
1446,st - $nmbr$ ( ng / ml ),C0036056;C0439275;C3272372
1446,st -,C0036056;C3272372
1446,st +,C0036056;C3272372
1446,st,C0036056;C3272372
1446,> $nmbr$ st and < $nmbr$ nd quartile,C0036056;C3272372
1446,< $nmbr$ st quartile,C0036056;C2828255;C3272372
1446,$nmbr$ st < $nmbr$ . $nmbr$,C0036056;C3272372
1446,$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0036056;C0439284;C3272372
1445,ohs graduate,C0268353;C1861455
1445,hs graduate / ged,C0588053;C1547183;C1880947
1445,college graduate or more,C0682187
1444,• death from any cause,C0007465
1444,death from cardiovascular causes,C0007226;C0007465;C3887460
1444,death from any cause,C0007465
1444,cause of death unknown,C0007465;C4050444
1444,by cause of death,C0007465;C4050444
1443,renal disease ),C0022658
1443,renal disease,C0022658
1443,nephropathy,C0022658
1443,kidney disease ( usrds ),C0022658
1443,established renal disease *,C0022658;C0443211;C1272684
1443,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
1443,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
1442,subgroup analyses,C2986480
1442,subgoup_name,C0027365;C1547383;C4522128
1442,prespecified subgroup analyses,C2986480
1442,additional subgroup analyses,C1524062;C2986480
1441,valproate,C0080356
1441,inappropriate,C1548788;C3537135;C3542467
1441,bisphosphonates,C0012544;C3541401
1440,naproxen,C0027396
1440,ibuprofen,C0020740
1440,fibrous,C0016059;C0439709
1440,fibrates,C1449704;C3540783
1439,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0000545;C0003695;C0085805;C0282379;C0439175;C0439632;C0439810;C0456603;C0536221;C0578022;C1235746;C1547037;C1709380;C1711350;C1882141;C2316832;C2699193;C3813197;C4281799;C4554792
1439,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
1439,sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
1439,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0007787;C0012000;C0033095;C0085805;C0369637;C0441923;C0460139;C0488055;C0536221;C0871420;C0871470;C1306345;C1306620;C2699239;C3813197;C4281799;C4284008
1439,dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799
1439,dbp,C0536221;C3813197;C4281799
1439,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0004083;C0005767;C0005768;C0005823;C0017654;C0018787;C0018810;C0027976;C0033095;C0039155;C0054015;C0085805;C0205088;C0229664;C0237753;C0332126;C0439849;C0449788;C0460139;C0536221;C0596306;C0699792;C1095989;C1271104;C1272641;C1275491;C1305855;C1306345;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3813197;C3889152;C4050156;C4281799;C4283901;C4284008;C4284038
1438,swollen,C0038999
1438,question $nmbr$ ( pain / swelling in joints other than neck / back / hips ),C0003862;C0013604;C0038999;C1522634
1438,number of swollen joints ( $nmbr$ assessed ),C0038999;C0449813
1438,number of swollen joints ( $nmbr$ - $nmbr$ ),C0038999;C0449813
1437,swollen joints > $nmbr$  n ( % ),C0152031
1437,joint swelling  effusion  or both on clinical examination — no . ( % ),C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
1437,joint swelling  effusion  or both on clinical examination,C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
1437,joint swelling,C0152031
1436,sotagliflozin ( n = $nmbr$ ),C3896939
1436,sotagliflozin,C3896939
1436,ertugliflozin,C4079805
1436,dapagliflozin ( n = $nmbr$ ),C2353951
1436,dapagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C2353951
1436,dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
1436,dapagliflozin  n *,C2353951
1436,dapagliflozin,C2353951
1436,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
1436,canagliflozin ( n = $nmbr$ ),C2974540
1436,canagliflozin,C2974540
1435,pooled empagliflozin ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
1435,empagliflozin pooled ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
1435,empagliflozin ( n   =   $nmbr$ ),C3490348
1435,empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C3490348
1435,empagliflozin ( n = $nmbr$ ),C3490348
1435,empagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C3490348
1435,empagliflozin,C3490348
1435,$nmbr$ mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
1434,epilepsy with grand mal seizures on awakening,C0014549;C0494475
1434,emotional well - being,C2984554;C3641833
1433,specific risk of bleeding ^,C0205369;C1552740;C3251812
1433,risk of bleeding,C3251812
1433,any acuity bleeding,C0333276
1432,renal impairment *,C1565489
1432,renal impairment ( crcl < $nmbr$ ml / min ),C0439445;C1565489;C1846718
1432,renal impairment  n ( % ),C1565489
1432,renal impairment,C1565489
1432,renal dysfunction,C1565489;C3279454
1432,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
1432,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
1432,no renal dysfunction,C1565489;C3279454
1432,impaired renal function †,C1565489
1432,impaired renal function §,C1565489
1432,history of impaired renal function  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
1432,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
1431,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
1431,renal subgroup,C0022646;C1079230;C1515021
1431,renal impairmentt,C0022646
1431,renal impairmentf,C0022646
1431,renal functionc  n ( % ),C0022646
1431,renal functionb,C0022646
1431,renal functiona,C0022646
1431,renal events,C0022646;C0441471;C3541888
1431,renal composite *,C0022646;C0205199;C1547335
1431,renal,C0022646
1431,exploratory kidney and microvascular outcomes,C0022646;C0227665
1430,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
1430,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
1430,normoglycemic {,C0580545
1430,normoglycemic ^,C0580545
1430,normoglycemic $nmbr$,C0580545
1430,normoglycemic,C0580545
1430,normoglycemia ^,C0580545
1430,normoglycemia,C0580545
1430,nonsevere hypoglycemia,C0020615;C4553659
1430,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
1430,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
1430,no nonsevere hypoglycemia,C0020615;C4553659
1430,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
1430,hypovolaemia,C0546884
1430,hyponatremia,C0020625;C4553967
1430,hypokalemia,C0020621;C4553966
1430,hypokalaemia,C0020621;C4553966
1430,hypoglycemia ^,C0020615;C4553659
1430,hypoglycemia,C0020615;C4553659
1430,baseline normoglycemia,C0168634;C0580545;C1442488
1430,b nonsevere hypoglycemia,C0020615;C4553659
1430,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
1429,low molecular weight heparin,C0019139;C3536766
1429,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
1429,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766
1429,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
1429,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
1429,low - molecular - weight heparin,C0019139;C3536766
1429,lmwh,C0019139;C3536766
1429,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
1429,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
1428,• any mi,C3810814
1428,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
1428,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
1428,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
1428,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
1428,nonfatal mi ( n = $nmbr$ ),C3810814
1428,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
1428,non - fatal mi,C1302234;C1518422;C1705232;C3810814
1428,nocad / mi,C3810814
1428,no myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
1428,no mi ( n - $nmbr$  $nmbr$ ),C3810814
1428,no mi,C3810814
1428,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
1428,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction within the previous $nmbr$ yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
1428,myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
1428,myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
1428,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction / cabg / pci < $nmbr$ years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
1428,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
1428,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction  n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction  ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
1428,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
1428,mi — no . ( % ),C3810814
1428,mi type unknown ( % ),C0332307;C1547052;C3810814
1428,mi or cad,C3810814
1428,mi > $nmbr$ months *,C0439231;C3810814
1428,mi < $nmbr$ months *,C0439231;C3810814
1428,mi *,C3810814
1428,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
1428,mi  n ( % ),C3810814
1428,mi,C3810814
1428,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
1428,index mi ( n - $nmbr$  $nmbr$ ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
1428,hx mi or stroke,C0262926;C3810814;C3814444
1428,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
1428,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
1428,fatal / nonfatal mi  n ( % ),C1302234;C1705232;C3810814
1428,cv death  myocardial infarction  stroke,C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4552959;C4554100
1428,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
1428,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
1428,cardiovascular death  myocardial infarction  or stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
1428,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
1428,any mi ( n - $nmbr$  $nmbr$ ),C3810814
1428,any mi,C3810814
1427,£ $nmbr$ min,C0702093;C1524029;C3813700
1427,£ $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1427,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1427,time to treatment initiation ( min,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1427,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
1427,time to balloon / needle  min *,C0027551;C0040223;C0336867;C0441144;C0702093;C1524029;C1882041;C3541383;C3813700
1427,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
1427,symptoms onset to first balloon inflation  min,C0021398;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700;C4086878
1427,range : min  max,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1427,range ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1427,range  ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1427,randomization to first balloon inflation  min,C0021398;C0034656;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700
1427,pm pef ( sd )  l / min,C0030266;C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700;C4049155
1427,pifr l / min,C0702093;C1524029;C3813700
1427,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
1427,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
1427,pef at baseline  l_ / min,C0030771;C0168634;C0702093;C1442488;C1518922;C1524029;C1542834;C3813700
1427,p $nmbr$ min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
1427,on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
1427,morning stiffness duration  min,C0449238;C0457086;C0702093;C1524029;C2926735;C3813700
1427,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
1427,min – max,C0702093;C1524029;C3813700
1427,min - ’,C0702093;C1524029;C3813700
1427,min - max age,C0001779;C0702093;C1524029;C3813700
1427,min - max,C0702093;C1524029;C3813700
1427,min  max,C0702093;C1524029;C3813700
1427,mean score ( min  max range ),C0702093;C1514721;C1524029;C2348147;C3533236;C3542016;C3813700
1427,mean duration of surgery ± sd  min,C0038894;C0038895;C0444504;C0449238;C0543467;C0702093;C1274039;C1524029;C2347634;C2348143;C2699239;C2926735;C3813700
1427,iduration of symptoms > $nmbr$ min,C0683368;C0702093;C1457887;C1524029;C3813700
1427,duration of symptoms > $nmbr$ min,C0436359;C0702093;C1524029;C3813700
1427,duration of ra  mean ( min - max ) ( yrs ),C0444504;C0449238;C0702093;C1524029;C2347634;C2348143;C2926735;C3538806;C3813700;C4048756
1427,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
1427,duration of pci  min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
1427,cross - damp time : < l : llhrs : min ( n = $nmbr$ ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
1427,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
1427,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
1427,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
1427,age  mean ( min - max ) ( yrs ),C0001779;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
1427,[ min  max ],C0702093;C1524029;C3813700
1427,> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
1427,> $nmbr$ min,C0702093;C1524029;C3813700
1427,> $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1427,> $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1427,< $nmbr$ min,C0702093;C1524029;C3813700
1427,< $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1427,< $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1427,( min ) *,C0702093;C1524029;C3813700
1427,$nmbr$ min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
1427,$nmbr$ min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
1427,$nmbr$ min,C0702093;C1524029;C3813700
1427,$nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1427,$nmbr$ - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
1427,$nmbr$ - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
1427,$nmbr$ - min walk distance  ft,C0429886;C0702093;C1524029;C1881534;C3813700;C3890579
1427,$nmbr$ - $nmbr$ min,C0702093;C1524029;C3813700
1426,aspirin < $nmbr$ hours,C0004057;C0439227
1426,$nmbr$ - hour postload glucose,C0017725;C0439227;C0564385
1426,$nmbr$ - hour masbp  mm hg,C0439227;C0439475;C0564385
1426,$nmbr$ - hour madbp  mm hg,C0439227;C0439475;C0564385
1426,$nmbr$ - $nmbr$ hours,C0439227
1425,inflotmas io mgluj versus piecew,C1046794;C3146236
1425,$nmbr$ ( io - $nmbr$ % ),C1046794;C3146236
1424,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450
1424,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392
1424,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C1313497;C1538440;C3273279
1424,angina symptoms ^,C0858277
1423,renin - angiotensin - aldosterone system blocker,C0086907
1423,non - biological systemic,C0205373;C0445097
1422,serious teaes,C0205404
1422,serious aes,C0205404;C1412268;C2699274
1422,serious ae,C0205404;C3887670
1422,serious,C0205404
1422,any serious teaes,C0205404
1422,> $nmbr$ serious aes,C0205404;C1412268;C2699274
1421,syncope — no . ( % ),C0039070;C3541349;C4554644
1421,syncope,C0039070;C3541349;C4554644
1420,t - jj ( $nmbr$ - $nmbr$ ),C2603360
1420,t $nmbr$ dm,C0011816;C2603360;C3250443
1420,t $nmbr$ d,C2603360
1420,t,C2603360
1420,other ( $nmbr$ . $nmbr$ % ) t,C2603360
1420,of t $nmbr$ dm ( years ),C0011816;C0439234;C2603360;C3250443
1420,neither t $nmbr$ dm nor mets,C0011816;C2603360;C3250443
1420,$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u,C0439148;C2603360
1420,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t,C2603360
1419,mae,C0286540;C4085238
1419,lv mass,C0455825
1419,base,C0002055;C0178499;C1880279
1418,hands,C0018563;C1552914
1418,hand,C0018563;C1552914
1418,flecainide,C0016229
1418,bumetanide,C0006376
1417,haq score,C0102923;C0451208
1417,haq pain scale  mean,C0102923;C0444504;C0451208;C1504479;C2347634;C2348143
1417,haq,C0102923;C0451208
1416,taci ( n = $nmbr$ ),C0666480;C1425349;C4284230
1416,taci,C0666480;C1425349;C4284230
1415,paci ( n = $nmbr$ ),C1165245
1415,paci,C1165245
1414,laa ostium,C0444567
1414,alaska native,C0682125
1413,laci ( n = $nmbr$ ),C1420705;C3273314;C4281721
1413,laci,C1420705;C3273314;C4281721
1412,tertiary endpoints :,C0205372;C2349179
1412,tertiary end points,C0205372;C2349179
1412,tertiary,C0205372
1411,seropositivity status  n,C0449438;C0521143
1411,seropositivity,C0521143
1410,empty,C1880497
1410,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
1409,streptokinase,C0038418
1409,reteplase,C0256103
1409,nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
1409,no estimate,C0750572
1409,estimate,C0750572
1409,effect estimate,C0750572;C1280500;C1518681;C2348382
1408,lifestyle behaviours,C0004927;C0023676;C0677505
1408,lifestyle behaviors,C0004927;C0023676;C0677505
1408,lifestyle,C0023676
1407,heparin use,C0239945
1407,headache,C0018681;C4553197
1406,pelvic fractures,C0149531
1406,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
1406,hip fracture + > $nmbr$,C0019557;C0149531;C4552776
1406,hip fracture,C0019557;C0149531;C4552776
1405,use of hormone replacement therapy ( a ),C0282402;C1524063
1405,pre - menopausal without hormone replacement,C0206158;C0282402
1405,pre - menopausal with hormone replacement,C0206158;C0282402
1405,oral hypoglycemics hormone replacement,C0282402;C0359086
1405,hrt,C0282402
1405,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
1405,hormone replacement therapy,C0282402
1405,hormone replacement ! !,C0282402
1405,hormone replacement,C0282402
1404,laser or vitrectomy,C0023089;C0458142;C1023865;C1706315
1404,laparoscopic cholecystectomy,C0162522
1404,carotid endarterectomy,C0014099
1404,atherectomy,C0162513
1403,pain in extremity,C0030196;C4553007
1403,aerobic exercise,C0001701
1403,aerobic activity,C0001701
1402,tests for categoric,C0589061
1402,teaes of special interest,C0205555;C0543488
1402,special interest categories,C0205555;C0543488;C0683312
1401,personal relationships,C1552027
1401,perfusion defectsatinclusion,C0031001;C4281794
1400,heterozygous familial hypercholesterolemia †,C0342882
1400,heterozygous familial hypercholesterolemia,C0342882
1399,radiographic characteristics at baseline and randomization,C0444708;C4684572
1399,no baseline characteristics,C4684572
1399,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
1399,disease characteristics *,C0599878
1399,disease characteristics  n ( % )  unless otherwise stated,C0599878
1399,disease characteristics,C0599878
1399,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
1399,baseline characteristics,C4684572
1398,selected clinical characteristics — no . / total no . ( % ),C0683325;C1707391
1398,selected clinical characteristics  n ( % ),C0683325;C1707391
1398,selected clinical characteristics,C0683325;C1707391
1398,other clinical characteristics,C0683325
1398,clinical characteristics ( % ),C0683325
1398,clinical characteristics  n ( % ),C0683325
1398,clinical characteristics,C0683325
1397,question $nmbr$ ( discomfort from any areas tender to touch / pressure ),C0152054;C0205146;C0234234;C0439815;C0702221;C1522634;C2364135;C4319729
1397,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146
1397,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146
1397,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
1397,gastrointestinal area involved  n / total n ( % ),C0017446;C0205146;C0521362
1397,colonic area involved,C0009368;C0017446;C0205146
1397,arterial area ( mm $nmbr$ ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
1397,areas,C0205146;C4319729
1397,area of retinal thickening within the grid  mean ( sd )  dab,C0017446;C0205146;C1302690
1397,area of retinal hemorrhage within the grid  mean ( sd )  dab,C0017446;C0035317;C0205146
1397,area of fluorescein leakage within the grid  mean ( sd )  dab,C0017446;C0205146;C4476700
1397,area,C0017446;C0205146
1397,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
1396,nyha functional class i,C0205245;C0542341;C1882084;C2700217
1396,nyha class i,C1882084
1396,> $nmbr$ : obese class iii,C1319441
1396,$nmbr$ - $nmbr$ . $nmbr$ : obese class ii,C3853263
1396,$nmbr$ - $nmbr$ . $nmbr$ : obese class i,C3853264
1395,alt or ast > $nmbr$ x uln $nmbr$,C1266129;C4553172
1395,alt increased,C1266129;C4553172
1395,alt and / or ast > $nmbr$ times uln consecutive #,C1266129;C4553172
1395,alt ( units / l ),C0439339;C1266129;C4553172
1395,alt  u / l,C0439339;C1266129;C4553172
1394,notes :,C1317574
1394,not severe,C4316743
1393,not available,C0686905
1393,not assessable,C1883425
1392,nausea and / or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1392,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1391,wrist fracture,C0435630;C4553927
1391,tibia fracture,C0040185
1391,thoracic cage fractures,C0222762
1391,skull  and facial bone fractures,C0037303;C2951888
1391,radius fracture,C0034628
1391,patella fracture,C0159849
1391,humerus fracture,C0020162
1391,hand fracture,C0435632
1391,forearm fracture,C1305215
1391,foot fracture,C0272774
1391,fibula fracture,C0149699
1391,femur fracture,C0015802
1391,clavicle fracture,C0159658
1391,ankle fracture,C0159877;C4552974
1390,pre - procedure,C3272300
1390,post - procedure,C3272301
1390,other diagnostic procedure *,C0430022;C1546908
1390,elective procedure,C0747973
1390,duration of procedure,C2346509
1390,dental procedure,C0011331
1390,cardiac procedure :,C1279986
1389,patient - reported outcome measures,C4277735
1389,outcome measure,C0086749
1389,intrathoracic or intraperitoneal surgery,C0595836
1389,chronic respiratory failure,C0264492
1388,prior biologic therapeutic failures  n ( % ),C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
1388,heat failure,C0018837;C0231174;C0680095
1388,failure,C0231174;C0680095
1388,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
1388,> $nmbr$ failure,C0231174;C0680095
1387,therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ ),C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
1387,question $nmbr$ ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
1387,fatigue ( range $nmbr$ - $nmbr$ ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
1387,fatigue,C0015672;C3463815;C4050243;C4554645
1387,facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
1387,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
1386,mercaptopurine,C0000618
1386,azathioprine / $nmbr$ - mercaptopurine,C0000618;C0004482
1386,$nmbr$ - mercaptopurine / azathioprine,C0000618;C0004482
1386,$nmbr$ - mercaptopurine,C0000618
1385,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
1385,glimepiride,C0061323
1384,torsemide,C0076840
1384,oxcarbazepine,C0069751
1384,lamotrigine,C0064636;C0524166
1384,lacosamide,C0893761
1384,chloroquine,C0008269
1384,caffeine,C0006644;C0236734
1383,body weiqht,C0242821;C0460148;C1268086;C4082212
1383,body weighta  kg,C0022718;C0242821;C0439209;C0460148;C1268086;C4054209;C4082212
1383,body height ( cm ),C0005890;C0487985
1382,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
1382,body mass indext,C0518010
1382,body mass indexf  < $nmbr$,C0518010
1382,body mass indexf,C0518010
1382,body mass indexc,C0518010
1382,body mass indexb,C0518010
1382,body mass indexa,C0518010
1382,body mass  kg,C0022718;C0439209;C0518010;C4054209
1382,body - mass indexj,C0518010
1382,body - mass indexf,C0518010
1381,sodium - glucose cotransporter $nmbr$ inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
1381,sodium  meq / l,C0037473;C0439375;C0597484;C3541959;C3714642
1381,sodium,C0037473;C0597484;C3541959;C3714642
1380,severity ofcopd ( gold $nmbr$ )  n ( % ),C0018026;C0439793;C0522510;C1304897
1380,severity of the disease ( gold $nmbr$ )  n ( % ),C0018026;C0521117;C1304897
1380,severity of copd  n ( % ) ( gold $nmbr$ ) : moderate,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
1380,severity of copd  ( gold $nmbr$ )  %,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
1380,gold stage — no . ( % ) * *,C0018026;C1304897
1380,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
1380,gold stage [ n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage ( % ) : c,C0018026;C0441785;C1304897
1380,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage  nf * ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage  n ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage  %,C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
1380,gold ii,C0018026;C1304897;C1710602;C4082587
1380,gold groups a - d using mmrcb,C0018026;C1304897
1380,gold group  n ( % ),C0018026;C0441848;C1304897
1380,gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n,C0018026;C1304897
1380,gold grade $nmbr$ and ics users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
1380,gold grade $nmbr$ and ics non - users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
1380,gold d,C0018026;C1304897
1380,gold c,C0018026;C1304897
1380,gold b,C0018026;C1304897
1380,gold a,C0018026;C1304897
1380,gold $nmbr$ groups  n ( % ),C0018026;C1304897
1380,gold $nmbr$ - $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
1380,gold $nmbr$ - $nmbr$ ( n = $nmbr$ ),C0018026;C1304897
1380,gold $nmbr$ - $nmbr$,C0018026;C1304897
1380,gold $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
1380,gold $nmbr$,C0018026;C1304897
1380,gold  n ( % ),C0018026;C1304897
1379,this study,C0557651;C2603343
1379,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
1379,study druga,C0557651;C2603343
1379,study $nmbr$ . $nmbr$,C0557651;C2603343
1379,study $nmbr$,C0557651;C2603343
1379,study,C0557651;C2603343
1379,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
1379,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
1379,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C2603343
1379,in extension study,C0231448;C0557651;C1880641;C2603343
1379,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
1379,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
1379,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
1379,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
1378,sinus tracts / perforation  ' ^ n ( % ),C0544791;C0549099;C0854572;C1185740;C1881710
1378,number of draining fistulae per patient  n,C0237753;C0449788;C0544791
1378,no draining fistulas *,C0544791
1378,draining fistulae  n ( % ),C0544791
1377,glucosamine + chondroitin sulfate ( n = $nmbr$ ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
1377,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
1377,chondroitin sulfate ( n = $nmbr$ ),C0008466
1377,chondroitin sulfate,C0008466
1376,treatment with open - label perindopril,C0136123;C3640652
1376,perindopril,C0136123
1375,non - fibrin - specific,C0015982;C0205370
1375,fibrin - specilic,C0015982
1375,fibrin - specific,C0015982
1374,periostin low,C0219433;C1424662;C3812270
1374,periostin high,C0219433;C1424662;C3812270
1374,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
1374,periostin,C0219433;C1424662;C3812270
1374,low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205251;C0219433;C0439275;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
1374,high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
1374,biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na,C0005516;C0205251;C0219433;C0439275;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
1374,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
1374,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
1373,tender joint count of $nmbr$ joints,C0451530
1373,tender joint count ( range $nmbr$ - $nmbr$ joints ),C0451530;C1514721;C2348147;C3542016
1373,tender joint count ( n / $nmbr$ ),C0451530
1373,tender joint count ( $nmbr$ joints ),C0451530
1373,tender joint count ( $nmbr$ - $nmbr$ possible joints ),C0240094;C4554549;C4696258
1373,tender joint count ( $nmbr$ - $nmbr$ joints ),C0451530
1373,tender joint count ( $nmbr$ - $nmbr$ ),C0451530
1373,tender joint count ( $nmbr$ - $nmbr$  per tender joint ),C0451530
1373,tender joint count  of $nmbr$,C0451530
1373,tender joint count,C0451530
1373,tender - joint count ( of $nmbr$ joints ),C0451530
1373,tender - joint count  of $nmbr$ joints examined,C0451530
1373,swollen joint count of $nmbr$ joints,C0451521
1373,swollen joint count ( range $nmbr$ - $nmbr$ joints ),C0451521;C1514721;C2348147;C3542016
1373,swollen joint count ( n / $nmbr$ ),C0451521
1373,swollen joint count ( $nmbr$ — $nmbr$  per swollen joint ),C0451521
1373,swollen joint count ( $nmbr$ joints ),C0451521
1373,swollen joint count ( $nmbr$ - $nmbr$ possible joints ),C0332149;C0451521;C1705910;C2362652
1373,swollen joint count ( $nmbr$ - $nmbr$ joints ),C0451521
1373,swollen joint count ( $nmbr$ - $nmbr$ ),C0451521
1373,swollen joint count  of $nmbr$,C0451521
1373,swollen joint count,C0451521
1373,swollen - joint count ( of $nmbr$ joints assessed ) — no .,C0451521
1373,swollen - joint count ( of $nmbr$ joints ),C0451521
1373,swollen - joint count  of $nmbr$ joints examined,C0451521
1372,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
1372,oct center point thickness  pm,C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732
1372,( points ),C1552961;C2347617;C3714763
1372,$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina ),C1552961;C2347617;C3714763
1372,$nmbr$ - point mace,C1552961;C2347617;C3714763
1371,question $nmbr$ ( morning stiffness since arising ),C0457086;C1522634
1371,question $nmbr$ ( length of morning stiffness since arising ),C0457086;C1444754;C1522634;C1706316
1371,indian ( indian subcontinent ),C0454693
1370,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
1370,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
1369,organ system involvement  no . ( % ),C0460002;C1314939
1369,involved gastrointestinal,C0521362;C1314939
1369,dip involvement  ! n ( % ),C1314939;C3539618
1368,pooled trials * n = $nmbr$,C0008976;C1709595;C2349200;C4522255
1368,pooled simva,C1709595;C2349200;C4522255
1368,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
1368,pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C1518422;C1709595;C2349200;C3281223;C4522255
1368,pooled itt,C1709595;C2349200;C4522255
1368,pooled eze / simva,C1709595;C2349200;C4522255
1368,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
1368,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
1368,pooled,C1709595;C2349200;C4522255
1368,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0337051;C0443252;C1509144;C1720467;C2349200
1368,pool of fh i and ii studies,C0337051;C1260386;C1509144;C2349200
1367,glinide 一 no . ( % ),C2266929
1367,glinide,C2266929
1366,lixisenatide ( n = $nmbr$ o ),C2973895
1366,lixisenatide ( n = $nmbr$ ),C2973895
1366,lixisenatide,C2973895
1365,gained bmd,C1517378
1365,chinese subgroup,C0008120;C0152035;C1079230;C1515021
1365,chinese,C0008120;C0152035
1364,stiffness subscale,C0427008
1364,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
1363,passive smoker,C0425309
1363,assigned to topiramate,C1516050;C1552601
1363,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
1362,time point,C2348792
1362,native latin,C0302891
1362,native coronary,C0018787;C0302891
1361,responders of three - item end point at $nmbr$ weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
1361,item,C1551338;C4554251
1360,thienopyridine + dipyridamole,C0012582;C1120149
1360,dipyridamole alone,C0012582
1360,dipyridamole,C0012582
1360,aspirin + dipyridamole ( n = $nmbr$ ),C0732279
1360,aspirin + dipyridamole,C0732279
1359,indian subpopulation,C1257890;C1524069
1359,indian ( american ) or alaskan native,C0596070;C1524069
1359,indian ( american ) or alaska native,C0596070;C1524069
1359,indian,C1524069
1358,timi flow ‡,C3272266
1358,final timi flow,C0205088;C1546485;C3272266;C3853528
1357,fish oil ( n = $nmbr$ ),C0016157
1357,fish oil,C0016157
1356,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
1356,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
1356,fibrinogen,C0016006;C1167394;C2587184;C3540039
1355,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
1355,final a $nmbr$ c ( % ),C0205088;C1546485;C3853528
1355,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
1355,final,C0205088;C1546485;C3853528
1354,italy ( n = $nmbr$ ),C0022277
1354,italy,C0022277
1353,not at goal,C0018017;C1518422;C1571704
1353,goal,C0018017;C1571704
1353,distance to ldl - c goal,C0012751;C0018017;C1571704
1353,at goal,C0018017;C1571704
1353,% to goal,C0018017;C1571704
1352,timi major / minor bleeding,C0019080;C4441842
1352,timi major / minor,C4441842
1352,immunomodulatory agents,C0005525
1352,immunomodulators,C0001551;C0005525;C1527392
1351,immobilization — no . ( % ),C0020944;C4048292
1351,immobilization at randomization  n ( % ),C0020944;C0034656;C4048292
1351,immobilization,C0020944;C4048292
1350,thrombolytic therapy,C0040044
1350,fibrinolytics,C0040044
1350,fibrinolytic therapy — no . ( % ),C0040044
1350,fibrinolytic,C0040044
1349,lymphocytes  $nmbr$ / + il,C0020898;C0021764;C0022271;C0024264;C4018897
1349,israel,C0022271
1349,il - $nmbr$,C0020898;C0021764;C0022271
1349,europe  israel  or australia,C0015176;C0022271
1349,canakinumab  il - $nmbr$ top tertilec,C0020898;C0021764;C0022271;C1704458;C2718773
1349,canakinumab  il - $nmbr$ middle tertile,C0020898;C0021764;C0022271;C0444598;C0549183;C1552826;C2718773
1349,canakinumab  il - $nmbr$ lowest tertile,C0020898;C0021764;C0022271;C1708760;C2718773
1349,canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
1349,canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
1348,cutoffs,C1442160
1347,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
1347,motor weakness,C1513492;C1705994;C3714552
1347,motor,C1513492;C1705994
1346,other / multiple,C0439064
1346,multiple tnfi and other bdmards §,C0439064
1346,multiple tnfi *,C0439064
1346,multiple diagnoses,C0011900;C0439064
1346,multiple ( $nmbr$ + ) chd risk,C0439064;C1282512
1346,multiple,C0439064
1345,hmgcoa rl,C0047420;C1419337;C3539667
1345,chylomicron triglycerides,C0008731;C0041004;C1325761
1345,chylomicron cholesterol,C0008377;C0008731;C1325761
1344,timi minor bleeding,C0019080;C0026193;C0205165
1344,minor bleeding,C0019080;C0026193;C0205165
1344,minor bleed,C0019080;C0026193;C0205165
1344,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
1344,minor,C0026193;C0205165
1343,status ( spmsq > $nmbr$,C0449438
1343,status ( spmsq < $nmbr$,C0449438
1343,smokinq status,C0449438
1343,other glucose status,C0017725;C0449438
1343,lev status  n ( % ),C0023556;C0449438
1343,ish status  n ( % ),C0449438
1343,hormonal status,C0449438;C0458083
1343,h . pylori status  n ( % ),C0079488;C0449438
1343,frailty status,C0424594;C0449438
1343,emotional status,C0013987;C0449438;C0849912
1343,cortteosterom relrsclory status,C0449438
1343,aha status at screeningb  n ( % ),C0050451;C0449438;C0772110
1343,aed inducer status,C0449438;C0887457;C3898767
1342,time from study drug administration to coronary revascularization  median ( iqr )  h,C0013175;C0040227;C0150270;C0206209;C2349982;C3469597
1342,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
1342,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
1342,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
1342,study drug,C0013175
1342,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
1342,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
1342,exposure to study drug — days,C0013175;C0332157;C0439228
1342,duration of study - drug administration — hr,C0013175;C2348354
1341,tobacco user,C3853727
1341,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
1341,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
1341,tobacco use  yes  n ( % ),C0040335;C0543414;C0841002;C1549445;C1705108;C1710701;C3853727
1341,tobacco use  n ( % ),C0040335;C0543414;C0841002;C3853727
1341,tobacco use,C0040335;C0543414;C0841002;C3853727
1341,tobacco abuse,C0040336
1341,prior tobacco use  n ( % ),C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
1341,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
1341,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
1341,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
1341,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
1340,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
1340,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
1340,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
1340,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
1340,mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
1340,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
1340,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
1340,follow - up in - trial at $nmbr$ yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
1340,follow - up,C0589120;C1522577;C1704685;C3274571
1340,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1340,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
1340,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
1340,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
1340,at end of follow - up — no . / total no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1340,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1340,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
1340,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
1340,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
1339,inhaled §,C0004048
1339,inhaled j $nmbr$ - agonist §,C0004048;C2987634
1339,inhaled corticosteroid - yes  n ( % ),C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
1339,inhaled corticosteroid,C0001617;C0004048;C3536709
1339,inhaled ^,C0004048
1339,figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .,C0001617;C0004048;C0016529;C0032042;C0032659;C0040363;C0041260;C0332152;C0740175;C0815320;C1257890;C1306036;C1696465;C1706408;C1883351;C2257086;C3536709;C3669034;C4551720
1339,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0001617;C0004048;C0007450;C0016529;C0018026;C0024115;C0024117;C0034394;C0152277;C0205191;C0205246;C0325090;C0424093;C0521346;C0524517;C0549186;C0585361;C0815320;C0871420;C1304897;C1306036;C1412502;C1443200;C1546767;C1553316;C2348867;C3536709;C3665481;C3714496;C3714541;C3826872;C3826977;C4050461;C4277733;C4284282;C4551720
1338,morning,C0332170
1338,duration of morning,C0332170;C0449238;C2926735
1337,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1337,doxazosin,C0114873
1336,tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
1336,tofacitinib,C2930696
1335,fondaparinux — no . ( % ),C1098510
1335,fondaparinux ( n = $nmbr$ ),C1098510
1335,fondaparinux ( n = $nmbr$  $nmbr$ ),C1098510
1335,fondaparinux,C1098510
1335,commercially available fondaparinux,C0470187;C1098510
1334,normalized womac score,C0449820;C1882115;C4050231
1334,normalized,C1882115
1334,losmapimod ( n = $nmbr$ ),C3272847
1334,losmapimod,C3272847
1333,nontraumatic leg or foot amputation,C0023216;C1140621
1333,lower limbs,C0023216
1333,lower limb fractures,C0023216
1333,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
1333,lower - limb arterial — no . ( % ),C0023216
1332,renal function  normal - mild,C0205307;C0231683;C0232804;C0439166;C2347086;C2945599;C4553972
1332,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
1332,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
1332,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
1332,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
1332,normal responders ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal responder ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
1332,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal hba $nmbr$ c  n = $nmbr$,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
1332,normal fasting glucose level ( n = $nmbr$ ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
1332,normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1739039;C2347086;C3811844;C3812682;C4553972
1332,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
1332,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
1332,normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g ),C0168634;C0205307;C0231683;C0439166;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
1332,normal > $nmbr$ - $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
1332,normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
1332,normal ( ≤   uln ) n   =   $nmbr$,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
1332,normal ( £ $nmbr$ ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
1332,normal ( egfr ≥ $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
1332,normal ( egfr > $nmbr$ ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
1332,normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
1332,normal ( > $nmbr$ ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
1332,normal ( > $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal ( < $nmbr$ . $nmbr$ u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
1332,normal  < $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
1332,normal,C0205307;C0231683;C0439166;C2347086;C4553972
1332,medium normal ( n = $nmbr$ ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
1332,lowest normal ( n = $nmbr$ ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
1332,low normal ( n = $nmbr$ ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
1332,high normal ( n = $nmbr$ ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
1332,crp ( normal < $nmbr$ . $nmbr$ mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
1331,tophi present  n ( % ),C0221248
1331,presence of tophi  n ( % ),C0150312;C0221248;C0392148;C3854307
1331,presence of tophi,C0150312;C0221248;C0392148;C3854307
1331,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
1330,adherence to study regimen — no . ( % ) ff,C1510802
1330,adherence to study regimen — no . ( % ),C1510802
1330,adherence > $nmbr$ %,C1510802
1329,rectum and sigmoid colon only,C0034896
1329,rectum,C0034896
1328,enthesitis score *,C0449820;C1282952;C4050231
1328,enthesitis count,C0750480;C1282952;C1705566
1328,enthesitis  n ( % ),C1282952
1328,enthesitis  % §,C1282952
1328,enthesitis,C1282952
1328,dermatitis atopic,C0011603
1328,cholecystitis chronic,C0008325;C1963083;C4553186
1327,edss stratification . no . ( % ),C0451246;C1514983;C3887783
1327,edss stratification  no . ( % ),C0451246;C1514983;C3887783
1327,edss score,C0451246;C3887783
1326,other diuretic,C0012798
1326,non diuretics,C0012798;C1518422
1326,diuretics ^,C0012798
1326,diuretics * *,C0012798
1326,diuretics ( % ),C0012798
1326,diuretics  n ( % ),C0012798
1326,diuretics  %,C0012798
1326,diuretics,C0012798
1326,diuretic — no . / total no . ( % ),C0012798
1326,diuretic — no . ( % ) surgery,C0012798
1326,diuretic use,C0012798;C0042153;C0457083;C1947944
1326,diuretic n ( % ),C0012798
1326,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
1326,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
1326,diuretic drugs,C0012798;C0013227;C3687832
1326,diuretic agents ( excluding antialdosterone ),C0012798;C0450442;C1254351;C1521826
1326,diuretic agents,C0012798;C0450442;C1254351;C1521826
1326,diuretic agent,C0012798;C0450442;C1254351;C1521826
1326,diuretic ( any ),C0012798
1326,diuretic,C0012798
1325,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
1325,time from qualifying ecg to balloon inflation,C0040223;C1514624;C1623258;C3541383
1325,si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs,C1623258;C4050619
1325,lvh by electrocardiogram  n ( % ),C0013798;C0149721;C1547122;C1623258
1325,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
1325,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
1325,electrocardiography,C0013798;C1623258
1325,electrocardiograph results  no . ( % ),C0013798;C0180600;C1623258
1325,electrocardiogram,C0013798;C1547122;C1623258
1325,ecg left ventricular,C1623258
1325,ecg changes ( % ) t,C1623258
1325,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
1325,ecg and imaging data,C1623258
1325,ecg abnormality ( resting )  %,C1623258;C1704258
1325,ecg,C1623258
1325,due to ecg changes,C1623258
1324,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
1324,ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
1324,high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high titre ( > $nmbr$ times of uln )  n ( % ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high crp or esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
1324,high crp and esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
1324,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( n = $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( i $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
1324,high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ . $nmbr$ u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ )  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( > $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( $nmbr$ - $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high ( $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
1324,fgf - $nmbr$ low / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1324,fgf - $nmbr$ low / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
1324,fgf - $nmbr$ high / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1324,fgf - $nmbr$ high / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
1324,elevated vs normalb,C0205250;C3163633
1324,elevated vs . normalc,C0205250;C3163633
1324,elevated vs . normalb,C0205250;C3163633
1324,elevated troponin — %,C0041199;C0205250;C3163633
1324,elevated troponin ( > $nmbr$ . $nmbr$ pg / l ),C0041199;C0205250;C0439278;C3163633
1324,elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %,C0041199;C0205250;C0439268;C3163633
1324,elevated troponin,C0041199;C0205250;C3163633
1324,elevated tg,C0205250;C0337445;C3163633
1324,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1324,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
1324,elevated hscrp,C0205250;C3163633
1324,elevated fasting glucose,C0205250;C3163633
1324,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C3163633
1324,elevated cardiac markers,C0205250;C1271630;C3163633
1324,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
1324,elevated biomarkers and st - segment changes,C0005516;C0205250;C3163633
1324,elevated at wk $nmbr$ — no . ( % ) $nmbr$,C0205250;C0332174;C0439230;C3163633
1324,elevated at wk $nmbr$ — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
1324,age > $nmbr$ yr  elevated biomarkers  and st - segment changes,C0001779;C0005516;C0205250;C0439234;C3163633
1324,age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular,C0001779;C0005516;C0205250;C0439234;C3163633
1323,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
1323,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
1323,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
1323,total daily insulin dose  units / kgt,C0021641;C0439148;C1519795;C1533581;C1579433;C2348070;C3714501;C3853603
1323,total daily insulin dose  u,C0021641;C0439148;C1533581;C1579433;C2348070;C3714501
1323,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
1323,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
1323,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
1323,placebo + insulin ( n   = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
1323,placebo + insulin ( n = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
1323,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
1323,oad plus insulin,C0021641;C1533581;C1579433;C3714501
1323,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
1323,mean ± sd fasting insulin  uu / ml,C0015663;C0021641;C0439342;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
1323,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
1323,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
1323,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
1323,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
1323,insulin treated,C0021641;C1533581;C1579433;C3714501
1323,insulin therapy  n ( % ) 本,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
1323,insulin therapy  n ( % ),C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
1323,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
1323,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
1323,insulin plus > $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
1323,insulin plus $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
1323,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
1323,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
1323,insulin dependentc,C0021641;C1533581;C1579433;C3714501
1323,insulin based,C0021641;C1533581;C1579433;C3714501
1323,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
1323,insulin alone,C0021641;C1533581;C1579433;C3714501
1323,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
1323,insulin - treated dm,C0021641;C1533581;C1579433;C3714501
1323,insulin - treated diabetes  %,C0021641;C1533581;C1579433;C3714501
1323,insulin - treated diabetes,C0021641;C1533581;C1579433;C3714501
1323,insulin - treated,C0021641;C1533581;C1579433;C3714501
1323,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
1323,insulin - requiring,C0021641;C1533581;C1579433;C3714501
1323,insulin - naive  n ( % ),C0021641;C1533581;C1579433;C3714501
1323,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
1323,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
1323,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
1323,insulin + oad,C0021641;C1533581;C1579433;C3714501
1323,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
1323,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
1323,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
1323,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
1323,insulin ( % ),C0021641;C1533581;C1579433;C3714501
1323,insulin  pmol / l,C0021641;C0439284;C1533581;C1579433;C3714501
1323,insulin  n ( % ),C0021641;C1533581;C1579433;C3714501
1323,insulin,C0021641;C1533581;C1579433;C3714501
1323,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
1323,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
1323,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
1323,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
1323,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
1323,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
1323,fasting insulin  pmol / l ( mean ± sd ),C0015663;C0021641;C0439284;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
1323,fasting insulin  iiiu / ml  mean ± sd,C0015663;C0021641;C0439526;C0444504;C1533581;C1579433;C1705224;C2347634;C2348143;C2699239;C3714501;C3887665
1323,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
1323,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
1323,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
1323,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
1323,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
1323,$nmbr$ - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
1322,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
1322,severe ( ipss > $nmbr$ ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
1322,severe ( ipss > $nmbr$ ) ( n = $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
1322,moderate ( ipss < $nmbr$ ) ( n = $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
1322,mean ipss  voiding subscore ( sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
1322,mean ipss  storage sub - score ( sd ),C0337174;C0542339;C1019118;C1264637;C1698986;C1753314;C1998280;C2699239;C2827405;C3533236;C3811063
1322,ipss voiding subscore,C1019118;C1998280;C2827405;C3811063
1322,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
1322,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
1322,ipss hrql,C1019118;C1998280;C2827405;C3811063
1322,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
1322,ipss - v,C1019118;C1998280;C2827405;C3811063
1322,ipss - s,C1019118;C1998280;C2827405;C3811063
1322,ipss  “ / o,C1019118;C1998280;C2827405;C3811063
1322,ipss,C1019118;C1998280;C2827405;C3811063
1322,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
1322,= international prostate symptom score,C1998280
1321,relative risk comparing icd therapy and placebo,C0021122;C0039798;C0087111;C0242492;C1363945;C1707455
1321,relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0039798;C0087111;C0242492;C0596019;C1363945;C1707455
1321,icd vs . placebo,C0021122
1321,icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0021122;C0039798;C0087111;C1363945
1321,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
1321,icd or crt - d,C0021122
1321,icd / crt - d  n ( % ),C0021122
1321,icd  n ( % ),C0021122
1321,icd  %,C0021122
1321,icd,C0021122
1320,tk,C0041405;C0220928;C4050092
1320,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
1320,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
1320,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
1320,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
1320,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
1320,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
1320,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023823;C0039411;C0040642;C0041004;C0041405;C0041698;C1436327;C1824670;C2744579;C2983605;C2986463;C3272447;C3884535;C3890735;C4048285;C4521369;C4522122;C4552600
1320,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0001645;C0003195;C0003591;C0003594;C0006684;C0008377;C0011849;C0012634;C0017977;C0023821;C0023824;C0039411;C0040642;C0041004;C0041405;C0041698;C0201950;C0202117;C0428473;C0441885;C0543421;C0549183;C0871420;C1319793;C1824670;C2698967;C2757014;C3272447;C3541930;C3715113;C4522122
1320,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
1320,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having,C0023128;C0039411;C0040642;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C3272447;C3642216;C4522122
1319,v total ( n = $nmbr$ ),C0439175;C0439810
1319,total updrs score ( range  $nmbr$ — $nmbr$ ) y,C0439175;C0439810;C3639721
1319,total updrs score ( range  $nmbr$ - $nmbr$ ) 卞,C0439175;C0439810;C3639721
1319,total updrs score ( baseline )  mean ( sd ),C0439175;C0439810;C3639721
1319,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1319,total stent length  mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
1319,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
1319,total sgrq score,C0439175;C0439810
1319,total sample = $nmbr$ ( % ),C0370003;C0439175;C0439810;C2347026
1319,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
1319,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
1319,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
1319,total randomized  n,C0034656;C0439175;C0439810;C3815594
1319,total randomized,C0439175;C0439810
1319,total randomised ( n ),C0439175;C0439810
1319,total phase $nmbr$ pooled ( n = $nmbr$ ),C0205390;C0439175;C0439810;C1710475
1319,total patients n = $nmbr$,C0030705;C0439175;C0439810
1319,total patients  n,C0030705;C0439175;C0439810
1319,total patients,C0030705;C0439175;C0439810
1319,total occlusion  n ( % ),C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
1319,total number of patients,C0439175;C0439810;C2360800
1319,total number of events / participants,C0439175;C0439810;C0679646;C4330837
1319,total no . of patients,C0439175;C0439810
1319,total no . of events / total no . of participants,C0439175;C0439810
1319,total no . of events / participants,C0439175;C0439810
1319,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810
1319,total no . $nmbr$,C0439175;C0439810
1319,total no .,C0439175;C0439810
1319,total n   =   $nmbr$,C0439175;C0439810
1319,total n = $nmbr$ n ( % ),C0439175;C0439810
1319,total n = $nmbr$,C0439175;C0439810
1319,total n $nmbr$,C0439175;C0439810
1319,total n,C0439175;C0439810
1319,total ldl - c *,C0439175;C0439810
1319,total invasive cancer,C0439175;C0439810;C0677898
1319,total included in combined analysis,C0439175;C0439810
1319,total ige — lu / ml,C0439175;C0439810;C2697941
1319,total ige  geometric,C0439175;C0439810
1319,total hipc,C0439175;C0439810
1319,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1319,total haq  $nmbr$ - $nmbr$,C0102923;C0439175;C0439810;C0451208
1319,total hands score,C0018563;C0439175;C0439810;C1552914
1319,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
1319,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C1333400
1319,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C1333400
1319,total deaths  n,C0011065;C0439175;C0439810;C1306577
1319,total deaths,C0011065;C0439175;C0439810;C1306577
1319,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
1319,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
1319,total cohort,C0009247;C0439175;C0439810;C0599755
1319,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
1319,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
1319,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
1319,total c ( mg / dl ) *,C0439175;C0439269;C0439810
1319,total c,C0439175;C0439810
1319,total > atients,C0439175;C0439810
1319,total - c,C0439175;C0439810
1319,total *,C0439175;C0439810
1319,total ( v = $nmbr$  $nmbr$ ),C0439175;C0439810
1319,total ( n   =   $nmbr$ ),C0439175;C0439810
1319,total ( n   = $nmbr$ ),C0439175;C0439810
1319,total ( n [ $nmbr$ ),C0439175;C0439810
1319,total ( n = $nmbr$ ),C0439175;C0439810
1319,total ( n = $nmbr$ $nmbr$ ),C0439175;C0439810
1319,total ( n = $nmbr$  $nmbr$ ) - -,C0439175;C0439810
1319,total ( n = $nmbr$  $nmbr$ ),C0439175;C0439810
1319,total ( n ),C0439175;C0439810
1319,total ( n $nmbr$ $nmbr$ ),C0439175;C0439810
1319,total $nmbr$,C0439175;C0439810
1319,total !,C0439175;C0439810
1319,total  n = $nmbr$ $nmbr$,C0439175;C0439810
1319,total  n = $nmbr$,C0439175;C0439810
1319,total,C0439175;C0439810
1319,sgrq - c total scoreb,C0439175;C0439810;C3826872
1319,o total randomized,C0439175;C0439810;C0483204
1319,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
1319,no . / total no . ( % ) t,C0439175;C0439810
1319,no . / total no . ( % ),C0439175;C0439810
1319,no . / total 	 no . ( % ),C0439175;C0439810
1319,no . / total,C0439175;C0439810
1319,men  total ( n 二 $nmbr$ ),C0025266;C0439175;C0439810
1319,men  total ( n = $nmbr$ ),C0025266;C0439175;C0439810
1319,linagliptin  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C2746078;C3541888
1319,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
1319,hf  total,C0018488;C0439175;C0439810;C1313497;C1538440;C3273279
1319,event / total,C0439175;C0439810;C0441471;C4019010
1319,duration of total exposure to study treatment  weeks,C0439175;C0439810;C2826870
1319,cvd  total,C0007222;C0439175;C0439810
1319,chd  total,C0280604;C0439175;C0439810;C3542407
1319,asian itt population total ( n = $nmbr$ ),C0032659;C0078988;C0439175;C0439810;C1257890
1319,$nmbr$ — no . / total no . ( % ),C0439175;C0439810
1319,$nmbr$ - $nmbr$ — no . / total no . ( % ),C0439175;C0439810
1319,$nmbr$  no . / total no . ( % ),C0439175;C0439810
1318,tpm subgroup  n = $nmbr$,C0076829;C1079230;C1515021
1318,subgroups,C1079230
1318,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
1318,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
1318,subgroup p valuef,C1079230;C1515021
1318,subgroup p value 本,C1079230;C1515021;C1709380
1318,subgroup p value !,C1079230;C1515021;C1709380
1318,subgroup p - value $nmbr$,C1079230;C1515021;C1709380
1318,subgroup overall,C0282416;C1079230;C1515021;C1561607
1318,subgroup no .,C1079230;C1515021
1318,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
1318,subgroup levels,C0441889;C1079230;C1515021
1318,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
1318,subgroup based on :,C1079230;C1515021
1318,subgroup $nmbr$,C1079230;C1515021
1318,subgroup,C1079230;C1515021
1318,secondary prevention subgroup,C0679699;C1079230;C1515021
1318,primary prevention subgroup,C0033144;C1079230;C1515021
1318,prespecified subgroups,C1079230
1318,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
1318,p  subgroup *,C0369773;C1079230;C1515021;C2603361
1318,outcome_subgroup,C1079230;C1274040;C1515021
1318,m $nmbr$ subgroup,C0369637;C0441923;C1079230;C1515021
1318,ltg subgroup  n = $nmbr$,C1079230;C1420817;C1515021;C4521367;C4521846
1318,genetic subgroup,C0017296;C0314603;C1079230;C1515021
1318,diuretic subgroup,C0012798;C1079230;C1515021
1318,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
1318,baseline subgroup,C0168634;C1079230;C1442488;C1515021
1318,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
1318,baseline hba $nmbr$ c subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
1318,asubset of the ≥ $nmbr$ years subgroup .,C0439234;C1079230;C1515021
1318,( subgroup ),C1079230;C1515021
1318,( a ) bmi subgroups,C0578022;C1079230
1317,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
1317,cough ( leading to study drug discontinuation ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1317,cough ( investigator reported ),C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727
1317,cough  n ( % ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1317,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1317,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
1316,ill -,C0231218
1316,alleles,C0002085
1316,all mis *,C0687670;C1333208;C1412384;C3538735
1316,all mis,C0687670;C1333208;C1412384;C3538735
1315,quality of life,C0034380;C0518214
1315,qol,C0518214
1314,total body ( without head ),C0018670;C0229960;C1706305
1314,total body,C0229960
1314,total bilirubin > $nmbr$ x uln $nmbr$,C0005437;C0368753;C1519815
1314,total bilirubin  mg / dl,C0005437;C0368753;C0439269
1313,olodaterol sgg,C2934193
1313,olodaterol $nmbr$ pg,C0030827;C0072225;C1266240;C2934193
1313,olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
1313,olodaterol $nmbr$ jig,C2934193
1313,olodaterol,C2934193
1313,h pylori serology *,C0036745;C0079488;C0220911;C0455278
1312,trandolapril ( n = $nmbr$ ),C0076891
1312,trandolapril,C0076891
1312,tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1312,tadalafil $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1312,tadalafil,C1176316
1311,hispanic american,C0019576
1311,hispanic / latin american,C0019576
1311,black / african,C0337824
1310,question $nmbr$ ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
1310,neck pain,C0007859;C1963180;C4553909
1310,back pain,C0004604;C1963071;C4553945
1309,statin + er niacin ( n = $nmbr$ ),C0027996;C0360714;C1142562;C3810541;C3811131
1309,niacin ( n = $nmbr$ ),C0027996;C1142562
1309,niacin  n ( % ),C0027996;C1142562
1309,niacin,C0027996;C1142562
1308,vertebrobasilar infarct,C0021308;C0545733
1308,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
1308,q waves in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
1308,q wave in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
1308,prior infarction,C0021308;C0332152;C2826257
1308,nonfatal myocardiail infarction,C0021308
1308,nonfatai myocardiai infarction,C0021308
1308,no infarct visible,C0021308
1308,myocardiai infarction,C0021308
1308,infarction before age $nmbr$ ( a ),C0001779;C0021308
1308,infarction > $nmbr$ days previously,C0021308;C0439228
1308,infarction $nmbr$ - $nmbr$ days,C0021308;C0439228
1308,infarct territory ( % ),C0021308;C1301808;C2983136
1308,infarct size,C0021308;C0456389
1308,infarct ion w ithin previous $nmbr$ day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
1308,infarct - related vessel ( % ),C0021308
1308,carotid infarct,C0021308;C0741968
1308,cardioembolic infarction  n ( % ),C0021308
1308,atherothrombotic infarction  n ( % ),C0021308
1308,any infarct,C0021308
1307,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
1307,transient ischemic attack,C0007787;C0917805
1307,transient ischaemic attack — no . ( % ),C0007787;C0917805
1307,transient ischaemic attack,C0007787;C0917805
1307,tia  n ( % ),C0007787;C0917805;C1054154
1307,tia,C0007787;C0917805;C1054154
1307,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
1307,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
1307,hemispheric tia n = $nmbr$,C0007787;C0205139;C0917805;C1054154
1306,coronary bypass graft,C1260596
1306,coronar y - artery bypass grafting,C0450140;C0741847
1306,arterial graft,C0450140
1305,north america plus australia and new zealand,C0004340;C0028405;C0332287
1305,north america n z $nmbr$,C0028405
1305,north america hr ( $nmbr$ % cl ),C0028405;C0596019
1305,north america / oceania,C0028405;C0282279;C4085681
1305,north america *,C0028405
1305,north america ( plus australia and new zealand ),C0004340;C0028405;C0332287
1305,north america ( plus america and new zealand ),C0028405;C0332287
1305,north america ( n = $nmbr$ ),C0028405
1305,north america ( % ),C0028405
1305,north america,C0028405
1304,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
1304,other forms of atherosclerosis ^,C0003850;C0004153;C0348078;C0376315
1304,other forms of,C0348078;C0376315
1304,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
1303,short term ^,C0443303
1303,short term ( n = $nmbr$ ) +,C0443303
1302,orthopnea  ( % ),C0085619
1302,orthopnea,C0085619
1301,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4521986
1301,oral β - adrenergics  n ( % ),C0001637;C0442027;C4521986
1301,oral treprostinil ( n = $nmbr$ ),C0442027;C1145760;C4521986
1301,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
1301,oral or other systemic corticosteroid,C0442027;C4521986
1301,oral fi - blockers,C0442027;C4050619;C4521986
1301,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
1301,oral antidiabetes combination therapy without insulina  n ( % ),C0009429;C0442027;C0556895;C4521986
1301,oral ( % ),C0442027;C4521986
1301,oral,C0442027;C4521986
1301,no po,C0032729;C0442027
1300,previous coronary artery bypass surgery  no . ( % ),C2144990
1300,previous coronary artery bypass grafting,C2144990
1300,previous coronary artery bypass graft,C2144990
1300,previous coronary angioplasty  n ( % ),C2114427
1300,previous coronary - artery bypass grafting,C2144990
1300,native coronary - artery lesions,C0205042;C0221198;C0302891
1300,coronary artery treated  no . ( % ),C0205042
1300,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
1300,coronary artery,C0205042
1299,nice secondary prevention onlyb,C0679699;C4087029
1299,nice primary prevention onlyb,C0033144;C4087029
1299,coronary events $nmbr$,C0741923
1299,acute coronary event,C0205178;C0741923
1298,single vessel coronary artery disease †,C0581374
1298,single vessel coronary artery disease *,C0581374
1298,single vessel coronary artery disease $nmbr$,C0581374
1298,no . of coronary vessels with > $nmbr$ % diameter stenosis,C0010075
1298,multi - vessel coronary artery disease,C1299432
1298,left main coronary artery bifurcation,C3898614
1298,ischemic coronary artery disease,C0852149
1298,history of coronary artery disease — no . { % ),C1881055
1298,history of coronary artery disease - n ( % ),C1881055
1298,history of coronary artery disease,C1881055
1298,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
1298,coronary artery stenosis > $nmbr$ %,C0242231
1298,coronar y artery disease,C0852949
1298,coronaiy artery disease,C0852949
1298,> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0242231;C0741968
1298,> $nmbr$ % coronary stenosis,C0242231
1297,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
1297,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
1297,previous coronary artery disease  n ( % ),C0010054;C0010068;C0205156;C1552607;C1956346
1297,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
1297,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
1297,multivessel coronary artery disease,C0010054;C0010068;C1956346
1297,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
1297,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
1297,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
1297,coronary heart disease ( % ),C0010054;C0010068;C1956346
1297,coronary heart disease  n ( % ) t,C0010054;C0010068;C1956346
1297,coronary heart disease  n ( % ) b,C0010054;C0010068;C1956346
1297,coronary heart disease,C0010054;C0010068;C1956346
1297,coronary disease,C0010068;C1956346
1297,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
1297,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
1297,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
1297,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
1297,coronary artery disease — %,C0010054;C0010068;C1956346
1297,coronary artery disease §,C0010054;C0010068;C1956346
1297,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
1297,coronary artery disease ^,C0010054;C0010068;C1956346
1297,coronary artery disease *,C0010054;C0010068;C1956346
1297,coronary artery disease ( n = $nmbr$ $nmbr$ ),C0010054;C0010068;C1956346
1297,coronary artery disease ( % ),C0010054;C0010068;C1956346
1297,coronary artery disease    n   ( % ),C0010054;C0010068;C1956346
1297,coronary artery disease  n ( % ),C0010054;C0010068;C1956346
1297,coronary artery disease  %,C0010054;C0010068;C1956346
1297,coronary artery disease,C0010054;C0010068;C1956346
1297,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
1297,any coronary artery disease,C0010054;C0010068;C1956346
1296,sle markers  n ( % ),C0005516;C0024141
1296,risk marker and model,C1519104
1296,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1296,cardiac biomarker  n ( % ),C1271630
1296,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1296,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1296,biomarker status,C0449442
1296,biomarker low,C0005516
1296,biomarker levels,C0005516;C0441889
1296,biomarker high,C0005516
1295,micral test result,C0456984;C0587081
1295,laboratory findings,C0587081
1294,prior llt,C0332152;C2347090;C2826257
1294,no prior llt,C0332152;C2347090;C2826257
1294,allhat - llt,C2347090
1293,transient st elevation,C0040704;C0205374;C0520886
1293,transient,C0040704;C0205374
1293,temporary risk factor,C0035648;C0205374;C1548539;C3245481
1293,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
1293,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
1293,associated with transient or reversible risk factor,C0040704;C0205374;C0332281
1292,severe oa symptoms at baselined,C0029408;C0436345;C3887876
1292,osteoarthritis,C0029408
1292,oa,C0029408;C3887876
1292,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
1292,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
1291,oma / oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
1291,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
1291,oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
1291,oat,C0028753;C0331496;C0939905;C3539067;C3897364
1290,trough fev $nmbr$,C0444506;C3714541
1290,screening % predicted fev $nmbr$,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
1290,prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
1290,pre fvc % pred,C0332152;C0740175;C2257086;C3669034;C3714541
1290,pre fev $nmbr$   % pred,C0332152;C0740175;C2257086;C3669034;C3714541
1290,pre - bronchodilator mean ( sd ) fev $nmbr$  . l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,pre - bronchodilator fev  % predicted,C2599602;C3714541
1290,pre - bronchodilation fvc,C0439566;C3714541
1290,pre - bronchodilation fev $nmbr$,C0439566;C3714541
1290,pre - bd fvc s $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
1290,pre - bd fvc < $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
1290,post fvc % pred,C0687676;C1704687;C3469826;C3714541
1290,post fvc,C0687676;C1704687;C3469826;C3714541
1290,post fev $nmbr$   % pred,C0687676;C1704687;C3469826;C3714541
1290,post fev $nmbr$,C0687676;C1704687;C3469826;C3714541
1290,post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd ),C0444504;C0456603;C1547037;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$  l  mean ( sd ) c,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1290,post - bronchodilation fvc,C0439576;C3714541
1290,post - bronchodilation fev $nmbr$,C0439576;C3714541
1290,percent of predicted fev $nmbr$,C1882327;C3714541
1290,mild ( fev  > $nmbr$ % predicted ),C2945599;C3714541
1290,mean prebronchodilator fev $nmbr$ ( sd )  % predicted,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,mean postbronchodilatora fev $nmbr$  % predicted ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1290,mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1290,mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,mean ( sd ) postbronchodilator fev $nmbr$ % predicted,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
1290,mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted,C0439165;C0444504;C1549488;C1561533;C2347634;C2348143;C2599594;C2699239;C3714541
1290,mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1290,iv : fev $nmbr$ < $nmbr$ % predicted,C0022326;C3714541;C4265176
1290,fvc ∗,C3714541
1290,fvc — liters,C0475211;C3714541
1290,fvc pre - bronchodilator,C2599602;C3714541
1290,fvc post - bronchodilator,C3714541
1290,fvc > $nmbr$ % predicted,C3714541
1290,fvc < $nmbr$ % predicted,C3714541
1290,fvc ( liters ),C0475211;C3714541
1290,fvc ( l ) *,C3714541
1290,fvc ( l ),C3714541
1290,fvc ( % predicted ),C3714541
1290,fvc % predicted !  t,C3714541
1290,fvc  ml,C0439526;C1705224;C3714541;C3887665
1290,fvc  l,C3714541
1290,fvc  % predicted  mean ( sd ),C3714541
1290,fvc  % predicted,C3714541
1290,fvc,C3714541
1290,fev_ ( l ) :,C3714541
1290,fev auc i $nmbr$ h,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
1290,fev $nmbr$ — liters,C0475211;C3714541
1290,fev $nmbr$ prebronchodilator [ l ]  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd,C0219433;C0444504;C1549735;C2347634;C2348143;C2599602;C2699239;C3541307;C3714541;C4049640;C4049767
1290,fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d,C2599602;C3714541
1290,fev $nmbr$ pre - bronchodilator,C2599602;C3714541
1290,fev $nmbr$ post - bronchodilator  % predicted normal,C3714541
1290,fev $nmbr$ post - bronchodilator,C3714541
1290,fev $nmbr$ percent predicted ( sd ),C0439165;C3714541
1290,fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0376690;C3714541
1290,fev $nmbr$ / fvc prebronchodilatort,C3714541
1290,fev $nmbr$ / fvc prebronchodilator  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1290,fev $nmbr$ / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
1290,fev $nmbr$ / fvc ( post - albuterol ),C3714541
1290,fev $nmbr$ / fvc %,C3714541
1290,fev $nmbr$ / fvc  post - albuterol  %,C3714541
1290,fev $nmbr$ / fvc  % a,C3714541
1290,fev $nmbr$ / fvc  % *,C3714541
1290,fev $nmbr$ / fvc,C3714541
1290,fev $nmbr$ ( post - albuterol )  l,C0001927;C0687676;C1704687;C3469826;C3714541
1290,fev $nmbr$ ( liters ),C0475211;C3714541
1290,fev $nmbr$ ( l ) pre - bronchodilator,C2599602;C3714541
1290,fev $nmbr$ ( l ),C3714541
1290,fev $nmbr$ ( % predicted normal ),C3714541
1290,fev $nmbr$ ( % predicted ),C3714541
1290,fev $nmbr$ % predicted ≥ $nmbr$ %,C3714541
1290,fev $nmbr$ % predicted normal,C3714541
1290,fev $nmbr$ % predicted at baseline,C3714541
1290,fev $nmbr$ % predicted < $nmbr$ %,C3714541
1290,fev $nmbr$ % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
1290,fev $nmbr$ % predicted ( post salbutamol ),C3714541
1290,fev $nmbr$ % predicted  post - albuterol  %,C3714541
1290,fev $nmbr$ % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1290,fev $nmbr$ % predicted,C3714541
1290,fev $nmbr$ % pred . ( post - albuterol )  %,C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
1290,fev $nmbr$ % pred,C3714541
1290,fev $nmbr$  post - albuterol  l,C0001927;C0687676;C1704687;C3469826;C3714541
1290,fev $nmbr$  mean  l,C0444504;C2347634;C2348143;C3714541
1290,fev $nmbr$  mean  % predicted,C0444504;C2347634;C2348143;C3714541
1290,fev $nmbr$  la,C0023031;C0023749;C0230347;C2346906;C3714541;C4553351
1290,fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
1290,fev $nmbr$  l *,C3714541
1290,fev $nmbr$  l,C3714541
1290,fev $nmbr$  % predicteda,C3714541
1290,fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
1290,fev $nmbr$  % predicted,C3714541
1290,fev $nmbr$,C3714541
1290,fev  > $nmbr$ % predicted,C3714541
1290,fev  < $nmbr$ % predicted,C3714541
1290,fev  % predicted,C3714541
1290,fev,C3714541
1290,c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
1290,baseline pre - bronchodilator fev $nmbr$  l,C0168634;C1442488;C2599602;C3714541
1290,absolute decline in fvc > $nmbr$ % predicted or death  n ( % ),C0205344;C3714541
1290,absolute decline in fvc > $nmbr$ % predicted,C0205344;C3714541
1290,% predicted fev ^,C0681842;C1882327;C3714541
1290,% predicted fev $nmbr$,C0681842;C1882327;C3714541
1290,% predicted fev,C0681842;C1882327;C3714541
1290,$nmbr$ ( fev $nmbr$ < $nmbr$ % pred ),C3714541
1289,fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412
1289,fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412
1289,fp ( n   = $nmbr$  $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1289,fp ( n [ $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1289,fp ( n = $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
1289,fp,C0016704;C1419068;C1419906;C3541238;C3541412
1288,flex aln ^,C0729594;C2681220
1288,fg > $nmbr$,C0016703;C0439214;C2348814
1287,lei > $nmbr$ ( n = $nmbr$ ),C0023401;C0428209
1287,lei $nmbr$,C0023401;C0428209
1286,ldl - cz,C0206578
1286,ez / simva n = $nmbr$ n ( % ),C0206578
1286,ez / simva < % >,C0206578
1286,ez / simva $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1286,ez / simva $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
1286,ez / simva,C0206578
1286,czech republic,C0206578
1286,all ez / simva,C0206578
1286,a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$,C0206578
1286,a $nmbr$ + ez n = $nmbr$,C0206578
1286,a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0206578
1286,a $nmbr$ + ez $nmbr$,C0206578
1285,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
1285,grip strength < meidan,C0429271;C2598165
1285,alt  ast  or both > $nmbr$ x uln,C3831581
1284,£ $nmbr$ m b ' m in,C1709500
1284,bloodpressure  mean ( sd )  m m hg,C0025424;C0428257;C0428886;C1709500;C2347108;C2347109;C2348272;C2699239
1283,st segment depression,C0520887
1283,st depression or elevation,C0520887
1283,st depression > $nmbr$ mm,C0520887;C4330985;C4554674
1283,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
1283,st - segment depression or t - wave inversion on ecg,C0520887
1283,st - segment depression > $nmbr$ mm — no . ( % ),C0520887;C4330985;C4554674
1283,st - segment depression > $nmbr$ mm,C0520887;C4330985;C4554674
1283,st - segment depression,C0520887
1283,st - depression and t - wave inversion,C0520887
1283,no st depression or elevation,C0520887
1282,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
1282,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
1282,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
1282,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
1282,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
1282,met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ ),C0392707;C0428210;C1550543;C3539705;C4317104
1282,met / tzd,C0428210;C1550543;C4317104
1282,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
1282,met ( n = $nmbr$ ),C0428210;C1550543;C4317104
1282,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
1282,add - on to met + su $nmbr$,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1282,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1282,add - on to met $nmbr$,C0428210;C1550543;C1883712;C4317104
1282,add - on to met,C0428210;C1550543;C1883712;C4317104
1281,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
1281,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
1281,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
1281,sitting systolic blood pressure ( mm hg ),C0277814;C2584297;C4050224
1281,sitting pulse  bpma,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
1281,seated sbp at $nmbr$ weeks  mmhg + * *,C0085805;C0277814;C0439230;C0439475;C1283233
1281,seated sbp at $nmbr$ weeks  mmhg +,C0085805;C0277814;C0439230;C0439475;C1283233
1281,seated sbp  n,C0085805;C0277814;C1283233
1281,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
1281,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
1281,baseline sitting sbp  $nmbr$ mm hg,C0085805;C0168634;C0277814;C0439475;C1442488;C2584297;C4050224
1281,baseline sitting dbp  * mm hg,C0168634;C0277814;C0439475;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
1280,tj ( $nmbr$ - $nmbr$ ),C0039247
1280,tj ( $nmbr$ % ),C0039247
1280,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
1280,- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti,C0039247;C0040302;C1553045;C1704756
1279,tt,C1452561;C4554543
1279,tgt,C1421391;C1428265;C4321338
1279,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
1279,gt,C1435727;C1704693;C2697657
1278,ze + statin,C0360714
1278,statins 一 no . ( % ),C0360714
1278,statins used during follow - up,C0360714
1278,statins / ezetimibe,C0360714;C1142985
1278,statins  no . ( % ),C0360714
1278,statins  n ( % ),C0360714
1278,statins,C0360714
1278,statin — no . / total no . ( % ),C0360714
1278,statin without other llt,C0360714;C2347090
1278,statin with other llt,C0360714;C2347090
1278,statin with niacin,C0027996;C0360714;C1142562
1278,statin with fibrate,C0360714
1278,statin with ezetimibe,C0360714;C1142985
1278,statin use — no . { % ),C0360714
1278,statin use at study entry  n ( % ),C0360714;C0869040;C1705654
1278,statin use ( % ),C0042153;C0360714;C0457083;C1947944
1278,statin use  n ( % ),C0042153;C0360714;C0457083;C1947944
1278,statin use,C0042153;C0360714;C0457083;C1947944
1278,statin usage,C0360714;C0457083
1278,statin potency stratum  n ( % ),C0360714;C3245505
1278,statin potency medium ( n = $nmbr$ ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
1278,statin or ezetimibe,C0360714
1278,statin only ( n = $nmbr$  $nmbr$ ),C0205171;C0360714;C1720467
1278,statin only  n ( % ),C0205171;C0360714;C1720467
1278,statin only,C0205171;C0360714;C1720467
1278,statin monotherapy,C0360714
1278,statin medication,C0013227;C0360714;C3244316;C4284232
1278,statin intolerant *,C0231200;C0360714
1278,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
1278,statin intensity $nmbr$ * $nmbr$,C0360714;C0522510
1278,statin and / or other lipid - lowering agent therapy,C0360714
1278,statin and / or ezetimibe,C0360714
1278,statin alone,C0360714
1278,statin + fibrate or niacin,C0360714
1278,statin + fibrate or,C0360714
1278,statin + ezetimibe { n = $nmbr$  $nmbr$ ),C0360714;C1142985
1278,statin + ezetimibe ( n = $nmbr$ . $nmbr$ ),C0360714;C1142985
1278,statin + ezetimibe  n ( % ),C0360714;C1142985
1278,statin + ezetimibe,C0360714;C1142985
1278,statin ( s ),C0360714
1278,statin ( open ),C0360714
1278,statin ( n = $nmbr$ ),C0360714
1278,statin ( n - $nmbr$ ),C0360714
1278,statin ( % ),C0360714
1278,statin  n ( % ),C0360714
1278,statin  % ( n ),C0360714
1278,statin,C0360714
1278,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1947944;C2945760
1278,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
1278,pbo + statin n = $nmbr$,C0031962;C0360714
1278,pbo + statin $nmbr$,C0031962;C0360714
1278,pbo + statin,C0031962;C0360714
1278,other statin,C0360714
1278,no statin vs statin alone vs any statin plus other llt,C0360714
1278,no statin use,C0042153;C0360714;C0457083;C1947944
1278,no statin ( + / - llt ),C0360714;C2347090
1278,no statin,C0360714
1278,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
1278,niacin + statin,C0027996;C0360714;C1142562
1278,neither pbo + statin eze + statin,C0031962;C0360714
1278,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
1278,moderate - intensity statin,C0360714;C4081855
1278,moderate - dose statin,C0360714;C1709056
1278,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
1278,ltt other than statin,C0360714
1278,llv wlalil $nmbr$ statin,C0360714
1278,llt other than statin at randomization,C0360714;C2347090
1278,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1278,high - dose statin use  n ( % ) e,C0042153;C0360714;C0444956;C0457083;C1947944
1278,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
1278,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
1278,eze + statin n = $nmbr$,C0360714
1278,eze + statin,C0360714
1278,extended - release niacin plus statin ( n = $nmbr$ ),C0027996;C0332287;C0360714;C1142562;C1707968
1278,combined statin and other lipid - lowering agent use,C0205195;C0360714
1278,baseline statin usec,C0168634;C0360714;C0439224;C1442488
1278,baseline statin,C0168634;C0360714;C1442488
1278,baseiine statin,C0360714
1278,any statin versus no statin at randomization,C0360714
1278,any statin + other llt,C0360714
1278,any statin ( with / without llt ),C0360714
1278,any statin,C0360714
1278,any llt other than statins  n ( % ) b,C0360714;C2347090
1278,all patients on maximally tolerated statin ± other llt,C0030705;C0360714
1277,total comparators ( n = $nmbr$ ),C0439175;C0439810;C1707454;C4553389;C4553390
1277,favors comparator,C0309049;C1707454;C4553389;C4553390
1277,comparator,C1707454;C4553389;C4553390
1276,pairwise comparison,C1707455
1276,comparison,C1707455
1276,a compared wi,C0043193;C1520135;C1707455
1276,a compared w,C1707455
1275,poor compliance / noncompliance,C0032646;C0376405;C0457432
1275,noncompliant,C0457432
1275,non - compliance,C0376405;C0457432
1274,loop or thiazide diuretic ^,C0445022
1274,loop or thiazide diuretic : ! :,C0445022
1274,loop or thiazide diuretic #,C0445022
1274,loop or thiazide diuretic,C0445022
1274,loop diureties,C0445022
1274,loop,C0445022
1273,myopathy,C0026848
1273,lymphadenopathy,C0497156;C4282165
1272,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
1272,non - ischaemic cardiomyopathy,C0349782;C1518422
1272,ischemic cardiomyopathy,C0349782
1272,ischaemic dilated cardiomyopathy,C1960867
1272,ischaemic cardiomyopathy,C0349782
1272,hypertrophic cardiomyopathy,C0007194;C4551472
1272,dilated cardiomyopathy,C0007193;C2984282
1271,two - dimensional echocardiography,C0013524
1271,radionuclide ventriculography,C0017200;C0034610
1271,normal coronary angiography,C0853522
1271,duplex ultrasonography,C3825392
1271,computed tomographic angiography,C1536105
1270,univariate p - value,C1709380
1270,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
1270,rr ( $nmbr$ aci ) [ p value ],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
1270,p — value for interaction,C1704675;C1709380
1270,p ‐ value *,C1709380
1270,p ‐ value,C1709380
1270,p   values of interaction,C1704675;C1709380
1270,p   values for interaction,C1704675;C1709380
1270,p   value for interaction,C1704675;C1709380
1270,p   value,C1709380
1270,p values,C1709380
1270,p value 十,C1709380
1270,p value ∥,C1709380
1270,p value § ® ( w,C1709380
1270,p value § ( < $nmbr$ vs . > = $nmbr$ years ),C1709380
1270,p value within category,C0683312;C1709380;C3889287
1270,p value versus placebo,C1709380
1270,p value interaction,C1704675;C1709380
1270,p value for interactiont,C1709380
1270,p value for interaction ®,C1704675;C1709380
1270,p value for interaction ^,C1704675;C1709380
1270,p value for interaction,C1704675;C1709380
1270,p value for,C1709380
1270,p value fo interactio,C1709380
1270,p value f,C0016327;C1709380
1270,p value c,C1709380
1270,p value by gt,C1435727;C1704693;C1709380;C2697657
1270,p value * $nmbr$,C1709380
1270,p value *,C1709380
1270,p value ( vs . previous time point ),C1709380
1270,p value ( on vs off omt ),C1709380
1270,p value ( nominal ),C1709380
1270,p value ( men versus women ),C0025266;C1709380
1270,p value ( interaction ),C1704675;C1709380
1270,p value ( inter ),C1709380
1270,p value ( int ),C1709380;C3272375
1270,p value ( cangrelor versus clopidogrel in women ),C1121991;C1709380
1270,p value ( cangrelor versus clopidogrel in men ),C1121991;C1709380
1270,p value ( aged > $nmbr$ vs . < $nmbr$ years ),C0001779;C0001792;C1709380;C1999167
1270,p value $nmbr$ . $nmbr$,C1709380
1270,p value $nmbr$,C1709380
1270,p value,C1709380
1270,p - value ‘ ’,C1709380
1270,p - value ¶,C1709380
1270,p - value },C1709380
1270,p - value vs . placebo,C1709380
1270,p - value n / n ( % ),C1709380
1270,p - value low vs . high nfs ^,C1709380
1270,p - value interaction,C1704675;C1709380
1270,p - value for variance,C1709380;C1711260;C2348152
1270,p - value for interaction,C1704675;C1709380
1270,p - value for,C1709380
1270,p - value * ' ',C1709380
1270,p - value *,C1709380
1270,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
1270,p - value ( vs placebo ),C1709380
1270,p - value ( overall ),C0282416;C1561607;C1709380
1270,p - value ( lnteraction ),C1709380
1270,p - value ( interaction ) ≠,C1704675;C1709380
1270,p - value ( int ),C1709380;C3272375
1270,p - value ( anova ),C0753802;C1709380
1270,p - value $nmbr$,C1709380
1270,p - value,C1709380
1270,p ' value,C1709380
1270,nteraction p value,C1709380
1270,multivariate p - value,C1709380
1270,interactior p - value,C1709380
1270,heterogeneity p value,C0019409;C0242960;C1709380
1270,chi - square p value,C1552646;C1709380
1270,bonferroni - adjusted p value  d vs a,C1709380;C1879894
1270,bonferroni - adjusted p value  c vs a,C1709380;C1879894
1270,bonferroni - adjusted p value  b vs a,C1709380;C1879894
1270,adjusted p - value for interaction,C0456081;C1704675;C1709380
1270,* p value,C1709380
1270,$nmbr$ p value,C1709380
1269,py = $nmbr$ . $nmbr$ ),C0030428;C3538810
1269,py = $nmbr$ ),C0030428;C3538810
1269,py *,C0030428;C3538810
1269,pa,C0030428;C3541314
1269,no pa,C0030428;C3541314
1269,$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C3541888
1269,$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C4019010
1269,$nmbr$ . $nmbr$ per $nmbr$ py,C0030428;C3538810
1268,om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
1268,om $nmbr$ mg / aml $nmbr$ mg,C0023465;C0023467;C0028971;C1319635;C1705272
1268,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
1268,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
1268,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1268,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1268,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
1268,om $nmbr$ / aml $nmbr$ /,C0023465;C0023467;C0028971;C1705272
1268,aml vs . lis,C0023465;C0023467
1268,aml vs . chl,C0023465;C0023467
1268,aml / hctz ( n = $nmbr$ ),C0020261;C0023465;C0023467
1268,aml ( n = $nmbr$ ),C0023465;C0023467
1268,aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
1268,aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C1319635
1268,aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
1268,aml $nmbr$ /,C0023465;C0023467
1268,aml,C0023465;C0023467
1268,a / aml ( n = $nmbr$ ),C0023465;C0023467
1267,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
1267,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
1267,type of ml  no . ( % ),C0332307;C0439526;C1547052;C1705224;C3887665
1267,quartiles of fgf - $nmbr$ ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
1267,pvr  ml,C0242852;C0439526;C0456261;C1419141;C1705224;C3887665
1267,pv  ml,C0030840;C0032463;C0439526;C1705224;C3887665
1267,prior ml or stroke at baseline,C0332152;C0439526;C1705224;C2826257;C3887665
1267,prior ml or abnormal angiogram,C0332152;C0439526;C1705224;C2826257;C3887665
1267,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
1267,prior history ml or stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
1267,previous ml or abnormal angiogram,C0205156;C0439526;C1552607;C1705224;C3887665
1267,previous ml ( interaction : p = $nmbr$ . $nmbr$ ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
1267,nontatal ml,C0439526;C1705224;C3887665
1267,nonfatal ml,C0439526;C1705224;C3887665
1267,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
1267,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
1267,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
1267,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
1267,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
1267,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
1267,ml c,C0439526;C1705224;C3887665
1267,ml ),C0439526;C1705224;C3887665
1267,ml,C0439526;C1705224;C3887665
1267,lvesv ( ml ),C0439526;C1705224;C3887665
1267,lvedv ( ml ),C0439526;C1705224;C3887665
1267,low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ ),C0014467;C0205251;C0439526;C1079230;C1515021;C1550472;C1705224;C3887665;C3890211;C4048187;C4321351;C4522223
1267,lav ( ml ),C0019682;C0439526;C1705224;C3887665
1267,high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
1267,decline #   ml · yr − $nmbr$,C0439234;C0439526;C1705224;C3887665
1267,cvdeath  ml  or ischemic stroke,C0439526;C1705224;C3887665
1267,alvesv ( per ml ),C0439526;C1705224;C3887665
1267,alvedv ( per ml ),C0439526;C1705224;C3887665
1267,alav ( per ml ),C0439526;C1705224;C3887665
1267,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
1267,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
1267,adjusted rate of fev $nmbr$   decline ( se )  ml / yr,C0036919;C0439234;C0439526;C0456081;C0871208;C1521828;C1705224;C3714541;C3887665
1267,> = $nmbr$ ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
1267,> $nmbr$ ml,C0439526;C1705224;C3887665
1267,< $nmbr$ ml,C0439526;C1705224;C3887665
1267,* nonfatal ml,C0439526;C1705224;C3887665
1267,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §,C0439526;C1705224;C3887665
1267,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
1267,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
1267,$nmbr$ - $nmbr$ ml / rain,C0034640;C0439526;C1705224;C3887665
1266,thrombophilia  no . ( % ) e,C0398623
1266,thrombophilia,C0398623
1266,thrombocytopenia,C0040034;C0392386
1266,profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0392386;C0439808
1266,mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C1856453
1266,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
1266,known thrombophilia — no . ( % ),C0205309;C0398623
1266,known thrombophilia,C0205309;C0398623
1265,thrombolysis,C0520997
1265,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
1264,weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg,C0022718;C0039725;C0039738;C0439209;C0549183;C0552346;C0876920;C1420718;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
1264,uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1300563;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,th c,C0039725;C0039738;C1420718;C4282123;C4285344
1264,th ( $nmbr$ % ),C0039725;C0039738;C1420718;C4282123;C4285344
1264,on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
1264,median ( $nmbr$ th  $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
1264,low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023824;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023822;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$,C0005893;C0039725;C0039738;C0549183;C0578022;C0876920;C1264641;C1305855;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
1264,age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
1264,age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,age  y ( $nmbr$ th  $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1264,age  median ( $nmbr$ th — $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,age  median ( $nmbr$ th - $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1264,$nmbr$ th — $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1264,$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
1264,$nmbr$ th - $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
1263,s $nmbr$ months,C0439231;C0565930;C2603362
1263,poor outcome at $nmbr$ months,C0439231;C3806166
1263,months since ra was first diagnosed  mean ( sd ),C0439231
1263,months since first ra symptom  mean ( sd ) f,C0439231
1263,months ( log - transformed ),C0439231
1263,month $nmbr$,C0332177;C0439231
1263,intensified $nmbr$ months ( n - $nmbr$ ),C0439231
1263,hba $nmbr$ c month $nmbr$ ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
1263,fall in last $nmbr$ months ( % ),C0085639;C0238715;C0439231;C4553726
1263,duration of sulphonylurea use ( months )  mean ± s . d .,C0038766;C0439231;C0444504;C1881378;C2347634;C2348143;C2826775;C3536898
1263,duration of previous use of vka  months,C0205156;C0439231;C1552607;C1881378;C2826775
1263,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
1263,duration of dementia symptoms  months,C0011265;C0436359;C0439231;C0497327
1263,ccsc at $nmbr$ month before enrollment,C0332177;C0439231;C1516705
1263,^ $nmbr$ months,C0439231
1263,> $nmbr$ months ( n = $nmbr$  $nmbr$ ),C0439231
1263,> $nmbr$ months  n ( % ),C0439231
1263,> $nmbr$ months,C0439231
1263,> $nmbr$ month n = $nmbr$,C0332177;C0439231
1263,< $nmbr$ months in - $nmbr$ kill,C0162388;C0439231;C0681205;C1550555
1263,< $nmbr$ months  n ( % ),C0439231
1263,< $nmbr$ months,C0439231
1263,< $nmbr$ month n = $nmbr$,C0332177;C0439231
1263,$nmbr$ – $nmbr$ months,C0439231
1263,$nmbr$ tob $nmbr$ months  n ( % ),C0439231;C1420851
1263,$nmbr$ tob $nmbr$ months,C0439231;C1420851
1263,$nmbr$ months,C0439231
1263,$nmbr$ month l,C0332177;C0439231
1263,$nmbr$ - < $nmbr$ months  n ( % ),C0439231
1263,$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ ),C0439231;C1570610
1263,$nmbr$ - $nmbr$ months ( n = $nmbr$ ),C0439231
1263,$nmbr$ - $nmbr$ months  n ( % ),C0439231
1263,$nmbr$ - $nmbr$ months,C0439231
1262,smoking status current smoker ( n = $nmbr$ ),C1519386;C3173209;C3241966
1262,smoking history : current smoker,C1519384;C3173209;C3241966
1262,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
1262,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
1262,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
1262,current smokers *,C3173209;C3241966
1262,current smokers ( n = $nmbr$ ),C3173209;C3241966
1262,current smokers ( itt ) ( n = $nmbr$ ),C3173209;C3241966
1262,current smokers ( % ),C3173209;C3241966
1262,current smokers    n   ( % ),C3173209;C3241966
1262,current smokers  n ( % ),C3173209;C3241966
1262,current smokers  %,C3173209;C3241966
1262,current smokers,C3173209;C3241966
1262,current smoker 一 no . ( % ),C3173209;C3241966
1262,current smoker — no . { % ),C3173209;C3241966
1262,current smoker — no . of patients ( % ),C3173209;C3241966
1262,current smoker — no . / total no . ( % ),C3173209;C3241966
1262,current smoker — no . ( % ) blood pressure — mm hg,C3173209;C3241966
1262,current smoker — no . ( % ),C3173209;C3241966
1262,current smoker »,C3173209;C3241966
1262,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
1262,current smoker at screeninga  n ( % ),C3173209;C3241966
1262,current smoker at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
1262,current smoker at baseline    n   ( % ),C0168634;C1442488;C3173209;C3241966
1262,current smoker : ex - smoker ( % ),C3173209;C3241966
1262,current smoker ( n z $nmbr$ ),C3173209;C3241966
1262,current smoker ( n = $nmbr$ ),C3173209;C3241966
1262,current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ ),C0205156;C0750523;C3173209;C3241966
1262,current smoker ( n = $nmbr$  $nmbr$ ),C3173209;C3241966
1262,current smoker ( % ),C3173209;C3241966
1262,current smoker  no . ( % ),C3173209;C3241966
1262,current smoker  no ( % ),C3173209;C3241966
1262,current smoker  n [ % ],C3173209;C3241966
1262,current smoker  n / n ( % ),C3173209;C3241966
1262,current smoker  n ( % },C3173209;C3241966
1262,current smoker  n ( % of patients ),C0030705;C3173209;C3241966
1262,current smoker  n ( % ) post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3173209;C3241966
1262,current smoker  n ( % ),C3173209;C3241966
1262,current smoker  %,C3173209;C3241966
1262,current smoker,C3173209;C3241966
1262,> $nmbr$ . $nmbr$ bpm current smoker,C3173209;C3241966
1261,≤ $nmbr$ ug / g,C0439272
1261,tcz $nmbr$ mg / kg n = $nmbr$,C0439272
1261,ind / glyb n = $nmbr$,C1415124;C4049864
1261,ind $nmbr$ mg q . d . n = $nmbr$,C0439422;C4049864
1261,bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$,C2700462;C2945744;C3540627;C3815109
1261,bud $nmbr$ ptg n = $nmbr$,C0039512;C1418830;C2700462;C2945744
1261,abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1261,abatacept $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1261,abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
1261,> $nmbr$ ug / g,C0439272
1261,$nmbr$ mg / kg ( n = $nmbr$ ),C0439272
1261,$nmbr$ mg / kg,C0439272
1260,≥ $nmbr$ to < $nmbr$ mg / g,C1300563
1260,≥ $nmbr$ mg / g,C1300563
1260,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
1260,uacra  mg / g  n ( % ),C1300563
1260,uacra  mg / g  gmean = gcv,C0017066;C1300563
1260,uacr — mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
1260,uacr *  mg / g ( q $nmbr$  q $nmbr$ ),C1300563
1260,uacr ( mg / g ),C1300563
1260,uacr ( mg / g  median [ iqr ] ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
1260,uacr  mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
1260,uac > $nmbr$ mg / g,C1300563
1260,uac $nmbr$ - $nmbr$ mg / g,C1300563
1260,normoalbuminuria ( uacr < $nmbr$ mg / g ),C1300563
1260,mg / g,C1300563
1260,cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
1260,cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
1260,acr > $nmbr$ mg / g,C1300563;C1412134;C1515941
1260,^ $nmbr$ mg / g  n ( % ),C1300563
1260,> = $nmbr$ mg / g,C1300563
1260,> $nmbr$ to $nmbr$ mg / g,C1300563
1260,> $nmbr$ mg / g,C1300563
1260,< $nmbr$ mg / g  n ( % ),C1300563
1260,< $nmbr$ mg / g,C1300563
1260,$nmbr$ − $nmbr$ mg / g,C1300563
1260,$nmbr$ to $nmbr$ mg / g,C1300563
1260,$nmbr$ mg / g  n ( % ),C1300563
1260,$nmbr$ mg / g,C1300563
1260,$nmbr$ - $nmbr$ mg / g,C1300563
1259,> $nmbr$ / $nmbr$ lung fields,C0225759
1259,< $nmbr$ . $nmbr$ tng > cll,C0023434
1259,$nmbr$ to < $nmbr$ cel,C0208736;C0346421;C0439237;C1413336
1259,$nmbr$ . $nmbr$ ± $nmbr$ . lf,C1416933;C2986618;C4554443
1258,iee at baseline : < $nmbr$ iu / l,C0168634;C0439457;C1442488
1258,> $nmbr$ to < $nmbr$ iu / l,C0439457
1258,> $nmbr$ iu / l,C0439457
1257,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
1257,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1257,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
1257,nt - probnp — pg / ml,C0439297;C0669479;C0754710
1257,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
1257,nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ ),C0439297;C0669479;C0754710
1257,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
1257,nt - probnp $nmbr$ pmol - l - $nmbr$,C0439284;C0669479;C0754710
1257,nt - probnp  pmol / l ^,C0439284;C0669479;C0754710
1257,nt - probnp  pmol / l,C0439284;C0669479;C0754710
1257,nt - probnp  pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1257,nt - probnp  pg / ml,C0439297;C0669479;C0754710
1257,nt - probnp  median pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
1257,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
1257,nt - pro bnp,C0669479;C0754710
1257,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
1257,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
1257,nt - pro - bnp,C0669479;C0754710
1257,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
1256,long term *,C0443252
1256,long term ( n = $nmbr$ ) +,C0443252
1256,long - term warfarin ( n = $nmbr$ ),C0043031;C0443252
1256,long - term warfarin ( n - $nmbr$ ),C0043031;C0443252
1256,long - term aspirin,C0004057;C0443252
1255,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
1255,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
1255,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
1255,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
1254,coenzyme q $nmbr$ p  g / ml #,C0041536;C1300565
1254,coenzyme q $nmbr$  ^ g / ml #,C0041536;C1300565
1254,coenzyme q $nmbr$,C0041536
1254,all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ ),C0041536
1253,squamous cell carcinoma,C0007137;C1302853
1253,hormone - refractory prostate carcinoma,C1328504
1252,necrotic core  mm ^,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653;C4330985;C4554674
1252,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
1252,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
1251,etn  no,C0014758;C0717758
1251,etanercept ( n = $nmbr$ ),C0717758
1251,etanercept,C0717758
1250,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
1250,abatacept ‡,C1619966
1250,abatacept plus mtx ( n = $nmbr$ ),C0025677;C1417487;C1619966
1250,abatacept monotherapy ( n = $nmbr$ ),C1619966
1250,abatacept / open - label abatacept,C1619966;C1709323
1250,abatacept ( n = $nmbr$ * ),C1619966
1250,abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ ),C1619966
1250,abatacept,C1619966
1249,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
1249,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
1249,beta bloekers,C0330390;C0439096;C2004068
1249,beta $nmbr$ selective,C0330390;C0439096;C2004068
1249,adjustedb  c beta ( se ),C0036919;C0330390;C0439096;C2004068
1248,ezetimibe use,C0042153;C0457083;C1142985;C1947944
1248,ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1248,ezetimibe $nmbr$ mg ( n — $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1248,ezetimibe $nmbr$ mg ( n = $nmbr$ * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1248,ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
1248,ezetimibe  n ( % ),C1142985
1248,ezetimibe,C1142985
1247,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
1247,ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
1247,ezetimibe / simvastatin,C1532737
1247,ezetimibe + simvastatin ( n = $nmbr$ * ),C1532737
1247,ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * ),C1532737
1246,systemic corticosteroids — no . ( % ),C4053960
1246,systemic corticosteroids  n ( % ) a,C4053960
1246,systemic corticosteroids  n ( % ),C4053960
1246,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
1246,catecholamines or corticosteroids without hospitalization,C0007412
1245,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C1514873;C3536709
1245,refractory to corticosteroids  n ( % ),C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
1245,prior corticosteroid treatment,C0001617;C1514463;C3536709
1245,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
1245,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1245,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
1245,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
1245,no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1245,no corticosteroid + no imm  n,C0001617;C3536709
1245,no corticosteroid  no imm,C0001617;C3536709
1245,no corticosteroid,C0001617;C3536709
1245,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1245,neither corticosteroid nor immunosuppressant,C0001617;C3536709
1245,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
1245,immy ( without corticosteroid )  n,C0001617;C3536709
1245,imm + corticosteroid  n,C0001617;C0205470;C3536709
1245,imm ( without corticosteroid ),C0001617;C0205470;C3536709
1245,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids ( excluding budesonide ),C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids ' $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
1245,corticosteroid or immunosuppressant,C0001617;C3536709
1245,corticosteroid or azathioprine / $nmbr$ - mercaptopurine,C0001617;C3536709
1245,corticosteroid and immunosuppressant,C0001617;C3536709
1245,corticosteroid - azathioprine / $nmbr$ - mercaptopurine,C0000618;C0001617;C0004482;C3536709
1245,corticosteroid + imm,C0001617;C0205470;C3536709
1245,corticosteroid ( without imm )  n,C0001617;C0205470;C3536709
1245,corticosteroid ( without imm ),C0001617;C0205470;C3536709
1245,corticosteroid ( with or without immunosuppressants ),C0001617;C3536709
1245,corticosteroid,C0001617;C3536709
1245,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
1245,concomitant oral corticosteroids  n ( % ) * *,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
1245,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1245,> $nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1244,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
1244,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
1244,atherosclerotic vascular disease — no .,C0004153
1244,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1244,atherosclerotic vascular disease history  no . ( % ) ‡,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1244,atherosclerotic vascular disease history  n ( % ) t,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
1244,atherosclerotic vascular disease  n ( % ) §,C0004153
1244,atherosclerotic cardiovascular disease *,C0004153
1244,atherosclerotic cardiovascular disease,C0004153
1243,other atherosclerotic event,C0333482;C0441471;C4019010
1243,other atherosclerotic cvdd  e,C0333482;C1859330
1243,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
1243,other atherosclerotic cvd * *,C0007222;C0333482
1243,other atherosclerotic cvd,C0007222;C0333482
1243,other atherosclerotic,C0333482
1243,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
1243,atherosclerotic disease *,C0012634;C0333482
1243,atherosclerotic disease ( % ),C0012634;C0333482
1243,atherosclerotic cvdj,C0333482
1243,atherosclerotic cvd §,C0007222;C0333482
1243,atherosclerotic cvd,C0007222;C0333482
1242,univariate logistic modela,C0242415
1242,multivariate logistic modelb,C0242415
1242,environmental stimuli,C0450025
1241,antithrombotic agents  n ( % ),C1704311
1241,antithrombotic agents,C1704311
1241,antithrombotic / coagulant,C0009117
1241,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
1240,symptomatic remissionb n / n ( % ),C0231220
1240,symptomatic pe,C0070939;C0231220;C1880476;C4284304
1240,symptomatic padt,C0231220
1240,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
1240,symptomatic hypotension with sbp < $nmbr$ mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
1240,symptomatic hypotension ( sbp < $nmbr$ mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
1240,symptomatic hypotension,C0020649;C0231220;C3163620
1240,symptomatic,C0231220
1240,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
1239,uncontrolled on oad ( s ),C0205318
1239,uncontrolled on basal insulin,C0205318;C0650607
1239,uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$,C0205318;C2919686
1239,uncontrolled,C0205318
1238,contrast volume > $nmbr$ ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1238,contrast volume > $nmbr$ ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1238,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1238,contrast volume  ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1238,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
1238,contrast used ( ml ) *,C0009924;C1979874
1237,oral corticosteroid use  n ( % ),C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
1237,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
1237,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
1237,current corticosteroid use  n,C0239126;C0521116;C1705970
1237,corticosteroid use at randomization    n   ( % ),C0034656;C0239126
1237,corticosteroid use at randomization,C0034656;C0239126
1237,corticosteroid use  n ( % ),C0239126
1237,corticosteroid use  %,C0239126
1237,corticosteroid use  $nmbr$ n ( % ),C0239126
1237,corticosteroid use,C0239126
1237,concomitant corticosteroid use  n ( % ),C0239126;C0521115
1237,concomitant corticosteroid use,C0239126;C0521115
1236,no concomitant antiplatelet,C0521115
1236,most common concomitant aeds  n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
1236,most common concomitant aeds  d n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
1236,main concomitant treatments  no . ( % ),C0087111;C0205225;C0521115;C1542147
1236,concomitant use of nsaids to week $nmbr$,C0003211;C0521115;C1524063
1236,concomitant use of mtx to week $nmbr$,C0025677;C0521115;C1417487;C1524063
1236,concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate,C0242708;C0439858;C0521115;C1524063;C1883254
1236,concomitant use of bosentan  n ( % ),C0252643;C0521115;C1524063
1236,concomitant treatments at randomization,C0034656;C0087111;C0521115
1236,concomitant oads  n ( % ),C0521115
1236,concomitant mtx —,C0025677;C0521115;C1417487
1236,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
1236,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
1236,concomitant drug treatment,C0150270;C0521115;C3469597
1236,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
1236,concomitant drug therapies  n ( % ),C0013216;C0521115
1236,concomitant antiplatelet,C0521115
1236,concomitant aedsb    n   ( % ),C0521115
1236,concomitant aedsb  n ( % ),C0521115
1236,concomitant aedsa,C0521115
1236,concomitant aeds  n ( % ),C0180309;C0521115
1236,concomitant,C0521115
1235,no antiplatelet therapy,C1096021
1235,long - term antiplatelet therapy,C0443252;C1096021
1235,dual antiplatelet therapy,C0205173;C1096021;C1554184
1235,antiplatelet therapy §,C1096021
1235,antiplatelet therapy dual,C1096021
1235,antiplatelet therapy,C1096021
1234,statin therapy,C1278454
1234,prerandomization statin therapy,C1278454
1234,intensity of statin therapy at baseline — no . { % ),C0522510;C1278454
1234,intensity of statin therapy,C0522510;C1278454
1233,phototherapy,C0031765
1233,no diuretic therapy,C0948575
1233,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
1233,estrogen therapy,C0279494
1233,diuretic therapy,C0948575
1233,combination therapy * *,C0009429;C0556895
1233,combination therapy ( n = $nmbr$ ),C0009429;C0556895
1233,combination therapy  n = $nmbr$,C0009429;C0556895
1233,anticoagulant therapy,C0150457
1232,udy entry,C1705654
1232,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
1232,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
1232,medications at study entry — no . / total no . ( % ),C0013175;C1705654
1232,entry hip fracture location  n ( % ),C1705654;C3260017
1232,entry category,C0683312;C1705654;C3889287
1232,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
1232,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
1232,controllertreatment before entry *,C1705654
1232,at entry,C1705654
1231,unknown — no . { % ),C0439673;C3541433;C4050014
1231,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
1231,unknown or missing,C0439673;C3541433;C4050014
1231,unknown / missing,C0439673;C3541433;C4050014
1231,unknown ( none of the above ),C0439673;C3541433;C4050014
1231,unknown ( % ),C0439673;C3541433;C4050014
1231,unknown,C0439673;C3541433;C4050014
1231,non - detectable / unknown  n ( % ),C0439673;C1518422;C3541433;C3830527;C4050014
1231,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
1231,no / unknown,C0439673;C3541433;C4050014
1230,knees ( n ),C0022742
1230,knee,C0022742;C0022745;C1963703
1230,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
1230,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
1229,prostate cancer,C0376358;C0600139;C2984325;C3541264
1229,prostate biopsy,C0194804
1229,propafenone,C0033429
1229,pravastatin sodium,C0700474
1229,orthostatic hypotension,C0020651
1228,unstable but no rest angina,C0443343;C1883468
1228,unstable anginat,C0443343;C1883468
1228,unstable anginad,C0443343;C1883468
1228,unstable,C0443343;C1883468
1228,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
1227,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
1227,probable stent thrombosis,C0033204;C0332148;C3897493
1227,probable,C0033204;C0332148
1227,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
1226,no . japanese,C0376247;C1556094
1226,japanese subpopulation,C0376247;C1257890;C1556094
1226,japanese subgroup ( n = $nmbr$ ),C0376247;C1079230;C1515021;C1556094
1226,japanese,C0376247;C1556094
1225,era monotherapy,C1521863;C3495919
1225,era and pde - $nmbr$ i,C1521863;C3495919
1225,era and pde $nmbr$ inhibitors,C1521863;C3495919
1225,era,C1521863;C3495919
1224,vein graft stented,C0042449;C0181074;C0332835;C1961139
1224,graft occlusionsa,C0181074;C0332835;C1961139
1224,graft  n ( % ),C0181074;C0332835;C1961139
1224,graft,C0181074;C0332835;C1961139
1223,lipid profile,C0023779;C1979963;C2003903
1223,fatty acid profile,C0015684;C1979963;C2003903
1222,non - frail,C0871754;C1518422
1222,frail,C0871754
1221,updrs  part ii ( adl ),C0001288;C0449719;C1420005;C1709471;C1710602;C3639721;C4082587
1221,adl,C0001288;C1420005
1220,overall dlqi score $nmbr$,C0282416;C1561607;C3899393
1220,overall dlqi score,C0282416;C1561607;C3899393
1220,dlqi §,C3899393
1220,dlqi score,C3899393
1220,dlqi  $nmbr$ - $nmbr$ *,C3899393
1220,dlqi,C3899393
1219,upper gastrointestinal tract,C3203348
1219,upper gastrointestinal,C3203348
1219,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
1219,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
1219,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
1219,gastrointestinal bleeding,C0017181
1218,tertiary amines,C3653356
1218,terrible,C3827840
1218,terminal ileum,C0227327
1218,sertraline,C0074393;C0524265
1218,heritable,C0439660
1217,prior vka experience,C0237607;C0332152;C0596545;C2826257
1217,experienced,C0237607;C0596545
1217,experience ( n  % ),C0237607;C0596545
1217,experience,C0237607;C0596545
1217,clinic research experience  n ( % ),C0008972;C0237607;C0596545
1217,cdmard experience  n ( % ),C0237607;C0596545
1217,> $nmbr$ yr warfarin experience,C0043031;C0237607;C0439234;C0596545
1216,everolimus - eluting,C0541315
1216,everolimus,C0541315
1216,evening mealb,C0587117
1216,evening,C0587117
1215,never used lev,C0023556;C1273517;C2003901
1215,never took alendronate,C2003901
1215,never smoking,C2003901
1215,never smoked — no . ( % ),C2003901
1215,never smoked  n ( % ),C0037366;C0439994;C1881674;C2003901
1215,never smoked,C2003901
1215,never or past,C2003901
1215,never drink,C2003901
1215,never been on a vka,C2003901
1215,never / rarely,C0522498;C2003901
1215,never,C2003901
1214,uc disease duration ( y ),C0872146
1214,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1214,duration of disease — yr ^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
1214,duration of disease — yr : t,C0439234;C0872146
1214,duration of disease — yr,C0439234;C0872146
1214,duration of disease since,C0872146
1214,duration of disease before baseline,C0872146
1214,duration of disease ( yr ),C0439234;C0872146
1214,duration of disease ( years ),C0439234;C0872146
1214,duration of disease  years,C0439234;C0872146
1214,duration of disease  y,C0872146
1214,duration of disease  n ( % ),C0872146
1214,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1214,disease duration b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1214,disease duration > $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1214,disease duration ( yr ),C0439234;C0872146
1214,disease duration ( years ),C0439234;C0872146
1214,disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1214,disease duration  years,C0439234;C0872146
1214,disease duration  y,C0872146
1214,disease duration  mean yr ( sd ),C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1214,disease duration,C0872146
1213,moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274776
1213,moderate dysfunction,C3274776
1212,risk ratio [ $nmbr$ % cl ],C0028873;C0242492;C0596019
1212,odds ‐ ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
1212,odds ratios ( $nmbr$ % ci ),C0008107;C0028873;C3259781
1212,odds ratio versus placebo ( $nmbr$ % ci ),C0028873
1212,odds ratio and $nmbr$ % cl,C0028873
1212,odds ratio adj ( $nmbr$ % cl ),C0001552;C0028873;C0596019;C2826286
1212,odds ratio ( $nmbr$ % cl ),C0028873;C0596019
1212,odds ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
1212,odds ratio,C0028873
1212,estimated odds ratio,C0028873;C0750572
1211,t $nmbr$ dm duration  y,C0011816;C0449238;C2603360;C2926735;C3250443
1211,symptom duration  months,C0439231;C0449238;C1457887;C2926735;C3854129
1211,symptom duration,C0449238;C1457887;C2926735;C3854129
1211,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
1211,ra symptom duration < $nmbr$ months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
1211,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
1211,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
1211,mean duration of pd  yr,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
1211,known duration of type $nmbr$ diabetes,C0205309;C0449238;C1320657;C2926735
1211,known duration of t $nmbr$ dm  y,C0011816;C0205309;C0449238;C2926735;C3250443
1211,known duration,C0205309;C0449238;C2926735
1211,extended - duration enoxaparin ( n = $nmbr$ ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
1211,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
1211,ed duration,C0449238;C2926735;C3538926
1211,duration since diagnosis ( years ),C0449238;C2926735
1211,duration of type $nmbr$ diabetes,C0449238;C1320657;C2926735
1211,duration of t $nmbr$ dm ( % ),C0011816;C0449238;C2926735;C3250443
1211,duration of t $nmbr$ dm  y,C0011816;C0449238;C2926735;C3250443
1211,duration of t $nmbr$ dm,C0011816;C0449238;C2926735;C3250443
1211,duration of t $nmbr$ d  y,C0449238;C2926735
1211,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
1211,duration of rat  years,C0034693;C0034721;C0439234;C0449238;C2926735
1211,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
1211,duration of ra ( time from symptom onset )  years,C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
1211,duration of ra,C0449238;C2926735;C3538806;C4048756
1211,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
1211,duration of pd  y,C0449238;C2926735;C4553228;C4553229
1211,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
1211,duration of infusion during medical management — hr,C0449238;C0574032;C1827465;C2926735
1211,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735
1211,duration of infusion before cabg — hr,C0449238;C0574032;C1827465;C2926735
1211,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735
1211,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
1211,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
1211,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
1211,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
1211,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
1211,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
1211,duration of asthma > $nmbr$ years,C0004096;C0439234;C0449238;C2926735;C2984299
1211,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
1211,duration of asthma  years,C0004096;C0439234;C0449238;C2926735;C2984299
1211,duration of asthma  y,C0004096;C0449238;C2926735;C2984299
1211,duration of asthma,C0004096;C0449238;C2926735;C2984299
1211,duration of assigned regimen before surgery post - randomisation characteristic * *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
1211,duration of assigned regimen before surgery post - randomisation characteristic *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
1211,duration of assigned regimen before surgery,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
1211,duration of as  years,C0449238;C2926735
1211,duration of as  n ( % ),C0449238;C2926735
1211,duration of,C0449238;C2926735
1211,duration alendronate use  years ( meanisd ),C0042153;C0102118;C0439234;C0449238;C0457083;C1947944;C2926735
1211,duration,C0449238;C2926735
1211,dm duration,C0011816;C0449238;C2926735;C3250443
1211,cornell voltage x duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1211,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
1211,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
1211,cornell voltage - duration product  mm × ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1211,cornell voltage - duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1211,asthma duration ( sd )  years,C0004096;C0439234;C0449238;C2699239;C2926735;C2984299
1210,poor,C0032854;C0542537;C2700379
1210,mh + crpnorr,C0026514;C2930980
1210,fair or poor,C2911689
1210,fair / poor,C0032854;C0542537;C2700379;C2911689
1209,upper tertile : > $nmbr$ . $nmbr$,C1282910
1209,upper,C1282910
1209,none of the above,C1282910;C1552828
1209,any of the above,C1282910;C1552828
1209,all of the above,C1282910;C1552828
1208,logistic regression,C0206031
1208,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828
1208,aunivariate logistic regression .,C0206031
1207,previously untreated isolated systolic hypertension,C0332155;C0745133
1207,isolated systolic hypertension ⁎,C0745133
1207,isolated systolic hypertension ^,C0745133
1207,isolated systolic hypertension  n ( ' % >,C0745133
1207,isolated systolic hypertension  n ( % ) “,C0745133
1207,isolated systolic hypertension,C0745133
1206,• ischemic stroke,C0948008
1206,prior ischemic stroke,C0332152;C0948008;C2826257
1206,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
1206,nonfatal ischemic stroke,C0948008
1206,minor ischaemic stroke,C0026193;C0205165;C0948008
1206,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
1206,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
1206,ischemic stroke subtype,C0449560;C0948008
1206,ischemic stroke or see,C0948008
1206,ischemic stroke ( vs . tia ),C0948008
1206,ischemic stroke ( incl . uncertain ),C0948008
1206,ischemic stroke ( % ),C0948008
1206,ischemic stroke,C0948008
1206,ischaemic stroke  n ( % ),C0948008
1206,ischaemic stroke,C0948008
1206,all ischemic stroke,C0948008
1205,time from end of fit  years ( meanisd ),C0036572;C0439234;C1522314;C2349186;C4048158;C4553125
1205,seizure worry,C0036572;C0233481;C1959629;C4553401
1205,seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401
1205,seizure types reported during baseline  n ( % ) a,C0036572;C0332307;C1959629;C4553401
1205,seizure types reported during baseline  b n ( % ),C0036572;C0332307;C1959629;C4553401
1205,convulsion,C0036572;C4048158
1204,urgent surgery,C2188405
1204,minor surgery,C0038904
1204,major surgery,C0679637
1204,emergent / urgent surgery,C0750573;C2188405
1204,cancer surgery,C0920424
1203,sbp ( office measurement )  mmhg,C0085805;C0242485;C0439475;C0442603
1203,measurements,C0242485
1203,measure,C0079809;C0242485
1203,lipid measure *,C0023779;C0079809;C0242485
1203,dbp ( office measurement )  mmhg,C0242485;C0439475;C0442603;C0536221;C3813197;C4281799
1202,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1202,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
1202,valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
1202,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
1202,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
1202,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
1202,surgery,C0038894;C0038895;C0543467;C1274039
1202,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
1202,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
1202,operative procedure,C0543467;C0677612
1202,cardiac valve surgery : no ( n = $nmbr$ ),C0018821;C0018826;C0038894;C0038895;C0184252;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
1202,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
1201,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
1201,median c - reactive protein — mg / dl ^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
1201,mean score on das $nmbr$ - $nmbr$ ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
1201,hs - crp < $nmbr$ . $nmbr$ nlg l,C3890735;C4048285
1201,hs - crp < $nmbr$ . $nmbr$ g / l,C0439294;C0456615;C3890735;C4048285
1201,hs - crp,C3890735;C4048285
1201,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
1201,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
1201,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
1201,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
1201,high - sensitivity c - reactive protein  mg / ltt,C0006560;C0024671;C0026410;C0439269;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
1201,high - sensitivity c - reactive protein  mg / l,C0006560;C0439268;C1413716;C1441604;C4048285
1201,das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % ),C0051767;C0057671;C3890735;C4048285
1201,das $nmbr$ ‐ crp,C0051767;C0057671;C3890735;C4048285
1201,das $nmbr$ - crp §,C0051767;C0057671;C3890735;C4048285
1201,das $nmbr$ - crp,C0051767;C0057671;C3890735;C4048285
1201,das $nmbr$ ( crp ),C0051767;C0057671;C3890735;C4048285
1201,das $nmbr$ ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
1201,crp,C3890735;C4048285
1201,c . das $nmbr$ - crp < $nmbr$ . $nmbr$,C0051767;C0057671;C3890735;C4048285
1201,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
1201,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
1201,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
1201,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
1201,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
1201,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
1201,c - reactive protein  u / l,C0006560;C0439339;C1413716;C4048285
1201,c - reactive protein  mg / l,C0006560;C0439268;C1413716;C4048285
1201,c - reactive protein  * mg / l,C0006560;C0439268;C1413716;C4048285
1201,c - reactive protein,C0006560;C1413716;C4048285
1201,asdas - crp   <   $nmbr$ . $nmbr$,C3890735;C4048285
1201,asdas - crp δ   ≥   $nmbr$ . $nmbr$,C3890735;C4048285
1201,asdas - crp *,C3890735;C4048285
1200,week $nmbr$ ( geometric mean  cv ),C0332174;C0439230;C2986759;C3538987;C4048877;C4318503
1200,urine acr geometric mean ( cv % )  a  b mg / g,C0042036;C0042037;C1300563;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
1200,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
1200,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1200,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
1200,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
1200,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
1200,no cv event ( n = $nmbr$  $nmbr$ ),C0441471;C3538987;C4019010;C4048877;C4318503
1200,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
1200,mdrd egfr geometric mean ( cv % )  a  b ml /,C0439526;C1705224;C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C3887665;C4048877;C4318503
1200,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
1200,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
1200,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
1200,cv risk factors  % of patients,C0030705;C0035648;C1553898;C3538987;C4048877;C4318503
1200,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
1200,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
1200,cv risk factor,C0035648;C3538987;C4048877;C4318503
1200,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
1200,cv historya,C3538987;C4048877;C4318503
1200,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
1200,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
1200,cv,C3538987;C4048877;C4318503
1200,baseline ( geometric mean  cv ),C0168634;C1442488;C2986759;C3538987;C4048877;C4318503
1200,ascvdor > $nmbr$ cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
1200,> $nmbr$ additional cv risk factors $nmbr$,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
1199,previous cd related surgery ( ref ) a,C0007928;C0034283;C0205156;C1552607;C4552032
1199,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
1199,patients with early cd ( n = $nmbr$ ),C0007928;C0030705;C0034283;C1279919;C4552032
1199,no previous cd related surgery $nmbr$,C0007928;C0034283;C0205156;C1552607;C4552032
1199,chads score  n ( % ),C0007928;C1413373
1199,chads score,C0007928;C1413373
1199,chads - $nmbr$ score,C0007928;C1413373
1199,chads $nmbr$   score    n   ( % ),C0007928;C1413373
1199,chads $nmbr$ scoret,C0007928;C1413373
1199,chads $nmbr$ scoref,C0007928;C1413373
1199,chads $nmbr$ scoreb,C0007928;C1413373
1199,chads $nmbr$ score per outcome stroke or systemic embolism,C0007928;C1413373
1199,chads $nmbr$ score > $nmbr$,C0007928;C1413373
1199,chads $nmbr$ score *,C0007928;C1413373
1199,chads $nmbr$ score $nmbr$ - $nmbr$  n ( % ),C0007928;C1413373
1199,chads $nmbr$ score $nmbr$,C0007928;C1413373
1199,chads $nmbr$ score  n ( % ),C0007928;C1413373
1199,chads $nmbr$ score  mean ± sd,C0007928;C1413373
1199,chads $nmbr$ score  mean ( ± sd ),C0007928;C1413373
1199,chads $nmbr$ score,C0007928;C1413373
1199,chads $nmbr$ components  n ( % ),C0007928;C0449432;C1413373
1199,chads $nmbr$ ^,C0007928;C1413373
1199,chads $nmbr$ < $nmbr$,C0007928;C1413373
1199,chads $nmbr$,C0007928;C1413373
1199,chad $nmbr$ > $nmbr$,C0007928;C1413373
1199,cd duration  y,C0007928;C0034283;C0449238;C2926735;C4552032
1199,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
1199,cd [ gemini $nmbr$ ] * ’,C0007928;C0034283;C4552032
1199,> $nmbr$ ( n  % ) chads $nmbr$ score,C0007928;C0369718;C0441922;C1413373
1199,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
1198,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
1198,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
1198,multivessel cad  n ( % ),C1504769;C2239547;C3813548;C4284121
1198,family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
1198,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
1198,familv historv of cad,C1504769;C2239547;C3813548;C4284121
1198,cad and abi < $nmbr$ - $nmbr$ §,C1504769;C2239547;C3813548;C4284121
1198,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
1198,cad *,C1504769;C2239547;C3813548;C4284121
1198,cad,C1504769;C2239547;C3813548;C4284121
1197,tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
1197,tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
1197,igg ( > $nmbr$ . $nmbr$ g / l )  %,C0439294;C0456615
1197,apob  g / l,C0003593;C0439294;C0456615;C3252643
1197,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
1197,> $nmbr$ . $nmbr$ - g / l,C0439294;C0456615
1197,$nmbr$ . $nmbr$ ( g . l ),C0439294;C0456615
1196,involved gl areas,C0018229;C1423073;C1427674;C1879646
1196,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
1196,bsl hb  gl - $nmbr$,C0018229;C0019046;C1423073;C1427674;C1549954
1195,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
1195,fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ ),C0340427;C0439267;C1413520;C3539652
1195,fdc $nmbr$ / $nmbr$ pg vs placebo,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1195,fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1195,fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1195,fdc $nmbr$ / $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
1194,olodaterol $nmbr$ m g,C0456715;C2934193
1194,alvmi ( per g / m $nmbr$ ),C0456715
1194,> $nmbr$ ^ mol / liter — no . ( % ),C0347982
1194,( $nmbr$ - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
1193,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
1193,fl ( $nmbr$ b ),C1300812;C1708024
1193,fl ( $nmbr$ . $nmbr$ ),C1300812;C1708024
1192,urine qmax  ml / s,C0042036;C0042037;C0439390;C2963137
1192,qmaxi rn l / s,C2827110;C3540639;C4281819
1192,qmax ( ml / s ),C0439390
1192,qmax  ml / s,C0439390
1192,> $nmbr$ ml / s,C0439390
1192,< $nmbr$ ml / s,C0439390
1191,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
1191,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
1191,epa  mol %,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
1191,aa  mol %,C0027960;C0282379;C0324740;C0439189;C1235746;C1456781;C1824986;C1882141;C3665593;C4554792
1190,> $nmbr$ per pl in $nmbr$ months before screening,C0439231;C3897966;C4049765
1190,> $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
1190,< $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
1190,/ pl $nmbr$ $nmbr$,C3897966;C4049765
1190,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
1189,rrr ( $nmbr$ % cl ),C0596019
1189,rr ( cl ),C0596019;C4554402
1189,rr ( $nmbr$ % cl ) p value,C0596019;C1709380;C4554402
1189,rr ( $nmbr$ % cl ) [ / ’ value ],C0596019;C1522609;C4554402
1189,rr ( $nmbr$ % cl ),C0596019;C4554402
1189,ratet ( $nmbr$ % cl ),C0596019
1189,qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ ),C0596019;C2349943;C3539704;C3713294
1189,qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ ),C0596019;C2349943;C3539704;C3713294
1189,p ( $nmbr$ % cl ),C0369773;C0596019;C2603361
1189,orc ( $nmbr$ % cl ),C0596019;C1167125
1189,oradj ( $nmbr$ % cl ),C0596019
1189,lsm ( $nmbr$ % cl ),C0596019
1189,hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
1189,hr ( $nmbr$ % cl ) pvalue,C0596019
1189,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ ),C0596019
1189,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),C0596019
1189,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ ),C0596019
1189,hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ ),C0596019
1189,hr ( $nmbr$ % cl ) *,C0596019
1189,hr ( $nmbr$ % cl ),C0596019
1189,hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *,C0596019
1189,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
1189,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
1189,hr $nmbr$ % cl,C0596019
1189,hr  ( $nmbr$ % cl ),C0596019
1189,hr  $nmbr$ % cl,C0596019
1189,hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo,C0216784;C0596019;C2985465
1189,hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo,C0596019;C0903898;C2985465
1189,hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0596019;C2985465
1189,cl - $nmbr$ ],C0596019
1189,cl $nmbr$ %,C0596019
1189,arr ( $nmbr$ % cl ),C0596019;C2170357;C4084934
1189,adj . hr ( $nmbr$ % cl ) a,C0001552;C0596019;C2826286
1189,[ $nmbr$ % cl ],C0596019
1189,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ ),C0596019
1189,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
1189,( %  $nmbr$ % cl ),C0596019
1189,( $nmbr$ % cl ),C0596019
1189,$nmbr$ cl ),C0596019
1189,$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
1189,$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
1189,$nmbr$ ( $nmbr$ cl ),C0596019
1189,$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ ),C0596019
1189,$nmbr$ % cl,C0596019
1188,normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C4296962
1188,crcl of $nmbr$ - $nmbr$ ml min '  n ( % ),C0439445;C1846718
1188,crcl at randomization - ml / min,C0034656;C0439445;C1846718
1188,crcl at randomization  ml / min,C0034656;C0439445;C1846718
1188,crcl < $nmbr$,C1846718
1188,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
1188,crcl $nmbr$ - $nmbr$,C1846718
1188,> $nmbr$ crcl,C1846718
1188,< $nmbr$ crcl  n ( % ),C1846718
1188,< $nmbr$ crcl,C1846718
1188,$nmbr$ - $nmbr$ crcl,C1846718
1187,stratified hazard ratio ( $nmbr$ % ci ),C0008107;C0205363;C2985465;C3259781
1187,strata modelb hr  $nmbr$ % ci  p value,C0008107;C1709380;C3259781
1187,rr ^ ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1187,rr ( $nmbr$ % ci ) c,C0008107;C3259781;C4554402
1187,rr ( $nmbr$ % ci ) *,C0008107;C3259781;C4554402
1187,rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1187,risk reduction ( %  $nmbr$ % ci ),C0008107;C1137094;C3259781
1187,relative risk { $nmbr$ % ci ),C0008107;C0242492;C3259781
1187,relative risk ( $nmbr$ % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
1187,relative risk ( $nmbr$ % ci ),C0008107;C0242492;C3259781
1187,reduction in risk ( $nmbr$ % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
1187,reduction in risk % ( $nmbr$ % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
1187,ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
1187,ratio fp / sal : sal ( $nmbr$ % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
1187,ratio ( $nmbr$ % ci ) *,C0008107;C0456603;C1547037;C3259781
1187,rate ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
1187,r elative risk ( $nmbr$ % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
1187,proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %,C0008107;C1709707;C3259781
1187,oradj ( $nmbr$ % ci ),C0008107;C3259781
1187,no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
1187,multivariable adjusted model hr ( $nmbr$ % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
1187,multivariable adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
1187,mean sf $nmbr$ score ( $nmbr$ % ci ),C0008107;C0037712;C3259781;C3533236
1187,mean pasi score ( $nmbr$ % ci ),C0008107;C3259781;C3533236;C4528685
1187,mean ham - d score ( $nmbr$ % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
1187,lsm ( $nmbr$ % ci ),C0008107;C3259781
1187,hradjusted ( $nmbr$ % ci ) b,C0008107;C3259781
1187,hradj ( $nmbr$ % ci ),C0008107;C3259781
1187,hr with edoxaban ( $nmbr$ % ci ),C0008107;C2975435;C3259781
1187,hr [ $nmbr$ % ci ),C0008107;C3259781
1187,hr ( $nmbr$ s % ci ),C0008107;C3259781
1187,hr ( $nmbr$ % ci ) “,C0008107;C3259781
1187,hr ( $nmbr$ % ci ) p   value,C0008107;C1709380;C3259781
1187,hr ( $nmbr$ % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
1187,hr ( $nmbr$ % ci ) *,C0008107;C3259781
1187,hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
1187,hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
1187,hr ( $nmbr$ % ci ),C0008107;C3259781
1187,hr $nmbr$ % ci,C0008107;C3259781
1187,hr  ( $nmbr$ % ci ),C0008107;C3259781
1187,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
1187,hazard ratiof ( $nmbr$ % ci ),C0008107;C0598697;C3259781
1187,harzard ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
1187,harzar ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
1187,from baseline ( $nmbr$ % ci ),C0008107;C0168634;C1442488;C3259781
1187,ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
1187,ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
1187,ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
1187,ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
1187,etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C3259781
1187,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
1187,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
1187,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
1187,etd ( % ) [ $nmbr$ % ci ],C0008107;C1180255;C3259781
1187,etd ( $nmbr$ % ci ),C0008107;C1180255;C3259781
1187,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
1187,d ( $nmbr$ % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
1187,cox hr ( $nmbr$ % ci ),C0008107;C1565830;C3259781
1187,cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c,C0008107;C0205341;C3259781
1187,cmh rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
1187,arr ( $nmbr$ % ci ),C0008107;C2170357;C3259781;C4084934
1187,adjusted ⁎ hazard ratio ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
1187,adjusted modelc hr  $nmbr$ % ci  p value,C0008107;C0456081;C1709380;C3259781
1187,adjusted hr * ( $nmbr$ % ci ),C0008107;C0456081;C3259781
1187,adjusted hr ( $nmbr$ % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
1187,adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$,C0008107;C0456081;C3259781
1187,adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
1187,adjusted hr  $nmbr$ % ci,C0008107;C0456081;C3259781
1187,adjusted hazard ratio ≠ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
1187,adjusted hazard ratio ‡ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
1187,adjusted hazard ratio § ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
1187,adjusted hazard ratio ( $nmbr$ % ci ) †,C0008107;C0456081;C2985465;C3259781
1187,absolute risk reduction ( $nmbr$ % ci )  % / y,C0008107;C3179139;C3259781
1187,[ $nmbr$ % ci ] *,C0008107;C3259781
1187,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$,C0008107;C3259781
1187,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$,C0008107;C3259781
1187,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
1187,* ci denotes confidence interval .,C0008107;C3259781
1187,( ci ) b,C0008107;C3259781
1187,( $nmbr$ % ci ] h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
1187,( $nmbr$ % ci ] $nmbr$,C0008107;C3259781
1187,( $nmbr$ % ci ) p value,C0008107;C1709380;C3259781
1187,( $nmbr$ % ci ) c,C0008107;C3259781
1187,( $nmbr$ % ci ) b,C0008107;C3259781
1187,( $nmbr$ % ci ) a,C0008107;C3259781
1187,( $nmbr$ % ci ),C0008107;C3259781
1187,% risk reduction ( $nmbr$ % ci ),C0008107;C1137094;C3259781
1187,% ( $nmbr$ % ci ),C0008107;C3259781
1187,$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
1187,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0008107;C3259781
1187,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ),C0008107;C3259781
1187,$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$,C0008107;C3259781
1187,$nmbr$ % ci for difference,C0008107;C1705241;C1705242;C3259781
1187,$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,C0008107;C3259781
1187,$nmbr$ % ci $nmbr$,C0008107;C3259781
1187,$nmbr$ % ci,C0008107;C3259781
1186,y es,C0013754;C0205944
1186,no cases,C0868928;C1533148
1186,cases,C0868928;C1533148
1185,subsets,C1515021
1185,other climate subset,C0008946;C1515021
1185,ics subset,C0815320;C1515021;C4551720
1185,ics / laba subset,C0815320;C1515021;C4551720
1185,hot climate subset,C0178683;C1515021
1184,user,C1548600;C1706077
1184,statin users ( n = $nmbr$ ),C0360714;C1706077
1184,statin users,C0360714;C1706077
1184,statin non - users ( n = $nmbr$ ),C0360714;C1518422;C1706077
1184,non - user $nmbr$,C1518422;C1548600;C1706077
1184,laba users,C1706077
1184,laba non - users,C1518422;C1706077
1184,ics non - users,C0815320;C1518422;C1706077;C4551720
1183,baseline acq - $nmbr$ score,C0168634;C1442488;C2919686
1183,aqlq score,C4055434
1183,aqlq ( si + $nmbr$ score ’,C0449820;C4050231;C4055434
1183,aqlq ( s ) score,C0449820;C4050231;C4055434
1183,aqlq ( s ) + $nmbr$ scorets,C4055434
1183,aqlq ( s ) + $nmbr$ scored,C4055434
1183,aqlq ( s ) + $nmbr$ score : §,C0449820;C4050231;C4055434
1183,acq - $nmbr$ scoret,C2919686
1183,acq - $nmbr$ score 本,C2919686
1183,acq - $nmbr$ score *,C2919686
1183,acq - $nmbr$ score ' ! ',C2919686
1183,acq - $nmbr$ score,C2919686
1183,acq $nmbr$ score,C2919686
1182,sss score,C0037052;C0723181
1182,nihss score,C1697238
1182,nih stroke scale,C1697238;C3484372
1182,midas score,C1309950;C1423498;C4049617
1182,gds score *,C0451184;C1149049;C1418244
1182,bii score,C1413059
1181,total vdh - s score ( $nmbr$ - $nmbr$ ) ( n ),C2964552
1181,total vdh - s score,C2964552
1181,total score §,C2964552
1181,total score > $nmbr$,C2964552
1181,total score < $nmbr$,C2964552
1181,total score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C1947916;C2964552
1181,total score,C2964552
1181,total feet score,C0016504;C0347981;C2964552
1181,sgrq total score * *,C2964552
1181,sgrq total score $nmbr$,C2964552
1181,sgrq total score,C2964552
1181,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
1181,ibdq total score,C2964552
1181,eacit - e total score ) |,C2964552
1181,ccq total score,C2964552
1181,cat total score $nmbr$,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
1181,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
1181,acq - $nmbr$ total score ∗,C2919686;C2964552
1180,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1180,pfo closure group ( n = $nmbr$ ),C0185003;C0441848;C1521802
1180,pfo closure,C0185003;C1521802
1180,laa closure ( n = $nmbr$ ),C0185003;C1521802
1180,laa closure ( n - $nmbr$ ),C0185003;C1521802
1180,laa closure,C0185003;C1521802
1180,closure,C0185003;C1521802
1180,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1179,left bundle - branch block,C0023211;C0344420;C2828132
1179,bundle branch block,C0006384;C1879286
1178,spirometry after bronchodilation §,C0037981;C1371299;C3537072
1178,before bronchodilation — liters §,C0475211;C1371299;C3537072
1178,before bronchodilation,C1371299;C3537072
1178,after bronchodilation,C1371299;C3537072
1177,sudden death,C0011071;C1964022;C4554103
1177,sudden cardiac death §,C0085298
1177,mental health,C0025353
1177,early death,C1836407
1176,using hrt or raloxifene at baseline ( % ),C1524063
1176,using alendronate at baseline ( % ),C1524063
1176,use of ticagrelor,C1524063;C1999375
1176,use of systemic glucocorticoid at random -,C0017710;C0205373;C1524063
1176,use of statins,C0360714;C1524063
1176,use of statin at any follow - up visit ( % ),C0360714;C1524063
1176,use of proton inhibitors  n ( % ),C0033727;C0243077;C1524063
1176,use of pci or thrombolysis within one day of randomization,C1524063;C4049621
1176,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
1176,use of methotrexate at randomization —,C0025677;C1524063
1176,use of low - dose aspirin ( < $nmbr$ mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
1176,use of low - dose aspirin ( < $nmbr$,C1524063;C2608320
1176,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C1524063;C3540777;C3540778
1176,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C1524063;C3540777;C3540778
1176,use of ics at baseline  %,C0815320;C1524063;C4551720
1176,use of high - dose inhaled glucocorticoid — no . { % ),C0444956;C1524063
1176,use of diuretics  n ( % ),C0012798;C1524063
1176,use of clopidogrel,C0070166;C1524063
1176,use of aspirin at time of qualifying event ( % ),C0004057;C1524063
1176,use of ace inhibitor,C0003015;C1524063;C4541021
1176,postoperative use of p - blocker,C0032790;C1524063
1176,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
1176,diabetes with no use of diabetes drugs,C0020616;C1524063
1176,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
1175,total bleeds,C0232100
1175,total bleeding,C0232100
1175,rectal bleeding subscore {,C0018932;C0267596
1175,rectal bleeding subscore,C0018932;C0267596
1174,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788
1174,> $nmbr$ beds,C0004916
1174,< $nmbr$ beds,C0004916
1173,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
1173,bleeding outcomes,C0019080;C1274040
1173,bleeding end points,C0019080;C2349179
1173,bleeding,C0019080
1173,any overt bleed,C0019080
1173,any gusto bleeding,C0019080
1172,usual care ( n = $nmbr$ la ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
1172,usual care ( n = $nmbr$ a ),C1947933;C3538928
1172,usual care ( n = $nmbr$ ),C1947933;C3538928
1172,usual care,C1947933;C3538928
1172,standard care,C1442989;C1947933;C2828392
1172,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
1172,care,C1947933
1171,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
1171,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
1171,mace +,C0349381;C0949745;C1445339
1171,mace,C0349381;C0949745;C1445339
1171,hard mace,C0018599;C0349381;C0949745;C1445339
1171,expanded mace,C0205229;C0349381;C0949745;C1445339
1171,b mace,C0349381;C0949745;C1445339
1171,adjudicated mace $nmbr$,C0349381;C0949745;C1445339
1171,$nmbr$ - polnt mace,C0349381;C0949745;C1445339
1170,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
1170,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
1170,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
1170,overall efficacy,C0282416;C1280519;C1561607;C1707887
1170,efficacy variable,C0439828;C1280519;C1707887;C4553760
1170,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
1170,efficacy measures,C1280519;C1707887
1170,efficacy endpoints *,C1280519;C1707887;C2349179
1170,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
1170,efficacy end points,C1280519;C1707887;C2349179
1170,efficacy and safety : net adverse clinical events *,C1280519;C1707887
1170,efficacy    n   ( % ) a,C1280519;C1707887
1170,efficacy,C1280519;C1707887
1169,uveitis,C0042164;C1963266
1169,synovitis,C0039103
1169,sinusitis,C0037199;C4553555
1169,rhinitis,C0035455
1169,osteitis,C0029400
1169,cystitis,C0010692;C0600041;C1963088
1169,bursitis,C0006444
1169,bronchitis,C0006277
1168,tendonitis,C0039503
1168,spondylitis,C0038012
1168,pancolitis,C0868908
1168,non - spondylitis,C0038012;C1518422
1167,serious infections,C0205404;C3714514
1167,lifestyle modifications,C0870811;C2960841
1167,laboratory investigations,C0022877;C1261322;C3244292;C4283904
1167,investigations,C1261322
1167,infections and infestations,C3714514
1167,infections,C3714514
1167,coexisting conditions,C0679225
1167,additional investigations,C2359834
1166,secondary endpoints :,C4528314
1166,pharyngitis,C0031350;C4553308
1166,oropharyngeal pain,C2363731;C4554669
1166,nasopharyngitis,C0027441
1166,key secondary end point : st,C0036056;C3272372;C4528314
1165,phenytoin,C0031507;C0202454
1165,phenobarbital,C0031412
1165,chondroitin,C0008454
1164,lung neoplasm malignant,C0024121
1164,inflammation,C0021368
1164,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
1163,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
1163,inflammatory,C0333348
1162,type of hospitalization,C3177060
1162,required hospitalization,C1708385
1162,primary indication,C1549995
1162,omega $nmbr$ allocation,C1706778;C1719844
1162,n - $nmbr$ allocation,C0369718;C0441922;C1706778
1162,mouth ulceration,C0149745
1162,method of insulin administration,C0025663;C0199782;C0449851;C0871511
1162,lung infection,C0876973;C4552950
1162,limb amputation,C0002689
1162,insulin glargine allocation,C0907402;C1706778
1162,insulin administration,C0199782
1162,glargine allocation,C0907402;C1706778
1161,telmisartan group ( n = $nmbr$ ),C0248719;C0441848
1161,telmisartan ( n = $nmbr$ ),C0248719
1161,telmisartan ( n = $nmbr$  $nmbr$ ),C0248719
1161,telmisartan,C0248719
1160,irbesartan ( n = $nmbr$ ),C0288171
1160,irbesartan,C0288171
1159,valsartan n / n,C0216784
1159,valsartan / hctz,C0020261;C0216784
1159,valsartan ( n = $nmbr$ ),C0216784
1159,valsartan  n / n ( % ),C0216784
1159,valsartan  n ( % ),C0216784
1159,valsartan,C0216784
1158,tolvaptan ( n = $nmbr$ ),C1176308
1158,tolvaptan,C1176308
1158,rosuvastatin   n   =   $nmbr$,C0965129
1158,rosuvastatin n = $nmbr$,C0965129
1158,rosuvastatin +,C0965129
1158,rosuvastatin ( n = $nmbr$ . $nmbr$ ),C0965129
1158,rosuvastatin ( n = $nmbr$ ),C0965129
1158,rosuvastatin ( n = $nmbr$  $nmbr$ ),C0965129
1158,rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
1158,rosuvastatin  n ( % ),C0965129
1158,rosuvastatin,C0965129
1158,i rosuvastatin ( n = $nmbr$ ),C0021966;C0221138;C0965129
1158,$nmbr$ mg  rosuvastatin $nmbr$ mg .,C0965129;C1319635
1157,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
1157,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
1157,ra,C3538806;C4048756
1157,all - baricitinib ra ( n = $nmbr$ ) *,C3538806;C4044947;C4048756
1156,medical treatment  n ( % ),C0679624
1156,medical treatment,C0679624
1156,medical therapy only ( n = $nmbr$ ),C0205171;C0418981;C1720467
1156,medical therapy only,C0205171;C0418981;C1720467
1156,medical therapy alone,C0418981
1156,medical therapy ( n = $nmbr$ ),C0418981
1156,medical therapy,C0418981
1156,medical therapies,C0418981
1155,general health vas  $nmbr$ - $nmbr$ mm,C0042815;C0424575;C3536884;C3827561;C4018875;C4330985;C4554674
1155,general health ( self - reported ),C0424575;C4018875
1155,general health  self - reported,C0424575;C4018875
1155,general health,C0424575;C4018875
1154,physical exam oedema,C0013604;C0031809;C1717255
1154,edema peripheral,C0013604;C1717255
1154,edema  peripheral,C0013604;C1717255
1154,edema  n ( % ),C0013604;C1717255
1154,edema  ( % ),C0013604;C1717255
1154,edema  % z,C0013604;C1717255
1153,pdqol scale,C0175659;C0349674;C1947916
1153,pasi score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
1153,morning stiffness severity  $nmbr$ - $nmbr$ scale,C0175659;C0349674;C0439793;C0457086;C0522510;C1947916
1153,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
1153,jsn score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231
1153,individuals with t $nmbr$ dm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
1153,haq score ( $nmbr$ – $nmbr$ scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
1153,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
1153,geometric mean blood eosinophil count on loge scale — cells / ^ ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
1153,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
1153,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C1947916;C1963185
1153,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
1152,overall ® $nmbr$ . $nmbr$,C0282416;C1561607
1152,overall treatment effect,C0282416;C1518681;C1561607
1152,overall study population,C0282416;C1561607;C2348561
1152,overall study period,C0282416;C1561607
1152,overall pad,C0282416;C1561607
1152,overall n = $nmbr$  $nmbr$,C0282416;C1561607
1152,overall n ( n / loopy ),C0282416;C1561607
1152,overall hr ( $nmbr$ % cl ),C0282416;C0596019;C1561607
1152,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
1152,overall ctd,C0282416;C1335071;C1442905;C1561607
1152,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
1152,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
1152,overall a phase population,C0282416;C1561607
1152,overall ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0282416;C1561607
1152,overall ( pp ) ( n = $nmbr$ ),C0030375;C0063017;C0282416;C1561607;C4319755
1152,overall ( per protocol ) ( n = $nmbr$ ),C0282416;C1561607;C1698058
1152,overall ( n = u $nmbr$ ),C0282416;C0439148;C1561607
1152,overall ( n = $nmbr$ vs $nmbr$ ),C0282416;C1561607
1152,overall ( n = $nmbr$ ),C0282416;C1561607
1152,overall ( n = $nmbr$  $nmbr$ ),C0282416;C1561607
1152,overall ( itt ) ( n = $nmbr$ ),C0282416;C1561607
1152,overall ( $nmbr$  $nmbr$ ),C0282416;C1561607
1152,overall $nmbr$,C0282416;C1561607
1152,overall  qvai $nmbr$ - sfc,C0282416;C1561607;C4521536
1152,overall  n = $nmbr$,C0282416;C1561607
1152,overall,C0282416;C1561607
1152,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
1152,calima overall ( n = $nmbr$ ),C0282416;C1561607
1152,a . overall and subgroups bv statin potency - -,C0282416;C1561607
1152,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
1151,values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0005823;C0022709;C0042295;C0054015;C0332307;C0428772;C0488728;C0597357;C0600137;C1095989;C1144709;C1291218;C1417808;C1452534;C1547052;C2709270;C2982014;C3537020;C3683557;C3888198
1151,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
1151,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0428772;C0488728
1151,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a,C0428772;C0488728
1151,lvef — no . ( % )  i,C0428772;C0488728
1151,lvef within $nmbr$ months  %,C0428772;C0439231;C0488728
1151,lvef within $nmbr$ mo  %,C0026544;C0332177;C0428772;C0488728
1151,lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline,C0428772;C0488728
1151,lvef > $nmbr$ %,C0428772;C0488728
1151,lvef < $nmbr$ . $nmbr$,C0428772;C0488728
1151,lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “,C0428772;C0488728
1151,lvef < $nmbr$ %,C0428772;C0488728
1151,lvef ( u ),C0428772;C0439148;C0488728
1151,lvef ( % ),C0428772;C0488728
1151,lvef  %,C0428772;C0488728
1151,lvef,C0428772;C0488728
1151,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0488728
1151,left ventricular ejection fraction — % §,C0428772;C0488728
1151,left ventricular ejection fraction — %,C0428772;C0488728
1151,left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
1151,left ventricular ejection fraction within previous $nmbr$ mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
1151,left ventricular ejection fraction < $nmbr$ %,C0428772;C0488728
1151,left ventricular ejection fraction ( % ),C0428772;C0488728
1151,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
1151,left ventricular ejection fraction  % *,C0428772;C0488728
1151,left ventricular ejection fraction  %,C0428772;C0488728
1151,left ventricular ejection fraction,C0428772;C0488728
1151,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0005823;C0010055;C0018787;C0018801;C0021122;C0022709;C0024117;C0085805;C0155626;C0162589;C0185098;C0205042;C0428772;C0439849;C0488055;C0488728;C0521942;C0536221;C0596306;C0699792;C0815017;C0871470;C1264633;C1271104;C1272641;C1275491;C1305855;C1306620;C1511726;C1532338;C1554103;C2733342;C2825184;C3245479;C3714741;C3813197;C3888198;C4281799
1151,data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0010055;C0011198;C0014442;C0017480;C0018801;C0021122;C0024117;C0032042;C0042508;C0085805;C0155626;C0162589;C0428772;C0428883;C0488055;C0488728;C0521942;C0815017;C0871470;C0965129;C1306620;C1452534;C1511726;C1532338;C1696465;C1706408;C3245479;C3541240;C3714741;C3888198;C4284014;C4521602
1150,vessel treated  n,C0005847
1150,vascular territory # $nmbr$,C0005847;C1301808;C1558950;C1801960;C2983136
1150,vascular risk score — no . { % ) ^,C0005847;C0035647;C1558950;C1801960;C4552904
1150,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1150,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
1150,vascular history  %,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
1150,vascular disordersb,C0005847;C1558950;C1801960
1150,vascular accidents  n ( % ),C0000924;C0005847;C1558950;C1801960
1150,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
1150,vascular,C0005847;C1558950;C1801960
1150,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
1150,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
1150,treated vessel ( s ),C0005847;C1522326
1150,treated vessel !,C0005847;C1522326
1150,treated vessel,C0005847;C1522326
1150,single vessel coronary artery diseasea,C0005847;C0265903
1150,restenotic vessel,C0005847;C0333186
1150,one vessel,C0005847;C0205447
1150,number of vessels treated  index pci,C0005847;C0237753;C0449788
1150,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
1150,number of treated vessels,C0005847;C0237753;C0449788;C1522326
1150,no culprit vessel identified,C0005847
1150,no . of vessels with > $nmbr$ % stenosis,C0005847
1150,no . of vessels treated,C0005847
1150,no . of vessels,C0005847
1150,no . of treated vessels,C0005847;C1522326
1150,multi vessel ( or left main ),C0005847;C0439064;C3266262
1150,culprit vessel,C0005847
1150,any vascular diasease,C0005847;C1558950;C1801960
1150,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
1150,> $nmbr$ vessels treated,C0005847
1150,> $nmbr$ lesions per vessel,C0005847;C0221198
1150,> $nmbr$ diseased vessels,C0005847
1150,$nmbr$ vessels or left main,C0005847
1150,$nmbr$ vessels,C0005847
1150,$nmbr$ vessel,C0005847
1149,sbp > $nmbr$ mnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
1149,sbp ( sd ),C0085805;C2699239
1149,sbp  last,C0085805
1149,sbp,C0085805
1149,ambulatory sbp  n,C0085805;C0439841
1148,low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205251;C1079230;C1415800;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
1148,high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
1148,feno — ppb,C1415800
1148,> $nmbr$ to < $nmbr$ ppb,C1415800
1148,> $nmbr$ ppb,C1415800
1148,< $nmbr$ ppb,C1415800
1147,vdz / pbo [ n = $nmbr$ ],C0031962
1147,pbo n = $nmbr$,C0031962
1147,pbo n ( % ),C0031962
1147,pbo - sc every other week ( n = $nmbr$ ),C0031962;C0282380
1147,pbo + mtx to mtx,C0025677;C0031962;C1417487
1147,pbo + mtx n = $nmbr$,C0025677;C0031962;C1417487
1147,pbo + mtx ^ mtx,C0025677;C0031962;C1417487
1147,pbo + mtx,C0025677;C0031962;C1417487
1147,pbo ( n   =   $nmbr$ ),C0031962
1147,pbo ( n = $nmbr$ ) vs,C0031962
1147,pbo ( n = $nmbr$ ),C0031962
1147,pbo ( n - $nmbr$ ),C0031962
1147,pbo ( n $nmbr$ ),C0031962
1147,pbo ( n $nmbr$ $nmbr$ ),C0031962
1147,pbo  no . ( o / o ) ^ ’,C0031962
1147,pbo  no . ( % ) ^,C0031962
1147,pbo  n = $nmbr$,C0031962
1147,pbo,C0031962
1147,ind + pbo ( n = $nmbr$ ),C0031962;C4049864
1147,ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1334085;C1708411
1147,flex pbo ®,C0031962
1146,r - tpa,C0032143
1146,alteplase group ( n = $nmbr$ ),C0032143;C0441848
1146,alteplase ( n = $nmbr$ ),C0032143
1146,alteplase,C0032143
1145,vdz / pla n = $nmbr$,C0456170
1145,pla « = $nmbr$,C0456170
1145,pla n = $nmbr$,C0456170
1145,pla,C0456170
1145,atio - pla,C0456170
1144,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
1144,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
1144,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
1144,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1144,pad details  n ( % ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1144,pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1144,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1144,no pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
1143,suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1143,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1143,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
1143,estradiol quartiles,C0014912;C2828255
1142,st - segment deviation timi risk score  %,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
1142,st - segment deviation > $nmbr$ mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
1142,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
1142,deviation  mm,C0012727;C0205419;C1705236;C4330985;C4554674
1141,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
1141,relative risk ® ( $nmbr$ % cl ),C0242492;C0596019
1141,relative risk ® ' ( $nmbr$ % cl ),C0242492;C0596019
1141,relative risk vs . placebo ( $nmbr$ % cl ),C0242492
1141,relative risk reduction ( $nmbr$ % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
1141,relative risk reduction ( $nmbr$ % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
1141,relative risk * ( $nmbr$ % cl ),C0242492;C0596019
1141,relative risk ( $nmbr$ % cl ),C0242492;C0596019
1141,mean wall thickness ( cm ),C0677535;C4054557
1140,size of left atrium normal — no . ( % ) £,C0225860;C0456389
1140,left atrial diameter : < $nmbr$ mm ( n = $nmbr$ ),C0225860;C0225861;C1301886;C4330985;C4554674
1140,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
1140,left atrial diameter,C0225860;C0225861;C1301886
1140,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
1139,treated with losartan ( n = $nmbr$ ),C0126174;C0332293
1139,treated with laba  %,C0332293
1139,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
1139,treated with cabg — no . / total no . ( % ),C0010055;C0332293
1139,treated with atenolol ( n = $nmbr$ ),C0004147;C0332293
1138,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
1138,treatment duration  days,C0439228;C0444921;C3259042
1138,duration of treatment in the healing study  n,C0444921
1137,stratification factors,C1514984
1137,stratification factor : menopausal status  n ( % ),C1513126;C1514984
1136,fluvastatin ( n = $nmbr$ ),C0082608
1136,clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
1136,atorvastatin { n = $nmbr$  $nmbr$ ),C0286651
1136,atorvastatin monotherapy ( n = $nmbr$ * ),C0286651
1136,atorvastatin ( n = $nmbr$  $nmbr$ ),C0286651
1136,atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0286651;C1142985;C1319635
1136,atorvastatin $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1136,atorvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1136,atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1136,atorvastatin $nmbr$ mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1136,atorvastatin  n ( % ),C0286651
1136,atorvastatin,C0286651
1135,normal albuminuria ( uacr < $nmbr$ ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
1135,macro - albuminuria,C0001925;C2984010
1135,any albuminuria — no . ( % ),C0001925
1135,any albuminuria,C0001925
1135,albuminuria and previous maerovaseular disease without established renal disease,C0001925
1135,albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g ),C0001925;C0702093;C1524029;C1635169;C1739039;C3811844;C3812682;C3813700
1135,albuminuria < $nmbr$ gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
1135,albuminuria ( g / g ),C0001925;C1319635
1135,albuminuria,C0001925
1134,vedolizumab n = $nmbr$,C2742797
1134,vedolizumab cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755;C2742797
1134,vedolizumab,C2742797
1134,mepolizumab,C0969324
1134,dupilumab $nmbr$,C3660996
1133,golimumab $nmbr$ mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
1133,golimumab,C2353893
1132,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
1132,omalizumab ( lsm ),C0966225
1132,omalizumab,C0966225
1131,evolocumab + soc ( n = $nmbr$ ),C3529352
1131,evolocumab ( n = $nmbr$ ),C3529352
1131,evolocumab ( $nmbr$ mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
1131,evolocumab $nmbr$ mg monthly ( n = $nmbr$ ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
1131,evolocumab,C3529352
1130,lebrikizumab ( n = $nmbr$ ),C2981360
1130,lebrikizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1130,lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1130,lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1130,lebrikizumab $nmbr$ - $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1130,benralizumab q $nmbr$ w ( n = $nmbr$ ),C2982078
1130,benralizumab q $nmbr$ w ( n - $nmbr$ ),C2982078
1130,benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
1130,benralizumab,C2982078
1129,reslizumab ( n = $nmbr$ ),C1869620
1129,reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ ),C0439272;C1869620
1129,reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1869620
1129,reslizumab,C1869620
1129,b reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
1129,a reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
1128,ultrasound carotid arteries,C0948945
1128,treatment satisfaction,C3476649
1127,notable abnormalities,C0000768;C0000769;C4288581
1127,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
1126,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
1126,patient - reported outcomes,C2987124
1126,no reperfusion,C0035124;C0684253
1126,acute reperfusion,C0035124;C0205178;C0684253
1125,sulphonamides  urea derivatives,C0038760;C0041942;C0243072
1125,propionic acid derivatives,C0033482;C0695274;C3540752
1125,mycophenolate ( any derivative ),C0883242
1125,dopa and dopa derivativese,C0013023
1125,adamantane derivatives,C3653470
1124,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
1124,other defined,C1704788;C3539106
1123,renal parameters,C0022646;C0449381
1123,parameters,C0449381
1123,other lipid parameters,C0023779;C0449381
1123,lipid parameters,C0023779;C0449381
1123,height in meters .,C0441074;C0489786
1123,glycaemic parameters,C0005802;C0449381
1123,biometric parameters,C0005544;C0449381;C2718322
1123,> = $nmbr$ meters,C0441074
1123,< $nmbr$ meters,C0441074
1122,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0231174;C0680095;C0699733;C2024216;C4554158
1122,devices,C0025080;C0220819;C0699733
1121,furosemide equivalent  mg / kg,C0016860;C0205163;C0439185;C0439272
1121,furosemide,C0016860
1120,apremilast $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
1120,apremilast,C1678805
1119,triacylglycerol  mmol / le,C0023190;C0041004;C0439090;C0439190;C1423767;C2697858
1119,total cholesterol  mmol / le,C0023190;C0201950;C0439090;C0439190;C0543421;C1423767;C2697858
1119,fema le,C0023190;C0439090;C1423767;C2697858
1118,thromboembolism,C0040038
1118,systemic embolism,C0013922;C0205373;C1704212
1118,non cns embolism,C0013922;C1518422;C1704212;C3714787
1118,embolism,C0013922;C1704212
1118,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
1117,very severe n z $nmbr$,C3641272;C4050419
1117,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
1117,very severe ( itt ) ( n = $nmbr$ ),C3641272;C4050419
1117,very severe ( gold $nmbr$ ),C0018026;C1304897;C3641272;C4050419
1117,very severe  gold $nmbr$,C0018026;C1304897;C3641272;C4050419
1117,very severe,C3641272;C4050419
1117,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
1117,$nmbr$ - $nmbr$ ( very severe ),C3641272;C4050419
1116,severe / moderate,C1299393
1116,moderate - to - severe copd exacerbation,C0740304;C1299393
1116,gusto severe / moderate,C1299393
1115,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
1115,re - medy,C0556581;C2986904
1115,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
1115,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
1115,re - cover $nmbr$ warfarin,C0180153;C0556581;C1999244;C2986904;C3888055
1115,re - cover $nmbr$ dabigatran,C0180153;C0556581;C1999244;C2986904;C3888055
1114,smedian prednisone dose  n ( % ),C0032952;C0178602;C0869039;C1114758
1114,prednisone use  %,C0032952;C0042153;C0457083;C1947944
1114,prednisone or equivalent dose ( mg / day ),C0032952
1114,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1114,prednisone - equivalent dose  mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1114,prednisone,C0032952
1114,oral glucocorticoid dose  mg ( prednisone equivalent ),C0017710;C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0442027;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761;C4521986
1114,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
1114,< median prednisone dose  n ( % ),C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
1114,% pred,C0032952;C0044955
1113,patients with ascvd but no prior ml hr ( $nmbr$ % cl ),C0030705;C3665365
1113,other ascvd  no . ( % ),C3665365
1113,other ascvd,C3665365
1113,no ascvd,C3665365
1113,ascvd no prior ml,C3665365
1113,ascvd including tia,C3665365
1113,ascvd as per protocol,C1698058;C3665365
1113,ascvd * . n ( % ),C3665365
1113,ascvd  n ( % ),C3665365
1113,ascvd  b no . ( % ),C3665365
1113,ascvd,C3665365
1112,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
1112,vi $nmbr$   µ g,C0205999;C0439267
1112,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
1112,tiotropium $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1112,tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ ),C0213771;C0439267
1112,tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1112,hgb  g / dl < $nmbr$ men  < $nmbr$ women,C0019029;C0019046;C0025266;C0043210;C0439267;C0518015;C1424337
1112,hgb  g / dl,C0019029;C0019046;C0439267;C0518015;C1424337
1112,hb decrease ≥ $nmbr$ g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
1112,hb  g / dl,C0019046;C0439267;C3642216;C3843510
1112,gly $nmbr$ μ g bid,C0017890;C0439267;C0523677
1112,glu $nmbr$ asp g . t,C0125690;C0439267
1112,g - blockers,C0439267
1112,g + c,C0439267
1112,g,C0439267
1112,formoterol $nmbr$   μ g ( n   =   $nmbr$ ),C0060657;C0439267
1112,bdp / ff / g ( n = $nmbr$ ),C0004906;C0439267;C1422585;C1538710;C4554348
1112,albumin  g / dl,C0001924;C0439267
1112,aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ ),C0439267;C2699757
1112,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b,C0439267;C2699757
1112,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a,C0439267;C2699757
1112,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ),C0439267;C2699757
1112,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
1112,$nmbr$ μ g bid ( n = $nmbr$ ),C0439267
1112,$nmbr$ μ g ( n = $nmbr$ ),C0439267
1112,$nmbr$ a . g,C0439267
1111,vildagliptin + metformin ( vldm ),C0025598;C1570906
1111,vildagliptin ( n = $nmbr$ ),C1570906
1111,vildagliptin $nmbr$ mg qd n = $nmbr$,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1111,vildagliptin $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1111,vildagliptin $nmbr$ mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1111,vildagliptin $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1111,vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1111,vildagliptin,C1570906
1110,with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1110,with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1110,with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1110,with alogliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
1110,alogliptin ( n = $nmbr$ ),C1958126
1110,alogliptin  n ( % ),C1958126
1110,alogliptin,C1958126
1109,sitagliptin ± oad,C1565750
1109,sitagliptin no . / total no .,C1565750
1109,sitagliptin n = $nmbr$,C1565750
1109,sitagliptin ( n = $nmbr$ ),C1565750
1109,sitagliptin $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
1109,sitagliptin $nmbr$,C1565750
1109,sitagliptin,C1565750
1109,saxagliptin ( n = $nmbr$ ),C1611934
1109,saxagliptin ( n = $nmbr$  $nmbr$ ),C1611934
1109,saxagliptin ( % ),C1611934
1109,saxagliptin $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
1109,saxagliptin,C1611934
1109,linagliptin / metformin,C3264599
1108,semaglutide exposure  nmol / l,C0274281;C0332157;C0439282;C3885068
1108,semaglutide ( n = $nmbr$ ),C3885068
1108,semaglutide,C3885068
1108,liraglutide n ( % ),C1456408
1108,liraglutide ( « = $nmbr$ ),C1456408
1108,liraglutide ( n = $nmbr$ ),C1456408
1108,liraglutide ( n = $nmbr$  $nmbr$ ),C1456408
1108,liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1108,liraglutide,C1456408
1108,dulaglutide $nmbr$ . $nmbr$ mgf,C1366394;C3179549;C3712803;C3887684
1107,multivitamins,C0301532;C3714835
1107,mucolytics,C0026698
1107,mucolytic agent,C0026698
1106,ultra,C0728475
1106,lira,C1555441
1105,previous limb or foot amputation,C0015385;C0205156;C1552607
1105,limb,C0015385
1104,vldl cholesterol,C0023826;C0523560
1104,vldl - c,C0523560
1104,vldl,C0523560
1104,ldlc : hdlc,C1416822;C1704429
1104,ldlc,C1416822
1103,ld,C0694649
1103,cg / ld,C0043444;C0694649;C1567075;C3540479
1103,< $nmbr$ . $nmbr$ ld,C0694649
1102,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
1102,total - c : hdl - c,C0439175;C0439810;C3715113
1102,non - hdl choleslerol,C1518422;C3715113
1102,ldl - c : hdl - c,C3715113
1102,ldl - c / hdl - cx,C3715113
1102,ldl - c / hdl - c,C3715113
1102,hdl choleslerol,C3715113
1102,hdl - cy,C0010622;C0332298;C2239193;C3715113
1102,hdl - cd,C0007928;C0034283;C3715113;C4552032
1102,hdl - c,C3715113
1102,hdl *,C3715113
1102,hdl $nmbr$ - c,C3715113
1102,hdl $nmbr$,C3715113
1102,hdl,C3715113
1101,reduced hdl cholesterol,C0151691
1101,low hdl cholesterol * |,C0151691
1101,low hdl cholesterol,C0151691
1101,low hdl - c,C0151691
1100,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
1100,mean age ± s . d .  years,C0444504;C1510829;C2347634;C2348143
1100,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
1100,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
1100,mean age ( years ),C0444504;C1510829;C2347634;C2348143
1100,mean age ( years  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1100,mean age  years ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
1100,mean age  years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
1100,mean age  years ( $nmbr$ % ci ),C0008107;C0444504;C1510829;C2347634;C2348143;C3259781
1100,mean age  years,C0444504;C1510829;C2347634;C2348143
1100,i $nmbr$ years of age,C0021966;C0221138;C1510829
1100,age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
1100,age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
1100,age ≥ $nmbr$ years  n ( % ),C1510829
1100,age ≥ $nmbr$ years,C1510829
1100,age £ $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
1100,age years,C1510829
1100,age s $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
1100,age range ( years ),C1510829;C1514721;C2348147;C3542016
1100,age range  years,C1510829;C1514721;C2348147;C3542016
1100,age mean age  years sex,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143
1100,age in years  mean,C0444504;C1510829;C2347634;C2348143
1100,age in years,C1510829
1100,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
1100,age groiro : < $nmbr$ years,C1510829
1100,age at entry ( years ),C1510829;C1705654
1100,age [ years ] ( interaction : p = $nmbr$ . $nmbr$ ),C1510829;C1704675
1100,age [ years ],C1510829
1100,age > = $nmbr$ years old,C1510829
1100,age > = $nmbr$ years,C1510829
1100,age > $nmbr$ years ( n = $nmbr$ ),C1510829
1100,age > $nmbr$ years ( median ),C1510829
1100,age > $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
1100,age > $nmbr$ years $nmbr$,C1510829
1100,age > $nmbr$ years  n ( % ),C1510829
1100,age > $nmbr$ years  %,C1510829
1100,age > $nmbr$ years,C1510829
1100,age > $nmbr$ ( years ) t,C1510829
1100,age < $nmbr$ years — no . ( % ),C1510829
1100,age < $nmbr$ years old,C1510829
1100,age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
1100,age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
1100,age < $nmbr$ years ( n = $nmbr$ ),C1510829
1100,age < $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
1100,age < $nmbr$ years ( n =,C1510829
1100,age < $nmbr$ years ( median ),C1510829
1100,age < $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
1100,age < $nmbr$ years $nmbr$,C1510829
1100,age < $nmbr$ years  n ( % ),C1510829
1100,age < $nmbr$ years,C1510829
1100,age : > $nmbr$ years,C1510829
1100,age : < $nmbr$ years ( n = $nmbr$ ),C1510829
1100,age : < $nmbr$ years,C1510829
1100,age . years,C1510829
1100,age - years,C1510829
1100,age ( years ) a,C1510829
1100,age ( years ) : > $nmbr$,C1510829
1100,age ( years ) : < $nmbr$,C1510829
1100,age ( years ) : $nmbr$ - < $nmbr$,C1510829
1100,age ( years ) :,C1510829
1100,age ( years ) +,C1510829
1100,age ( years ) *,C1510829
1100,age ( years )  mean ± s . d .,C0444504;C1510829;C2347634;C2348143
1100,age ( years )  mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
1100,age ( years ),C1510829
1100,age ( years ( s . d . ) ),C1510829
1100,age ( years  sd ),C1510829;C2699239
1100,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
1100,age ( per $nmbr$ years ),C1510829
1100,age $nmbr$ years or more,C1510829
1100,age $nmbr$ years ( n = $nmbr$ ),C1510829
1100,age $nmbr$ years,C1510829
1100,age $nmbr$ - $nmbr$ years ( n = $nmbr$ ),C1510829
1100,age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
1100,age $nmbr$ + years,C1510829
1100,age $ $nmbr$ years § *,C1510829
1100,age  years “,C1510829
1100,age  years mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
1100,age  years ^,C1510829
1100,age  years *,C1510829
1100,age  years ( sd ),C1510829;C2699239
1100,age  years ( mean _ + sd ) sex  n ( % ) :,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143;C2699239
1100,age  years $nmbr$ ',C1510829
1100,age  years,C1510829
1100,age  median ( range ) ( years ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1100,age  mean ( range ) years,C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
1100,age  ( years ),C1510829
1100,age  $nmbr$ years,C1510829
1100,> $nmbr$ years of age  n ( % ),C1510829
1100,> $nmbr$ years of age,C1510829
1100,< $nmbr$ years of age,C1510829
1099,gender n ( % ),C0079399;C1522384
1099,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender [ n ( % ) ],C0079399;C1522384
1099,gender : male    n   ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender :,C0079399;C1522384
1099,gender - n ( % ),C0079399;C1522384
1099,gender - male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1099,gender ( male )  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender ( female : male  % ),C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
1099,gender    n   ( % men ),C0025266;C0079399;C1522384
1099,gender    n   ( % ),C0079399;C1522384
1099,gender  women n  % ),C0043210;C0079399;C1522384
1099,gender  no . ( % ),C0079399;C1522384
1099,gender  n ( % ],C0079399;C1522384
1099,gender  n ( % ),C0079399;C1522384
1099,gender  male ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender  male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender  male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
1099,gender  female  n ( % ),C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
1099,gender  % of patients,C0030705;C0079399;C1522384
1099,gender  %,C0079399;C1522384
1099,gender,C0079399;C1522384
1099,female sex  n ( % of patients ),C0009253;C0030705;C0036864;C0043210;C0079399;C0086287;C0150831;C0150905;C0804628;C1314687;C1522384;C1705497;C1705498
1099,eze / simva gender,C0079399;C1522384
1099,age  y sex  no . ( % ),C0001779;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
1099,age  y gender  n ( % ),C0001779;C0079399;C1522384
1098,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
1098,tier $nmbr$ aes,C1412268;C2699274
1098,other selected aes,C1412268;C1707391;C2699274
1098,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
1098,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
1098,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
1098,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
1098,any aes  n ( % ),C1412268;C2699274
1098,any aes,C1412268;C2699274
1098,aes related to,C1412268;C2699274
1098,aes leading to dose reduction of study drugb,C1412268;C2699274
1098,aes leading to discontinuation of study drugb,C1412268;C2699274
1098,aes leading to,C1412268;C2699274
1098,aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §,C0030705;C0376247;C1412268;C1556094;C2699274
1098,aes *,C1412268;C2699274
1098,> $nmbr$ aes leading to discontinuation,C1412268;C2699274
1098,> $nmbr$ aes,C1412268;C2699274
1097,standard therapy ( n = $nmbr$ ),C2936643
1097,standard therapy,C2936643
1097,hormone therapy use,C0042153;C0279025;C0457083;C1947944
1097,hormone therapy,C0279025
1097,hormonal therapy — no . ( % ),C0279025
1097,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
1097,combined therapy vsdutasteride,C0033972
1097,combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$,C0033972
1096,pharmacotherapy,C0013216;C0013217
1096,other drug therapy  n ( % ),C0013216;C0013217
1096,drug therapy at admission 一 no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
1096,drug therapy at admission — no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
1096,drug therapy  no . ( % ),C0013216;C0013217
1096,drug therapy  n ( % ),C0013216;C0013217
1096,drug therapy,C0013216;C0013217
1095,unhappy,C1688635
1095,nap,C0870935;C1423800;C4283878
1094,voluntary,C0439656;C3543419
1094,sedentary,C0205254
1094,hungary,C0020174
1093,permanent users  n,C0205355;C1706077
1093,permanent users,C0205355;C1706077
1093,permanent af,C0205355;C0344434;C4049859
1093,permanent ( n  % ),C0205355
1093,permanent  n ( % ),C0205355
1093,permanent,C0205355
1093,perianal or anus,C0442158
1093,perianal gi tract,C0017189;C0442158
1093,perianal  n ( % ),C0442158
1092,peripheral vasodilators,C0724804
1092,peripheral sensory neuropathy,C0151313;C4554142
1092,peripheral neuropathy,C0031117
1092,peripheral embolism,C0013922;C0205100;C1704212
1092,peripheral edema,C0085649
1092,peripheral,C0205100
1091,very high vs . normalb,C0442804;C4321397
1091,very high vs . normal,C0442804;C4321397
1091,very high ( >   $nmbr$ xuln ) n   =   $nmbr$,C0442804;C4321397
1091,very high,C0442804;C4321397
1090,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
1090,vorapaxar no . ( $nmbr$ - y km % ),C2974521
1090,vorapaxar n = $nmbr$,C2974521
1090,vorapaxar group ( n = $nmbr$ ),C0441848;C2974521
1090,vorapaxar ( n = $nmbr$ . $nmbr$ ),C2974521
1090,vorapaxar ( n = $nmbr$ )  n ( % ),C2974521
1090,vorapaxar ( n = $nmbr$ ),C2974521
1090,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521
1090,vorapaxar ( n = $nmbr$  $nmbr$ ),C2974521
1090,vorapaxar $nmbr$ - y,C2974521
1090,vorapaxar,C2974521
1089,verapamil sr strategy ( n = $nmbr$  $nmbr$ ),C0679199;C1527129
1089,verapamil sr n = $nmbr$ no . ( % ),C1527129
1089,verapamil sr n = $nmbr$,C1527129
1089,verapamil sr ( no . = $nmbr$ ),C1527129
1089,verapamil sr,C1527129
1089,verapamil - sr strategy,C0679199;C1527129
1089,verapamil - sr ( « = $nmbr$ $nmbr$ ),C1527129
1088,carvedilol  % ( n ),C0054836
1088,carvedilol,C0054836
1087,varespladib ( n = $nmbr$ ),C2713485
1087,varespladib,C2713485
1086,variables .,C0439828
1086,variables *,C0439828
1086,variables $nmbr$,C0439828
1086,variables,C0439828
1086,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
1086,variable ' ! ',C0439828;C4553760
1086,variable,C0439828;C4553760
1086,stratification variables,C0439828;C1514983
1085,early use intended,C1279919
1085,early routine,C0205547;C1279919
1085,early load,C1279919
1085,early eptifibatide,C0253563;C1279919
1085,early clopidogrel intended,C0070166;C1279919
1085,early - start group ( n = $nmbr$ ),C1279919
1085,early - eptifibatide group ( n = $nmbr$ ),C0253563;C0441848;C1279919
1085,early ( n = $nmbr$ ),C1279919
1085,early  n ( % ),C1279919
1085,early,C1279919
1084,lrg,C1428862
1084,hrg,C1437978;C1705020
1083,arr ( % ),C2170357;C4084934
1083,arr,C2170357;C4084934
1082,use of rescue medication,C0240320
1082,use of other medications — no . ( % ),C0240320
1082,rescue medication use  inh / d {,C0022209;C0240320
1082,prior medication use  n ( % ),C0240320;C0332152;C2826257
1082,no use ofdiabetes drugs — no . ( % ),C0240320
1082,medication use before enrollment  no . ( % ),C0240320;C1516879;C1696073;C3888021
1082,medication use at entry ( % ),C0240320;C1705654
1082,medication use ( % ),C0240320
1082,medication use  n ( % ),C0240320
1082,medication use,C0240320
1082,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
1082,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
1082,concomitant medication use,C0240320;C0521115
1082,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
1081,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
1081,incidence of each outcome,C0021149;C0220856;C1274040
1081,incidence ^,C0021149;C0220856
1081,incidence *,C0021149;C0220856
1081,incidence  ° / o ( $nmbr$ / $nmbr$ cl ),C0021149;C0220856;C0596019
1081,incidence  %,C0021149;C0220856
1081,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
1081,event incidence / n,C0021149;C0220856;C0441471;C4019010
1081,event / patients in group ( incidence / $nmbr$ person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
1081,cumulative incidence lyear,C0021149;C0220856;C1511559
1081,cumulative incidence $nmbr$ years,C0021149;C0220856;C0439234;C1511559
1081,^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .,C0021149;C0220856;C0374505
1081,$nmbr$ - year cumulative incidence  % ( ci ),C0008107;C0021149;C0220856;C0439234;C0439508;C1511559;C3259781
1080,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
1080,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4521986
1080,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0040223;C0205435;C0220880;C0441471;C1279901;C3541383;C4019010
1080,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
1080,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
1080,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
1080,time - to - first - infusion from hip surgery ( days )  n ( % ),C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
1080,received first loading dose,C0205435;C1279901;C1514756;C3714444
1080,mean time to first subcutaneous injectiong  h in relation to surgery  hr,C0033727;C0040223;C0205435;C0369286;C0441932;C0443315;C0444504;C0564385;C1279901;C2347634;C2348143;C3541383;C4528284
1080,mean time to first oral dose postsurgeryh  hr,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
1080,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1555582;C1705685
1080,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
1080,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
1080,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
1080,initial heparin treatment duration on or after randomization,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1080,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1080,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
1080,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
1080,first year *,C0205435;C0439234;C0439508;C1279901
1080,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
1080,first loading dose,C0205435;C1279901;C3714444
1080,first hhf,C0205435;C1279901
1080,first diagnosed,C0205435;C1279901
1080,first - recorded event  no . ( and % ) of patients,C0205435;C1279901
1080,first - generation stentt,C0079411;C0205435;C1279901;C3146294
1080,first ( n = $nmbr$ ),C0205435;C1279901
1080,components of the first cid,C0205435;C0449432;C1279901;C1707433
1080,> = $nmbr$ day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1080,> = $nmbr$ ^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
1079,serum k + level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261
1079,patients with level > $nmbr$ pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
1079,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
1079,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
1079,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
1079,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
1079,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
1079,level of thyroperoxidase antibody at baseline,C0021965;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1547707;C2946261;C3272921
1079,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
1079,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
1079,level $nmbr$ immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
1079,level $nmbr$ immobility ^,C0231441;C0441889;C0456079;C1547707;C2946261
1079,level $nmbr$,C0441889;C0456079;C1547707;C2946261
1079,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
1079,ldl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261
1079,hscrp level,C0441889;C0456079;C1547707;C2946261
1079,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1079,hdl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261;C3715113
1079,hdl - c level  < $nmbr$ mg / dld,C0024671;C0026410;C0439269;C0441889;C0456079;C1414063;C1547707;C1960952;C2346927;C2826331;C2946261;C3715113;C4321396;C4521761
1079,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
1079,european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
1079,elevated natriuretic peptide level ( n = $nmbr$ ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
1079,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
1079,cardiac troponin t level > $nmbr$ . $nmbr$ pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
1079,cardiac troponin t level  median ( iqr )  pg / l,C0439278;C0441889;C0456079;C0549183;C0876920;C1547707;C2347635;C2348144;C2939193;C2946261;C3538889
1079,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
1079,baseline total pcsk $nmbr$ level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
1079,baseline total pcsk $nmbr$ level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
1079,baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1079,baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1079,baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1079,baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1079,baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1079,baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1079,baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1079,baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1079,baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1079,baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1079,baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1079,baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1079,baseline free pcsk $nmbr$ level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
1079,baseline free pcsk $nmbr$ level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
1079,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
1079,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
1079,> $nmbr$ . $nmbr$ hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
1078,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
1078,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups,C0015663;C0020443;C0369773;C0439209;C0439300;C0439583;C0441889;C0456079;C0456962;C0475211;C0750194;C0871208;C1316572;C1317574;C1516879;C1521828;C1522133;C1547707;C1696073;C1704788;C1707455;C1719797;C2603361;C2911648;C2919575;C2946261;C2985769;C3539106;C3888021
1077,flex ain ' ’,C0347129
1077,ain  no . ( % ) “ *,C0347129
1077,ain  no . ( % ) * *,C0347129
1076,anacetrapib ( n = $nmbr$ ),C2604745
1076,anacetrapib ( n = $nmbr$  $nmbr$ ),C2604745
1076,anacetrapib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1076,anacetrapib $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1076,anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1075,spacer use during the study,C0221874;C0869040
1075,placebo - control study,C0683952
1074,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419
1074,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
1073,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
1073,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
1073,b - agonists ( short - acting ) a,C0243192;C2987634
1073,b - agonists ( long - acting ) a,C0243192;C2987634
1072,absolute time spent “ on ” without troublesome dyskinesia  h / day,C0439546
1072,absolute time spent “ on ” with troublesome dyskinesia  h / day,C0439546
1072,absolute time spent “ on ”  h / day,C0439546
1071,eosinophils ( cells / ll ) inclusion criteria  n ( % ),C0682547
1071,eosinophil counf cells pl ',C0682547;C3897966;C4049765
1071,baseline eosinophil < $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1071,baseline eosinophil $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
1070,target nail napsi score ( $nmbr$ – $nmbr$ scale ),C0027342;C1432728;C1521840;C2986546;C3538766
1070,nail involvement  %,C0027342;C1314939;C1432728;C3538766
1069,metabolizer phenotype ( % ) §,C0031437;C1285572
1069,clinical copd phenotype ^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
1068,sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ ),C0030827;C0072225;C0585361;C1266240;C4521536
1068,sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
1068,salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
1068,sal $nmbr$ pg ( n = $nmbr$ ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
1068,qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ ),C0030827;C0072225;C0332173;C1266240
1068,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
1068,nt - probnp  pg / mlt,C0030827;C0072225;C0669479;C0754710;C1266240;C4553833
1068,indacaterol $nmbr$ pg,C0030827;C0072225;C1266240;C1722260
1068,gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$,C0030827;C0072225;C0152277;C1266240;C1415124
1068,fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
1068,formoterol $nmbr$ pg vs placebo,C0030827;C0060657;C0072225;C1266240
1068,formoterol $nmbr$ pg,C0030827;C0060657;C0072225;C1266240
1068,ff $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
1068,aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
1068,aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C2699757
1068,aclidinium $nmbr$ pg,C0030827;C0072225;C1266240;C2699757
1068,ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
1068,ab $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240
1067,diffusion capacity of the lung for carbon monoxide  % predicted !,C0231971
1066,ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness,C0029040
1066,either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years,C3844638
1065,values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295
1065,values were calculated using t tests for continuous variables and chi - square,C0042295
1065,nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0042295;C0669479;C0754710
1065,laboratory values in patients with history of diabetes,C0022877;C0030705;C0042295;C3244292;C4283904
1065,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
1065,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
1065,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0005910;C0042295;C0043100;C0332288;C0439209;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
1065,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0332288
1065,( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled,C0042295
1064,method used to diagnose the incident pulmonary embolism  no . ( % ),C0025663;C0449851;C0871511
1064,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
1063,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931
1063,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C1301931;C1524003;C3541383
1062,menopausal status and use of ht,C1513126
1062,menopausal status and use of hrt ( % ) y,C1513126
1062,menopausal status and hormone therapy use premenopausal,C1513126
1062,menopausal status and hormone therapy use,C1513126
1061,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
1061,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
1061,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
1060,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
1060,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
1060,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
1060,fasting plasma glucose categories  n ( % ),C0015663;C0202042;C0455280;C0683312
1060,fasting plasma glucose *,C0015663;C0202042;C0455280
1060,fasting plasma glucose ( mmol / l ) $nmbr$,C0015663;C0202042;C0455280;C1532563
1060,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
1060,fasting plasma glucose ( mg / dl ) $nmbr$,C0015663;C0202042;C0439269;C0455280
1060,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
1060,fasting plasma glucose $nmbr$ medan,C0015663;C0202042;C0455280
1060,fasting plasma glucose  mg / dl,C0015663;C0202042;C0439269;C0455280
1060,fasting plasma glucose,C0015663;C0202042;C0455280
1060,fascng plasma glucose a medan,C0202042;C0455280
1060,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
1060,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
1060,$nmbr$ - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
1060,$nmbr$ - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
1059,migraine — no . ( % ) $,C0149931
1059,migraine severity score,C0149931;C0457451
1059,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
1059,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
1058,mitral regurgitation  n ( % ),C0026266
1058,mitral regurgitation  ( % ),C0026266
1058,mitral insufficiency  n ( % ),C0026266
1058,mitral insufficiency,C0026266
1057,daily iglar dose at week $nmbr$ ( u ),C0560588;C2348070
1057,daily dose of study medication prescribed,C0013175;C2348070
1057,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
1057,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
1057,average daily dose,C1510992;C2348070;C2825518
1056,total intravenous loop diuretics  mg,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C1960952;C2346927;C4321396;C4521761
1056,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
1056,intravenous vasodilators ( % ),C0443081
1056,intravenous vasoactive drugs  % y,C0683092;C1980011
1056,intravenous nitrates,C0028125;C0348016
1056,intravenous loop diuretics !,C0348016;C0354100
1056,intravenous inotropes or vasopressors ( % ),C0348016;C1258199
1056,intravenous dobutamine,C0012963;C0348016
1056,intravenous ( n = $nmbr$ ),C0348016
1055,indacaterol n = $nmbr$,C1722260
1055,indacaterol group ( n = $nmbr$ ),C0441848;C1722260
1055,indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .,C0439417;C1722260;C3814772
1055,indacaterol - glycopyrronium group ( n = $nmbr$ ),C0441848;C1722260;C3814772
1055,indacaterol + tiotropium ( n [ $nmbr$ ),C0213771;C1722260
1055,indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C1722260
1055,indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211;C1722260
1055,indacaterol $nmbr$ ug ( n = $nmbr$ ),C0041573;C0439211;C1722260
1055,indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1055,differences between indacaterol + tiotropium versus tiotropium + placebo,C0213771;C1705241;C1705242;C1722260
1054,waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl,C0025266;C0043210;C0455829
1054,waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women ),C0025266;C0455829
1054,no . men,C0025266
1054,men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
1054,men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
1054,men : qvai $nmbr$ - sfc,C0025266;C4521536
1054,men ( n 二 $nmbr$ ),C0025266
1054,men ( n [ % ] ),C0025266
1054,men ( n = $nmbr$ vs $nmbr$ ),C0025266
1054,men ( n = $nmbr$ )  n / n ( % ),C0025266
1054,men ( n = $nmbr$ ),C0025266
1054,men ( n = $nmbr$ $nmbr$ ),C0025266
1054,men ( n  % ),C0025266
1054,men ( % ),C0025266
1054,men    n   ( % ),C0025266
1054,men  no . ( % ),C0025266
1054,men  n ( % ) *,C0025266
1054,men  n ( % ),C0025266
1054,men  > $nmbr$ cm,C0025266
1054,men  < $nmbr$ cm,C0025266
1054,men  %,C0025266
1054,men,C0025266
1054,low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl ),C0025266;C0151691;C0439269
1054,high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl ),C0025266;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
1054,gmi ( men ),C0025266
1054,chd men,C0025266;C0280604;C3542407
1054,chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0007820;C0025266;C0280604;C3542407
1054,all men,C0025266
1054,$nmbr$ - $nmbr$ ( men ),C0025266
1053,left circumflex coronary artery,C0226037
1053,left circumflex artery  n ( % ),C0226037
1053,left circumflex artery,C0226037
1053,left circumflex,C0205091;C0443246;C1552822;C1880089
1053,circumflex,C1880089
1052,waist circumference — cmj,C0455829
1052,waist circumference — cm,C0455829
1052,waist circumference .,C0455829
1052,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
1052,waist circumference ( cm ),C0455829
1052,waist circumference  mean ( sd )  in,C0444504;C0455829;C2347634;C2348143;C2699239
1052,waist circumference  mean ( sd )  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1052,waist circumference  cm mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1052,waist circumference  cm ( sd ),C0455829;C2699239
1052,waist circumference  cm  mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
1052,waist circumference  cm,C0455829
1052,waist circumference  ( cm ),C0455829
1052,waist circumference,C0455829
1052,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
1052,hip circumference — cm,C0562350
1051,ileum or colon,C0020885
1051,ileum only,C0020885;C0205171;C1720467
1051,ileum and colon  n ( % ),C0020885
1051,ileum and colon  ' n ( % ),C0020885
1051,ileum and colon,C0020885
1051,ileum,C0020885
1050,dense calcium  mm ’,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611;C4330985;C4554674
1050,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
1050,calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611
1050,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
1050,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
1050,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
1050,calcium  mmol $nmbr$ $nmbr$,C0006675;C0006726;C0439190;C2936886;C3540037;C3714611
1049,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
1049,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
1049,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
1048,walk for exercise ( % ),C0015259;C0080331;C1522704
1048,walk for exercise,C0015259;C0080331;C1522704
1048,some physical activity,C0015259;C0026606
1048,physical activity §,C0015259;C0026606
1048,physical activity ( hours walking / wk ),C0015259;C0026606;C0439227
1048,physical activity  kcal / wk < $nmbr$,C0015259;C0026606;C0332174;C0439230;C0439259
1048,physical activity  kcal / wk *,C0015259;C0026606;C0332174;C0439230;C0439259
1048,physical activity  kcal / wk,C0015259;C0026606;C0332174;C0439230;C0439259
1048,intense physical activity,C0015259;C0026606;C0522510
1048,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
1048,exercise status,C0015259;C0449438;C1522704
1048,exercise at least weekly ( a ),C0015259;C1522704
1048,exercise > once weekly ?,C0015259;C1522704
1048,exercise > once weekly,C0015259;C1522704
1048,exercise ( % ),C0015259;C1522704
1048,exercise  n ( % ),C0015259;C1522704
1048,exercise,C0015259;C1522704
1047,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects with imputed value for end ‐ of ‐ treatment body weight,C0681850;C1522609;C1550501;C1706203;C2349001;C2697811;C2699638
1047,subjects who did receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects who did not receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects ( n ),C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects $ $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects  $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
1047,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1047,subject disposition  n ( % ),C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
1047,subject completion status  n ( % ),C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
1047,number of subjects in analysis,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1047,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
1047,non - diabetic subjects  n = $nmbr$,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
1047,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
1047,diabetic subjects  n = $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
1047,( $nmbr$ subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
1046,non - lad artery,C0003842;C0226004;C1518422
1046,lad artery,C0003842;C0226004
1046,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
1046,bladder,C0005682;C4319531
1045,hazard ratiof,C0598697
1045,hazard interaction,C0598697;C1704675
1045,hazard inleraction,C0598697
1045,hazard,C0598697
1044,three arm,C0205449;C0446516;C3715044;C4553528
1044,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
1044,czp combined arms ( n = $nmbr$ ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
1044,arm,C0446516;C3715044;C4553528
1043,subdural / epidural,C0038541;C0228134;C0812144
1043,subarachnoid hemorrhage,C0038525
1043,lumbar epidural,C0581283
1042,structural,C0678594
1042,intraperitoneal,C0442120
1042,intracranial,C0524466
1042,intracerebral,C0442111
1042,extracranial,C0580586
1041,t - score categories lumbar spineb,C0024090;C0683312;C3854607
1041,lumbar,C0024090
1040,war,C0043027
1040,ag,C0002037;C0051080;C0152305;C3888235
1040,aa,C0282379;C1235746;C1882141;C4554792
1039,ovary,C0029939;C0227898
1039,avr,C0449217
1038,warfarin naive,C0043031
1038,warfarin n = $nmbr$ n / n ( % ),C0043031
1038,warfarin n = $nmbr$,C0043031
1038,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
1038,warfarin group ( n = $nmbr$ ),C0043031;C0441848
1038,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
1038,warfarin ( s $nmbr$ % cl ),C0043031;C0596019
1038,warfarin ( n = $nmbr$ )  n ( % / y ),C0043031
1038,warfarin ( n = $nmbr$ ),C0043031
1038,warfarin ( n - $nmbr$  $nmbr$ ),C0043031
1038,warfarin ( % ),C0043031
1038,warfarin % ( n / n ),C0043031
1038,warfarin  no . ( % ),C0043031
1038,warfarin,C0043031
1038,warf,C0043031
1038,> $nmbr$ days warfarin,C0043031;C0439228
1037,urinary acr,C0042027;C1412134;C1515941;C1524119
1037,sprint acr > $nmbr$ - $nmbr$,C1412134;C1515941
1037,sprint acr < $nmbr$ - $nmbr$,C1412134;C1515941
1037,evaluable for acr $nmbr$ at week $nmbr$  n,C1412134;C1515941;C1516986
1037,categories of urinary acr  ^ g / mg,C0042027;C0683312;C1300563;C1412134;C1515941;C1524119
1037,b . acr $nmbr$,C1412134;C1515941
1037,acr deciles,C1412134;C1515941
1037,acr $nmbr$,C1412134;C1515941
1037,acr,C1412134;C1515941
1037,accord acr > $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
1037,accord acr < $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
1037,a . acr $nmbr$,C1412134;C1515941
1036,week $nmbr$ overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
1036,week $nmbr$ ( itt population ),C0032659;C0332174;C0439230;C1257890
1036,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,uplift ® population,C0032659;C1257890
1036,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
1036,subpopulation,C1257890
1036,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
1036,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
1036,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
1036,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
1036,populations :,C0032659;C1257890
1036,population,C0032659;C1257890
1036,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
1036,patients in the placebo group  nt - probnp values were reported for $nmbr$ patients,C0030705;C0032042;C0042295;C0441833;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
1036,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
1036,p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo,C0020625;C0032042;C0441833;C0687744;C1176308;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408;C1709380;C4553967
1036,overall vero population,C0032659;C0282416;C1257890;C1561607
1036,overall population ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1036,overall population ( n - $nmbr$ ),C0032659;C0282416;C1257890;C1561607
1036,overall population,C0032659;C0282416;C1257890;C1561607
1036,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
1036,overall freedom population ( n = $nmbr$ ),C0016694;C0032659;C0282416;C1257890;C1561607
1036,open - label population,C0032659;C1257890;C1709323
1036,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,mn population  n,C0026327;C0026405;C0032659;C1257890;C4285072
1036,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
1036,mitt population ( n = $nmbr$ ),C0032659;C1257890
1036,mitt population,C0032659;C1257890
1036,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
1036,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1036,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
1036,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
1036,itt population  n,C0032659;C1257890
1036,itt population,C0032659;C1257890
1036,intent - to - treat population  n ( % ),C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1036,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1036,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
1036,in the spironolactone group and $nmbr$ patients in the placebo group .,C0037982;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
1036,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
1036,group dif . ( $nmbr$ ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
1036,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
1036,gold $nmbr$ groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
1036,full population,C0032659;C0443225;C1257890
1036,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
1036,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
1036,epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,disease activity outcomes ( itt population ) week $nmbr$,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
1036,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1036,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
1036,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
1036,d population,C0032659;C0073187;C0332173;C1257890;C4484261
1036,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
1036,copd population ( n = $nmbr$ ),C0024117;C0032659;C1257890;C1412502;C3714496
1036,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
1036,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
1036,bmi group ( kg / m ^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
1036,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
1036,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0005910;C0009226;C0011816;C0011849;C0013227;C0019016;C0019046;C0022709;C0025598;C0029167;C0032042;C0040372;C0043100;C0073187;C0175795;C0304289;C0332173;C0332287;C0439209;C0441833;C0521115;C0681850;C0687744;C0700307;C1185738;C1254351;C1257890;C1305855;C1305866;C1512211;C1519504;C1550501;C1696465;C1705104;C1705428;C1705429;C1706132;C1706203;C1706408;C1825777;C2349001;C2697811;C3250443;C3538758;C4288115;C4484261;C4553328
1036,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C0008107;C0008377;C0019409;C0023820;C0034656;C0042295;C0231290;C0242960;C0332282;C0332287;C0441833;C0475211;C0687744;C1079230;C1257890;C1511726;C1518681;C1519504;C1705428;C1705429;C1719797;C1883712;C2911648;C3245479;C3259781;C3714741
1036,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1036,$nmbr$ - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
1035,rv and pulmonary vascular,C0035190;C3889272
1034,lacunar,C0241970;C1459585
1034,glomerular,C0022663;C0268731
1033,ulcers / gangrene,C0017086;C0041582
1033,ulcer  n ( % ) a,C0041582;C3887532
1033,ulcer,C0041582;C3887532
1032,plac,C0048838
1032,b lack,C0332268
1031,other / multiracial,C1881928
1031,multiracial or other,C1881928
1031,multiracial  n ( % ),C1881928
1031,multiracial,C1881928
1030,mean lumbar spine t score,C0024091;C3533236;C3887615
1030,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
1030,lumbar spine bmd t -,C0024091;C3887615
1030,lumbar spine,C0024091;C3887615
1029,updrs score,C3639721
1029,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
1029,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
1028,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0456389
1028,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788
1028,weekly number of hives score $nmbr$,C0042109;C0237753;C0332174;C0449788
1028,urticaria,C0042109;C1559188
1027,eligibility stratum,C0013893;C1548635
1027,eligibility strata,C0013893;C1548635
1027,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
1027,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors  no . ( % ) t,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors  % t ascvo,C0013893;C0035648;C1548635;C1553898
1027,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
1027,* eligibility risk factors  n ( % ) *,C0013893;C0035648;C1548635;C1553898
1026,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
1026,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
1026,b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo,C0015684;C0582802;C0679214;C1555721;C1698987;C1706204;C1719844;C3241971
1026,b digit symbol substitution  insulin glargine vs standard care,C0291665;C0582802;C0679214;C0907402;C1555721;C1698987;C1706204;C3241971
1025,weeks_measured,C0439230
1025,weeks,C0439230
1025,week   $nmbr$,C0332174;C0439230
1025,week and,C0332174;C0439230
1025,week - $nmbr$ changea,C0332174;C0439230;C4349366
1025,week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230
1025,week $nmbr$ outcomes,C0332174;C0439230;C1274040
1025,week $nmbr$ outcome,C0332174;C0439230;C1274040
1025,week $nmbr$ mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
1025,week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1025,week $nmbr$ crp,C0332174;C0439230;C3890735;C4048285
1025,week $nmbr$ a,C0332174;C0439230
1025,week $nmbr$ / et,C0332174;C0439230
1025,week $nmbr$ * ’ ’,C0332174;C0439230
1025,week $nmbr$ *,C0332174;C0439230
1025,week $nmbr$ ( non - ee responders ),C0332174;C0439230;C1518422
1025,week $nmbr$ ( mmol / l ),C0332174;C0439230;C1532563
1025,week $nmbr$ ( before ee ),C0332174;C0439230
1025,week $nmbr$ % of patients,C0030705;C0332174;C0439230
1025,week $nmbr$  % ( n ) §,C0332174;C0439230
1025,week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §,C0332174;C0439230
1025,week $nmbr$  % ( n ) j,C0332174;C0439230
1025,week $nmbr$  % ( n ) ^,C0332174;C0439230
1025,week $nmbr$  % ( n ) * *,C0332174;C0439230
1025,week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
1025,week $nmbr$  % ( n ) $nmbr$,C0332174;C0439230
1025,week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
1025,week $nmbr$  % ( n ) #,C0332174;C0439230
1025,week $nmbr$  % ( n ),C0332174;C0439230
1025,week $nmbr$,C0332174;C0439230
1025,week,C0332174;C0439230
1025,triglycerides ( week $nmbr$ ) a,C0041004;C0332174;C0439230
1025,tdi total score ( week $nmbr$,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
1025,sgrq total score ( week,C0332174;C0439230;C2964552
1025,score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C0036919;C0332174;C0439230;C1705241;C1705242;C3259781;C3533236
1025,pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1025,night - time awakenings / week,C0332174;C0439230;C0860510
1025,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1025,mtx dose > $nmbr$ mg / week  %,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1025,mtx average weekly dose  mg / week  mean ( sd ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1510992;C1960952;C2346927;C2347634;C2348143;C2699239;C2825518;C4321396;C4521761
1025,ldl particle size ( week $nmbr$ ),C0332174;C0439230;C3641256
1025,ldl particle numbers ( week $nmbr$ ),C0237753;C0332174;C0439230;C0449788;C2612459
1025,hdl cholesterol ( week $nmbr$ ) a,C0023822;C0332174;C0392885;C0439230
1025,habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ ),C0205353;C0332174;C0439230;C0556216;C1519269
1025,fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0031962;C0036919;C0332174;C0439230;C0444504;C1705241;C1705242;C2347634;C2348025;C2348143;C3714541
1025,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1025,clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
1025,cfb at week $nmbr$,C0009002;C0332174;C0439230;C1824728
1025,calculated ldl cholesterol ( week $nmbr$ ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
1025,bw at $nmbr$ weeks  kg +,C0005910;C0006041;C0022718;C0439209;C0439230;C2986891;C4054209
1025,beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % ),C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
1025,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1025,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1025,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1025,at weeks $nmbr$ and $nmbr$,C0439230
1025,at week $nmbr$,C0332174;C0439230
1025,at six weeks,C0205452;C0439230
1025,apob ( week $nmbr$ ),C0003593;C0332174;C0439230;C3252643
1025,additional radiographic findings at week $nmbr$,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
1025,acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230;C1412134;C1515941
1025,> $nmbr$ weeks,C0439230
1025,> $nmbr$ to < $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1025,> $nmbr$ servings / wk ( n = $nmbr$ ),C0332174;C0439230;C1519269
1025,> $nmbr$ / week,C0332174;C0439230
1025,> $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
1025,< $nmbr$ weeks,C0439230
1025,< $nmbr$ week,C0332174;C0439230
1025,- - week $nmbr$ - -,C0332174;C0439230
1025,( week ),C0332174;C0439230
1025,$nmbr$ wk,C0332174;C0439230
1025,$nmbr$ week,C0332174;C0439230
1025,$nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1025,$nmbr$ / week,C0332174;C0439230
1025,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1025,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
1025,$nmbr$ - $nmbr$ / week,C0332174;C0439230
1024,« $nmbr$ kg,C0022718;C0439209;C4054209
1024,£ $nmbr$ kg,C0022718;C0439209;C4054209
1024,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
1024,q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1024,q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1024,q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
1024,o $nmbr$ kg  n ( % ),C0022718;C0439209;C0483204;C4054209
1024,nonobese ( < $nmbr$ kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
1024,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
1024,low body weight ( < $nmbr$ kg ),C0022718;C0041667;C0439209;C4054209
1024,kg,C0022718;C0439209;C4054209
1024,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
1024,dose adjustment reason < $nmbr$ kg,C0022718;C0439209;C2826286;C4054209
1024,bw  kg,C0005910;C0006041;C0022718;C0439209;C2986891;C4054209
1024,bmi : < $nmbr$ kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
1024,bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
1024,baseline weight  kg,C0022718;C0439209;C1303013;C4054209
1024,> = $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1024,> = $nmbr$ kg,C0022718;C0439209;C4054209
1024,> $nmbr$ kg — no . ( % ),C0022718;C0439209;C4054209
1024,> $nmbr$ kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
1024,> $nmbr$ kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
1024,> $nmbr$ kg,C0022718;C0439209;C4054209
1024,> $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1024,> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1024,> $nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
1024,< = € $nmbr$ kg,C0022718;C0439209;C4054209
1024,< = $nmbr$ kg,C0022718;C0439209;C4054209
1024,< $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1024,< $nmbr$ kg  n ( % ),C0022718;C0439209;C4054209
1024,< $nmbr$ kg  mj ( reference ),C0022718;C0439209;C0439254;C4054209;C4284025
1024,< $nmbr$ kg,C0022718;C0439209;C4054209
1024,< $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
1024,. $nmbr$ kg,C0022718;C0439209;C4054209
1024,$nmbr$ to < $nmbr$ kg,C0022718;C0439209;C4054209
1024,$nmbr$ kg,C0022718;C0439209;C4054209
1024,$nmbr$ - < $nmbr$ kg,C0022718;C0439209;C4054209
1024,$nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
1024,# $nmbr$ kg,C0022718;C0439209;C4054209
1023,treatment with sulphonylurea + biguanide  n { % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
1023,treatment with sulphonylurea + biguanide  n ( % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
1023,treatment with sulphonylurea  n ( % ),C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
1023,sulphonylureas only,C0038766;C0205171;C1720467
1023,sulphonylureas,C0038766
1023,sulphonylurea,C0038766;C3536898
1023,sulfonylureas,C0038766;C3653359
1023,sulfonylurea — no . ( % ),C0038766;C3536898
1023,sulfonylurea derivatives,C0038766
1023,sulfonylurea based,C0038766;C3536898
1023,sulfonylurea,C0038766;C3536898
1023,other sulfonylurea 一 no . ( % ),C0038766;C3536898
1023,on sulfonylurea,C0038766;C3536898
1023,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
1023,any sulfonylurea,C0038766;C3536898
1022,weight  kg blood pressure  mm hg,C0005823;C0005910;C0022718;C0043100;C0439209;C0439475;C1271104;C1272641;C1305866;C1705104;C4054209
1022,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
1022,lvh by ecgt blood pressure  mm hg,C0005823;C0149721;C0439475;C1271104;C1272641
1022,heart rate ( sd )  bpm blood pressure  mm hg,C0005823;C0018810;C0439475;C1271104;C1272641;C2699239
1022,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1022,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1022,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure while seated — mm hg,C0005823;C1271104;C1272641
1022,blood pressure systolic  mm hg,C0005823;C0039155;C0439475;C1271104;C1272641
1022,blood pressure eontrolt,C0005823;C1271104;C1272641
1022,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1022,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1022,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
1022,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
1022,blood pressure > $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure < $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % ),C0005823;C0439475;C1271104;C1272641
1022,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
1022,blood pressure ( mm hg ) systolic,C0005823;C0439475;C1271104;C1272641
1022,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
1022,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
1022,blood pressure ( % ),C0005823;C1271104;C1272641
1022,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
1022,blood pressure  mmhg systolic,C0005823;C0439475;C1271104;C1272641
1022,blood pressure  mmhg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure  mm hg,C0005823;C0439475;C1271104;C1272641
1022,blood pressure  mm,C0005823;C1271104;C1272641;C4330985;C4554674
1022,blood pressure,C0005823;C1271104;C1272641
1022,arterial blood pressure  mm hg,C0439475;C1272641
1021,kdl cholesterol ( mmol / ),C0008377;C0439190
1021,hba $nmbr$ c — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
1021,csf cholesterol,C0008377;C3540512;C3889436
1021,cholesterol — mmol / liter,C0008377;C0439190;C0475211
1021,cholesterol ( ng / ml ),C0008377;C0439275
1021,cholesterol ( mmol / l ),C0008377;C1532563
1021,cholesterol ( % ),C0008377
1021,cholesterol  mmol / l,C0008377;C1532563
1021,cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % ),C0008377;C1532563
1021,cholesterol,C0008377
1021,aldl cholesterol,C0008377
1020,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
1020,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
1020,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
1020,hypercholesterolemia — no . ( % ),C0020443;C1522133
1020,hypercholesterolemia *,C0020443;C1522133
1020,hypercholesterolemia ( > $nmbr$ mg / dl ),C0020443;C0439269;C1522133
1020,hypercholesterolemia ( % ),C0020443;C1522133
1020,hypercholesterolemia  no . ( % ),C0020443;C1522133
1020,hypercholesterolemia  n ( % ),C0020443;C1522133
1020,hypercholesterolemia,C0020443;C1522133
1020,hypercholesterolaemia ( % ),C0020443;C1522133
1020,hypercholesterolaemia,C0020443;C1522133
1020,elevated cholesterol,C0020443
1019,non ‐ elderly,C0001792;C1518422;C1999167
1019,non - elderly ( < $nmbr$ years ),C0001792;C0439234;C1518422;C1999167
1019,elderly ( > $nmbr$ years ),C0001792;C0439234;C1999167
1019,elderly,C0001792;C1999167
1018,diagnostic angiography,C0002978
1018,contrast angiography,C0002978;C0009924;C1979874
1018,angiography — no . ( % ),C0002978
1018,angiography and revascularization,C0002978
1018,angiography,C0002978
1018,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
1018,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
1018,angiographic data and treatment :,C0002978;C1511726;C3245479;C3714741
1018,angiographic data,C0002978;C1511726;C3245479;C3714741
1018,additional angiography,C0002978;C1524062
1018,> $nmbr$ ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
1017,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
1017,symptomatic heart fail,C0018787;C0231220
1017,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
1017,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
1017,hospitaiization for heart faiiure,C0018787
1017,heart failurea,C0018787
1017,coronary,C0018787
1017,cor revasc,C0018787;C0056331;C0378365
1017,congestive heart,C0018787;C0742742
1017,cardiac stretch,C0018787;C0600080;C1522601
1017,cardiac risk,C0018787;C0035647;C1522601;C4552904
1017,cardiac parameters,C0018787;C0449381;C1522601
1017,cardiac mediations,C0018787;C0680727;C1522601
1017,cardiac failurec,C0018787;C1522601
1017,cardiac enzyates raised,C0018787;C1522601
1017,cardiac diseasec,C0018787;C1522601
1017,cardiac and echocardiography parameters,C0018787;C1522601
1017,cardiac,C0018787;C1522601
1017,bmi ( kg / m $nmbr$ ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
1016,taiwan,C0039260
1016,cuban,C1553379
1016,caribbean,C0043122;C0206155;C1331005
1015,china / tjapan,C0008115
1015,china / japan,C0008115;C0022341
1015,china,C0008115
1014,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
1014,white race ( n = $nmbr$ $nmbr$ ),C0007457;C0043157
1014,white race  n ( % ),C0007457;C0043157
1014,caucasians,C0007457;C0043157
1014,caucasian simva,C0007457;C0043157
1014,caucasian race ( % ),C0007457
1014,caucasian race,C0007457
1014,caucasian eze / simva,C0007457;C0043157
1014,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
1014,caucasian ( % ),C0007457;C0043157
1014,caucasian $nmbr$,C0007457;C0043157
1014,caucasian  %,C0007457;C0043157
1014,caucasian,C0007457;C0043157
1013,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1013,white race — no . { % ) t,C0007457;C0043157;C0220938
1013,white race — no . { % ) - i -,C0007457;C0043157;C0220938
1013,white race — no . { % ) ' i ',C0007457;C0043157;C0220938
1013,white race — no . { % ) $,C0007457;C0043157;C0220938
1013,white race — no . / total no . ( % ) f,C0007457;C0043157;C0220938
1013,white race — no . / total no . ( % ) $,C0007457;C0043157;C0220938
1013,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0043157;C0220938
1013,white race — no . ( % ) f,C0007457;C0043157;C0220938
1013,white race — no . ( % ) : t,C0007457;C0043157;C0220938
1013,white race — no . ( % ) :,C0007457;C0043157;C0220938
1013,white race  %,C0007457;C0043157
1013,white race,C0007457;C0043157
1013,white or caucasian  n ( % ),C0007457;C0043157;C0220938
1013,white not of hispanic origin,C0007457;C0043157;C0220938
1013,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1013,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
1013,white ethnic origin,C0007457;C0015031;C0043157;C0220938
1013,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
1013,white / other,C0007457;C0043157;C0220938
1013,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
1013,white / caucasian,C0043157
1013,white ( n — $nmbr$ ),C0007457;C0043157;C0220938
1013,white ( n   = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1013,white ( n = $nmbr$ ),C0007457;C0043157;C0220938
1013,white ( n = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
1013,white ( $nmbr$ . $nmbr$ % ),C0007457;C0043157;C0220938
1013,white  no . ( % ),C0007457;C0043157;C0220938
1013,white  n / n ( % ),C0007457;C0043157;C0220938
1013,white  n ( % ),C0007457;C0043157;C0220938
1013,white  %,C0007457;C0043157;C0220938
1013,white,C0007457;C0043157;C0220938
1013,racea white,C0007457;C0043157;C0220938
1013,non white,C0007457;C0043157;C0220938;C1518422
1013,non - white raceb,C0007457;C0043157;C0220938;C1518422
1013,non - white race,C0007457;C0043157;C1518422
1013,non - white,C0007457;C0043157;C0220938;C1518422
1013,non - caucasian simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1013,non - caucasian simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1013,non - caucasian simva,C0007457;C0043157;C1518422
1013,non - caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
1013,non - caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
1013,non - caucasian eze / simva,C0007457;C0043157;C1518422
1013,non - caucasian,C0007457;C0043157;C1518422
1013,caucasians ( n = $nmbr$ ),C0007457;C0043157
1013,caucasian simva ( „ = $nmbr$ },C0007457;C0043157
1013,caucasian simva ( n = $nmbr$ ),C0007457;C0043157
1013,caucasian n = $nmbr$  $nmbr$,C0007457;C0043157
1013,caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157
1013,caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157
1013,caucasian  n ( % ) *,C0007457;C0043157
1013,caucasian  n ( % ),C0007457;C0043157
1012,total hip or knee replacement,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
1012,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
1012,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
1012,total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1012,total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C2699239;C3538851;C4284725
1012,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
1012,standardized total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
1012,hip + other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725
1012,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
1012,hip + $nmbr$ vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
1012,hip  wrist  or spine *,C0019552;C0022122;C0043262;C1322271;C1505163;C3538851;C4284725
1012,hip  femur,C0015811;C0019552;C0022122;C1505163;C3538851;C4284725
1012,hip,C0019552;C0022122;C1505163;C3538851;C4284725
1011,p value for adjusted hr,C0456081;C1709380
1011,nonblack ( n = $nmbr$ )  adjusted hazard ratio *,C0456081;C2985465
1011,black ( n = $nmbr$ )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
1011,adjusted or ( $nmbr$ % cl ),C0456081
1011,adjusted or ( $nmbr$ % ci ) c,C0456081
1011,adjusted or ( $nmbr$ % ci ) b,C0456081
1011,adjusted hr losartan vs atenolol *,C0126174;C0456081
1011,adjusted hr * ( $nmbr$ % cl ) pvalue,C0456081;C0596019
1011,adjusted hr ( enl vs lcz ) ( $nmbr$ % cl ),C0456081
1011,adjusted hr ( $nmbr$ % cl ),C0456081;C0596019
1011,adjusted *   hr,C0456081
1011,adjusted * or ( $nmbr$ % ci ) p value,C0456081
1011,adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl ),C0126174;C0456081;C1137094
1011,adjusted $nmbr$ or ( $nmbr$ % cl ),C0456081
1011,adjusted,C0456081
1010,unadjusted p value,C1439367;C1709380
1010,unadjusted p - value for interaction,C1439367;C1704675;C1709380
1010,unadjusted or ( $nmbr$ % ci ) p value,C1439367
1010,unadjusted model hr  $nmbr$ % ci  p value,C0008107;C1439367;C1709380;C3161035;C3259781;C3274659;C3714583;C3853906
1010,unadjusted irr,C1439367;C4082285
1010,unadjusted hr .,C1439367
1010,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
1010,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
1010,unadjusted hr ( $nmbr$ % ci ) a,C0008107;C1439367;C3259781
1010,unadjusted hr,C1439367
1010,unadjusted,C1439367
1009,with ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
1009,tg  triglycerides . * median values ( standard deviation for medians ) .,C0041004;C0042295;C0399532;C0549183;C1442989;C2828392
1009,standard therapyy ( n = $nmbr$ ),C1442989;C2828392
1009,standard care n ( % ) / $nmbr$ py,C0030428;C1442989;C1947933;C2828392;C3538810
1009,standard care n ( % ),C1442989;C1947933;C2828392
1009,standard care allocation,C1442989;C1706778;C1947933;C2828392
1009,standard care ( n = $nmbr$ ),C1442989;C1947933;C2828392
1009,standard allocation,C1442989;C1706778;C2828392
1009,standard ( n = $nmbr$ ),C1442989;C2828392
1009,standard ( $nmbr$ ),C1442989;C2828392
1009,standard,C1442989;C2828392
1009,sd  standard,C1442989;C2699239;C2828392
1009,no - ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
1009,$nmbr$ standard ( n = $nmbr$ ),C1442989;C2828392
1008,with des,C0011702;C4551552
1008,older des ( n = $nmbr$ ),C0011702;C0580836;C4551552
1008,no des,C0011702;C4551552
1008,new des ( n = $nmbr$ ),C0011702;C0205314;C4551552
1008,des implantation for restenosis  n ( % ),C0011702;C0021107;C0029976;C0333186;C4551552
1008,des,C0011702;C4551552
1007,≥ $nmbr$ sae,C1519255;C1622657;C4553214
1007,serious adverse events,C1519255
1007,saes,C1519255;C1622657;C4553214
1007,due to sae,C1519255;C1622657;C4553214
1007,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
1007,because of sae,C1519255;C1622657;C4553214
1007,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
1007,any sae,C1519255;C1622657;C4553214
1006,used,C1273517
1006,unspecified,C0205370;C1549663;C2983689;C4048188
1006,unclassified,C0205426;C1546437;C2347854;C4085229
1006,pleased,C3829994;C4264468
1005,sys : ns dia : < $nmbr$ . $nmbr$,C0038944;C1112705;C1425041;C1705982;C1706546
1005,ns,C0038944;C1112705;C1705982
1004,with events ( % ),C0441471;C3541888
1004,w event ( rate ),C0441471;C0871208;C1521828;C4019010
1004,vorapaxar event rate ( n = $nmbr$ )  %,C0441471;C0871208;C1521828;C2974521;C4019010
1004,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1004,total events  n,C0439175;C0439810;C0441471;C3541888
1004,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
1004,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
1004,rosuvastatin  events / patients ( % ),C0030705;C0441471;C0965129;C3541888
1004,probability  of event %,C0033204;C0441471;C4019010
1004,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
1004,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
1004,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
1004,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
1004,prior lgi event,C0332152;C0441471;C2826257;C4019010
1004,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1004,pneumonia events  n,C0032285;C0441471;C3541888
1004,placebo event rate ( n = $nmbr$ )  %,C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
1004,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
1004,patients with uncomplicated events ( p = o - $nmbr$ 十 ),C0030705;C0441471;C0443334;C3541888
1004,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
1004,patients with hospitalized pneumonia events  n ( % ),C0032285;C0441471;C0870668;C3541888
1004,patients with complicated events ( p = $nmbr$ - $nmbr$ 十 ),C0030705;C0231242;C0441471;C3541888
1004,patients with complicated events,C0030705;C0231242;C0441471;C3541888
1004,patients / events n,C0030705;C0441471;C3541888
1004,participants with an event per $nmbr$ patient - years,C0441471;C0679646;C4019010
1004,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
1004,overal event rate,C0441471;C0871208;C1521828;C4019010
1004,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
1004,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
1004,normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
1004,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1004,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
1004,no prior lgi event,C0332152;C0441471;C2826257;C4019010
1004,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
1004,no of events womenmen *,C0441471;C3541888
1004,no of events women men *,C0025266;C0043210;C0441471;C3541888
1004,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
1004,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1004,no . of events / totol no . ( % ),C0441471;C3541888
1004,no . of events / total no . ( % ),C0441471;C3541888
1004,no . of events / total no . $nmbr$ % ),C0441471;C3541888
1004,no . of events / total,C0441471;C3541888
1004,no . of events / sample size i i,C0441471;C3541888
1004,no . of events / sample size,C0441471;C3541888
1004,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
1004,no . of events / patients,C0030705;C0441471;C3541888
1004,no . of events / no . of patients,C0441471;C3541888
1004,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
1004,no . of events,C0441471;C3541888
1004,neurologicai events,C0441471;C3541888
1004,n events / n subjects,C0369718;C0441471;C0441922;C3541888
1004,n events / n at risk,C0369718;C0441471;C0441922;C3541888
1004,n events ( % ),C0369718;C0441471;C0441922;C3541888
1004,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
1004,n ( $nmbr$ yr km event rate  % ),C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
1004,km event ( % ) at $nmbr$ y,C0441471;C3887676;C4019010
1004,impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
1004,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
1004,hospitalized pneumonia events  n,C0032285;C0441471;C0701159;C3541888
1004,gastrointestinal event,C0441471;C0521362;C4019010
1004,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
1004,freqency of events,C0441471;C3541888
1004,events requiring assistance,C0441471;C3541888
1004,events consistent with volume depletion,C0441471;C3541888
1004,events consistent with uti,C0441471;C3541888
1004,events consistent with genital infection,C0441471;C3541888
1004,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
1004,events / n,C0441471;C3541888
1004,events ( % ),C0441471;C3541888
1004,events  no .,C0441471;C3541888
1004,events  n ( % / y ),C0441471;C3541888
1004,events  n ( % ),C0441471;C3541888
1004,events,C0441471;C3541888
1004,event { n ( % ),C0441471;C4019010
1004,event rates  %,C0441471;C0871208;C1521828;C4019010
1004,event rate ( per $nmbr$ person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1004,event rate ( per $nmbr$ person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
1004,event rate ( per $nmbr$,C0441471;C0871208;C1521828;C4019010
1004,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
1004,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
1004,event rate,C0441471;C0871208;C1521828;C4019010
1004,event during overall,C0282416;C0441471;C1561607;C4019010
1004,event during on -,C0441471;C4019010
1004,event / patients ( $nmbr$ / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
1004,event ( p = $nmbr$ . $nmbr$ o + ),C0441471;C4019010
1004,event ( % ),C0441471;C4019010
1004,event  n ( % ),C0441471;C4019010
1004,event,C0441471;C4019010
1004,epa hr events ( % ),C0441471;C3541888
1004,empagliflozin n with event / n,C0441471;C3490348;C4019010
1004,cvd events,C0007222;C0441471;C3541888
1004,cumulative events,C0441471;C1511559;C3541888
1004,composite events,C0205199;C0441471;C1547335;C3541888
1004,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
1004,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
1004,bleeding events during first $nmbr$ days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
1004,biochemical events,C0205474;C0441471;C3541888
1004,atients with event,C0441471;C4019010
1004,any event,C0441471;C4019010
1004,adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0871208;C1521828;C3541888
1004,adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0701159;C0871208;C1521828;C3541888
1004,acs event,C0441471;C0742343;C4019010;C4318612
1004,$nmbr$ no . of events,C0441471;C3541888
1004,$nmbr$ events [ $nmbr$ . $nmbr$ ],C0441471;C3541888
1004,$nmbr$ events,C0441471;C3541888
1003,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
1003,ischemic tvr,C0475224
1003,ischemic hf  % ( n ),C0018488;C0475224;C1313497;C1538440;C3273279
1003,ischemic cause,C0015127;C0475224;C1524003
1003,ischemic,C0475224
1003,ischaemic skin lesions,C0037284;C0475224
1003,ischaemic or unknown stroke,C0475224
1003,ischaemic cause,C0015127;C0475224;C1524003
1003,ischaemic ( n = $nmbr$ l $nmbr$ ),C0475224
1003,ischaemic ( n = $nmbr$ ),C0475224
1003,ischaemic  n ( % ),C0475224
1003,ischaemic,C0475224
1002,symptomatic ich,C0019191;C0231220;C3272597;C3281105
1002,ich,C0019191;C3272597;C3281105
1001,with highest hba $nmbr$ cc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
1001,cc,C0008318;C3538933
1000,simvastatin monotherapy ( n = $nmbr$  $nmbr$ * ),C0074554
1000,simvastatin ( n = $nmbr$ . $nmbr$ ),C0074554
1000,simvastatin ( n = $nmbr$ ),C0074554
1000,simvastatin ( n = $nmbr$  $nmbr$ ),C0074554
1000,simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ ),C0074554;C0439422
1000,simvastatin ( $nmbr$ / $nmbr$ mg / d ),C0074554;C0439422
1000,simvastatin $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1000,simvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1000,simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1000,simvastatin  n ( % ),C0074554
1000,simvastatin,C0074554
1000,placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ ),C0032042;C0074554;C0439422;C1696465;C1706408
1000,placebo + $nmbr$ mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
1000,exetimibe / simvastatin,C0074554
999,with long - acting j $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
999,short - acting b $nmbr$ - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
999,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
999,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
999,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
999,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
999,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
999,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
999,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
999,long - acting b $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
999,long - acting ^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
999,long - acting  intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
999,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
999,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
999,baseline short - acting anticholinergics  n ( % ),C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
999,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
999,act total score ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
999,act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
999,act . $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
999,act - $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
998,southern hemisphere,C0205139;C1710133
998,south or central american,C1710133
998,south or central america,C1710133
998,south asian,C1519427
998,south asia,C0037723;C1519427
998,south american,C0425359
998,south america ( n = $nmbr$ ),C0037713
998,south america ( % ),C0037713
998,south america,C0037713
998,south africa / south america,C0001737;C0002454;C0037712;C0037713
998,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
998,south  n ( % ),C1710133
998,north american,C0425358;C2700615
997,total asthma symptom score :,C0004096;C2984299;C3533163
997,total asthma symptom score  mean ± sdz,C0004096;C0444504;C2347634;C2348143;C2984299;C3533163
997,total asthma symptom score  mean ± sd ‡,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
997,total asthma symptom score,C0004096;C2984299;C3533163
997,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
997,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
997,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
997,asthma population ( n = $nmbr$ ),C0004096;C0032659;C1257890;C2984299
997,asthma - related health -,C0004096;C2984299
997,asthma,C0004096;C2984299
996,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,with corticosteroid treatment > $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
996,with corticosteroid treatment < $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
996,vka therapy,C0039798;C0087111;C1363945
996,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
996,type of insulin therapy — no . ( % ) $nmbr$,C0039798;C0087111;C0457592;C1363945
996,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
996,treatments at randomisation,C0034656;C0087111
996,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,treatment after randomization  in the single - dummy phase — days ],C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
996,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
996,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0039798;C0087111;C0178602;C0366686;C0682295;C0869039;C1114758;C1363945;C1880019;C4303340
996,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
996,therapy,C0039798;C0087111;C1363945
996,therapies,C0087111
996,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0019409;C0022885;C0039593;C0039798;C0087111;C0205120;C0205448;C0242960;C0332849;C0392366;C0441833;C0456984;C0489786;C0687744;C1257890;C1515976;C1519504;C1522326;C1533734;C1552595;C1552839;C1704675;C1705169;C1705428;C1705429;C1707455;C3538994;C3831328;C3887704;C4048755;C4318744
996,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
996,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
996,sample size  n ( % ) by treatment,C0037793;C0039798;C0087111;C0242618;C0456389;C1522326;C1533734;C1705169;C3538994;C3887704
996,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
996,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
996,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
996,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
996,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
996,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
996,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0023779;C0039798;C0087111;C0184661;C0189695;C0242751;C0392347;C0441994;C0522523;C0545743;C0680443;C0886296;C1273869;C1511726;C1522326;C1533734;C1705169;C2003888;C2827881;C3245479;C3538994;C3714741;C3887704;C4049621
996,oab therapy,C0039798;C0087111;C1363945
996,noninsulin therapy,C0039798;C0087111;C1363945
996,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
996,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
996,long term vka therapy,C0039798;C0087111;C0443252;C1363945
996,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
996,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
996,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
996,ineffective therapy,C0039798;C0087111;C1363945;C3242229
996,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy,C0020473;C0039798;C0042153;C0087111;C0428465;C0457083;C1363945;C1947944;C4555212
996,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
996,h $nmbr$ blocker ( n  % ) long - term vka therapy,C0033727;C0039798;C0087111;C0369286;C0441932;C0443252;C0564385;C1363945;C4528284
996,ed therapy,C0039798;C0087111;C1363945;C3538926
996,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
996,diabetic therapy use  n ( % ) * no therapy,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
996,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
996,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
996,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
996,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .,C0008107;C0009667;C0017431;C0017446;C0022661;C0030705;C0039798;C0087111;C0126174;C0205147;C0233324;C0683454;C1280500;C1515273;C1518681;C1522326;C1533734;C1704675;C1705169;C1705313;C1707455;C2348382;C2360800;C2826302;C3259781;C3538994;C3887704
996,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
996,background therapy,C0039798;C0087111;C1363945;C1706907
996,background lipid therapy per acc / aha definition    n   ( % ) a,C0023767;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
996,background aha therapy at screening  n ( % ) §,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
996,background aha therapy at screening  n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
996,background aha therapy at screening  n,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
996,background aha therapy at screening  a   n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
996,background aha therapy at screening  a,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
996,atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .,C0018017;C0023824;C0039798;C0087111;C0210243;C0237455;C0286651;C0332174;C0439230;C0674679;C0680230;C1079230;C1145759;C1334862;C1515021;C1518422;C1522326;C1533734;C1571704;C1704675;C1705169;C1709380;C2360800;C3538994;C3887704
996,any therapy — no . ( % ),C0039798;C0087111;C1363945
996,antithrombotic therapy,C0039798;C0087111;C1363945
996,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
996,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
996,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
996,all treatments,C0087111
996,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
996,* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the,C0039798;C0087111;C0439175;C0439810;C0589120;C0667477;C0699794;C0871208;C1521828;C1522326;C1522577;C1533734;C1704685;C1705169;C1708728;C1709380;C2360800;C2986775;C3274571;C3538994;C3887704;C4086639
995,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
995,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
995,treatment stratum ^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
995,treatment groups [ n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
995,treatment groups  n ( % ),C0039798;C0087111;C0441848;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment group  on - treatment il - $nmbr$ threshold,C0020898;C0021764;C0022271;C0039798;C0087111;C0441833;C0449864;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
995,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
995,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment for latent tuberculosis ^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
995,treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment difference ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
995,treatment difference ( $nmbr$ % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
995,treatment difference % ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
995,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
995,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
995,treatment diff . vs tio ( $nmbr$ % ci ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
995,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
995,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment before randomization  %,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,treatment ( de vs warfarin ) by thrombophilia interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,treated,C1522326
995,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
995,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
995,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
995,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
995,p  treatment - by - region interaction,C0017446;C0039798;C0087111;C0205147;C0369773;C1522326;C1533734;C1704675;C1705169;C2603361;C3538994;C3887704
995,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
995,on antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
995,no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
995,month $nmbr$ subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
995,ls mean treatment difference ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
995,ls mean [ $nmbr$ % ci ] treatment difference vs placebo,C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
995,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
995,lcz $nmbr$ treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,interaction between treatment and baseline bmi category,C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
995,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
995,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
995,events treatment ( $nmbr$ ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
995,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
995,epa treatment ( n = $nmbr$ ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,continuous lvef $nmbr$ treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
995,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
995,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
995,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
995,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
995,background treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
995,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
995,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
995,antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
995,anti - hypertensive treatment history  n ( % ),C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0432633;C0857121;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
995,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
995,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
995,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
995,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
995,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
995,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
994,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0012113;C0030705;C0034656;C0035171;C0036043;C0038013;C0039798;C0041912;C0087111;C0274281;C0332157;C0332174;C0332257;C0333052;C0374505;C0439230;C0439531;C0439751;C0441471;C0441655;C0444667;C0680240;C0868928;C0871208;C0877248;C1140263;C1412268;C1511726;C1512346;C1519255;C1521828;C1522326;C1533148;C1533734;C1552866;C1622657;C1705169;C1705187;C1706408;C1709637;C1948053;C2347664;C2360800;C2607870;C2699274;C2700399;C2983265;C2986888;C3179547;C3245479;C3538994;C3541888;C3714741;C3815594;C3887670;C3887704;C4553214
994,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .,C0002778;C0003364;C0034036;C0034037;C0039798;C0040808;C0085805;C0087111;C0201976;C0221102;C0232108;C0242492;C0332307;C0439234;C0439508;C0439828;C0441833;C0504085;C0600061;C0687744;C0750591;C0936012;C0947630;C1257890;C1272641;C1274040;C1516050;C1519504;C1522326;C1524024;C1533734;C1547052;C1704324;C1705169;C1705428;C1705429;C2699704;C2945654;C3161035;C3538994;C3887704;C4288391
994,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .,C0001924;C0009667;C0010294;C0019046;C0022661;C0036773;C0080103;C0126174;C0168634;C0201976;C0205345;C0229671;C0242492;C0301630;C0392756;C0439234;C0439508;C0441471;C0456603;C0486293;C0589120;C0596019;C0597277;C0600061;C0728877;C0871208;C1137094;C1293152;C1442488;C1518681;C1521828;C1522577;C1546774;C1547037;C1547039;C1549954;C1550100;C1561535;C1626828;C1704685;C1708601;C1708728;C2986775;C3274571;C3541888;C4281686;C4551656
994,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0030705;C0168634;C0201976;C0439234;C0441471;C0589120;C0596019;C0597277;C0600061;C0683312;C0871208;C1442488;C1521828;C1522577;C1549954;C1565830;C1704685;C1708601;C2985465;C3161035;C3274571;C3274659;C3541888;C3714583;C3853906;C3889287
994,bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp,C0005823;C0008107;C0009667;C0012634;C0017446;C0022661;C0030705;C0034510;C0035078;C0039155;C0039798;C0040223;C0087111;C0205088;C0205147;C0441471;C0441833;C0687744;C0871208;C1257890;C1319635;C1519504;C1521828;C1522326;C1533734;C1705169;C1705428;C1705429;C1706779;C2316810;C2826245;C2985465;C3259781;C3538994;C3541383;C3853635;C3887704;C4019010
993,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0001675;C0001779;C0001792;C0003364;C0003850;C0004153;C0005823;C0007273;C0008377;C0011198;C0017480;C0019664;C0019665;C0020538;C0030688;C0040704;C0042295;C0080103;C0151526;C0205252;C0205345;C0205374;C0262512;C0262926;C0277793;C0280604;C0439234;C0439475;C0441833;C0441889;C0449286;C0542560;C0679841;C1261512;C1271104;C1272641;C1304680;C1425219;C1516050;C1518340;C1547039;C1552601;C1705255;C1706365;C1706450;C1963138;C1999167;C1999270;C2004062;C2348088;C2744579;C3245503;C3541240;C3542407;C4018905;C4552600
993,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .,C0001675;C0015663;C0017725;C0020261;C0023822;C0024671;C0025266;C0026410;C0028754;C0039798;C0041004;C0042295;C0087111;C0205437;C0220825;C0231290;C0243161;C0262926;C0332282;C0439070;C0439269;C0439475;C0441833;C0524620;C0600653;C0687744;C0918012;C1257890;C1261322;C1511790;C1519504;C1522326;C1532718;C1533734;C1547282;C1552854;C1637833;C1704706;C1705160;C1705169;C1705428;C1705429;C1706365;C1960952;C1963185;C1999270;C2241628;C2346927;C2986546;C3538994;C3539687;C3887704;C4321396;C4521761
993,treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0005823;C0011849;C0012641;C0018787;C0023822;C0030705;C0035647;C0037623;C0039411;C0039798;C0040642;C0041004;C0041405;C0041698;C0042295;C0065055;C0085805;C0087111;C0168634;C0184661;C0201950;C0205251;C0237403;C0280604;C0332293;C0374505;C0428883;C0439828;C0441833;C0443252;C0488055;C0543421;C0549178;C0687744;C0871420;C0871470;C0886296;C1257890;C1273869;C1305855;C1306620;C1415692;C1442488;C1519504;C1522326;C1522609;C1533734;C1550472;C1705169;C1705428;C1705429;C1707455;C1708288;C1824670;C1947933;C2699239;C2986530;C3272447;C3538994;C3542407;C3887704;C3890211;C4048187;C4318478;C4321351;C4522122;C4522223;C4552904
993,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .,C0001675;C0005507;C0006560;C0011847;C0011849;C0030705;C0042295;C0065055;C0087111;C0150375;C0168634;C0243073;C0369773;C0679841;C1292734;C1413716;C1441604;C1442488;C1510438;C1522326;C1706450;C2603361;C2983605;C3245503;C3642216;C3898312;C4048285
993,ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0001675;C0002680;C0006938;C0011816;C0011849;C0023732;C0025424;C0025663;C0028873;C0030705;C0033095;C0035648;C0037623;C0039798;C0065055;C0085805;C0086858;C0087111;C0162791;C0168634;C0178587;C0205145;C0205246;C0205430;C0220845;C0282423;C0428257;C0428883;C0439070;C0439475;C0441833;C0445247;C0449438;C0449851;C0456081;C0460139;C0552449;C0680230;C0750572;C0871511;C1306345;C1415692;C1442488;C1515974;C1521840;C1522326;C1533734;C1705160;C1705169;C1705241;C1705242;C1706365;C1706450;C1708288;C1999270;C2347108;C2347109;C2348272;C2744579;C2825164;C2986546;C3160715;C3245503;C3250443;C3538994;C3887704;C3887950;C4050020;C4068104;C4284008;C4318478;C4552600
992,without aspirin ( n = $nmbr$  $nmbr$ ),C0004057
992,with aspirin ( n = $nmbr$  $nmbr$ ),C0004057
992,therapy ( asa $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
992,therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
992,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
992,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
992,prior aspirin,C0004057;C0332152;C2826257
992,pfo + asa,C0004057;C3853627
992,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
992,no prior aspirin,C0004057;C0332152;C2826257
992,no aspirin or ppi,C0004057
992,no aspirin,C0004057
992,no asa,C0004057;C3853627
992,medication use ( % ) aspirin,C0004057;C0240320
992,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977
992,combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036
992,baseline $nmbr$ - asa,C0004057;C0168634;C1442488;C3853627
992,baseiine aspirin,C0004057
992,aspirin 一 no . ( % ),C0004057
992,aspirin — no . ( % ),C0004057
992,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
992,aspirin use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
992,aspirin use ( p = $nmbr$ - $nmbr$ 十 ),C0004057;C0042153;C0457083;C1947944
992,aspirin use ( p = $nmbr$ - $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
992,aspirin use ( > $nmbr$ mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
992,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
992,aspirin use,C0004057;C0042153;C0457083;C1947944
992,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
992,aspirin or thienopyridines ( % ),C0004057
992,aspirin or other antiplatelet or anticoagulant agent,C0004057
992,aspirin or other antiplatelet drug,C0004057
992,aspirin or other antiplatelet agents,C0004057
992,aspirin or other antiplatelet agent,C0004057
992,aspirin only ( n = $nmbr$  $nmbr$ ),C0004057;C0205171;C1720467
992,aspirin only,C0004057;C0205171;C1720467
992,aspirin but no ppi,C0004057
992,aspirin and thienopyridine therapy,C0004057
992,aspirin and ppi,C0004057
992,aspirin and other antiplatelet,C0004057
992,aspirin alone group no of events / total n ( % ),C0004057;C2826346
992,aspirin alone,C0004057
992,aspirin < $nmbr$ day,C0004057;C0332173;C0439228;C0439505
992,aspirin / other antiplatelet agents  n ( % ),C0004057
992,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
992,aspirin / antiplatelet,C0004057
992,aspirin - erdp ( n = $nmbr$  $nmbr$ ),C0004057
992,aspirin + thienopyridine,C0004057;C1120149
992,aspirin ( n = $nmbr$ ) no . of participants with events ( % ),C0004057
992,aspirin ( n = $nmbr$ ),C0004057
992,aspirin ( n = $nmbr$ $nmbr$ ),C0004057
992,aspirin ( n = $nmbr$  $nmbr$ ),C0004057
992,aspirin ( n  % ),C0004057
992,aspirin ( asa ) ( » = $nmbr$ $nmbr$ ),C0004057;C3853627
992,aspirin ( any dose ),C0004057
992,aspirin ( % ),C0004057
992,aspirin $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
992,aspirin $nmbr$  $nmbr$,C0004057
992,aspirin $nmbr$,C0004057
992,aspirin  no . ( % ),C0004057
992,aspirin  n ( % ),C0004057
992,aspirin,C0004057
992,asas partial remission    n   ( % ),C0004057;C1521726;C3853627;C4552913;C4552914
992,asas partial remission  %,C0004057;C1521726;C3853627;C4552913;C4552914
992,asas $nmbr$ / $nmbr$    n   ( % ),C0004057;C3853627
992,asas $nmbr$ / $nmbr$    %,C0004057;C3853627
992,asas $nmbr$    %,C0004057;C3853627
992,asas $nmbr$  %,C0004057;C3853627
992,asas $nmbr$,C0004057;C3853627
992,asa or antiplatelet agent,C0004057;C3853627
992,asa  n ( % ),C0004057;C3853627
992,asa,C0004057;C3853627
992,acetylsalicylic acid,C0004057
992,acetyl - salicylic acid,C0004057
992,$nmbr$ aspirin ( n = $nmbr$ $nmbr$ ),C0004057
991,without ckd ( $nmbr$ ),C1561643
991,with ckd ( $nmbr$ ),C1561643
991,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
991,no ckd n,C1561643
991,no ckd ( % ),C1561643
991,no ckd,C1561643
991,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
991,established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
991,ckd stages,C1306673;C1561643
991,ckd stage $nmbr$ ( % ),C0205390;C1300072;C1306673;C1561643
991,ckd stage $nmbr$,C0205390;C1300072;C1306673;C1561643
991,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
991,ckd n,C1561643
991,ckd *,C1561643
991,ckd ( egfr < $nmbr$ b ),C1561643;C1739039;C3811844;C3812682
991,ckd ( egfr < $nmbr$ )  n ( % ),C1561643;C1739039;C3811844;C3812682
991,ckd  n ( % ) t,C1561643
991,ckd,C1561643
991,chronic renal insufficiency  %,C0403447;C1561643
991,chronic renal insufficiency,C0403447;C1561643
991,chronic renal failure  n ( % ),C0022661;C1561643;C2316810
991,chronic renal failure,C0022661;C1561643;C2316810
991,chronic renal disease — no . ( % ),C0022661;C1561643
991,chronic renal disease,C0022661;C1561643
991,chronic kidney disease †,C1561643;C4553188
991,chronic kidney disease ( % ),C1561643;C4553188
991,chronic kidney disease  no . ( % ) t,C1561643;C4553188
991,chronic kidney disease  n ( % ),C1561643;C4553188
991,chronic kidney disease,C1561643;C4553188
991,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
990,prior copd medicationa  n ( % ),C0024117;C0332152;C1412502;C2826257;C3714496
990,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
990,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
990,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
990,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
990,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd — days ^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
990,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd  yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd  years,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
990,duration of copd  y,C0024117;C0449238;C1412502;C2926735;C3714496
990,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
990,copd — no . ( % ) medication use,C0024117;C1412502;C3714496
990,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
990,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
990,copd severityy,C0024117;C1412502;C3714496
990,copd severitya    n   ( % ),C0024117;C1412502;C3714496
990,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
990,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
990,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1412502;C3714496
990,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
990,copd severity ( gold $nmbr$ ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
990,copd severity  n ( % ) a,C0024117;C0439793;C0522510;C1412502;C3714496
990,copd severity  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
990,copd severity  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
990,copd severity  %,C0024117;C0439793;C0522510;C1412502;C3714496
990,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
990,copd or asthma  ( % ),C0024117;C1412502;C3714496
990,copd or asthma,C0024117;C1412502;C3714496
990,copd medication taken for at least $nmbr$ months before study entry,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
990,copd medication taken for at least $nmbr$ months before st,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
990,copd duration  y,C0024117;C0449238;C1412502;C2926735;C3714496
990,copd - rosuvastatin ( n = $nmbr$ ),C0024117;C0965129;C1412502;C3714496
990,copd - rosuvastatin ( $nmbr$ pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
990,copd ( n = $nmbr$ ),C0024117;C1412502;C3714496
990,copd ( % ),C0024117;C1412502;C3714496
990,copd    n   ( % ),C0024117;C1412502;C3714496
990,copd,C0024117;C1412502;C3714496
990,chronic obstructive pulmonary disease — no . ( % ),C0024117
990,chronic obstructive pulmonary disease  n ( % ),C0024117
990,chronic obstructive pulmonary disease,C0024117
990,chronic obstructive lung disease,C0024117
990,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
989,without concomitant ics,C0521115;C0815320;C4551720
989,with ics  n ( % ),C0815320;C4551720
989,with concomitant ics,C0521115;C0815320;C4551720
989,use of ics,C0815320;C1524063;C4551720
989,total ics dose at entry  / xg / d,C0017209;C0815320;C1292284;C1421532;C1705654;C2986497;C4551720
989,total daily dose of ics  mean  μ gc,C0444504;C0815320;C2347634;C2348070;C2348143;C3537453;C4281799;C4551720
989,other ics versus no ics,C0815320;C4551720
989,other ics,C0815320;C4551720
989,no ics,C0815320;C4551720
989,neither ics nor laba,C0815320;C4551720
989,mean ics use at enrolment ( pg ) *,C0444504;C0815320;C2347634;C2348143;C4551720
989,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0444504;C0815320;C2347634;C2348143;C4551720
989,laba   +   ics,C0815320;C4551720
989,laba / ics use at screening  n ( % ),C0815320;C4551720
989,laba / ics #,C0815320;C4551720
989,laba + ics versus indzgly lsm difference ( $nmbr$ % cl ),C0815320;C4551720
989,laba + ics n = $nmbr$,C0815320;C4551720
989,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
989,laba + ics,C0815320;C4551720
989,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
989,ics users at baseline  n ( % ),C0168634;C0815320;C1442488;C1706077;C4551720
989,ics users at baseline  %,C0168634;C0815320;C1442488;C1706077;C4551720
989,ics users : qvai $nmbr$ - sfc,C0815320;C1706077;C4521536;C4551720
989,ics users  n ( % ),C0815320;C1706077;C4551720
989,ics users,C0815320;C1706077;C4551720
989,ics use yes / no  %,C0815320;C4551720
989,ics use yes,C0815320;C4551720
989,ics use no,C0815320;C4551720
989,ics use at screeningg  n ( % ),C0815320;C4551720
989,ics use at screening  n ( % ),C0815320;C4551720
989,ics use at screening,C0815320;C4551720
989,ics use at enrollment  mean  mg / d,C0815320;C4551720
989,ics use at baseline : yes,C0815320;C4551720
989,ics use at baseline : no,C0815320;C4551720
989,ics use at baseline  n ( % ),C0815320;C4551720
989,ics use at baseline,C0815320;C4551720
989,ics use  yes / no %,C0815320;C4551720
989,ics use  yes / no  %,C0815320;C4551720
989,ics use  %,C0815320;C4551720
989,ics use,C0815320;C4551720
989,ics usage,C0457083;C0815320;C4551720
989,ics plus laba,C0815320;C4551720
989,ics only,C0205171;C0815320;C1720467;C4551720
989,ics nonusers  n ( % ),C0815320;C4551720
989,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
989,ics non - users : qvai $nmbr$ - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
989,ics no laba,C0815320;C4551720
989,ics dose of stable maintenance treatment ( μ g ) ∗  †,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
989,ics alone,C0815320;C4551720
989,ics ? laba ( free or fdc ),C0815320;C4551720
989,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
989,ics : no,C0815320;C4551720
989,ics / lama,C0815320;C0999593;C1416775;C4551720
989,ics / labd,C0396059;C0815320;C4551720
989,ics / laba therapy  n ( % ),C0039798;C0087111;C0815320;C1363945;C4551720
989,ics / laba,C0815320;C4551720
989,ics + laba,C0815320;C4551720
989,ics # #,C0815320;C4551720
989,ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0815320;C4551720
989,ics  no laba  n ( % ),C0815320;C4551720
989,ics  n ( % ),C0815320;C4551720
989,ics,C0815320;C4551720
989,high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
989,high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
989,high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
989,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ),C0178602;C0815320;C2986497;C4551720
989,calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y,C0178602;C0815320;C2986497;C4551720
989,baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0815320;C1442488;C2827928;C4551720
989,- ics / + laba n z $nmbr$,C0815320;C4551720
989,+ ics / + laba nz $nmbr$,C0027978;C0815320;C4551720
989,+ ics / + laba n z $nmbr$,C0815320;C4551720
988,without t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
988,without dm ( n = $nmbr$ i $nmbr$ * ),C0011816;C3250443
988,without dm,C0011816;C3250443
988,with t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
988,with dm,C0011816;C3250443
988,patients without dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
988,patients without dm ( n = $nmbr$  $nmbr$ ),C0011816;C0030705;C3250443
988,patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
988,patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
988,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
988,patients with dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
988,no dm ( n = $nmbr$ ),C0011816;C3250443
988,no dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
988,no dm,C0011816;C3250443
988,new dm,C0011816;C0205314;C3250443
988,dm or diabetic complications,C0011816;C3250443
988,dm or ckd *,C0011816;C3250443
988,dm absent,C0011816;C3250443
988,dm ( n = $nmbr$ ),C0011816;C3250443
988,dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
988,dm  n ( % ),C0011816;C3250443
988,dm,C0011816;C3250443
988,diff_measure ( dm added this as table had multiple headings ),C0011816;C0079809;C0242485;C3250443
987,waisthip ratio,C0205682;C0456603;C1547037
987,waist : hip ratio,C0205682
987,waist - to - hip ratio,C0205682
987,waist - to - hip  male,C0019552;C0022122;C0086582;C0230097;C1505163;C1706180;C1706428;C1706429;C3538851;C4284725
987,waist - to - hip  female,C0019552;C0022122;C0043210;C0086287;C0230097;C1505163;C1705497;C1705498;C3538851;C4284725
987,waist - hip ratio,C0205682
987,waist ( cm ),C0230097
986,ast increased,C1415181;C3891303
986,ast  u / l,C0439339;C1415181;C3891303
985,within last $nmbr$ d,C1517741
985,last study visit,C1517741
984,total basdai score  mean   ±   sd,C0439175;C0439810;C1998004
984,total basdai score  mean ( sd ),C0439175;C0439810;C1998004
984,basdai ⁎ ⁎,C1998004
984,basdai score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
984,basdai score  mean ( sd ),C1998004
984,basdai responses at week $nmbr$,C0332174;C0439230;C0871261;C1998004
984,basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
984,basdai $nmbr$  n ( % ),C1998004
984,basdai $nmbr$  %,C1998004
984,basdai  total  mean ± sd,C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
983,both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use,C1122087
983,both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use,C1122087
983,both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use,C1122087
983,both adalimumab groups ( n = $nmbr$ ),C1122087
983,adalimumab group ( n = $nmbr$ ) t,C0036669;C1122087
983,adalimumab croup  n / n ( % ),C0010380;C1122087
983,adalimumab ( n = $nmbr$ ),C1122087
983,adalimumab,C1122087
982,systolic bp at baseline :,C0168634;C0871470;C1442488
982,systolic bp ( mmhg ) *,C0439475;C0871470
982,systolic bp ( mmhg ),C0439475;C0871470
982,systolic bp ( mm hg ),C0439475;C0871470
982,systolic bp  mmhg ( sd ),C0439475;C0871470;C2699239
982,systolic bp  mmhg,C0439475;C0871470
982,systolic bp  mm hg,C0439475;C0871470
982,systolic bp,C0871470
982,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
982,systolic blood pressure ^,C0488055;C0871470;C1306620
982,systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0439475;C0488055;C0871470;C1306620;C1704675
982,systolic blood pressure > $nmbr$ mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure > $nmbr$ mm hg or diastolic,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure > $nmbr$ mm hg  n ( % ),C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure < $nmbr$ mm hg and diastolic,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mmhg *,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mmhg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mm   hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mm hq,C0488055;C0871470;C1306620;C4330985;C4554674
982,systolic blood pressure  mm hg ^,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mm hg < $nmbr$,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  mm hg ( sd ),C0439475;C0488055;C0871470;C1306620;C2699239
982,systolic blood pressure  mm hg,C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure  ( mm hg ),C0439475;C0488055;C0871470;C1306620
982,systolic blood pressure,C0488055;C0871470;C1306620
982,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
982,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
982,mean systolic blood pressure  mm hg ( sd ),C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
982,baseline systolic bp,C0168634;C0871470;C1442488
981,dyslipidemia — no . { % ),C0242339
981,dyslipidemia — no . ( % ) |,C0242339
981,dyslipidemia — no . ( % ),C0242339
981,dyslipidemia $nmbr$,C0242339
981,dyslipidemia  n ( % ),C0242339
981,dyslipidemia,C0242339
981,dyslipidaemia 本,C0242339
981,dyslipidaemia — no . ( % ),C0242339
981,dyslipidaemia including hypercholesterol — no . ( % ),C0242339
981,dyslipidaemia and hypertensiont,C0242339
981,dyslipidaemia and hypertension  n ( % ),C0242339
981,dyslipidaemia  n ( % ),C0242339
981,dyslipidaemia,C0242339
981,baseline dyslipidemia,C0168634;C0242339;C1442488
980,without dvt dvt alone,C0149871;C2926618;C3899446
980,symptomatic deep - vein thrombosis,C0149871;C0231220
980,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
980,residual deep - vein thrombosis  no . ( % ),C0149871;C1609982
980,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
980,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
980,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
980,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
980,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
980,neither deep - vein thrombosis nor pulmonary embolism §,C0149871
980,neither deep - vein thrombosis nor pulmonary embolism ^,C0149871
980,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
980,dvt,C0149871;C2926618;C3899446
980,deep vein thrombosis only,C0149871;C0205171;C1720467
980,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0149871
980,deep - vein thrombosis only,C0149871;C0205171;C1720467
980,deep - vein thrombosis ( % ),C0149871
980,deep - vein thrombosis,C0149871
980,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0521115;C2926618;C3899446
980,concomitant dvt  n ( % ),C0149871;C0521115;C2926618;C3899446
980,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0149871;C1314792;C2926618;C3899446
980,causes of dvt or pe  n ( % ),C0015127;C0149871;C1314792;C2926618;C3899446
980,cause of dvt or pe — no . ( % ),C0015127;C0149871;C1524003;C2926618;C3899446
980,both deep - vein thrombosis and pulmonary embolism,C0149871
979,volumetric bmd by qct,C0412669;C0445383
979,morphometric vertebral,C0200760;C0549207
979,geometric mean uacr,C2986759
979,geometric mean of baseline,C0168634;C1442488;C2986759
979,geometric mean,C2986759
979,baseline geometric mean ( $nmbr$ ® / l ),C0168634;C1442488;C2986759
978,tiotropium salmeterol no . of patients / total no .,C0073992;C0213771
978,salmeterol ( n [ $nmbr$ ),C0073992
978,salmeterol ( n = $nmbr$ ),C0073992
978,salmeterol $nmbr$ gg bid,C0017454;C0018370;C0073992
978,salmeterol,C0073992
977,without metabolic syndrome,C0524620
977,with metabolic syndrome,C0524620
977,the metabolic syndrome ^,C0524620
977,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
977,participants without metabolic syndrome,C0524620;C0679646
977,participants with metabolic syndrome,C0524620;C0679646
977,no metabolic syndrome,C0524620
977,metabolic syndrome — no . ( % ) ^,C0524620
977,metabolic syndrome — no . ( % ) $nmbr$,C0524620
977,metabolic syndrome — no . ( % ) !,C0524620
977,metabolic syndrome w / o t $nmbr$ dm,C0011816;C0524620;C3250443
977,metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata,C0524620
977,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
977,metabolic syndrome * n = $nmbr$,C0524620
977,metabolic syndrome *,C0524620
977,metabolic syndrome ( n = $nmbr$ ),C0524620
977,metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics ),C0524620;C1521970
977,metabolic syndrome ( % ) b,C0524620
977,metabolic syndrome ( % ),C0524620
977,metabolic syndrome $nmbr$ baseline lipids  mg / dl,C0023779;C0168634;C0439269;C0524620;C1442488
977,metabolic syndrome $nmbr$ *,C0524620
977,metabolic syndrome  n / n ( % ) *,C0524620
977,metabolic syndrome  n ( % ),C0524620
977,metabolic syndrome  ! n ( % ),C0524620
977,metabolic syndrome,C0524620
976,plus metformin,C0025598;C0332287
976,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
976,not on metformin,C0025598;C1518422
976,no metformin,C0025598
976,metformin 一 no . ( % ),C0025598
976,metformin — no . ( % ),C0025598
976,metformin ± other oral anti - dm drugs,C0025598
976,metformin use  n ( % ),C0025598;C0042153;C0457083;C1947944
976,metformin open - label *,C0025598
976,metformin only,C0025598;C0205171;C1720467
976,metformin monotherapy,C0025598
976,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
976,metformin dose,C0025598;C0178602;C0869039;C1114758
976,metformin alone,C0025598
976,metformin : no / yes  %,C0025598
976,metformin - dose,C0025598;C0178602;C0869039;C1114758
976,metformin + sulphonylureas,C0025598;C0038766
976,metformin ( n = $nmbr$ ),C0025598
976,metformin ( n $nmbr$ $nmbr$ ),C0025598
976,metformin ( hdm ),C0025598
976,metformin  n ( % ),C0025598
976,metformin,C0025598
976,mean ( s . d . ) metformin dose †  mg / day,C0025598;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
976,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
976,distribution of metformin dose at randomization  n ( % ),C0025598;C0178602;C0520511;C0869039;C1114758;C1704711
975,idm,C0270221
974,ramus,C3538818
974,cards,C2930619;C3275277
973,without stent,C0038257
973,with stent ^ l,C0038257
973,with stent,C0038257
973,with any stent,C0038257
973,stenting plus medical therapy ( n = $nmbr$ ),C0038257;C0418981;C2348535
973,stent plus medical therapy,C0038257;C0418981
973,stent group ( n = $nmbr$ ),C0038257;C0441848
973,stent ( n = $nmbr$ ),C0038257
973,stent,C0038257
973,prior stent,C0038257;C0332152;C2826257
973,other stent,C0038257
973,no . of stents,C0038257
973,multivessel stenting,C0038257;C2348535
973,minimum stent diameter,C0038257;C4054490
973,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
972,without mets,C0812270;C1705694;C2939420
972,with mets,C0812270;C1705694;C2939420
972,mets w / o t $nmbr$ dm,C0011816;C0812270;C1705694;C2939420;C3250443
972,mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C0812270;C1705694;C2939420
972,mets  n ( % ),C0812270;C1705694;C2939420
972,mets,C0812270;C1705694;C2939420
972,i without mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
972,i with mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
971,tcz + mtx ( n ),C0025677;C1417487
971,ssz + mtx ( n = $nmbr$ ),C0025677;C1417487
971,non - mtx csdmards,C0025677;C1417487;C1518422
971,non - mtx,C0025677;C1417487;C1518422
971,mtx ≥ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx ≤ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx £ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
971,mtx only,C0025677;C0205171;C1417487;C1720467
971,mtx naive or free,C0025677;C1417487
971,mtx n = $nmbr$,C0025677;C1417487
971,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
971,mtx > $nmbr$ – $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx > $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx > $nmbr$ and £ $nmbr$ mg / week,C0025677;C1417487
971,mtx > $nmbr$ and si $nmbr$ mg / week,C0025677;C1417487
971,mtx < $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
971,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
971,mtx + othetcsdmards,C0025677;C1417487
971,mtx + other csomards,C0025677;C1417487
971,mtx + other csdmards,C0025677;C1417487
971,mtx + non - mtx,C0025677;C1417487;C1518422
971,mtx ( n = $nmbr$ ),C0025677;C1417487
971,mtx ( n ),C0025677;C1417487
971,mtx,C0025677;C1417487
971,methotrexate user,C0025677;C1548600;C1706077
971,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
971,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
971,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
971,methotrexate use,C0025677;C0042153;C0457083;C1947944
971,methotrexate plus other csdmardfl,C0025677
971,methotrexate alone ^,C0025677
971,methotrexate,C0025677
971,lef + mtx ( n = $nmbr$ ),C0025677;C1417487
971,hcq + mtx ( n = $nmbr$ ),C0020336;C0025677;C1417487
971,etn + mtx ( n = $nmbr$ ),C0014758;C0025677;C0717758;C1417487
971,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
971,czp + mtx n = $nmbr$,C0025677;C0054841;C1417487;C1861828;C1872109
971,czp + mtx ^ mtx,C0025677;C0054841;C1417487;C1861828;C1872109
971,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
971,csdmards + mtx ( n = $nmbr$ ),C0025677;C1417487
971,csdmard otherthan methotrexate,C0025677
971,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
971,concomitant methotrexate use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1947944
971,concomitant methotrexate  n ( % ),C0025677;C0521115
971,concomitant csdmards other than methotrexate  n ( % ),C0025677;C0521115
971,. $nmbr$ kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
971,$nmbr$ tcz + mtx mtx,C0025677;C1417487
971,$nmbr$ tcz + mtx,C0025677;C1417487
971,$nmbr$ non - mtx,C0025677;C1417487;C1518422
970,nyha classes iii - iv,C0278962
970,nyha class iv,C1882087
970,nyha class iii / iv,C0278962
970,nyha class ii ( n = $nmbr$ l $nmbr$ ),C1882085
970,nyha class ii ( n = $nmbr$ ),C1882085
970,nyha class ii,C1882085
970,nyha class > ii,C1882085
970,nyha class  n ( % ) ii,C1882085
970,killip class lll - iv,C1261077;C2697847
970,killip class ii - iv  n ( % ),C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
970,killip class ii  iii  or iv — %,C0439070;C1705160;C1710602;C2697845;C2697846;C4082587
970,killip class i — no . ( % ),C2697844
970,killip class > ii ( % ),C2697845
970,killip class > i  %,C2697844
969,vein bypass graft stented,C0398147
969,prior bypass graft surgery,C0185098;C0455610
969,previous bypass surgery  n ( % ),C0205156;C1536078;C1552607
969,bypass surgery,C1536078
969,bypass graft §,C0185098
969,bypass graft,C0185098
968,£ $nmbr$ % bsa psoriasis  no . ( % ),C0033860
968,without psoriasis ( zi = $nmbr$ ),C0033860;C0043476
968,without psoriasis ( zi = $nmbr$  $nmbr$ ),C0033860;C0043476
968,without psoriasis ( n = $nmbr$ ),C0033860
968,without psoriasis ( n = $nmbr$  $nmbr$ ),C0033860
968,with psoriasis ( zi = $nmbr$ ),C0033860;C0043476
968,with psoriasis ( n = $nmbr$ ),C0033860
968,randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
968,psoriasis duration  yrs *,C0033860;C0449238;C2926735
968,psoriasis duration  years,C0033860;C0439234;C0449238;C2926735
968,psoriasis covering > $nmbr$ % bsa  n ( % ) §,C0033860;C0180153;C0439844
968,psoriasis characteristics,C0033860;C1521970
968,psoriasis bsa > $nmbr$ %  n ( % ),C0033860
968,psoriasis affecting > $nmbr$ % of body - surface,C0033860;C0392760;C0489451;C1314939
968,psoriasis > $nmbr$ % of bsa,C0033860
968,psoriasis ( n =,C0033860
968,psoriasis,C0033860
968,patients without psoriasis ( n = $nmbr$ ),C0030705;C0033860
968,patients with psoriasis > $nmbr$ % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
968,patients with psoriasis ( n = $nmbr$ ),C0030705;C0033860
968,patients with psoriasis ( bsa ≥   $nmbr$ % ),C0030705;C0033860
968,patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % ),C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
968,dlqi ( patients with £ $nmbr$ % bsa psoriasis ),C0030705;C0033860;C3899393
967,pulse pressure ( mmhg ),C0439475;C0949236
967,pulse pressure ( mm hg ),C0439475;C0949236
967,pulse pressure,C0949236
967,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
967,pcs score ( $nmbr$ – $nmbr$ scale ),C1864389;C1882368
967,pcs score,C1864389;C1882368
966,systoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
966,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
966,pressure,C0033095;C0460139;C1306345;C4284008
966,diastoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
965,physiological measures,C0079809;C0205463;C1879489
965,measures of lung function,C0035245;C0079809;C1879489
965,measures ( mmol / l ),C0079809;C0242485;C1879489
965,measures ( % ),C0079809;C1879489
965,measures,C0079809;C1879489
965,ipeated - measures state examinatioi,C0079809;C1879489
964,physician global assessment of disease,C0012634;C4050369
964,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
964,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
964,physician ' s global assessment !,C4050369
964,physician ' s global assessment,C4050369
964,pga subscore,C0016410;C3541266;C4050369
964,pga  $nmbr$ - $nmbr$,C0016410;C3541266;C4050369
964,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
963,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
963,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
963,potassium supplement,C0304475
963,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
963,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
963,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
963,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
963,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
963,potassium  mmol / l,C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
963,potassium  meq / l,C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
963,potassium  meq / dl  mean,C0032821;C0202194;C0304475;C0444504;C0597277;C1532568;C2347634;C2348143;C3714637
963,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
963,hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
963,hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
962,normal function or mild impairment,C4296962
962,infarction  date not reported,C0011008;C0021308;C2348077
962,infarct on brain imaging 丰,C0751955
962,infarct on brain imaging ^,C0751955
962,dates of recruitment,C0011008;C2348077;C2949735
961,saphenous vein graft,C0729538
961,saphenous - vein graft,C0729538
961,hypertension requiring treatment,C0578998
961,hypertension  receiving treatment  n ( % ),C0578998;C1514756
960,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
960,symptom onset to randomization,C0034656;C4086878
960,symptom onset to pci  h,C0033727;C0369286;C0441932;C0564385;C4049621;C4086878;C4528284
960,symptom onset to hospitalization,C0019993;C4086878
960,symptom onset to hospital admission,C0184666;C4086878
960,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685;C4086878
960,symptom onset - to - randomization,C0034656;C4086878
960,symptom onset - to -,C4086878
960,symptom onset,C4086878
959,without tamsulosin,C0257343
959,with tamsulosin,C0257343
959,tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0257343
959,tamsulosin ( n = $nmbr$ ),C0257343
959,tamsulosin $nmbr$ . $nmbr$ mg vs . placebo,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
959,tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
959,tamsulosin,C0257343
958,score distribution : < $nmbr$,C0449820;C0520511;C1704711;C4050231
958,score distribution :,C0449820;C0520511;C1704711;C4050231
958,geographic distribution - no . ( % ),C0681686
958,distribution — no . { % ),C0520511;C1704711
958,distribution — no . ( % ),C0520511;C1704711
958,distribution time,C0040223;C0520511;C1704711;C3541383
958,bmi distribution  n ( % ),C0520511;C0578022;C1704711
958,age distribution  years  n ( % ),C0001782;C0439234;C0520511;C1510829;C1704711
958,age distribution  n ( % ),C0001782
958,age distribution,C0001782
958,age  years geographical distribution of patients,C0030705;C0681686;C1510829
958,a $nmbr$ c distribution ( % ),C0520511;C1704711
957,dactylitis severity score ) score > $nmbr$ — no . { % ),C0239161;C0457451
957,dactylitis score ( $nmbr$ – $nmbr$ scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
957,dactylitis score ( $nmbr$ - $nmbr$ ),C0239161;C0449820;C4050231
957,dactylitis score,C0239161;C0449820;C4050231
957,dactylitis count,C0239161;C0750480;C1705566
957,dactylitis  n ( % ),C0239161
957,dactylitis  % #,C0239161
957,dactylitis,C0239161
956,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415
956,oral glucocorticoid use,C0017710;C1527415
956,no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778
956,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
956,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
956,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
956,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
956,glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778
956,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
956,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
956,glucocorticoids *,C0017710;C3540777;C3540778
956,glucocorticoids,C0017710;C3540777;C3540778
956,glucocorticoid ],C0017710
956,glucocorticoid,C0017710
956,any glucocorticoid *,C0017710
955,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
955,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
955,other biologic agent,C0005515
955,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
955,biological,C0005532;C0205460
955,biologic naive,C0005515;C0205460
955,biologic agents,C0005515
955,biologic,C0005515;C0205460
954,use of loop diuretics  n ( % ),C0354100;C1524063
954,use of loop diuretics,C0354100;C1524063
954,loop diuretics,C0354100
954,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
954,loop diuretic,C0354100;C3536704
953,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
953,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
953,pulmonary embolismb  n / n ( % ),C0024109;C2707265;C2709248;C4522268
953,pulmonary embolisma  n / n ( % ),C0024109;C2707265;C2709248;C4522268
953,lung,C0024109
953,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
953,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
953,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
953,baseline pulmonary medication  b n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
953,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
953,any pulmonary medication  n ( % ),C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
953,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
952,with lowest hba $nmbr$ cd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
952,with lowest bwb,C1708760
952,lowest tg tertile,C0337445;C1708760
952,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
952,lowest,C1708760
951,others  n ( % ),C1955473;C3539125
951,others  classes i and iiic,C0441885;C1319793;C1955473;C2698967;C3539125
951,others,C1955473;C3539125
951,all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
951,all others  n ( % ),C1955473;C3539125
951,all others,C1955473;C3539125
950,non high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956;C1518422
950,higher dose,C0444956
950,higher - dose,C0444956
950,high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956
950,high dose,C0444956
950,high - dose statin,C0360714;C0444956
950,high - dose aspirin,C0004057;C0444956
950,high - dose arb ( n = $nmbr$ ),C0444956;C3888198
949,height loss ( cm ),C0424641
949,height loss,C0424641
948,with highest bwa,C0006041;C1522410
948,highest tg tertile,C0337445;C1522410
948,highest killip classiciation pre - pci,C1522410
948,highest,C1522410
947,work and school,C0043227
947,womac pain score,C0582148
947,schwab & england score,C0014282
947,haq pain score,C0102923;C0451208;C0582148
946,voiding subscore,C0042034;C4067975
946,storage subscore,C0337174;C1698986;C1753314
946,irritative subscore,C0441723;C1706307;C2700617
946,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
945,whole cohort,C0009247;C0444667;C0599755
945,secondary - prevention cohort,C0009247;C0599755;C0679699
945,primary - prevention cohort,C0009247;C0033144;C0599755
945,itt cohort  overall study period,C0009247;C0599755
945,full cohort,C0009247;C0443225;C0599755
945,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
945,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
945,entire cohort,C0009247;C0439751;C0444667;C0599755
945,cohort $nmbr$ ( n = $nmbr$ ) f,C0009247;C0016327;C0599755
945,cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755
945,cohort,C0009247;C0599755
945,$nmbr$ mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
944,women  qva $nmbr$ - sfc,C0043210;C4521536
944,sfc ( n   = $nmbr$  $nmbr$ ),C4521536
944,sfc ( n [ $nmbr$ ),C4521536
944,sfc ( n = $nmbr$ ),C4521536
944,sfc $nmbr$ mg / $nmbr$ mg,C1319635;C4521536
944,sfc,C4521536
944,severe cord * : qvai $nmbr$ - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
944,moderate cord * : qva $nmbr$ - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
944,age > $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
944,age < $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
943,su monotherapy,C0038642;C1705534
943,su / tzd,C0038642;C1705534
943,su / met,C0038642;C1705534
943,su  n ( % ),C0038642;C1705534
943,su,C0038642;C1705534
943,metformin ? su,C0025598;C0038642;C1705534
943,metformin + su + tzd,C0025598;C0038642;C1705534
943,metformin + su,C0025598;C0038642;C1705534
942,alirocumab n = $nmbr$,C3491162
942,alirocumab ( n = $nmbr$ ),C3491162
942,alirocumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
942,alirocumab,C3491162
941,rituximab  n = $nmbr$,C0393022
941,rituximab,C0393022
940,ustekinumab ® ( n = $nmbr$ ),C1608841
940,ustekinumab combined,C1608841
940,ustekinumab ' ’ ( n = $nmbr$ ),C1608841
940,ustekinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
940,ustekinumab,C1608841
939,of variation )  iu,C0049272;C0205419;C0439453;C0694756
939,iuss score  mean ( sd ),C0439453
939,iu,C0049272;C0439453;C0694756
938,wrist,C0043262;C1322271
938,rib,C0035561
937,lis,C2247545
937,lips,C0023759
937,lipc,C1416867
936,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
936,£ median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,£ median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
936,wt  second  median,C0205436;C0457385;C0549183;C0565930;C0876920;C1561503;C1705190;C1883559;C2347635;C2348144;C2700323;C2939193
936,weight ( median [ iqr ] )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
936,weight  median ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2699239;C2939193;C4054209
936,weight  median ( iqr )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
936,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
936,weight  kg  median ( $nmbr$ th  $nmbr$ th ),C0005910;C0022718;C0039725;C0039738;C0043100;C0439209;C0549183;C0876920;C1305866;C1420718;C1705104;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
936,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
936,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
936,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
936,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
936,urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C0455271;C0549183;C0876920;C1318330;C1627892;C2347635;C2348144;C2939193
936,uacr  median ( iqr )  mg / g,C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
936,triglycerides ( mmol / l ) ( median  iqr ),C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,triglycerides ( median  iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,triglycerides  median ( ql  q $nmbr$ )  mmol / l,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,triglycerides  median ( qi  q $nmbr$ )  mmol / l,C0041004;C0376586;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,triglycerides  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
936,triglycerides  median ( iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ],C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
936,total ige levelx ( iu / ml )  median ( range ),C0439175;C0439458;C0439810;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,total cholesterol ( median  iqr )  mg / dl,C0201950;C0439269;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
936,time to end - of - study ivus  median ( iqr )  days,C0439548;C0444930;C0549183;C0557651;C0876920;C1456025;C2347635;C2348144;C2603343;C2746065;C2939193
936,time from  median ( iqr )  h,C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C3541383;C4528284
936,tg mg / dl  median ( sd ),C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
936,tg ( mg / dl )  median ± sd,C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
936,tg  median ( sdy rng / cjl,C0337445;C0549183;C0876920;C1424906;C2347635;C2348144;C2939193
936,tg  median ( min  max ),C0337445;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,tg  median ( interquartile range ),C0337445;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
936,systolic blood pressure ( median $nmbr$ . $nmbr$ ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
936,systolic blood pressure  mm hg  median ( range ),C0439475;C0488055;C0549183;C0871470;C0876920;C1306620;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,serum ctx - $nmbr$  ng / ml  median ( iqr ),C0010377;C0229671;C0439275;C0549183;C0631180;C0876920;C1546774;C1550100;C2347635;C2348144;C2939193;C3539598
936,serum cholesterol  median ( iqr )  mg / dl,C0439269;C0549183;C0587184;C0876920;C2347635;C2348144;C2939193
936,seizure frequency during $nmbr$ ‐ week baseline  median ( range ),C0149775;C0168634;C0332174;C0439230;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
936,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
936,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
936,score improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411;C4050231
936,sbp > median ( n = $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
936,sbp < median ( n = $nmbr$ o $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
936,sbp ( mm hg )  median ( iqr ),C0085805;C0439475;C0549183;C0876920;C2347635;C2348144;C2939193
936,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
936,pulse pressure ( median $nmbr$ . $nmbr$ ],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
936,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
936,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
936,pra  median ( min  max )  ng / ml / h,C0033727;C0369286;C0441932;C0549183;C0564385;C0633231;C0702093;C0876920;C1141951;C1419788;C1524029;C1533072;C2347635;C2348144;C2827900;C2939193;C3274822;C3669212;C3813700;C4050009;C4283900;C4528284
936,percent improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439165;C0439230;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411
936,pci duration in min ( median  iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
936,pasi [ c ]  median ( min - max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C4528685
936,pasi  median ( range ) * *,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4528685
936,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
936,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
936,mtss  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
936,mmp - $nmbr$  median ( iqr )  gg / l,C0017454;C0018370;C0549183;C0623362;C0876920;C0919336;C2347635;C2348144;C2939193
936,middle tg tertile,C0337445;C0444598;C0549183;C1552826
936,middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$,C0444598;C0549183;C1552826
936,middle east  africa  or asia - pacific,C0001737;C0001741;C0026068;C0444598;C0549183;C1552826
936,middle,C0444598;C0549183;C1552826
936,medians ( iqr ),C0549183
936,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
936,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
936,median — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
936,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
936,median §,C0549183;C0876920;C2347635;C2348144;C2939193
936,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,median time to first exacerbation ( months [ $nmbr$ % ci ] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
936,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
936,median time since diagnosis * ( range )  yr,C0040223;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383
936,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
936,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
936,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
936,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
936,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
936,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
936,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
936,median m / kg $nmbr$ ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
936,median infusions — no . ( range ),C0549183;C0574032;C0876920;C2347635;C2348144;C2939193
936,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
936,median feno  ppba,C0549183;C0876920;C2347635;C2348144;C2939193
936,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
936,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
936,median duration oftype $nmbr$ diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
936,median duration of symptoms ( range )  yr,C0436359;C0439234;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
936,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
936,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
936,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
936,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
936,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
936,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
936,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
936,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
936,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
936,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
936,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
936,median age [ interquartile range ] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
936,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,median age ( $nmbr$ %  $nmbr$ % )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,median age  years ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,median age  y ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median ( range ) treatment duration  d,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
936,median ( range ) total ige level ( iuml ~ ’ ) $nmbr$,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
936,median ( range ) duration of hospital stayi  d,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
936,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
936,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
936,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median ( q $nmbr$ – q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
936,median ( q $nmbr$ : q $nmbr$ ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
936,median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
936,median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
936,median ( q $nmbr$ : q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( q $nmbr$  q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight,C0168634;C0444504;C0549183;C0876920;C1442488;C2347634;C2347635;C2348143;C2348144;C2939193
936,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score,C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
936,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
936,median ( iqr )  h,C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
936,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
936,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
936,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
936,median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f,C0008107;C0034746;C0332174;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
936,median  y ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median  range,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,median  ml,C0439526;C0549183;C0876920;C1705224;C2347635;C2348144;C2939193;C3887665
936,median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,median  iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
936,median  iqr,C0549183;C0876920;C2347635;C2348144;C2939193
936,median,C0549183;C0876920;C2347635;C2348144;C2939193
936,lvef  %  median ( iqr ),C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
936,lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
936,lp ( a )  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
936,local eosinophil count [ cells / µ l ]  median ( range ),C0200638;C0205276;C0347983;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,local eosinophil count [ cells / ml ]  median ( range ),C0200638;C0205276;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2699156;C2939193;C3542016
936,lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
936,lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l,C0065058;C0125953;C0376586;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
936,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
936,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
936,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
936,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
936,left ventricular ejection fraction  median ( iqr )  %,C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
936,ldl cholesterol ( mmol / l ) ( median  iqr ),C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
936,ldl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
936,laboratory parameters  median ( iqr ),C0022877;C0449381;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
936,jsn  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,insulin dose ( iu / day )  median,C0366513;C0439465;C0549183;C0876920;C2347635;C2348144;C2939193
936,insulin  median ( ql  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
936,insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
936,insulin  iu / ml  median ( q $nmbr$  q $nmbr$ ),C0021641;C0439458;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
936,index event to randomization  median ( iqr )  h,C0033727;C0034656;C0369286;C0441471;C0441932;C0549183;C0564385;C0600653;C0876920;C0918012;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C4019010;C4528284
936,ige ( ku / l )  median ( range ) c,C0439340;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,hscrp ( mg / l )  median ( minimum ‒ maximum ),C0439268;C0549183;C0806909;C0876920;C1524031;C1552614;C1552615;C2347635;C2348144;C2826545;C2826546;C2939193
936,hscrp ( mg / l )  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
936,hscrp ( mg / l )  median ( first  third quartiles ),C0205435;C0205437;C0439268;C0549183;C0876920;C1279901;C2347635;C2348144;C2828255;C2939193
936,hscrp  mg / l  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
936,hscrp  median ( min  max )  mg / l,C0549183;C0876920;C2347635;C2348144;C2827895;C2939193
936,hscrp  median ( iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
936,hs - crp ( mg / l  median ),C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,hs - crp ( median  iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
936,homa_ % b  median ( q $nmbr$  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
936,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
936,homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
936,homa . % b  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
936,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
936,homa - ir  median ( q $nmbr$  q $nmbr$ ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
936,hemoglobin ale  %  median ( iqr ),C0019046;C0549183;C0678386;C0876920;C2347635;C2348144;C2632076;C2939193
936,heart rate ( median $nmbr$ . $nmbr$ },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
936,hdl cholesterol ( mmol / l ) ( median  iqr ),C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,hdl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
936,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
936,hbalc in %  median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
936,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
936,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
936,hbalc  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
936,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
936,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
936,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,hba $nmbr$ c ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
936,hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
936,fpg  median ( ql  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
936,final median  mg / l,C0205088;C0439268;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
936,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
936,fasting tgs  median ( q $nmbr$ : q $nmbr$ ),C0015663;C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
936,fasting serum glucose ( mg / dl )  median ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
936,fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ ),C0015663;C0202041;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193;C3534430
936,fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
936,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
936,fasting insulin  * median ( iqr )  gu / ml,C0015663;C0021641;C0120446;C0439526;C0549183;C0876920;C1533581;C1579433;C1705224;C2347635;C2348144;C2939193;C3714501;C3887515;C3887665
936,euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £,C0039725;C0039738;C0242415;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
936,euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §,C0039725;C0039738;C0442796;C0549183;C0876920;C1420718;C1550602;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
936,esr ( mm / h )  median ( min - max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
936,esr ( mm / h )  median ( min  max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
936,esr  median ( range ) mm / hour,C0439227;C0549183;C0564385;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3811131;C4330985;C4554674
936,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
936,eosinophil count ( cells / pl )  median ( range ) c,C0007584;C0007634;C0200638;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3897966;C4049765
936,enthesitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1282952;C1442488;C2347635;C2348144;C2939193;C4050231
936,egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr ),C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
936,egfr  median ( sd )  ml / min,C0439445;C0549183;C0876920;C1739039;C2347635;C2348144;C2699239;C2939193;C3811844;C3812682
936,duration of pci ( min )  median n ( iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
936,duration of pci ( min )  median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
936,duration of disease ( y )  median ( min  max },C0549183;C0702093;C0872146;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,duration of diabetes mellitus  median ( iqr )  y,C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
936,duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ ),C0439231;C0449238;C0521116;C0549183;C0876920;C1514721;C1517205;C1705970;C2347635;C2348144;C2348147;C2926735;C2939193;C3540542;C3542016
936,disease duration ( y )  median ( m / n  max ),C0369637;C0441923;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
936,disease duration  years : median ( range ),C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,disease duration  year ( median ),C0439234;C0439508;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
936,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,difference  % median,C0549183;C0876920;C1705241;C1705242;C2347635;C2348144;C2939193
936,diastolic blood pressure  mm hg  median ( range ),C0428883;C0439475;C0549183;C0876920;C1305849;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,diabetes duration  median ( iqr )  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
936,dbp ( mm hg )  median ( iqr ),C0439475;C0536221;C0549183;C0876920;C2347635;C2348144;C2939193;C3813197;C4281799
936,dactylitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0239161;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C4050231
936,crp median ( se )  rng / l,C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,crp [ mg / l ]  median,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,crp ( mg / l ) [ b ]  median ( min - max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,crp ( mg / l )  median ± sd,C0439268;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3890735;C4048285
936,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
936,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
936,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
936,crp  mg / dl  median,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,crp  median ( range ) mg / literl,C0024671;C0026410;C0439269;C0549183;C0876920;C1514721;C1960952;C2346927;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285;C4321396;C4521761
936,crp  median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
936,creatinine ( ^ mol / l ) ( median  iqr ),C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
936,crcl  median ( iqr )  ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
936,complete mayo clinic score  median ( min  max },C0002424;C0205197;C0442592;C0449820;C0454788;C0549183;C0702093;C0725685;C0876920;C1077578;C1524029;C2347635;C2348144;C2939193;C3813700;C3853530;C4050231;C4283785
936,clinical variables  median ( iqr ),C0205210;C0439828;C0549183;C0876920;C2347635;C2348144;C2939193
936,cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr ),C0162734;C0369637;C0439445;C0441923;C0549183;C0876920;C1561643;C2347635;C2348144;C2939193;C4281721
936,c - reactive protein  median ( q $nmbr$  q $nmbr$ ),C0006560;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
936,c - reactive protein  median ( iqr )  mg / l,C0006560;C0439268;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
936,c - peptide  median ( ql  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
936,c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
936,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
936,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
936,body mass index  median ( iqr ) b,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
936,body mass index  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
936,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
936,bnp  * median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
936,bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
936,bmi ( median  iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
936,bmi ( kg / m $nmbr$ )  median ( range ),C0549183;C0578022;C0876920;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
936,bmi  median ( sd )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2699239;C2939193
936,bmi  median ( iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
936,bmi  median ( iqr ),C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
936,bmi  kg / m $nmbr$  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
936,below median,C0549183;C0876920;C2347635;C2348144;C2939193
936,baseline tg  ( mg / dl )  median ( iqr ),C0168634;C0337445;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline tav - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline tav - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline pos frequency per $nmbr$ days  median ( min  max ),C0168634;C0549183;C0585290;C0702093;C0876920;C1262869;C1442488;C1524029;C2347635;C2348144;C2939193;C3496112;C3496399;C3813700
936,baseline pav - > = median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline pav - < median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline median [ mg / l ],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
936,baseline median  mg / l,C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline median  mg / dl,C0168634;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline lipoprotein ( a ) ( nmol / l )  median ( iqr ),C0065058;C0125953;C0168634;C0439282;C0549183;C0876920;C1096202;C1439335;C1442488;C2347635;C2348144;C2939193
936,baseline laboratory values  median ( iqr ) d,C0022877;C0042295;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C3244292;C4283904
936,baseline hemoglobin  median ( iqr  g / dl ),C0019046;C0168634;C0439267;C0549183;C0876920;C1319312;C1442488;C2347635;C2348144;C2939193;C3642216
936,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
936,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
936,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
936,baseline fev $nmbr$  median ( range )  l,C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3714541
936,baseline creatinine  median ( range ) mg / dl,C0010294;C0168634;C0439269;C0549183;C0876920;C1442488;C1514721;C1561535;C2347635;C2348144;C2348147;C2939193;C3542016
936,and after pci  median ( iqr )  d,C0549183;C0876920;C2347635;C2348144;C2939193;C4049621
936,albumin / creatinine ratio - mg / mmol  median ( iqr ),C0486293;C0549183;C0567349;C0876920;C1318293;C2347635;C2348144;C2348885;C2939193
936,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
936,age in years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age - years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age ( years ) - > = median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age ( years ) - < median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age ( y )  median ( min  max },C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,age ( y )  median ( min  max ),C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,age ( y )  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age ( median [ iqr ] )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age ( median  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age ( median  iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  yrs  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  yrs  median ( $nmbr$ th  $nmbr$ th ),C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
936,age  year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  y  median ( q $nmbr$ – q $nmbr$ ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  median years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age  median ( iqr )  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
936,age  median ( iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
936,age  median ( interquartile range )  y,C0001779;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
936,age  median ( $nmbr$ th  $nmbr$ th )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
936,a median,C0549183;C0876920;C2347635;C2348144;C2939193
936,a $nmbr$ c > = median,C0549183;C0876920;C2347635;C2348144;C2939193
936,a $nmbr$ c < median,C0549183;C0876920;C2347635;C2348144;C2939193
936,a $nmbr$ c < $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
936,a $nmbr$ = $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
936,^ median > median,C0549183;C0876920;C2347635;C2348144;C2939193
936,^ median,C0549183;C0876920;C2347635;C2348144;C2939193
936,> median ( $nmbr$ mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
936,> median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
936,> median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,> median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,> median ( $nmbr$ % ),C0549183;C0876920;C2347635;C2348144;C2939193
936,> median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
936,> median,C0549183;C0876920;C2347635;C2348144;C2939193
936,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
936,> $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,< median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
936,< median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
936,< median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
936,< median,C0549183;C0876920;C2347635;C2348144;C2939193
936,< $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
936,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
936,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
936,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
936,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
936,( median  h ),C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
936,& median,C0549183;C0876920;C2347635;C2348144;C2939193
936,$nmbr$ - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
935,pvd,C0085096;C4521226
935,peripheral vascular disease  n ( % ),C0085096
935,peripheral vascular disease,C0085096
935,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
935,peripheral arterial disease — no . ( % ),C0085096;C1704436
935,peripheral arterial disease §,C0085096;C1704436
935,peripheral arterial disease ( n = $nmbr$ $nmbr$ ),C0085096;C1704436
935,peripheral arterial disease  n ( % ),C0085096;C1704436
935,peripheral arterial disease,C0085096;C1704436
935,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .,C0003211;C0007787;C0013227;C0019664;C0019665;C0020443;C0023779;C0042373;C0085096;C0149721;C0262512;C0262926;C0439165;C0441994;C0455536;C0679646;C0700287;C0802604;C0917805;C1054154;C1522133;C1524063;C1549488;C1561533;C1705255;C2003888;C2004062;C2598133;C2698741;C4284232;C4521226;C4554048
935,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .,C0003211;C0007787;C0012634;C0023779;C0030685;C0035078;C0085096;C0149721;C0201976;C0282402;C0340279;C0391871;C0439180;C0441994;C0600061;C0680255;C0753208;C1283071;C1305855;C1515187;C1565489;C1704788;C1709991;C1963578;C2003888;C3539106;C3813610;C3890900;C3891546;C4521226
935,any peripheral arterial disease,C0085096;C1704436
935,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
934,ltg - naive,C1420817;C4521367;C4521846
934,ltg - exposed,C1420817;C4521367;C4521846
934,js $nmbr$ - agonists,C0243192;C1552154;C2987634
934,atm - locus,C1708726;C3711796
934,atm - locm,C3711796
934,$nmbr$ [ $nmbr$ - $nmbr$ js,C1552154
933,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
933,m $nmbr$ s,C0439493;C1513009
932,ff / vi ( n   =   $nmbr$ ),C0205999;C4554348
932,ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ ),C0205999;C1319635;C4554348
932,ff / vi $nmbr$ / $nmbr$   µ g,C0205999;C0439267;C4554348
932,ff / vi $nmbr$ / $nmbr$ pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
932,ff / vi $nmbr$ . $nmbr$,C0205999;C4554348
932,ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999;C4554348
932,ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % ),C0205999;C4554348
932,ff / vi,C0205999;C4554348
932,ff - blocker,C4554348
932,ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
932,ff $nmbr$   µ g,C0439267;C4554348
932,ff $nmbr$ pgod,C4554348
932,ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
931,£ l $nmbr$ kg,C1637390
931,- o . os,C2673162
931,$nmbr$ % clf,C3540486;C4553190
931,$nmbr$ % cit,C0008864;C0523573;C1427027;C4553421
930,crp   ≤   uln,C1519815;C3890735;C4048285
930,crp   >   uln,C1519815;C3890735;C4048285
930,cpk > $nmbr$ times uln,C0040223;C1519815;C1632851
930,ck > $nmbr$ xuln,C0009212;C0010287;C1872855
930,ck > $nmbr$ x uln $nmbr$,C0009212;C0010287;C1519815;C1872855
930,> $nmbr$ uln,C1519815
929,x cr $nmbr$ . $nmbr$ x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
929,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
929,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
929,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
929,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
928,radial access site,C0442038;C0589360;C0920847
928,digitalis glycoside,C0012253
928,cardiac glycosides,C0007158
928,access site,C0589360
927,oral aminosalicylates,C0368663;C0442027;C4521986
927,no aminosalicylates  n,C0368663
927,aminosalicylates * *,C0368663
927,aminosalicylates  n,C0368663
927,aminosalicylates,C0368663
927,aminosalicylate,C0368663;C2825094
927,$nmbr$ - aminosalicylates ’ i  i ‘,C0021966;C0221138;C0368663
927,$nmbr$ - aminosalicylates | | | |,C0368663
927,$nmbr$ - aminosalicylates {,C0368663
926,us site,C0205145;C1515974;C2825164
926,sites,C0205145
926,site,C0205145;C1515974;C2825164
926,internal carotid artery sites,C0007276;C0205145
926,critical site,C0205145;C1511545;C1515974;C2825164
926,common carotid artery sites,C0007272;C0162859;C0205145
926,carotid bulb sites,C0007281;C0205145
926,any site,C0205145;C1515974;C2825164
926,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C1171258;C1515974;C2825164
926,$nmbr$ carotid artery sites,C0007272;C0162859;C0205145
925,anti - anaemics,C0857322
925,angiogenesis,C0302600;C1519670
925,anaesthesia / analgesia,C0002905
924,philippines,C0031529
924,methylxanthines,C0066447
923,“ on ” without troublesome dyskinesia,C0013384
923,“ on ” with troublesome dyskinesia,C0013384
923,more than $nmbr$ vessels stented,C0005847;C0205172
923,more than $nmbr$ lesions per vessel,C0205172
922,xanthines $nmbr$,C0043318;C3541955
922,xanthines  b   n ( % ),C0043318;C3541955
922,xanthines,C0043318;C3541955
922,xanthine,C0043314;C0043318
921,chd plus cerebral infarction,C0007785;C0280604;C3542407
921,chd + cerebral infarction,C0007785;C0280604;C3542407
921,cerebral thrombosis,C0079102;C0151945;C0795687
921,cerebral ischemia,C0007785;C0917798
921,cerebral infarction,C0007785
921,cerebral hemorrhage,C2937358
921,cerebral embolism,C0007780
920,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
920,use of parenteral antithrombotic,C0030547;C1524063;C4522267
920,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
919,sf - $nmbr$ physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
919,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
919,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
919,physical examinations,C0031809
919,physical examination,C0031809;C1744699
919,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
919,physical characteristics,C0031809;C0205485;C1509143;C1521970
919,physical and cognitive examination : ! :,C0031809;C0205485;C1509143
918,prior angioplasty,C0162577;C0332152;C1548817;C2826257
918,peripheral angioplasty,C0162577;C0205100;C1548817
918,erysipelas,C0014733
918,angioplasty,C0162577;C1548817
917,familial,C0015576;C0241888
917,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
916,whitea,C1021495
916,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
916,limited,C0439801;C2674459;C3542948;C4050251
916,delighted,C3830544
915,thyroid hormone,C0040135;C4522017
915,thyroid disease,C0040128
915,thiazide diuretics,C0012802
915,thiazide diuretic *,C0012802;C3536861
915,thiazide diuretic,C0012802;C3536861
915,diuretic thiazide,C0012802
915,any thiazide diuretic,C0012802;C3536861
914,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
914,myocardial ischaemia,C0010054;C0151744
914,ischemic heart disease *,C0010054;C0151744
914,ischemic heart disease ( % ),C0010054;C0151744
914,ischemic heart disease  no . ( % ),C0010054;C0151744
914,ischemic heart disease  n ( % ),C0010054;C0151744
914,ischemic heart disease  ( % ),C0010054;C0151744
914,ischemic heart disease  %,C0010054;C0151744
914,ischemic heart disease,C0010054;C0151744
914,ischaemic heart disease or cerebrovascular disorder  n ( % ),C0010054;C0151744
914,ischaemic heart disease  n ( % ),C0010054;C0151744
914,ischaemic heart disease,C0010054;C0151744
914,ihd,C0151744
914,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744;C0205195
913,total mayo score $ | |,C0454788;C1077578;C2964552
913,total mayo score,C0454788;C1077578;C2964552
913,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
913,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
913,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
913,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
913,mayo < $nmbr$  n,C0454788;C1077578
913,mayo $ $nmbr$  n,C0454788;C1077578
913,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
912,tnfi - ir,C0022065;C0022071;C1448132
912,tnf - ir,C0022065;C0022071;C1448132;C1448177
912,on metformin ir or metformin xr $nmbr$   mg / d,C0022065;C0022071;C0025598;C1448132
912,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
912,homa - ir ( % ) b,C0022065;C0022071;C1448132
912,homa - ir,C0022065;C0022071;C1448132
912,dmard - ir,C0022065;C0022071;C0242708;C1448132
912,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
912,bdmard - ir,C0022065;C0022071;C1448132
911,patients with prior dmard use  n ( % ) a,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
911,other dmards,C0242708
911,other dmard use,C0042153;C0242708;C0457083;C1947944
911,dmard − ( n   =   $nmbr$ ),C0242708
911,dmard | |,C0242708
911,dmard user,C0242708;C1548600;C1706077
911,dmard or corticosteroid,C0242708
911,dmard at baseline,C0168634;C0242708;C1442488
911,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
911,dmard + ( n   =   $nmbr$ ),C0242708
911,baseline dmard use  n ( % ),C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
910,ldl : hdl ratio,C0428621
910,ldl - c goal attainment,C0680230
910,ldl - c : hdl - c ratio,C0428621
910,ldl - c / hdl - c ratio,C0428621
910,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
909,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
909,bdi focal score $nmbr$,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
909,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
908,other glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
908,hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ],C0018301;C0243071;C1422069;C1425391;C1539338;C2350813;C2985465
908,glp - $nmbr$ receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
908,glp - $nmbr$ receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
908,glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
908,glp - $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
907,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
907,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os ),C0229090;C0230028;C0262950;C0393706;C1561953
906,fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes,C0439269;C1532563;C2983605
906,fc - ldl - c  friedewald - calculated,C2983605
905,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
905,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
905,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
905,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
905,plasma glucose $nmbr$ hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
905,glucose — mmol / liter,C0017725;C0439190;C0475211
905,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
905,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
905,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
905,> $nmbr$ / tmol / liter — no . ( % ),C0475211
905,> $nmbr$ . $nmbr$ pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
905,> $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
905,> $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
905,< $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
905,< $nmbr$ . $nmbr$ mmol / liter triglyceride level,C0428475;C0439190;C0475211
905,< $nmbr$ . $nmbr$ mmol / liter estimated gfr,C0439190;C0475211
905,< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
905,< $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
904,£ $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
904,supine after $nmbr$ minutes change from baseline,C0038846;C0439232;C0700321;C0702093;C1282918;C2347166
904,standing after $nmbr$ minutes change from baseline,C0231472;C0439232;C0700321;C0702093;C1282918;C2347166
904,standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1705241;C2347166;C4319952
904,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
904,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
904,minutes from symptom onset to prehospital ecg  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C2347166;C4086878
904,minutes from prehospital ecg to pci  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C1623258;C2347166
904,minutes from pre - pci angiography to post - pci angiography  median ( iqr ),C0002978;C0332152;C0439232;C0700321;C0702093;C0740175;C1282918;C2257086;C2347166;C3669034;C4049621
904,< $nmbr$ ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
904,< $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
904,( < $nmbr$ ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
904,$nmbr$ to < $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
904,$nmbr$ - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
903,st - segment depression > $nmbr$ . $nmbr$ mv on admission  %,C0520887;C1454484;C1705503;C4281602
903,st - segment depression > $nmbr$ . $nmbr$ mv,C0520887;C1454484;C1705503;C4281602
903,st - segment depression < $nmbr$ . $nmbr$ mv  %,C0520887;C1454484;C1705503;C4281602
903,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
903,sokoiow - lyon voitage  mv,C1454484;C1705503;C4281602
902,south africa,C0037712
902,short form $nmbr$ ( sf - $nmbr$ ),C0037712;C2964478
902,sf ‐ $nmbr$ health survey,C0018762;C0037712
902,sf - $nmbr$ summary scores,C0037712;C1552616;C1706244
902,sf - $nmbr$ pcs score,C0037712;C1864389;C1882368
902,sf - $nmbr$ pcs,C0037712;C1864389;C1882368
902,sf - $nmbr$ mcs score,C0037712
902,sf - $nmbr$ mcs,C0037712
902,sf $nmbr$ - pcs,C0037712;C1864389;C1882368
902,australia / new zealand / south africa,C0037712;C4289954
901,> $nmbr$ rd quartile,C0694666;C2828255;C4553350
901,$nmbr$ rd > $nmbr$ . $nmbr$,C0694666;C4553350
900,third heart sound  n ( % ),C0232237;C0232278
900,third heart sound,C0232237;C0232278
899,^ $nmbr$ hrs,C1568891
899,> $nmbr$ hrs,C1568891
899,> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ ),C0702093;C1524029;C1568891;C3813700
899,< $nmbr$ hrs,C1568891
898,itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
898,itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
898,itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
898,itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
898,itch nrs $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
898,itch nrs,C0033774;C1422257;C2240043;C4050142
897,xi = ° - ° $nmbr$,C1720296
897,xi = oo  p = o - $nmbr$,C1720296
897,xi = o - $nmbr$  p = o - $nmbr$,C1720296
897,xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$,C1720296
897,xi = $nmbr$ . $nmbr$,C1720296
897,xi = $nmbr$ - l  p = $nmbr$ - $nmbr$,C1720296
897,xi = $nmbr$ - $nmbr$  p = o - l,C1720296
897,xi = $nmbr$ - $nmbr$  p = $nmbr$ - l,C1720296
897,xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,C1720296
897,xi = $nmbr$ - $nmbr$  p = $nmbr$,C1720296
897,xi = $nmbr$ - $nmbr$,C1720296
897,xi = $nmbr$,C1720296
896,years male gender  n ( % ),C0086582;C0439234;C1706180
896,sexa male,C0086582;C1706180;C1706428;C1706429
896,sex : male ( n = $nmbr$ ),C0086582
896,sex : male,C0086582
896,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
896,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
896,sex ( male ) ethnic origin,C0015031;C0086582
896,sex ( male ) - no . ( % ),C0086582
896,sex ( male )  n ( % ),C0086582
896,sex ( male )  %,C0086582
896,sex ( male ),C0086582
896,sex ( male  % ),C0086582
896,sex  n ( % ) male,C0086582
896,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
896,sex  male  no . ( % ),C0086582
896,sex  male  n ( % ),C0086582
896,sex  male,C0086582
896,sex  % male,C0086582
896,overall  male : female,C0043210;C0086287;C0086582;C0282416;C1561607;C1705497;C1705498;C1706180;C1706428;C1706429
896,males [ n ( % ) ],C0086582
896,males ( n = $nmbr$ ),C0086582
896,males ( itt ) ( n = $nmbr$ ),C0086582
896,males ( % ),C0086582
896,males  n ( % ),C0086582
896,males  > $nmbr$ . $nmbr$,C0086582
896,males  > $nmbr$,C0086582
896,males  < $nmbr$ . $nmbr$,C0086582
896,males  < $nmbr$,C0086582
896,males  %,C0086582
896,males,C0086582
896,male vs . female,C0086582;C1706180;C1706428;C1706429
896,male subjects ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
896,male simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male simva,C0086582;C1706180;C1706428;C1706429
896,male sex 一 no . ( % ),C0086582
896,male sex — no . { % ),C0086582
896,male sex — no . of patients ( % ),C0086582
896,male sex — no . / total no . ( % ),C0086582
896,male sex — no . ( % ) weight — no . ( % ),C0086582
896,male sex — no . ( % ) risk factors,C0086582
896,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
896,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582
896,male sex — no . ( % ) f,C0086582
896,male sex — no . ( % ),C0086582
896,male sex — %,C0086582
896,male sex ^,C0086582
896,male sex \ no . ( % ),C0086582
896,male sex ( % ) race or ethnic group ( % ) f,C0034510;C0086582;C1706779;C3853635
896,male sex ( % ),C0086582
896,male sex  no . / total no . ( % ),C0086582
896,male sex  no . ( % ),C0086582
896,male sex  n [ % ],C0086582
896,male sex  n ( % ),C0086582
896,male sex  ( % ),C0086582
896,male sex  %,C0086582
896,male sex,C0086582
896,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
896,male gender ( % ),C0086582;C1706180
896,male gender    n   ( % ),C0086582;C1706180
896,male gender  n ( % ),C0086582;C1706180
896,male gender,C0086582;C1706180
896,male eze / simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
896,male eze / simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male eze / simva,C0086582;C1706180;C1706428;C1706429
896,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
896,male *  n ( % ),C0086582;C1706180;C1706428;C1706429
896,male ( n   = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male ( n z $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male ( n - $nmbr$ ),C0086582;C1706180;C1706428;C1706429
896,male ( % ),C0086582;C1706180;C1706428;C1706429
896,male    n   ( % ),C0086582;C1706180;C1706428;C1706429
896,male  no ( % ),C0086582;C1706180;C1706428;C1706429
896,male  n / n ( % ),C0086582;C1706180;C1706428;C1706429
896,male  n ( % ),C0086582;C1706180;C1706428;C1706429
896,male  n,C0086582;C1706180;C1706428;C1706429
896,male  % ( n ),C0086582;C1706180;C1706428;C1706429
896,male  %,C0086582;C1706180;C1706428;C1706429
896,male,C0086582;C1706180;C1706428;C1706429
896,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
896,genital mycotic infections male $nmbr$,C0086582;C0740330;C1706180;C1706428;C1706429
896,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
896,gender  n [ % ] male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
896,gender  n ( % ) male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
896,gender  male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
896,[ cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
896,[ cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
895,other / mixed ( n = $nmbr$ ),C0205430;C3160715
895,mixed ( n = $nmbr$ ),C0205430;C3160715
895,mixed ( itt ) ( n = $nmbr$ ),C0205430;C3160715
895,mixed,C0205430;C3160715
895,insulin lispro mix $nmbr$,C0205430;C0293359;C1421951;C1720722;C4553942
894,years of follow - up  mean ( sd ) [ maximum ],C0439234;C0444504;C0589120;C0806909;C1522577;C1552615;C1704685;C2347634;C2348143;C2699239;C2826546;C3274571
894,years of education  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
894,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
894,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
894,weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0022718;C0332174;C0439209;C0439230;C0444504;C1303013;C2347634;C2348143;C2699239;C4054209
894,weight  mean ± sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weight  mean ( sd ) lbs .,C0005910;C0043100;C0439219;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C3161851
894,weight  mean ( sd ) kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weight  mean ( sd ) ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weight  mean ( sd )  kgb,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
894,weight  mean ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weight  mean $nmbr$ sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,weeko mean + sem,C0444504;C2347634;C2348143
894,week $nmbr$ mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
894,week $nmbr$ mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
894,week $nmbr$ mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
894,week $nmbr$ mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
894,week $nmbr$ mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
894,week $nmbr$ hba $nmbr$ c  mean ( s . e . ),C0019016;C0332174;C0439230;C0444504;C1825777;C2347634;C2348143;C3538758
894,week $nmbr$ fpg  mean ( s . e . ),C0332174;C0439230;C0444504;C2347634;C2348143
894,week $nmbr$ ( mean  sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
894,vital signs  mean ( sd ),C0150404;C0444504;C0518766;C2347634;C2348143;C2699239
894,vessel size  mean ( sd )  mm,C0005847;C0444504;C0456389;C2347634;C2348143;C2699239;C4330985;C4554674
894,van der heijde mtss  mean ( sd ),C0444504;C0557775;C1511780;C2347634;C2348143;C2699239
894,untreated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,untreated at baseline  mean ( sd )  mm hg,C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,units per week  mean ( sd ),C0444504;C0560588;C2347634;C2348143;C2699239
894,uc duration  y  mean ( range ),C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2926735;C3542016
894,type $nmbr$ collagen  mean ( sd )  ng / ml £,C0009325;C0332307;C0439275;C0444504;C1547052;C2347634;C2348143;C2699239
894,triglycerides ( mmol / l )  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
894,triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
894,triglycerides  mmol / l  mean ± sd,C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
894,triglycerides  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
894,triglyceride  mg / dl  mean ( sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
894,triacylglycerol  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
894,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
894,treated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
894,treated at baseline  mean ( sd )  mm hg,C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
894,total stent length ( mm )  mean ± sd,C0038257;C0439175;C0439810;C0444504;C1444754;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
894,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
894,total periventricular wml score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552
894,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
894,total macular volume  mean ( sd )  mm $nmbr$,C0332574;C0444504;C0449468;C2347634;C2348143;C2699239;C4330985;C4554674
894,total length of implanted stents  mm  mean ( sd ),C0021102;C0439175;C0439810;C0444504;C0449462;C2347634;C2348143;C2699239;C2828363;C4330985;C4554674
894,total cigarette pack - years  mean ( sd ),C0439175;C0439810;C0444504;C1303175;C2347634;C2348143;C2699239
894,total cholesterol ( mmol / l )  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
894,total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
894,total cholesterol  mmol / l  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
894,total cholesterol  mg / dl  mean ( sd ),C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
894,total cholesterol  mean ( sd )  mg / dl,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
894,total cholesterol  mean ( sd ),C0201950;C0444504;C0543421;C2347634;C2348143;C2699239
894,total c ( mmol / l  mean ),C0439175;C0439810;C0444504;C1532563;C2347634;C2348143
894,total basdai  mean ( sd ),C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
894,total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd,C0004604;C0175659;C0349674;C0444504;C1947916;C1963071;C2347634;C2348143;C2699239;C2964552;C4330985;C4553945;C4554674
894,total back pain  mean ( sd ),C0004604;C0439175;C0439810;C0444504;C1963071;C2347634;C2348143;C2699239;C4553945
894,total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0004600;C0042815;C0205095;C0439175;C0439810;C0444504;C0460009;C1995000;C2347634;C2348143;C2699239;C4330985;C4554674
894,tjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
894,tjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,tjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,time  mean ( sd )  min procedure,C0040223;C0184661;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C2700391;C3274430;C3539779;C3541383;C3813700
894,tg  mg / dl  mean ± sd,C0337445;C0439269;C0444504;C2347634;C2348143;C2699239
894,tender joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451530;C2347634;C2348143;C2699239
894,tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
894,tender joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451530;C2347634;C2348143;C2699239
894,tender joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
894,tender joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
894,tchdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,tc level  mean ( sd ) mg / dl,C0039411;C0040642;C0041405;C0041698;C0439269;C0441889;C0444504;C0456079;C1547707;C1824670;C2347634;C2348143;C2699239;C2946261;C3272447;C4522122
894,tc  mg / dl  mean ± sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
894,tc  mg / dl  mean + sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
894,tc  mean ( sd )  rrig / dl,C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C3642216;C4522122
894,tc  mean ( sd ),C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
894,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
894,systolic pulmonary arterial pressure  mean ( sd )  mm hg,C0024109;C0039155;C0439475;C0444504;C0871470;C1168098;C2347634;C2348143;C2699239;C2707265;C2709248;C4522268
894,systolic pressure at ankle level ( mmhg )  mean ± sd,C0003086;C0003087;C0039155;C0439475;C0441889;C0444504;C0445074;C0456079;C0871470;C1547707;C2347634;C2348143;C2699239;C2946261
894,systolic bp  mmhg  mean ± sd,C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
894,systolic bp  mmhg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
894,systolic bp  mm   hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
894,systolic bp  mm hg ( mean ) nyha class,C0039155;C0439475;C0444504;C0488053;C0871470;C1882083;C2347634;C2348143
894,systolic bp  mm hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
894,systolic blood pressure mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure ( mmhg )  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure ( mm hg )  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure  mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure  mm hg  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure  mm hg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic blood pressure  mean ( sd )  mm hga,C0039155;C0428886;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239;C4330985;C4554674
894,systolic blood pressure  mean ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
894,systolic ( mean  sd ),C0039155;C0444504;C2347634;C2348143;C2699239
894,systolic  mean ( sd )  mm hg h,C0025424;C0039155;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
894,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
894,swollen joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451521;C2347634;C2348143;C2699239
894,swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
894,swollen joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451521;C2347634;C2348143;C2699239
894,swollen joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
894,swollen joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
894,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
894,sjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
894,sjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,sjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,size ( cm $nmbr$ ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
894,shs  mean ± sd,C0444504;C2347634;C2348143;C2699239
894,shs  mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
894,sgrq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,sf - $nmbr$ v $nmbr$ pcs  mean [ sd ],C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
894,sf - $nmbr$ v $nmbr$ mcs  mean [ sd ],C0037712;C0444504;C2347634;C2348143;C2699239
894,sf - $nmbr$ pcs  mean ± sd,C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
894,sf - $nmbr$ mcs  mean ± sd,C0037712;C0444504;C2347634;C2348143;C2699239
894,sesbp ( mmhg ) [ mean _sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
894,sesbp ( mmhg ) [ mean - sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
894,ses - cd  mean ( sd ),C0007928;C0034283;C0444504;C2347634;C2348143;C2699239;C4552032
894,serum total cholesterol ( mmol / l )  mean ( sd ),C0444504;C0587184;C1287371;C1532563;C2347634;C2348143;C2699239
894,serum potassium level  mean ( sd )  meq / l,C0302353;C0439375;C0444504;C0543465;C2347634;C2348143;C2699239
894,serum potassium  mean ( sd ) mmol / l,C0302353;C0444504;C0543465;C1532563;C2347634;C2348143;C2699239
894,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
894,serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd ),C0019020;C0444504;C0683149;C2347634;C2348143;C2699239;C3889898
894,serum creatinine level  mean ( sd )  mg / dl,C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine - mean ( sd  n ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine ( pmol / l )  mean ( sd ),C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine  mg / dl  mean ( sd ),C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine  mean ( sd ) mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine  mean ( sd )  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum creatinine  gmol / ' l  mean ( sd ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
894,serum cholesterol  mean ( sd ) mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
894,serum cholesterol  mean ( sd )  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
894,serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd ),C0220853;C0439275;C0444504;C0683149;C2347634;C2348143;C2699239
894,sedbp ( mmhg ) [ mean_ sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
894,sedbp ( mmhg ) [ mean _sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
894,seated sbp  mean ( sd )  mmhg,C0085805;C0277814;C0439475;C0444504;C1283233;C2347634;C2348143;C2699239
894,seated dbp  mean ( sd )  mmhg,C0277814;C0439475;C0444504;C0536221;C1283233;C2347634;C2348143;C2699239;C3813197;C4281799
894,sdai  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3871128
894,scsbp  mean ( sd )  mmhge,C0444504;C2347634;C2348143;C2699239
894,scdbp  mean ( sd )  mmhgf,C0444504;C2347634;C2348143;C2699239
894,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp ( mmhg )  mean ± sd,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp ( mmhg )  mean ( sd ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp ( mmghg )  mean ( sd ),C0085805;C0444504;C2347634;C2348143;C2699239
894,sbp ( mean over $nmbr$ h )  mmhg,C0033727;C0085805;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
894,sbp  mm hg ( office measurement )  mean ( sd ),C0085805;C0242485;C0439475;C0442603;C0444504;C2347634;C2348143;C2699239
894,sbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0085805;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
894,sbp  mm hg  mean ± sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
894,sbp  mm hg  mean + sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
894,sbp  mean ± sd ( mmhg ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp  mean = sd  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp  mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp  mean ( sd )  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,sbp  mean ( sd )  mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
894,risk factors bmi ( kg / m $nmbr$ )  mean + sd,C0035648;C0444504;C0578022;C1532718;C1553898;C2347634;C2348143;C2699239
894,reversibility to salbutamolc  d  mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2699239
894,reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$,C0444504;C0449261;C2347634;C2348143;C2699239;C2987634
894,reversibility ( anticholinergic )  %  mean ( sd ) $,C0242896;C0444504;C0449261;C2347634;C2348143;C2699239;C3537004
894,rescue use : mean no . of inhalations / d,C0042153;C0444504;C0457083;C1947944;C2347634;C2348143
894,rescue medication use  mean inhalations / previous $nmbr$ d,C0004048;C0205156;C0240320;C0354922;C0444504;C1552607;C2347634;C2348143
894,ra duration ( years )  mean ( s . e . ),C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3538806;C4048756
894,qmax  ml / s  mean ( sd ),C0439390;C0444504;C2347634;C2348143;C2699239
894,pvr volume  ml  mean ( sd ),C0242852;C0439526;C0444504;C0449468;C0456261;C1419141;C1690016;C1705102;C1705224;C2347634;C2348143;C2699239;C2700258;C3887665
894,pulse rate ( mean $nmbr$ h )  bpm *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
894,pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
894,pulmonary function tests ( post - bronchodilator )  mean ( sd ),C0024119;C0444504;C2347634;C2348143;C2598152;C2599594;C2699239
894,ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †,C0444504;C1292728;C2347634;C2348143;C2699239;C4330985;C4554674
894,psoriasis duration ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,psa duration ( years )  mean ( sd ),C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3810537;C3813209
894,psa  ng / ml  mean ( sd ),C0439275;C0444504;C2347634;C2348143;C2699239;C3810537;C3813209
894,ppbc score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,potassium ( meql )  mean + sd  available for $nmbr$ patients,C0032821;C0202194;C0304475;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
894,potassium  mean ( sd )  meq / l,C0032821;C0202194;C0304475;C0439375;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
894,plp - c  mean ( sd )  mg / dl,C0034266;C0439269;C0444504;C1175541;C1257874;C1705623;C2347634;C2348143;C2699239
894,pioglitazone dose  mean ( sd )  mg,C0024671;C0026410;C0071097;C0178602;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,physician global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4050369
894,physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4050369;C4330985;C4554674
894,physician ' s global assessment . mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239;C4050369
894,phosphatase  mean ( sd )  ng / ' mlf,C0017887;C0028074;C0031678;C0066495;C0444504;C1149880;C2347634;C2348143;C2699239;C4522024
894,pga score  mean ( sd ),C0016410;C0444504;C0449820;C2347634;C2348143;C2699239;C3541266;C4050231;C4050369
894,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
894,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
894,pav  mean ( $nmbr$ % ci ),C0008107;C0058890;C0444504;C2347634;C2348143;C3259781
894,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
894,patient global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
894,patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd ),C0030193;C0030198;C0030705;C0444504;C0518090;C0679830;C1962977;C2347634;C2348143;C2699239;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
894,patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4054228;C4330985;C4554674
894,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
894,pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
894,pasi score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
894,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
894,pasi score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
894,pasi  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4528685
894,partial mayo score  mean ( sd ),C0444504;C0449820;C0454788;C0728938;C1077578;C1550516;C2347634;C2348143;C2699239;C4050231
894,pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd,C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd ),C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C4330985;C4554674
894,pack - years  mean ( sd ),C0444504;C1277691;C2347634;C2348143;C2699239
894,ocs dose *  mean ( sd ),C0178602;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
894,oab - q score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3641332;C4050231
894,number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0234234;C0444504;C0449813;C2347634;C2348143;C2699239
894,number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0038999;C0444504;C0449813;C2347634;C2348143;C2699239
894,number of implanted stents  n  mean ( sd ),C0237753;C0444504;C0449788;C0522776;C2347634;C2348143;C2699239
894,number of diseased vessels  mean ( sd ),C0005847;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
894,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
894,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
894,non - hdl - c  mmol / l  mean ( sd ),C0444504;C1518422;C1532563;C2347634;C2348143;C2699239;C3715113
894,non - hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
894,non - hdl - c  mean ( sd )  rng / dl,C0444504;C1518422;C2347634;C2348143;C2699239;C3642216;C3715113
894,non - hdl - c  mean ( sd ),C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
894,nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0042815;C0444504;C1970122;C2347634;C2348143;C2699239;C3536884;C3827561;C4330985;C4554674
894,no . previous dmard  mean ( sd ),C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
894,nighttime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0240526;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
894,nighttime mean dbp ( abpm ) at week $nmbr$  mmhg,C0240526;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
894,mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
894,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
894,mtss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,msasss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,ms  mean [ sd ],C0444504;C2347634;C2348143;C2349943;C2699239;C3539704;C3713294
894,motor updrs subscore ( baseline )  mean ( sd ),C0168634;C0444504;C1442488;C1513492;C1705994;C2347634;C2348143;C2699239;C3639721
894,mnapsi  mean [ sd ] d,C0444504;C2347634;C2348143;C2699239
894,mnapsi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
894,mental activities updrs subscore ( baseline )  mean ( sd ),C0168634;C0229992;C0441655;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721
894,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
894,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
894,mean — yr,C0439234;C0444504;C2347634;C2348143
894,mean — mm hg,C0439475;C0444504;C2347634;C2348143
894,mean — ml / min,C0439445;C0444504;C2347634;C2348143
894,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
894,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
894,mean — g / dl,C0439267;C0444504;C2347634;C2348143
894,mean — %,C0444504;C2347634;C2348143
894,mean ±   sd,C0444504;C2347634;C2348143;C2699239
894,mean ± sd unless otherwise indicated,C0444504;C2347634;C2348143;C2699239
894,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
894,mean ± sd msdbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
894,mean ± sd bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
894,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
894,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
894,mean ± sd $nmbr$ - h adbp  mm hg,C0033727;C0168370;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
894,mean ± sd  n ( % ),C0444504;C2347634;C2348143;C2699239
894,mean ± sd  n,C0444504;C2347634;C2348143;C2699239
894,mean ± sd,C0444504;C2347634;C2348143;C2699239
894,mean ± s . d . hba $nmbr$ c,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
894,mean ± s . d . fpg,C0444504;C2347634;C2348143
894,mean ± s . d . bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
894,mean ± s . d . age  years,C0444504;C1510829;C2347634;C2348143
894,mean ± s . d .,C0444504;C2347634;C2348143
894,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
894,mean yearly decline,C0444504;C2347634;C2348143
894,mean weight  kg  mean = sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
894,mean treatment exposure  wk,C0039798;C0087111;C0274281;C0332157;C0332174;C0439230;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
894,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
894,mean total serum ige ( sd )  iu / ml,C0229671;C0439175;C0439458;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
894,mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0439175;C0439810;C0444504;C0578022;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
894,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
894,mean systolic bp  mmhg  mean = sd,C0439475;C0444504;C0871470;C2347634;C2348143;C2699239
894,mean sitting systolic blood pressure,C0444504;C2347634;C2348143
894,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
894,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
894,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
894,mean serum potassium  mg / dl,C0302353;C0439269;C0444504;C0543465;C2347634;C2348143
894,mean serum glucose  mg / dl  mean = sd,C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
894,mean serum creatinine  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143
894,mean serum cholesterol  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143
894,mean selena - sledai score ± sd,C0444504;C0451528;C2347634;C2348143
894,mean sd mssbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
894,mean sd ldl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
894,mean sd hdl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,mean sd fpg  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
894,mean sd $nmbr$ - h asbp  mm hg,C0033727;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
894,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
894,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
894,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
894,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
894,mean or n,C0444504;C2347634;C2348143
894,mean of mean cimt  mean ( sd )  mm,C0444504;C2347634;C2348143;C2699239;C4330985;C4554674
894,mean of maximum cimt  mean ( sd )  mm,C0444504;C0806909;C1552615;C2347634;C2348143;C2699239;C2826546;C4330985;C4554674
894,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
894,mean number of puffs per day,C0237753;C0444504;C0449788;C1533107;C2347634;C2348143
894,mean number of caes in past $nmbr$ months ( number per patient ) ] |,C0237753;C0444504;C0449788;C2347634;C2348143
894,mean number of antihypertensive medications at $nmbr$ year   *,C0003364;C0444504;C1718138;C2347634;C2348143
894,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C2347634;C2348143
894,mean no . agents ( sd ) other medications,C0444504;C2347634;C2348143
894,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
894,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
894,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
894,mean involved bsa  % ( $nmbr$ % ci ),C0444504;C2347634;C2348143
894,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
894,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
894,mean hbaic = • = s . d .  %,C0444504;C2347634;C2348143
894,mean hba $nmbr$ c ± s . d .  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
894,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
894,mean fpg  mmol / l,C0444504;C1532563;C2347634;C2348143
894,mean fev $nmbr$  l ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
894,mean doseb,C0444504;C2347634;C2348143
894,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
894,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
894,mean dlqi score ( $nmbr$ % ci ),C0444504;C2347634;C2348143;C3899393
894,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
894,mean disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143
894,mean disease duration  y ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
894,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
894,mean difference ( $nmbr$ % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
894,mean diastolic bp  mmhg  mean = sd,C0428883;C0439475;C0444504;C2347634;C2348143;C2699239
894,mean crp level  mg / l ( sd ),C0439268;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
894,mean copd duration  y ( sd ),C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
894,mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
894,mean cdai score ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
894,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
894,mean body mass index ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,mean body mass index ( kg / m $nmbr$ ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
894,mean body mass index ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
894,mean body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
894,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
894,mean body - mass index ( = sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,mean body - mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
894,mean bmii 士 s . d .  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143
894,mean bmi ± sd ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean bmi ± s . d .  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143
894,mean bmi ± s . d .  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
894,mean bmi ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
894,mean bmi ( kg / m $nmbr$ ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean bmi ( $nmbr$ % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
894,mean bmi  kg / m $nmbr$ ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean bmi  kg / m $nmbr$ ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean bmi  kg / m $nmbr$ ( s . d . ),C0022718;C0439209;C0444504;C0578022;C1512018;C2347634;C2348143;C4054209
894,mean bmi,C0444504;C0578022;C2347634;C2348143
894,mean bmd ( = sd )  g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
894,mean bm $nmbr$ ± s . d .  kg / m $nmbr$,C0006416;C0444504;C1532718;C2347634;C2348143
894,mean baseline ucdai score,C0168634;C0444504;C1442488;C2347634;C2348143
894,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
894,mean baseline ei score,C0022067;C0168634;C0444504;C1414370;C1442488;C2347634;C2348143;C2348481
894,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
894,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
894,mean asui scored,C0444504;C2347634;C2348143
894,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
894,mean alc  %,C0444504;C1424945;C2347634;C2348143;C3811058
894,mean age 士 s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
894,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
894,mean age ± s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
894,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
894,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
894,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,mean age ( y ),C0001779;C0444504;C2347634;C2348143
894,mean age ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
894,mean age ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
894,mean age ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
894,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,mean age  yrs,C0001779;C0444504;C2347634;C2348143
894,mean age  y ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,mean age  y  mean = sd,C0001779;C0444504;C2347634;C2348143;C2699239
894,mean age  y,C0001779;C0444504;C2347634;C2348143
894,mean acrn,C0444504;C2347634;C2348143
894,mean acq - $nmbr$ scores,C0444504;C2347634;C2348143;C2919686
894,mean acq - $nmbr$ score at randomization  !,C0444504;C2347634;C2348143;C2919686
894,mean a ± sem ( % ),C0444504;C2347634;C2348143
894,mean a ± sdt,C0444504;C2347634;C2348143
894,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
894,mean a ± sd  mg / dl ( mmol / $nmbr$ ),C0444504;C2347634;C2348143
894,mean = sd,C0444504;C2347634;C2348143;C2699239
894,mean - sd change in pre - bronchodilator fev $nmbr$  l,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
894,mean *,C0444504;C2347634;C2348143
894,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
894,mean ( ± s . d . ),C0444504;C2347634;C2348143
894,mean ( sd ) years daily ocs use  n ( % ),C0332173;C0439234;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
894,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
894,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
894,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
894,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
894,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
894,mean ( sd ) periostin  ng / ml,C0219433;C0439275;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
894,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
894,mean ( sd ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
894,mean ( sd ) improvement from baseline to week $nmbr$ in basdai,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
894,mean ( sd ) hba $nmbr$ c level  %,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
894,mean ( sd ) hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,mean ( sd ) fevi / fvc  %,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
894,mean ( sd ) fevi / evc  %,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
894,mean ( sd ) fevi  ml,C0429706;C0439526;C0444504;C0849974;C1561566;C1705224;C2347634;C2348143;C2699239;C3887665;C4528367
894,mean ( sd ) fev $nmbr$ postbronchodilator  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
894,mean ( sd ) fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2699239;C3714541
894,mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
894,mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
894,mean ( sd ) fev $nmbr$  l,C0444504;C2347634;C2348143;C2699239;C3714541
894,mean ( sd ) feno  ppb,C0444504;C1415800;C2347634;C2348143;C2699239
894,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) esr  mm / h *,C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
894,mean ( sd ) eevi  ml,C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
894,mean ( sd ) duration of t $nmbr$ dm  y,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
894,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
894,mean ( sd ) duration of smoking  pack - years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
894,mean ( sd ) duration of copd  years,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
894,mean ( sd ) disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
894,mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
894,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,mean ( sd ) change from pre - to post - bronchodilator fevi  nil,C0332152;C0442734;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
894,mean ( sd ) change from pre - to post - bronchodilator fevi  ml,C0332152;C0439526;C0444504;C0687676;C0740175;C1704687;C1705224;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034;C3887665
894,mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
894,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
894,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,mean ( sd ) body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,mean ( sd ) bmi ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean ( sd ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
894,mean ( sd ) bmd in g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) baseline scores,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
894,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
894,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
894,mean ( sd ) age  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) age  years,C0444504;C1510829;C2347634;C2348143;C2699239
894,mean ( sd ) age  y race  n ( % ) *,C0001779;C0034510;C0444504;C1706779;C2347634;C2348143;C2699239;C3853635
894,mean ( sd ) age  y,C0001779;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) [ range ],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) % reversibility fev $nmbr$ at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
894,mean ( sd ) % predicted normal fev $nmbr$,C0444504;C2347634;C2348143;C2699239
894,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
894,mean ( sd ) % of predicted normal fev $nmbr$,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
894,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
894,mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0444504;C2347634;C2348143;C2699239
894,mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
894,mean ( sd )  ng / ml £,C0439275;C0444504;C2347634;C2348143;C2699239
894,mean ( sd )  mmhg,C0439475;C0444504;C2347634;C2348143;C2699239
894,mean ( sd )  mg / kg $nmbr$,C0439272;C0444504;C2347634;C2348143;C2699239
894,mean ( sd )  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143;C2699239
894,mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,mean ( s . e . ) t,C0444504;C2347634;C2348143
894,mean ( s . e . ),C0444504;C2347634;C2348143
894,mean ( s . d . ) total pcsk $nmbr$  ng / ml,C0439175;C0439275;C0439810;C0444504;C2347634;C2348143
894,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
894,mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143
894,mean ( s . d . ) ldl particle size  nm,C0203634;C0312860;C0444504;C2347634;C2348143;C3641256;C3890923
894,mean ( s . d . ) ldl particle number  nmol / l,C0237753;C0439282;C0444504;C0449788;C2347634;C2348143;C2612459
894,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
894,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
894,mean ( s . d . ) free pcsk $nmbr$  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
894,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
894,mean ( s . d . ) duration of t $nmbr$ dm  years,C0011816;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
894,mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143
894,mean ( s . d . ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
894,mean ( s . d . ) baseline hba $nmbr$ c  %,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
894,mean ( s . d . ) baseline fpg  mmol / l,C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
894,mean ( s . d . ) apoc - ll $nmbr$  mg / dl,C0003594;C0444504;C2347634;C2348143
894,mean ( s . d . ) apob  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C3252643
894,mean ( s . d . ) age  years,C0444504;C1510829;C2347634;C2348143
894,mean ( s . d . ),C0444504;C2347634;C2348143
894,mean ( median ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C0549183;C0876920;C1960952;C2346927;C2347634;C2347635;C2348143;C2348144;C2939193;C4321396;C4521761
894,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
894,mean ( $nmbr$ % ci ) difference vs saxa + dapa + met,C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
894,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
894,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
894,mean % predicted value prebronchodilation,C0444504;C2347634;C2348143
894,mean % predicted fvc ( sd ),C0444504;C2347634;C2348143
894,mean % predicted dlco * ( sd ),C0444504;C2347634;C2348143
894,mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
894,mean $nmbr$ mwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
894,mean  sd,C0444504;C2347634;C2348143;C2699239
894,mean  ml ( sd ),C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
894,mean  mg / dl,C0439269;C0444504;C2347634;C2348143
894,mean,C0444504;C2347634;C2348143
894,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
894,mayo score  mean ( sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
894,mayo clinic score  mean ± sd,C0002424;C0442592;C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
894,mases ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
894,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
894,lung function  mean,C0035245;C0444504;C2347634;C2348143
894,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
894,ls mean difference ( se ) vs placebo,C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
894,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
894,ls mean difference ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
894,ls mean difference ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
894,ls mean ( $nmbr$ % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
894,ls mean ( $nmbr$ % ci )  %,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
894,ls mean ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
894,ls mean,C0023668;C0444504;C2347634;C2348143
894,ls - mean difference ® ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
894,lp ( a )  nmol / l  mean ( sd ),C0065058;C0439282;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
894,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
894,low - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023824;C0444504;C1532563;C2347634;C2348143;C2699239
894,lipids  mean ( sd )  mg / dlt,C0023779;C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
894,lipids  mean ( sd )  mg / dlf,C0023779;C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,lipid values  mean ( sd ),C0023779;C0042295;C0444504;C2347634;C2348143;C2699239
894,lipid parameters  mg / dl  mean ( sd ),C0023779;C0439269;C0444504;C0449381;C2347634;C2348143;C2699239
894,levodopa dose  mean ± sd  mg / day,C0023570;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
894,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
894,lei  mean [ sd ] c,C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
894,lei  mean ( sd ),C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
894,left ventricular ejection fraction  mean ( sd )  %,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
894,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
894,leeds dactylitis index - basic  mean ( sd ) ’ ' ^,C0239161;C0444504;C0600653;C0918012;C1527178;C1552854;C1637833;C2347634;C2348143;C2699239;C2986546
894,least - squares mean difference ( $nmbr$ % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
894,least - squares mean difference ( $nmbr$ % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
894,ldl cholesterol ( mmol / l )  mean ( sd ),C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
894,ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl cholesterol  mmol / l  mean ± sd,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
894,ldl cholesterol  mmol / l  mean ( sd ) §,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
894,ldl cholesterol  mean ( sd )  mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl / hdl cholesterol ratio  mean ( sd ) §,C0008377;C0428621;C0444504;C2347634;C2348143;C2699239
894,ldl - to - hdl cholesterol ratio  mean ( sd ),C0008377;C0428621;C0444504;C1171408;C2347634;C2348143;C2699239
894,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,ldl - cholesterol  mg / dl  mean ( sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl - cholesterol  mean ( sd ) mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261
894,ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] ),C0444504;C1532563;C2347634;C2348143;C2699239
894,ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
894,ldl - c / hdl - c ratio  mean ( sd ),C0428621;C0444504;C2347634;C2348143;C2699239
894,ldl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143
894,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
894,ldl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
894,ldl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
894,ldl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,ldi  mean [ sd ] b,C0444504;C2347634;C2348143;C2699239
894,ldi  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239
894,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
894,jsn score  mean $nmbr$ sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,jsn  mean ± sd,C0444504;C2347634;C2348143;C2699239
894,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
894,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
894,intensity of rest pain ( mmvas )  mean ± sd,C0035253;C0234253;C0444504;C0522510;C1320357;C1622890;C2347634;C2348143;C2699239;C4085211
894,in previous year  mean ( sd ),C0205156;C0439234;C0439508;C0444504;C1552607;C2347634;C2348143;C2699239
894,in ibdq total score at week $nmbr$  mean [ se ],C0036919;C0332174;C0439175;C0439230;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
894,imaging data  mean ( sd ),C0011923;C0079595;C0444504;C1511726;C2347634;C2348143;C2699239;C3245479;C3714741
894,ileum ses - cd score  mean ( sd ),C0007928;C0020885;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4552032
894,ibdq total score  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C2964552
894,ibdq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,ibdq  mean ± sd,C0444504;C2347634;C2348143;C2699239
894,hscrp  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,hours from clopidogrel loading  mean ( sd ),C0070166;C0439227;C0444504;C1708715;C2347634;C2348143;C2699239
894,homa - ir  mean ( sd ),C0022065;C0022071;C0444504;C1448132;C2347634;C2348143;C2699239
894,high - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023822;C0444504;C1532563;C2347634;C2348143;C2699239
894,hemoglobin a $nmbr$ c  mean ( sd )  % b,C0062248;C0444504;C2347634;C2348143;C2699239
894,hemoglobin a $nmbr$ c  mean ( sd )  %,C0019020;C0444504;C2347634;C2348143;C2699239;C3889898
894,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
894,height ( cm )  mean ( sd ) a,C0444504;C0489786;C2347634;C2348143;C2699239
894,height ( cm )  mean ( s . e . ),C0439392;C0444504;C0489786;C2347634;C2348143
894,height  mean ( sd )  cm,C0444504;C0489786;C2347634;C2348143;C2699239
894,height  cm ( mean ± s . d . ),C0439392;C0444504;C0489786;C2347634;C2348143
894,height  cm  mean ( sd ),C0444504;C0489786;C2347634;C2348143;C2699239
894,heart rate  min_ $nmbr$ ( mean ),C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
894,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
894,heart rate  mean ( sd ) [ range ]  beats / min,C0018810;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ ),C0018810;C0444504;C2347634;C2348143;C2699239
894,heart rate  mean ( sd )  beats / min,C0018810;C0444504;C2347634;C2348143;C2699239
894,heart rate  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
894,heart rate  bpm  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
894,hdl cholesterol ( mmol / l )  mean ( sd ),C0023822;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
894,hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
894,hdl cholesterol  mmol / l  women  mean ± sd,C0023822;C0043210;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
894,hdl cholesterol  mmol / l  men  mean ± sd,C0023822;C0025266;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
894,hdl cholesterol  mean ( sd )  mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
894,hdl - cholesterol  mg / dl  mean ( sd ),C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
894,hdl - cholesterol  mean ( sd ) mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
894,hdl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3715113
894,hdl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143;C3715113
894,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3715113
894,hdl  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
894,hbalc ( % )  mean ( sd ) ^,C0444504;C2347634;C2348143;C2699239
894,hbalc  mean ( s . d . ),C0444504;C2347634;C2348143
894,hbalc  %  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
894,hbaic ( % )  mean ± s . d .,C0444504;C2347634;C2348143
894,hba $nmbr$ ca  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3887642
894,hba $nmbr$ c ( % )  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  mmol / mol  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
894,hba $nmbr$ c  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  % ( mean ± sd ) [ range ],C0019016;C0444504;C1514721;C1825777;C2347634;C2348143;C2348147;C2699239;C3538758;C3542016
894,hba $nmbr$ c  % ( mean $nmbr$ sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  %  mean ( sd ) b,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,hba $nmbr$ c  %  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
894,haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd,C0444504;C0449820;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4050231;C4321476
894,haq - di total score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552;C3826998;C4321476
894,haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3826998;C4050231;C4321476
894,haq - di ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
894,haq - di  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4321476
894,haq - di  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
894,haq - di  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
894,haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients,C0019046;C0439267;C0444504;C1319312;C2347634;C2348143;C2699239;C3642216
894,hab $nmbr$ c ( mean ± sem )  %,C0444504;C2347634;C2348143
894,gout history  mean ± sd years,C0018099;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
894,glycohemoglobin  %  mean ( sd ),C0202054;C0444504;C0696092;C2347634;C2348143;C2699239
894,glycated hemoglobin  mean ( sd )  %,C0017853;C0444504;C2347634;C2348143;C2699239
894,glycated hemoglobin  %  mean ( sd ),C0017853;C0444504;C2347634;C2348143;C2699239
894,fvc  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
894,fsn score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,fsg  mg / dl ( mean ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239
894,fpi  mean ( sd )  pu / rnff,C0018387;C0444504;C2347634;C2348143;C2699239
894,fpi  mean ( sd )  pu / mlt,C0018387;C0444504;C2347634;C2348143;C2699239;C4553833
894,fpg ( mmol / l )  mean ± s . d .,C0439433;C0444504;C2347634;C2348143
894,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg ( mmol / l )  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg  mmol / l ( mean ± sd ),C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
894,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg  mean ( sd )  mg / dlt,C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
894,fpg  mean ( sd )  mg / dlf,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
894,fpg  mean ( sd )  mg / dl [ mmol / l ],C0439269;C0444504;C1532563;C2347634;C2348143;C2699239
894,fpg  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
894,flex baseline bmd  mean ( sd )  g / cm $nmbr$,C0168634;C0439267;C0444504;C1442488;C2347634;C2348143;C2699239
894,final mean  mg / dl,C0205088;C0439269;C0444504;C1546485;C2347634;C2348143;C3853528
894,fevi  l  mean ( sd ) $nmbr$,C0429706;C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
894,fev $nmbr$ / fvc  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
894,fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$,C0444504;C2347634;C2348143;C2699239;C3714541
894,fev $nmbr$ ( l )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
894,fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc,C0005126;C0332152;C0444504;C0740175;C2257086;C2344255;C2347634;C2348143;C2699239;C3669034;C3714541;C4050145
894,fev $nmbr$  litres ( pre salbutamol )  mean ( sd ),C0001927;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
894,fev $nmbr$  litres ( pre ipratropium )  mean ( sd ),C0027235;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
894,fev $nmbr$  litres ( post ipratropium )  mean ( sd ),C0027235;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
894,fev $nmbr$  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
894,fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
894,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,fcal  mg / g  mean ± sd,C0444504;C1300563;C2347634;C2348143;C2699239
894,fasting triglycerides  mean ( sd ) mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
894,fasting triglycerides  mean ( sd )  mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
894,fasting triglyceride level  mean ( sd )  mg / dl,C0015663;C0428475;C0439269;C0444504;C2347634;C2348143;C2699239
894,fasting serum glucose level  mean ( sd )  mg / dl,C0015663;C0202045;C0229671;C0439269;C0444504;C0583332;C1546774;C1550100;C2347634;C2348143;C2699239
894,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
894,fasting plasma glucose  mg / dl  mean ( sd ),C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
894,fasting glucose  mg / dl  mean ( sd ) §,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
894,fasting glucose  mean ( sd )  mg / dl,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
894,fasting blood glucose  mean ( sd )  mg / dlt,C0024671;C0026410;C0428568;C0439269;C0444504;C1261430;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
894,fas  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,exact - pro total score  mean ( sd ),C0033382;C0444504;C0523852;C2347634;C2348143;C2699239;C2828393;C2964552;C2987124;C4050514
894,estimated mean $nmbr$ % cl,C0444504;C0596019;C0750572;C2347634;C2348143
894,estimated mean,C0444504;C0750572;C2347634;C2348143
894,esr ( mm / h )  mean ( sd ),C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
894,esr  mean ± sd mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3811131
894,erosion score  mean ± sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
894,erosion score  mean $nmbr$ sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
894,erosion  mean ± sd,C0333307;C0444504;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524
894,enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1282952;C2347634;C2348143;C2699239;C4050231
894,egfr — mean ( sd  n ),C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
894,egfr  mean ± sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
894,ef ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,education in years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
894,education  yrs  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
894,education  years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
894,education  y  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
894,education  mean ( sd ) years,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
894,education  mean ( sd )  ya,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
894,education  mean ( sd )  y,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
894,duration of ra  mean ± sd years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3538806;C4048756
894,duration of psoriasis ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of paod ( years )  mean ± sd,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of oral antidiabetic treatment  y  mean ( sd ),C0442027;C0444504;C0444921;C0935929;C2347634;C2348143;C2699239;C4521986
894,duration of initial anticoagulation  mean ( sd )  mo,C0003281;C0026544;C0205265;C0332177;C0444504;C0449238;C1279901;C1555582;C1705685;C2347634;C2348143;C2699239;C2917212;C2919015;C2926735;C3537050
894,duration of epilepsy  years  mean ( sd ),C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of epilepsy  mean ( sd )  years,C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes mellitus  y  mean ( sd ) §,C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes ( years )  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes ( years )  mean  ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes  years  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes  y  mean ( sd ),C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of diabetes  mean ( sd )  y,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,duration of copd ( years )  mean ( sd ),C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
894,duration of alendronate use  mean ( sd )  y,C0102118;C0444504;C1881378;C2347634;C2348143;C2699239;C2826775
894,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,dlqi ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3899393
894,disease duration [ year ]  mean ± sda,C0276477;C0439234;C0439508;C0444504;C0872146;C1428349;C1553165;C2347634;C2348143
894,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
894,disease duration ( yr )  mean ± sd,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
894,disease duration ( years )  mean ± s . d .,C0439234;C0444504;C0872146;C2347634;C2348143
894,disease duration  yrs  mean ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
894,disease duration  y  mean ± sd,C0444504;C0872146;C2347634;C2348143;C2699239
894,disease duration  mean [ sd ] years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
894,dietary calcium intake  mean ( sd )  mg / d,C0439422;C0444504;C0489458;C2347634;C2348143;C2699239
894,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
894,diastolic bp  mmhg  mean ± sd,C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
894,diastolic bp  mm   hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
894,diastolic bp  mm hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
894,diastolic blood pressure mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
894,diastolic blood pressure ( mm hg )  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
894,diastolic blood pressure  mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
894,diastolic blood pressure  mm hg  mean ± sd,C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
894,diastolic blood pressure  mm hg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
894,diastolic ( mean  sd ),C0012000;C0444504;C2347634;C2348143;C2699239
894,diastolic  mean ( sd )  mm hg,C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
894,diary variables  mean ( sd ),C0376660;C0439828;C0444504;C2347634;C2348143;C2699239
894,diagnosis ( y )  mean ( sd ),C0011900;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239
894,diabetesduration  mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
894,diabetes history  mean ( sd )  years,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
894,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,diabetes duration  years ( mean ± sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,dha intake on food frequency questionnaire  mean ( sd )  mg / d,C0034394;C0142831;C0439422;C0444504;C1286336;C1512806;C2347634;C2348143;C2348308;C2699239;C2986698
894,demographic characteristics  mean ± sd unless otherwise indicated,C0444504;C0683970;C2347634;C2348143;C2699239
894,demographic characteristics  mean ( sd )  unless otherwise stated,C0444504;C0683970;C2347634;C2348143;C2699239
894,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp ( mmhg )  mean ( sd ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp ( mmghg )  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp ( mean over $nmbr$ h )  mmhg,C0033727;C0369286;C0439475;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
894,dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C0536221;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mm hg ( office measurement )  mean ( sd ),C0242485;C0439475;C0442603;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0428257;C0444504;C0456680;C0536221;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239;C3813197;C4281799
894,dbp  mm hg  mean ± sdc,C0439475;C0444504;C0536221;C1419891;C2347634;C2348143;C3273112;C3813197;C4281799
894,dbp  mean ± sd ( mmhg ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mean ( sd )  mmhg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mean ( sd )  mm hg glycaemic parameters,C0005802;C0439475;C0444504;C0449381;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mean ( sd )  mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,dbp  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
894,daytime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0332169;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
894,daytime mean dbp ( abpm ) at week $nmbr$  mmhg,C0332169;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
894,das - $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,das $nmbr$ - hscrp  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
894,das $nmbr$ - esr  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
894,das $nmbr$ ( esr )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
894,das $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,das $nmbr$  mean ± sd,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
894,das $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
894,daily “ off ” time  mean ± sd  h / dayf,C0033727;C0040223;C0332173;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C3541383;C4528284
894,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
894,dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0750480;C1705566;C2347634;C2348143;C2699239
894,d - dimer level  mean ( sd )  ng / mld,C0017887;C0023522;C0028074;C0060323;C0441889;C0444504;C0456079;C1539265;C1547707;C2347634;C2348143;C2699239;C2946261;C3539688;C3539689
894,cwt  mean ( se )  mm,C0036919;C0444504;C2347634;C2348143;C4330985;C4554674
894,cumulative nsaid score  mean   ±   sd,C0003211;C0444504;C0449820;C1511559;C2347634;C2348143;C2699239;C3536840;C4050231
894,crusade bleeding score  mean ( sd ) ^,C0019080;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,crp level  mean ± sd mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
894,crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd ),C0086715;C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,crp ( mg / l )  mean ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,crp  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,crp  mean mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
894,crp  mean [ sd ] mg / $nmbr$,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C3890735;C4048285;C4321396;C4521761
894,creatinine ( mg / dl )  mean ( sd ),C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
894,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
894,crcl  ml / min mean ( sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
894,crcl  mean  ml / min ( ± sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
894,copd duration  mean ( sd )  yr *,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
894,continuous variables  mean ( sd ) ^,C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
894,continuous variables  mean ( sd ),C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
894,concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ],C0001617;C0368663;C0444504;C0449820;C0454788;C0521115;C1077578;C2347634;C2348143;C2699239;C3539185;C3540725;C3540726;C3540727;C4050231
894,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
894,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
894,comorbidity score  mean ( sd ) t,C0009488;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
894,colon ' ses - cd score  mean ( sd ),C0007928;C0009368;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C3888384;C4050231;C4552032
894,cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e,C0444504;C0450989;C1516691;C2347634;C2348143;C2699239
894,clinical dementia rating sum of boxes  mean ( sd ) f,C0444504;C0451074;C1515051;C1517104;C2347634;C2348143;C2699239
894,cigarette smoking  mean pack - years ( sd ),C0037369;C0444504;C0453996;C1303175;C1881674;C2347634;C2348143;C2699239
894,cholesterol - mean ( sd  n ),C0008377;C0444504;C2347634;C2348143;C2699239
894,cholesterol  mg / dl  mean ( sd ) §,C0008377;C0439269;C0444504;C2347634;C2348143;C2699239
894,chads $nmbr$  mean ± sd,C0007928;C0444504;C1413373;C2347634;C2348143;C2699239
894,cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd,C0444504;C0449820;C1420648;C2347634;C2348143;C2699239;C3714751;C4050231
894,cha $nmbr$ ds $nmbr$ - vasc  mean ± sd,C0444504;C1420648;C2347634;C2348143;C2699239;C3714751
894,cdai  mean [ sd ],C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
894,cdai  mean ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
894,cat score  mean ( sd ),C0007450;C0325090;C0444504;C0449820;C0524517;C1443200;C2347634;C2348143;C2699239;C3665481;C4050231;C4050461;C4284282
894,caleitonin  ng / l  males mean ± sd,C0086582;C0439297;C0444504;C2347634;C2348143;C2699239
894,caleitonin  ng / l  females mean ± sd,C0086287;C0439297;C0444504;C2347634;C2348143;C2699239
894,bw  mean ( sd )  kg,C0005910;C0006041;C0022718;C0439209;C0444504;C2347634;C2348143;C2699239;C2986891;C4054209
894,bsa ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,bone mineral density ( g / cm $nmbr$ )  mean ( sd ),C0005938;C0177804;C0439267;C0444504;C2347634;C2348143;C2699239
894,bone erosion score  mean ( sd ),C0444504;C0449820;C0587240;C2347634;C2348143;C2699239;C4050231
894,body weight ( kg )  mean ± sd,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
894,body weight ( kg )  mean ( sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
894,body weight ( kg )  mean ( s . d . ),C0005910;C0444504;C1275571;C1305866;C2347634;C2348143
894,body weight  mean ± sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
894,body weight  mean = sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
894,body weight  kg ( mean ± sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
894,body massindex  mean ( sd ) a,C0242821;C0444504;C0460148;C1268086;C2347634;C2348143;C2699239;C4082212
894,body mass index [ kg / m $nmbr$ ]  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,body mass index ( kg / m $nmbr$ ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index ( kg / m $nmbr$ )  mean ( sd ) c,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean ± sd ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean ( sd ) t,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,body mass index  mean ( sd ) kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean ( sd ) d,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,body mass index  mean ( sd ) [ range ] a,C0005893;C0444504;C0578022;C1305855;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,body mass index  mean ( sd ) ( kg m ) $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,body mass index  kg / rn \ mean ( sd ),C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
894,body mass index  kg / m ^ mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  kg / m $nmbr$ ( mean ± sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  kg / m $nmbr$  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  kg / m $nmbr$  mean + sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  kg / m $nmbr$  mean ( sd ) §,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body mass index  kg / m $nmbr$  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body - mass index ( kg / m $nmbr$ ) ( mean  sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body - mass index ( kg / m $nmbr$ )  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
894,body - mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
894,bmi — mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0012727;C0020261;C0205419;C0428886;C0444504;C1305855;C1705236;C2347634;C2348143
894,bmi in kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .,C0017480;C0033727;C0039155;C0042036;C0042037;C0085805;C0152060;C0369286;C0428883;C0428886;C0441932;C0444504;C0488053;C0488055;C0564385;C0700320;C0871470;C1305855;C1306620;C1441672;C1511726;C1522472;C1552923;C1705191;C2347634;C2348143;C2699638;C2963137;C3245479;C3714523;C3714741;C3854019;C4528284
894,bmi ( kg / m ^ )  mean ± s . d .,C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C0578022;C1275571;C1513009;C2347634;C2348143;C4054209
894,bmi ( kg / m ^ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ ) [ mean - sd ],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ )  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ )  mean ( sd ) a,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi ( kg / m $nmbr$ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ± sd,C0444504;C0578022;C2347634;C2348143;C2699239
894,bmi  mean ( sd ) kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ( sd ) b,C0444504;C0578022;C2347634;C2348143;C2699239
894,bmi  mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ( sd )  kg / rn $nmbr$,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
894,bmi  mean ( sd )  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ( sd )  kg / m $nmbr$ c,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  mean ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
894,bmi  mean  kg / m $nmbr$ ( ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m ^  mean ( sd ) ’,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m ^  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m $nmbr$ ( mean $nmbr$ sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m $nmbr$  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m $nmbr$  mean + sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bmi  kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
894,bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . ),C0006416;C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C1275571;C1513009;C2347634;C2348143;C4054209
894,blood pressure : systolic / diastolic ( mm hg ) ( mean  sd ),C0439475;C0444504;C2347634;C2348143;C2699239;C2704328
894,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
894,bl mean  mg / dl ( mmol / $nmbr$ ),C0005918;C0006413;C0439190;C0439269;C0444504;C0567349;C1552663;C2347634;C2348143;C2348885;C2827109;C3642216
894,biochemical parameters at randomization  mean,C0034656;C0205474;C0444504;C0449381;C2347634;C2348143
894,biochemical measures  mean ( sd ),C0079809;C0205474;C0444504;C1879489;C2347634;C2348143;C2699239
894,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
894,beam values ( mg / dl )  mean ( sd ),C0042295;C0338248;C0439269;C0444504;C2347634;C2347880;C2348143;C2699239;C4521565
894,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
894,basfi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,baseline total ipss  mean ( sd ),C0168634;C0439175;C0439810;C0444504;C1019118;C1442488;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
894,baseline tjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline systolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274438
894,baseline sua  mean ± sd mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline spga  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline skin pain vas  mean ( sd ),C0042815;C0168634;C0241136;C0444099;C0444504;C1123023;C1442488;C1963195;C2347634;C2348143;C2699239;C3536884;C3827561;C4520765
894,baseline sjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline sesbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline sedbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline sbp  mean ± sd  mm hg,C0085805;C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline pasi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C4528685
894,baseline mssbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline msdbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline mean serum uric acid  pmol / l ( sd ),C0168634;C0439284;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143;C2699239
894,baseline mean seated sbp  mm hg ( sd ),C0085805;C0168634;C0277814;C0439475;C0444504;C1283233;C1442488;C2347634;C2348143;C2699239
894,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline mean fev $nmbr$ ( sd )  ml,C0168634;C0439526;C0444504;C1442488;C1705224;C2347634;C2348143;C2699239;C3714541;C3887665
894,baseline mean ambulatory sbp  mm hg ( sd ) *,C0085805;C0168634;C0439475;C0439841;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline mean ( mg / dl ],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
894,baseline mean  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
894,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
894,baseline lipids  mean ± sd ( mmol / $nmbr$ ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239
894,baseline hbi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline hba $nmbr$ c  mean ( s . e . ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
894,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
894,baseline fpg  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
894,baseline dlqi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3899393
894,baseline diastolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274392
894,baseline dbp  mean ± sd  mm hg,C0168634;C0439475;C0444504;C0536221;C1442488;C2347634;C2348143;C2699239;C3813197;C4281799
894,baseline das $nmbr$  mean ( s . e . ),C0051767;C0057671;C0168634;C0444504;C1442488;C2347634;C2348143
894,baseline characteristics  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239;C4684572
894,baseline cdai  mean ( sd ),C0168634;C0444504;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706
894,baseline bsa  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline bii  mean ( sd ),C0168634;C0444504;C1413059;C1442488;C2347634;C2348143;C2699239
894,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
894,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline . mean _ sd  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline ( mean  sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,baseline  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
894,at femoral neck  mean ( sd ),C0015815;C0444504;C2347634;C2348143;C2699239
894,as duration  y  mean ( sd ),C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
894,aqlq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
894,aqlq score  mean,C0444504;C0449820;C2347634;C2348143;C4050231;C4055434
894,aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f,C0016327;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
894,apolipoprotein b  mean ( sd )  g / l,C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239
894,apob  g / l  mean ( sd ),C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239;C3252643
894,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
894,apo b  mg / dl  mean ( sd ),C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
894,apo b  mean ( sd )  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
894,apo b  mean ( sd ),C0003593;C0444504;C2347634;C2348143;C2699239;C3252643
894,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
894,apo a - $nmbr$  mean ( sd )  mg / dl,C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
894,apo a $nmbr$  mg / dl  mean ( sd ),C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
894,apo a $nmbr$  mean ( sd ),C0003592;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
894,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
894,anthropometrics  mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,allergic rhinitis duration  mean ± sd  y *,C0444504;C0449238;C1334103;C2347634;C2348143;C2607914;C2699239;C2926735;C4552864
894,all participants  mm hg : sbp  mean ( sd ),C0085805;C0439475;C0444504;C0679646;C2347634;C2348143;C2699239
894,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,age in years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
894,age at enrollment ( years )  mean ( sd ),C0444504;C1510829;C1516879;C1696073;C2347634;C2348143;C2699239;C3888021
894,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( yrs )  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
894,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years ) ( mean  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years )  mean   ±   sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years )  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years )  mean _ sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( years )  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age ( year )  mean ± sd,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
894,age  yr mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
894,age  years mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years ( mean = sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years ( mean $nmbr$ sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years  mean + sd,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  y mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,age  y ( mean ± s . d . ),C0001779;C0444504;C2347634;C2348143
894,age  y  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  y  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ± sd years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ± sd ( year ),C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
894,age  mean ± sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ± sd  y,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean yr ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
894,age  mean years ( sd ) ’ gender  n ( % ),C0079399;C0444504;C1510829;C1522384;C2347634;C2348143;C2699239
894,age  mean years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean years  [ sd ],C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean = sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ( sd ) years  n ( % ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ( sd ) [ range ]  y,C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
894,age  mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ( sd )  yrs,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
894,age  mean ( sd )  yearsa,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean ( sd )  y ethnicity  no . ( % ),C0001779;C0015031;C0243103;C0444504;C2347634;C2348143;C2699239
894,age  mean ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean ( s . e . ),C0001779;C0444504;C2347634;C2348143
894,age  mean $nmbr$ sd years,C0444504;C1510829;C2347634;C2348143;C2699239
894,age  mean  yrs ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
894,age  mean  years ( ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
894,adjusted mean ± se ( $nmbr$ % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
894,adjusted mean difference ( $nmbr$ % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
894,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
894,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
894,adjusted mean ( se ) trough fevi  ml,C0036919;C0429706;C0439526;C0444504;C0444506;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
894,adjusted mean ( se ) fevi auco_ $nmbr$  ml,C0036919;C0429706;C0439526;C0444504;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
894,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
894,activity ( range $nmbr$ - $nmbr$ )  mean ± sd,C0205177;C0439167;C0441655;C0444504;C1514721;C1561536;C2347634;C2348143;C2348147;C2699239;C3542016;C3668946;C4049938;C4049939
894,activities of daily living updrs subscore ( baseline )  mean ( sd ),C0001288;C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721;C4050548
894,acr ( mg / g )  mean ( sd ),C0444504;C1300563;C1412134;C1515941;C2347634;C2348143;C2699239
894,acq score  mean,C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
894,acq - $nmbr$ score  mean ( sd ) e,C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
894,acq $nmbr$ score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
894,> mean,C0444504;C2347634;C2348143
894,> $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
894,< mean,C0444504;C2347634;C2348143
894,< $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
894,( sd ) l / min acq - $nmbr$ score  mean ( sd ),C0444504;C0449820;C0702093;C1524029;C2347634;C2348143;C2699239;C2919686;C3813700;C4050231
894,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
894,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
894,( mean difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
894,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
894,( mean % difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
894,( % )  $nmbr$ mean ( sd ),C0444504;C2347634;C2348143;C2699239
894,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
894,$nmbr$ mo  mean ( sd ) x,C0026544;C0332177;C0444504;C2347634;C2348143;C2699239
894,$nmbr$ baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
894,$nmbr$ - h pmg  mmol / l ( mean ± sd ),C0444504;C2347634;C2348143;C2699239;C2827804
893,smoking status — no . { % ),C1519386
893,smoking status — no . ( % ),C1519386
893,smoking status current,C0521116;C1519386;C1705970
893,smoking status . no . ( % ),C1519386
893,smoking status *,C1519386
893,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
893,smoking status ( ongoing ) ( n ),C0549178;C1519386
893,smoking status ( % ),C1519386
893,smoking status  no . ( % ),C1519386
893,smoking status  n [ % ] ®,C1519386
893,smoking status  n ( % ) former,C1519386
893,smoking status  n ( % ) *,C1519386
893,smoking status  n ( % ),C1519386
893,smoking status,C1519386
893,marital status  married,C0024819;C1716536;C3172566
892,missing data — no . / total no . ( % ),C4684714
892,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
892,missing data,C4684714
891,mmse score *,C0449820;C0451306;C4050231
891,mmse score,C0449820;C0451306;C4050231
891,mmse > $nmbr$,C0451306
891,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
891,mmse < $nmbr$,C0451306
891,mmse ( points ),C0451306
891,mmse $nmbr$ - $nmbr$,C0451306
891,mini - mental state examination  mean ( sd ) d,C0444504;C0451306;C2347634;C2348143;C2699239
891,mini - mental state examination,C0451306
891,a mini - mental state examination  insulin glargine vs standard care,C0451306;C0907402
890,years  n ( % ) smoking  n ( % ) current,C0037369;C0439234;C0453996;C0521116;C1705970;C1881674
890,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
890,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
890,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
890,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
890,smoking pack - yearsb  n ( % ),C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
890,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
890,smoking pack - years,C0037369;C0453996;C1277691;C1881674
890,smoking in the past year,C0037369;C0453996;C1881674;C4086728
890,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
890,smoking : ex - smoker,C0037369;C0453996;C1881674
890,smoking : current smoker,C0037369;C0453996;C1881674
890,smoking * ( > $nmbr$ pack - years ),C0037369;C0453996;C1277691;C1881674
890,smoking *,C0037369;C0453996;C1881674
890,smoking ( ever ),C0037369;C0453996;C1881674
890,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
890,smoking ( a ),C0037369;C0453996;C1881674
890,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
890,smoking ( % ),C0037369;C0453996;C1881674
890,smoking ' ! ',C0037369;C0453996;C1881674
890,smoking  n ( % ),C0037369;C0453996;C1881674
890,smoking  mean,C0037369;C0444504;C0453996;C1881674;C2347634;C2348143
890,smoking  % current,C0037369;C0453996;C0521116;C1705970;C1881674
890,smoking  %,C0037369;C0453996;C1881674
890,smoking,C0037369;C0453996;C1881674
890,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
890,no smoking,C0037369;C0453996;C1881674
890,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking — no . / total no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking  n ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking  %,C0037369;C0453996;C0521116;C1705970;C1881674
890,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
889,yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
889,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
889,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
889,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
889,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight of < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight in kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
889,weight in kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight group  no . ( % ),C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
889,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
889,weight ab  %,C0005910;C0043100;C1305866;C1705104
889,weight ^,C0005910;C0043100;C1305866;C1705104
889,weight [ kg ],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight > $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight > $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight < $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight < $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight < $nmbr$,C0005910;C0043100;C1305866;C1705104
889,weight - kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
889,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
889,weight ( kg }  median ( min  max },C0005910;C0043100;C0549183;C0876920;C1305866;C1532757;C1705104;C2347635;C2348144;C2939193
889,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight ( kg ) bmi ( kg / m $nmbr$ ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
889,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight ( kg )  median ( m / n  max ),C0005910;C0043100;C0549183;C0876920;C1305866;C1532718;C1705104;C2347635;C2348144;C2939193
889,weight ( kg )  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
889,weight ( kg )  mean   ±   sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight ( kg )  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight ( kg )  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight ( kg )  mean ( s . e . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
889,weight ( kg )  mean ( s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
889,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight $nmbr$ - $nmbr$,C0005910;C0043100;C1305866;C1705104
889,weight $nmbr$ +,C0005910;C0043100;C1305866;C1705104
889,weight $ $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n,C0005910;C0043100;C1305866;C1319635;C1705104
889,weight # $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight  lbs,C0005910;C0043100;C0439219;C1305866;C1705104;C3161851
889,weight  kg mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight  kg duration of pah  n ( % ),C0005910;C0022718;C0030123;C0043100;C0439209;C0449238;C1305866;C1705104;C2926735;C3203102;C4054209;C4284467
889,weight  kg : mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight  kg *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight  kg ( mean ± s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
889,weight  kg ( mean $nmbr$ sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight  kg $nmbr$,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight  kg  median ( range ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1514721;C1705104;C2347635;C2348144;C2348147;C2939193;C3542016;C4054209
889,weight  kg  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight  kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,weight  kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
889,weight,C0005910;C0043100;C1305866;C1705104
889,total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C0439175;C0439810;C0456081;C1305866;C1705104
889,plasma dha  mean ( sd ) weight  %,C0005910;C0032105;C0043100;C0142831;C0444504;C1305866;C1550098;C1705104;C2347634;C2348143;C2348308;C2699239;C4521445
889,per body weight  u / kg,C0005910;C1300561;C1305866
889,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
889,median weight  kg ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
889,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
889,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
889,mean ± s . d . weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
889,mean weight ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,mean body weight ( sd )  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
889,mean body weight  kg ( range ),C0005910;C0022718;C0439209;C0444504;C1305866;C1514721;C2347634;C2348143;C2348147;C3542016;C4054209
889,mean ( sd ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
889,mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0019664;C0019665;C0034510;C0042295;C0043100;C0262512;C0262926;C0439209;C0441074;C0444504;C0457987;C0475211;C0486293;C0549183;C0557651;C0577559;C0577573;C0600653;C0724655;C0750572;C0876920;C0918012;C1096155;C1305866;C1306372;C1318293;C1514721;C1552854;C1637833;C1705104;C1705255;C1706779;C1719797;C2004062;C2347634;C2347635;C2348143;C2348144;C2348147;C2603343;C2699239;C2911648;C2939193;C2986546;C3152252;C3539882;C3542016;C3853635;C4283905
889,mean ( s . d . ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
889,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
889,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
889,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
889,bodyweight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight at randonization { ixrs ),C0005910;C1305866
889,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
889,body weight *,C0005910;C1305866
889,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight ( kg )  n ( % ),C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight  kg ^,C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight  kg ( sd ),C0005910;C0022718;C0439209;C1305866;C2699239;C4054209
889,body weight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
889,body weight  %,C0005910;C1305866
889,body weight,C0005910;C1305866
889,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .,C0000723;C0005910;C0008377;C0009667;C0010068;C0011847;C0011849;C0021308;C0031831;C0033095;C0035647;C0038454;C0043100;C0043210;C0168634;C0201950;C0205082;C0205164;C0242492;C0439209;C0439269;C0439475;C0439526;C0441074;C0449820;C0460139;C0475209;C0543421;C0596019;C0804815;C1305866;C1306345;C1320716;C1442488;C1532563;C1705104;C1705224;C1706378;C2700400;C3887665;C4050231;C4284008;C4318856;C4521762;C4552904;C4554100;C4554402
889,^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .,C0005910;C0011847;C0011849;C0011900;C0020443;C0020538;C0025424;C0043100;C0201950;C0237753;C0428257;C0439269;C0439475;C0439828;C0441074;C0444686;C0449788;C0488055;C0489786;C0543421;C0577559;C0577573;C0600653;C0681906;C0871470;C0918012;C1096155;C1305866;C1306372;C1306620;C1441506;C1522133;C1532563;C1552854;C1637833;C1705104;C1963138;C2347108;C2347109;C2348272;C2700446;C2986546;C3152252;C3539882;C4283905;C4524803
889,> $nmbr$ kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
889,> $nmbr$ ( n  % ) weight  kg,C0005910;C0022718;C0043100;C0369718;C0439209;C0441922;C1305866;C1705104;C4054209
889,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0015663;C0022709;C0023821;C0023824;C0041061;C0043100;C0185098;C0202042;C0205369;C0441074;C0444686;C0455280;C0475211;C0857690;C1305855;C1305866;C1441506;C1511726;C1705104;C1719797;C2911648;C2936173;C3245479;C3714741
888,renal insufficiency — no . ( % ),C0035078;C1565489
888,renal insufficiency or failure,C0035078;C1565489
888,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
888,renal insufficiency *,C0035078;C1565489
888,renal insufficiency $nmbr$,C0035078;C1565489
888,renal insufficiency,C0035078;C1565489
888,renal fmclicn : creatntoe clearance,C0232813;C0699829
888,renal failure,C0035078;C1963154
887,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
887,lack of efficacy with > $nmbr$ bdmard,C0235828
887,lack of efficacy with > $nmbr$ anti - interleukin $nmbr$,C0235828
887,lack of efficacy,C0235828
887,lack of effectiveness,C0235828
886,number of treated patients,C1522326;C2360800
886,number of patients with fractures,C2360800
886,number of patients with exacerbations in the previous $nmbr$ months  n ( % ),C2360800
886,number of patients with events,C2360800
886,number of patients with dose available,C2360800
886,number of patients with available data,C2360800
886,number of patients with,C2360800
886,number of patients randomized,C2360800
886,number of patients > $nmbr$ years ( % ),C0439234;C2360800
886,number of patients ( % ) or mean 士 sd,C2360800
886,number of patients ( % ) or mean ± sd,C2360800
886,number of patients,C2360800
886,number of hospitalizations in last year prior to baseline,C4086639
886,number of ( % ) patients > $nmbr$ years,C0439234;C2360800
886,number ( % ) of patients with event,C2360800
886,number ( % ) of patients,C2360800
886,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
885,number of medications  n ( % ),C1718138
885,number of antihypertensive medications used  n ( % ) no antihypertensive therapy,C0003364;C1718138
885,number of antihypertensive medications at study entry,C0003364;C1718138
885,number of antihypertensive medications  n ( % ),C0003364;C1718138
884,numbers of events ( % ) :,C4330837
884,number of visits  median,C1549755
884,number of visits  mean ± sd,C0444504;C1549755;C2347634;C2348143;C2699239
884,number of treated lesions ( per patient ),C0449791;C1522326
884,number of treated lesions,C0449791;C1522326
884,number of lesions  n ( % ) a,C0449791
884,number of individuals,C1549735
884,number of events ( annualised rate [ % ] ),C4330837
884,number of events  event per $nmbr$ person - years,C4330837
884,number of events,C4330837
883,type of treatment  n ( % ),C0455708
883,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
883,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
883,type of event — no . ( % ),C1561488
883,type of event :,C1561488
883,type of event,C1561488
882,extent of disease — no . / total no . ( % ) § ^ |,C0449279;C4553144
882,extent of disease  n ( % ),C0449279;C4553144
882,extent of disease  %,C0449279;C4553144
882,extent of disease,C0449279;C4553144
882,angiographic extent of disease,C0002978;C0449279;C4553144
881,sleeping problems in the past $nmbr$ weeks ( % ),C0700201;C2987125
881,night - time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C2987125
881,night - time awakenings in past $nmbr$ weeks ( sd ) *,C0860510;C2699239;C2987125
880,pneumonia in past year,C0032285;C4086728
880,over past $nmbr$ years  n ( % ),C4086728
880,cigarette smoking in the past year,C0239059;C0700219;C4086728
879,younger subjects ( aged < $nmbr$ years ),C0332239
879,younger patients ( aged $nmbr$ years ),C0030705;C0332239
879,older subjects ( aged > $nmbr$ years ',C0580836
879,older patients ( aged > $nmbr$ years ),C0030705;C0580836
879,age at diagnosis s $nmbr$ years,C0439234;C1828181;C3173302
879,age at diagnosis of sle  years,C0024141;C0439234;C1828181;C3173302
879,age at diagnosis of ln  years,C0439234;C0861352;C1428884;C1828181;C3173302;C3714709
879,age at diagnosis < $nmbr$ years,C0439234;C1828181;C3173302
879,age at diagnosis  y,C1828181;C3173302
879,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
878,peri - or postmenopausal,C0347985
878,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
878,peri - op statins : no ( n = $nmbr$ ),C0347985;C0360714
878,peri - op beta - blockers : no ( n = $nmbr$ ),C0001645;C0347985
877,beta - carotene ( n = $nmbr$  $nmbr$ ),C0053396;C0696105
877,beta - carotene,C0053396;C0696105
876,phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ ),C0031676;C0202177;C0441889;C1719844
876,omega - $nmbr$ fatty acids,C0015684;C1719844
876,omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl ),C0015684;C1719844
876,omega - $nmbr$ fatty acid ( n = $nmbr$ ),C0015684;C1719844
876,omega - $nmbr$ fatty acid,C0015684;C1719844
876,omega - $nmbr$ fa ( n = $nmbr$ ),C1719844
876,omega - $nmbr$ fa,C1719844
876,number omega - $nmbr$ number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
876,a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo,C0015684;C0451306;C1719844
875,panel b,C0441833;C1706365;C1999270
875,panel a,C0441833;C1706365;C1999270
875,device group,C1706365
874,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
874,place !,C0442504;C1533810;C1704765;C1882509
873,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
873,non - diabetic patients,C0241863;C1829939
873,diabetics • no ( n = $nmbr$  $nmbr$ ),C0241863
873,diabetics - yes ( n = $nmbr$  $nmbr$ ),C0241863;C1549445;C1705108;C1710701
873,diabetics - no ( n = $nmbr$  $nmbr$ ),C0241863
873,diabetics ( n = $nmbr$ ),C0241863
873,diabetics,C0241863
873,diabetic treatments !,C0087111;C0241863
873,diabetic status  n ( % ),C0241863;C0449438
873,diabetic status,C0241863;C0449438
873,diabetic patients,C0030705;C0241863
873,diabetic no,C0241863
873,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
873,diabetic ( no ),C0241863
873,diabetic $nmbr$,C0241863
873,diabetic  n ( % ),C0241863
873,diabetic,C0241863
873,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
872,piroxicam,C0031990
872,meloxicam,C0083381
872,estonia,C0014908
872,atonic,C0541791
871,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
871,zoledronic acid ( n = $nmbr$ ),C0257685
871,zoledronic acid,C0257685
871,ethacrynic acid,C0014963
870,valdecoxib,C0913246
870,rofecoxib,C0762662
870,celecoxib ( n = $nmbr$ ),C0538927
870,celecoxib,C0538927
869,etoricoxib group ( n = $nmbr$ $nmbr$ ),C0441848;C0972314
869,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
869,etoricoxib ( n = $nmbr$ ),C0972314
869,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314
869,etoricoxib ( n = $nmbr$  $nmbr$ ),C0972314
869,etoricoxib,C0972314
868,colonoscopy,C0009378;C1548837
868,autonomic neuropathy,C0259749
867,tonic – clonic,C3543842
867,tonic,C3543842
866,topical therapy,C0039798;C0087111;C0332237;C1363945
866,topical prescription,C0033080;C0332237;C1521941
866,topical non - prescription,C0033080;C0332237;C1518422;C1521941
866,topical,C0332237
865,nsclc,C0007131
865,non – small - cell lung cancer,C0007131;C2984258;C3539721
864,mineralocorticoid receptor antagonists,C1373021;C1579268
864,mineralocorticoid receptor antagonist n ( % ),C1579268
864,mineralocorticoid receptor antagonist,C1579268
864,mineralcorticoid receptor antagonist,C4543207
864,leukotriene receptor antagonists,C0595726;C2757015;C3542962
864,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
864,glucagon - like peptide - $nmbr$ receptor agonist,C0014361;C4543206
864,glucagon - like peptide - $nmbr$ agonist,C0014361;C2987634
864,endothelin - receptor antagonists,C1134681;C2266875
864,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
864,aldosterone receptor antagonists,C1579268
863,rheumatoid arthritis,C0003873
863,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
863,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
863,duration of rheumatoid arthritis  year,C0003873;C0439234;C0439508;C0449238;C2926735
862,vitamin k antagonists,C3653316
862,postbaseline binding antibodies,C0003241;C1145667;C1167622
862,histamine - $nmbr$ - receptor antagonist,C0019590;C4521896
862,anti - histamines,C0019590
862,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
861,patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C3863761
861,dactylitis in > $nmbr$ digit,C3863761
860,direct thrombin inhibitors,C0003440;C3541936
860,antithrombin,C0003438;C0003440;C4521254
859,dip joint arthritis,C0003864;C0932510;C4552845
859,arthritis type *,C0003864;C0332307;C1547052;C4552845
859,arthritis,C0003864;C4552845
858,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
858,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
858,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
858,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
858,rec . ischemia leading to hosp,C0022116;C1424025;C2606415;C4321499
858,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
858,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
858,rec . ischemia due to ecg changes,C0022116;C0678226;C1424025;C1623258;C2606415;C4321499
858,rec . ischemia,C0022116;C1424025;C2606415;C4321499
858,no ischemia ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
858,ischemia on cecg ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
858,ischemia on cecg ( % ),C0022116;C4321499
858,ischemia driven revascularization,C0022116;C4321499
858,ischemia - driven revascularization,C0022116;C4321499
858,ischemia,C0022116;C4321499
858,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
858,global ischemia,C0022116;C0205246;C2348867;C4321499
858,anti - ischaemia agents *,C0022116;C0040616;C4321499
857,nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline,C1275491
857,nyha ii  n ( % ),C1275491;C1710602;C4082587
857,nyha ii,C1275491;C1710602;C4082587
857,nyha functional classification — no . ( % ) i,C0205245;C0542341;C1275491;C2700217
857,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
857,nyha,C1275491
857,( nyha grade iii or iv ),C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4283820;C4283821;C4283822
856,no known frtrontxtfufoc cond aon,C0205309
856,known tiromtcch * c ccndifeon,C0205309
856,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
856,known prothrombotic genotype,C0017431;C0205309
855,non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
855,non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
855,non - smokers receiving lipid - lowering drugs  p blockers,C0337672;C4554605
855,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
854,amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
854,amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg,C1962523
854,amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
854,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
854,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
854,amlodipine - amlodipine / valsartan,C1962523
853,d - dimer levelsatinclusion,C0060323
853,d - dimer ( ng / ml ),C0060323;C0439275
852,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439775;C0441889;C0702240
852,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
852,elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
852,cardiac biomarker elevation,C0439775;C0702240;C1271630
851,transient monocular blindness,C0149793
851,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
851,maintenance dose,C3714445
851,current non - smoker,C0425311
850,regadenoson ( n = $nmbr$ ),C1698215
850,regadenoson,C1698215
849,peri - op amiodarone : no ( n = $nmbr$ ),C0002598;C0347985
849,no amiodarone,C0002598
849,i amiodarone,C0002598;C0021966;C0221138
849,amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0002598
849,amiodarone vs . placebo,C0002598
849,amiodarone use at baseline yes $nmbr$  $nmbr$,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
849,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
849,amiodarone ote at baseline,C0002598;C0168634;C1442488
849,amiodarone ( n = $nmbr$ ),C0002598
849,amiodarone ( n  % ),C0002598
849,amiodarone  n ( % ),C0002598
849,amiodarone,C0002598
848,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
848,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
848,education level,C0013621;C0013658
848,education in years  mean,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143
848,education > $nmbr$ yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
848,education > $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
848,education > $nmbr$ y,C0013621;C0013622;C0013658;C0039401
848,education < $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
848,education < $nmbr$ y,C0013621;C0013622;C0013658;C0039401
848,education *,C0013621;C0013622;C0013658;C0039401
848,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
848,education ( % ),C0013621;C0013622;C0013658;C0039401
848,education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
848,education $nmbr$ - $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
848,education  y,C0013621;C0013622;C0013658;C0039401
848,education,C0013621;C0013622;C0013658;C0039401
848,age of completion of highest education  years ( sd ),C0013621;C0013622;C0013658;C0039401;C0205197;C1510829;C1522410;C1554962;C2699239
848,> $nmbr$ years education,C0013621;C0013622;C0013658;C0039401;C0439234
848,< $nmbr$ yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
847,pravastatin vs usual care,C0085542
847,pravastatin n = $nmbr$,C0085542
847,pravastatin ( n = $nmbr$ >,C0085542
847,pravastatin ( n = $nmbr$ ),C0085542
847,pravastatin,C0085542
847,diet plus pravastatin group ( n = $nmbr$ ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
847,diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
847,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
847,diet - i - pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
847,diet + pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
847,diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
847,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
847,atorvastatin - pravastatin,C0085542;C0286651
846,years [ range ],C0439234;C1514721;C2348147;C3542016
846,total scores ( total score range : $nmbr$ - $nmbr$ ),C1514721;C2348147;C2964552;C3542016
846,selena - sledai ( range u - $nmbr$ u $nmbr$ ) t,C0439148;C0451528;C1514721;C2348147;C3542016
846,range of sbp,C0085805;C1514721;C2348147;C3542016
846,range,C1514721;C2348147;C3542016
846,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
846,motor subscale ( range  $nmbr$ - $nmbr$ ),C1513492;C1514721;C1705994;C2348147;C3542016
846,median pasi score { range ) ' i  i ',C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
846,mean daily dose ( range ) — mg  i,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
846,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
846,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
846,mean age  years ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
846,mean age  y : ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
846,mean age  y ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
846,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
846,health assessment questionnaire ( $nmbr$ - $nmbr$ range ),C0451208;C1514721;C2348147;C3542016
846,haq di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
846,haq - di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
846,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
846,age yr  range,C0001779;C0439234;C1514721;C2348147;C3542016
846,age y  median ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
846,age range  y,C0001779;C1514721;C2348147;C3542016
846,age range,C0001779;C1514721;C2348147;C3542016
846,age [ years ]  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
846,age ( years )  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
846,age ( y )  mean ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
846,age  years : median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
846,age  years  mean ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
846,adl subscale ( range  $nmbr$ - $nmbr$ ) *,C0001288;C1420005;C1514721;C2348147;C3542016
846,( range ),C1514721;C2348147;C3542016
846,$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
846,$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
845,right ventriculardysfunction atinclusion,C0205090;C0444532
845,right,C0205090;C0444532
845,r | r ' ' ' ( $nmbr$ % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
845,r ight coronary,C0205090;C0684010;C2603358
845,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
845,r $nmbr$,C0205090;C0684010;C2603358
845,r,C0205090;C0684010;C2603358
845,c  right - sided vhd ( n = $nmbr$ ),C0205090;C0444532
845,> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental,C0205090;C0451306;C0684010;C2603358
844,bivalirudin used during pci,C0168273
844,bivalirudin used,C0168273
844,bivalirudin only,C0168273;C0205171;C1720467
844,bivalirudin alone ( n = $nmbr$ ),C0168273;C0205171;C0439044;C0679994
844,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
844,bivalirudin ( n = $nmbr$ ),C0168273
844,bivalirudin ( n = $nmbr$  $nmbr$ ),C0168273
844,bivalirudin,C0168273
843,ivabradine group ( n = $nmbr$ ),C0257190;C0441848
843,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
843,ivabradine ( n = $nmbr$ ),C0257190
843,ivabradine,C0257190
842,rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0332287;C1739768
842,rivaroxaban plus aspirin ( n = $nmbr$ ),C0004057;C0332287;C1739768
842,rivaroxaban plus aspirin ( $nmbr$ % cl ),C0004057;C0332287;C0596019;C1739768
842,rivaroxaban plus,C1739768
842,rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0205171;C0439044;C0679994;C1739768
842,rivaroxaban alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C1739768
842,rivaroxaban + aspirin,C0004057;C1739768
842,rivaroxaban +,C1739768
842,rivaroxaban ( n   = $nmbr$ ),C1739768
842,rivaroxaban ( n = $nmbr$ ),C1739768
842,rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
842,rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
842,rivaroxaban,C1739768
842,low - dose rivaroxaban plus aspirin ( n = $nmbr$ ),C0332287;C1739768;C2608320
842,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
841,stratum ii,C1710602;C4082587
841,period ii,C0439531;C1710602;C1948053;C4082587
841,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
841,lavolta ii,C1710602;C4082587
841,ii chiorthaiidone amiodipine,C1710602;C4082587
841,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
841,ii - iv,C0022326;C1710602;C4082587;C4265176
841,ii ( n = $nmbr$ ),C1710602;C4082587
841,ii $nmbr$ ( ii . $nmbr$ ),C1710602;C4082587
841,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
840,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
840,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
840,white hispanic - n ( % ),C1533020;C1533021
840,white hispanic,C1533020;C1533021
840,white  non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
840,not hispanic or latino ( n — $nmbr$ ),C1518424
840,not hispanic or latino ( n = $nmbr$ ),C1518424
840,not hispanic or latino,C1518424
840,not hispanic / latino ( n = $nmbr$  $nmbr$ ),C0086528;C1518424
840,not hispanic / latino,C0086528;C1518424
840,not hispanic,C1518424
840,non - hispanic white,C0007457;C0043157;C0220938;C1518424
840,non - hispanic or latino,C1518424
840,non - hispanic and latino,C1518424
840,non - hispanic / latino,C0086528;C1518424
840,non - hispanic  non - latino,C0086528;C1518424
840,non - hispanic,C1518424
839,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
839,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
839,black hispanic - n ( % ),C1533017;C1533018
839,black hispanic,C1533017;C1533018
839,black  non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
839,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0220938;C0439541;C1533017;C1533018;C1533020;C1533021
838,mixed hispanic,C0086409;C0205430;C3160715
838,hispanic — no . ( % ),C0086409
838,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409
838,hispanic or latino ethnic groupf,C0086409
838,hispanic or latino ethnic groupb,C0086409
838,hispanic or latino ethnic group *,C0086409
838,hispanic or latino ethnic group !,C0086409
838,hispanic or latino ( n — $nmbr$ ),C0086409
838,hispanic or latino ( n = $nmbr$ ),C0086409
838,hispanic or latino,C0086409
838,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0086409;C1879937
838,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C1879937
838,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
838,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937
838,hispanic ethnic group  n ( % ),C0015031;C0086409;C0441848;C0680174
838,hispanic / non - hispanic,C0086409;C1518422
838,hispanic / latino ethnicity  n ( % ),C0015031;C0086409;C0086528;C0243103
838,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
838,hispanic / latino ( n = $nmbr$ ),C0086409;C0086528
838,hispanic ( n = $nmbr$ l $nmbr$ ),C0086409
838,hispanic ( n = $nmbr$ ),C0086409
838,hispanic  n ( % ),C0086409
838,hispanic,C0086409
838,ethnicitya hispanic or latino,C0086409
838,ethnicity - - hispanic or latino,C0015031;C0086409;C0243103
838,biack hispanic,C0086409
838,american hispanic ( n   = $nmbr$ ),C0086409;C0596070
837,exercise category ( % ),C3669314
837,age categories ( y )  n ( % ),C2916832
837,age categories  n ( % ),C2916832
837,age categories,C2916832
836,associated with hiv infection,C0019693;C0332281
836,associated with drug or toxin exposure,C0013227;C0332281;C1254351
836,associated with drug / toxin,C0013221;C0332281
836,associated with ctd,C0332281;C1335071;C1442905
836,associated with corrected,C0205202;C0332281
836,associated with an atrial septal defect,C0018817;C0332281
835,rest ofworld,C0035253;C1622890
835,rest ofthe world,C0035253;C1622890;C2700280
835,rest of world n z $nmbr$,C0035253;C1622890;C2700280
835,rest of world,C0035253;C1622890;C2700280
835,rest of the world,C0035253;C1622890;C2700280
835,rest - of - world ( n = $nmbr$ ),C0035253;C1622890;C2700280
835,pao $nmbr$ at rest  mm hg,C0035253;C0232555;C0439475;C1423784;C1427155;C1622890;C4318615
835,heart rate at rest — beats / min,C0018810;C0035253;C1622890
835,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C1622890
835,aapo $nmbr$ at rest  mm hg,C0035253;C0439475;C1622890
834,voided volume  ml,C0042034;C0439526;C0449468;C1552835;C1690016;C1705102;C1705224;C2700258;C3887665
834,t $nmbr$ lesion volume  mm ',C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
834,t $nmbr$ lesion volume  mm $nmbr$,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
834,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
834,prostate volume ( cm $nmbr$ ),C1441416
834,normalized volume measures,C0449468;C1690016;C1705102;C1882115;C2700258
834,brain volume  cm ',C1113695
834,brain volume  cm $nmbr$,C1113695
833,the american college of rheumatology ) .,C0035452;C0557806;C0596070
833,some college / tech,C0557806;C1826596
833,some college,C0557806
833,college degree or higher,C0441889;C0449286;C0542560;C0557806;C2348088
832,olmesartan along with diuretic ( n - $nmbr$ ),C0012798;C1098320
832,olmesartan along with ccb ( n - $nmbr$ ),C0006684;C1098320
832,olmesartan / ccb - olmesartan / diuretic,C0006684;C1098320
832,olmesartan ( n = $nmbr$ ),C1098320
831,lesion length ≥ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
831,lesion length > $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
831,lesion length $ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
831,laa length,C1444754;C1706316
830,stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive,C0007591;C0017654;C0021966;C0023806;C0221138;C0332257;C0369637;C0439445;C0441766;C0441923;C0456533;C0702093;C1424601;C1524029;C3813700
830,glomerular filtration rate §,C0017654;C1561549
830,glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma,C0017654;C0024443;C0439445;C1561549;C3887485
830,glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1561549
830,gfr as assessed by mdrd,C0017654;C1424601
830,gfr > $nmbr$,C0017654;C1424601
830,gfr < $nmbr$,C0017654;C1424601
830,gfr ( ml / min per $nmbr$ . $nmbr$ nr ),C0017654;C0027496;C0439445;C1424601;C3844738
830,gfr $nmbr$ - $nmbr$,C0017654;C1424601
830,gfr $nmbr$ $nmbr$,C0017654;C1424601
830,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
830,estimated gfr — no . ( % ) $nmbr$,C0017654;C0750572;C1424601
830,estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
830,estimated gfr at baseline  ml • min $nmbr$,C0017654;C0168634;C0439445;C0750572;C1424601;C1442488
830,estimated gfr ^,C0017654;C0750572;C1424601
830,estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
830,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
830,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
830,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601;C2699239
830,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr  ml / min,C0017654;C0439445;C0750572;C1424601
830,estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *,C0017654;C0369637;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
830,estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
830,estimated gfr,C0017654;C0750572;C1424601
830,by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0076836;C0241863;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732
830,by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !,C0017654;C0076836;C1199517;C1419603;C1424601;C3539732
830,by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0241863;C0679646;C0702093;C1424601;C1524029;C3813700
830,by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !,C0017654;C0439445;C0679646;C1424601
829,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
829,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
829,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
829,lipids — mg / dl,C0023779;C0439269
829,lipids,C0023779
829,lipid values  mmol / l,C0023779;C0042295;C1532563
829,lipid values,C0023779;C0042295
829,lipid trial participantss,C0008976;C0023779
829,lipid trial participantsk,C0008976;C0023779
829,lipid modifiers,C0023779;C4284280
829,lipid measures at baseline — mg / dl,C0023779
829,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
829,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
829,lipid concentrations,C0023779;C0086045
829,lipid and lipoprotein values ( mg / dl ),C0023779
829,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
829,lipid - lowerinq druq,C0023779
829,lipid,C0023779
829,drinking  n ( % ) lipid values  mmol / l,C0001948;C0023779;C0042295;C0684271;C1532563
828,troponin positive ( n = $nmbr$ ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
828,ruled out non - fatal pe with or,C1446409
828,rf positive ( > $nmbr$ iu / ml )  n ( % ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
828,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
828,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
828,rf - positive  > $nmbr$ iu / ml  %,C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
828,rf  % positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
828,positive vs . negative,C0439178;C1446409;C1514241;C2825490;C3812269
828,positive troponin or ck - mb,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
828,positive troponin i or t  no . ( % ),C0077401;C0439178;C1446409;C1514241;C2825490;C3812269
828,positive hla - b $nmbr$ status  n ( % ),C0439178;C0449438;C1426226;C1446409;C1514241;C2825490;C3812269
828,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
828,positive for hla - b $nmbr$  n ( % ),C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
828,positive cu index test  z n ( % ),C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
828,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
828,positive ctnl ( n = $nmbr$ ),C0439178;C1446409;C1514241;C2825490;C3812269
828,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
828,positive,C0439178;C1446409;C1514241;C2825490;C3812269
828,low complement / anti - dsdna positive ( n = $nmbr$ ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
828,hla ‐ b $nmbr$ positive    n   ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
828,hla - b $nmbr$ positive at baseline  n ( % ),C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
828,hla - b $nmbr$ positive  n ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
828,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
828,anticyclic citrullinated peptide positive ^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
828,anti - gad positive ( n = $nmbr$ ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
828,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
828,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
828,anti - ccp positive ( > $nmbr$ u / ml )  n ( % ),C0432633;C0439178;C0439340;C1446409;C1514241;C1525410;C1704514;C1880521;C2825490;C2945590;C3812269
828,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
828,acpa positive ( > $nmbr$ iu / ml )  n ( % ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
828,acpa positive  no . ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
828,acpa positive  n ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
828,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
828,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
828,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
827,basal insulin doset,C0650607
827,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
827,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
827,basal insulin,C0650607
826,insulin detemir,C0537270
826,detemir / insulin glargine  %,C0537270;C0907402
825,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
825,linagliptin ( n z $nmbr$ ),C2746078
825,linagliptin ( n = $nmbr$ ) ',C2746078
825,linagliptin ( n = $nmbr$ ),C2746078
825,linagliptin,C2746078
825,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
824,teaes in a $nmbr$ % of individuals,C0027361;C0237401
824,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C1709707
824,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0237401;C1709707
824,other individual and exploratory end points,C0027361;C0237401
824,normoglycaemic individuals  n ( % ),C0027361;C0237401;C0580545
824,no . ( % ) of individuals *,C0027361;C0237401
824,individuals with type $nmbr$ diabetes  n ( % ),C0027361;C0237401;C1320657
824,individuals with prediabetes,C0027361;C0237401;C0362046
824,individuals with pre - diabetes  n ( % ),C0027361;C0237401;C0362046
824,individuals with normoglycaemia,C0027361;C0237401;C0580545
824,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
824,individual endpoints,C0027361;C0237401;C2349179
823,class iv only,C0205171;C0441888;C1720467;C2698970
823,class iv glomerulonephritis,C0017658;C0441888;C2698970
823,class iv,C0441888;C2698970
823,class ii ( b - blockers ),C0441886;C2698968
823,class ii,C0441886;C2698968
823,class > ii,C0441886;C2698968
822,class i or no symptoms,C0441885;C1319793;C2698967
822,class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967
822,class i,C0441885;C1319793;C2698967
821,time from ra diagnosis  years  median,C0011900;C0556970;C1704338;C1704656;C3538806;C4048756
821,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
821,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
821,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
821,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
821,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
821,diagnosis of hefh  n ( % ),C0011900;C1704338;C1704656
821,diagnosis of diabetes  n ( % ),C0011847;C0011849;C0011900;C1704338;C1704656
821,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
821,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
821,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
821,diagnosed  y,C0011900
821,af first diagnosis > $nmbr$ years  n ( % ),C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
820,use of supplemental oxygen  n ( % ),C4067893;C4554557
820,supplementary oxygen,C0030054
820,supplemental oxygen,C4534306
819,st segment elevation,C0520886
819,st elevation,C0520886
819,st - segment elevation mi,C0520886;C3810814
819,st - segment elevation,C0520886
819,st - elevation mi,C0520886;C3810814
818,isolated upper gastrointestinal disease behavior  n ( % ),C0004927;C0205409;C0810300;C1548221;C2707008
818,isolated pulmonary embolism,C0034065;C0205409;C1548221
818,isolated impaired glucose tolerance — no .,C0205409;C1548221
818,isolated igt,C0205409;C1548221
817,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
817,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
817,presence of honeycombing  $nmbr$ n ( % ),C0150312;C0332468;C0349384;C0392148;C3854307
817,presence of erosions  n ( % ),C0150312;C0333307;C0392148;C1959609;C3854307
817,presence of enthesitis  n ( % ),C0150312;C0392148;C1282952;C3854307
817,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
817,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
817,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
817,presence of angioedema at baseline,C0002994;C0150312;C0392148;C3854307
817,no in - trial stroke n = $nmbr$  $nmbr$,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
817,in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$,C0008976;C0150312;C0332285;C1707101
817,in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0150312;C0332285;C1707101
817,in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1521828;C1707101;C3541888;C4288115
817,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
817,in - clinic uas $nmbr$,C0002424;C0150312;C0332285;C0442592;C1707101
816,orthopnea  frequent / continuous,C0085619;C0332183;C0549178
816,most frequent serious teaes,C0205393;C0205404;C0332183
816,most frequent aesa,C0205393;C0332183
816,frequent or continuous,C0332183
816,frequent exacerbator,C0332183
815,type of drug - eluting stent  n ( % ),C0038257;C0332307;C0457591;C1322815;C1547052
815,non - drug - eluting stent,C1322815;C1518422
815,drug eluting stent,C1322815
815,drug - eluting stent — no . ( % ),C1322815
815,drug - eluting stent implanted — no . ( % ),C1322815
815,drug - eluting stent implanted ( at least one ),C1322815
815,drug - eluting stent implanted,C1322815
815,drug - eluting stent  n ( % ),C1322815
815,drug - eluting stent,C1322815
814,syndesmophyte present  n ( % ),C0150312;C0221690;C0449450
814,presentation to tertiary care hospital — %,C0337954;C0449450
814,presentation *,C0449450
814,present smokerc,C0150312;C0449450
814,present smoker,C0150312;C0337664;C0449450
814,present ( £ $nmbr$ mg / dl ),C0150312;C0439269;C0449450
814,present ( > $nmbr$ mg / dl ),C0150312;C0439269;C0449450
814,present,C0150312;C0449450
814,dx at presentation  n ( % ),C0449450;C3538936
814,dm present,C0011816;C0150312;C0449450;C3250443
814,acs presentation,C0449450;C0742343;C4318612
813,week $nmbr$ czp dose combined ( n   =   $nmbr$ ),C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
813,week $nmbr$ czp dose combined,C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
813,sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
813,rolofylline dose,C0166128;C0178602;C0869039;C1114758
813,ptrend across doses,C0178602
813,pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
813,patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % ),C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
813,methotrexate dose | |  mg,C0024671;C0025677;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
813,methotrexate dose on day $nmbr$ — mg per wl < $nmbr$,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
813,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
813,leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
813,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
813,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
813,edoxaban dose adjusted at randomisation  n ( % ) *,C0178602;C0869039;C1114758;C2975435
813,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
813,dose reduction at randomization — no . ( % )  i,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
813,dose reduction at randomization  %,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
813,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
813,dose reduced at randomization *,C0178602;C0869039;C1114758
813,dose ratio at week $nmbr$ ( $nmbr$ % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
813,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
813,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
813,dose adjusted,C0178602;C0869039;C1114758
813,dose ( n ),C0178602;C0869039;C1114758
813,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
813,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
813,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
813,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
813,canakinumab dose,C0178602;C0869039;C1114758;C2718773
813,baseline su dose > $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
813,baseline su dose < $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
813,baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
813,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
813,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
813,all doses ( n = $nmbr$ ),C0178602
813,all doses,C0178602
813,( phase $nmbr$ dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
812,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
812,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
812,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
812,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
812,low - density lipoprotein cholesterol  %,C0023824
812,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
812,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
812,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
812,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
812,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
812,ldl cholesterol ^ :,C0023824;C0202117
812,ldl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
812,ldl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
812,ldl cholesterol ( sd )  mg / dl,C0023824;C0202117;C0439269;C2699239
812,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
812,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
812,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
812,ldl cholesterol  mmol / l 丰,C0023824;C0202117;C1532563
812,ldl cholesterol  mmol / l *,C0023824;C0202117;C1532563
812,ldl cholesterol  mmol / l,C0023824;C0202117;C1532563
812,ldl cholesterol  mg / dl,C0023824;C0202117;C0439269
812,ldl cholesterol,C0023824;C0202117
812,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
812,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
812,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
812,ldl - cholesterol (,C0023824;C0202117
812,ldl - cholesterol  mmol / lf,C0023824;C0202117;C0439190;C1416933;C2986618;C4554443
812,ldl - cholesterol  mmol / l,C0023824;C0202117;C1532563
812,ldl - cholesterol,C0023824;C0202117
812,data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .,C0002780;C0023824;C0042295;C0168634;C0202117;C0369718;C0441922;C0871881;C1442488;C1511726;C1711260;C2348152;C3245479;C3714741
812,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
812,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1442488
812,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
812,- ldl cholesterol,C0023824;C0202117
812,$nmbr$ mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
811,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0018623;C0018787;C0027976;C0030705;C0032042;C0032615;C0042508;C0201950;C0428772;C0439849;C0488728;C0543421;C0596019;C0596306;C0699792;C1275491;C1696465;C1704610;C1706408
811,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0004083;C0018787;C0027976;C0201950;C0428772;C0439849;C0543421;C0596019;C0596306;C0699792
811,total cholesterol ^,C0201950;C0543421
811,total cholesterol *,C0201950;C0543421
811,total cholesterol ( week $nmbr$ ),C0201950;C0332174;C0439230;C0543421
811,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
811,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
811,total cholesterol ( mmo $nmbr$ / $nmbr$ ),C0201950;C0543421
811,total cholesterol  mmol / l 本,C0201950;C0543421;C1532563
811,total cholesterol  mmol / l ( sd ),C0201950;C0543421;C1532563;C2699239
811,total cholesterol  mmol / l,C0201950;C0543421;C1532563
811,total cholesterol  %,C0201950;C0543421
811,total cholesterol,C0201950;C0543421
811,tertile of total cholesterol at baseline  mean ( sd )  mmol / l,C0201950;C0543421
811,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
810,eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0003591;C0003594;C0008377;C0023821;C0023824;C0024671;C0026410;C0031529;C0033684;C0039225;C0041004;C0201950;C0439267;C0439269;C0543421;C0577559;C0577573;C0600653;C0674390;C0918012;C1096155;C1142985;C1306372;C1532737;C1538326;C1552854;C1637833;C1705223;C1960952;C2346927;C2986546;C3152252;C3539882;C3541325;C3891451;C4054077;C4283905;C4319774;C4321396;C4521761
810,apolipoprotein,C0003591
810,* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0003591;C0008377;C0009247;C0023189;C0023821;C0023822;C0036919;C0039411;C0040642;C0041004;C0041405;C0041698;C0062152;C0065055;C0074554;C0178587;C0178602;C0201950;C0337445;C0369773;C0439175;C0439751;C0439810;C0444504;C0444667;C0543421;C0549183;C0599755;C0729627;C0876920;C1142985;C1518422;C1708438;C1709595;C1710181;C1824670;C2347634;C2347635;C2348143;C2348144;C2349200;C2603361;C2939193;C3272447;C3715113;C4522122;C4522255
809,use of ace inhibitors / arbs  n ( % ),C0003015;C1524063;C3888198
809,use of ace inhibitor  arb  or both — no . ( % ),C0003015;C1524063;C3888198;C4541021
809,no ace inhibitor / arb,C0003015;C3888198;C4541021
809,neither ace inhibitor nor arb,C0003015;C4541021
809,dipeptidyl peptidase - $nmbr$ inhibitor,C0003015;C2757044;C3536837
809,dipeptidyl peptidase $nmbr$ inhibitors,C0003015
809,dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
809,both ace inhibitor and arb,C0003015;C4541021
809,angiotensin - converting enzyme inhibitors ^,C0003015;C2757044
809,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
809,angiotensin - converting enzyme inhibitors,C0003015;C2757044
809,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C2757044;C3536837;C4541021
809,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
809,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
809,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
809,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
809,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C2757044;C3536837;C4541021
809,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
809,ace inhibitors or arbs,C0003015
809,ace inhibitors or arb,C0003015
809,ace inhibitors or angiotensin receptor blockers,C0003015
809,ace inhibitors or angiotensin ii blockers,C0003015
809,ace inhibitors or angiotensin ii,C0003015
809,ace inhibitors or angiotensin - receptor blockers ^,C0003015
809,ace inhibitors or angiotensin - receptor blockers,C0003015
809,ace inhibitors and arb,C0003015
809,ace inhibitors / sartans,C0003015;C1563745
809,ace inhibitors / arbs  n ( % ),C0003015;C3888198
809,ace inhibitors / arbs,C0003015;C3888198
809,ace inhibitors / arb,C0003015
809,ace inhibitors,C0003015
809,ace inhibitor — no . ( % ),C0003015;C4541021
809,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
809,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
809,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
809,ace inhibitor or arb use,C0003015;C4541021
809,ace inhibitor or arb at last follow - up,C0003015;C4541021
809,ace inhibitor or arb at enrollment,C0003015;C4541021
809,ace inhibitor or arb,C0003015;C4541021
809,ace inhibitor or angiotensin receptor blocker,C0003015;C4541021
809,ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021
809,ace inhibitor or angiotensin ii receptor,C0003015;C4541021
809,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C4541021
809,ace inhibitor monotherapy,C0003015;C4541021
809,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
809,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
809,ace inhibitor and / or arb,C0003015;C4541021
809,ace inhibitor / arb  %,C0003015;C3888198;C4541021
809,ace inhibitor / arb,C0003015;C3888198;C4541021
809,ace inhibitor  n ( % ),C0003015;C4541021
809,ace inhibitor  arb  or both,C0003015;C3888198;C4541021
809,ace inhibitor  %,C0003015;C4541021
809,ace inhibitor,C0003015;C4541021
809,ace - inhibitors / arbs  n ( % ),C0003015;C3888198
809,ace - inhibitors  n ( % ),C0003015
809,ace - inhibitors,C0003015
809,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
809,ace - inhibitor or arb ( % ),C0003015;C4541021
809,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0006684;C0014122;C0022067;C0025424;C0042295;C0428257;C0439385;C0439453;C0444504;C0597357;C1319894;C1881173;C2347108;C2347109;C2347634;C2348143;C2348272;C2757044;C3536837;C3536851;C3888198;C4521885;C4541021;C4554371
808,nateglinide n / n,C0903898
808,nateglinide and repaglinide,C0903898
808,nateglinide ( n = $nmbr$ ),C0903898
808,meglitinides ( glinides ),C0065880;C1579432;C3537178
808,meglitinide,C0065880
807,biguanides ¶,C0005382;C0360396;C3540012
807,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
807,biguanides,C0005382;C0360396;C3540012
807,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
807,biguanide,C0005382;C3537187;C4317165
806,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
806,ideglira - ideg - lira,C1555441;C4308663
806,ideglira - ideg,C4308663
806,ideglira,C4308663
805,triglycerides — mmol / liter,C0041004;C0439190;C0475211
805,triglycerides — mmol / l,C0041004;C1532563
805,triglycerides — mg / dl | |,C0041004;C0439269
805,triglycerides — mg / dl ^,C0041004;C0439269
805,triglycerides — mg / dl,C0041004;C0439269
805,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
805,triglycerides mean,C0041004;C0444504;C2347634;C2348143
805,triglycerides level  mg / dl,C0428475;C0439269
805,triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
805,triglycerides > $nmbr$ mg / dl,C0041004;C0439269
805,triglycerides > $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
805,triglycerides < $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
805,triglycerides - mg / dl * *,C0041004;C0439269
805,triglycerides * *,C0041004
805,triglycerides * ( mg / dl ),C0041004;C0439269
805,triglycerides *,C0041004
805,triglycerides ( sd )  mg / dl,C0041004;C0439269;C2699239
805,triglycerides ( mmol / l ) :,C0041004;C1532563
805,triglycerides ( mmol / l ),C0041004;C1532563
805,triglycerides ( mg / dl ) * *,C0041004;C0439269
805,triglycerides ( mg / dl ),C0041004;C0439269
805,triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
805,triglycerides  mmol / lf,C0041004;C0439190;C1416933;C2986618;C4554443
805,triglycerides  mmol / l ®,C0041004;C1532563
805,triglycerides  mmol / l §,C0041004;C1532563
805,triglycerides  mmol / l,C0041004;C1532563
805,triglycerides  mg / l,C0041004;C0439268
805,triglycerides  mg / dl ^,C0041004;C0439269
805,triglycerides  mg / dl,C0041004;C0439269
805,triglycerides  * mmol / l,C0041004;C1532563
805,triglycerides,C0041004
805,triglyceride level,C0428475
805,triglyceride a,C0041004
805,triglyceride ( mmol / l ) t,C0041004;C1532563
805,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
805,triglyceride ( mmol / l ),C0041004;C1532563
805,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
805,triglyceride ( mg / dl ) $nmbr$,C0041004;C0439269
805,triglyceride ( mg / dl ),C0041004;C0439269
805,triglyceride  mmol / l,C0041004;C1532563
805,triglyceride,C0041004
805,- triglycerides,C0041004
805,$nmbr$ . $nmbr$ mg / dl triglycerides ^,C0041004;C0439269
804,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
804,budesonide - formoterol ( n = $nmbr$ ),C1276807
804,budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807;C1319635
804,budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C0439267;C1276807
804,budesonide - budesonide / formoterol,C1276807
803,budesonide — no . ( % ),C0054201
803,budesonide ( n = $nmbr$ ),C0054201
803,budesonide $nmbr$ ^ g ( n = $nmbr$ ),C0054201;C0439267
803,budesonide  n ( % ),C0054201
803,budesonide,C0054201
802,absolute risk reductions,C3179139
802,absolute risk reduction ( $nmbr$ % cl ) *,C0596019;C3179139
802,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
802,absolute risk difference ( $nmbr$ % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
802,absolute difference estimate vs placebo ( $nmbr$ % ci ),C0750572;C1549031
802,absolute change,C1549031
802,absolute ( l ),C0205344
802,absolute  litres,C0205344;C0475211
801,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
801,albiglutide ( n = $nmbr$ ),C2607479
800,two lesions,C0205448;C0221198
800,treated lesions ‡,C0221198;C1522326
800,stents per lesion  n,C0038257;C0221198;C1546698
800,stented lesions,C0038257;C0221198
800,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
800,no . of treated lesions,C0221198;C1522326
800,mean total stent length per lesion  mm ( sd ) ‡,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
800,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
800,mean stent diameter per lesion  mm ( sd ) †,C0038257;C0221198;C0552409;C1546698;C2699239;C4330985;C4554674
800,lesions treated per patient,C0221198
800,lesions b $nmbr$ / c,C0221198;C1546698
800,lesions,C0221198
800,lesion ( s ),C0221198;C1546698
800,intervention in complex lesions,C0221198;C1292781
800,age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
800,age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
800,age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
800,age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
800,age / gd lesion,C0001779;C0221198;C1546698
799,probenecid,C0033209
799,pregnancy,C0032961
799,poland,C0032356
799,legend,C2729544
798,open — no . ( % ),C0175566
798,open triple ( n = $nmbr$ ),C0175566
798,open,C0175566
797,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
797,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
797,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
797,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
797,prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
797,prior heart failure  n / n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
797,prior heart failure  n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
797,prior heart failure  %,C0018801;C0018802;C0332152;C2826257;C4554158
797,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
797,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
797,prior congestive heart failure,C0018802;C0332152;C2826257
797,prior chf  %,C0018802;C0332152;C2826257
797,prior chf,C0018802;C0332152;C2826257
797,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
797,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
797,participants without heart failure,C0018801;C0018802;C0679646;C4554158
797,participants with heart failure,C0018801;C0018802;C0679646;C4554158
797,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
797,no prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
797,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
797,no heart failure,C0018801;C0018802;C4554158
797,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
797,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
797,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
797,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
797,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
797,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
797,histor y of heart failure,C0018801;C0018802;C4554158
797,histor y of congestive heart failure — no . ( % ),C0018802
797,heart failure ‡,C0018801;C0018802;C4554158
797,heart failure — no . / total no . ( % ),C0018801;C0018802;C4554158
797,heart failure — no . ( % ),C0018801;C0018802;C4554158
797,heart failure or lvef < $nmbr$ % associated with index acs event,C0018801;C0018802;C4554158
797,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
797,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
797,heart failure at entry  no . ( % ),C0018801;C0018802;C1705654;C4554158
797,heart failure *,C0018801;C0018802;C4554158
797,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C4554158
797,heart failure ( nyha ii ‐ iii )  n ( % ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
797,heart failure ( hf )  ( % ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
797,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
797,heart failure $nmbr$ yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
797,heart failure $nmbr$ month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
797,heart failure $nmbr$ mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
797,heart failure  no . / total no . ( % ),C0018801;C0018802;C4554158
797,heart failure  n ( % ),C0018801;C0018802;C4554158
797,heart failure  lvef < $nmbr$ %  or both,C0018801;C0018802;C0428772;C0488728;C4554158
797,heart failure  hospitalized or fatal,C0018801;C0018802;C4554158
797,heart failure,C0018801;C0018802;C4554158
797,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
797,congestive heart failure †,C0018802
797,congestive heart failure — no . ( % ) | |,C0018802
797,congestive heart failure — no . ( % ) |,C0018802
797,congestive heart failure — no . ( % ),C0018802
797,congestive heart failure — %,C0018802
797,congestive heart failure §,C0018802
797,congestive heart failure at randomisation,C0018802;C0034656
797,congestive heart failure ( definite ),C0018802
797,congestive heart failure ( chf ) ( in past $nmbr$ weeks ),C0018802;C2987125
797,congestive heart failure ( < $nmbr$ wk ),C0018802;C0332174;C0439230
797,congestive heart failure  n ( % ),C0018802
797,congestive heart failure,C0018802
797,chronic heart failure,C0018802;C0264716
797,chf score ( u ),C0018802;C0439148;C0449820;C4050231
797,chf ( % ),C0018802
797,chf,C0018802
797,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
797,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
797,cardiac failure —,C0018801;C0018802
797,cardiac failure §,C0018801;C0018802
797,cardiac failure *,C0018801;C0018802
797,cardiac failure  n ( % ),C0018801;C0018802
797,cardiac failure,C0018801;C0018802
796,valsartan / hctz ( n = $nmbr$ ),C0020261;C0216784
796,valsartan / hctz  n / n ( % ),C0020261;C0216784
796,val / hctz ( n = $nmbr$ ),C0020261;C0042285;C0523975
796,v alsartan / hctz  n ( % ),C0020261
796,v / hctz ( n = $nmbr$ ),C0020261
796,v / hctz,C0020261
796,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
796,olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$,C0020261;C1098320
796,hydrochlorothiazide,C0020261
796,hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .,C0020261
796,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C1511726;C3245479;C3714741
796,hctz * ( n = $nmbr$ ),C0020261
796,hctz *,C0020261
796,hctz,C0020261
795,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
795,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
795,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
795,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
795,prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
795,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
795,prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
795,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
795,participants without hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
795,participants with hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
795,no prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
795,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
795,no prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
795,no hx of hf ( n = $nmbr$ ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
795,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
795,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
795,hosp . for hf,C0018488;C1313497;C1538440;C3273279
795,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
795,hf without known reduced ef ( n = $nmbr$ ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
795,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
795,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
795,hf or lvef < $nmbr$ % associated with index event,C0018488;C1313497;C1538440;C3273279
795,hf hosp .,C0018488;C1313497;C1538440;C3273279
795,hf duration  y  n ( % ),C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
795,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
795,hf  lvd  or both,C0018488;C1313497;C1538440;C3273279
795,hf,C0018488;C1313497;C1538440;C3273279
795,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
795,duration of hf  y,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
795,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
795,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
795,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
795,admission for hf in previous year  n ( % ),C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
795,admission for hf in previous year,C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
794,parental history of myocardial infarction before age $nmbr$ y yes,C0030551;C1275835
794,parental history of myocardial infarction before age $nmbr$ y,C0030551;C1275835
794,parental history of myocardial infarction before $nmbr$ yr of age ( % ),C0030551;C1275835
794,non - q - wave myocardial infarction,C0542269;C3537181
794,history of myocardial infarction ( % ),C1275835
794,history of myocardial infarction  n ( % ),C1275835
794,history of myocardial infarction,C1275835
794,history myocardial infarction,C0155668;C1275835
794,family history of myocardial infarction prior to age $nmbr$  %,C0455406
793,prior myocardial infarction 一 no . ( % ),C0155668
793,prior myocardial infarction — no . { % ),C0155668
793,prior myocardial infarction — no . / total no . ( % ),C0155668
793,prior myocardial infarction — no . ( % ),C0155668
793,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
793,prior myocardial infarction ( % ),C0155668
793,prior myocardial infarction  no . / total no . ( % ),C0155668
793,prior myocardial infarction  n ( % ),C0155668
793,prior myocardial infarction  %,C0155668
793,prior myocardial infarction,C0155668
793,anterior myocardial infarction — no . / total no . ( % ),C0340293
793,anterior myocardial infarction — no . ( % ),C0340293
793,> $nmbr$ prior myocardial infarction — no . ( % ),C0155668
792,history of cardiac arrhythmia,C3494593
792,colectomy ( partial or total ),C0009274
792,aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470
791,nonischemic cardiomyopathy — no . ( % ),C0878544
791,nonischemic cardiomyopathy,C0878544
791,combined cardiac failure  cardiomyopathy or other cardiac disorders,C0018801;C0018802;C0205195;C0878544
791,combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % ),C0018801;C0018802;C0205195;C0878544
791,cardiomyopathy,C0878544
790,total mortality all,C0026565;C0026566;C0439175;C0439810
790,total mortality,C0026565;C0026566;C0439175;C0439810
790,shfm annual mortality,C0026565;C0026566;C0332181
790,overall mortality,C0026565;C0026566;C0282416;C1561607
790,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
790,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
790,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
790,mortality outcomes,C0026565;C0026566;C1274040
790,mortality  shock or congestive heart failure within $nmbr$ days,C0026565;C0026566;C0036974
790,mortality,C0026565;C0026566
790,cvd mortality,C0007222;C0026565;C0026566
790,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
790,all - causa mortality,C0026565;C0026566;C3903827
789,participants taking insulin,C0679646
789,participants randomized,C0679646
789,participants n,C0679646
789,participants at baseline  n,C0168634;C0679646;C1442488
789,participants  no . ( % ),C0679646
789,participants  n,C0679646
789,participants,C0679646
789,participant - reported hypertension — no . { % ),C0679646;C2698741;C4554048
789,number of participants with an event,C0237753;C0449788;C0679646
789,number of participants,C0237753;C0449788;C0679646
789,nondiabetic participants !,C0679646
789,nonblack participants,C0679646
789,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
789,no . of participants with events ( % ),C0679646
789,no . of participants per $nmbr$ patient - yr,C0679646
789,no . of participants ( % ),C0679646
789,no . of participants,C0679646
789,no . ( % ) of participants,C0679646
789,n participants,C0369718;C0441922;C0679646
789,diabetic participants !,C0241863;C0679646
789,diabetic participants,C0241863;C0679646
789,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
789,all participants ^ ^ ( n = $nmbr$ / $nmbr$ ),C0679646
789,all participants * ( n = $nmbr$ / $nmbr$ ),C0679646
789,all participants ( n = $nmbr$ ),C0679646
789,all participants,C0679646
789,aii participants ( n = $nmbr$ ),C0679646;C1424250;C2698414
789,$nmbr$ % participants,C0679646
788,previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery,C0003483;C0205156;C1552607
788,aortic,C0003483
787,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
787,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
787,calcification  n ( % ),C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
787,acitretin,C0050559
786,option,C1518601;C1550456
786,contusion,C0009938
786,constitutional,C1511487
786,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
786,congestion *,C0700148;C2826600
786,ambition,C0870128
785,• hospitalization for unstable angina,C0002965;C0019993
785,unstable angina requiring hospitalization,C0002965;C0019993
785,prior hospitalizations  n ( % ),C0019993;C0332152;C2826257
785,prior hospitalization for hf  %,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
785,prior hf hospitalization ( n = $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
785,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
785,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
785,no prior hf hospitalization ( n   = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
785,no prior hf hospitalization ( n = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
785,no hospitalization in the past $nmbr$ months prior to baseline ( ref ),C0019993;C4331910
785,hospitalizations  n,C0019993
785,hospitalizations,C0019993
785,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
785,hospitalization stratum  n ( % ),C0019993
785,hospitalization in the past $nmbr$ months prior to baseline,C0019993;C4331910
785,hospitalization for unstable angina,C0002965;C0019993
785,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
785,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
785,hospitalization for acs,C0019993;C0742343;C4318612
785,hospitalization for / due to,C0019993
785,hospitalization for,C0019993
785,hospitalization  n ( % ),C0019993
785,hospitalization,C0019993
785,hospitalisation related to exacerbation  n ( % ),C0019993
785,hospitalisation for chf within $nmbr$ years of randomisation,C0018802;C0019993
785,hospitalisation,C0019993
785,hf hospitalizations  median ( iqr ),C0018488;C0019993;C0549183;C0876920;C1313497;C1538440;C2347635;C2348144;C2939193;C3273279
785,hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279
785,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
785,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
785,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
785,first hospitalization for chf or cv death,C0018802;C0019993;C0205435;C1279901
785,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
784,upper abdominal pain,C0232492
784,= cerebrospinal fluid .,C0007806;C0007807
783,eosinoohil count,C0750480;C1705566
783,< $nmbr$ with no historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
783,< $nmbr$ with historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
783,< $nmbr$ regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
782,prior mi diagnosis :,C0332132;C3810814
782,prior diagnosis - no . ( % ),C0332132
782,previous diagnosis,C0332132
782,no previous diagnosis of diabetes mellitus,C0011849;C0332132
781,qol due to urinary symptoms,C0426359;C0518214;C0678226
781,amputation due to diabetes — no . ( % ),C0598284;C0678226
780,symptom onset to hospital arrival  median ( iqr )  h,C0019994;C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1555577;C1706079;C2347635;C2348144;C2939193;C4086878;C4528284
780,symptom onset to hospital arrival  hours,C0019994;C0439227;C1510665;C1555577;C1706079;C4086878
780,symptom onset to arrival in catheterization laboratory,C1555577;C1706079;C4086878
780,randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079
779,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
779,outcomes during accord,C0680240;C1274040
779,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0680240;C1274040
779,outcome according to primary cancer site — no . / total no . ( % ),C0680240;C0872338;C1274040
779,outcome according to no . of risk factors for vte,C0035648;C0680240;C1274040;C1553898
778,liver disorder,C0023895
778,lipid disorder,C0154251
778,hepatic disorders,C0023895
778,chest discomfort,C0235710
777,neurocognitive disorders,C0029227;C4041080
777,gastrointestinal disorders,C0017178
777,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
777,acute rheumatic disorders,C0001314
776,卞 at discharge .,C0012621;C0030685;C2926602
776,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
776,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
776,medications at discharge or day $nmbr$  if earlier ( % ),C0806915
776,medications at discharge,C0806915
776,cardiac medications at discharge  %,C0018787;C0806915;C1522601
775,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
775,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
775,microvascular disease history  no . ( % ),C0443258;C0683519
775,microvascular disease history  n ( % ),C0443258;C0683519
775,microvascular disease history,C0443258;C0683519
775,history of thyroid disease  n ( % ),C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
775,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
775,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
775,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
775,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
775,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
775,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
775,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
775,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
775,history of macrovascular disease at baseline  n ( % ),C0683519;C0730226;C0850708;C0944983
775,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
775,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
775,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
775,history of fistullzing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
775,history of fistulizing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
775,history of fistulising disease  n [ % ],C0683519;C0730226;C0850708;C0944983
775,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0683519;C0730226;C0850708;C0944983
775,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
775,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
775,history of coronary heart disease  no . ( % ),C0018787;C0683519;C0730226;C0850708;C0944983
775,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
775,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
775,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
775,disease history,C0683519
775,ccv history / condition at baseline,C0168634;C0683519;C1442488
775,ccv history / condition,C0683519
775,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
774,levetiracetam,C0377265;C3693636
774,infrequent exacerbator,C0521114
774,implanted pacemaker,C0848753
774,biventricular pacemaker,C1719274
773,prior nonvertebral fracture at age > $nmbr$ years,C0016658;C0332152;C1510829;C2826257
773,prior nonvertebral fracture,C0016658;C0332152;C2826257
773,nonvertebral fractures,C0016658
773,nonvertebral fracture,C0016658
773,fractures ( site not specified ),C0016658
773,fractures,C0016658
773,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
773,fracture,C0016658
773,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
773,bone fracture,C0016658
772,fibrillation / flutter ),C0016385;C0232197;C2242390
772,atrial flutter / fibrillation,C0155709
772,atrial flutter,C0004239;C0344423;C1963068
772,atrial fibrillation / flutter  n ( % ),C0155709
772,atrial fibrillation / flutter,C0155709
772,atrial fibrillation / atrial flutter  %,C0155709
772,arial flutter or fibrillation,C0016385;C2242390
771,without baseline vertebral fracture,C0080179;C0168634;C1442488
771,with baseline vertebral fracture,C0080179;C0168634;C1442488
771,vertebral fractures at baseline,C0080179;C0168634;C1442488
771,vertebral fracture and / or t score s - $nmbr$ . $nmbr$,C0080179
771,vertebral fracture and / or t score - $nmbr$ . $nmbr$,C0080179
771,vertebral fracture,C0080179
771,spinal fractures,C0080179;C0518450
771,clinical vertebral fractures,C0080179;C0205210
771,baseline vertebral fracture,C0080179;C0168634;C1442488
770,predictive factor,C0683956
770,heart disease risk factors,C0741920
770,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
770,alternative disability,C0231170;C1523987
769,psoriatic arthropathy,C0003872
769,psoriatic arthritis pain ],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
769,psoriatic arthritis  %,C0003872
769,psoriatic arthritis,C0003872
769,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
769,atorvastatin factorial study,C0286651;C2826344
768,ulcerative colitis,C0009324
768,duration of ulcerative colitis,C0009324;C0449238;C2926735
768,disseminated tuberculosis,C0152915
767,obstructive subscore,C0549186
767,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
766,unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
766,risk group,C0242444
765,• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke,C0011065;C0439070;C1306577;C1705160;C3538987;C4048877;C4082313;C4318503;C4552775
765,• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days,C0011065;C0018799;C0439228;C0545743;C0581603;C1306577;C1710602;C3810814;C4082313;C4082587;C4552775
765,• death from cv causes  major coronary event  or nonfatal stroke,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
765,• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke,C0011065;C1306577;C4082313;C4552775
765,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
765,sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline,C0011065;C0022661;C0035078;C0443318;C0678226;C1306577;C2316810;C4082313;C4552775
765,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
765,noncardiac death,C0011065;C1306577;C4082313;C4552775
765,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
765,no . of deaths,C0011065;C1306577
765,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
765,macce ( death  mi  stroke ),C0011065;C0038454;C1306577;C3810814;C4082313;C4552775;C4554100
765,hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci ),C0011065;C0027051;C1306577;C2985465;C4082313;C4552775
765,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
765,deaths  n ( % ),C0011065;C1306577
765,deaths,C0011065;C1306577
765,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
765,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
765,death or mi at $nmbr$ days,C0011065;C1306577;C4082313;C4552775
765,death or ich,C0011065;C1306577;C4082313;C4552775
765,death or disabling stroke,C0011065;C1306577;C4082313;C4552775
765,death or absolute fvc decrease > $nmbr$ %,C0011065;C1306577;C4082313;C4552775
765,death or $nmbr$ mwd decrease > $nmbr$ m,C0011065;C1306577;C4082313;C4552775
765,death from,C0011065;C1306577;C4082313;C4552775
765,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
765,death due to renal failure or sustained esrd,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
765,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
765,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
765,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
765,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
765,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
765,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death *,C0011065;C1306577;C4082313;C4552775
765,death ( all cause ),C0011065;C1306577;C4082313;C4552775
765,death ( all - cause ),C0011065;C1306577;C4082313;C4552775
765,death  with pe not,C0011065;C0070939;C1306577;C1880476;C4082313;C4284304;C4552775
765,death  q wave mi or ischemia - driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775
765,death  n ( % ),C0011065;C1306577;C4082313;C4552775
765,death  mi  idr  st or gusto severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death  mi  idr  st  or gusto moderate / severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death  mi  idr  st  or gusto mod / sev bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death  mi  idr  st  or any timi bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
765,death  mi  idr  or st,C0011065;C1306577;C3810814;C4082313;C4552775
765,death,C0011065;C1306577;C4082313;C4552775
765,dead ( n = $nmbr$ ),C0011065
765,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia,C0007226;C0011065;C0022116;C0027051;C0428953;C0439234;C0439508;C1306577;C1511726;C1720943;C2926063;C3245479;C3538987;C3714741;C3810814;C3887460;C4048877;C4082313;C4318503;C4321499;C4552775;C4552959
765,cv death or ml,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death or hf hospitalization n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death or hf hosp .,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
765,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
765,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
765,cv death  non - fatal mi or non - fatal stroke,C0011065;C1302234;C1306577;C1518422;C1705232;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death  ml or ischemic stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
765,cv death  ml  or stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
765,cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure,C0002965;C0011065;C0019993;C0439526;C0581603;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
765,cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua,C0011065;C0018488;C0018787;C0041580;C0042014;C0056331;C0378365;C0439526;C0948008;C1306577;C1313497;C1538440;C1705224;C3273279;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
765,cv death  ml  ischemic stroke,C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
765,cv death  mi  stroke  recurrent ischemia,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death  mi  stroke  or urgent coronary revascularization,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
765,cv death  mi  stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
765,cv death  mi  or stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death  mi  or ischemic stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua,C0011065;C0018488;C0019993;C0041580;C0042014;C0376297;C0581603;C0877341;C0948008;C1306577;C1313497;C1538440;C3273279;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death  mi  ischemic stroke,C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
765,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
765,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
765,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
765,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death or hospitalized hf,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
765,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
765,cardiovascular death  nonfatal myocardial infarction  nonfatal stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
765,cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
765,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
765,any death,C0011065;C1306577;C4082313;C4552775
765,all death,C0011065;C1306577;C4082313;C4552775
765,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
765,* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”,C0008902;C0011065;C0015127;C0205199;C0205435;C0243132;C0439234;C0566415;C0679646;C1279901;C1299582;C1306577;C1524003;C1547335;C1554210;C2698741;C2745955;C4048706;C4082313;C4321405;C4552775;C4554048
765,$nmbr$ days composite of death / new mi / urgent revascularization and definite st,C0011065;C0205199;C0439609;C0581603;C1306577;C1547335;C3272275;C3810814;C4082313;C4552775;C4689466
764,赛 $nmbr$ years,C0439234
764,〉 $nmbr$ years,C0439234
764,■ $nmbr$ years,C0439234
764,≥ $nmbr$ years,C0439234
764,≥ $nmbr$ to < $nmbr$ years,C0439234
764,≥ $nmbr$ . $nmbr$ years,C0439234
764,≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years,C0439234
764,≤ $nmbr$   year,C0439234;C0439508
764,≤ $nmbr$ years,C0439234
764,» $nmbr$ yr,C0439234
764,» $nmbr$ years,C0439234
764,£ $nmbr$ yr,C0439234
764,£ $nmbr$ years,C0439234
764,£ $nmbr$ to < $nmbr$ years,C0439234
764,years with gouty arthritis,C0003868;C0439234
764,years with gout  mean ± sd,C0018099;C0439234;C0444504;C2347634;C2348143;C2699239
764,years with gout,C0018099;C0439234
764,years since symptom onset,C0439234
764,years since pd diagnosis  mean ± sd,C0439234
764,years since pah diagnosis,C0439234
764,years since myocardial infarction,C0439234
764,years since mi ( median,C0439234
764,years since menopause,C0439234
764,years since last gout flare,C0439234
764,years since diagnosis of type $nmbr$ diabetes  n ( % ),C0439234
764,years since diagnosis  mean,C0439234
764,years since diagnosis,C0439234
764,years modified hoehn and yahr stage  n ( % ),C0439234
764,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
764,years ),C0439234
764,years ( sd ),C0439234;C2699239
764,years,C0439234
764,year - $nmbr$,C0439234;C0439508
764,year $nmbr$,C0439234;C0439508
764,year  n ( % ),C0439234;C0439508
764,x $nmbr$ years,C0439234
764,women > $nmbr$ years,C0043210;C0439234
764,women < $nmbr$ years,C0043210;C0439234
764,type $nmbr$ diabetes duration  years,C0439234;C0449238;C1320657;C2926735
764,type $nmbr$ diabetes duration  mean ( sd )  years,C0439234;C0444504;C0449238;C1320657;C2347634;C2348143;C2699239;C2926735
764,teaes  cases per $nmbr$ - patient years ( ci ),C0008107;C0030705;C0439234;C0868928;C1533148;C3259781
764,t $nmbr$ dm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
764,t $nmbr$ d duration  years,C0439234;C0449238;C2603360;C2926735
764,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
764,ss years,C0439234;C2699257;C3891295;C4551874
764,severe episodes in previous year — no . / patient,C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
764,s $nmbr$ years ( n = $nmbr$ ),C0439234;C2986823
764,s $nmbr$ years,C0439234;C0565930;C2603362
764,recurrent infections ( > $nmbr$ per year ),C0239998;C0439234;C0439508
764,rates per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
764,rate per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
764,rate per $nmbr$ - patient - years ( control vs alirocumab ) i,C0030705;C0439234;C0871208;C1521828
764,rate per $nmbr$ - patient - years ( control vs alirocumab ) *,C0030705;C0439234;C0871208;C1521828
764,rate / $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
764,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
764,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
764,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
764,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
764,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
764,placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
764,person - years,C0027361;C0439234;C2347489
764,persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
764,pbo / simva - $nmbr$ yr km rale ( % ),C0031962;C0034642;C0439234;C3887676
764,patients per $nmbr$ patient - years,C0030705;C0439234
764,patient - years ) hr ( unadjusted ),C0030705;C0439234
764,older than $nmbr$ years,C0439234;C0580836
764,no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
764,no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years ),C0027361;C0439234;C1320716;C2347489
764,no . / $nmbr$ person - yr,C0027361;C0439234;C2347489
764,new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
764,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
764,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
764,median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
764,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
764,mean years since menopause,C0439234;C0444504;C2347634;C2348143
764,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
764,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
764,mean ( se ) $nmbr$ - year rates per $nmbr$ population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
764,mean ( sd ) [ range ] duration of epilepsy  years,C0014544;C0439234;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
764,mean $nmbr$ - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
764,known duration of type $nmbr$ diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
764,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
764,interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % ),C0439234;C1272706;C1552654;C1552713
764,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
764,incidence  $nmbr$ person - year,C0021149;C0027361;C0220856;C0439234;C0439508;C2347489
764,improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
764,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
764,hospitalization in previous year with management of heart failure,C0019993;C0205156;C0439234;C0439508;C1552607
764,hospitalization for hf previous year  ( % ),C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
764,framingham $nmbr$ - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
764,formal education  years,C0439234;C0681344
764,eze / simva - $nmbr$ yr km rale ( % ),C0034642;C0439234;C3887676
764,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
764,exacerbations in previous year requiring hospitalization and / or ed visit  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
764,exacerbations in previous year requiring hospitalization  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
764,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
764,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
764,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
764,event rates per $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
764,evenls per $nmbr$  $nmbr$ palienl - years,C0439234
764,ed duration > $nmbr$ yr  n ( % ),C0439234;C0449238;C2926735;C3538926
764,ed > $nmbr$ yr  no . ( % ),C0439234;C3538926
764,duration — yr,C0439234;C0449238;C2926735
764,duration ofdiabetes — yr,C0439234;C0449238;C2926735
764,duration of type $nmbr$ diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
764,duration of type $nmbr$ diabetes mellitus  years,C0439234;C0449238;C1320657;C2926735
764,duration of type $nmbr$ diabetes ( years ),C0439234;C0449238;C1320657;C2926735
764,duration of type $nmbr$ diabetes  years,C0439234;C0449238;C1320657;C2926735
764,duration of t $nmbr$ dm > $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
764,duration of t $nmbr$ dm < $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
764,duration of t $nmbr$ dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
764,duration of t $nmbr$ dm  years,C0011816;C0439234;C0449238;C2926735;C3250443
764,duration of t $nmbr$ d ( years ),C0439234;C0449238;C2926735
764,duration of epilepsy  years,C0014544;C0439234;C0449238;C2926735
764,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
764,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
764,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
764,duration > $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
764,duration > $nmbr$ to < $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
764,duration < $nmbr$ year  n ( % ),C0439234;C0439508;C0449238;C2926735
764,dm duration  years,C0011816;C0439234;C0449238;C2926735;C3250443
764,difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
764,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
764,dabigatran $nmbr$ mg $nmbr$ mg % per yr,C0439234;C1319635;C2348066
764,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
764,copd exacerbation history in the previous year  n ( % ),C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
764,cardiovascular mortality ( per $nmbr$ person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
764,baseline to year $nmbr$,C0168634;C0439234;C0439508;C1442488
764,at $nmbr$ years,C0439234
764,aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0004057;C0027361;C0439234;C0441848;C2347489
764,ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
764,all - cause mortality ( per $nmbr$ person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
764,age at menopause ( yr ),C0439234;C1625754;C1629609
764,a $nmbr$ years,C0439234
764,> year $nmbr$,C0439234;C0439508
764,> l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
764,> = medan ( $nmbr$ year - old ),C0439234;C0439508;C0580836
764,> = $nmbr$ yr,C0439234
764,> = $nmbr$ years and < $nmbr$ years,C0439234
764,> = $nmbr$ years ( n = $nmbr$ ),C0439234
764,> = $nmbr$ years,C0439234
764,> $nmbr$   years,C0439234
764,> $nmbr$ yr — no . { % ),C0439234
764,> $nmbr$ yr — no . ( % ),C0439234
764,> $nmbr$ yr — %,C0439234
764,> $nmbr$ yr since menopause,C0439234
764,> $nmbr$ yr from the united states,C0041703;C0439234
764,> $nmbr$ yr ( n = $nmbr$ ),C0439234
764,> $nmbr$ yr ( % ),C0439234
764,> $nmbr$ yr  n ( % ),C0439234
764,> $nmbr$ yr,C0439234
764,> $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
764,> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ ),C0439234
764,> $nmbr$ years to < $nmbr$ years,C0439234
764,> $nmbr$ years simva ( „ = $nmbr$ },C0439234
764,> $nmbr$ years simva ( n = $nmbr$ ),C0439234
764,> $nmbr$ years simva,C0439234
764,> $nmbr$ years or < $nmbr$ crcl  n ( % ),C0439234
764,> $nmbr$ years old,C0439234
764,> $nmbr$ years n z $nmbr$,C0439234
764,> $nmbr$ years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
764,> $nmbr$ years eze / simva ( „ = $nmbr$ },C0439234
764,> $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
764,> $nmbr$ years bmi,C0439234;C0578022
764,> $nmbr$ years baseline ldl - c,C0168634;C0439234;C1442488
764,> $nmbr$ years ( n = $nmbr$ ),C0439234
764,> $nmbr$ years ( % ),C0439234
764,> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0439234
764,> $nmbr$ years  n ( % ),C0439234
764,> $nmbr$ years,C0439234
764,> $nmbr$ year,C0439234;C0439508
764,> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
764,> $nmbr$ to < = $nmbr$ years  n ( % ),C0439234
764,> $nmbr$ to < $nmbr$ yr,C0439234
764,> $nmbr$ to < $nmbr$ years,C0439234
764,> $nmbr$ to $nmbr$   years,C0439234
764,> $nmbr$ to $nmbr$ years,C0439234
764,> $nmbr$ - < $nmbr$ years,C0439234
764,> $nmbr$ - $nmbr$ yr,C0439234
764,> $nmbr$ - $nmbr$ years,C0439234
764,< median ( $nmbr$ year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
764,< l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
764,< = $nmbr$ yr,C0439234
764,< = $nmbr$ year  n ( % ),C0439234;C0439508
764,< $nmbr$ yr — no . { % ),C0439234
764,< $nmbr$ yr — no . ( % ),C0439234
764,< $nmbr$ yr since menopause,C0439234
764,< $nmbr$ yr ( n = $nmbr$ ),C0439234
764,< $nmbr$ yr,C0439234
764,< $nmbr$ years simva ( n = $nmbr$ },C0439234
764,< $nmbr$ years simva ( n = $nmbr$ ),C0439234
764,< $nmbr$ years simva,C0439234
764,< $nmbr$ years n z $nmbr$,C0439234
764,< $nmbr$ years eze / simva ( n = $nmbr$ },C0439234
764,< $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
764,< $nmbr$ years eze / simva,C0439234
764,< $nmbr$ years ( n = $nmbr$ ),C0439234
764,< $nmbr$ years ( % ),C0439234
764,< $nmbr$ years  n ( % ),C0439234
764,< $nmbr$ years,C0439234
764,< $nmbr$ year,C0439234;C0439508
764,< $nmbr$ . $nmbr$ years,C0439234
764,( years ),C0439234
764,% / yr,C0439234
764,% / year,C0439234;C0439508
764,$nmbr$ — < $nmbr$ years,C0439234
764,$nmbr$ — $nmbr$ years,C0439234
764,$nmbr$ yr km % ( n ),C0439234;C3887676
764,$nmbr$ yr,C0439234
764,$nmbr$ years or older,C0439234
764,$nmbr$ years or more,C0439234
764,$nmbr$ years ( n = $nmbr$ ),C0439234
764,$nmbr$ years  n ( % ),C0439234
764,$nmbr$ years,C0439234
764,$nmbr$ year or more,C0439234;C0439508
764,$nmbr$ to < $nmbr$ yr — no . { % ),C0439234
764,$nmbr$ to < $nmbr$ yr — no . ( % ),C0439234
764,$nmbr$ to < $nmbr$ yr,C0439234
764,$nmbr$ to < $nmbr$ years,C0439234
764,$nmbr$ to $nmbr$ yr,C0439234
764,$nmbr$ to $nmbr$ years,C0439234
764,$nmbr$ moto < $nmbr$ yr  n ( % ),C0439234
764,$nmbr$ mo to $nmbr$ yr,C0026544;C0332177;C0439234
764,$nmbr$ e $nmbr$ years,C0439234
764,$nmbr$ = $nmbr$ yr — no . ( % ),C0439234
764,$nmbr$ - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
764,$nmbr$ - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
764,$nmbr$ - yr %,C0439234
764,$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$,C0439234;C0439508;C1282512
764,$nmbr$ - year risk of chd  % #,C0439234;C0439508;C1282512
764,$nmbr$ - year risk for chd,C0439234;C0439508;C1282512
764,$nmbr$ - year predicted risk ( % ) of,C0439234;C0439508
764,$nmbr$ - year mortality,C0026565;C0026566;C0439234;C0439508
764,$nmbr$ - year km %,C0439234;C0439508;C3887676
764,$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
764,$nmbr$ - year framingham chd risk  %,C0439234;C0439508;C1282512;C3166866
764,$nmbr$ - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
764,$nmbr$ - < $nmbr$ years,C0439234
764,$nmbr$ - $nmbr$ yr — no . ( % ),C0439234
764,$nmbr$ - $nmbr$ yr ( % ),C0439234
764,$nmbr$ - $nmbr$ yr,C0439234
764,$nmbr$ - $nmbr$ years,C0439234
764,$nmbr$ $nmbr$ years  n ( % ),C0439234
764,$ $nmbr$ years ( n = $nmbr$ ),C0439234
764,$ $nmbr$ years,C0439234
764,# $nmbr$ year,C0439234;C0439508
763,very good or excellent,C3641222
763,$nmbr$ hr after glucose challenge,C3840385
762,left anterior descending  n ( % ),C0205386;C0441998;C1547177
762,left anterior descending,C0205386;C0441998;C1547177
762,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
762,descent,C0205386;C0680043
761,venous insufficiency,C0042485
761,sufficient,C0205410
761,j $nmbr$ coefficient,C1707429
761,coefficient,C1707429
761,acute respiratory insufficiency,C0865850
760,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
760,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
760,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
760,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
760,screening prebronchodilator fev $nmbr$  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
760,screening hba $nmbr$ c ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
760,screening fev $nmbr$   % predicted,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
760,screening bmi ( kg / m $nmbr$ ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
760,screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,screening absolute reversibility fev $nmbr$  ml,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,screening ( visit $nmbr$ ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
760,screening % reversibility fev $nmbr$,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
760,screening  mean ( sd ) morning pef  mean,C0030771;C0220908;C0220909;C0332170;C0444504;C1518922;C1542834;C1698960;C1710031;C1710032;C1710477;C2347634;C2348143;C2348164;C2699239
760,screening  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
760,predose fev ^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
760,pre - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
760,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
760,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
760,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
760,post - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
760,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
760,post - bronchodilator fev $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
760,oad at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
760,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
760,lama use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
760,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
760,laba use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
760,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
760,insulin glargine dose at screening visit  iu,C0049272;C0178602;C0220908;C0220909;C0366513;C0439453;C0545082;C0694756;C0869039;C0907402;C1114758;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
760,fev $nmbr$   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
760,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
760,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
760,> $nmbr$ per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
760,> $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
759,caffeine users  n ( % ),C3532939
759,caffeine user  n ( % ),C3532939
759,caffeine user,C3532939
759,caffeine consumption *,C0948365
759,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
758,dose of aspirin,C4696290
758,aspirin dose at randomization,C0034656;C4696290
758,aspirin dose  mg / d,C0439422;C4696290
758,aspirin dose,C4696290
758,aspirin at any dose,C4696290
757,worsened,C1457868;C4084902
757,significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
757,significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
757,significant worsening in kccq clinical,C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
757,no worsening in pga  %,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
756,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
756,us site of enrollment,C1516879;C1696073;C2945843;C3888021
756,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
756,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
756,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
756,statin at enrollment,C0360714;C1516879;C1696073;C3888021
756,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
756,reason for enrollment in active a,C0392360;C1516879;C1696073;C3888021
756,primary enrollment diagnoses  n ( % ),C0332137;C0801658;C1516879;C1696073;C3888021
756,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
756,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
756,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
756,medications at enrollment  n ( % ) :,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
756,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
756,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
756,loop at enrollment,C0445022;C1516879;C1696073;C3888021
756,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
756,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
756,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
756,arb at enrollment,C1516879;C1696073;C3888021;C3888198
756,age at enrolment  years,C1510829;C1516879;C1696073;C3888021
756,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
755,p  net difference,C0369773;C1456447;C1705241;C1705242;C2603361;C3853572;C3887809;C3890893
755,net ep $nmbr$,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
755,net clinical benefit : on - treatment vte or major bleeding,C0039798;C0087111;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4684590
755,net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding,C0011065;C0038454;C1306577;C1456447;C3538987;C3810814;C3853572;C3887809;C3890893;C4048877;C4082313;C4318503;C4552775;C4554100;C4684590
755,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
755,net adverse clinical events at day $nmbr$,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
754,without dyspnoea,C0013404;C1963100
754,with dyspnoea,C0013404;C1963100
754,no dyspnoea ( n = $nmbr$ ),C0013404;C1963100
754,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
754,mmrc dyspnea scale  n ( % ),C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
754,dyspnoea ( n = $nmbr$ ),C0013404;C1963100
754,dyspnea t,C0013404;C1963100
754,dyspnea,C0013404;C1963100
754,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
754,cdr - sob,C0013404;C4521843
754,borg dyspnea score who functional class  n ( % ),C0013404;C0449820;C1963100;C4050231
753,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
753,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
753,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
753,trough fev $nmbr$   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
753,trough fev  response ( l ) i,C0021966;C0221138;C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
753,stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,sri response  %,C0871261;C1420401;C1704632;C1706817;C2911692
753,previous loss of response to infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
753,previous loss of response to and intolerance of infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
753,peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
753,patients with weekly iss mid response  n ( % ) v,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
753,patients with previous loss of response to infliximab,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
753,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
753,patient ' s global assessment of response to therapy score,C0871261;C1704632;C1706817;C2911692;C4054229
753,pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$,C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
753,pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$,C0025677;C0168634;C0871261;C1417487;C1442488;C1704632;C1706817;C2911692;C4528685
753,pasi $nmbr$ response },C0871261;C1704632;C1706817;C2911692;C4528685
753,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
753,mean eq - $nmbr$ d response ( $nmbr$ % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
753,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
753,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
753,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
753,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
753,inadequate response or intolerance to > $nmbr$ anti - tnfdrug,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
753,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
753,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
753,bronchodilator response  ml,C0006280;C0439526;C0871261;C1704632;C1705224;C1706817;C2911692;C3887665
753,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
753,acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$,C0025677;C0168634;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C2911692
753,acr response  % acr $nmbr$,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
753,acr response  %,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
753,acr $nmbr$ response at week $nmbr$  n ( % ),C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
753,acr $nmbr$ response  n / n ( % ),C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
753,acr $nmbr$ response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
752,nx *,C0445085
751,npi - $nmbr$ score *,C1412208;C1549728;C3539727
751,npi,C1412208;C1549728;C3539727
750,ni,C0028075;C2348274;C3869926;C3869927
750,> $nmbr$ ml / niin / l $nmbr$ ni -,C0028075;C1635169;C2348274;C3869926;C3869927
750,< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -,C0028075;C0439445;C2348274;C3869926;C3869927
749,≥ $nmbr$ a ( n = $nmbr$ ),C0369718;C0441922
749,without ( n = $nmbr$ $nmbr$ ),C0369718;C0441922
749,with ( n = $nmbr$ ),C0369718;C0441922
749,us n = $nmbr$,C0369718;C0441922
749,us ( n = $nmbr$ ),C0369718;C0441922
749,other { n = $nmbr$ ),C0369718;C0441922
749,other n ( % ),C0369718;C0441922
749,other * ( n = $nmbr$ ),C0369718;C0441922
749,other ( n — $nmbr$ ),C0369718;C0441922
749,other ( n   = $nmbr$ ),C0369718;C0441922
749,other ( n = $nmbr$ ),C0369718;C0441922
749,other ( n = $nmbr$  $nmbr$ ],C0369718;C0441922
749,other ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
749,other ( n  % ),C0369718;C0441922
749,other  n ( % ),C0369718;C0441922
749,none ( n = $nmbr$ ),C0369718;C0441922
749,no ( n = $nmbr$ ),C0369718;C0441922
749,no ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
749,neither n = $nmbr$  $nmbr$,C0369718;C0441922
749,n_,C0369718;C0441922
749,n t % ),C0369718;C0441922
749,n observed,C0369718;C0441922
749,n o,C0369718;C0441922
749,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
749,n analysed,C0369718;C0441922
749,n = $nmbr$ t,C0369718;C0441922
749,n = $nmbr$ lesions,C0369718;C0441922
749,n = $nmbr$,C0369718;C0441922
749,n =,C0369718;C0441922
749,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
749,n / pyr,C0369718;C0441922
749,n / n   ( % ),C0369718;C0441922
749,n / n ( % / yr ),C0369718;C0439234;C0441922
749,n / n ( % ),C0369718;C0441922
749,n / n $nmbr$ / $nmbr$,C0369718;C0441922
749,n / n,C0369718;C0441922
749,n .,C0369718;C0441922
749,n - $nmbr$ pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
749,n - $nmbr$ pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
749,n - $nmbr$ pufa,C0032615;C0369718;C0441922
749,n - $nmbr$ fatty acit,C0369718;C0441922
749,n - $nmbr$ fatty acids slope lsm ± se ( mm / year ),C0015684;C0369718;C0441922
749,n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
749,n - $nmbr$ fatty acids ( n = $nmbr$ ),C0015684;C0369718;C0441922
749,n - $nmbr$ fatty acids,C0015684;C0369718;C0441922
749,n - $nmbr$ - pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
749,n + v ( n = $nmbr$ ),C0369718;C0441922
749,n *,C0369718;C0441922
749,n ( stented lesions ),C0369718;C0441922
749,n ( lesions ),C0369718;C0441922
749,n ( iqr ),C0369718;C0441922
749,n ( % of patients ),C0030705;C0369718;C0441922
749,n ( % ) unless otherwise specified,C0369718;C0441922
749,n ( % ) responders,C0369718;C0441922
749,n ( % ) liraglutide $nmbr$ placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
749,n ( % ),C0369718;C0441922
749,n %,C0369718;C0441922
749,n $nmbr$ yrs,C0369718;C0441922
749,n $nmbr$ / n $nmbr$,C0369718;C0441922
749,n $nmbr$,C0369718;C0441922
749,n,C0369718;C0441922
749,all n = $nmbr$ $nmbr$,C0369718;C0441922
749,all n = $nmbr$  $nmbr$,C0369718;C0441922
749,all n = $nmbr$,C0369718;C0441922
749,all ( n = $nmbr$ f ),C0016327;C0369718;C0441922
749,all ( n = $nmbr$ * ),C0369718;C0441922
749,all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0369718;C0441922
749,all ( n = $nmbr$ ),C0369718;C0441922
749,all ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
749,a $nmbr$ n = $nmbr$,C0369718;C0441922
749,a $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,> $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
749,> $nmbr$ . $nmbr$  n ( % ),C0369718;C0441922
749,> $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
749,> $nmbr$ ( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
749,> $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,> $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
749,> $nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
749,> $nmbr$ %  n ( % ),C0369718;C0441922
749,> $nmbr$  n ( % ) gender  n ( % ),C0079399;C0369718;C0441922;C1522384
749,> $nmbr$  n ( % ),C0369718;C0441922
749,< $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
749,< $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
749,< $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
749,< $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,< $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
749,< $nmbr$ %  n ( % ),C0369718;C0441922
749,< $nmbr$  n ( % ),C0369718;C0441922
749,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
749,( n = l $nmbr$ ),C0369718;C0441922
749,( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
749,( n = $nmbr$ ) ( n = $nmbr$ ),C0369718;C0441922
749,( n = $nmbr$ )  ' ( n = $nmbr$ ),C0369718;C0441922
749,( n = $nmbr$ ),C0369718;C0441922
749,( n = $nmbr$,C0369718;C0441922
749,( n $nmbr$ $nmbr$ ),C0369718;C0441922
749,$nmbr$ to < $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
749,$nmbr$ to < $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,$nmbr$ n qi,C0369718;C0376586;C0441922
749,$nmbr$ n / n,C0369718;C0441922
749,$nmbr$ - $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
749,$nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,$nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
749,$nmbr$ ( n $nmbr$ $nmbr$ ),C0369718;C0441922
749,$nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
749,$ $nmbr$ to  $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,$ $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
749,$ $nmbr$ %  n ( % ),C0369718;C0441922
748,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
748,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
748,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
748,physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale ),C0031843;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1522492;C1705273;C1806781;C2350002;C2964478;C4049916;C4255237
748,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
748,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
748,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
748,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
748,nyha functional class $nmbr$,C0205245;C0542341;C1882083;C2700217
748,nyha functional class  n ( % ),C0205245;C0542341;C1882083;C2700217
748,nyha functional class,C0205245;C0542341;C1882083;C2700217
748,lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients ),C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
748,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
748,functional outcome ( mrs $nmbr$ - $nmbr$ ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
748,function subscale,C0031843;C0542341;C0700205;C1705273
748,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
748,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
748,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
748,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
748,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
748,acr functional class  n ( % ),C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
747,sample sizea,C0370003;C2347026
747,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
747,abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .,C0000723;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0439828;C0731033;C0871472;C1256463;C1280412;C1510411;C1527178;C1704614;C1705938;C1707455;C1708728;C1739039;C1881413;C2347026;C2986759;C2986775;C3811844;C3812682;C4318736
746,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
746,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C0039593;C0392366;C1709380
745,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
745,serum creatinine concentration and randomization to losartan,C0010294;C0086045;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
745,patients with baseline crp concentration £ $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
745,patients with baseline crp concentration < $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
745,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
745,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
745,ldl - c concentration,C0086045;C1446561;C3827302
745,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
745,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
745,geometric c $nmbr$ concentration  mg / dl,C0086045;C0439269;C0449829;C1446561;C3827302
745,crp concentration > $nmbr$ mg / l  n ( % ) \,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
745,crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
745,blood leucocyte concentration ( $nmbr$ cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
745,blood eosinophil concentration  $nmbr$ cells per l,C0014467;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
744,without lipid - lowering agents,C0086440
744,with lipid - lowering agents,C0086440
744,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
744,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
744,other lipid lowering drugs,C0086440
744,lipid ‐ lowering therapies  n ( % ),C0585943
744,lipid lowering therapy,C0585943
744,lipid lowering drugs,C0086440
744,lipid lowering agents,C0086440
744,lipid lowering agent n ( % ),C0086440
744,lipid - lowering therapy — no . ( % ),C0585943
744,lipid - lowering therapy - no . ( % ),C0585943
744,lipid - lowering therapy,C0585943
744,lipid - lowering drugs  n ( % ),C0086440
744,lipid - lowering drugs,C0086440
744,lipid - lowering drug * *,C0086440
744,lipid - lowering drug,C0086440
744,lipid - lowering agents ( % ),C0086440
744,lipid - lowering agents,C0086440
744,lipid - lowering agent §,C0086440
744,lipid - lowering agent,C0086440
744,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
744,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
744,background lipid - lowering therapy,C0585943;C1706907
744,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
744,any lipid - lowering agent,C0086440
743,tnf antagonist - failure population ( n - $nmbr$ ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
743,tnf - naivea,C1448177
743,tnf - naive patientsa,C1448177
743,tnf - failurea,C1448177
743,tnf - failure patientsa,C0231174;C0680095;C1448177
743,prior anti - tnf treatment,C1448177;C1514463
743,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
743,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
743,anti - tnf,C1448177
742,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
742,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
742,rank based on treatment   =   placebo,C0667477;C0699794
742,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
742,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
742,log - rank,C0667477;C0699794;C1708728;C2986775
742,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
742,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
741,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
741,urine albumin / creatinine ratio  mg / mmol,C0455271;C0567349;C1318330;C2348885
741,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
741,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
741,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
741,urine albumin - to - creatinine ratio,C0455271;C1318330
741,urinary protein - to - creatinine ratio | |,C1096054
741,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
741,urinary albumin : creatinine ratio ^,C0455271;C1318330
741,urinary albumin : creatinine ratio *,C0455271;C1318330
741,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
741,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
741,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
741,urinary albumin - to - creatinine ratio §,C0455271;C1318330
741,urinary albumin - to - creatinine ratio ^,C0455271;C1318330
741,urinary albumimcreatinine ratio,C1273442
741,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
741,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
741,albumin creatinine ratio,C0486293;C1318293
741,albumin / creatinine ratio  n ( % ),C0486293;C1318293
741,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
741,albumin - to - creatinine ratio ' i  /,C0021966;C0221138;C0486293;C1318293
741,albumin - to - creatinine ratio,C0486293;C1318293
740,high - sensitivityc - reactive protein  mg / l,C0033684;C0205250;C0205332;C0439268;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
740,c - reactive proteinc,C0205332
740,batellna c - reective protein,C0033684
739,pulse — beats / min,C0232117;C0391850;C1947910
739,pulse rate ( bpm ),C0232117
739,pulse in beats / minute  mean ( sd ),C0232117;C0391850;C0439385;C0444504;C1947910;C2347634;C2348143;C2699239
739,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910
739,pulse  beats / min,C0232117;C0391850;C1947910
738,luts = lower urinary tract symptoms  is =,C0574785
738,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
737,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
737,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
737,pah - ssc,C0030123;C3203102;C3897657;C4284467
737,pah - sle,C0024141;C0030123;C3203102;C4284467
737,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
737,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
737,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
737,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
736,no atopy ( n = $nmbr$ ),C0392707;C3539705
736,atopy by phadiatop test  n ( % ),C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
736,atopy ( specific ige ) c  n ( % ),C0205369;C0392707;C1552740;C3539705
736,atopy ( n = $nmbr$  $nmbr$ ),C0392707;C3539705
736,atopic ( based on phadiatop test ),C0392707
736,atopic,C0392707
735,apolipoprotein b ^,C0003593
735,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
735,apolipoprotein b,C0003593
735,apob : apoal,C0003593;C3252643
735,apob : apoa $nmbr$,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
735,apob $nmbr$,C0003593;C3252643
735,apob,C0003593;C3252643
735,apo b *,C0003593;C3252643
735,apo b,C0003593;C3252643
735,apo - b,C0003593;C3252643
734,sita / pio $nmbr$ / $nmbr$,C0030800;C2347712
734,sita $nmbr$ + pio $nmbr$,C0030800;C2347712
734,pio $nmbr$,C0030800;C2347712
733,section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
733,section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
733,section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
733,risk reduction ( $nmbr$ % cl ),C0596019;C1137094
733,risk reduction  %,C1137094
733,direction of hr,C0449738
733,% risk reduction ( $nmbr$ % cl ),C0596019;C1137094
732,erosion score ( $nmbr$ – $nmbr$ scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
732,erosion score ( $nmbr$ - $nmbr$ ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
732,erosion,C0333307;C1880549;C1959609;C3887524
732,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
732,> $nmbr$ erosion  n ( % ),C0333307;C1880549;C1959609;C3887524
731,resection performed — no . { % ),C0015252;C0728940
731,resection performed  %,C0015252;C0728940
731,lv ejection fraction > $nmbr$ % and < $nmbr$ %,C0023128;C0489482;C0731033;C1881413;C2700378
731,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
731,lv ejection fraction  mean ( sd ) [ range ]  %,C0023128;C0444504;C0489482;C0731033;C1514721;C1881413;C2347634;C2348143;C2348147;C2699239;C2700378;C3542016
731,lv ejection fraction  % ( n = $nmbr$ ),C0023128;C0489482;C0731033;C1881413;C2700378
731,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
731,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
731,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
731,ejection fraction category,C0489482;C0683312;C2700378;C3889287
731,ejection fraction based on local reading,C0489482;C2700378
731,ejection fraction : < $nmbr$ % ( n = $nmbr$ ),C0489482;C2700378
731,ejection fraction *,C0489482;C2700378
731,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
731,ejection fraction ( % ),C0489482;C2700378
731,ejection fraction  percent ( sd ),C0439165;C0489482;C2699239;C2700378
731,ejection fraction  mean ( sd )  %,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
731,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
731,ejection fraction  %,C0489482;C2700378
731,ejection fraction,C0489482;C2700378
730,spironolactone ( n = $nmbr$ ),C0037982
730,spironolactone  n ( % ),C0037982
730,spironolactone,C0037982
730,outcomes by treatment ( spironolactone vs placebo ),C0037982;C0085415
730,mra ( spironolactone or eplerenone ),C0037982;C0243032;C1609165;C3891069
729,sustained decrease of > $nmbr$ % in egfr ®,C0392756;C0443318;C0547047
729,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
729,rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl ),C0301630;C0392756;C0596019;C1293152;C4551656;C4554402
729,relative decrease > $nmbr$ %,C0080103;C0205345;C0392756;C0547047;C1547039
729,reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %,C0019016;C0301630;C0392756;C1293152;C1825777;C3538758;C4551656
729,reduction in odds %,C0301630;C0392756;C1293152;C4551656
729,reduced ef,C0392756
729,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
729,primary outcome : $nmbr$ % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
729,patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +,C0005910;C0006041;C0030705;C0392756;C0547047;C2986891
729,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
729,dose reduction  n ( % ),C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
729,composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes,C0205199;C0301630;C0392756;C1293152;C1547335;C4551656
729,body weight reduction > $nmbr$ %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
729,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
729,absolute fvc decrease > $nmbr$ %,C0205344;C0392756;C0547047;C3714541
729,absolute decrease > $nmbr$ %,C0205344;C0392756;C0547047
729,a decrease of > $nmbr$ points in the cdai score,C0392756;C0547047;C2924612
729,% with haq - di decrease > $nmbr$ . $nmbr$,C0392756;C0547047;C3826998;C4321476
729,% reduction,C0301630;C0392756;C1293152;C4551656
729,$nmbr$ ‐ point reduction in selena – sledai score  %,C0301630;C0392756;C0451528;C1293152;C1552961;C2347617;C3714763;C4551656
729,$nmbr$ % decrease in womac pain score,C0392756;C0547047;C0582148
728,serum values ^,C0042295;C0229671;C1546774;C1550100
728,serum values,C0042295;C0229671;C1546774;C1550100
728,serum urea nitrogen  mg / dl,C0028158;C0229671;C0439269;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
728,serum trap - $nmbr$ b ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
728,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
728,serum p $nmbr$ np ( ^ g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
728,serum n - propeptide of type $nmbr$ collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
728,serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
728,serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
728,serum gastrint  pg / ml,C0229671;C0439297;C1546774;C1550100
728,serum fg  mg / dl,C0016703;C0229671;C0439214;C0439269;C1546774;C1550100;C1638318;C2348814;C3642216
728,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
728,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
728,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
728,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
728,serum $nmbr$ - hydroxyvitamin d  ng / ml,C0020337;C0229671;C0439275;C1546774;C1550100
728,serum,C0229671;C1546774;C1550100
728,patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % ),C0030705;C0220853;C0229671;C1546774;C1550100
727,enoxaparin only,C0205171;C0206460;C1720467
727,enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0206460
727,enoxaparin / vka,C0206460
727,enoxaparin ( n = $nmbr$ ),C0206460
727,enoxaparin ( n = $nmbr$  $nmbr$ ),C0206460
727,enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
727,enoxaparin,C0206460
726,enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0014025
726,enalapril dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C3250443
726,enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C1120110;C3250443
726,enalapril + aliskiren ( n = $nmbr$ ),C0014025;C1120110
726,enalapril ( n = $nmbr$ ),C0014025
726,enalapril,C0014025
725,not - japan n = $nmbr$  $nmbr$,C0022341;C1518422
725,not - japan,C0022341;C1518422
725,japan n = $nmbr$,C0022341
725,japan and south korea,C0022341
725,japan,C0022341
725,calima japan ( n = $nmbr$ ),C0022341
724,apolipoprotein a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508
724,apolipoprotein a,C0003592;C0523508
724,apoa - $nmbr$  g / l,C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
724,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
724,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
724,apo a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
724,apo a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
723,apolipoprotein a - i *,C0085201;C1677784
723,apolipoprotein a - i,C0085201;C1677784
723,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
723,apoa - i,C0085201;C1677784
723,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
723,apo a - i  mg / dl,C0085201;C0439269;C1677784
723,apo a - i,C0085201;C1677784
722,apixaban vs . placebo,C1831808
722,apixaban dose ( or matching placebo ),C0178602;C0869039;C1114758;C1831808
722,apixaban ( n = $nmbr$ ),C1831808
722,apixaban  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
722,apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
722,apixaban,C1831808
721,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
721,paroxysmal af,C0235480
721,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
721,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
720,paroxysmal ( n  % ),C0205311
720,paroxysmal !,C0205311
720,paroxysmal  n ( % ),C0205311
720,paroxysmal,C0205311
720,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
719,rsg $nmbr$ mg / day,C0439422
719,rasagiline  $nmbr$ mg / day,C0439422;C0525678
719,no . of $nmbr$ - mg acetaminophen tablets / day,C0439422;C1243102
719,mg / day,C0439422
719,liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C1456408
719,itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ ),C0165330;C0439422
719,ics  mg / day,C0439422;C0815320;C4551720
719,i - $nmbr$ mg / d ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
719,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
719,> $nmbr$ mg / day,C0439422
719,> $nmbr$ mg / d peq,C0439422
719,> $nmbr$ . $nmbr$ mg / day  %,C0439422
719,< $nmbr$ mg / day,C0439422
719,< $nmbr$ mg / d peq,C0439422
719,$nmbr$ mg / day early - start - delayed start,C0439422
719,$nmbr$ mg / day early - start - delayed - start,C0439422
719,$nmbr$ mg / day early - start,C0439422
719,$nmbr$ mg / day delayed - start,C0439422
719,$nmbr$ mg / day - placebo,C0032042;C0439422;C1696465;C1706408
719,$nmbr$ mg / day,C0439422
719,$nmbr$ mg / d ( n = $nmbr$ ),C0439422
718,≥ $nmbr$ ae,C3887670
718,laboratory ae  n ( % },C0022877;C3244292;C3887670;C4283904
718,due to ae,C3887670
718,because of ae,C3887670
718,any serious ae  n ( % ),C0205404;C3887670
718,any ae leading to discontinuation  n ( % ),C3887670
718,any ae  n ( % ) ‡,C3887670
718,any ae,C3887670
718,ae / e ' ratio ( per $nmbr$ unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
718,ae / a ratio ( per $nmbr$ . $nmbr$ unit ),C3887670
717,facit - f score,C0449820;C3272505;C4050231
717,facit - f,C3272505
717,ease - $nmbr$,C1331418
717,azl - ma,C0024443;C3887485
717,ascot - lla,C0718674
716,ttf - fv,C1332112;C1705840;C4087167
716,> $nmbr$ ft,C1881534;C3890579
716,< $nmbr$ ft,C1881534;C3890579
716,$nmbr$ - $nmbr$ ft,C1881534;C3890579
715,mean score on haq - di §,C3533236;C3826998;C4321476
715,health assessment questionnaire - disability index,C4321476
715,haq di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
715,haq di,C3826998;C4321476
715,haq - di scoreff,C3826998;C4321476
715,haq - di scored,C3826998;C4321476
715,haq - di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
715,haq - di score,C0449820;C3826998;C4050231;C4321476
715,haq - di mcide,C3826998;C4321476
715,haq - di improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3826998;C4321476
715,haq - di improvement > $nmbr$ . $nmbr$,C2986411;C3826998;C4321476
715,haq - di * *,C3826998;C4321476
715,haq - di *,C3826998;C4321476
715,haq - di ( $nmbr$ - $nmbr$ ),C3826998;C4321476
715,haq - di  number ( % ),C0237753;C0449788;C3826998;C4321476
715,haq - di,C3826998;C4321476
715,( haq - di  $nmbr$ - $nmbr$ ),C3826998;C4321476
714,mean hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
714,hemoglobin a    ( % ),C0019016
714,hba „ ( % ),C0019016;C1825777;C3538758
714,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
714,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c   at randomization,C0019016;C0034656;C1825777;C3538758
714,hba $nmbr$ c   ( % ),C0019016;C1825777;C3538758
714,hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
714,hba $nmbr$ c strata,C0019016;C1825777;C3538758
714,hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
714,hba $nmbr$ c distribution at baseline  n ( % ),C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
714,hba $nmbr$ c distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
714,hba $nmbr$ c distribution,C0019016;C0520511;C1704711;C1825777;C3538758
714,hba $nmbr$ c category  n ( % ),C0019016;C0683312;C1825777;C3538758;C3889287
714,hba $nmbr$ c category,C0019016;C0683312;C1825777;C3538758;C3889287
714,hba $nmbr$ c categories  n ( % ),C0019016;C0683312;C1825777;C3538758
714,hba $nmbr$ c at week $nmbr$,C0019016;C0332174;C0439230;C1825777;C3538758
714,hba $nmbr$ c at $nmbr$ weeks *,C0019016;C0439230;C1825777;C3538758
714,hba $nmbr$ c \n,C0019016;C1825777;C3538758
714,hba $nmbr$ c > = $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c > $nmbr$ · $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c > $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
714,hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
714,hba $nmbr$ c > $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
714,hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c < $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
714,hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
714,hba $nmbr$ c < $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c ( sd )  %,C0019016;C1825777;C2699239;C3538758
714,hba $nmbr$ c ( n ),C0019016;C1825777;C3538758
714,hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % ),C0019016;C0030705;C1825777;C3538758
714,hba $nmbr$ c ( % ) all countries,C0019016;C0454664;C1825777;C3538758
714,hba $nmbr$ c ( % ) *,C0019016;C1825777;C3538758
714,hba $nmbr$ c ( % ),C0019016;C1825777;C3538758
714,hba $nmbr$ c % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
714,hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
714,hba $nmbr$ c $nmbr$ - < = $nmbr$ %,C0019016;C1825777;C3538758
714,hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
714,hba $nmbr$ c  n,C0019016;C1825777;C3538758
714,hba $nmbr$ c  mmol / mold,C0019016;C0369241;C0439190;C1825777;C3538758
714,hba $nmbr$ c  median ( sd )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2699239;C2939193;C3538758
714,hba $nmbr$ c  mean = sd  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
714,hba $nmbr$ c  mean ( sd )  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
714,hba $nmbr$ c  > $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
714,hba $nmbr$ c  < $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
714,hba $nmbr$ c  ( % ),C0019016;C1825777;C3538758
714,hba $nmbr$ c  % §,C0019016;C1825777;C3538758
714,hba $nmbr$ c  % d,C0019016;C1825777;C3538758
714,hba $nmbr$ c  % *,C0019016;C1825777;C3538758
714,hba $nmbr$ c  % ( sd ),C0019016;C1825777;C2699239;C3538758
714,hba $nmbr$ c  %  n ( % ) b,C0019016;C1825777;C3538758
714,hba $nmbr$ c  %,C0019016;C1825777;C3538758
714,hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
714,hba $nmbr$ c,C0019016;C1825777;C3538758
714,hba  c ( % ),C0019016;C1825777;C3538758
714,hba  % $nmbr$ c,C0019016;C1825777;C3538758
714,hba   ( % ),C0019016;C1825777;C3538758
714,glycaemic control ( hba $nmbr$ c )  n ( % ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
714,any hba $nmbr$ c,C0019016;C1825777;C3538758
714,$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
714,$nmbr$ % < hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
713,smoking ( during the previous month ),C0332177;C0439231;C2114448
713,serum ua < $nmbr$ mg / dl by month $nmbr$,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
713,no . in the $nmbr$ mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
713,monthly,C0332177
713,fpg month $nmbr$ ( mg / dl ),C0332177;C0439231;C0439269
713,fall in last $nmbr$ mo,C0026544;C0085639;C0238715;C0332177;C4553726
713,duration of macular edema  mo,C0024440;C0026544;C0271051;C0332177;C0449238;C2926735
713,duration of disease — mo,C0026544;C0332177;C0872146
713,at least $nmbr$ / mo,C0026544;C0332177
713,antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177
713,> $nmbr$ mo,C0026544;C0332177
713,< $nmbr$ mo  n ( % ),C0026544;C0332177
713,< $nmbr$ mo,C0026544;C0332177
713,$nmbr$ week to $nmbr$ month,C0332174;C0332177;C0439230;C0439231
713,$nmbr$ to < $nmbr$ mo,C0026544;C0332177
713,$nmbr$ mo - $nmbr$ y,C0026544;C0332177
713,$nmbr$ mo,C0026544;C0332177
713,$nmbr$ - < $nmbr$ mo  n ( % ),C0026544;C0332177
713,$nmbr$ - $nmbr$ mo,C0026544;C0332177
713,$nmbr$ - $nmbr$ / month,C0332177;C0439231
712,sulfasalazine,C0036078
712,not hispanie / latino,C0086528;C1518422
712,nilvadipine,C0132512
712,latino,C0086528
712,hydralazine,C0020223
712,hispanie / latino,C0086528
712,hispanic / latino,C0086409;C0086528
711,radiate,C0332301
711,pramlintide,C0537551
711,haplotype,C0018591
710,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
710,fatal or nonlatal stroke,C1302234;C1705232
710,fatal or nonlatal myocardial inlarctlon,C1302234;C1705232
710,fatal or nonfatal stroke,C1302234;C1705232
710,fatal or nonfatal myocardial infarction,C1302234;C1705232
710,fatal or non - fatal stroke,C1302234;C1705232
710,fatal or non - fatal myocardial infarction,C1302234;C1705232
710,fatal chd and nonfatal mia,C0280604;C1302234;C1705232;C3542407
710,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
710,fatal bleeding,C0019080;C1302234;C1705232
710,fatal bleed,C0019080;C1302234;C1705232
710,fatal and nonfatal stroke,C1302234;C1705232
710,fatal and nonfatal ml,C1302234;C1705232
710,fatal aes,C1302234;C1412268;C1705232;C2699274
710,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
710,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
710,fatal / nonfatal mi ( excluding silent mi ),C1302234;C1705232;C3810814
710,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
710,fatal & nonfatal ccvd,C1302234;C1705232
710,fatal,C1302234;C1705232
710,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
709,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation ( n = $nmbr$ $nmbr$ ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation  no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
709,symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % ),C0004238;C0344434;C0683368;C1457887;C1963067
709,symptoms of atrial fibrillation in the $nmbr$ months before randomiza -,C0004238;C0344434;C0683368;C1457887;C1963067
709,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
709,no atrial fibrillation,C0004238;C0344434;C1963067
709,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0205435;C0332189;C0344434;C1279901;C1963067
709,ecg atrial fibrillation  n ( % ),C0004238;C0344434;C1623258;C1963067
709,duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
709,duration of last qualifying episode of atrial fibrillation > $nmbr$ days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
709,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
709,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation type  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
709,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
709,atrial fibrillation or flutter — no . ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation or flutter ( ecg ) §,C0004238;C0344434;C1963067
709,atrial fibrillation or flutter,C0004238;C0344434;C1963067
709,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
709,atrial fibrillation alone ),C0004238;C0344434;C1963067
709,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation !,C0004238;C0344434;C1963067
709,atrial fibrillation    n   ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
709,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
709,atrial fibrillation  %,C0004238;C0344434;C1963067
709,atrial fibrillation,C0004238;C0344434;C1963067
709,af pattern,C0344434;C0449774;C4049859
709,af or atrial flutter 卞,C0344434;C4049859
709,af or atrial flutter !,C0344434;C4049859
709,af duration  n ( % ),C0344434;C0449238;C2926735;C4049859
709,af alone,C0344434;C4049859
709,af,C0344434;C4049859
709,> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0004238;C0332189;C0344434;C1963067
708,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
708,ld edoxaban vs warfarin,C0694649;C2975435
708,higher dose edoxaban regimen,C0205250;C2348331;C2975435
708,higher - dose edoxaban vs warfarin,C0444956;C2975435
708,higher - dose edoxaban ( n = $nmbr$ )  n ( % / y ),C0444956;C2975435
708,high - dose edoxaban vs warfarin,C0444956;C2975435
708,high - dose edoxaban ( n = $nmbr$ ),C0444956;C2975435
708,high - dose edoxaban,C0444956;C2975435
708,hd edoxaban vs warfarin,C2975435
708,edoxaban warfarin,C0043031;C2975435
708,edoxaban vs . warfarin,C2975435
708,edoxaban n = $nmbr$ n / n ( % ),C2975435
708,edoxaban n = $nmbr$,C2975435
708,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
708,edoxaban lower dose vs warfarin,C2975435
708,edoxaban higher dose vs warfarin,C0444956;C2975435
708,edoxaban ( n = $nmbr$ ),C2975435
708,edoxaban,C2975435
707,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
707,standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0439475;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
707,patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478
707,patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
707,patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0030705;C0037623;C0439475;C1415692;C1708288;C4318478
707,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
707,on bp medication  n ( % ),C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
707,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
707,key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac,C0015663;C0017725;C0037623;C1415692;C1708288;C2983605;C4318478
707,intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0162425;C0439475;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
707,bp variable  mm hg,C0037623;C0439475;C0439828;C1415692;C1708288;C4318478;C4553760
707,bp in pre - treated patients,C0037623;C1415692;C1708288;C4318478
707,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
707,bp goal at week $nmbr$,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
707,bp goal  no . ( % ),C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
707,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
707,bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478
707,bp < $nmbr$ / $nmbr$  n ( % ),C0037623;C1415692;C1708288;C4318478
707,bp - lowering treatments  n ( % ),C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
707,bp - lowering treatment ( n = $nmbr$ ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
706,prior pacemaker  n ( % ),C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
706,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
706,pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703
706,pacemaker  n ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
706,pacemaker  ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
706,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
706,cardiac pacemaker — no . ( % ),C0030163;C0037189
705,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
705,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
705,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
705,parameter  n ( % ),C0549193;C1704769;C2350001
705,parameter  % ( $nmbr$ % ci ),C0008107;C0549193;C1704769;C2350001;C3259781
705,parameter,C0549193;C1704769;C2350001
705,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
705,$nmbr$ parameter,C0549193;C1704769;C2350001
704,octi & mate $nmbr$,C0682323;C1260875
704,mate !,C0682323;C1260875
704,mate,C0682323;C1260875
704,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
704,companion : $nmbr$ - $nmbr$ hours,C0031268;C0335343;C0439227;C0682323
703,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
703,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
703,ratio of women to men — %,C0043210;C0456603;C1547037
703,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
703,ratio of urinary albumin ( mg ) to creatinine ( g ),C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
703,ratio of ldl to hdl cholesterol,C0456603;C1547037
703,ratio of ldl to hdl,C0456603;C1547037
703,ratio of hrs ( $nmbr$ % cl )  p for sex interaction,C0456603;C0596019;C1547037;C1568891
703,ratio of hrs ( $nmbr$ % ci )  p for sex interaction,C0008107;C0456603;C1547037;C1568891;C3259781
703,ratio of fev $nmbr$ to fvc ( % ),C0456603;C1547037;C3714541
703,ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
703,ratio,C0456603;C1547037
703,rate ratio { $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
703,rate ratio vs placebo ( $nmbr$ % ci ),C0456603;C0871208;C1521828;C1547037
703,rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl ),C0456603;C0871208;C1521828;C1547037;C2981360
703,rate ratio ( $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
703,rate ratio ( $nmbr$ % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
703,rate ratio,C0456603;C0871208;C1521828;C1547037
703,post - bronchodilator ratio of fev $nmbr$ to fvc — %,C0456603;C1547037;C2599594;C3714541
703,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
703,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
703,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
703,hzard ratio,C0456603;C1547037
703,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
703,fev $nmbr$ : fvc ratio,C0456603;C1547037;C3714541
703,fev $nmbr$ / fvc ratio *,C0456603;C1547037;C3714541
703,fev $nmbr$ / fvc ratio  % ( sd ),C0456603;C1547037;C2699239;C3714541
703,fev $nmbr$ / fvc ratio  %,C0456603;C1547037;C3714541
703,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
703,e / a ratio,C0456603;C1547037
703,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
703,cardiothoracic ratio > $nmbr$ . $nmbr$,C0456603;C1547037;C4055270
703,cardiothoracic ratio,C0456603;C1547037;C4055270
703,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
703,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
703,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
703,apob : apoa - $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
703,apob : apoa $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
703,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
702,subcutaneous unfractionated heparin,C0353681
702,subcutaneous injections,C0021499
702,subcutaneous ( n = $nmbr$ ),C0443315
701,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
701,intravenous heparin,C0354566
700,statin intolerance $nmbr$  n ( % ),C0231199;C0360714;C1744706;C2355652
700,previous intolerance of infliximab  n ( % ) *,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
700,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
700,intolerance ®,C0231199;C1744706;C2355652
700,intolerance ',C0231199;C1744706;C2355652
700,intolerance,C0231199;C1744706;C2355652
699,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
699,in ambulance,C0002422;C3846685
699,ambulance ( % ),C0002422;C3846685
699,ambulance  n ( % ),C0002422;C3846685
699,ambulance,C0002422;C3846685
698,number insulin glargine,C0237753;C0449788;C0907402
698,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C3273373;C3665488
698,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C2344255;C4050145
698,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C2344255;C4050145
698,insulin glargine   ±   oad,C0907402
698,insulin glargine vs standard care least - squares mean ( $nmbr$ % cl ),C0907402
698,insulin glargine n ( x ),C0907402
698,insulin glargine n ( % ) / $nmbr$ py,C0030428;C0907402;C3538810
698,insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ ),C0004446;C0293359;C0907402
698,insulin glargine ( n = $nmbr$ ll ),C0907402
698,insulin glargine ( n = $nmbr$ ),C0907402
698,insulin glargine,C0907402
698,iglar ( insulin glargine l $nmbr$ u ),C0439148;C0907402
698,glargine n ( n / loopy ),C0907402
698,glargine $nmbr$,C0907402
698,glargine,C0907402
697,volume change  mm ^,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952;C4330985;C4554674
697,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
697,total psa ‐ modified shs,C0392747;C2986589;C3889737
697,third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205437;C0392747;C0439612;C0439631;C0443172;C1705241;C3639721;C4319952
697,tadalafil $nmbr$ mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
697,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
697,subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0168634;C0392747;C0443172;C1442488;C1705241;C2986480;C4319952
697,st change > $nmbr$ mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
697,sf ‐ $nmbr$ pcs  ls mean change ± se,C0023668;C0036919;C0037712;C0392747;C0443172;C0444504;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
697,sf - $nmbr$ pcs  ls mean change from baseline   ±   se,C0023668;C0036919;C0037712;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
697,sf - $nmbr$ bodily pain  mean change from baselinee,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
697,sf - $nmbr$ bodily pain  mean change from baselineb,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
697,secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
697,second primary ( estimated change in total updrs score from baseline to wk $nmbr$ ),C0205225;C0205436;C0392747;C0439175;C0439612;C0439631;C0439810;C0443172;C0457385;C0565930;C0750572;C1561503;C1705190;C1705241;C3639721;C4319952
697,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
697,prior lipid - modifying therapy,C0023779;C0392747;C1514463
697,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
697,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
697,patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
697,patients with change from baseline in psa - modified total shs score # $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
697,pain vas  mean change from baselined,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,pain vas  mean change from baselinea,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
697,nominal change,C0392747;C0443172;C1705241;C4319952
697,no change,C0392747;C0443172;C1705241;C4319952
697,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
697,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
697,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
697,modified has - bled score  mean ± sd,C0392747;C3889737
697,modified has - bled > $nmbr$,C0392747;C3889737
697,modified has - bled < $nmbr$,C0392747;C3889737
697,modified has - bled $ $nmbr$,C0392747;C3889737
697,modified has - bled,C0392747;C3889737
697,modified hachinski ischemia scale  mean ( sd ) c,C0022116;C0175659;C0349674;C0392747;C0444504;C1947916;C2347634;C2348143;C2699239;C3889737;C4321499
697,modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C0392747;C3541413;C3889737
697,median change in atheroma volume  %,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
697,mean percentage change from baseline to final visit,C0168634;C0392747;C0439165;C0443172;C0444504;C1442488;C1549488;C1561533;C1705241;C2347634;C2348143;C4319952
697,mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0439175;C0439810;C0443172;C0444504;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
697,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,mean change in sbp from baseline  mmhg  mean ( sd ),C0085805;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,mean change in radiographic end points shs  mean ± sd,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C2699239;C4319952
697,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
697,mean change in fev $nmbr$,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
697,mean change in dbp from baseline  mg / dl  mean ( sd ),C0392747;C0443172;C0444504;C0536221;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952
697,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
697,mean change from baseline in the number of,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change from baseline in acq overall score ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change from baseline bp at week $nmbr$,C0168634;C0392747;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change from baseline  % ‐ points,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change from baseline  %,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,mean change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,mean change  % ( se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
697,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,ls mean change from baseline ( se )  %,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls mean change from baseline $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls mean change from baseline  ml ( se ) a,C0023668;C0036919;C0168634;C0392747;C0439526;C0443172;C0444504;C1442488;C1705224;C1705241;C2347634;C2348143;C3887665;C4319952
697,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
697,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,ls - mean change from baseline ( $nmbr$ % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
697,hscrp  exp ls mean change ± se ‡,C0023668;C0036919;C0392747;C0443172;C0444504;C1417055;C1705241;C2347634;C2348143;C4319952
697,hba $nmbr$ c ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
697,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
697,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
697,first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205435;C0392747;C0439612;C0439631;C0443172;C1279901;C1705241;C3639721;C4319952
697,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
697,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0242485;C0392747;C0443172;C0729333;C1705241;C4319952
697,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
697,das $nmbr$ - crp  ls mean change from baseline ( se ) §,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
697,das $nmbr$ - crp  ls mean change from baseline ( se ) ¥,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
697,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
697,changes in shs,C0392747;C0443172
697,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C1705241;C4319952
697,change to   week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
697,change to week $nmbr$ * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
697,change to week $nmbr$ *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
697,change to week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
697,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
697,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
697,change in sesbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,change in sedbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,change in sbp ( $nmbr$ months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
697,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
697,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
697,change in psa ‐ modified shs  baseline to week $nmbr$ ‡,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
697,change in psa ‐ modified shs  baseline to week $nmbr$,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
697,change in pav  mean ( $nmbr$ % cl )  %,C0058890;C0392747;C0443172;C0444504;C0596019;C1705241;C2347634;C2348143;C4319952
697,change in nt - probnp at $nmbr$ months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
697,change in nt - probnp at $nmbr$,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
697,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
697,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
697,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
697,change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl ),C0392747;C0443172;C1705241;C4319952
697,change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % ),C0019016;C0392747;C0443172;C1705241;C1825777;C3538758;C4319952
697,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
697,change in fpg $nmbr$ to month $nmbr$ ( mg / dl ),C0392747;C0443172;C1705241;C4319952
697,change in fev $nmbr$ at week $nmbr$,C0392747;C0443172;C1705241;C3714541;C4319952
697,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0392747;C0443172;C1705241;C4319952
697,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
697,change in das $nmbr$ > $nmbr$ . $nmbr$,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
697,change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
697,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
697,change from,C0392747;C0443172;C1705241;C4319952
697,change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
697,change $nmbr$,C0392747;C0443172;C1705241;C4319952
697,change,C0392747;C0443172;C1705241;C4319952
697,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
697,before a change to the enrollment form was implemented in august $nmbr$ . bnp,C0348078;C0376315;C0392747;C0443172;C1516879;C1522492;C1696073;C1705241;C3888021;C4255237;C4319952
697,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
697,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
697,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
697,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
697,basdai  mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
697,basdai  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
697,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
697,asqol  ls mean change ± se,C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,asqol  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ],C0008107;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
697,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
697,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
697,( mean change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
697,( mean % change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
697,% change median baseline crp > $nmbr$ mg / l,C0392747;C0443172;C1705241;C4319952
697,% change from baseline  mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
697,% change ( median  q $nmbr$  q $nmbr$ ),C0392747;C0443172;C1705241;C4319952
697,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
697,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
697,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
697,% change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C1705241;C3259781;C4319952
697,% change,C0392747;C0443172;C1705241;C4319952
697,$nmbr$ year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
696,prior cardiovascular disease,C0007222;C0332152;C2826257
696,no cvd,C0007222
696,no cardiovascular disorder $nmbr$ ',C0007222
696,no cardiovascular disease ( n = $nmbr$ ),C0007222
696,medical history of cv disease or heart failure  n ( % ),C0007222;C0262926
696,cvd without ml ^ troke,C0007222;C0439526;C1705224;C3887665
696,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
696,cvd without miatroke,C0007222
696,cvd without mi or stroke ( n = $nmbr$ ),C0007222;C3810814
696,cvd subjects,C0007222
696,cvd or mi,C0007222
696,cvd deaths,C0007222;C0011065;C1306577
696,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
696,cvd / stroke / see,C0007222;C0038454;C4554100
696,cvd / mi / stroke / urgent vascular hospitalization,C0007222;C3810814
696,cvd / mi / stroke / urgent coronary revascularization,C0007222;C3810814
696,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
696,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
696,cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina,C0007222;C0038454;C3810814;C4554100
696,cvd  mi  stroke  or recurrent ischemia - urgent revascularization,C0007222;C0038454;C3810814;C4554100
696,cvd  mi  or stroke,C0007222;C3810814
696,cvd  ckd,C0007222;C1561643
696,cvd,C0007222
696,cv disease,C0007222
696,current cvd / diabetes  n ( % ),C0007222;C0011847;C0011849;C0521116;C1705970
696,combined cvd,C0007222;C0205195
696,combined $nmbr$ - year cvd,C0007222;C0205195;C0439234;C0439508
696,chronic cvd,C0007222;C0205191
696,cardiovascular disorder  n ( % ),C0007222
696,cardiovascular disorder,C0007222
696,cardiovascular disease n ( % ),C0007222
696,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
696,cardiovascular disease history  n ( % ) *,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
696,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
696,cardiovascular disease *,C0007222
696,cardiovascular disease ( n = $nmbr$ ),C0007222
696,cardiovascular disease,C0007222
696,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
696,any cardiovascular disease,C0007222
696,$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ ),C0007222
696,$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ ),C0007222
695,atenolol use at $nmbr$ month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
695,atenolol strategy ( n = $nmbr$ ),C0004147;C0679199
695,atenolol strategy ( n = $nmbr$  $nmbr$ ),C0004147;C0679199
695,atenolol strategy,C0004147;C0679199
695,atenolol n = $nmbr$ no . ( % ),C0004147
695,atenolol n = $nmbr$,C0004147
695,atenolol - losartan,C0004147;C0126174
695,atenolol *,C0004147
695,atenolol ( « = $nmbr$ $nmbr$ ),C0004147
695,atenolol ( no . = $nmbr$ ),C0004147
695,atenolol ( n = $nmbr$ ),C0004147
695,atenolol ( n = $nmbr$  $nmbr$ ),C0004147
695,atenolol,C0004147
694,femoral neckc,C0015811
694,femoral access — no . / total no . ( % ),C0015811
694,femoral access,C0015811;C0444454;C1554204
694,femoral,C0015811
693,serum ldl cholesterol,C0428474
693,non ‐ hdl cholesterol,C0729627;C1535899
693,non - hdl cholesterol j,C0729627;C1535899
693,non - hdl cholesterol ( week $nmbr$ ),C0332174;C0439230;C0729627;C1535899
693,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
693,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
693,non - hdl cholesterol,C0729627;C1535899
693,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
692,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
692,placebo ‐ controlled period,C0439531;C1706408;C1948053
691,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
691,test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
691,ppg post - meal test  mmol / l,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C1532563;C3831328;C4318744
691,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
691,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
691,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
691,laboratory tests,C0022885
691,laboratory testing,C0022885
691,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
691,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
690,without beta blocker,C0001645
690,with beta blocker,C0001645
690,use of beta - blockers,C0001645;C1524063
690,use of beta - blocker,C0001645;C1524063
690,no betablocker use,C0001645;C0042153;C0457083;C1947944
690,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
690,no beta - blocker,C0001645
690,betablocker use,C0001645;C0042153;C0457083;C1947944
690,betablocker,C0001645
690,beta blockers,C0001645
690,beta blocker users,C0001645;C1706077
690,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
690,beta blocker use,C0001645;C0042153;C0457083;C1947944
690,beta blocker  n ( % ),C0001645
690,beta blocker  %,C0001645
690,beta blocker,C0001645
690,beta - blockers ( all )  n ( % ),C0001645
690,beta - blockers  n ( % ),C0001645
690,beta - blockers  ( % ),C0001645
690,beta - blockers,C0001645
690,beta - blocker — no . / total no . ( % ),C0001645
690,beta - blocker — no . ( % ),C0001645
690,beta - blocker use,C0001645;C0042153;C0457083;C1947944
690,beta - blocker n ( % ),C0001645
690,beta - blocker ( except sotalol ),C0001645;C0037707
690,beta - blocker !,C0001645
690,beta - blocker  %,C0001645
690,beta - blocker,C0001645
690,beta - adrenergic blocker,C0001645;C2757061;C3536830
689,alpha blockers,C0001641
689,alpha - blockers,C0001641
689,alpha - blocker / other vasodilator,C0001641
689,alpha - blocker,C0001641
689,alpha $nmbr$ blockers,C0001641
688,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
688,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
688,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
688,oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
688,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
688,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
688,lower tertile : b $nmbr$ . $nmbr$,C0441994;C1548802;C2003888
688,lower,C0441994;C1548802;C2003888
688,lipid lowering,C0023779;C0441994;C2003888
688,lipid - lowering medications ^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
688,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
688,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
688,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
688,lipid - lowering,C0023779;C0441994;C2003888
688,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
688,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
688,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
688,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
688,concomitant oral glucose - lowering agents  zz ( % ),C0017725;C0441994;C0442027;C2003888;C2347310;C2347852;C4521986
688,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
688,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
688,> $nmbr$ glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
687,upper respiratory tract inflammation,C0877266
687,upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ ),C0041912
687,upper respiratory tract infection,C0041912
687,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
687,respiratory rate  breaths / min,C0231832;C0439386;C0489258
687,inspiratory capacity ( l ),C0021610;C0802663
686,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
686,laboratory variables,C0022877;C0439828;C3244292;C4283904
686,laboratory values,C0022877;C0042295;C3244292;C4283904
686,laboratory measures,C0022877;C3244292;C4283904
686,laboratory measurements,C0681902
686,laboratory examination,C0260877
686,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
686,laboratory determinations,C0022877;C0680730;C3244292;C4283904
686,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
685,nitrates ( oral or topical ),C0028125;C0699857;C3848573
685,nitrates ( % ),C0028125;C0699857;C3848573
685,nitrates  n ( % ),C0028125;C0699857;C3848573
685,nitrates  ( % ),C0028125;C0699857;C3848573
685,nitrates,C0028125;C0699857;C3848573
685,nitrate — no . ( % ),C0028125;C0699857;C3848573
685,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
685,nitrate ( oral or topical ),C0028125;C0699857;C3848573
685,nitrate ( oral or intravenous ),C0028125;C0699857;C3848573
685,nitrate,C0028125;C0699857;C3848573
684,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
684,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1547111;C3714652;C4321495
684,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
684,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
684,rheumatoid factor or acpa positive  or both,C0035448;C0201660
684,rheumatoid factor and acpa positive,C0035448;C0201660
684,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
684,rheumatoid factor !,C0035448;C0201660
684,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
684,rf positive and acpa negative  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
684,rf positive  no . ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
684,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
684,rf or acpa positive,C0035448;C0201660;C0748398;C1547111
684,rf negative and acpa positive  n ( % ),C0035448;C0201660;C0205160;C0748398;C1513916;C1547111;C2825415;C2825491;C3853545
684,rf and acpa positive  n ( % ),C0035448;C0201660;C0748398;C1547111
684,rf and acpa negative $nmbr$,C0035448;C0201660;C0748398;C1547111
684,rf and acpa negative  n ( % ),C0035448;C0201660;C0748398;C1547111
684,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
684,% rf +,C0035448;C0201660;C0748398;C1547111
683,randomised patients with basdai assessment at baseline and week $nmbr$  n,C0679830;C1998004
683,patient global assessment of disease,C0012634;C4054229
683,patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C0679830
683,patient assessment of disease activity  mm,C0679830;C1292728;C4330985;C4554674
683,patient assessment of arthritis pain  mm,C0679830;C4317006;C4330985;C4554674
683,patient ' s global assessment of disease,C0012634;C4054229
683,patient ' s global assessment of,C4054229
683,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
683,patient ' s global assessment !,C4054229
683,patient ' s global assessment,C4054229
683,patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas ),C0042815;C0679830
682,percent change from baseline to week $nmbr$ in auc ( mean  sem ),C3272907
682,percent change from baseline at week $nmbr$,C3272907
681,patient ' s preference not to take vka  only reason * *,C0376409
681,patient ' s preference not to take vka  only reason,C0376409
681,patient ' s preference not to take,C0376409
681,action tested is between the continuous variable and treatment .,C0441472;C3266814
680,treatment effect ( hr ),C1518681
680,genotype - specific treatment effect hazard ratio ( $nmbr$ % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
680,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0073633;C1280500;C1518681;C2348382
680,effect of covariates on slopes,C1280500;C1518681;C2348382
680,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
679,use of antiplatelet agents — no . / total no . ( % ),C0085826;C1524063
679,use of antiplatelet agents ^,C0085826;C1524063
679,use of antiplatelet agents  n ( % ),C0085826;C1524063
679,other antiplatelet agents  n ( % ),C0085826
679,other antiplatelet agents,C0085826
679,other antiplatelet agent 一 no . ( % ),C0085826
679,antiplatelets agents,C0085826
679,antiplatelet drugs,C0085826;C2963157
679,antiplatelet drug,C0085826
679,antiplatelet agents ( % ),C0085826
679,antiplatelet agents,C0085826
679,antiplatelet agent or anticoagulant,C0085826
679,antiplatelet agent n ( % ),C0085826
679,antiplatelet agent,C0085826
678,creatinine clearance category [ ml / min ],C0439445;C0683312;C0812399;C3889287
678,creatinine clearance category  ml / min  no . ( % ) b,C0439445;C0683312;C0812399;C3889287
678,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
678,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
678,creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f,C0151280
678,creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$,C0373595;C0439445;C0683312;C3889287
678,creatine clearance category,C0373595;C0683312;C3889287
678,creatine clearance  ml / min,C0373595;C0439445
677,renal function : creatinine clearance,C0232804;C0812399
677,creatinine clearance ， : : $nmbr$ ml / min  %,C0439445;C0812399
677,creatinine clearance — no . ( % ),C0812399
677,creatinine clearance — ml / min,C0439445;C0812399
677,creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % ),C0439445;C0812399
677,creatinine clearance < $nmbr$ ml / min ( % ),C0439445;C0812399
677,creatinine clearance < $nmbr$ ml / min  no . / total ( % ),C0439445;C0812399
677,creatinine clearance < $nmbr$ ml / min,C0439445;C0812399
677,creatinine clearance ( ml / min )  mean ± sd,C0439445;C0444504;C0812399;C2347634;C2348143;C2699239
677,creatinine clearance ( ml / min ),C0439445;C0812399
677,creatinine clearance  no . ( % ),C0812399
677,creatinine clearance  n ( % ),C0812399
677,creatinine clearance  ml / min - $nmbr$ *,C0439445;C0812399
677,creatinine clearance  ml / min,C0439445;C0812399
677,creatinine clearance  an   ( % ),C0812399
677,creatinine clearance,C0812399
677,baseline creatinine clearance,C0168634;C0812399;C1442488
676,receiving concomitant nsaids and / or cox - $nmbr$ inhibitors,C1514756
676,receiving concomitant corticosteroids,C1514756
676,receiving antihypertensive treatment -,C1514756
676,receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd ),C1514756
676,receiving antihypertensive,C1514756
676,received drug - eluting stent,C1322815;C1514756
676,received antihypertensive within last $nmbr$ days  n ( % ),C0003364;C0439228;C1514756
676,received an oral aha within $nmbr$ weeks prior to screening,C1514756
676,received > $nmbr$ prior anti - tnf therapies  n,C0279936;C0332152;C0432633;C1514756;C2826257
676,received $nmbr$ prior anti - tnf therapy  n,C0279936;C0332152;C0432633;C1514756;C2826257
675,types of fibrinolytic agent,C0016018;C0332307
675,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
675,thrombolytic agents,C0016018
675,fibrinolytic agents before or after entry,C0016018
675,fibrinolytic agent — no . ( % ) : t,C0016018
675,fibrinolytic agent given,C0016018
675,fibrinolytic agent before randomisation,C0016018;C0034656
674,time in therapeutic range before inclusion,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
674,time in therapeutic range  median ( iqr )  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
674,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
674,median time in therapeutic range for warfarin recipients  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
674,in therapeutic range for warfarin subjects,C0043031;C0460097
674,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C1547707;C1554109;C2946261;C3541383;C3810851
673,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western,C0205120;C0449820;C0489786;C1552595;C1705493;C4050369
673,height — cm,C0489786
673,height ( cm ),C0489786
673,height '  cm,C0489786
673,height  inches,C0439204;C0489786
673,height  cm *,C0489786
673,height  cm,C0489786
672,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
672,peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0205390;C1300072;C1306673;C1306889
672,peripheral artery occlusive disease,C1306889
672,peripheral artery diseasef,C0489868
672,peripheral artery diseaseb,C0489868
672,peripheral artery disease 一 no . ( % ),C1704436;C4025272
672,peripheral artery disease — no . ( % ),C1704436;C4025272
672,peripheral artery disease details,C1704436;C4025272
672,peripheral artery disease - -,C1704436;C4025272
672,peripheral artery disease *,C1704436;C4025272
672,peripheral artery disease,C1704436;C4025272
672,peripheral artery,C0489868
672,peripheral arterial stenosis,C4025272
672,peripheral - artery stenosis,C4025272
672,peripheral - artery disease — no . ( % ),C1704436;C4025272
672,peripheral - artery disease ( % ),C1704436;C4025272
672,peripheral - artery disease,C1704436;C4025272
672,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
671,pvalue for heterogeneity,C0019409;C0242960
671,pfor heterogeneity,C0019409;C0242960;C1151635
671,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0242960;C0289313;C1709380
671,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0019409;C0242960;C0289313;C1709380
671,p value for heterogeneity,C0019409;C0242960;C1709380
671,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
671,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
671,heterogeneity or trend p value,C0019409;C0242960
671,heterogeneity or trend p vaiue,C0019409;C0242960
671,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
671,* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .,C0019409;C0242960;C0369773;C1518681;C2603361
670,other hypoglycemic agent  n ( % ),C0020616
670,other antihyperglycemic agents  not listed,C0020616
670,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
670,hypoglycemic agent,C0020616
670,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
670,hypoglycaemic agents,C0020616
670,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
670,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
670,antihyperglycemic,C0020616
669,id genotype,C0009450;C0017431;C0600091;C1441613
669,genotyping,C1285573
669,genotype,C0017431
669,by genotyping,C1285573
668,feet,C0016504;C0347981
668,beyond popliteal pedal,C0016504;C0442037;C0687080
667,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
667,pe with / without dvt,C0070939;C1880476;C4284304
667,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
667,pe associated with dvt at diagnosis,C0070939;C1880476;C4284304
667,pe and dvt,C0070939;C1880476;C4284304
667,pe ( with or without dvt ),C0070939;C1880476;C4284304
667,pe,C0070939;C1880476;C4284304
667,neither pe nor dvt,C0070939;C1880476;C4284304
666,stroke of undetermined cause,C0015127;C0038454;C1524003
666,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
666,pah origin / cause,C0015127;C1418251;C1524003
666,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
666,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
666,other determined etiology,C0015127;C0521095;C1314792;C1524003
666,other cause  n ( % ),C0015127;C1524003
666,other cause,C0015127;C1524003
666,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
666,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
666,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
666,ischemic etiology  %,C0015127;C0475224;C1314792;C1524003
666,ischemic etiology,C0015127;C0475224;C1314792;C1524003
666,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
666,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
666,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
666,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
666,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
666,etiology ( % ),C0015127;C1314792;C1524003
666,etiology    n   ( % ),C0015127;C1314792;C1524003
666,etiology  n ( % ),C0015127;C1314792;C1524003
666,etiology,C0015127;C1314792;C1524003
666,ed etiology  no . ( % ),C0015127;C1314792;C1524003;C3538926
666,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
666,any cause,C0015127;C1524003
666,all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortality or hf hospitalization ^,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
666,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortality ( n = $nmbr$ ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
666,all - cause mortalitv,C0015127;C1524003
666,all - cause hospitalization,C0015127;C0019993;C1524003
666,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
666,all - cause death / stroke / see,C0011065;C0015127;C0038454;C1306577;C1524003;C4082313;C4552775;C4554100
666,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
666,all - cause,C0015127;C1524003
666,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
666,aetiology,C0015127;C1314792;C1524003
666,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
665,patients with diabetic nephropathy,C0011881;C0030705;C1442864
665,diabetic kidney disease,C0011881
664,type ii diabetes,C0011860
664,diabetes type ii  n ( % ),C0011860
663,prediabetes — no . ( % ) $nmbr$,C0362046
663,prediabetes  n ( % ),C0362046
663,prediabetes  %,C0362046
663,pre – diabetes mellitus  n = $nmbr$,C0362046
663,pre – diabetes mellitus,C0362046
663,ifg / prediabetes ^,C0362046;C1334085;C1708411
662,type $nmbr$ diabetes 一 no . ( % ),C1320657
662,type $nmbr$ diabetes — no . { % ) §,C1320657
662,type $nmbr$ diabetes — no . ( % ) §,C1320657
662,type $nmbr$ diabetes — no . ( % ),C1320657
662,type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1320657
662,type $nmbr$ diabetes mellitusa,C1320657
662,type $nmbr$ diabetes mellitus ’,C1320657
662,type $nmbr$ diabetes mellitus ' $nmbr$ ',C1320657
662,type $nmbr$ diabetes mellitus  n ( % ),C1320657
662,type $nmbr$ diabetes mellitus,C1320657
662,type $nmbr$ diabetes meiiitus,C1320657
662,type $nmbr$ diabetes . n ( % ),C1320657
662,type $nmbr$ diabetes *,C1320657
662,type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
662,type $nmbr$ diabetes  no . ( % ),C1320657
662,type $nmbr$ diabetes  n ( % ) d,C1320657
662,type $nmbr$ diabetes  n ( % ),C1320657
662,type $nmbr$ diabetes,C1320657
662,no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
662,duration of type $nmbr$ diabetes categories  n ( % ),C1320657;C1547660
662,diabetes mellitus ( type $nmbr$ or $nmbr$ ),C1320657
662,diabetes mellitus ( type $nmbr$ )  n ( % ),C1320657
661,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
661,diet group ( n = $nmbr$ ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
661,diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949
661,diet alone,C0012155;C0012159;C1519433;C2983588;C3668949
661,diet ( n 二 $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
661,diet ( n = $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
661,diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
661,diet,C0012155;C0012159;C1519433;C2983588;C3668949
660,without diabetes,C0011847;C0011849
660,with diabetes,C0011847;C0011849
660,undiagnosed diabetes mellitus  n = $nmbr$,C0011849;C1408353
660,undiagnosed diabetes mellitus,C0011849;C1408353
660,undiagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C1408353
660,short ( < $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
660,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
660,people without diabetes n = $nmbr$,C0011847;C0011849;C0027361
660,people with diabetes n = $nmbr$,C0011847;C0011849;C0027361
660,other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ ),C0011847;C0011849;C1704675
660,non - diabetes,C0011847;C0011849;C1518422
660,no diabetes mellitus,C0011849
660,no diabetes ( p = . o $nmbr$ ),C0011847;C0011849
660,no diabetes ( p = . $nmbr$ ),C0011847;C0011849
660,no diabetes ( n = $nmbr$  $nmbr$ ),C0011847;C0011849
660,no diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
660,no diabetes,C0011847;C0011849
660,new diabetes — no . ( % ),C0011847;C0011849;C0205314
660,new diabetes,C0011847;C0011849;C0205314
660,new - onset diabetes §,C0011847;C0011849;C0746890
660,new - onset diabetes,C0011847;C0011849;C0746890
660,n o diabetes,C0011847;C0011849;C0369718;C0441922
660,long ( i $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
660,long ( > $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
660,individuals without diabetes  n = $nmbr$  $nmbr$,C0011847;C0011849;C0027361;C0237401
660,individuals with diabetes  n = $nmbr$,C0011847;C0011849;C0027361;C0237401
660,hx of diabetes  n ( % ),C0011847;C0011849;C0262926;C3814444
660,high risk of diabetes,C0011847;C0011849;C0332167
660,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
660,duration of diabetes — yr ^,C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
660,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
660,duration of diabetes mellitus,C0011849;C0449238;C2926735
660,duration of diabetes in years  median ( iqr ),C0011847;C0011849;C0449238;C2926735
660,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
660,duration of diabetes > $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes < $nmbr$ yrs,C0011847;C0011849;C0449238;C2926735
660,duration of diabetes < $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
660,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
660,duration of diabetes  yrs,C0011847;C0011849;C0449238;C2926735
660,duration of diabetes  years  median ( iqr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
660,duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C2926735
660,duration of diabetes  y,C0011847;C0011849;C0449238;C2926735
660,duration of diabetes  median ( iqr ),C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
660,duration of diabetes,C0011847;C0011849;C0449238;C2926735
660,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
660,diagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C0011900
660,diabetes — no . ( % ),C0011847;C0011849
660,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
660,diabetes | |,C0011847;C0011849
660,diabetes t,C0011847;C0011849
660,diabetes present $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849;C0150312;C0449450
660,diabetes n ( % ),C0011847;C0011849
660,diabetes mellitust,C0011847;C0011849
660,diabetes mellitus 一 no . ( % ),C0011849
660,diabetes mellitus — no . / total no . ( % ),C0011849
660,diabetes mellitus — no . ( % ),C0011849
660,diabetes mellitus yes ( n  % ) hypertension,C0011849;C0020538;C1549445;C1705108;C1710701;C1963138
660,diabetes mellitus n = $nmbr$  $nmbr$,C0011849
660,diabetes mellitus duration ( sd )  y,C0011849;C0449238;C2699239;C2926735
660,diabetes mellitus duration  y ( sd ),C0011849;C0449238;C2699239;C2926735
660,diabetes mellitus duration  y,C0011849;C0449238;C2926735
660,diabetes mellitus [ n ( % ) ],C0011849
660,diabetes mellitus :,C0011849
660,diabetes mellitus ( % ),C0011849
660,diabetes mellitus !,C0011849
660,diabetes mellitus  § n ( % ),C0011849
660,diabetes mellitus  no . / total no . ( % ),C0011849
660,diabetes mellitus  no . ( % ),C0011849
660,diabetes mellitus  n = $nmbr$,C0011849
660,diabetes mellitus  n / n ( % ),C0011849
660,diabetes mellitus  n ( % ) yes,C0011849;C1549445;C1705108;C1710701
660,diabetes mellitus  n ( % ),C0011849
660,diabetes mellitus  ( % ),C0011849
660,diabetes mellitus  %,C0011849
660,diabetes mellitus,C0011849
660,diabetes melitus,C0011847;C0011849
660,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
660,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
660,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
660,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
660,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
660,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
660,diabetes duration ( known )  % of patients,C0011847;C0011849;C0449238;C2926735
660,diabetes duration  years ^,C0011847;C0011849;C0439234;C0449238;C2926735
660,diabetes duration  years,C0011847;C0011849;C0439234;C0449238;C2926735
660,diabetes duration  ycars “,C0011847;C0011849;C0449238;C2926735
660,diabetes duration  y,C0011847;C0011849;C0449238;C2926735
660,diabetes duration  n ( % ),C0011847;C0011849;C0449238;C2926735
660,diabetes duration,C0011847;C0011849;C0449238;C2926735
660,diabetes classificationa,C0011847;C0011849
660,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
660,diabetes and untreated hypertension,C0011847;C0011849
660,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849
660,diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849
660,diabetes ^,C0011847;C0011849
660,diabetes *,C0011847;C0011849
660,diabetes ( p = . oo $nmbr$ ),C0011847;C0011849
660,diabetes ( p = . o $nmbr$ ),C0011847;C0011849
660,diabetes ( p = . $nmbr$ ),C0011847;C0011849
660,diabetes ( n [ % ] ) *,C0011847;C0011849
660,diabetes ( n = $nmbr$ ),C0011847;C0011849
660,diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
660,diabetes ( % ),C0011847;C0011849
660,diabetes $nmbr$ ( % ),C0011847;C0011849
660,diabetes $nmbr$,C0011847;C0011849
660,diabetes  no . ( % ) c,C0011847;C0011849
660,diabetes  no . ( % ),C0011847;C0011849
660,diabetes  n ( % ),C0011847;C0011849
660,diabetes  * n ( % ),C0011847;C0011849
660,diabetes  %,C0011847;C0011849
660,diabetes,C0011847;C0011849
660,all without diabetes ( n = $nmbr$ ),C0011847;C0011849
660,all with diabetes ( n = $nmbr$ ),C0011847;C0011849
659,valvular disease ( % ),C3258293
659,valvular disease  mitral,C3258293
659,valvular disease,C3258293
659,severe disease,C1836348
659,extensive disease other,C0849867
659,$nmbr$ ( severe disease ),C1836348
658,patients with cardiac disorders  n ( % ) §,C0012634;C0018799;C0030705;C0741926
658,patients with cardiac disorders  n ( % ) c,C0012634;C0018799;C0030705;C0741926
658,no cardiac disease,C0018799
658,no apparent heart disease,C0018799;C0750489
658,isehemie heart disease,C0018799
658,cardiac disorders ( soc ),C0018799
658,cardiac disorder  n ( % ) §,C0018799
658,cardiac disorder,C0018799
658,cardiac disease,C0018799
657,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
657,unacceptable adverse events,C0877248;C1705413;C1883420
657,gall bladder adverse event ( n = $nmbr$ ),C0016976;C0877248
657,any early adverse event,C0877248;C1279919
657,any adverse event leading to study drug discontinuation  n ( % ),C0877248
657,any adverse event ( ae ),C0877248;C3887670
657,adverse events leading to premature treatment discontinuation,C0877248;C1705413
657,adverse events ( any grade ),C0877248;C1705413
657,adverse event,C0877248
656,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
656,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
656,evidence or thombus  n ( % ),C3887511
656,clinically evident vascular disease,C0042373;C3887511
655,tenecteplase and pci ( n = $nmbr$ ),C0872913
655,tenecteplase,C0872913
654,major diabetic eye disease  n ( % ),C0205082;C0205164;C0342245;C4318856;C4521762
654,diabetic eye disease,C0342245
654,diabetes status  no . ( % ),C1317301
654,diabetes status  n ( % ),C1317301
654,diabetes status,C1317301
654,diabetes mellitus status,C1317301
653,diabetes therapy at baseline ( alone or in combination ),C0168634;C1442488;C3274787;C3539002
653,diabetes therapy  n ( % ),C3274787;C3539002
653,diabetes therapy,C3274787;C3539002
652,catheterization performed for qualifying event,C0007430
652,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
652,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
652,catheter site — femoral,C0449652
652,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
651,three or more lesions,C0205449
651,three or more drugs,C0205449
651,three or more agents,C0205449
651,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
651,multivessel ( two vessel  three vessel  or left main ),C0205449;C4012475;C4037954
650,observed case,C0868928;C1441672;C1706255;C1706256
650,observed,C1441672
650,observation,C0302523;C0700325;C1964257;C3889687
649,absent ( < $nmbr$ mg / dl ),C0332197;C0439269;C4285062
649,absent,C0332197;C4285062
649,absence,C0332197;C1689985
648,fixed triple ( n = $nmbr$ ),C0205174;C0443218;C2827483;C3714578
648,adhere,C3714578
647,generalized,C0205246
647,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
647,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
647,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
647,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
647,general,C0205246;C3812897;C3891294;C4521767
646,previous pneumonia,C0032285;C0205156;C1552607
646,pneumonia,C0032285
646,neutropenia,C0023530;C0027947;C0853697
646,leukopenia,C0023530;C0750394
646,bacterial pneumonia,C0004626
645,romania,C0035826
645,indomethacin,C0021246
645,coumadin,C0699129
644,with tiotropium,C0213771
644,tiotropium vs . salmeterol,C0213771
644,tiotropium group ( n = $nmbr$ ),C0213771;C0441848
644,tiotropium + placebo ( n [ $nmbr$ ),C0032042;C0213771;C1696465;C1706408
644,tiotropium + placeb ( n [ $nmbr$ ),C0213771
644,tiotropium ( nz $nmbr$ ),C0027978;C0213771
644,tiotropium ( n z $nmbr$ ),C0213771
644,tiotropium ( n = $nmbr$ ),C0213771
644,tiotropium $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
644,tiotropium $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
644,tiotropium $nmbr$ meg ( n = $nmbr$ ),C0024489;C0025175;C0072225;C0213771
644,tiotropium $nmbr$ m g,C0213771;C0456715
644,tiotropium $nmbr$ . $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
644,tiotropium $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
644,tiotropium,C0213771
644,placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0032042;C0213771;C1518422;C1696465;C1706408
644,non - tiotropium,C0213771;C1518422
644,laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0332287;C0815320;C1696465;C1706408;C4551720
644,laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C1696465;C1706408
644,ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
644,formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0060657;C0213771;C1518422
644,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ ),C0213771;C1518422
644,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$,C0213771;C1518422
644,( tiotropium n = $nmbr$  placebo n =,C0032042;C0213771;C1696465;C1706408
644,( tiotropium n = $nmbr$  placebo n,C0032042;C0213771;C1696465;C1706408
643,regular alcohol consumption per week  no . ( % ),C0001948;C0205272;C0332174;C0439230
643,no alcohol consumption  on average,C0001948;C1510992;C2825518
643,drinking  n ( % ),C0001948;C0684271
643,drinking,C0001948;C0684271
643,alcohol use ( > $nmbr$ drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
643,alcohol use ( % ),C0001948
643,alcohol use ( %  > $nmbr$ / day ),C0001948;C0332173;C0439228;C0439505
643,alcohol use  n ( % ),C0001948
643,alcohol use  drinks / wk *,C0001948
643,alcohol use  drinks / wk,C0001948
643,alcohol use,C0001948
643,alcohol intake never / rarely,C0001948;C0522498;C2003901
643,alcohol intake ( a ),C0001948
643,alcohol intake ( + ) ( % ),C0001948
643,alcohol intake  drinks / week,C0001948
643,alcohol intake,C0001948
643,alcohol consumption at baseline,C0001948;C0168634;C1442488
643,alcohol consumption > once weekly,C0001948
643,alcohol consumption *,C0001948
643,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
643,alcohol consumption ( % ),C0001948
643,alcohol consumption !,C0001948
643,alcohol consumption  no . ( % ),C0001948
643,alcohol consumption  n ( % ),C0001948
643,alcohol consumption,C0001948
642,hub,C0063034;C1414372;C1708389
642,hps,C0242994
642,ho,C0019905;C1832110;C3889614
642,hc,C0020268;C0262499;C1413512
641,white  n ( % ) medical history  n ( % ),C0007457;C0043157;C0220938;C0262926;C1704706
641,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0003209;C0003211;C0010055;C0012000;C0019664;C0019665;C0042295;C0085805;C0262512;C0262926;C0536221;C0577559;C0577573;C0600653;C0745413;C0871470;C0918012;C1096155;C1306372;C1552854;C1637833;C1705255;C2004062;C2986546;C3152252;C3539882;C3813197;C4281799;C4283905
641,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,type $nmbr$ diabetes history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
641,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
641,seizure history  n ( % ),C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
641,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
641,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
641,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
641,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
641,prior cv history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
641,presenting history or diagnosis — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0449450;C1705255;C2004062
641,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
641,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
641,parental history of ml before age $nmbr$ y yes,C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
641,parental history of mi before age $nmbr$ y,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
641,other medical history — no . / total no . ( % ),C0262926;C1704706
641,other medical history — no . ( % ),C0262926;C1704706
641,other medical history  no . ( % ),C0262926;C1704706
641,oad history  years,C0019664;C0019665;C0262512;C0262926;C0439234;C1705255;C2004062
641,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
641,no history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
641,no history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
641,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
641,no history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
641,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
641,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,medical history — no . / total no . ( % ),C0262926;C1704706
641,medical history — no . ( % ),C0262926;C1704706
641,medical history — %,C0262926;C1704706
641,medical history of diabetic retinopathy §,C0011884;C0262926
641,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
641,medical history and risk factors — no . ( % ),C0262926;C1704706
641,medical history and risk factors ( % ),C0262926;C1704706
641,medical history and risk factors  no . / total ( % ) *,C0262926;C1704706
641,medical history and risk factors,C0262926;C1704706
641,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
641,medical history . no . ( % ),C0262926;C1704706
641,medical history ( % ),C0262926;C1704706
641,medical history    n   ( % ),C0262926;C1704706
641,medical history  no . ( % ),C0262926;C1704706
641,medical history  n ( % ),C0262926;C1704706
641,medical history,C0262926;C1704706
641,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C0011847;C0011849;C0015385;C0019664;C0019665;C0034510;C0065374;C0079399;C0085096;C0184661;C0262512;C0262926;C0280604;C0369773;C0581603;C1522384;C1704436;C1704675;C1705255;C1706779;C1709380;C2004062;C2603361;C2700391;C3274430;C3539779;C3542407;C3853635
641,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
641,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history ot chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
641,history ol mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
641,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
641,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
641,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
641,history of upper gl events ( perforations  ulcers  bleeding )  n ( % ),C0018229;C0019664;C0019665;C0041582;C0262512;C0262926;C0441471;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
641,history of upper gi events ( perforations  ulcers and bleeding ) n ( % ),C0019664;C0019665;C0041582;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
641,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
641,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
641,history of tia or stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
641,history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
641,history of tia  n ( % ),C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
641,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
641,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke or transient ischemic attack,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke or tia — no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke or tia - n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke or tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke at baseline,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke / see / tia  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke / see / tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke $nmbr$,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
641,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
641,history of second prior mi  n ( % ),C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
641,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
641,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
641,history of pci  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
641,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
641,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
641,history of oxygen use - yes  n ( % ),C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
641,history of or current cardiac disorders  %,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
641,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
641,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
641,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
641,history of more than $nmbr$ prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
641,history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi or stroke  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi or stroke  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of lvh on electrocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
641,history of lvh on echocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
641,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
641,history of htn  %,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
641,history of high cholesterol ( a ) $nmbr$,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
641,history of hf or lvef b $nmbr$ % with index event  no . ( % ),C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
641,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
641,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
641,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
641,history of elms  n ( % ),C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
641,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
641,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
641,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
641,history of diabetes { p = $nmbr$ * $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
641,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
641,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of cvd  n ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
641,history of coronary revascularization  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
641,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
641,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
641,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
641,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of chf  nyha class ii or iii — no . ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C1882085;C2004062
641,history of chf  n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of chd at baseline §,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of chd at baseline d  g,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of chd at baseline  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
641,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
641,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
641,history of cabg  n ( % ),C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history of bowel resections  n ( % ),C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
641,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
641,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
641,history of atrial arrhythmia  n ( % ),C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
641,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
641,history of amputation  no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
641,history of amputation  n ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
641,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
641,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
641,history of > $nmbr$ previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
641,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
641,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
641,history coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
641,history  pack - years,C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
641,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
641,fracture history ( predefined )  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,fracture history  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,ed history  n ( % yes ),C0019664;C0019665;C0262512;C0262926;C1549445;C1705108;C1705255;C1710701;C2004062;C3538926
641,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
641,cv disease history  no . ( % ) §,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
641,current smokers  n ( % ) medicai history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3173209;C3241966
641,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
641,copd exacerbation history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
641,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
641,clinical history  no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
641,clinical history  n ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
641,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,chd history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
641,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
641,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
641,cad history and risk factors  n ( % ),C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
641,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
641,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
641,any cv history / risk factors  n ( % ),C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
641,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
641,* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .,C0008107;C0009667;C0019664;C0019665;C0205210;C0205447;C0262512;C0262926;C0332849;C0428475;C0439165;C0439190;C0439241;C0441889;C0475211;C0549183;C0567349;C0876920;C1137094;C1522609;C1705255;C2004062;C2347285;C2347635;C2348144;C2348885;C2939193;C3259781
641,$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0001792;C0005847;C0008377;C0008976;C0010054;C0010055;C0012171;C0016327;C0018787;C0019664;C0019665;C0022671;C0023759;C0023779;C0023981;C0024027;C0035647;C0036453;C0038454;C0038952;C0039711;C0039798;C0074554;C0085542;C0085565;C0086153;C0087111;C0150158;C0184661;C0199176;C0204932;C0205082;C0205164;C0206579;C0220921;C0231220;C0239110;C0240951;C0242994;C0262512;C0262926;C0277793;C0280604;C0282416;C0420180;C0439394;C0439673;C0441471;C0441994;C0444504;C0446516;C0475224;C0489835;C0557651;C0565930;C0589120;C0591720;C0679698;C0680782;C0687676;C0745413;C0886296;C0948008;C1232424;C1260596;C1261512;C1273869;C1304680;C1522326;C1522577;C1522601;C1533734;C1545588;C1558950;C1561607;C1704685;C1704687;C1705169;C1705255;C1705493;C1706420;C1706495;C1736144;C1801960;C1947933;C1999167;C1999230;C2003888;C2004062;C2004580;C2347090;C2347634;C2348143;C2603343;C2603362;C2700409;C2930619;C2937358;C3274571;C3275277;C3469826;C3538994;C3541433;C3541888;C3542407;C3642216;C3642217;C3665546;C3669039;C3715044;C3810814;C3887704;C3898312;C4050014;C4084853;C4318856;C4521762;C4552904;C4553014;C4553528;C4554100
640,sample size ( n ),C0242618
640,sample size  n,C0242618
640,sample size,C0242618
640,effect size ^,C0814843
640,effect size !,C0814843
639,pharmaco - invasive n = $nmbr$,C0205281;C1334278
639,pharmaco - invasive ( n = $nmbr$ ),C0205281;C1334278
639,invasive,C0205281;C1334278
639,early invasive *,C0205281;C1279919;C1334278
639,early invasive $nmbr$,C0205281;C1279919;C1334278
638,increase creatinine  > $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
638,increase creatinine  < $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
638,estimated creatinine clearancet,C0010294;C0750572;C1561535
638,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
638,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
638,creatinine ≥ $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C1561535
638,creatinine — mg / dl,C0010294;C0439269;C1561535
638,creatinine ratio $nmbr$ - $nmbr$,C0010294;C0456603;C1547037;C1561535
638,creatinine ratio,C0010294;C0456603;C1547037;C1561535
638,creatinine clearanceb  ml / min,C0010294;C0439445;C1561535
638,creatinine ciearance,C0010294;C1561535
638,creatinine > $nmbr$ x baseline,C0010294;C0168634;C1442488;C1561535
638,creatinine > $nmbr$ . $nmbr$ x baseline and above uln,C0010294;C0168634;C1442488;C1561535
638,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
638,creatinine ( p  mol / l ),C0010294;C0347982;C1561535
638,creatinine ( mg / dl ),C0010294;C0439269;C1561535
638,creatinine  pmol / l,C0010294;C0439284;C1561535
638,creatinine  mmol 八,C0010294;C0439190;C1561535
638,creatinine  mg / dl_,C0010294;C0439269;C1561535
638,creatinine  mg / dl  mean,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143
638,creatinine  mg / dl,C0010294;C0439269;C1561535
638,creatinine,C0010294;C1561535
637,visits $nmbr$ e $nmbr$,C0545082;C1512346;C2826704
637,visit $nmbr$ sbp  mm hg,C0085805;C0439475;C0545082;C1512346;C2826704
637,visit $nmbr$ ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
637,visit $nmbr$ dbp  mm hg,C0439475;C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
637,visit $nmbr$ blood pressures :,C0545082;C1272641;C1512346;C2826704
637,visit,C0545082;C1512346;C2826704
637,sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
637,no . with visit,C0545082;C1512346;C2826704
637,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
637,ed visit related to exacerbation  n ( % ),C0545082;C1512346;C2826704;C3538926
637,ed severity  visit $nmbr$ * *,C0439793;C0522510;C0545082;C1512346;C2826704;C3538926
637,ed duration  visit $nmbr$ * *,C0449238;C0545082;C1512346;C2826704;C2926735;C3538926
637,dbp at visit $nmbr$,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
636,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
636,time to randomization from symptom onset,C0034656;C0040223;C3541383
636,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
636,time to randomization,C0034656;C0040223;C3541383
636,time to randomisation from symptom onset ( h ),C0034656;C0040223;C3541383
636,time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C0439227;C1704675;C3541383
636,time to first cv hospitalization or death from any cause,C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
636,time to angiography — hr,C0002978;C0040223;C3541383
636,time since start of fit  years ( meanisd ),C0040223;C3541383
636,time since start of fit  mean ( sd )  y,C0040223;C3541383
636,time since start insulin ( years ),C0040223;C3541383
636,time since rheumatoid arthritis diagnosis  years,C0040223;C3541383
636,time since randomization,C0040223;C3541383
636,time since qualifying event,C0040223;C3541383
636,time since psoriasis diagnosis  years $nmbr$,C0040223;C3541383
636,time since psa onset  mean years ( sd ),C0040223;C3541383
636,time since psa diagnosis ( years )  mean ( sd ),C0040223;C3541383
636,time since prior alendronate use  n ( % ),C0040223;C3541383
636,time since primary diagnosis,C0040223;C3541383
636,time since pd diagnosis  mean ± sd,C0040223;C3541383
636,time since pah diagnosisc ( years ),C0040223;C3541383
636,time since onset ( h ),C0040223;C3541383
636,time since most recent myocardial,C0040223;C3541383
636,time since ipf diagnosisa  mean years ( sd ),C0040223;C3541383
636,time since first psoriasis diagnosis ( y )  mean ( sd ),C0040223;C3541383
636,time since first luts ( years ),C0040223;C3541383
636,time since first copd diagnosis ( years ),C0040223;C3541383
636,time since first af diagnosis  yrs,C0040223;C3541383
636,time since epilepsy diagnosis ( years ),C0040223;C3541383
636,time since end of fit  mean ( sd )  y,C0040223;C3541383
636,time since diagnosis — mo,C0040223;C3541383
636,time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
636,time since diagnosis of type $nmbr$ diabetes - no . ( % ),C0040223;C3541383
636,time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
636,time since diagnosis of t $nmbr$ dm  y  n ( % ),C0040223;C3541383
636,time since diagnosis of t $nmbr$ dm,C0040223;C3541383
636,time since diagnosis of sle  years,C0040223;C3541383
636,time since diagnosis of psa ( years )  mean ( sd ),C0040223;C3541383
636,time since diagnosis of pah — yrf,C0040223;C3541383
636,time since diagnosis of pah years #,C0040223;C3541383
636,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
636,time since diagnosis of ln  years,C0040223;C3541383
636,time since diagnosis of heart failure,C0040223;C3541383
636,time since diagnosis of diabetesa  n ( % ),C0040223;C3541383
636,time since diagnosis of diabetes — no . ( % ),C0040223;C3541383
636,time since diagnosis of diabetes ( years ) ( median  iqr ),C0040223;C3541383
636,time since diagnosis of diabetes  n ( % ),C0040223;C3541383
636,time since diagnosis of diabetes  mean ( sd ),C0040223;C3541383
636,time since diagnosis of diabetes,C0040223;C3541383
636,time since diagnosis of copd  years,C0040223;C3541383
636,time since diagnosis of ciu / csuf ( y ),C0040223;C3541383
636,time since diagnosis of ciu / csu ( years ) $nmbr$,C0040223;C3541383
636,time since diagnosis  years,C0040223;C3541383
636,time since copd diagnosis ( yrs ),C0040223;C3541383
636,time since cessation of full - dose warfarin therapy,C0040223;C3541383
636,time since cabg,C0040223;C3541383
636,time since bph diagnosis ( years ),C0040223;C3541383
636,time since asthma diagnosis years,C0040223;C3541383
636,time since asthma diagnosis [ years ]  median ( range ),C0040223;C3541383
636,time since asthma diagnosis ( years ),C0040223;C3541383
636,time since asthma,C0040223;C3541383
636,time since as diagnosis ( years )  mean   ±   sd,C0040223;C3541383
636,time since as diagnosis ( years )  mean ( sd ),C0040223;C3541383
636,time since as diagnosis  mean ( sd ) years,C0040223;C3541383
636,time sample drawn ( h ),C0040223;C3541383
636,time of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C1704675;C3541383
636,time of randomization,C0034656;C0040223;C3541383
636,time in trial,C0040223;C3541383
636,time from randomization to pci — hr,C0034656;C0040223;C3541383
636,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C3541383
636,time from randomization to pci ( non - st - elevation mi )  h,C0034656;C0040223;C3541383
636,time from randomization to coronary angiography — hr,C0034656;C0040223;C3541383
636,time from randomization to cabg — hr,C0034656;C0040223;C3541383
636,time from randomisation to $nmbr$ st balloon inflation ( h ),C0034656;C0040223;C3541383
636,time from qualifying mi  yrs,C0040223;C1514624;C3541383;C3810814
636,time from qualifying mi  %,C0040223;C1514624;C3541383;C3810814
636,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
636,time from psoriatic arthritis diagnosis [ a ]  years,C0003872;C0011900;C0040223;C1704338;C1704656;C3541383
636,time from presentation to randomization — hr,C0040223;C0449450;C3541383
636,time from parkinson ’ s disease diagnosis in months  mean ( sd ),C0011900;C0030567;C0040223;C1704338;C1704656;C3541383
636,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
636,time from longest event to randomisation,C0040223;C0441471;C1522425;C3541383;C4019010
636,time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ ),C0040223;C0694649;C3541383
636,time from index acs event to randomisation ( days ),C0040223;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
636,time from hospitalization to randomization — hr,C0019993;C0040223;C3541383
636,time from event to randomization — days,C0040223;C0441471;C3541383;C4019010
636,time from acute coronary syndrome to randomization ( days ),C0040223;C0948089;C3541383
636,time from acs to randomization ( median  iqr ),C0040223;C0742343;C3541383;C4318612
636,time from acs to randomization,C0040223;C0742343;C3541383;C4318612
636,time between index acs and randomization — days,C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
636,time between index acs and randomization ( days ),C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
636,time ( sec ) *,C0040223;C0565930;C3541383
636,on oac at time of randomisation  n ( % ),C0034656;C0040223;C3541383
636,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
636,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
636,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
636,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
636,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0040223;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
636,mean time since diagnosis ( years ),C0040223;C0444504;C2347634;C2348143;C3541383
636,mean time since diagnosis  y,C0040223;C0444504;C2347634;C2348143;C3541383
636,mean time since asthma,C0040223;C0444504;C2347634;C2348143;C3541383
636,mean time since as diagnosis  years  mean ± sd,C0040223;C0444504;C2347634;C2348143;C3541383
636,at any time,C0040223;C3541383
636,$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .,C0040223;C0041536;C1079230;C3541383
635,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
635,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
635,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
635,higher risk ( n = $nmbr$ ),C0332167;C3272283;C4050568;C4319571
635,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
635,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
635,high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571
635,high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571
635,high risk *  %,C0332167;C3272283;C4050568;C4319571
635,high risk ( ri ≥ $nmbr$ ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
635,high risk ( n $nmbr$ $nmbr$ ),C0332167;C3272283;C4050568;C4319571
635,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
635,high risk ( > $nmbr$ ),C0332167;C3272283;C4050568;C4319571
635,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
635,high risk ( $nmbr$ - $nmbr$ ),C0332167;C3272283;C4050568;C4319571
635,high risk,C0332167;C3272283;C4050568;C4319571
635,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
635,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
635,high cardiovascular risk  n ( % ) ^,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
635,high - risk cvd  n ( % ),C0007222;C0332167;C3272283;C4050568;C4319571
635,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
635,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
635,high - risk,C0332167;C3272283;C4050568;C4319571
635,high ( > $nmbr$ risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
635,> $nmbr$ ( high risk ),C0332167;C3272283;C4050568;C4319571
634,— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
634,— $nmbr$ . $nmbr$ < fn t - score,C0449820;C1570610;C4050231
634,womac stiffness score,C0427008;C0449820;C4050231
634,womac score,C0449820;C4050231
634,ukpds $nmbr$ - year risk score > $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
634,ukpds $nmbr$ - year risk score < $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
634,tlmi risk score,C0035647;C0449820;C4050231;C4552904
634,timi risk score — no . / total no . ( % ) f,C0035647;C0449820;C4050231;C4552904
634,timi risk score — no . / total no . ( % ) : c,C0035647;C0449820;C4050231;C4552904
634,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
634,timi risk score — %,C0035647;C0449820;C4050231;C4552904
634,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
634,timi risk score > $nmbr$  n ( % ),C0035647;C0449820;C4050231;C4552904
634,timi risk score > $nmbr$  %,C0035647;C0449820;C4050231;C4552904
634,timi risk score *,C0035647;C0449820;C4050231;C4552904
634,timi risk score ( interaction : p = $nmbr$ . $nmbr$ ),C0035647;C0449820;C1704675;C4050231;C4552904
634,timi risk score $nmbr$ - $nmbr$,C0035647;C0449820;C4050231;C4552904
634,timi risk score !,C0035647;C0449820;C4050231;C4552904
634,timi risk score  n / n ( % ),C0035647;C0449820;C4050231;C4552904
634,timi risk score  %,C0035647;C0449820;C4050231;C4552904
634,timi risk score,C0035647;C0449820;C4050231;C4552904
634,tim $nmbr$ nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
634,stroke risk score,C0449820;C1277291;C4050231
634,shs ( $nmbr$ - $nmbr$  per $nmbr$ score ),C0449820;C4050231
634,sf - $nmbr$ score,C0037712;C0449820;C4050231
634,sf - $nmbr$ ( health transition score ),C0037712;C0376627;C0449820;C4050231
634,scores for global and pain assessments §,C0205246;C0449820;C2348867
634,score 一 no . ( % ),C0449820;C4050231
634,score on the minnesota living with heart failure scaled,C0026183;C0449820;C0595998;C4050231;C4520849;C4551704
634,score of > $nmbr$ . $nmbr$ — %,C0449820;C4050231
634,score of $ $nmbr$  no . ( % ),C0449820;C4050231
634,score of # $nmbr$  no . ( % ),C0449820;C4050231
634,score > $nmbr$ . $nmbr$,C0449820;C4050231
634,score > $nmbr$ %  % of patients,C0030705;C0449820;C4050231
634,score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or,C0449820;C4050231
634,score $nmbr$ . $nmbr$,C0449820;C4050231
634,score $nmbr$ - $nmbr$,C0449820;C4050231
634,score  no . ( % ),C0449820;C4050231
634,score  %,C0449820;C4050231
634,score,C0449820;C4050231
634,rope score * *,C0449820;C1563164;C4050231
634,rope score,C0449820;C1563164;C4050231
634,rentrop score,C0449820;C4050231
634,patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
634,pasi score > $nmbr$ *,C0449820;C4050231;C4528685
634,pasi score ( $nmbr$ - $nmbr$ ) d,C0449820;C4050231;C4528685
634,pasi score ( $nmbr$ - $nmbr$ ),C0449820;C4050231;C4528685
634,pasi score $nmbr$,C0449820;C4050231;C4528685
634,pasi score ! * *,C0449820;C4050231;C4528685
634,pasi score  $nmbr$ - $nmbr$ *,C0449820;C4050231;C4528685
634,pasi score,C0449820;C4050231;C4528685
634,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
634,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
634,modified rankin score,C0392747;C0449820;C3889737;C4050231
634,mhis score,C0449820;C4050231
634,mayo score ( $nmbr$ - $nmbr$ ),C0449820;C0454788;C1077578;C4050231
634,ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
634,jsn score ( $nmbr$ - $nmbr$ ),C0449820;C4050231
634,jsn score,C0449820;C4050231
634,joint space narrowing score  mean ( sd ),C0444504;C0449820;C1859695;C2347634;C2348143;C2699239;C4050231
634,joint space narrowing score,C0449820;C1859695;C4050231
634,iga mod $nmbr$ score  n ( % ),C0011860;C0449820;C2825347;C4050231
634,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
634,hit - $nmbr$ score,C0272285;C0332159;C0449820;C1708373;C4050231
634,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
634,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
634,framingham risk score  arbitrary units,C0035647;C0439183;C0449820;C3166866;C4050231;C4552904
634,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
634,fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
634,fn t - score < = - $nmbr$ . $nmbr$ ( % ),C0449820;C1570610;C4050231
634,flex fn f - score < - $nmbr$ . $nmbr$,C0016327;C0449820;C1570610;C4050231
634,femoral neck t - score,C0015815;C0449820;C4050231
634,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
634,femoral neck bmd t - score,C0015815;C0449820;C4050231
634,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
634,crusade score,C0449820;C4050231
634,crusade bleeding score,C0019080;C0449820;C4050231
634,crohn ' s disease activity index score ],C0449820;C0451071;C4050231
634,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
634,charlson comobility score  n ( % ),C0449820;C4050231
634,cha $nmbr$ s $nmbr$ score,C0449820;C1420648;C4050231
634,cha $nmbr$ ds $nmbr$ vasc score ( % ),C0449820;C1420648;C3714751;C4050231
634,cha $nmbr$ ds $nmbr$ vasc score,C0449820;C1420648;C3714751;C4050231
634,cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
634,cha $nmbr$ ds $nmbr$ - vasc score    n   ( % ),C0449820;C1420648;C3714751;C4050231
634,cha $nmbr$ ds $nmbr$ - vasc score,C0449820;C1420648;C3714751;C4050231
634,cadillac score,C0449820;C4050231
634,baseline dyspnea index score,C0449820;C1511069;C4050231
634,accp score,C0449820;C4050231
634,- $nmbr$ < flex fn f - score,C0016327;C0449820;C1570610;C4050231
634,- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
634,- $nmbr$ . $nmbr$ < ls t - score,C0023668;C0449820;C4050231
634,- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$,C0016327;C0449820;C1570610;C4050231
634,% improvement in enthesitis score at week $nmbr$  n,C0449820;C1282952;C2986411;C4050231
634,% improvement in dactylitis score at week $nmbr$  n,C0239161;C0449820;C2986411;C4050231
634,$nmbr$ ms score †,C0449820;C2349943;C3539704;C3713294;C4050231
633,patent foramen ovale,C0016522;C0344724
633,bare metal,C0025552
633,bare - metal,C0025552
632,rarely / never,C4035880
632,rarely,C0522498
631,married,C0024841;C0555047
631,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
631,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
630,lateral,C0205093
630,late load,C0205087
630,labd alone,C0396059
629,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
629,ale < $nmbr$,C0678386;C2632076
629,ale,C0678386;C2632076
628,large mi,C0549177;C3810814
628,large / very large,C0442824;C0549177;C2984081
628,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
627,atypical absence,C0595948
627,arterial access site,C3272298
627,arterial access,C0003842;C0221464;C0444454;C1554204
626,australia and new zealand,C0004340
626,australia / nz,C0004340;C0027978
626,australia,C0004340
625,africa or near east,C0001737
625,africa *,C0001737
625,africa ! near east,C0001737;C1707877
625,africa  asia  or the middle east,C0001737;C0003980
625,africa,C0001737
624,paracetamol,C0000970
624,acetaminophen,C0000970;C2917659
623,paclitaxel - eluting,C0144576
623,paclitaxel,C0144576
622,cataract removal,C0007389
622,cataract,C0086543;C4555209
622,african descent,C0027567
622,african,C0027567
621,vessels with stenosis > $nmbr$ %,C0679403
621,non - stenotic vessels  n ( % ),C0679403;C1518422
621,> $nmbr$ vessels with > $nmbr$ % stenosis,C0679403
620,polyvascular disease * status,C3176928
620,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
620,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
620,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
619,killip class — no . / total no . ( % ) i,C1881332
619,killip class — no . ( % ) i,C1881332
619,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
619,killip class > $nmbr$  no . ( % ),C1881332
619,killip class *,C1881332
619,killip class ( interaction : p = $nmbr$ . $nmbr$ ),C1704675;C1881332
619,killip class $nmbr$ / $nmbr$,C1881332
619,killip class $nmbr$,C1881332
619,killip class  n ( % ) i,C1881332
619,killip class  n ( % ),C1881332
619,killip class,C1881332
619,baseline killip class,C0168634;C1442488;C1881332
619,< $nmbr$ baseline killip class,C0168634;C1442488;C1881332
618,othery ethnicity  n ( % ) *,C0015031;C0243103
618,othery ethnicity  n ( % ),C0015031;C0243103
618,hispanic ethnicity  n ( % ),C0015031;C0086409;C0243103
618,hispanic ethnicity,C0015031;C0086409;C0243103
618,ethnicity t,C0015031;C0243103
618,ethnicity - no . ( % ),C0015031;C0243103
618,ethnicity ( % ),C0015031;C0243103
618,ethnicity $nmbr$ ',C0015031;C0243103
618,ethnicity  not hispanic / latino    n   ( % ),C0015031;C0243103
618,ethnicity  no . ( % ),C0015031;C0243103
618,ethnicity  n ( % ) b,C0015031;C0243103
618,ethnicity  n ( % ) :,C0015031;C0243103
618,ethnicity  n ( % ) *,C0015031;C0243103
618,ethnicity  n ( % ),C0015031;C0243103
618,ethnicity  location,C0015031;C0243103;C0450429;C1515974;C4284930;C4284931
618,ethnicity  hispanic / latino  n ( % ),C0015031;C0086409;C0086528;C0243103
618,ethnicity  %,C0015031;C0243103
618,ethnicity,C0015031;C0243103
618,ethnic origin white,C0007457;C0015031;C0043157;C0220938
618,ethnic origin *,C0015031
618,ethnic origin  n ( % ),C0015031
618,ethnic origin,C0015031
618,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
618,ethnic group — no . ( % ) ',C0015031;C1879937
618,ethnic group ( % ),C0015031;C1879937
618,ethnic group,C0015031;C1879937
618,ethnic background,C0015031
617,without p blockers,C0369773;C2603361
617,with p blockers,C0369773;C2603361
617,p   vs . placebo,C0369773;C2603361
617,p vs placebo,C0369773;C2603361
617,p valuey,C0369773;C2603361
617,p valuer,C0369773;C0401806;C2603361
617,p valuej ',C0369773;C2603361
617,p valued,C0369773;C2603361
617,p valuec,C0369773;C2603361
617,p valueb,C0369773;C2603361
617,p valuea,C0369773;C2603361
617,p vaiue ( interaction ),C0369773;C1704675;C2603361
617,p vaiue,C0369773;C2603361
617,p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
617,p interaction women vs men,C0043210;C0369773;C1704675;C2603361
617,p interaction,C0369773;C1704675;C2603361
617,p inter,C0369773;C2603361
617,p int . f,C0016327;C0369773;C2603361;C3272375
617,p inleraclion,C0369773;C2603361
617,p for interaction *,C0369773;C1704675;C2603361
617,p for interaction,C0369773;C1704675;C2603361
617,p for inter - act,C0369773;C2603361
617,p for i,C0021966;C0221138;C0369773;C2603361
617,p blockersubgroup,C0369773;C2603361
617,p blockers ( % ),C0369773;C2603361
617,p blockers,C0369773;C2603361
617,p blocker *,C0369773;C2603361
617,p blocker,C0369773;C2603361
617,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
617,p [ int ],C0369773;C2603361;C3272375
617,p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1959644;C2603343;C2603361
617,p : interaction,C0369773;C1704675;C2603361
617,p / interaction,C0369773;C1704675;C2603361
617,p . o ),C0369773;C2603361
617,p . interaction,C0369773;C1704675;C2603361
617,p - valuec,C0369773;C2603361
617,p - valueb,C0369773;C2603361
617,p - valuea,C0369773;C2603361
617,p - val . ( $nmbr$ ),C0042285;C0369773;C0523975;C2603361
617,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
617,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
617,p - interaction,C0369773;C1704675;C2603361
617,p - interactio n,C0369773;C2603361
617,p - inter,C0369773;C2603361
617,p - inte faction,C0369773;C2603361
617,p - int .,C0369773;C2603361;C3272375
617,p - int,C0369773;C2603361;C3272375
617,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
617,p - for interaetion,C0369773;C2603361
617,p - blockers ( % ),C0369773;C2603361
617,p - blockers  n ( % ),C0369773;C2603361
617,p - blockers,C0369773;C2603361
617,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
617,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
617,p - blocker intake at randomisation ( n = $nmbr$ o ),C0034656;C0369773;C1512806;C2603361
617,p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
617,p - blocker ( % ),C0369773;C2603361
617,p - blocker,C0369773;C2603361
617,p +,C0369773;C2603361
617,p *,C0369773;C2603361
617,p ) atients with > $nmbr$ exacerbations resulting in emergency department visit,C0369773;C2603361;C4086268
617,p ( women vs men ),C0043210;C0369773;C2603361
617,p ( losartan versus placebo ),C0126174;C0369773;C2603361
617,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
617,p ( inter ),C0369773;C2603361
617,p $nmbr$ z $nmbr$ ( n = $nmbr$ ),C0369773;C2603361
617,p $nmbr$ y $nmbr$ inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
617,p $nmbr$ y $nmbr$ inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
617,p $nmbr$ y $nmbr$ antagonists,C0243076;C0369773;C2603361
617,p $nmbr$ y $nmbr$ antagonist,C0231491;C0369773;C2603361
617,p $nmbr$ vs usual care,C0369773;C2603361
617,p $nmbr$ vs placebo,C0369773;C2603361
617,p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361
617,p $nmbr$ interaction women vs men,C0043210;C0369773;C1704675;C2603361
617,p $nmbr$ interaction,C0369773;C1704675;C2603361
617,p  regional difference *,C0369773;C0682132;C2603361
617,p  regional difference,C0369773;C0682132;C2603361
617,p  interaction !,C0369773;C1704675;C2603361
617,p  all vs all,C0369773;C2603361
617,p,C0369773;C2603361
617,no p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
616,medical historv,C0199168;C0205476
616,medical characteristics,C0199168;C0205476;C1521970
616,medical and lifestyle history,C0199168;C0205476
616,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C1279901
616,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
616,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
615,american ‐ indian / alaska native,C0002460
615,american indian or native alaskan,C0002460
615,american indian or alaskan native,C0002460
615,american indian or alaskan,C0002460
615,american indian or alaska native  :,C0002460
615,american indian or alaska native,C0002460
615,american indian or alaska,C0002460
615,american indian or,C0002460
615,american indian / native alaskan,C0002460;C0682125
615,american indian / alaskan native  n ( % ),C0002460;C0238611;C0302891;C0886378;C1524069
615,american indian / alaskan native,C0002460;C0238611
615,american indian / alaska native,C0002460
615,american indian /,C0002460
615,american indian  alaskan native  or aboriginal canadian,C0002460;C0238611
615,american indian,C0002460
614,surgical technique,C0683469
614,clinical endpoint,C2347784
614,clinical dementia rating score,C4304227
613,sustained mucosal healingc n / n ( % ),C0026724;C0443318
613,sustained mucosal healingc,C0026724;C0443318
613,mucosal healingf,C0026724
613,mucosal healingc n / n ( % ),C0026724
612,prior clinical fracture ( since age $nmbr$ ),C0016658;C0205210;C0332152;C2826257
612,no clinical or lesion rfs for st,C0205210
612,history of clinical fracture ( > $nmbr$ years old ),C0205210;C0439234;C1272071
612,history of clinical fracture ( > $nmbr$ years ),C0205210;C0439234;C1272071
612,durable clinical responseg,C0205210
612,durable clinical remissionh,C0205210
612,clinical responsed,C0205210
612,clinical remissione,C0205210
612,clinical outcome,C0205210;C1274040
612,clinical or lesion rf for st,C0205210
612,clinical indication at the index procedure  n ( % ),C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
612,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
612,clinical fracture,C0016658;C0205210
612,clinical details,C0205210;C1522508
612,clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated,C0205210
612,clinical and patient - reported characteristics at baseline and randomization,C0205210
612,clinical and laboratory measurements,C0205210
612,clinical ae  n ( % },C0205210;C3887670
612,clinical,C0205210
612,c clinical fractures ( fas ),C0016658;C0205210
612,any clinical or lesion rf for st,C0205210
612,any clinical ae,C0205210;C3887670
611,dilatative  n ( % ),C0002940;C0012359;C0700124;C1322279
611,dilatative,C0002940;C0012359;C0700124;C1322279
610,rivastigmine ( n = $nmbr$ ),C0649350
610,rivastigmine,C0649350
609,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
609,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
609,distal,C0205108;C4522154
609,digitalis  n ( % ),C0012252;C0304520
609,digitalis,C0012252;C0304520
608,thiazides,C0541746
608,thiazide users,C0541746;C1706077
608,thiazide,C0541746
608,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
607,oxidative stress,C0242606
607,medication effects,C1319171
607,medication adherence,C2364172
606,use oforal glucose - lowering agent — no . ( % ),C0042153;C0457083;C1947944
606,use ( % ),C0042153;C0457083;C1947944
606,use,C0042153;C0457083;C1947944
606,systemic glucocorticoid use at randomization  n ( % ),C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
606,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
606,sulfasalazine use at randomization    n   ( % ),C0034656;C0036078;C0042153;C0457083;C1947944
606,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
606,sirolimus - eluting stent use  n ( % ),C0038257;C0042153;C0072980;C0457083;C1947944
606,saba use in past $nmbr$ days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
606,saba use  occasions / weekt,C0042153;C0457083;C1947944
606,rotablator use  n ( % ),C0042153;C0457083;C1260867;C1947944
606,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
606,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
606,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
606,paclitaxel - eluting stent use  n ( % ),C0038257;C0042153;C0144576;C0457083;C1947944
606,other llt use,C0042153;C0457083;C1947944;C2347090
606,oam use [ n ( % ) ],C0042153;C0457083;C1947944
606,oad use  n ( % ),C0042153;C0457083;C1947944
606,no use,C0042153;C0457083;C1947944
606,no metformin use,C0025598;C0042153;C0457083;C1947944
606,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
606,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
606,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
606,multivitamin use,C0042153;C0301532;C0457083;C1947944
606,mtx use at randomization  n ( % ),C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
606,methotrexate use at randomization    n   ( % ),C0025677;C0034656;C0042153;C0457083;C1947944
606,metformin use,C0025598;C0042153;C0457083;C1947944
606,mesalamine use  n ( % ) a,C0042153;C0127615;C0457083;C1947944
606,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
606,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
606,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
606,low - dose aspirin use . strata *  n ( % ),C0042153;C0457083;C1947944;C2608320
606,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
606,lama use  n ( % ),C0042153;C0457083;C0999593;C1416775;C1947944
606,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
606,laba use  % patients,C0030705;C0042153;C0457083;C1947944
606,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
606,hrt use,C0042153;C0282402;C0457083;C1947944
606,cox - $nmbr$ selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
606,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
606,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
606,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
606,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
606,concomitant antibiotic use  n [ % ],C0003232;C0042153;C0457083;C0521115;C1947944
606,cholinesterase inhibitor use at baseline  no . ( % ),C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
606,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
606,cgm use,C0042153;C0457083;C1947944
606,care use,C0042153;C0457083;C1947933;C1947944
606,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
606,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
606,background laba use - yes  n ( % ),C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
606,background laba use,C0042153;C0457083;C1706907;C1947944
606,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
606,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
606,any use,C0042153;C0457083;C1947944
606,antithrombotic use before enrollment  no . ( % ),C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
606,antithrombotic use,C0042153;C0457083;C1947944
606,antiplatelet use,C0042153;C0457083;C1947944
606,anorexigen use,C0042153;C0457083;C1947944
606,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
605,ukraine,C0041580
605,ua ( n = $nmbr$ ),C0041580;C0042014
605,ua,C0041580;C0042014
604,self - reported disease severity  $nmbr$ - $nmbr$ scale *,C0175659;C0349674;C0521117;C0681906;C1947916;C2700446
604,self - reported descent  n ( % ),C0681906;C2700446
604,reported in ecrf,C0684224;C0700287;C4319718;C4551412
604,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
603,respiratory - related ^,C0439849;C0445223;C0521346;C1546767
603,related to study druga,C0439849;C0445223
603,diabetes - related medication use    n   ( % ),C0011847;C0011849;C0240320;C0439849;C0445223
602,dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0766326
602,dronedarone ( n = $nmbr$ ),C0766326
602,dronedarone,C0766326
601,extracranial carotid stenosis  n ( % ),C0007282;C0580586
601,carotid stenosis,C0007282
601,carotid artery stenosis  n ( % ),C0007282
601,aortic stenosis  n ( % ),C0003507
601,aortic stenosis,C0003507
600,degree of stenosis  % of diameter,C1301886;C4034225
600,$nmbr$ degree of ica stenosis 丰,C0201519;C4034225
599,current cigarette smoking  no . ( % ),C0239059;C0521116;C0700219;C1705970
599,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
599,cigarette smoking  n ( % ),C0239059;C0700219
599,cigarette smoking,C0239059;C0700219
599,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
599,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
598,use of compression stockings  no . ( % ),C0038348;C1524063
598,compression stockings,C0038348
597,primary trial end point,C0008976;C2986535
597,primary renal endpoint or death,C0022646;C2986535
597,primary renal endpoint,C0022646;C2986535
597,primary endpoint ’,C2986535
597,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
597,primary endpoint at $nmbr$ months,C0439231;C2986535
597,primary endpoint at $nmbr$ days,C0439228;C2986535
597,primary endpoint ^,C2986535
597,primary endpoint :,C2986535
597,primary endpoint $nmbr$,C2986535
597,primary endpoint,C2986535
597,primary end point |,C2986535
597,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
597,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
597,primary end point *,C2986535
597,primary end point  no . of events / total no . ( % ),C2986535
597,primary end point,C2986535
597,primary end - point,C2986535
597,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
597,nace ( primary endpoint ),C2986535
597,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
596,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0030705;C1709707
596,proportions  n ( % ),C1709707
596,proportion taking pulmonary medications ( % ) b,C1709707
596,proportion of responders n / n ( % ),C1709707
596,proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % ),C0030705;C1709707
596,proportion of patients who achieved acr $nmbr$ n / n ( % ),C0030705;C1709707
596,proportion of patients in corticosteroid - free clinical remission at week $nmbr$,C0030705;C1709707
596,proportion of days without heartburn at week $nmbr$  percentage,C0439228;C1709707
596,proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x,C0002994;C0332296;C0439228;C1709707;C1880497;C1996904
596,proportion,C1709707
596,fvc ( l ) proportion taking pulmonary medications ( % ) b,C1709707;C3714541
596,blood eosinophil proportion ( % ),C0014467;C1709707
595,non - early crohn ' s disease,C0010346;C1279919;C1518422
595,median crohn ' s disease duration  y ( range ),C0010346;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
595,history of crohn ' s disease surgery  n ( % ),C0010346;C0455610
595,early crohn ' s disease *,C0010346;C1279919
595,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
595,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
595,crohn ’ s disease related surgery,C0010346
595,crohn ' s disease duration,C0010346;C0449238;C2926735
595,crohn ' s disease - related medication at baseline  n ( % ),C0010346
595,crohn ' s disease,C0010346
594,current drinker,C0556297
594,alcohol users  n ( % ),C0556297
594,alcohol consumption ( % ) < $nmbr$ drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
594,alcohol > $nmbr$ drinks per week,C0332174;C0439230;C0556297
594,alcohol  % with > $nmbr$ drink / d,C0001948;C0556297
593,regions  n ( % ),C0017446;C0205147
593,region 一 no . ( % ),C0017446;C0205147
593,region — no . { % ),C0017446;C0205147
593,region — no . ( % ),C0017446;C0205147
593,region united states,C0017446;C0041703;C0205147
593,region ofthe world,C0017446;C0205147;C2700280
593,region ofenrollment — %,C0017446;C0205147
593,region of world — no . ( % ),C0017446;C0205147;C2700280
593,region of the world,C0017446;C0205147;C2700280
593,region of residence ( p = $nmbr$ $nmbr$ ),C0017446;C0205147;C0237096
593,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
593,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
593,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
593,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
593,region north america,C0017446;C0028405;C0205147
593,region n ( % ),C0017446;C0205147
593,region latin american,C0017446;C0205147
593,region :,C0017446;C0205147
593,region - north america,C0017446;C0028405;C0205147
593,region - no . ( % ),C0017446;C0205147
593,region - n ( % ),C0017446;C0205147
593,region *,C0017446;C0205147
593,region ( us ),C0017446;C0205147
593,region ( pooled ),C0017446;C0205147
593,region ( % ),C0017446;C0205147
593,region    n   ( % ),C0017446;C0205147
593,region  north america,C0017446;C0028405;C0205147
593,region  no . / total ( % ),C0017446;C0205147
593,region  no . ( % ) c,C0017446;C0205147
593,region  no . ( % ),C0017446;C0205147
593,region  n ( % ) a,C0017446;C0205147
593,region  n ( % ),C0017446;C0205147
593,region  latin america,C0017446;C0023122;C0205147
593,region  europe,C0015176;C0017446;C0205147
593,region  %,C0017446;C0205147
593,region,C0017446;C0205147
593,other ® region — no . ( % ),C0017446;C0205147
593,grouped region,C0017446;C0205147;C0439745;C4319846
593,geographical region ( % ),C0017446
593,geographical region  n ( % ),C0017446
593,geographical region,C0017446
593,geographic site  %,C0017446
593,geographic region — number ( % ),C0017446;C0237753;C0449788
593,geographic region — no . ( % ),C0017446
593,geographic region ^,C0017446
593,geographic region ?,C0017446
593,geographic region - other,C0017446
593,geographic region - north america,C0017446;C0028405
593,geographic region - europe,C0015176;C0017446
593,geographic region  n ( % ),C0017446
593,geographic region  %,C0017446
593,geographic region,C0017446
593,geographic location,C0017446
593,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
593,enrollment by region  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
593,age years geographic region,C0017446;C1510829
593,* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers,C0004340;C0015176;C0017446;C0205147;C0237753;C0449788;C1511726;C3245479;C3714741
592,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
592,venous,C0042449;C0348013
592,vein bypass stented,C0042449;C0741847
592,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
592,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
591,denosumab ( n = $nmbr$ ) n ( % ),C1690432
591,denosumab ( n = $nmbr$ ),C1690432
591,denosumab,C1690432
590,prior tnf inhibitor exposure  no . ( % ),C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
590,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
590,prior immunosuppressive exposure  n ( % ),C0021081;C0274281;C0332152;C0332157;C2826257
590,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
590,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
590,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
590,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
590,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
590,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
590,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
590,exposure,C0274281;C0332157
590,exposed ( n = $nmbr$ ),C0332157
590,exposed,C0332157
589,us resident,C1320928;C1549439;C2347958;C3835651
589,gastroduodenum,C0391900
589,gastroduodenal,C0450199
589,carotid imt,C0334121;C0741968;C1704614;C4318736
589,carotid,C0741968
588,vasoprotectives,C0304533
588,progestins,C0033306
588,gastroenteritis,C0017160
588,argentina,C0003761;C1504311
587,no nadroparin ( n = $nmbr$ ),C0206232
587,nadroparin vs control,C0206232
587,nadroparin ( n = $nmbr$ ),C0206232
587,nadroparin,C0206232
586,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
586,dihydropyridine ccbs,C0006684;C0012315;C0220821
586,dihydropyridine,C0012315;C0220821
585,thienopyridine use,C0042153;C0457083;C1120149;C1947944
585,thienopyridine type,C0332307;C1120149;C1547052
585,thienopyridine n = $nmbr$,C1120149
585,thienopyridine at baseline,C0168634;C1120149;C1442488
585,thienopyridine alone,C1120149
585,thienopyridine ( n = $nmbr$ ),C1120149
585,thienopyridine,C1120149
585,planned thienopyridine at enrollment,C1120149;C1709561
585,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
585,no thienopyridine,C1120149
585,- thienopyridine,C1120149
585,+ thienopyridine,C1120149
584,thiazolidinediones *,C1257987;C3541957
584,thiazolidinediones,C1257987;C3541957
584,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
584,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
584,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
584,thiazolidinedione no,C0289779;C1257987;C3537039
584,thiazolidinedione based,C0289779;C1257987;C3537039
584,thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039
584,thiazolidinedione,C0289779;C1257987;C3537039
584,any thiazolidinedione,C0289779;C1257987;C3537039
583,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
583,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
583,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
583,drug discontinuation not due to death,C0013227;C0457454;C1254351;C1444662;C4552847
583,discontinued,C1444662
583,discontinuations teaes,C0457454
583,discontinuations due to ae,C0457454;C0678226;C3887670
583,discontinuations,C0457454
583,discontinuation of lama prior to baseline  n ( % ),C0457454;C0999593;C1416775;C1444662;C4552847
583,discontinuation of ics / laba prior to baseline  n ( % ),C0457454;C0815320;C1444662;C4551720;C4552847
582,iv inotropic drug,C1971835
582,inotropic agent,C0304509
581,tiotropium + olodaterol $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
581,tiotropium + olodaterol $nmbr$ / $nmbr$,C4032878
581,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
580,ticagrelor pre ‐ hosp ( n = $nmbr$ ),C0332152;C0740175;C1999375;C2257086;C3669034
580,ticagrelor in ‐ hosp ( n = $nmbr$ ),C1999375
580,prehospital ticagrelor ( n = $nmbr$ ),C1999375
580,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
580,pre - hospital ticagrelor ( n = $nmbr$ ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
580,in hospital ticagrelor,C0019994;C1510665;C1999375
580,in - hospital ticagrelor ( n = $nmbr$ ),C0019994;C1510665;C1999375
579,trochanter,C0162370
579,intertrochanteric,C0745355
578,intracranial hemorrhage †,C0151699;C4554169
578,intracranial hemorrhage  n ( % ),C0151699;C4554169
578,intracranial hemorrhage,C0151699;C4554169
578,intracranial bleeding,C0151699
578,intracranial bleed,C0151699
577,prebronchodilator fevj ( % predicted ),C2599602
577,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
577,prebronchodilator fevi ( % predicted ),C0849974;C1561566;C2599602;C4528367
577,prebronchodilator fev $nmbr$ / fvc,C2599602;C3714541
577,prebronchodilator fev $nmbr$ ( l ) t,C2599602;C3714541
577,prebronchodilator fev $nmbr$ ( l ),C2599602;C3714541
577,prebronchodilator fev $nmbr$ ( % predicted normal ) t,C2599602;C3714541
577,prebronchodilator fev $nmbr$ ( %,C2599602;C3714541
577,prebronchodilator fev $nmbr$  l,C2599602;C3714541
577,prebronchodilator fev $nmbr$,C2599602;C3714541
577,prebronchodilator,C2599602
577,pre - bronchodilator fvc ’ % pred,C2599602;C3714541
577,pre - bronchodilator fvc ( l ),C2599602;C3714541
577,pre - bronchodilator fevr l,C1708033;C2599602
577,pre - bronchodilator fevr % pred,C1708033;C2599602
577,pre - bronchodilator fevj,C2599602
577,pre - bronchodilator fevi change,C0849974;C1561566;C2599602;C4528367
577,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
577,pre - bronchodilator fev ^ ( l ),C2599602;C3714541
577,pre - bronchodilator fev $nmbr$ / fvc ratio *,C0456603;C1547037;C2599602;C3714541
577,pre - bronchodilator fev $nmbr$ / fvc ( % ),C2599602;C3714541
577,pre - bronchodilator fev $nmbr$ ( l ),C2599602;C3714541
577,pre - bronchodilator fev $nmbr$ ( % predicted normal ),C2599602;C3714541
577,pre - bronchodilator fev $nmbr$  l *,C2599602;C3714541
577,pre - bronchodilator fev $nmbr$,C2599602;C3714541
577,pre - bronchodilator fev  ( l ),C2599602;C3714541
577,pre - bronchodilator,C2599602
577,a prebronchodilator fevl ( % predicted ),C2599602
576,postbronchodilator fevj ( % predicted ),C2599594
576,postbronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
576,postbronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
576,postbronchodilator fev $nmbr$  l,C2599594;C3714541
576,postbronchodilator fev $nmbr$  % predicted,C2599594;C3714541
576,postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C2599594
576,postbronchodilator,C2599594
576,post - bronchodilator percent of predicted fev $nmbr$  % ( sd ),C1882327;C2599594;C2699239;C3714541
576,post - bronchodilator fvc ( l ) a,C2599594;C3714541
576,post - bronchodilator fevx ( l ),C2599594
576,post - bronchodilator fev i reversibility  % b,C0021966;C0221138;C0449261;C2599594;C3714541
576,post - bronchodilator fev $nmbr$ — liters,C0475211;C2599594;C3714541
576,post - bronchodilator fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
576,post - bronchodilator fev $nmbr$ reversibility  % a,C0449261;C2599594;C3714541
576,post - bronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ml,C0439526;C1705224;C2599594;C3714541;C3887665
576,post - bronchodilator fev $nmbr$ / fvc ( % ) a,C2599594;C3714541
576,post - bronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ( l ) a,C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ( l ) *,C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ( l ),C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ( % predicted normal ) a,C2599594;C3714541
576,post - bronchodilator fev $nmbr$ ( % predicted * ),C2599594;C3714541
576,post - bronchodilator fev $nmbr$ % predictedb,C2599594;C3714541
576,post - bronchodilator fev $nmbr$  l *,C2599594;C3714541
576,post - bronchodilator fev $nmbr$  l,C2599594;C3714541
576,post - bronchodilator fev $nmbr$  % predicted of normal value,C2599594;C3714541
576,post - bronchodilator fev $nmbr$  % predicted,C2599594;C3714541
576,post - bronchodilator fev  reversibility,C0449261;C2599594;C3714541
576,post - bronchodilator fev  / fvc,C2599594;C3714541
576,post - bronchodilator fev  ( l ),C2599594;C3714541
576,post - bronchodilator fev  % predicted,C2599594;C3714541
576,post - bronchodilator fev   % predicted,C2599594;C3714541
576,post - bronchodilator,C2599594
576,b postbronchodilator fevl ( % predicted ),C2599594
575,non - extensive,C0205231;C1518422
575,no extensive colitis  n,C0009319;C0205231;C1963084
575,extensive colitisy,C0205231
575,extensive colitis or pancolitis,C0009319;C0205231;C1963084
575,extensive colitis  n,C0009319;C0205231;C1963084
575,extensive colitis,C0009319;C0205231;C1963084
575,extensive / pancolitis,C0205231;C0868908
575,extensive  n ( % ),C0205231
575,extensive,C0205231
574,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
574,troponin negative ( n = $nmbr$ ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
574,negative ctnl ( n = $nmbr$  $nmbr$ ),C0205160;C1513916;C2825415;C2825491;C3853545
574,negative ( < $nmbr$ . $nmbr$ )  n ( % ),C0205160;C1513916;C2825415;C2825491;C3853545
574,negative,C0205160;C1513916;C2825415;C2825491;C3853545
574,anti - gad negative ( n = $nmbr$ ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
574,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
573,stent thrombosis or mi,C3897493
573,stent thrombosis - related mi,C3897493
573,stent thrombosis *,C3897493
573,stent thrombosis,C3897493
573,non stent thrombosis - related mi,C1518422;C3897493
573,definite stent thrombosis,C0439544;C1704787;C3897493
573,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
573,any risk factor for stent thrombosis,C0035648;C3897493
573,acute stent thrombosis ( definite or probable ),C0205178;C3897493
573,acute stent thrombosis,C0205178;C3897493
572,increased waist circumference,C0205217;C0442805;C0455829
572,increased risk for thrombotic cardiovascular event ^  n ( % ),C0087086;C0205217;C0442805;C1273410
572,augment copd,C0205217
571,no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314
571,no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314;C0333307;C1959609
571,no new a or and no more than $nmbr$ new bilag b domain score  %,C0205314
571,new vertebral fracture at $nmbr$ months,C0080179;C0205314;C0439231
571,new use of gpa,C0205314;C1524063;C3495801;C4553145
571,new or worsentna neohrodathv,C0205314
571,new or worsening vertebral fracture at $nmbr$ months,C0205314
571,new or worsenina neohrodathv,C0205314
571,new or suspected thrombus,C0205314
571,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
571,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
570,patients with eot data  n,C2707520
570,* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .,C1880022;C2707520
569,daytime nasal symptoms score change from baseline  mean ± se,C0231918;C0332169
569,baseline daytime nasal symptoms score  mean ± sd,C0168634;C0231918;C0332169;C1442488
568,took prior antihyperglycemic agent ( any ),C1515187
568,taking statins  n ( % ) a,C0360714;C1515187
568,taking calcium supplements at baseline  n ( % ),C0006675;C0006726;C1515187;C2936886;C3540037;C3714611
568,taking antihypertensive treatment at,C1515187
568,taking antihypertensive medication at baseline  no . ( % ) e,C1515187
567,positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff,C0003241;C0035448;C0201660;C0439178;C0439596;C0741132;C1320283;C1446409;C1511572;C1514241;C2825490;C3812269;C4505301
567,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
567,anti - ccp antibody positive  n ( % ),C0432633;C0741132;C1525410;C1704514
567,anti - ccp antibody positive,C0741132;C4318437
567,anti - ccp antibody - positive  n ( % ),C0432633;C0741132;C1525410;C1704514
567,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
567,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
566,patients with specific disease characteristics  n ( % ),C0030705;C0205369;C0599878;C1552740
566,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
566,patients with specific disease characteris -,C0205369;C0683521;C1552740
566,patients with remission,C1277626
566,patients ' characteristics,C0815172
566,patient characteristics at randomization,C0034656;C0815172
566,patient characteristics,C0815172
565,potential predictor,C2698872;C3245505
565,potential injection site reactions,C0151735;C3245505
565,potassium - sparing diuretic,C0304490;C3536751
564,intention to treat,C0162425;C1283828
564,intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828
564,intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828
564,intention - to - treat,C0162425;C1283828
564,intent to use gp iib / iiia,C0162425;C1283828;C1550453
564,intent to use glycoprotein iib / iiia inhibitor,C0162425;C1283828;C1550453
564,intent to use dti,C0162425;C1283828;C1550453
564,intent to use direct thrombin,C0162425;C1283828;C1550453
564,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
564,intent of conservative strategy  %,C0162425;C0679199;C1283828;C1550453
564,intent - to - treatb,C0162425;C1283828;C1550453
564,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
563,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .,C0001288;C0030567;C0034394;C0165921;C0353697;C0681889;C1423759;C1521736;C3273355;C3639721;C4553228;C4553229
563,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
563,entacapone,C0165921
562,pathological q waves,C0429090
562,pathologic q waves — no . ( % ),C0429090
562,pathologic q waves  n ( % ),C0429090
562,electrophysiological study — no . ( % ) weight — ibj,C0850293
561,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
561,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
561,hemoglobin level  %,C0019029;C1314664
561,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
561,hemoglobin a ^ c  %,C0019020;C3889898
561,hemoglobin a $nmbr$ c ( % ),C0019020;C3889898
561,hemoglobin a $nmbr$ c  %,C0019020;C3889898
561,hemoglobin a $nmbr$ c,C0019020;C3889898
561,hemoglobin - a $nmbr$ c ( % ) ' • ■ * *,C0019020;C3889898
561,hemoglobin ( g r $nmbr$ ),C0205090;C0684010;C1319312;C2603358
561,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
561,hemoglobin ( g $nmbr$ ! ),C1319312
561,hemoglobin  g / dlf,C1319312
561,hemoglobin  g / dl,C0019046;C0439267;C1319312;C3642216
561,hemoglobin  g $nmbr$ $nmbr$,C1319312
561,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
560,troponin or ckmb value,C0041199
560,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
560,troponin ( - ),C0041199
560,troponin ( + ),C0041199
560,troponin $nmbr$ at baseline *,C0041199;C0168634;C1442488
560,troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
560,troponin,C0041199
559,troponin t ( pg / ml ),C0077404;C0439297;C1420827
559,troponin t,C0077404;C1420827
559,elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
558,theophyllines,C0039771
558,theophylline compound,C0039771;C0205198;C1706082
558,rolofylline rx,C0166128;C1425688;C1521941;C2709207
558,rolofylline n,C0166128
558,rolofylline ( n = $nmbr$ ),C0166128
558,rolofylline ( n = $nmbr$  $nmbr$ ),C0166128
558,rolofylline $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
558,rolofylline,C0166128
557,walking,C0080331;C4283795;C4321241;C4321242
557,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
557,no smo king,C1311076;C1364142;C1423784
557,hong kong,C0019907;C2987742
557,coping,C0009967
556,exenatide ± oad,C0167117
556,exenatide no . of events / total no . ( % ),C0167117
556,exenatide n = $nmbr$,C0167117
556,exenatide lar,C0167117
556,exenatide er,C0167117;C3810541;C3811131
556,exenatide,C0167117
555,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
555,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
555,no antidiabetic drug,C0935929
555,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
555,antidiabetic medications,C0935929
555,antidiabetic medication | |,C0935929
555,antidiabetic medication,C0935929
555,antidiabetic drug,C0935929
555,antidiabetic agents,C0935929
555,antidiabetic agent,C0935929
555,antidiabetic,C0935929
555,> $nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
555,$nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
554,rate estimate ( $nmbr$ % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
554,estimated response rate and odds ratio,C0237629;C0750572
554,estimated proportions ( % ) and odds ratios,C0750572;C1709707
554,estimated means and treatment differences ( % ),C0750572;C1704970
554,estimated means and difference,C0750572;C1704970
554,estimated glomerular filtration,C0232809;C0750572
554,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
554,estimated creatinine clearance — ml / min  i,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
554,estimated creatinine clearance < $nmbr$ rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
554,estimated creatinine clearance < $nmbr$ ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
554,estimated creatinine clearance < $nmbr$ ml / min *,C0439445;C0750572;C0812399
554,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
554,estimated creatinine clearance  !,C0750572;C0812399
554,estimated * creatinine clearance < $nmbr$ mlvmin  %,C0750572;C0812399
554,estimate ( $nmbr$ % cl ),C0596019;C0750572
554,estimate ( $nmbr$ % ci ),C0008107;C0750572;C3259781
553,investigator - reported hypoglycaemia *,C0035173
553,investigator - reported hypoglycaemia,C0035173
553,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
553,investigator - determined myocardial infarction,C0035173
553,investigator - defined drug - related aes,C0035173
552,stratified by,C0205363
552,stratified analyses,C0002778;C0205363;C0936012;C1524024
552,stent placement,C0522776
552,stent implanted — no . ( % ),C0522776
552,stent implanted,C0522776
551,vitamins,C0042890;C3540032;C3714649
551,vitamin e,C0042874;C3714803
551,other plain vitamin preparations,C0042890
551,i vitamin e ( n = $nmbr$ ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
551,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
551,$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ ),C0042874;C3714803
551,$nmbr$ vitamin e,C0042874;C3714803
550,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
550,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
550,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
550,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
550,$nmbr$ ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
549,vitamin c,C0003968;C2349136;C3714687;C4522080
549,vitality,C0424589
549,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
549,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
549,hospitalized !,C0701159
549,hospitalized,C0701159
548,utis,C0042029
548,uti,C0042029;C0077906;C1412376
548,urinary tract infection,C0042029;C0262655;C4554638
547,dual ii,C0205173;C1554184;C1710602;C4082587
547,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
547,dual antiplatelet,C0205173;C1554184
546,stating,C1301808;C1442792;C3148680
546,state,C1301808;C1442792;C3148680
546,metastatic,C0036525;C1522484;C4085632
546,epistaxis,C0014591;C4554627
545,statistic * *,C2348149;C2828391
545,sample statistics,C2348149
544,full po pulatio n,C0443225;C0946289
544,duration of full - dose warfarin therapy before enrollment ( mo ),C0366686;C0443225;C0444917
543,received $nmbr$ prior biologic therapy  n,C0278947;C1514756
543,received $nmbr$ prior biologic therapies  n,C0278947;C1514756
543,prior biologic therapy ( including anti - tnfs ),C0278947
542,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
542,lipid trial participants #,C0023779;C1997894;C2242969
542,lipid trial participants  no . ( % ),C0023779;C1997894;C2242969
542,lipid trial participants,C0023779;C1997894;C2242969
542,lioid trial participants,C1997894;C2242969
541,boost intensify premix i ( global patient population ),C1511253;C1874596
541,boost intensify all ( pan - asian patient population ),C1511253;C1874596
540,sacubitril / valsartan ( n = $nmbr$ ),C4033631
540,sacubitril / valsartan,C4033631
540,aliskiren / valsartan ( n = $nmbr$ ),C2733073
539,time to treatment  h,C0033727;C0369286;C0441932;C0564385;C3494202;C4528284
539,time to treatment,C3494202
539,teaes ( > $nmbr$ % in any treatment group ) *,C0374505
539,teaes ( > $nmbr$ % in any treatment group ),C0374505
539,on - treatment,C4684449
539,methotrexate treatment !,C0746573
539,conventional treatment ( n = $nmbr$ ),C2945704
539,conventional treatment,C2945704
539,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
539,active treatment,C1704532
538,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
538,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
538,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
538,serum creatinine — mg / dl,C0201976;C0439269;C0600061
538,serum creatinine level,C0600061
538,serum creatinine > $nmbr$ pmol / l . n ( % ) |,C0201976;C0439284;C0600061
538,serum creatinine > $nmbr$ mmol / l  n ( % ),C0201976;C0600061;C1532563
538,serum creatinine > $nmbr$ / xmol / l  n ( % ) | |,C0201976;C0600061
538,serum creatinine . mg / dl,C0201976;C0439269;C0600061
538,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
538,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
538,serum creatinine ( gmol / ),C0201976;C0600061
538,serum creatinine  弘 mol 儿 | |,C0027960;C0201976;C0324740;C0439189;C0600061;C1456781;C1824986;C3665593
538,serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl,C0201976;C0439269;C0600061
538,serum creatinine  μ mol / l,C0201976;C0347982;C0600061
538,serum creatinine  umol / lf,C0201976;C0439194;C0600061;C1416933;C2986618;C4554443
538,serum creatinine  mg / dlb,C0024671;C0026410;C0201976;C0439269;C0600061;C0752347;C1960952;C2346927;C3890365;C4321396;C4521761
538,serum creatinine  mg / dl,C0201976;C0439269;C0600061
538,serum creatinine  limo $nmbr$ $nmbr$,C0201976;C0600061
538,serum creatinine  gmol / l |,C0201976;C0600061
538,serum creatinine  ^ mol / l,C0201976;C0347982;C0600061
538,serum creatinine  / xmol / l | |,C0201976;C0600061
538,serum creatinine,C0201976;C0600061
538,preoperative serum creatinine > $nmbr$ pmol / l,C0201976;C0439284;C0445204;C0600061
538,increase in serum creatinine,C0201976;C0442805;C0600061
538,first serum creatinine,C0201976;C0205435;C0600061;C1279901
538,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
538,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0168634;C0201976;C0205173;C0600061;C1442488;C1705764
538,composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes,C0022658;C0201976;C0205088;C0205173;C0205199;C0600061;C1547335;C1705764
538,composite endpoint of doubling of serum creatinine  esrd,C0022661;C0035078;C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2316810;C2349179;C2826544
538,changes in serum creatinine  pmol / l,C0201976;C0392747;C0439284;C0443172;C0600061
538,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
537,with ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
537,severity ofhypertension [ n ( % ) ] b,C0439793;C0522510
537,severity of hypertensionb,C0439793;C0522510
537,severity of heartburnb,C0439793;C0522510
537,severity of copda  combined assessment of copd  n ( % ),C0439793;C0522510
537,severity of copd — no . ( % ) f,C0024117;C0439793;C0522510;C1412502;C3714496
537,severity of copd *  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
537,severity of copd  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
537,severity of copd  combined assessment  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
537,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
537,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
537,severity n ( % ),C0439793;C0522510
537,severity,C0439793;C0522510
537,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
537,no - ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
537,nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ],C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
537,luts severity,C0439793;C0522510;C0574785
537,lowzmedium intensity,C0522510
537,intensive therapy ( n = $nmbr$ ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
537,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
537,intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453
537,intensity $nmbr$,C0522510
537,intense,C0522510
537,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
537,ed severity * *  n ( % ) :,C0439793;C0522510;C3538926
537,ed severity  no . ( % ) a,C0439793;C0522510;C3538926
537,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
537,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
537,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
537,baseline luts severity  n ( % ) :,C0168634;C0439793;C0522510;C0574785;C1442488
537,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
537,baseline heart failure severity amongthose with priorheartfailure  %,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
537,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
537,any severity,C0439793;C0522510
536,chlor,C0308648
536,chl,C0019829
536,charm,C0849759
535,ct ratio > $nmbr$ . $nmbr$,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
535,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
535,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
535,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
535,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
535,ct,C0007673;C3540513;C3813556;C3888140
534,no cs and is,C0010182;C0271160;C3540510;C4085345
534,no cs and imm,C0010182;C0271160;C3540510;C4085345
534,neither cs nor imm,C0010182;C0271160;C3540510;C4085345
534,glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
534,glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
534,cs use : no,C0010182;C0271160;C3540510;C4085345
534,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
534,cs and is,C0010182;C0271160;C3540510;C4085345
534,cs and imm,C0010182;C0271160;C3540510;C4085345
534,cs and im,C0010182;C0271160;C3540510;C4085345
534,cs,C0010182;C0271160;C3540510;C4085345
533,concurrent prednisolone,C0032950;C0205420
533,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
533,concurrent medication,C0013227;C0205420;C3244316;C4284232
533,concurrent illness,C0205420;C0221423
533,concomitant therapy  no . ( % ),C1707479
533,concomitant therapy  n [ % ],C1707479
533,concomitant therapy,C1707479
533,concomitant therapies n ( % ),C1707479
533,concomitant therapies at hospital discharge,C0586003;C1707479
532,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
532,concomitant cardiovascular therapy ( taken > $nmbr$ days ),C0007226;C0521115;C0587038;C1707479;C3887460
532,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
532,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
532,cardiovascular therapies — no . { % ),C0587038
531,dihydropyridine calcium - channel blocker,C2945601
531,calcium channel,C0006685
531,calcium - channel inhibitor,C0006685;C1999216
531,calcium - channel blockersubgroup,C0006685
531,calcium - channel blockerf,C0006685
530,other combination,C0205195;C1947911;C3811910
530,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
530,golimumab combined ( n = $nmbr$ ),C0205195;C2353893
530,combined n = $nmbr$,C0205195
530,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
530,combined golimumab groups,C0205195;C2353893
530,combined fatal / nonfatal outcomes,C0205195;C0206277
530,combined estimated gfr and albuminuria status,C0205195
530,combined end poir,C0205195;C0444930;C2746065
530,combined end points,C0205195;C2349179
530,combined end point,C0205195;C2349179;C2826544
530,combined efficacy and safety endpoint,C0205195;C1280519;C1707887
530,combined chd,C0205195;C0280604;C3542407
530,combined ( n = $nmbr$ ),C0205195
530,combined,C0205195
530,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
530,combination - facilitated pci ( n = $nmbr$ ),C0205195;C1947911;C3811910
530,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
530,combination ( n = $nmbr$ ),C0205195;C1947911;C3811910
530,combination,C0205195;C1947911;C3811910
529,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
529,chest x - ray,C0039985
528,community hospital ( % ),C0020003
528,community hospital  n ( % ),C0020003
528,community hospital,C0020003
527,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
527,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
527,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
527,c peptide  nmol / l * ',C0006558;C0439282
527,c - peptide,C0006558
527,$nmbr$ - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
526,doubling of creatinine level,C0205173;C0428279;C1705764
526,creatinine level,C0428279
526,calcium level,C0201925;C0428302
525,scale — cognitive portion  ldl — low -,C0175659;C0349674;C0449719;C1516691;C1947916
525,cognitive,C1516691
524,cbz - naive,C0006949
524,cbz - exposed,C0006949
524,carbamazepine,C0006949;C0006950;C0682993
523,comorbidity  no . ( % ),C0009488
523,comorbidities other than diabetes,C0009488;C0011847;C0011849
523,comorbidities and concomitant medications,C0009488
523,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
523,comorbidities ( % ),C0009488
523,comorbidities  no . ( % ),C0009488
523,comorbidities  n ( % ) a,C0009488
523,comorbidities  %,C0009488
523,comorbidities,C0009488
523,comorbid illnesses,C0009488;C0221423
523,comorbid diseasesa diabetesb,C0009488
523,comorbid conditionsb,C0009488
523,co - morbidities  n ( % ),C0009488
523,co - morbidities  a n ( % ),C0009488
523,co - morbidities,C0009488
522,other - candesartan,C0717550
522,candesartan group ( n = $nmbr$ ),C0441848;C0717550
522,candesartan $nmbr$ / $nmbr$,C0717550
522,candesartan,C0717550
521,canada or united states,C0006823
521,canada,C0006823
520,mexico  central / south america,C0007674;C0025885;C0037713;C0205099;C1710133;C1879652
520,centre,C0205099;C3810851
520,central or south america,C0205099;C1879652
520,central and south america and mexico,C0205099;C1879652
520,central and south america,C0205099;C1879652
520,central and eastern europe,C0205099;C1879652
520,central / south america and mexico,C0007674;C0037713;C0205099;C1710133;C1879652
520,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
520,central / south,C0205099;C1710133;C1879652
520,central / eastern europe and russia hr ( $nmbr$ % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
520,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
520,central / eastern,C0205099;C1707877;C1879652
520,center location,C0205099
520,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
520,center,C0205099;C3810851
519,cyp $nmbr$ a $nmbr$ inhibitors,C0243077;C1418793;C2634343
519,cyp $nmbr$ a $nmbr$,C1418793;C2634343
518,canvas - r,C0205090;C0684010;C2603358;C3281223
518,canvas,C3281223
517,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
517,comparison : cat . $nmbr$ vs . cat . $nmbr$,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
517,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
517,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
517,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
517,cat > = $nmbr$ ( n = $nmbr$  $nmbr$ ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
517,cat > = $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
517,cat > $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
517,cat < $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
517,cat . $nmbr$ n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
516,postmenopausal  current hormone therapy use,C0019932;C0042153;C0232970;C0279025;C0457083;C0521116;C1705970;C1947944;C2827774;C4521914
516,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
516,currently smokes,C0521116
516,currently smoker,C0337664;C0521116
516,currently,C0521116
516,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
516,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
516,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
516,current prescribed medications,C0521116;C1705970;C3166216;C3202967
516,current other ( predefined ) medical conditions,C0521116;C1705970
516,current or prior smoking  %,C0521116;C1705970
516,current or previous atrial fibrillation,C0521116;C1705970
516,current or former smoker,C0521116;C1705970
516,current nonsmokers,C0337672;C0521116;C1705970;C4554605
516,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
516,current n z $nmbr$,C0521116;C1705970
516,current lra use,C0521116;C1705970
516,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
516,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
516,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
516,current enthesitis  n ( % ) ’,C0521116;C1282952;C1705970
516,current dactylitis  n,C0239161;C0521116;C1705970
516,current cigarette use  n ( % ),C0521116;C0694535;C1705970
516,current cigarette use,C0521116;C0694535;C1705970
516,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
516,current bone disease,C0005940;C0521116;C1705970
516,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
516,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0521116;C1705970
516,current alcohol use  n ( % ),C0001948;C0521116;C1705970
516,current alcohol drinking  n ( % ),C0001948;C0521116;C0556297;C1705970
516,current alcohol  n ( % ),C0001962;C0001975;C0521116;C1705970
516,current / past,C0521116;C1444637;C1705970;C4284302
516,current ( n   = $nmbr$  $nmbr$ ),C0521116;C1705970
516,current ( % ),C0521116;C1705970
516,current ( $nmbr$ + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
516,current (  $nmbr$ cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
516,current  n ( % ),C0521116;C1705970
516,current,C0521116;C1705970
515,types of antihypertensive medications at last visit   §,C0003364;C0332307
515,types of antihypertensive medications at $nmbr$ year   †,C0003364;C0332307
515,type of tnf failure  n ( % ) b,C0231174;C0332307;C0680095;C1547052;C3887647
515,type of tnf antagonist failure  n ( “ / o ) ”,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
515,type of tnf antagonist failure  n ( % ) ' ’,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
515,type of stent at index procedure,C0038257;C0332307;C1547052
515,type of mi ( % ),C0332307;C1547052;C3810814
515,type of mi,C0332307;C1547052;C3810814
515,type of hospital care,C0259945;C0332307;C1547052
515,type of des at index procedure,C0011702;C0332307;C1547052;C4551552
515,type of des,C0011702;C0332307;C1547052;C4551552
515,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052
515,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052
515,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
515,type of antihypertensive medication use among patients using antihypertensive medications  n ( % ),C0003364;C0332307;C1524063;C1547052
515,type of af  n ( % ),C0332307;C0344434;C1547052;C4049859
515,type of af,C0332307;C0344434;C1547052;C4049859
515,type ic,C0020750;C0332307;C1547052;C4554818
515,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
515,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
515,type / no . of valves repaired / replaced mitral,C0332307;C1547052
515,type $nmbr$  n ( % ),C0332307;C1547052
515,type,C0332307;C1547052
515,stent type implanted,C0038257;C0332307;C1547052
515,stent type,C0038257;C0332307;C1547052
515,qualifying mi type,C0332307;C1514624;C1547052;C3810814
515,phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
515,endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
515,des type,C0011702;C0332307;C1547052;C4551552
515,barc types $nmbr$  $nmbr$  or $nmbr$,C0332307
515,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
515,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
515,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
515,af type,C0332307;C0344434;C1547052;C4049859
515,> $nmbr$ type,C0332307;C1547052
515,> $nmbr$ des type,C0011702;C0332307;C1547052;C4551552
514,type of vessel involved,C1282017
514,two - vessel disease,C0581375
514,triple - vessel disease  n ( % ),C0856738
514,three - vessel disease,C3272265
514,one - vessel disease,C3275121
514,large vessel atherosclerosis,C0003850;C0004153;C0225990
514,large vessel,C0225990
513,target vessel diameter,C0449618;C1301886
513,target vessel,C0449618
513,stented vessels,C0183521
513,stented vessel,C0183521
513,small vessel,C0225988
513,number of target vessels,C0237753;C0449618;C0449788
513,no . of target vessels,C0449618
512,valvular heart disease — no . ( % ),C0018824;C1963123
512,valvular heart disease  n ( % ),C0018824;C1963123
512,valvular heart disease,C0018824;C1963123
512,structural heart disease — no . ( % ) f,C1290384
512,structural heart disease §,C1290384
512,structural heart disease,C1290384
512,cardiac valvular disease,C0018824
511,pulmonary vascular resistance  dyne • s • cm $nmbr$,C0308914;C0456261;C0488644;C0600130
511,jugular venous distention > $nmbr$ cm,C0425687
511,jugular venous distension  n ( % ),C0425687
510,vessel disease,C0042373
510,vascular disease,C0042373
510,previous vascular disease,C0042373;C0205156;C1552607
510,other vascular disease — no . ( % ),C0042373
510,other vascular disease ( cvd or pad )  %,C0007222;C0042373
510,other vascular disease,C0042373
510,number of vessels disease,C0042373;C0237753;C0449788
510,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
510,any vascular disease,C0042373
509,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
509,responder analyses ( achieving alc < $nmbr$ . $nmbr$ % ),C0002778;C0936012;C1524024
509,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
509,prespecified analysis,C0002778;C0936012;C1524024
509,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
509,pooled analysis of sustain $nmbr$ — $nmbr$ trials,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
509,patients ( full analysis sety )  n,C0002778;C0030705;C0443225;C0936012;C1524024
509,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
509,integrated analysis set ( n = $nmbr$ ),C0002778;C0936012;C1158478;C1524024;C1705422
509,included in analysis,C0002778;C0332257;C0936012;C1524024
509,full analysis set  n,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
509,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
509,final analysis ( all patients ),C0002778;C0205088;C0936012;C1524024;C1546485;C3853528
509,crude analysis  n ( % ),C0002778;C0936012;C1524024
509,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0936012;C1524024
509,analysis,C0002778;C0936012;C1524024
509,$nmbr$ days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
508,treated with pci — no . / total no . ( % ),C0332293;C4049621
508,tertile $nmbr$ index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
508,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
508,secondary pci,C0027627;C0175668;C0205436;C4049621
508,reteplase / abciximab - facilitated pci ( n = $nmbr$ ),C0256103;C0288672;C4049621
508,ret / abx - facil . pci,C0389252;C4049621
508,received pci,C1514756;C4049621
508,prior pci or cabg surgery,C0332152;C2826257;C4049621
508,prior pci or cabg,C0332152;C2826257;C4049621
508,prior pci  %,C0332152;C2826257;C4049621
508,prior pci,C0332152;C2826257;C4049621
508,prerandomization pci,C4049621
508,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
508,pci — no . { % ),C4049621
508,pci — no . ( % ),C4049621
508,pci postindex event,C0441471;C4019010;C4049621
508,pci performed,C4049621
508,pci orcabg,C4049621
508,pci or cabg surgery for index event,C4049621
508,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
508,pci duration,C0449238;C2926735;C4049621
508,pci delay due to low risk,C4049621
508,pci alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C4049621
508,pci > $nmbr$ month ago,C0332177;C0439231;C4049621
508,pci :,C4049621
508,pci ( % ),C4049621
508,pci  n ( % ),C4049621
508,pci,C4049621
508,no prior pci,C0332152;C2826257;C4049621
508,no pci or cabg — no . ( % ),C4049621
508,no pci,C4049621
508,multivessel pci,C4049621
508,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
508,index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
508,facilitated pci ( n = $nmbr$ ),C4049621
508,combo - facilitated pci,C4049621
508,before pci,C4049621
508,after pci,C4049621
508,abx - facil . pci,C4049621
508,abciximab - facilitated pci ( n = $nmbr$ ),C0288672;C4049621
508,abciximab - facilitated pci,C0288672;C4049621
508,$nmbr$ vessel pci,C0005847;C4049621
507,bb after randomisation,C0004739;C0034656;C0332297
507,bb,C0004739;C0332297
507,- < — ■ bb — - ►,C0004739;C0332297
506,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
506,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
506,bl h / y : unilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
506,bl h / y : bilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
506,bl bml > $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
506,bl bml > $nmbr$ ke / m ^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
506,bl bml < $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
506,bl bmioo kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
506,bl bm $nmbr$ < $nmbr$ kg / m ^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
506,bl,C0005918;C0006413;C1552663;C2827109
506,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
505,plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005893;C0006448;C0006539;C0008377;C0017887;C0019664;C0019665;C0020538;C0022709;C0030125;C0041004;C0042295;C0181074;C0205120;C0205210;C0262512;C0262926;C0332288;C0332835;C0439190;C0489786;C0578022;C0885378;C1305855;C1452534;C1552595;C1705255;C1820373;C1879745;C1883728;C1961139;C1963138;C2004062;C2828386;C2936173;C3854028;C4321248;C4522126
505,obese ( bmi £ $nmbr$ ),C0028754;C0578022
505,median body mass index  kg / m $nmbr$ ( range ),C0005893;C0549183;C0578022;C0876920;C1305855;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
505,median body mass index  kg / m $nmbr$ ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
505,mean body - mass index  kg / m $nmbr$   ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
505,mean body - mass index  kg / m $nmbr$ ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
505,mean bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
505,bodymass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
505,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
505,body mass index mean kg / m $nmbr$ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
505,body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
505,body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
505,body mass index category  no . ( % ) l,C0005893;C0578022;C0683312;C1305855;C3889287
505,body mass index ^,C0005893;C0578022;C1305855
505,body mass index > $nmbr$ — no . ( % ) f,C0005893;C0578022;C1305855
505,body mass index > $nmbr$ t,C0005893;C0578022;C1305855
505,body mass index > $nmbr$ kg / m $nmbr$ *,C0005893;C0578022;C1305855;C1532718
505,body mass index > $nmbr$ kg / m $nmbr$  n ( % ),C0005893;C0578022;C1305855;C1532718
505,body mass index > $nmbr$ kg / m  n ( % ),C0005893;C0578022;C1305855;C1532718
505,body mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
505,body mass index < $nmbr$ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body mass index :,C0005893;C0578022;C1305855
505,body mass index - kg / m $nmbr$ t,C0005893;C0578022;C1305855;C1532718
505,body mass index +,C0005893;C0578022;C1305855
505,body mass index *,C0005893;C0578022;C1305855
505,body mass index ( range ) ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
505,body mass index ( mg / m $nmbr$ ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
505,body mass index ( kgm _ $nmbr$ ),C0005893;C0578022;C1305855
505,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
505,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
505,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m ^ ) ^,C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m ^ ),C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m $nmbr$ ) ∗,C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m $nmbr$ ) * ',C0005893;C0578022;C1305855;C1532718
505,body mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
505,body mass index ( bmi )  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
505,body mass index $nmbr$,C0005893;C0578022;C1305855
505,body mass index  mean kg / m ^ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
505,body mass index  kg / m ’,C0005893;C0578022;C1305855;C1532718
505,body mass index  kg / m ^ ^,C0005893;C0578022;C1305855;C1532718
505,body mass index  kg / m ^ ( meanisd ),C0005893;C0578022;C1305855;C1532718
505,body mass index  kg / m ^,C0005893;C0578022;C1305855;C1532718
505,body mass index  kg / m $nmbr$   ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
505,body mass index  kg / m $nmbr$ ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
505,body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
505,body mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body mass index  * kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body mass index  %,C0005893;C0578022;C1305855
505,body mass index,C0005893;C0578022;C1305855
505,body - mass index ”,C0005893;C0578022;C1305855
505,body - mass index — no . ( % ) : i :,C0005893;C0578022;C1305855
505,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
505,body - mass index §,C0005893;C0578022;C1305855
505,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
505,body - mass index ^ :,C0005893;C0578022;C1305855
505,body - mass index ^,C0005893;C0578022;C1305855
505,body - mass index \ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body - mass index > $nmbr$ kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
505,body - mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
505,body - mass index > $nmbr$,C0005893;C0578022;C1305855
505,body - mass index : ! :,C0005893;C0578022;C1305855
505,body - mass index - kg / m $nmbr$  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
505,body - mass index - ! ',C0005893;C0578022;C1305855
505,body - mass index *,C0005893;C0578022;C1305855
505,body - mass index ) -,C0005893;C0578022;C1305855
505,body - mass index ) ',C0005893;C0578022;C1305855
505,body - mass index ),C0005893;C0578022;C1305855
505,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
505,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
505,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m   $nmbr$ ),C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m $nmbr$ ) t,C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m $nmbr$ ) *,C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
505,body - mass index ( kg / cm $nmbr$ ),C0005893;C0578022;C1305855;C4054689
505,body - mass index $,C0005893;C0578022;C1305855
505,body - mass index  kq / nrn,C0005893;C0578022;C1305855;C1425210
505,body - mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
505,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
505,body - mass index  !,C0005893;C0578022;C1305855
505,body - mass index,C0005893;C0578022;C1305855
505,bmi   kg · m − $nmbr$,C0578022;C1532718
505,bmi o $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
505,bmi kg · m − $nmbr$,C0578022;C1532718
505,bmi kg - m - $nmbr$,C0578022;C1532718
505,bmi category ( kg / m $nmbr$ ),C0578022;C0683312;C1532718;C3889287
505,bmi category ( % ),C0578022;C0683312;C3889287
505,bmi category  no . ( % ),C0578022;C0683312;C3889287
505,bmi categories  n ( % ),C0578022;C0683312
505,bmi a $nmbr$,C0578022
505,bmi ^,C0578022
505,bmi [ kg / m $nmbr$ ],C0578022;C1532718
505,bmi > = $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi > = $nmbr$,C0578022
505,bmi > $nmbr$ — no . { % ) $,C0578022
505,bmi > $nmbr$ — no . ( % ) f,C0578022
505,bmi > $nmbr$ obese,C0578022
505,bmi > $nmbr$ kg / m $nmbr$ *,C0578022;C1532718
505,bmi > $nmbr$ kg / m $nmbr$ ( % ),C0578022;C1532718
505,bmi > $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
505,bmi > $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi > $nmbr$ ( % ),C0578022
505,bmi > $nmbr$  n ( % ),C0578022
505,bmi > $nmbr$,C0578022
505,bmi < = $nmbr$,C0578022
505,bmi < $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi < $nmbr$,C0578022
505,bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi - kg / m $nmbr$,C0578022;C1532718
505,bmi ( sd )  kg / m $nmbr$,C0578022;C1532718;C2699239
505,bmi ( kg = m $nmbr$ ),C0578022;C1532718
505,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
505,bmi ( kg / m ’ ),C0578022;C1532718
505,bmi ( kg / m ^ ),C0578022;C1532718
505,bmi ( kg / m ),C0578022;C1532718
505,bmi ( kg / m $nmbr$ ) a,C0578022;C1532718
505,bmi ( kg / m $nmbr$ ) < $nmbr$,C0578022;C1532718
505,bmi ( kg / m $nmbr$ ) *,C0578022;C1532718
505,bmi ( kg / m $nmbr$ ) ( sd ),C0578022;C1532718;C2699239
505,bmi ( kg / m $nmbr$ ),C0578022;C1532718
505,bmi ( kg / ( m ) $nmbr$ ),C0578022;C1532718
505,bmi ( . kg / m - ) *,C0578022;C1532718
505,bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0578022
505,bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,C0578022
505,bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$,C0578022
505,bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$,C0578022
505,bmi $nmbr$,C0578022
505,bmi # kg - m “ $nmbr$,C0578022;C1532718
505,bmi  x $nmbr$ kg / m $nmbr$,C0578022;C1532718
505,bmi  no . ( % ),C0578022
505,bmi  n ( % ),C0578022
505,bmi  mean ± sd kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
505,bmi  mean ± sd  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
505,bmi  mean  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
505,bmi  kg per m $nmbr$,C0578022;C1532718
505,bmi  kg / m ’,C0578022;C1532718
505,bmi  kg / m ^ *,C0578022;C1532718
505,bmi  kg / m ^,C0578022;C1532718
505,bmi  kg / m $nmbr$ uac  no . ( % ),C0578022;C1532718
505,bmi  kg / m $nmbr$ ( sd ),C0578022;C1532718;C2699239
505,bmi  kg / m $nmbr$  n ( % ),C0578022;C1532718
505,bmi  kg / m $nmbr$  n,C0578022;C1532718
505,bmi  kg / m $nmbr$  mean,C0444504;C0578022;C1532718;C2347634;C2348143
505,bmi  kg / m $nmbr$,C0578022;C1532718
505,bmi,C0578022
505,* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .,C0001779;C0002871;C0004083;C0005893;C0005910;C0009253;C0010055;C0018787;C0025266;C0027976;C0030705;C0032042;C0034510;C0036864;C0040223;C0040363;C0041260;C0042295;C0043100;C0079399;C0086715;C0184661;C0205088;C0205447;C0332288;C0332307;C0332490;C0376558;C0439175;C0439209;C0439810;C0439849;C0441074;C0441833;C0441889;C0441994;C0445022;C0449820;C0475211;C0522523;C0578022;C0596306;C0596672;C0687744;C0699792;C0804628;C0886296;C1000483;C1144709;C1257890;C1273869;C1275491;C1281911;C1292769;C1305855;C1305866;C1314687;C1317554;C1444637;C1452534;C1519504;C1522384;C1547052;C1548802;C1696465;C1705104;C1705314;C1705315;C1705428;C1705429;C1706408;C1706779;C1719797;C1882084;C1883351;C2003888;C2709270;C2825907;C2911648;C3537020;C3541383;C3827682;C3853635;C4284014;C4284038;C4284302;C4554633
505,$nmbr$ bmi  kg / m,C0578022;C1532718
505,$nmbr$ < bmi < $nmbr$,C0578022
504,patients with evaluable endoscopy,C0014245;C2986511
504,endoscopy subscore  n ( % ),C0014245
504,endoscopy subscore,C0014245
504,endoscopic disease severity,C0014245;C0442418;C0521117
503,prior use of osteoporosis medications  n ( % ),C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
503,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
503,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
503,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
503,osteoporosis,C0029456;C4554622
502,pulsed blood pressure,C0232108
502,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
502,baseline systolic blood pressure,C4274438
501,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0023779;C0168634;C0597357;C1442488
501,receptor blockers  n ( % ),C0597357
501,receptor blockers,C0597357
501,receptor blocker,C0597357
500,obesity t,C0028754;C1963185
500,obesity *,C0028754;C1963185
500,obesity ( % ) §,C0028754;C1963185
500,obesity  % *,C0028754;C1963185
500,obesity,C0028754;C1963185
500,obese,C0028754
500,> $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
500,$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
499,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
499,model $nmbr$ §,C3161035;C3274659;C3714583;C3853906
499,model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
499,model $nmbr$ +,C3161035;C3274659;C3714583;C3853906
499,model $nmbr$,C3161035;C3274659;C3714583;C3853906
499,model  n,C3161035;C3274659;C3714583;C3853906
499,crude model hr ( $nmbr$ % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
499,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
498,daily bowel movements,C0011135;C0332173
498,bowel function,C0011135
497,c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
497,c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
497,c $nmbr$ e $nmbr$ fab bolus,C1186706;C1511237;C1705509;C3812160
497,bolus of heparin given,C0019134;C0770546;C1186706;C1511237;C1705509;C3812160
497,bolus and infusion,C1186706;C1511237;C1705509;C3812160
497,bolus and corrections,C1186706;C1511237;C1705509;C3812160
497,bolus alone,C1186706;C1511237;C1705509;C3812160
497,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
497,bolus,C1186706;C1511237;C1705509;C3812160
497,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
496,glycemic status f,C0016327;C1320980
496,glycemic status,C1320980
496,glycemic indexes,C1136206
496,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
496,albumin measurements ^ ^,C0201838
495,dm - ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
495,dm + ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
495,aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C1120110;C3250443
495,aliskiren ( n = $nmbr$ ),C1120110
495,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
495,aliskiren,C1120110
494,sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ],C0037712;C1880389;C1883221;C3541951
494,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
494,iief - ef domain score  visit $nmbr$ y,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
494,iief - ef domain score  visit $nmbr$ * *,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
494,ibdq domain scores  mean [ sd ],C1880389;C1883221;C3541951
494,ef domain,C1880389;C1883221;C3541951
493,syndrome  n ( % ),C0039082
493,specific syndromes,C0039082;C0205369;C1552740;C1558916
493,nonmetabolic syndrome ( n = $nmbr$ ),C0039082
493,cardiometabolic syndrome  ^ n ( % ),C0039082
492,stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
492,statin during admission,C0184666;C0360714;C0809949
492,risk level at admission,C0184666;C0809949;C2923839
492,potassium at admission  mmol / l - $nmbr$,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C1532563;C3714637
492,p blocker before admission,C0184666;C0369773;C0809949;C2603361
492,no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
492,no statin during admission,C0184666;C0360714;C0809949
492,medical therapy before admission,C0184666;C0418981;C0809949
492,before admission )  %,C0184666;C0809949
492,aspirin before admission,C0004057;C0184666;C0809949
492,admission k  mmol / l,C0184666;C0597277;C0809949;C1532563;C1708601
492,admission grace score,C0184666;C0809949
492,admission crcl,C0184666;C0809949;C1846718
492,$nmbr$ blocker before admission,C0184666;C0809949
491,steroid - sparing remission *,C0038317;C0544452;C0687702
491,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
491,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
491,remission  n ( % ),C0544452;C0687702
491,remission,C0544452;C0687702
491,das $nmbr$ - esr remission  %,C0051767;C0057671;C0544452;C0687702;C3811131
491,das $nmbr$ - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
491,das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %,C0051767;C0057671;C0444504;C0544452;C0687702;C2347634;C2348143;C2699239;C3811131
491,asdas inactive disease  %,C0544452
490,ifx + aza ( n = $nmbr$ ),C0004482;C0020823
490,azathioprine monotherapy,C0004482
490,azathioprine ( n = $nmbr$ ),C0004482
490,azathioprine,C0004482
490,aza ( n = $nmbr$ ),C0004482
489,ipah / hpah,C0152171;C0340543;C0637939;C1150929
489,ipah  hpah  hiv  drug or toxin induced,C0013227;C0019682;C0019699;C0152171;C0340543;C0637939;C1150929;C1254351
488,time from onset of pain to randomization — hr,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
488,pain  mm,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
488,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
487,year from randomization,C0034656;C0439234;C0439508
487,vka at randomization,C0034656
487,treatmentofpulmonary embolismpriorto randomization,C0034656
487,to randomization,C0034656
487,thienopyridine at randomization,C0034656;C1120149
487,renal function at randomization,C0034656;C0232804
487,randomized treatments  n ( % ),C0034656;C0087111;C3815594
487,randomized treatment  % ( n ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
487,randomized to receiveaspirin,C0034656;C3815594
487,randomized to receive vitamin e,C0034656;C3815594
487,randomized to receive beta carotene,C0034656;C3815594
487,randomized to receive aspirin yes,C0034656;C3815594
487,randomized to canakinumab $nmbr$ mg,C0034656;C3815594
487,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
487,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
487,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
487,randomized < $nmbr$ hr after presentation — %,C0034656;C0449450;C3815594
487,randomized  double - blind reversal phase ( baseline = week $nmbr$ ),C0034656;C3815594
487,randomized,C0034656;C3815594
487,randomization to end of study,C0034656
487,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
487,randomization to angiography,C0002978;C0034656
487,randomization to,C0034656
487,randomization stratum,C0034656
487,randomization groups $nmbr$ and $nmbr$,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
487,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
487,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
487,randomization - to - angiography,C0002978;C0034656
487,randomization - to -,C0034656
487,randomization ),C0034656
487,randomization  n ( % ),C0034656
487,randomization,C0034656
487,randomisation scheme,C0034656;C1519193
487,randomisation,C0034656
487,other llt at randomization,C0034656;C2347090
487,no vka at randomization,C0034656
487,no . randomized,C0034656;C3815594
487,nihss at randomization  $nmbr$ - $nmbr$,C0034656;C1697238
487,nihss at randomization,C0034656;C1697238
487,medications at timing of randomization  n ( % ),C0034656;C2359859
487,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981
487,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
487,length of stay ( randomization to discharge  h ),C0023303;C0034656
487,labs at randomization,C0034656;C0587081
487,killip class iv at randomization,C0034656;C2697847
487,index stroke > $nmbr$ days before randomization — no . ( % ),C0034656;C0439228;C0456712
487,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
487,heparin at randomization,C0019134;C0034656;C0770546
487,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
487,edoxaban at randomization  n ( % ),C0034656;C2975435
487,diabetes at randomization,C0011847;C0011849;C0034656
487,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
487,creatinine clearance at randomization,C0034656;C0812399
487,coronary revascularization $nmbr$ days after randomization,C0034656;C0439228;C0877341
487,at randomization,C0034656
487,asastoppedat randomization  n,C0034656
487,antiplatelet at randomization,C0034656
487,antihypertensive randomization  no . ( % ) a,C0003364;C0034656
487,all randomized women,C0034656;C0043210;C3815594
487,age at randomization ( years ),C0034656;C1510829
487,age at randomization,C0001779;C0034656
487,age at randomisation,C0001779;C0034656
487,age at lipid randomization ( y ),C0001779;C0034656;C0065033
486,glycaemic control group,C0005802;C0009932
486,events / control group,C0009932;C0441471;C3541888
486,diet controlled or no,C0743195
486,diet - controlled ( % ),C0743195
486,control group,C0009932
485,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
485,mental component,C0229992;C0449432;C1705248
485,mental,C0229992
484,other countries,C0454664
484,country : argentina ( n = $nmbr$ ),C0003761;C0454664;C1504311;C1511538
484,country  n ( % ),C0454664;C1511538
484,country,C0454664;C1511538
484,all countries,C0454664
483,acuity minor,C0750509
483,acuity major or,C0750509
483,acuity major,C0750509
483,acuity - defined bleeding,C0750509
483,acuity - bleeding major / minor,C0750509
482,acute reaction,C0205178;C0443286
482,acute and delayed reaction,C0205178
482,acute ( < $nmbr$ hr ),C0205178
481,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
481,not anterior,C0205094;C1518422
481,non - anterior,C0205094;C1518422
481,anterior { % ),C0205094
481,anterior or non - anterior ml,C0205094
481,anterior circulation,C0005775;C0205094;C1516559
481,anterior ( n  % ),C0205094
481,anterior,C0205094
480,standard control ( n = $nmbr$ ) no . of patients ( percent ),C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
480,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
480,rhythm - control group ( n = $nmbr$ ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
480,intensive control ( n = $nmbr$ ) no . of patients ( percent ),C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
480,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
480,good control ( < $nmbr$ ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,fair control ( $nmbr$ - $nmbr$ . $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
480,controls ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,controlled : acq - $nmbr$ < $nmbr$ . $nmbr$,C2587213;C2911690;C2919686
480,controlled $nmbr$ — no . ( % ),C2587213;C2911690
480,controlled,C2587213;C2911690
480,control of sitting bp at week $nmbr$,C0037623;C0243148;C0277814;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
480,control n = $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control group ( n = $nmbr$ ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
480,control baseline ( n - $nmbr$ ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
480,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control ( nz $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control ( n z $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control ( n - $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,control $nmbr$ months ( n - $nmbr$ ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
480,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
480,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
480,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
480,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
480,( % ) control ( $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
480,% asthma control days {  #,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
479,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
479,lo ( lo - lo ),C0206579;C1232424
479,$nmbr$ . $nmbr$ ( lo . i ),C0021966;C0206579;C0221138;C1232424
479,$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ ),C0206579;C1232424
478,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
478,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
478,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
478,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
478,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
478,$nmbr$ to < $nmbr$ cells,C0007584;C0007634
477,white blood cell count  cellsx $nmbr$,C0023508;C0427512
477,white - cell count — x $nmbr$ _ $nmbr$ / liter,C0023508;C0427512;C0475211
477,blood leukocyte count ( $nmbr$ cells per l ),C0023508;C0023516;C0347983;C0427512
476,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
476,> $nmbr$ cells / ul,C0439378
476,< $nmbr$ cells / ul $nmbr$ $nmbr$,C0439378
475,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
475,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
475,no . of background glucose - lowering therapies  no . ( % ),C0017725;C0087111;C0441994;C1706907;C2003888
475,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
475,glucose - lowering therapy  n ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
475,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
475,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
475,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
475,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
475,glucose  non - fasting or random ( nmol / l ),C0017725
475,blood glucose - lowering treatments  n ( % ),C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
475,blood glucose - lowering drugs  excluding insulin  n ( % ),C0005802;C0013227;C0017725;C0018938;C0441994;C2003888;C3687832
475,$nmbr$ hr prandial glucose ' * ’,C0017725;C1998602;C4553624
474,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
474,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
474,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
474,implantable cardioverter - defibrillator,C0162589;C2825184
473,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
473,mean fecal calprotectin level  mg / g stool ( sd ),C0015733;C0183622;C0441889;C0444504;C0456079;C0950624;C1300563;C1335798;C1366582;C1547707;C2347634;C2348143;C2699239;C2946261
473,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
472,total cholesterol - to - hdl cholesterol ratio,C0428619
472,serum cholesterol ( mg / l ) *,C0439268;C0587184
472,serum cholesterol  mg / dld,C0024671;C0026410;C0439269;C0587184;C1414063;C1960952;C2346927;C2826331;C4321396;C4521761
472,serum cholesterol  mg / dl,C0439269;C0587184
472,lathosterol ( jimol / l ),C0064673
472,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
471,terol  hdl - c  high - density lipoprotein cholesterol,C0023822
471,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
471,high density lipoprotein cholesterol  mg / dl ^,C0023822;C0439269
471,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
471,high - density lipoprotein cholesterol metabolic syndrome  patients were to,C0023822;C0030705;C0524620
471,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
471,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
471,high - density lipoprotein cholesterol  mg / dl,C0023822;C0439269
471,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
471,hdl cholesterol §,C0023822;C0392885
471,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
471,hdl cholesterol ^ :,C0023822;C0392885
471,hdl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
471,hdl cholesterol < $nmbr$ mg / dl *,C0023822;C0392885;C0439269
471,hdl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
471,hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women ),C0023822;C0025266;C0392885
471,hdl cholesterol *,C0023822;C0392885
471,hdl cholesterol ( sd )  mg / dl,C0023822;C0392885;C0439269;C2699239
471,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
471,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
471,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
471,hdl cholesterol  mmol / 冲,C0023822;C0392885;C0439190
471,hdl cholesterol  mmol / l *,C0023822;C0392885;C1532563
471,hdl cholesterol  mmol / l,C0023822;C0392885;C1532563
471,hdl cholesterol  mg / dl,C0023822;C0392885;C0439269
471,hdl cholesterol  ( mmol / l ),C0023822;C0392885;C1532563
471,hdl cholesterol,C0023822;C0392885
471,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
471,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
471,hdl - cholesterol  mmol / le,C0023190;C0023822;C0392885;C0439090;C0439190;C1423767;C2697858
471,hdl - cholesterol  mmol / l,C0023822;C0392885;C1532563
471,hdl - cholesterol,C0023822;C0392885
471,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
471,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
471,- hdl cholesterol,C0023822;C0392885
470,median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl,C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
470,lp ( a ) §,C0065058;C1439335;C4553379
470,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
470,lp ( a ) ( week $nmbr$ ),C0065058;C0332174;C0439230;C1439335;C4553379
470,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
470,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
470,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
470,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
470,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0020538;C0065058;C0125953;C0521116;C0578022;C1096202;C1439335;C1705970;C1963138
470,baseline lp ( a )  mg / dl,C0065058;C0168634;C0439269;C1439335;C1442488;C4553379
469,temporal data and management strategy,C0442043;C1511726;C2362314;C3245479;C3714741
469,pci data,C1511726;C3245479;C3714741;C4049621
469,no ef data | |,C1511726;C3245479;C3714741
469,fpg data ',C1511726;C3245479;C3714741
469,data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C0023820;C0031831;C0062152;C0073187;C0178587;C0205251;C0332173;C0337445;C0428883;C0439475;C0549183;C0804815;C0876920;C1305849;C1511726;C1550472;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741;C3890211;C4048187;C4321351;C4484261;C4522223
469,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status,C0205250;C0449820;C1511726;C3245479;C3714741
469,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
469,data missing,C1511726;C3245479;C3714741
469,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1518422;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
469,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
469,data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .,C0009235;C0010055;C0021966;C0022718;C0023190;C0023821;C0023823;C0035487;C0047420;C0162577;C0189695;C0221138;C0439090;C0439209;C0522520;C0522523;C0545743;C0549183;C0597153;C0700307;C0876920;C1305855;C1423767;C1444656;C1511726;C1514721;C1522231;C1548817;C1655741;C1826843;C2347635;C2348144;C2348147;C2697858;C2936173;C2939193;C3245479;C3542016;C3714741;C4054209
469,data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .,C0023820;C0023821;C0030705;C0042295;C0205120;C0489786;C1305855;C1511726;C1516606;C1552595;C3245479;C3714741
469,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C1511726;C3245479;C3714741
469,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation,C0439453;C0439836;C1511726;C1719797;C2911648;C3245479;C3714741
469,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C0007226;C0007447;C0010055;C0018787;C0022709;C0027051;C0037455;C0184661;C0238884;C0439453;C0439836;C0565930;C0886296;C1273869;C1511726;C1516705;C1719797;C2603362;C2911648;C3245479;C3714741;C3887460;C4049621
469,data  ' ' n,C1511726;C3245479;C3714741
469,available data,C0470187;C1511726;C3245479;C3714741
469,at c data,C1511726;C3245479;C3714741
469,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$,C0000723;C0021308;C0022709;C0035647;C0205369;C0439526;C0439836;C1511726;C1514721;C1705224;C1719797;C2348147;C2911648;C3245479;C3542016;C3714741;C3887665;C4552904
469,* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0009247;C0012634;C0018787;C0074554;C0280604;C0369773;C0439751;C0444504;C0444667;C0599755;C1142985;C1511726;C1710181;C2347634;C2348143;C2603361;C3245479;C3542407;C3714741
469,* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .,C1511726;C3245479;C3714741
469,* data are expressed as median ± sd  except,C1511726;C3245479;C3714741
469,* data are expr,C1511726;C3245479;C3714741
468,valve replacement / repair with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
468,valve repair / replacement with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
468,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
468,surgical repair of vsd or pda > $nmbr$ - year duration,C0018818;C0374711
467,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0168634;C0449381;C1442488;C4281788
467,haemodynamics and lv function,C0019010;C4281788
466,who / idf impaired fasting glucose,C1272092
466,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
466,impaired glucose tolerance or impaired fasting glucose,C0271650
466,impaired fasting glucose §,C1272092
466,impaired fasting glucose ( > $nmbr$ mg / dl ) ( % ),C0439269;C1272092
466,impaired fasting glucose,C1272092
466,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0271650
466,ada impaired fasting glucose,C1060325;C1272092;C3811629
465,percent impairment while working due to asthma,C0221099;C0439165;C0684336
465,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
465,mild impairment ( £ $nmbr$ to,C0221099;C0684336;C2945599
465,mild impairment ( $nmbr$ to < $nmbr$ ),C0221099;C0684336;C2945599
465,mild impairment ( $nmbr$ to $nmbr$ ml / min ),C0221099;C0439445;C0684336;C2945599
465,mild impairment  < $nmbr$ to < $nmbr$,C0221099;C0684336;C2945599
465,mild impairment,C0221099;C0684336;C2945599
465,impaired fasting glucosex,C0221099
465,impaired fasting glucose level ( n = $nmbr$ ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
465,impaired fasting giucose levei ( n = $nmbr$ ),C0221099
464,simplified disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869582;C4050231
464,simplified disease activity index score,C0449820;C3869582;C4050231
464,simplified disease activity index,C3869582
464,high disease activity : > $nmbr$ . $nmbr$  n ( % ),C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
464,disease activity ],C1292728
464,disease activity ( n ( % ) ),C1292728
464,disease activity,C1292728
464,clinical disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869583;C4050231
464,clinical disease activity index,C3869583
463,disease stage,C0699749
463,disease severity,C0521117
463,decreased appetite,C0232462
463,copd disease severity,C0024117;C0521117;C1412502;C3714496
462,prior antiinflammatory / antirheumatic products  n ( % ),C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
462,polyarticular arthritis  no rheumatoid nodules,C0162323
462,anti - inflammatory drugs,C0003209
461,prior cardiac resynchronization therapy  n ( % ),C0332152;C1167956;C2826257
461,cardiac rhythm disorders,C0264886
461,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
461,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
461,cardiac resynchronization therapy n ( % ),C1167956
461,cardiac resynchronization therapy,C1167956
461,cardiac catheterization,C0018795
461,cardiac catheterisation or pci for index event,C0018795
460,prior urate lowering therapies  n ( % ),C0441994;C0729829;C0935936;C1514463;C2003888
460,prior treatment — no . ( % ),C1514463
460,prior treatment — %,C1514463
460,prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
460,prior treatment,C1514463
460,prior tnfi treatment,C1514463
460,prior therapy  %,C1514463
460,prior lev treatment    n   ( % ),C0023556;C1514463
460,prior lev treatment,C0023556;C1514463
460,prior ed therapy,C1514463;C3538926
459,sinus rhythm at baseline,C0168634;C0232201;C1442488
459,sinus rhythm,C0232201
459,conversion to sinus rhythm in < $nmbr$ days,C1321500
458,prior arrhythmias  n ( % ),C0003811;C0332152;C2826257
458,cardiac arrhythmia  n ( % ),C0003811;C0264886;C1560249
458,cardiac arrhythmia,C0003811;C0264886;C1560249
458,arrhythmias,C0003811
458,arrhythmia !,C0003811
458,arrhythmia,C0003811
457,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
457,the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .,C0205225;C0439612;C0439631;C0871424;C1079230;C1547647
457,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
457,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
457,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
457,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
457,primary pcit,C0205225;C0439612;C0439631
457,primary pci no .,C0205225;C0439612;C0439631;C4049621
457,primary pci n = $nmbr$,C0205225;C0439612;C0439631;C4049621
457,primary pci ( n = $nmbr$ ),C0205225;C0439612;C0439631;C4049621
457,primary pci,C0205225;C0439612;C0439631;C4049621
457,primary outcomes,C0205225;C0439612;C0439631;C1274040
457,primary outcome plus revascularization or nonfatal hf,C0205225;C0332287;C0439612;C0439631;C0581603;C1274040
457,primary outcome ( $nmbr$ - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
457,primary outcome ! ( n = $nmbr$ ),C0205225;C0439612;C0439631;C1274040
457,primary outcome !,C0205225;C0439612;C0439631;C1274040
457,primary outcome,C0205225;C0439612;C0439631;C1274040
457,primary nonresponse,C0205225;C0439612;C0439631
457,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
457,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
457,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
457,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
457,primary composite ^,C0205199;C0205225;C0439612;C0439631;C1547335
457,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
457,primary angioplasty ( n = $nmbr$ ),C0162577;C0205225;C0439612;C0439631;C1548817
457,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .,C0007787;C0011849;C0205225;C0439612;C0439631;C1272706;C1552654;C1552713
457,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
457,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
457,primary *,C0205225;C0439612;C0439631
457,primary,C0205225;C0439612;C0439631
457,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
457,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
457,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
457,fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % ),C0016017;C0205225;C0439612;C0439631;C1305868;C4049621
457,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
457,accord primary  n ( % ),C0205225;C0439612;C0439631;C0680240
457,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
456,• any stroke,C0038454;C4554100
456,time from qualifying stroke to randomization,C0038454;C0040223;C1514624;C3541383;C4554100
456,time from onset of qualifying stroke to randomization,C0038454;C0449244;C1514624;C4554100
456,stroke — no . / total no . ( % ),C0038454;C4554100
456,stroke — no . ( % ),C0038454;C4554100
456,stroke thought due to atherothrombotic disease,C0038454;C4554100
456,stroke subtype  n ( % ),C0038454;C0449560;C4554100
456,stroke subtype,C0038454;C0449560;C4554100
456,stroke ortiab,C0038454;C4554100
456,stroke ortia,C0038454;C4554100
456,stroke or transient ischemic attack,C0038454;C4554100
456,stroke or tia — no . ( % ),C0038454;C4554100
456,stroke or tia,C0038454;C4554100
456,stroke or systemic embolism,C0038454;C4554100
456,stroke or systemic,C0038454;C4554100
456,stroke or see,C0038454;C4554100
456,stroke or se ( s / se ),C0038454;C4554100
456,stroke or pvd  ( % ),C0038454;C4554100
456,stroke or cerebrovascular disease,C0038454;C4554100
456,stroke or,C0038454;C4554100
456,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
456,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
456,stroke non - fatal,C0038454;C4554100
456,stroke n = $nmbr$,C0038454;C4554100
456,stroke n ( % ),C0038454;C4554100
456,stroke deaths,C0011065;C0038454;C1306577;C4554100
456,stroke at entry ( vs transient ischemic attack ),C0038454;C1705654;C4554100
456,stroke at entry,C0038454;C1705654;C4554100
456,stroke any,C0038454;C4554100
456,stroke and tia  n ( % ),C0038454;C4554100
456,stroke / transient ischemic attack,C0038454;C4554100
456,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
456,stroke / see,C0038454;C4554100
456,stroke / se,C0036919;C0038454;C4554100
456,stroke / non -,C0038454;C4554100
456,stroke / m $nmbr$,C0038454;C0369637;C0441923;C4554100
456,stroke / embolism,C0013922;C0038454;C1704212;C4554100
456,stroke ( vs tia ),C0038454;C4554100
456,stroke ( fatal / nonfatal ),C0038454;C4554100
456,stroke  total,C0038454;C4554100
456,stroke  see  or death,C0038454;C4554100
456,stroke  see  or cv death,C0038454;C4554100
456,stroke  n ( % ),C0038454;C4554100
456,stroke  fatal and nonfatal,C0038454;C4554100
456,stroke,C0038454;C4554100
456,sensorimotor stroke,C0038454;C4554100
456,qualifying stroke,C0038454;C1514624;C4554100
456,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
456,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
456,prior stroke,C0038454;C0332152;C2826257;C4554100
456,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
456,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
456,nonfatal stroke ®,C0038454;C4554100
456,nonfatal stroke ( n = $nmbr$ ),C0038454;C4554100
456,nonfatal stroke,C0038454;C4554100
456,nondisabling  nonfatal stroke,C0038454;C4554100
456,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
456,no stroke n = $nmbr$ $nmbr$,C0038454;C4554100
456,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
456,no stroke ( n = $nmbr$ ),C0038454;C4554100
456,no prior stroke,C0038454;C0332152;C2826257;C4554100
456,no . of strokes / no . of patients in category ( and % ),C0038454
456,no . of strokes ( % ),C0038454
456,new stroke *,C0038454;C0205314;C4554100
456,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
456,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
456,hemispheric stroke n = $nmbr$,C0038454;C0205139;C4554100
456,fatal stroke,C0038454;C1302234;C1705232;C4554100
456,fatal / nonfatal stroke  n ( % ),C0038454;C1302234;C1705232;C4554100
456,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
456,disabling stroke,C0038454;C4554100
456,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
456,cerebrovascular accident,C0038454
456,atherothrombotic stroke  n ( % ),C0038454;C4554100
456,any stroke ( n = $nmbr$ ),C0038454;C4554100
456,any stroke,C0038454;C4554100
456,all stroke,C0038454;C4554100
456,a stroke,C0038454;C4554100
455,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
455,recent cardiovascular eventf,C0007226;C0332185;C3887460
455,primary cardiovascular endpoint,C0007226;C2986535;C3887460
455,previous history of cardiovascular events,C0007226;C2004062;C3887460
455,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
455,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
455,exploratory cardiovascular and death outcomes,C0007226;C3887460
455,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
455,cardiovascular status,C0007226;C0449438;C3887460
455,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3887460
455,cardiovascular mortality  mi  or revascularization,C0007226;C0026565;C0026566;C3810814;C3887460
455,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
455,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
455,cardiovascular hospitalization,C0007226;C0019993;C3887460
455,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
455,cardiovascular death ( n = $nmbr$ ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
455,cardiovascular death  mi  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
455,cardiovascular and respiratory,C0007226;C3887460
455,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C3887460
455,cardiovascular,C0007226;C3887460
455,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
455,any cardiovascular diseased,C0007226;C3887460
455,all cardiovascular,C0007226;C3887460
454,other cardiovascular risk factors,C0850624
454,nonglycemic cardiovascular risk factors,C0850624
454,cardiovascular risk factors — no . { % ),C0850624
454,cardiovascular risk factors — no . / total no . ( % ),C0850624
454,cardiovascular risk factors and medical history,C0850624
454,cardiovascular risk factors and history — no . ( % ),C0850624
454,cardiovascular risk factors and history ( % ),C0850624
454,cardiovascular risk factors and history,C0850624
454,cardiovascular risk factors alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C0850624
454,cardiovascular risk factors  no . ( % ),C0850624
454,cardiovascular risk factors  n ( % ),C0850624
454,cardiovascular risk factors,C0850624
454,cardiovascular risk factor — no . { % ),C0850624
454,at least two cardiovascular risk factors,C0205448;C0850624
453,patients with microvascular complications  n ( % ),C0009566;C0030705;C0443258;C1171258
453,microvascular outcome,C0443258;C1274040
453,microvascular eye diseased,C0015392;C0443258;C0700042
453,microvascular complicationsb,C0443258
453,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
452,prior cardiovascular history,C0332152;C1880008;C2826257
452,past cardiovascular history  no . ( % ),C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
452,cardiovascular history 一 no . ( % ),C1880008
452,cardiovascular history — no . / total no . ( % ),C1880008
452,cardiovascular history — no . ( % ),C1880008
452,cardiovascular history,C1880008
451,endovascular — no . ( % ),C0524425
451,endovascular,C0524425
450,without cerebrovascular disease,C0007820
450,with cerebrovascular disease,C0007820
450,prior cerebrovascular disease,C0007820;C0332152;C2826257
450,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
450,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
450,only cerebrovascular disease,C0007820;C0205171;C1720467
450,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
450,cerebrovascular or peripheral arterial disease    n   ( % ),C1880018
450,cerebrovascular or peripheral arterial disease  n ( % ),C1880018
450,cerebrovascular or peripheral arterial disease,C1880018
450,cerebrovascular disorders  n ( % ),C0007820
450,cerebrovascular disease n ( % ),C0007820
450,cerebrovascular disease  n ( % ),C0007820
450,cerebrovascular disease  %,C0007820
450,cerebrovascular disease,C0007820
450,cerebrovascular,C1880018
450,cerebral vascular disease,C0007820
449,previous cardiovascular events,C0205156;C1320716;C1552607
449,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
449,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
449,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
449,cardiovascular medications  %,C0007220
449,cardiovascular medications,C0007220
449,cardiovascular medication usage,C0007220;C0457083
449,cardiovascular events,C1320716
449,cardiovascu lar subg roup,C0276828;C1419115;C3814448
449,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
449,baseline cardiovascular medications  n ( % ),C0007220;C0168634;C1442488
449,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
449,baseline cardiovascular medication,C0007220;C0168634;C1442488
448,value for nteraction,C1522609
448,value *,C1522609
448,value,C1522609
448,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
448,d - value,C1522609
448,baseline value,C0168634;C1442488;C1522609
448,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0814908;C1522609;C3887950
448,/ ’ - value $nmbr$ ’,C1522609
448,/ ’ - value,C1522609
447,ta ( n = $nmbr$ ),C0039297;C1506978;C1705538;C3272501;C4553364
447,ta,C0039297;C1506978;C1705538;C3272501;C4553364
446,ga / a,C0016993
446,ga,C0016993
446,a / ga,C0016993
445,with baseline crp level of > $nmbr$ mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
445,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
445,week $nmbr$ - baseline,C0168634;C0332174;C0439230;C1442488
445,use at baseline  n,C0042153;C0168634;C0457083;C1442488;C1947944
445,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
445,triglycerides at baseline,C0041004;C0168634;C1442488
445,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
445,treated at baseline,C0168634;C1442488;C1522326
445,supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0019016;C0039224;C0168634;C0392747;C0443172;C0456603;C0730345;C1442488;C1547037;C1705241;C1706074;C1825777;C3538758;C4319952
445,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
445,subpopulation analyses according to baseline hba $nmbr$ c,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
445,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
445,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
445,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
445,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
445,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
445,smokers ( at baseline ),C0168634;C0337664;C1442488
445,smoker at baseline,C0168634;C0337664;C1442488
445,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
445,sbp at baseline,C0085805;C0168634;C1442488
445,sbp  baseline,C0085805;C0168634;C1442488
445,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
445,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
445,ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml,C0168634;C0456603;C1442488;C1547037
445,ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll,C0168634;C0456603;C1442488;C1547037
445,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
445,pt baseline ( week $nmbr$ ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
445,pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
445,post - bronchodilator fev $nmbr$  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594;C3714541
445,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
445,parameters at baseline,C0168634;C0449381;C1442488
445,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
445,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
445,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
445,open - label phase ( baseline = week $nmbr$ ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
445,one at baseline,C0168634;C0205447;C1442488
445,on steroid at baseline,C0038317;C0168634;C1442488
445,on statins at baseline,C0168634;C0360714;C1442488
445,on aspirin at baseline,C0004057;C0168634;C1442488
445,on antihypertensive medication at baseline  n ( % ) ‡,C0003364;C0168634;C1442488
445,ocs at baseline,C0168634;C1442488
445,nvf at flex baseline - $nmbr$ < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
445,normonatremic ( > $nmbr$ meq / l ) at baseline,C0168634;C0439375;C1442488
445,normoalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
445,none at baseline,C0168634;C1442488
445,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
445,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
445,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
445,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
445,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
445,no chd at baseline,C0168634;C0280604;C1442488;C3542407
445,no aspirin at baseline,C0004057;C0168634;C1442488
445,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
445,nihss at baseline,C0168634;C1442488;C1697238
445,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
445,mtx at baseline  n ( % ),C0025677;C0168634;C1417487;C1442488
445,mtx at baseline,C0025677;C0168634;C1417487;C1442488
445,mtss at baseline observed case,C0168634;C1442488
445,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
445,mmrc at baseline,C0168634;C1442488;C3826977
445,microalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C0730345;C1442488
445,memantine use at baseline  no . ( % ),C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
445,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
445,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
445,medication use at baseline  n ( % ),C0168634;C0240320;C1442488
445,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
445,macroalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
445,low ( < $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
445,low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
445,ldl - c at baseline :,C0168634;C1442488
445,killip at baseline,C0168634;C1442488
445,intensified baseline ( n - $nmbr$ ),C0168634;C1442488
445,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
445,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
445,improvement from baseline ≥   $nmbr$,C0168634;C1442488;C2986411
445,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
445,hyponatremic ( < $nmbr$ meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
445,hypertension severity at baseline  n ( % ),C0168634;C1442488;C4013784
445,hscrp at baseline,C0168634;C1442488
445,high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
445,high ( > $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
445,hdl - c at baseline .,C0168634;C1442488;C3715113
445,hba $nmbr$ c   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
445,hba $nmbr$ c at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
445,hba $nmbr$ c at baseline  %,C0019016;C0168634;C1442488;C1825777;C3538758
445,hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
445,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0017480;C0168634;C0301630;C0392747;C0392756;C0443172;C0456603;C0679646;C1273442;C1293152;C1442103;C1442488;C1522544;C1547037;C1547049;C1704695;C1705241;C1705242;C1707455;C2698741;C2986759;C3854019;C4551656;C4554048
445,for baseline hemoglobin < $nmbr$ g $nmbr$ ',C0168634;C1319312;C1442488
445,for baseline hemoglobin $nmbr$ g $nmbr$ ’,C0168634;C1319312;C1442488
445,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
445,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
445,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
445,flex baseline bmd  g / cm ^ ( meanisd ),C0168634;C0439267;C1442488
445,fev $nmbr$   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
445,fev $nmbr$ at baseline,C0168634;C1442488;C3714541
445,fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
445,fev  at baseline,C0168634;C1442488;C3714541
445,fbg baseline,C0168634;C1442488
445,elevated baseline crp,C0168634;C0742906;C1442488
445,dlqi improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3899393
445,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
445,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
445,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
445,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
445,db baseline ( week $nmbr$ ),C0168634;C0332174;C0439230;C1418892;C1442488
445,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
445,csdmard use at baseline ^,C0042153;C0168634;C0457083;C1442488;C1947944
445,crcl at baseline < $nmbr$ ml / min,C0168634;C0439445;C1442488;C1846718
445,crcl at baseline  ml / min,C0168634;C0439445;C1442488;C1846718
445,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
445,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
445,corticosteroid use at baseline,C0168634;C0239126;C1442488
445,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
445,concentrations at baseline,C0086045;C0168634;C1442488
445,comparison with baseline,C0168634;C1442488;C1707455
445,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
445,coiticosieroids at baseline,C0168634;C1442488
445,ckd at baseline,C0168634;C1442488;C1561643
445,chd at baseline,C0168634;C0280604;C1442488;C3542407
445,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .,C0168634;C0392747;C0443172;C1442488
445,changes at baseline,C0168634;C0392747;C0443172;C1442488
445,change from baseline to week $nmbr$ in weekly size of largest hive score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to week $nmbr$ in weekly no . of hives score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to week $nmbr$ in weekly iss,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to week $nmbr$ in uas $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to week $nmbr$ in dlqi scorez,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to final apbm,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to eos  uu / ml,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline to eos  mg / dl,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline stage $nmbr$ ckd,C0168634;C0597205;C0679846;C1442488;C1561643
445,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in rescue medication use ( puffs per day ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in pre - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in post - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in mean $nmbr$ - h sbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in mean $nmbr$ - h dbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in hba $nmbr$ c ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in fevj ( mb ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in das $nmbr$ - esr  mean $nmbr$ sd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in acq - $nmbr$ score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in acq - $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in % predicted fev $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline at week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline  mmhg,C0168634;C0392747;C0439475;C0443172;C1442488;C1705241;C4319952
445,change from baseline  mg / dl  mean ( sd ),C0168634;C0392747;C0439269;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952
445,change from baseline  median ( iqr ),C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
445,change from baseline  adjusted mean ( $nmbr$ % ci )  %,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline  adjusted mean ( $nmbr$ % ci ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,body mass index ( kg / m $nmbr$ ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
445,bmi at baseline ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
445,biomarkers at baseline,C0005516;C0168634;C1442488
445,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
445,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
445,baseline £ std  mm,C0168634;C1442488;C4330985;C4554674
445,baseline who functional class,C0168634;C1442488
445,baseline who function class,C0168634;C1442488
445,baseline vfx,C0168634;C1442488
445,baseline variable,C0168634;C0439828;C1442488;C4553760
445,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
445,baseline use of adm  n ( % ),C0168634;C0215825;C1442488;C1524063;C4521767
445,baseline uric acid,C0041980;C0168634;C1442488
445,baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
445,baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ ),C0168634;C0567349;C1442488;C2348885
445,baseline uas $nmbr$,C0168634;C1442488
445,baseline uacr > $nmbr$ mg / g,C0168634;C1300563;C1442488
445,baseline uacr < $nmbr$ mg / g,C0168634;C1300563;C1442488
445,baseline trl - c by quintiles,C0168634;C1442488;C1508496
445,baseline triglycerides in $nmbr$ classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
445,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
445,baseline triglycerides > $nmbr$ mg / dl and,C0041004;C0168634;C0439269;C1442488
445,baseline triglycerides < $nmbr$ mg / dl,C0041004;C0168634;C0439269;C1442488
445,baseline triglycerides,C0041004;C0168634;C1442488
445,baseline trig > $nmbr$ millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
445,baseline treatments  n ( % ) a,C0087111;C0168634;C1442488
445,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
445,baseline tophusa,C0168634;C1442488
445,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
445,baseline tg > $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
445,baseline tg < $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
445,baseline tg,C0168634;C0337445;C1442488
445,baseline tc  mg / dl,C0039411;C0040642;C0041405;C0041698;C0168634;C0439269;C1442488;C1824670;C3272447;C4522122
445,baseline tbp,C0168634;C1442488
445,baseline tava,C0168634;C1442488
445,baseline t - score at femoral neck  n ( % ),C0015815;C0168634;C0449820;C1442488;C4050231
445,baseline ste in worst lead  mm,C0023175;C0168634;C0181586;C1420459;C1442488;C1442948;C1522166;C1522538;C2348269;C3275067;C3811127;C4330985;C4554674
445,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
445,baseline smoking status,C0168634;C1442488;C1519386
445,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
445,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
445,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
445,baseline shs ( $nmbr$ - $nmbr$ ),C0168634;C1442488
445,baseline sgrq total score,C0168634;C1442488;C2964552
445,baseline sgrq score,C0168634;C1442488
445,baseline serum mg > = $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
445,baseline serum mg < $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
445,baseline serum k +  meq / l,C0168634;C0302353;C0439375;C1442488
445,baseline serum calcium level  n ( % ),C0036785;C0168634;C0728876;C1442488
445,baseline scales  median ( range ),C0168634;C1442488
445,baseline sbp { p = o - $nmbr$ ),C0085805;C0168634;C1442488
445,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
445,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
445,baseline sbp,C0085805;C0168634;C1442488
445,baseline rst - segment elevation  mm,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488;C4330985;C4554674
445,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
445,baseline risk factors,C0035648;C0168634;C1442488;C1553898
445,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
445,baseline ptga,C0168634;C1442488
445,baseline pssi score  mean ( sd ),C0168634;C1442488
445,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C1442488
445,baseline prediabetes,C0168634;C0362046;C1442488
445,baseline ppasi score  mean ( sd ),C0168634;C1442488
445,baseline post - bronchodilator fev $nmbr$   ( sd )  ml,C0168634;C0439526;C1442488;C1705224;C2599594;C2699239;C3714541;C3887665
445,baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use,C0168634;C1442488
445,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use,C0168634;C1442488
445,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium,C0168634;C1442488
445,baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use,C0168634;C1442488
445,baseline post - bronchodilator % predicted fev  < $nmbr$ %,C0168634;C1442488
445,baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
445,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
445,baseline pcsi < $nmbr$ a,C0168634;C1442488
445,baseline pava,C0135567;C0168634;C1442488
445,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
445,baseline ocs use : yes,C0168634;C1442488
445,baseline numberf of adm classes  n ( % ),C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
445,baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
445,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
445,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
445,baseline nihss score  median ( range ),C0168634;C1442488;C1697238
445,baseline nihss,C0168634;C1442488;C1697238
445,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
445,baseline nbp,C0168634;C1442488
445,baseline mssbp / msdbp  mm hg,C0168634;C0439475;C1442488
445,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
445,baseline microalbumin : < $nmbr$,C0168634;C0201838;C1442488;C2362049
445,baseline metformin,C0025598;C0168634;C1442488
445,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
445,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
445,baseline medical therapy  n ( % ),C0168634;C0418981;C1442488
445,baseline medical therapy,C0168634;C0418981;C1442488
445,baseline measurements,C0168634;C0242485;C1442488
445,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
445,baseline lvef  %,C0168634;C0428772;C0488728;C1442488
445,baseline lvef,C0168634;C0428772;C0488728;C1442488
445,baseline los angeles grade of eo  n ( % ),C0024015;C0168634;C1442488
445,baseline lipids  mg / dl,C0023779;C0168634;C0439269;C1442488
445,baseline lipids,C0023779;C0168634;C1442488
445,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
445,baseline lipid parameters  mg / dl  mmol / l or g / l,C0023779;C0168634;C0439269;C0449381;C1442488;C1532563
445,baseline lipid and lipoprotein values,C0023779;C0168634;C1442488
445,baseline lipid and apolipoprotein levels,C0023779;C0168634;C1442488
445,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
445,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
445,baseline ldl ‐ c  mg / dl,C0168634;C0439269;C1442488
445,baseline ldl - c strata  n ( ° / o ),C0168634;C1442488
445,baseline ldl - c > $nmbr$ mg / dl,C0168634;C0439269;C1442488
445,baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
445,baseline ldl - c :,C0168634;C1442488
445,baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
445,baseline ldl - c  mg / dl,C0168634;C0439269;C1442488
445,baseline ldl - c,C0168634;C1442488
445,baseline insulin dose ( u = kg ) [ lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
445,baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
445,baseline if have $nmbr$ yr follow - up *,C0168634;C1442488
445,baseline ics use : yes,C0168634;C0815320;C1442488;C4551720
445,baseline ics use : no,C0168634;C0815320;C1442488;C4551720
445,baseline ics use  n ( % ),C0168634;C0815320;C1442488;C4551720
445,baseline ics dose  n ( % ),C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
445,baseline ics,C0168634;C0815320;C1442488;C4551720
445,baseline ibdq total score  mean,C0168634;C0444504;C1442488;C2347634;C2348143;C2964552
445,baseline hstni,C0168634;C1442488
445,baseline hs - crp tertiles ( mg / i ],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
445,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
445,baseline height ( cm ),C0168634;C0489786;C1442488
445,baseline heart rate,C0018810;C0168634;C1442488
445,baseline hdl ‐ c  mg / dl,C0168634;C0439269;C1442488;C3715113
445,baseline hdl - c  mg / dl,C0168634;C0439269;C1442488;C3715113
445,baseline hdl - c,C0168634;C1442488;C3715113
445,baseline hbalc ’,C0168634;C1442488
445,baseline hbalc ^,C0168634;C1442488
445,baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ),C0168634;C1442488;C3829066
445,baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
445,baseline hbalc > $nmbr$ % to < $nmbr$ %,C0168634;C1442488
445,baseline hbalc > $nmbr$ %,C0168634;C1442488
445,baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
445,baseline hbalc < $nmbr$ %,C0168634;C1442488
445,baseline hbalc,C0168634;C1442488
445,baseline hba ^ c,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
445,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
445,baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
445,baseline hba $nmbr$ c concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
445,baseline hba $nmbr$ c ^,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
445,baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
445,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c  %,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hba $nmbr$ c,C0019016;C0168634;C1442488;C1825777;C3538758
445,baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$,C0062408;C0168634;C0439267;C1442488
445,baseline hb $nmbr$ g i $nmbr$ n = $nmbr$,C0062408;C0086706;C0168634;C1442488
445,baseline glycated,C0168634;C1442488
445,baseline fvc  l,C0168634;C1442488;C3714541
445,baseline fpg  mg / dl,C0168634;C0439269;C1442488
445,baseline fpg,C0168634;C1442488
445,baseline fev $nmbr$ % predicted,C0168634;C1442488;C3714541
445,baseline fev $nmbr$ #,C0168634;C1442488;C3714541
445,baseline fev $nmbr$  l *,C0168634;C1442488;C3714541
445,baseline fev $nmbr$,C0168634;C1442488;C3714541
445,baseline fev  ( l ),C0168634;C1442488;C3714541
445,baseline fecal caicrctectin,C0015733;C0168634;C1442488
445,baseline fc - ldl - c,C0168634;C1442488;C2983605
445,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
445,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
445,baseline estimated gfr,C0168634;C1442488
445,baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C1442488
445,baseline ecro < $nmbr$ mumin,C0168634;C1442488
445,baseline ecrcl k $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
445,baseline ecrcl $nmbr$ $nmbr$ ml / min,C0168634;C0439445;C1442488
445,baseline ecrcl,C0168634;C1442488
445,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
445,baseline dipeptidyl peptidase $nmbr$,C0022709;C0168634;C1442488
445,baseline diabetes mellitus therapy  n ( % ),C0168634;C0948092;C1442488
445,baseline diabetes,C0011847;C0011849;C0168634;C1442488
445,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
445,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
445,baseline dad ( n   = $nmbr$ + $nmbr$ ),C0168634;C1442488;C3641946
445,baseline cv treatment  n ( % ) y,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
445,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
445,baseline crp levels ≥ $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
445,baseline crp levels < $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
445,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
445,baseline crp < $nmbr$ mg / l,C0168634;C0439268;C1442488;C3890735;C4048285
445,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
445,baseline crp,C0168634;C1442488;C3890735;C4048285
445,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
445,baseline crcl  ml / min,C0168634;C0439445;C1442488;C1846718
445,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
445,baseline characteristic,C0168634;C1442488
445,baseline chads $nmbr$ a  c,C0007928;C0168634;C1413373;C1442488
445,baseline cdr - sb ( n   = $nmbr$ + $nmbr$ ),C0038111;C0168634;C1442488;C3811240;C4521843
445,baseline cdai score  mean ( sd ),C0168634;C0683448;C1413248;C1442488;C3273706
445,baseline cdai score  mean ( s . d . ),C0168634;C0683448;C1413248;C1442488;C3273706
445,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
445,baseline cardiovascular disease,C0007222;C0168634;C1442488
445,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
445,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
445,baseline bp  mean ( sd ) *,C0168634;C0488053;C1442488;C2699239
445,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
445,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
445,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi > $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi < $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi ( kg / m ^ ),C0168634;C0578022;C1442488;C1532718
445,baseline bmi ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
445,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
445,baseline bmi,C0168634;C0578022;C1442488
445,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
445,baseline basfi,C0168634;C1442488
445,baseline basdai,C0168634;C1442488;C1998004
445,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
445,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
445,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
445,baseline antihyperglycemic medications  n ( % ),C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
445,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
445,baseline anti - hyperglycemic medications  n ( % ),C0013227;C0168634;C0432633;C0802604;C1442488;C2598133;C4284232
445,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
445,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
445,baseline alc < $nmbr$ . $nmbr$ %,C0168634;C1424945;C1442488;C3811058
445,baseline albuminuria,C0001925;C0168634;C1442488
445,baseline albumin : < $nmbr$,C0001924;C0168634;C1442488
445,baseline age,C0001779;C0168634;C1442488
445,baseline adas - cog $nmbr$,C0168634;C1442488;C3539026
445,baseline a $nmbr$ c ( % ) [ lsm ( se ) ],C0036919;C0168634;C1442488
445,baseline a $nmbr$ c ( % ),C0168634;C1442488
445,baseline ^ ste  mm,C0168634;C1420459;C1442488;C3811127;C4330985;C4554674
445,baseline / concomitant therapies,C0168634;C1442488;C1707479
445,baseline - adjusted hr,C0168634;C1442488
445,baseline - - mdrd,C0168634;C1442488;C3839656
445,baseline ( sd ),C0168634;C1442488;C2699239
445,baseline ( n ),C0168634;C1442488
445,baseline ( mmol / l ),C0168634;C1442488;C1532563
445,baseline % predicted fev $nmbr$,C0168634;C1442488
445,baseline % bsa involvement,C0168634;C1314939;C1442488
445,baseline $nmbr$ - mlnute walk distance :,C0168634;C0429886;C1442488
445,baseline $nmbr$ - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
445,baseline $nmbr$ - hour mean sbp  mm hg,C0085805;C0168634;C0439227;C0439475;C0444504;C0564385;C1442488;C2347634;C2348143
445,baseline  no . ( % ),C0168634;C1442488
445,baseline  mm hg,C0168634;C0439475;C1442488
445,baseline  mg / dl ( mmol / l ),C0168634;C0439269;C1442488;C1532563
445,baseline  % ( n ),C0168634;C1442488
445,baseline,C0168634;C1442488
445,b - blockers at baseline,C0168634;C1442488
445,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
445,atrial fibrillation on baseline ecg  n ( % ),C0168634;C0344434;C1442488
445,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
445,at baseline — no . ( % ),C0168634;C1442488
445,at baseline,C0168634;C1442488
445,asthma control test score at baseline,C0168634;C1442488;C2733224
445,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
445,aspirin dose at baseline  mg,C0004057;C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4086581;C4321396;C4521761;C4696290
445,aspirin at baseline,C0004057;C0168634;C1442488
445,asa use at baseline  n ( % ),C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
445,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
445,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
445,alc < $nmbr$ . $nmbr$ % at baseline  n ( % ),C0168634;C1424945;C1442488;C3811058
445,albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
445,age at baseline years,C0168634;C1442488;C1510829
445,age at baseline in years  mean ( sd ),C0001779;C0168634;C1442488
445,age at baseline ( years ),C0168634;C1442488;C1510829
445,af on baseline ecg  n ( % ),C0168634;C0344434;C1442488;C1623258;C4049859
445,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488
445,adjusted for all baseline variables $nmbr$,C0168634;C0439828;C0456081;C1442488
445,adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up,C0168634;C0439828;C0456081;C1442488;C1704675
445,a from baseline,C0168634;C1442488
445,a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %,C0168634;C1442488
445,a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %,C0168634;C1442488
445,> $nmbr$ mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
445,> $nmbr$ med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
445,> $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
445,< $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
445,( baseline ),C0168634;C1442488
445,% predicted ” fev  at baseline  % *,C0168634;C0681842;C1442488;C1882327;C3714541
445,% change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
445,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
445,$nmbr$ med at baseline,C0168634;C1442488;C4321267
444,two or more at baseline,C0205448
444,two or more antihypertensive medications,C0205448
444,two or more,C0205448
444,two of the above,C0205448
444,two arm,C0205448;C0446516;C3715044;C4553528
444,ast > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
444,alt > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
444,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0010287;C0013175;C0026845;C0035173;C0205448;C0332281;C0439849;C0445223;C0521095;C0683368;C0805162;C1266129;C1415181;C1457887;C1516048;C1519815;C1704788;C3539106;C3891303;C4083049;C4553172
443,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
443,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
443,who fc ii symptoms at baseline $nmbr$,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
443,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
443,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
443,time from symptoms to randomization  h,C0040223;C0683368;C1457887;C3541383
443,time from symptoms onset to $nmbr$ st balloon inflation ( h ),C0449244;C0683368;C1457887
443,time from symptom onset to start of fibrinolytic therapy — hr,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
443,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
443,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
443,time from symptom onset to balloon inflation,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
443,systemic symptoms,C0205373;C0683368;C1457887
443,symptoms and feelings,C0683368;C1457887
443,symptoms,C0683368;C1457887
443,symptom bother,C1457887;C3854129
443,symptom - free days in the past $nmbr$ weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
443,placebo ( symptom days a week ),C0032042;C0439228;C1457887;C1696465;C1706408;C3854129
443,number of symptom days per week,C0237753;C0439228;C0449788;C1457887;C3854129
443,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
443,no symptoms,C0683368;C1457887
443,hf symptoms and signs,C0018488;C0683368;C1313497;C1457887;C1538440;C3273279
443,hf symptom worsened,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
443,hf symptom unchanged,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
443,group d ( high risk  more symptoms )  n ( % ),C0332167;C0441848;C0683368;C1457887;C3272283;C4050568;C4319571
443,group b ( low risk  more symptoms )  n ( % ),C0441848;C0683368;C1457887;C3272281;C3538919
443,daytime symptoms more than twice per week,C0332169;C0683368;C1457887;C1720725;C1948050
443,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
443,budesonide { symptom days a week ),C0054201;C0439228;C1457887;C3854129
443,budesonide ( symptom days a week ),C0054201;C0439228;C1457887;C3854129
443,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
443,asthma symptoms in the past $nmbr$ weeks,C0004096;C0683368;C1457887;C2984299;C2987125
443,> lto £ $nmbr$ symptom days per week,C0677547;C1457887;C3854129
443,> $nmbr$ symptom days per week,C0677547;C1457887;C3854129
443,$nmbr$ to $nmbr$ symptom days per week,C0677547;C1457887;C3854129
443,$nmbr$ = no symptoms,C0683368;C1457887
443,$nmbr$ = minor symptoms  no limitations,C0026193;C0205165;C0683368;C1457887
442,pancreatic cancer,C0235974;C0346647;C2984259
442,pacific islander,C0242191
442,other pacific islander,C0242191
442,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
442,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
441,charlson comorbidity index  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4546361
441,charlson comorbidity index,C4546361
440,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0037455;C0175659;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460
440,ccs class §,C1879987
439,cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901
439,cardiogenic shock,C0036980
438,carotid artery — no . ( % ),C0007272;C0162859
438,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
438,carotid artery diseaset,C0007272;C0162859
437,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
437,other cardiac surgery  n ( % ),C0018821;C0524727
437,cardiac therapy §,C3654025
437,cardiac therapy  n ( % ) d,C3654025
437,cardiac therapy,C3654025
437,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
437,cardiac rhythm,C0232187
437,cardiac death,C0376297
436,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
436,chronic bronchitis ( n = $nmbr$ ),C0008677
436,chronic bronchitis ( itt ) ( n = $nmbr$ ),C0008677
436,chronic bronchitis ( % ),C0008677
436,chronic bronchitis !,C0008677
436,chronic bronchitis,C0008677
435,with higher classes indicating greater limitations on physical activity owing to,C0205250;C0456387;C1518526;C1705943;C4019422
435,renal biopsy class,C0194073;C0456387;C1518526;C1705943
435,non - hdl - c in $nmbr$ classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
435,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
435,modified acc / aha lesion class b $nmbr$ or cj,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
435,modified acc / aha lesion class b $nmbr$ / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
435,modified acc - aha lesion class b $nmbr$ or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
435,kilip class,C0456387;C1518526;C1705943
435,egfr in $nmbr$ classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
435,class ll - iv,C0456387;C1518526;C1705943
435,class l / ll heart failure,C0456387;C1518526;C1705943
435,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
435,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
435,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
435,class > $nmbr$,C0456387;C1518526;C1705943
435,class $nmbr$ or no symptoms,C0456387;C1518526;C1705943
435,class $nmbr$ antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
435,class $nmbr$,C0456387;C1518526;C1705943
435,calculated ldl - c in $nmbr$ classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
435,baseline trl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
435,baseline lp ( a ) in $nmbr$ classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
435,baseline hdl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
435,baseline hba $nmbr$ c in $nmbr$ classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
435,baseline albumin / creatinine ratio in $nmbr$ classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
435,age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
435,acc / aha lesion class b $nmbr$ or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
434,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205191;C0679831
434,chronic cox $nmbr$ inhibitors,C0085387;C0205191
434,chronic bronchitist,C0205191
433,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
433,coronary angiography — no . ( % ),C0085532;C1548829
433,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
433,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
433,coronary angiography and intervention,C0085532;C1548829
433,coronary angiography,C0085532;C1548829
432,rosuvastatin + fenofibric acid,C0060179;C0965129
432,rosuvastain + fenofibric acid   n   =   $nmbr$,C0060179
432,rosuvastain + fenofibric acid $nmbr$ = $nmbr$,C0060179
432,fenofibric acid   n   =   $nmbr$,C0060179
432,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
432,fenofibric acid - $nmbr$ - low - dose statin,C0060179;C0360714;C0445550;C1708745
432,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
432,fenofibric acid $nmbr$ = $nmbr$,C0060179
432,fenofibric acid,C0060179
432,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
432,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179
431,undetermined etiology  n ( % ),C0478157
431,undetermined etiology,C0478157
431,metformin • pioglitazone,C1635037
431,metformin ? pioglitazone,C1635037
430,linear regression,C0023733;C2346679
430,inversion,C0021943;C0021945;C1705687;C2349984
430,antidepressant,C0003289
429,undetermined  other  or cardioembolism,C0205258;C3536725;C4082977
429,undetermined,C0205258;C3536725;C4082977
429,indeterminate or unknown,C0205258
429,indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ ),C0205258;C1513839
429,indeterminate ! !,C0205258
428,hiatus hernia,C3489393
428,health practices,C0018684
428,health habits,C0679786
428,esophageal hiatal hernia *,C3489393
427,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
427,bph - related health status,C0005001;C1704272
427,benign prostatic hyperplasia,C1704272
426,idiopathic / familial,C0015576;C0241888;C0332240
426,idiopathic,C0332240
426,cryptogenic,C0332240
425,ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446
425,ventricular tachyarrhythmias,C3827656
425,supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833
425,other supraventricular tachycardia,C0039240;C1963244;C3815188
425,lelt ventricular hypertrophy *,C0340279
425,left ventricular ejection,C2733342
425,left ventricular dysfunction,C0242698
424,variable demographic characteristics,C0439828;C0683970;C4553760
424,demographic features,C0683970
424,demographic feature,C0683970
424,demographic data,C4684639
424,demographic characteristics,C0683970
423,india,C0021201;C2700456
423,ebria,C1917247
423,= sia,C1225105;C1551538
422,pyrexia,C0015967
422,dyspepsia,C0013395;C4552968
421,paresthesia,C0030554;C4553220
421,east asia,C0015631
421,austria,C0004348
421,australasia,C0282279;C1257882
421,aphasia,C0003537
420,myalgia,C0231528;C4552646
420,malaysia,C0024552
420,arthralgia,C0003862;C4551938
420,antimalarial,C0003374;C3536844;C4552582
419,trait,C0599883
419,gait,C0016928
419,ai $nmbr$,C0003504;C4551710
418,hiv,C0019682;C0019699
418,fh ii,C1854107
417,oil,C0028908;C0032085;C1517288;C3541397
417,- oil,C0028908;C0032085;C1517288;C3541397
417,$nmbr$ nil,C0442734
417,$nmbr$ ix,C0015491
416,sotalol,C0037707
416,cilostazol,C0055729
415,salbutamol  %,C0001927
415,albuterol use,C0001927;C0042153;C0457083;C1947944
414,hrqol,C4279947;C4300252
414,health - related quality of life,C4279947
413,algorithm $nmbr$,C0002045;C1553907
412,allopurinol $nmbr$ mg ( n = $nmbr$ ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
412,allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
412,allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
412,allopurinol,C0002144
411,alcohol usef  n ( % ),C0001962;C0001975
411,alcohol useb,C0001962;C0001975
411,alcohol drinker  n ( % ),C0001962;C0001975;C0556338
411,alcohol drinker,C0001962;C0001975;C0556338
411,alcohol abuse,C0085762;C4050601
411,alcohol ^,C0001962;C0001975
411,alcohol > $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
411,alcohol < = $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
411,alcohol,C0001962;C0001975
410,no history of hypertension ( n = $nmbr$ ),C0455527
410,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
410,history of systemic hypertension,C0205373;C0455527
410,history of hypertension — no . ( % ),C0455527
410,history of hypertension for $nmbr$ mo or more,C0455527
410,history of hypertension ^  %,C0455527
410,history of hypertension . no . ( % ),C0455527
410,history of hypertension - n ( % ),C0455527
410,history of hypertension *,C0455527
410,history of hypertension ( n = $nmbr$ ),C0455527
410,history of hypertension ( a ) c,C0455527
410,history of hypertension ( % ),C0455527
410,history of hypertension  no . ( % ),C0455527
410,history of hypertension  n ( % ),C0455527
410,history of hypertension,C0455527
410,history of diagnosed hypertension prior to randomization  n ( % ),C0011900;C0455527
410,history of diagnosed hypertension n ( % ),C0011900;C0455527
410,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
409,helicobacter pylori infection ( + ) ( n ),C0850666
409,h . pylori infection,C0850666
408,no methotrexate  hydroxychloroquine  or sulfasalazine treatment,C0020336;C0025677
408,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
408,hydroxychloroquine,C0020336
407,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
407,history of peripheral vascular disease,C1881056
407,history of hyperlipidemia ( % ),C4695788
407,history of hypercholesterolemia  n ( % ),C1533076
407,history of hypercholesterolemia,C1533076
407,history of falls in year before randomization,C1561668;C2919132
407,history of falls,C1561668;C2919132
407,history of cerebrovascular disease — no . { % ),C0585890
407,history of cerebrovascular disease,C0585890
407,history of cardiovascular disease — no . { % ),C0455539
407,history of cardiovascular disease — no . ( % ) ^ |,C0455539
407,history of cardiovascular disease — no . ( % ),C0455539
407,history of cardiovascular disease,C0455539
407,history of a transient ischaemic attack,C0455536
406,no history of migraine,C0455512
406,no history of cancer,C0455471
406,history of pvd  no . ( % ),C4534349
406,history of pvd  n ( % ),C4534349
406,history of pvd,C4534349
406,history of cancer,C0455471
406,history of alcohol use,C0551571;C0552479
405,no history of heart failure at baseline,C0455531
405,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
405,history of heart failure — no . { % ),C0455531
405,history of heart failure — no . ( % ),C0455531
405,history of heart failure at baseline,C0455531
405,history of heart failure  no . ( % ),C0455531
405,history of heart failure  n ( % ),C0455531
405,history of heart failure,C0455531
405,history of congestive heart failure,C0455531;C0742742
405,any history of congestive heart failure,C0455531;C0742742
404,rhabdomyolysis or myopathy,C0035410;C4552660
404,rhabdomyolysis ( n = $nmbr$ ),C0035410;C4552660
404,rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln,C0026848;C0035410;C4552660
404,rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0026848;C0035410;C4552660
404,rhabdomyolysis,C0035410;C4552660
403,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
403,treated hypertension :,C0020538;C1522326;C1963138
403,treated for hypertension  %,C0020538;C1522326;C1963138
403,systemic hypertension,C0020538
403,systemic arterial hypertension  n ( % ),C0020538
403,resistant htn n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
403,resistant htn : spiro n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
403,resistant htn : placebo n = $nmbr$,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
403,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
403,prior hypertension,C0020538;C0332152;C1963138;C2826257
403,previous hypertension,C0020538;C0205156;C1552607;C1963138
403,no resistant htn n = $nmbr$  $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
403,no hypertension ( n = $nmbr$ ),C0020538;C1963138
403,no hypertension,C0020538;C1963138
403,no htn,C0020538
403,isoiated systoiic hypertension *,C0020538;C1963138
403,hypertension 本,C0020538;C1963138
403,hypertension 一 no . ( % ),C0020538;C1963138
403,hypertension — no . / total no . ( % ),C0020538;C1963138
403,hypertension — no . ( % ) |,C0020538;C1963138
403,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
403,hypertension — no . ( % ),C0020538;C1963138
403,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
403,hypertension §,C0020538;C1963138
403,hypertension severity,C0020538;C0439793;C0522510;C1963138
403,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
403,hypertension requiring medical treatment,C0020538;C1963138
403,hypertension n ( % ),C0020538;C1963138
403,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
403,hypertension and left ventricular hypertrophy,C0020538;C1963138
403,hypertension absent,C0020538;C1963138
403,hypertension ^,C0020538;C1963138
403,hypertension : no ( n = $nmbr$ ),C0020538;C1963138
403,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
403,hypertension *,C0020538;C1963138
403,hypertension ( n 二 $nmbr$ ),C0020538;C1963138
403,hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication ),C0020538;C0037623;C0439475;C1415692;C1708288;C1963138;C4318478
403,hypertension ( > $nmbr$ / $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
403,hypertension ( % ) : t,C0020538;C1963138
403,hypertension ( % ),C0020538;C1963138
403,hypertension $nmbr$ ( % ),C0020538;C1963138
403,hypertension !,C0020538;C1963138
403,hypertension    n   ( % ),C0020538;C1963138
403,hypertension  treated,C0020538;C1963138
403,hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % ),C0020538;C1963138
403,hypertension  n / n ( % ),C0020538;C1963138
403,hypertension  n ( % ) yes,C0020538;C1549445;C1705108;C1710701;C1963138
403,hypertension  n ( % ),C0020538;C1963138
403,hypertension  * n ( % ),C0020538;C1963138
403,hypertension  ( % ),C0020538;C1963138
403,hypertension  %,C0020538;C1963138
403,hypertension,C0020538;C1963138
403,hyper - tension,C0020538;C1963138
403,htn hx,C0020538;C0262926;C3814444
403,htn,C0020538
403,high blood pressure,C0020538;C2926615
403,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
403,elevated blood pressure,C0020538;C0497247
403,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
403,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
403,duration of hypertension  y,C0020538;C0449238;C1963138;C2926735
403,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
403,arterial hypertension — no . ( % ),C0020538
403,arterial hypertension *,C0020538
403,arterial hypertension  no . ( % ),C0020538
403,arterial hypertension  n ( % ),C0020538
403,arterial hypertension,C0020538
403,> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :,C0020538;C1532718;C1963138
402,onset of chest pain,C0024902;C0206132;C0332162
402,onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
402,age of onset < $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
402,age of onset $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
402,age of onset,C0206132;C3175530
402,age of asthma onset  years,C0004096;C0206132;C0439234;C2984299;C3175530
402,age at onset  y,C0206132;C3870509
402,age at disease onset  years *,C0012634;C0206132;C0439234;C3870509
402,age at disease onset  n ( % ) *,C0012634;C0206132;C3870509
401,stage $nmbr$ b : > = $nmbr$ and < $nmbr$,C0441781
401,stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441781;C0441923
401,stage $nmbr$ b,C0441781
400,safety variable,C0036043;C0439828;C1705187;C4553760
400,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
400,safety population,C0032659;C0036043;C1257890;C1705187
400,safety    n   ( % ) b,C0036043;C1705187
400,safety  %,C0036043;C1705187
399,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
399,stage iv,C0205390;C1300072;C1306673
399,stage > $nmbr$ chronic kidney disease ( % ),C0205390;C1300072;C1306673
399,stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ ),C0205390;C1300072;C1306673
399,stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ ),C0205390;C1300072;C1306673
399,stage $nmbr$ a ckd cohort ( secondary analysis ),C0205390;C1300072;C1306673
399,stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users ),C0205390;C1300072;C1306673
399,stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
399,stage $nmbr$ a : > = $nmbr$ and < $nmbr$,C0205390;C1300072;C1306673
399,stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
399,stage $nmbr$ a,C0205390;C1300072;C1306673
399,stage $nmbr$ : > = $nmbr$,C0205390;C1300072;C1306673
399,stage $nmbr$ : < $nmbr$,C0205390;C1300072;C1306673
399,stage $nmbr$ ( four - variable modification of diet in kidney disease ),C0205390;C1300072;C1306673
399,stage $nmbr$ ( cockcroft - gault ),C0205390;C1300072;C1306673
399,stage $nmbr$,C0205390;C1300072;C1306673
399,participation in phase a,C0205390;C0679823;C1710475
399,hoehn and yahr stage ( range  $nmbr$ - $nmbr$ ),C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
399,hoehn and yahr stage ( baseline )  mean ( sd ),C0168634;C0205390;C0444504;C1300072;C1306673;C1442488;C2347634;C2348143;C2699239
399,hoehn and yahr stage,C0205390;C1300072;C1306673
399,hoehn & yahr stage ( “ on ” )  n ( % ),C0205390;C1300072;C1306673
399,hoehn & yahr stage ( “ off ” )  n ( % ),C0205390;C1300072;C1306673
399,hoehn & yahr stage,C0205390;C1300072;C1306673
399,double - dummy phase * *,C0205390;C1710475;C4684647
398,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
398,aged ≥ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
398,aged a $nmbr$ years,C0001779;C0001792;C1999167
398,aged ^ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
398,aged < $nmbr$ years,C0001779;C0001792;C0439234;C1999167
398,aged $nmbr$ y or older  n ( % ),C0001779;C0001792;C1999167
398,age\\yr,C0001779;C0439234
398,age ≥ $nmbr$ yearsa,C0001779
398,age — yrf,C0001779
398,age — yr race — no . ( % ) f,C0001779;C0439234
398,age — yr,C0001779;C0439234
398,age — y £,C0001779
398,age — y  meantsd,C0001779
398,age   ≥ $nmbr$   y  n ( % ),C0001779
398,age ± sd ( yrs ),C0001779;C2699239
398,age £ $nmbr$,C0001779
398,age yrs,C0001779
398,age when diabetes first diagnosed — yr,C0001779
398,age when diabetes first diagnosed ( years )  mean ( sd ),C0001779
398,age subgroups,C0001779;C1079230
398,age subgroup  y,C0001779;C1079230;C1515021
398,age s * $nmbr$ yr,C0001779;C0439234
398,age s $nmbr$,C0001779
398,age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers,C0001779
398,age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers,C0001779
398,age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes,C0001779
398,age groups  n ( % ),C0001779;C0441848
398,age group ( y ),C0001779;C0441858
398,age group  n ( % ),C0001779;C0441848
398,age b $nmbr$ y ( n = $nmbr$ ),C0001779
398,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
398,age a $nmbr$,C0001779
398,age ^ $nmbr$ yrs  n ( % ),C0001779
398,age ^ $nmbr$,C0001779
398,age [ year ]  mean ± sda,C0001779;C0276477;C0439234;C0439508;C0444504;C1428349;C1553165;C2347634;C2348143
398,age > = $nmbr$ yrs,C0001779
398,age > = $nmbr$,C0001779
398,age > : $nmbr$,C0001779
398,age > $nmbr$ yrs *,C0001779
398,age > $nmbr$ yrs  n ( % ),C0001779
398,age > $nmbr$ yrs  %,C0001779
398,age > $nmbr$ yrs,C0001779
398,age > $nmbr$ yr 十,C0001779;C0439234
398,age > $nmbr$ yr — no . ( % ),C0001779;C0439234
398,age > $nmbr$ yr and st - segment changes,C0001779;C0439234
398,age > $nmbr$ yr and elevated biomarkers,C0001779;C0439234
398,age > $nmbr$ yr ( % ),C0001779;C0439234
398,age > $nmbr$ yr  no . ( % ),C0001779;C0439234
398,age > $nmbr$ yr,C0001779;C0439234
398,age > $nmbr$ y * *,C0001779
398,age > $nmbr$ y *,C0001779
398,age > $nmbr$ y ( n = $nmbr$ ),C0001779
398,age > $nmbr$ y ( % ),C0001779
398,age > $nmbr$ y  n / n ( % ),C0001779
398,age > $nmbr$ y  n ( % ),C0001779
398,age > $nmbr$ y  %,C0001779
398,age > $nmbr$ y,C0001779
398,age > $nmbr$ vears n = $nmbr$,C0001779
398,age > $nmbr$  y,C0001779
398,age > $nmbr$  %,C0001779
398,age > $nmbr$,C0001779
398,age >,C0001779
398,age < $nmbr$ yrs,C0001779
398,age < $nmbr$ yr or > $nmbr$ yr,C0001779;C0439234
398,age < $nmbr$ yr,C0001779;C0439234
398,age < $nmbr$ y ( n = $nmbr$ ),C0001779
398,age < $nmbr$ y,C0001779
398,age < $nmbr$ vears n = $nmbr$,C0001779
398,age < $nmbr$,C0001779
398,age :,C0001779
398,age . y,C0001779
398,age . . . . . . . . y ( n = $nmbr$ ),C0001779
398,age *,C0001779
398,age ( yrs ) < $nmbr$,C0001779
398,age ( yrs ) $nmbr$ - $nmbr$,C0001779
398,age ( yrs )  mean *,C0001779;C0444504;C2347634;C2348143
398,age ( yrs ),C0001779
398,age ( yr ) *,C0001779;C0439234
398,age ( yr )  mean ( sd ) bmd t - score  mean ( sd ),C0001779;C0439234;C2699239;C3533236
398,age ( yr )  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
398,age ( yr ),C0001779;C0439234
398,age ( yij,C0001779
398,age ( year ),C0001779;C0439234;C0439508
398,age ( y ) ∗,C0001779
398,age ( y ) [ mean - sd ],C0001779;C0444504;C2347634;C2348143;C2699239
398,age ( y )  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
398,age ( y ),C0001779
398,age ( sd )  y,C0001779;C2699239
398,age ( p = o - $nmbr$ ),C0001779
398,age ' ^ $nmbr$ yrs,C0001779
398,age ' $nmbr$ y ( n $nmbr$ ),C0001779
398,age & $nmbr$,C0001779
398,age $nmbr$ y,C0001779
398,age $nmbr$ - $nmbr$ y ( n = $nmbr$ ),C0001779
398,age $nmbr$ - $nmbr$,C0001779
398,age $nmbr$ + yrs,C0001779
398,age $nmbr$ + y,C0001779
398,age $nmbr$ +,C0001779
398,age $nmbr$ * $nmbr$ yr,C0001779;C0439234
398,age $nmbr$ $nmbr$ y,C0001779
398,age $nmbr$,C0001779
398,age $ $nmbr$ yrs,C0001779
398,age # $nmbr$ yrs,C0001779
398,age  yt,C0001779;C1412122
398,age  yrs *,C0001779
398,age  yrs ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
398,age  yrs  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
398,age  yrs,C0001779
398,age  yr  n ( % ),C0001779;C0439234
398,age  yr  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
398,age  yr,C0001779;C0439234
398,age  yf $nmbr$ - $nmbr$,C0001779
398,age  year,C0001779;C0439234;C0439508
398,age  ya,C0001779
398,age  y < $nmbr$,C0001779
398,age  y . o .,C0001779
398,age  y ( sd ),C0001779;C2699239
398,age  y ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
398,age  y,C0001779
398,age  x,C0001779
398,age  n ( % ),C0001779
398,age  mean yr,C0001779;C0439234;C0444504;C2347634;C2348143
398,age  mean,C0001779;C0444504;C2347634;C2348143
398,age,C0001779
398,> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
398,< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
398,- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C0001779;C1079230;C4684719
398,( b ) age subgroups,C0001779;C1304659
397,old stroke *,C1536121
397,aldosterone use,C0002006;C0042153;C0457083;C1947944
397,aldosterone blockers,C0002006
397,aldosterone blocker  %,C0002006
397,aldosterone blocker,C0002006
396,dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0754659
396,dutasteride ( n = $nmbr$ ),C0754659
396,dutasteride,C0754659
396,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
395,ras - aldosterone inhibitor ^,C0002006;C0002007;C0034678;C0525678;C1514727
395,aldosterone inhibitor,C0002007
395,aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004
395,aldosterone antagonists,C0002007;C2757004
395,aldosterone antagonist,C0002007;C2757004;C3536833
394,salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .,C0086706;C0939232
394,salmeterol - fluticasone group ( n = $nmbr$ ),C0441848;C0939232
394,fluticasone - salmeterol ( n = $nmbr$ ),C0939232
394,fluticasone - fluticasone / salmeterol,C0939232
393,cluster seizures,C0036572;C1555715;C1704332
393,cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
393,cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
393,cluster $nmbr$ : diuretic ( n = $nmbr$ ),C1555715;C1704332
392,steroid use at baseline,C0168634;C0281991;C1442488
392,steroid use  %,C0281991
392,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
391,western europe plus other,C0043129
391,western europe hr ( $nmbr$ % cl ),C0043129;C0596019
391,western europe and other,C0043129
391,western europe and lebanon,C0043129
391,western europe and israel,C0043129
391,western europe and australia,C0043129
391,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
391,western europe / australia,C0004340;C0015176;C0043128;C0043129
391,western europe ( n   = $nmbr$  $nmbr$ ),C0043129
391,western europe ( n = $nmbr$ ),C0043129
391,western europe ( including south africa ),C0043129
391,western europe ( % ),C0043129
391,western europe  israel  australia  or south africa,C0004340;C0015176;C0022271;C0043128;C0043129
391,western europe,C0043129
390,no estrogen,C0014939;C2936882;C4542544
390,estrogens,C0014939;C3537250;C3541386;C3714615
390,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
390,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
390,estrogen ( ' % ? ),C0014939;C2936882;C4542544
390,estrogen,C0014939;C2936882;C4542544
389,strategy,C0679199
389,planned treatment strategy,C0599880;C0679199
389,early invasive strategy ( n = $nmbr$  $nmbr$ ),C0205281;C0679199;C1279919;C1334278
389,conservative strategy ( n = $nmbr$  $nmbr$ ),C0679199
388,southern europe,C0037724
388,eastern european,C0239309
388,eastern europe and africa,C0015177
388,eastern europe ( n   = $nmbr$  $nmbr$ ),C0015177
388,eastern europe ( n = $nmbr$ ),C0015177
388,eastern europe ( % ),C0015177
388,eastern europe  africa,C0001737;C0001741;C0015176;C0015177
388,eastern europe,C0015177
388,eastern and central europe,C1707877
388,east europe,C0015176;C1707877
388,central europe,C0682369
387,western friroce,C1705493
387,western eu  australia  new zealand,C0015179;C0027978;C0043128;C0324547;C1705493;C3665627;C4289954
387,western,C1705493
386,repaired s - p shunts,C0205340
386,repaired chd,C0205340;C0280604;C3542407
386,pre - specified trial endpoints,C2826245
386,pre - specified hr ( $nmbr$ % cl ),C2826245
385,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
385,prevalent vertebral fracture  n ( % ),C0033105;C0080179;C0220900
385,prevalent vertebral fracture,C0033105;C0080179;C0220900
385,prevalent cvd,C0007222;C0033105;C0220900
385,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
384,vte / vte - related deathsb  n / n ( % ),C0439849;C0445223;C0630906
384,vte / vte - related deathsa  n / n ( % ),C0439849;C0445223;C0630906
384,unprovoked vte n ( % ),C0630906
384,previous vte — no . ( % ),C0205156;C0630906;C1552607
384,previous vte n ( % ),C0205156;C0630906;C1552607
384,previous vte  n ( % ),C0205156;C0630906;C1552607
384,previous vte,C0205156;C0630906;C1552607
384,any vte or vte - related death — no . ( % ),C0630906
384,any vte - related death,C0425043;C0630906
383,sri ‐ $nmbr$ response rate  %,C0237629;C1420401
383,reversibility to salbutamol  %,C1271924
383,preferred term  %,C1709637;C2347664
383,fevi reversibility — %,C3830088
382,reversible to bronchodilator  b %,C0006280;C0205343
382,reversible to albuterolc  d  n ( % ),C0205343
382,reversible ( % ),C0205343
382,reversible,C0205343
382,non - reversible ( % ),C0205343;C1518422
381,preamendment,C1548596
381,before amendment ( % ),C0680532;C2346732
381,before amendment,C0680532;C2346732
381,after amendment ( % ),C0680532;C2346732
381,after amendment,C0680532;C2346732
380,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
380,treatment arm,C1522541
380,by treatment arm,C1522541
379,preoperative heart rate ( beats per minute ),C0018810;C0445204
379,heart rates ( beats / minutes ),C0018810
379,heart rate 一 beats / min,C0018810
379,heart rate — bpm,C0018810
379,heart rate — beats / min,C0018810
379,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
379,heart rate at baseline  bpm,C0018810;C0168634;C1442488
379,heart rate > $nmbr$ bpm,C0018810
379,heart rate < $nmbr$ bpm,C0018810
379,heart rate ( sd )  bpm,C0018810;C2699239
379,heart rate ( sd ),C0018810;C2699239
379,heart rate ( min − $nmbr$ ),C0018810;C0702093;C1524029;C3813700
379,heart rate ( bpm ) *,C0018810
379,heart rate ( bpm ),C0018810
379,heart rate ( bpm $nmbr$ ) *  * *,C0018810
379,heart rate ( beats per minute ),C0018810
379,heart rate ( beats per min ),C0018810
379,heart rate ( beats / min ),C0018810
379,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
379,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
379,heart rate  bpm,C0018810
379,heart rate  beats per minute,C0018810
379,heart rate  beats per min,C0018810
379,heart rate  beats / min  mean ± sd,C0018810
379,heart rate  beats / min,C0018810
379,heart rate  b . p . m . mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
379,heart rate  / min,C0018810;C0702093;C1524029;C3813700
379,heart rate,C0018810
379,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
379,baseline heart rate ( beats / min ),C0018810;C0168634;C1442488
379,$nmbr$ - lead ecg heart rate  beats / min,C0018810;C0179504
378,saba reversibility,C0449261
378,reversibility ’ ' %,C0449261
378,reversibility — %,C0449261
378,reversibility to,C0449261
378,reversibility stratum *,C0449261
378,reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
378,reversibility of fev $nmbr$ ( % ),C0449261;C3714541
378,reversibility [ % ]  median ( range ),C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
378,reversibility > $nmbr$ % ( n = $nmbr$ ),C0449261
378,reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
378,reversibility < $nmbr$ % ( n = $nmbr$ ),C0449261
378,reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
378,reversibility : > $nmbr$ - < $nmbr$ %,C0449261
378,reversibility : > $nmbr$ %,C0449261
378,reversibility : < $nmbr$ %,C0449261
378,reversibility *,C0449261
378,reversibility ( % predicted fev $nmbr$ ) *,C0449261
378,reversibility ( % ) t,C0449261
378,reversibility ( % )  median ( range ) c,C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
378,reversibility ( % ),C0449261
378,reversibility %,C0449261
378,reversibility  %,C0449261
378,reversibility,C0449261
378,fev $nmbr$ reversibility  % b,C0449261;C3714541
378,fev $nmbr$ reversibility  % *,C0449261;C3714541
378,fev $nmbr$ % reversibility ( sd ),C0449261;C2699239;C3714541
378,fev $nmbr$ % reversibility,C0449261;C3714541
378,bronchial reversibility %,C0205039;C0449261;C1442216
378,albuterol reversibility  %,C0001927;C0449261
378,airway reversibility  mean  %,C0178987;C0444504;C0449261;C0458827;C2347634;C2348143
378,airway reversibility  %,C0178987;C0449261;C0458827
378,airflow reversibility — no . ( % ) |,C0231999;C0449261
378,absolute reversibility in fev $nmbr$  ml *,C0205344;C0439526;C0449261;C1705224;C3714541;C3887665
378,% reversibility in fev ^ at,C0449261;C3714541
378,% reversibility,C0449261
378,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
377,weekly iss {,C0332174;C1740819;C1845118
377,weekly iss $nmbr$,C0332174;C1740819;C1845118
377,weekly,C0332174
377,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
376,network,C0150775;C1513822;C1705739;C1882071
376,enox,C3147679
375,jejunum,C0022378
375,belgium,C0004950
374,region  europe union,C0015179;C0017446;C0205147
374,european union,C0015179
374,eu,C0015179;C3665627
374,eastern eu,C0015179;C1707877;C3665627
373,yes  no,C1512698
373,hla - b $nmbr$,C0019737;C0550853;C1415561
373,hl 土 $nmbr$ . $nmbr$,C1453952;C4085347
373,( yes / no ),C1512698
372,p . b “ int,C1539794;C3272375
372,p . b * int,C1539794;C3272375
372,int . p *,C3272375
371,xho  p = o - $nmbr$,C4050013
371,tp vs no tp,C0036183;C3541334
370,cox bsl onlyc,C1549954;C1565830
370,cox bsl + yr $nmbr$ hbd,C0439234;C1549954;C1565830
369,p value for dm vs . no dm,C4086240
369,cha $nmbr$ ds $nmbr$ - vasc > $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc < $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc # $nmbr$,C1420648;C3714751
369,cha $nmbr$ ds $nmbr$ - vasc,C1420648;C3714751
369,baseline cha $nmbr$ ds $nmbr$ - vascb  c,C0168634;C1420648;C1442488;C3714751
368,qids - sr $nmbr$,C4331197
368,adcs - adl score *,C0449820;C3641947;C4050231
368,adcs - adl,C3641947
368,a $nmbr$ s - hydroxy -,C0700307
367,tass ’,C0559483
367,mtss cfb,C0009002;C1824728
367,class iii,C0441887;C2698969
366,das $nmbr$ score,C0051767;C0057671
366,das $nmbr$ - hscrp,C0051767;C0057671
366,das $nmbr$ - esr lda,C0051767;C0057671;C3811131;C4553195
366,das $nmbr$ - esr,C0051767;C0057671;C3811131
366,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t,C0051767;C0057671;C3811131
366,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *,C0051767;C0057671;C3811131
366,das $nmbr$ - $nmbr$ ( esr ) $nmbr$,C0051767;C0057671;C3811131
366,das $nmbr$ - $nmbr$ ( esr ),C0051767;C0057671;C3811131
366,das $nmbr$ ( esr ),C0051767;C0057671;C3811131
366,das $nmbr$,C0051767;C0057671
365,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
365,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
365,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
365,updrs  part iii ( motor ),C0439070;C0449719;C1513492;C1705160;C1705994;C1709471;C3639721
365,nyha iii or iv § ( n = $nmbr$ $nmbr$ ),C0439070;C1275491;C1705160
365,nyha iii or iv,C0439070;C1275491;C1705160
365,nyha iii  n ( % ),C0439070;C1275491;C1705160
365,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
365,ncep atp - iii metabolic syndrome features  n ( % ),C0439070;C0524620;C1705160;C2744579;C4552600
365,iii or iv,C0439070;C1705160
365,iii and iv ejection fraction,C0439070;C1705160
365,iii and iv,C0439070;C1705160
365,iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted,C0439070;C1705160;C3714541
365,iii / iv,C0022326;C0439070;C1705160;C4265176
365,iii - iv,C0022326;C0439070;C1705160;C4265176
365,iii ( n z $nmbr$ ),C0439070;C1705160
365,iii ( $nmbr$ ),C0439070;C1705160
365,iii & iv,C0022326;C0439070;C1705160;C4265176
365,iii,C0439070;C1705160
365,ii / iii,C0439070;C1705160;C1710602;C4082587
365,ii - iii,C0439070;C1705160;C1710602;C4082587
365,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
365,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
365,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
365,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
365,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
364,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
364,no gi bleed,C1708130;C3539617;C4050121
364,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
364,gi bleed,C1708130;C3539617;C4050121
364,$nmbr$ - gi,C1708130;C3539617;C4050121
363,six - minute walk distance  m,C0012751;C0369637;C0441923;C3900196
363,moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
363,min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923;C0702093;C1524029;C3813700
363,mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
363,mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
363,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
363,mab,C0003250;C0369637
363,m being,C0369637;C0441923
363,m,C0369637;C0441923
363,k - m % n,C0369637;C0441923;C0597277;C1708601
363,k - m %,C0369637;C0441923;C0597277;C1708601
363,hr ( b . p . m . ),C0369637;C0441923
363,gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1424601
363,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area,C0017446;C0017654;C0205146;C0369637;C0439445;C0441923;C0489451;C0750572;C1424601
363,cardiac index  l • mn ' • m $nmbr$,C0026327;C0026405;C0369637;C0428776;C0441923;C4285072
363,baseline pfd  m,C0016065;C0168634;C0369637;C0441923;C1442488;C1839454;C2827389;C3889643
363,baseline mwd  m,C0168634;C0369637;C0441923;C1442488
363,baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
363,baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
363,baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
363,baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
363,baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
363,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
363,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
363,baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
363,baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
363,baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
363,baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
363,azl - m / cld ( n = $nmbr$ ),C0369637;C0441923
363,azl - m + hctz ( n = $nmbr$ ),C0020261;C0369637;C0441923
363,azl - m + cldb,C0369637;C0441923
363,azl - m $nmbr$ mg + cld $nmbr$ mg,C0369637;C0441923;C1319635
363,azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ ),C0369637;C0441923;C2827881
363,azl - m,C0369637;C0441923
363,> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
363,> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923
363,> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
363,> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
363,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
363,< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
363,$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1705224;C3887665
363,$nmbr$ to < $nmbr$ m um in,C0369637;C0441923
363,$nmbr$ mwt ( m ),C0369637;C0441923
363,$nmbr$ mwd decrease > $nmbr$ m,C0369637;C0392756;C0441923;C0547047
363,$nmbr$ mwd  m,C0369637;C0441923
363,$nmbr$ mw distance  m,C0012751;C0024548;C0026385;C0369637;C0441923;C0556966
363,$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
363,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
363,$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
362,use of medications for pah — no . ( % ),C0013227;C0802604;C1524063;C2598133;C4284232
362,use of medication from randomization through $nmbr$ hr — no . / total no . ( % ),C0013227;C1524063;C3244316;C4284232
362,use of medication for pah,C0013227;C1524063;C3244316;C4284232
362,use of medication at baseline — no . ( % ),C0013227;C1524063;C3244316;C4284232
362,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
362,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
362,systemic sle medications  n ( % ),C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
362,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
362,study medication  pre - dose,C0013227;C0557651;C2603343;C3244316;C4284232
362,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
362,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
362,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
362,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
362,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
362,periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *,C0013227;C0024671;C0026410;C0070166;C0439269;C0802604;C1960952;C2346927;C2598133;C4284232;C4321396;C4521761
362,periprocedural medications  n ( % ),C0013227;C0802604;C2598133;C4284232
362,periprocedural medications,C0013227;C0802604;C2598133;C4284232
362,other medications,C0013227;C0802604;C2598133;C4284232
362,other medication usage,C0013227;C0457083;C3244316;C4284232
362,other drugs — no . ( % ),C0013227;C3687832
362,other drugs,C0013227;C3687832
362,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,no . of previous ciu / csu medications  mean ( median ),C0013227;C0205156;C0444504;C0549183;C0578870;C0802604;C0876920;C1552607;C2347634;C2347635;C2348143;C2348144;C2598133;C2939193;C4284232
362,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
362,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
362,no . of drugs,C0013227;C3687832
362,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
362,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
362,medications through day $nmbr$,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
362,medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232
362,medications on admission  %,C0013227;C0802604;C2598133;C4284232
362,medications in use at baseline — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
362,medications in use at baseline — no . ( % ),C0013227;C0802604;C2598133;C4284232
362,medications in use at baseline  n ( % ),C0013227;C0802604;C2598133;C4284232
362,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0802604;C1510665;C2598133;C4284232
362,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0802604;C2598133;C4284232
362,medications during hospitalization or at discharge,C0013227;C0019993;C0802604;C2598133;C4284232
362,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
362,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
362,medications at baselinet,C0013227;C0802604;C2598133;C4284232
362,medications at baseline  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
362,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
362,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
362,medications *,C0013227;C0802604;C2598133;C4284232
362,medications ( % ),C0013227;C0802604;C2598133;C4284232
362,medications  no . ( % ),C0013227;C0802604;C2598133;C4284232
362,medications  n ( % of patients ),C0013227;C0030705;C0802604;C2598133;C4284232
362,medications  n ( % ),C0013227;C0802604;C2598133;C4284232
362,medications  n,C0013227;C0802604;C2598133;C4284232
362,medications,C0013227;C0802604;C2598133;C4284232
362,medication — no . ( % ),C0013227;C3244316;C4284232
362,medication within $nmbr$ days before enrolment,C0013227;C0439228;C3244316;C4284232
362,medication useb,C0013227;C3244316;C4284232
362,medication use — no . { % ),C0013227;C3244316;C4284232
362,medication use — no . ( % ) ^ |,C0013227;C3244316;C4284232
362,medication use — no . ( % ),C0013227;C3244316;C4284232
362,medication use  no . / total no . ( % ),C0013227;C3244316;C4284232
362,medication taken alone or in combination,C0013227;C3244316;C4284232
362,medication prior to admission  ( % ),C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
362,medication in use at the baseline,C0013227;C3244316;C4284232
362,medication continued into double - blind treatment period,C0013227;C3244316;C4284232
362,medication at randomization  n ( % ),C0013227;C0034656;C3244316;C4284232
362,medication at randomization  %,C0013227;C0034656;C3244316;C4284232
362,medication at randomization,C0013227;C0034656;C3244316;C4284232
362,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
362,medication $nmbr$ ( $nmbr$ . $nmbr$ ),C0013227;C3244316;C4284232
362,medication  n ( % ),C0013227;C3244316;C4284232
362,medication,C0013227;C3244316;C4284232
362,lowering drugs,C0013227;C0441994;C2003888;C3687832
362,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
362,lipid medication  n ( % ),C0013227;C0023779;C3244316;C4284232
362,ipah / fpah / drug and toxin,C0013227;C0152171;C1254351;C1419079
362,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
362,immunomodulatory drugs,C0013227;C3687832
362,glycemic drugs,C0005802;C0013227;C3687832
362,epilepsy drug,C0013227;C0014544;C1254351
362,due to drug - relateda ae,C0013227;C1254351;C3887670
362,drugs used in diabetes  n ( % ),C0013227;C3687832
362,drugs used in diabetes,C0013227;C3687832
362,drugs and toxins,C0013227;C3687832
362,drug ‐ relateda,C0013227;C1254351
362,drug naive,C0013227;C1254351
362,drug eluting,C0013227;C1254351
362,drug and insulint,C0013227;C1254351
362,drug - relateda,C0013227;C1254351
362,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
362,drug - related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
362,drug - related teaes,C0013227;C0439849;C0445223;C1254351
362,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
362,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
362,drug - eluting,C0013227;C1254351
362,dm medication  n ( % ) c,C0011816;C0013227;C3244316;C3250443;C4284232
362,discharge medication  n ( % ),C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
362,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
362,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
362,creatinine $nmbr$ . $nmbr$ mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
362,concomitant pd medications at baseline  n ( % ) c  d,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
362,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications in > $nmbr$ % of subjects  no . ( % ),C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
362,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
362,concomitant medications ( yes )  n ( % },C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
362,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications  no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications  n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications  * n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications  %,C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
362,concomitant medication — no . { % ) | ace inhibitor,C0013227;C0521115;C3244316;C4284232
362,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
362,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
362,concomitant medication ( > $nmbr$ % ),C0013227;C0521115;C3244316;C4284232
362,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
362,concomitant medication  no . ( % ),C0013227;C0521115;C3244316;C4284232
362,concomitant medication  n [ % ],C0013227;C0521115;C3244316;C4284232
362,concomitant medication  n ( % ) d,C0013227;C0521115;C3244316;C4284232
362,concomitant medication  n ( % ),C0013227;C0521115;C3244316;C4284232
362,concomitant medication,C0013227;C0521115;C3244316;C4284232
362,concomitant drugs  %,C0013227;C0521115;C3687832
362,concomitant drugs,C0013227;C0521115;C3687832
362,concomitant asthma medications  n ( % ),C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
362,cardiac medications during indexhospitalization and / or discharge,C0013227;C0018787;C0802604;C1522601;C2598133;C4284232
362,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
362,cardiac medications during index hospitalization  %,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
362,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
362,cardiac medications during index hospital stay and / or discharge,C0013227;C0428776;C0802604;C2598133;C3489408;C4284232
362,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
362,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
362,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
362,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
362,baseline medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
362,baseline cv medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
362,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
362,any medication,C0013227;C3244316;C4284232
362,any drug - related ae  n ( % ),C0013227;C0439849;C0445223;C1254351;C3887670
362,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
362,antithrombotic medications  n ( % ),C0013227;C0802604;C2598133;C4284232
362,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
362,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
362,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
362,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
362,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
362,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
362,annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^,C0013227;C3687832
362,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
362,> $nmbr$ drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
362,> $nmbr$ drug - related,C0013227;C0439849;C0445223;C1254351
362,> $nmbr$ concomitant medication,C0013227;C0521115;C3244316;C4284232
361,uncertain,C0087130;C4085655
361,shoulder pain,C0037011
361,rest pain,C0234253
361,bodily pain,C3890602
360,neoplasia  n ( % ),C0027651;C1882062
360,neoplasia,C0027651;C1882062
360,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
359,western european includinq australia  israel  and south africa,C0004340;C0022271;C0043128;C0239307;C0239312;C1535514
359,non - european trial,C0008976;C0239307;C1518422;C1535514
359,non - european,C0239307;C1518422;C1535514
359,european trial,C0008976;C0239307;C1535514
359,european subcategories,C0239307;C1515010;C1535514
359,european or arab,C0239307;C1535514
359,european,C0239307;C1535514
358,severity of copda  airflow limitation  n ( % ),C0231999;C0439793;C0443288;C0449295;C0522510
358,severity of copd  airflow limitation  n ( % ),C0024117;C0231999;C0439793;C0443288;C0449295;C0522510;C1412502;C3714496
358,severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
358,severity of airflow limitation ( gold $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
358,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
358,restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852
358,$nmbr$ = some restrictions  no help needed,C0443288
357,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
357,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
357,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1552654;C1552713;C4086878
357,interval from randomization to angiography,C0034656;C1272706;C1552654;C1552713
357,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
357,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
357,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
357,interval between clinical evaluation and initiation of treatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
356,regional anaesthesia,C0002911
356,general anaesthesia,C0002915;C2930406
356,centrilobular emphysema,C0221227
356,centrally acting sympathomimetics,C3653511
356,central america and south america,C0007674
355,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
355,neuraxial alonee,C3714787
355,central nervous system,C3540014;C3714787
354,other anti - platelet agents,C0005821;C0040616
354,nonaspirin antiplatelet agent,C0085826;C0722138
354,nonaspirin antiplatelet,C0722138
353,requiring assistance,C0018896;C1269765
353,$nmbr$ = help needed  still independent,C1269765;C1552861
352,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
352,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
352,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0542331;C1299392;C1442858
352,pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
352,pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
352,large shunt,C0232180;C0542331;C0549177;C1442858
352,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
352,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
352,assoc  with corrected congenital shunts,C0009678;C0205202;C0232180;C0542331;C1442858;C1744681
351,social functioning,C0037395
351,social function,C0037395
351,severe dysfunction,C3274777
351,normal renal function,C0232805
351,erectile dysfunction,C0242350;C1961100
351,cognitive functioning,C0392334;C0392335
350,physical functioning,C0516981;C4049916
350,physical function,C0516981;C4049916
350,assessment of physical function ( $nmbr$ - $nmbr$  haq - di ),C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C3826998;C4049916;C4321476
349,serious decline in kidney function *,C0205404;C0232804
349,serious decline in kidney function $nmbr$,C0205404;C0232804
349,renal function subgroups,C0232804;C1079230
349,renal function : ! : n ( % ),C0232804
349,renal function *,C0232804
349,renal function ( ml / min ),C0232804;C0439445
349,renal function  severe,C0232804
349,renal function  moderate,C0232804
349,renal function  bn ( % ),C0005005;C0034700;C0232804;C1706574;C4551963
349,renal function,C0232804
349,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0868945
348,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
348,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
348,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
348,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
348,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
348,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
348,non - black  us,C0005680;C0027567;C0085756;C0439541;C1518422
348,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
348,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
348,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
348,black or african heritage,C0005680;C0027567;C0085756;C0439541
348,black or african american,C0005680;C0027567;C0085756;C0439541
348,black or african america,C0005680;C0027567;C0085756;C0439541
348,black or african - american,C0005680;C0027567;C0085756;C0439541
348,black / african american *,C0085756
348,black / african american,C0085756
348,black / african - american ( $nmbr$ . $nmbr$ % ),C0085756
348,black / african - american,C0085756
348,black / af rican american,C0085756;C0344434;C4049859
348,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541
348,african americans,C0085756
348,african american n = $nmbr$,C0085756
348,african american / black,C0005680;C0027567;C0085756;C0439541
348,african american  n ( % ),C0085756
348,african american,C0085756
348,african america,C0085756
348,african - latin american,C0085756
348,african - american / african heritage ( n = $nmbr$ ),C0085756;C2986513
348,african - american,C0085756
348,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541
348,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
348,$nmbr$ fe black *,C0005680;C0027567;C0085756;C0439541;C3848561
347,non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
347,non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
347,non - black race ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
347,non - black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541;C1518422
347,non - black  worldwide,C0005680;C0027567;C0085756;C0439541;C1518422
347,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541
347,black race — no . / total no . ( % ) f,C0005680;C0027567;C0085756;C0439541
347,black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680
347,black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -,C0005680
347,black race ( n = $nmbr$ vs $nmbr$ ),C0005680
347,black race  n ( % ),C0005680
347,black race,C0005680
347,black or asian,C0005680;C0027567;C0085756;C0439541
347,black or african,C0005680;C0027567;C0085756;C0439541
347,black and other,C0005680;C0027567;C0085756;C0439541
347,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
347,black /,C0005680;C0027567;C0085756;C0439541
347,black *,C0005680;C0027567;C0085756;C0439541
347,black ( n — $nmbr$ ),C0005680;C0027567;C0085756;C0439541
347,black ( n   = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
347,black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
347,black  worldwide,C0005680;C0027567;C0085756;C0439541
347,black  us,C0005680;C0027567;C0085756;C0439541
347,black  no . ( % ),C0005680;C0027567;C0085756;C0439541
347,black  n ( % ),C0005680;C0027567;C0085756;C0439541
347,black,C0005680;C0027567;C0085756;C0439541
346,pasi ^ i,C0021966;C0221138;C4528685
346,pasi < $nmbr$ *,C4528685
346,pasi *,C4528685
346,pasi $nmbr$ a,C4528685
346,pasi $nmbr$  no . / total no . ( % ) $nmbr$,C4528685
346,pasi $nmbr$,C4528685
346,pasi # $nmbr$ at week $nmbr$,C0332174;C0439230;C4528685
346,pasi,C4528685
345,past smoker,C0337664;C1444637;C4284302
345,past or nonsmoker ( n = $nmbr$ ),C1444637;C4284302
345,past or nonsmoker,C1444637;C4284302
345,past or never,C1444637;C4284302
345,past or current angina pectoris,C1444637;C4284302
345,past or current,C1444637;C4284302
345,past,C1444637;C4284302
345,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
345,current / past smoker,C1444637;C3173209;C3241966;C4284302
344,ptca or pci,C2936173
344,ptca only,C0205171;C1720467;C2936173
344,ptca < $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
344,ptca / cabg,C0010055;C2936173
344,ptca,C2936173
344,prior ptca or pci,C0332152;C2826257;C2936173
344,prior ptca or cabg,C0332152;C2826257;C2936173
344,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
344,percutaneous transluminal coronary angioplasty,C2936173
344,both ptca and cabg,C2936173
343,perindopril - indapamide,C1273169
343,pctindopnl - indapamide ( n = $nmbr$ ),C0021186
342,tpm - naive,C0076829
342,tpm - exposed,C0076829
342,topiramate,C0076829
341,proximal to the splenic flexure,C0205107;C0227387;C4489236
341,proximal gl tract  n ( % ),C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
341,proximal gi tract,C0017189;C0205107;C4489236
341,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
341,proximal - mainleft,C0205107;C4489236
341,proximal,C0205107;C4489236
340,lower - limb angioplasty or bypass surgery,C0745788
340,coronary angioplasty or stenting,C0002997;C0190211
340,balloon angioplasty — no . ( % ),C0002996;C0002997
340,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
340,balloon angioplasty,C0002996;C0002997
339,pulmonary embolism only,C0034065;C0205171;C1720467
339,pulmonary embolism,C0034065
339,pulmonary disease — no . ( % ),C0024115
339,pulmonary disease,C0024115
338,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
338,st ‐ str ≥ $nmbr$ % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
338,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
338,post svc,C0231957;C0687676;C1704687;C3469826
338,post - salbutamol fev $nmbr$ / fvcb  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
338,post - salbutamol fev $nmbr$ ( l ) b  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
338,post - cabg,C0010055;C0687676;C1704687;C3469826
338,post - albuterol % predicted fev $nmbr$ mean ( sd ) e,C0001927;C0687676;C1704687;C3469826
338,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
337,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
337,lone atrial fibrillation — no . ( % ) §,C0340489
337,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
337,glatiramer acetate  no . ( % ),C0289884
337,fluindione  no . ( % ),C0117899
337,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
337,elevated crp ( > ulnt )  n ( % ),C0742906
337,elevated crp  n ( % ),C0742906
337,dopamine agonist use  no . ( % ),C0178601;C3536925
337,coronary risk factors — no . ( % ),C2024776
337,adults ( aged   ≥ $nmbr$ y )  no . ( % ),C0001675
337,adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % ),C0205653
337,abdominal aortic — no . ( % ),C0003484
336,simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /,C0033228;C0074554;C0332287;C1319635
336,fluticasone furoate and vilanterol ( n = $nmbr$ ),C1948374
336,fluticasone furoate  n = $nmbr$,C1948374
336,fenofibrate ( n = $nmbr$ ),C0033228
335,riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ ),C0683610;C4553947
335,notatincreased fall risk ( n - $nmbr$  $nmbr$ ),C1268740
335,normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
335,no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c,C0068000;C1948062
335,low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
335,at increased fall risk ( n - $nmbr$ ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
334,prevention )  n ( % ) patients on llt ( other than statin )  n ( % ),C0030705;C0199176;C1706420;C2347090;C2700409
334,leeds enthesitis index ^ score > $nmbr$ — no . { % ),C0451148
334,leeds enthesitis index  mean ( sd ) ’ ’ * ’,C0444504;C0451148;C2347634;C2348143;C2699239
334,gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$,C0199176;C1706420;C2700409
333,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C1556315
333,right ventricular dysfunction  n / n ( % ) j,C0242707;C1556315
333,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
333,negative for helicobacter pylori — no . / total no . ( % ),C4688581
333,method of identification ofstenosis ( % ),C1301921
333,maintenance use — no . ( % ),C0024501
333,maintenance ocs use  n ( % ),C0024501
333,left ventricular systolic dysfunction  n ( % ),C1277187;C1963159;C4553199
333,lacunar infarction  n ( % ),C0333559
333,injection - site reaction  n ( % ),C0151735;C4551923
333,helicobacter pylori - negative  n ( % ),C4688581
333,geographical location  n ( % ),C4545686
333,current medication — no . ( % ),C0746467
333,current medication  n ( % ),C0746467
332,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
332,residual perfusion defect > $nmbr$ % on lung scan  no . ( % ),C1457869;C1518040;C1609982
332,involved intestinal area  n ( % ),C0021853;C1879646
332,draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177
332,chronic sinusitis + nasal polypsd  n ( % ),C0028429;C0149516;C4520890
332,bone erosion ( judged by physician )  n ( % ),C0587240
332,abdominal or perianal fistula at baseline  n ( % ),C0000726
331,vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
331,vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
331,vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
331,vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
331,vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
331,umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ ),C0205999
331,umec / vi $nmbr$ . $nmbr$ / $nmbr$,C0205999
331,tnf - r $nmbr$ a ( ng / ml ),C1363984;C1706001
331,tg  mmol / l [ mg / dl ],C0337445;C3642216;C3898312
331,tg  mmol / l ( mg / dl ) [ median ],C0337445;C0549183;C0876920;C2347635;C2348144;C2939193;C3642216;C3898312
331,tc  mmol / l ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3642216;C3898312;C4522122
331,ldl - c  mmol / l ( mg / dl ),C3642216;C3898312
331,irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,C4082285
331,hdl - c  mmol / l ( mg / dl ),C3642216;C3715113;C3898312
331,hazard ratio  umec / vi vs . tio ( $nmbr$ % ci ),C0205999;C2985465
331,fpg  mmol / l ( mg / dl ),C3642216;C3898312
331,apo a - l ( g / l ),C0628062
331,[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ ),C0043476
331,- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r,C0722969
331,$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %,C0205999
331,$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %,C0205999
330,eos serum k +  meq / l,C0302353;C0439375;C1623465;C1861303
330,elevated bun ( > $nmbr$ . $nmbr$ meq / l ),C0151539;C0439375
330,baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
330,baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
330,baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
329,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
329,pace  no . ( $nmbr$ ),C0287990;C1552930;C4048252
329,hscrp > $nmbr$ . $nmbr$ mga .,C0065879
329,hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ ),C0065879
329,age group — no . ( % ),C0027362;C2348001
329,age group ( ≥ $nmbr$ years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
329,age group ( ≥ $nmbr$ ) — no . ( % ),C0027362;C2348001
329,age group  no . ( % )  y,C0027362;C2348001
329,age group  no . ( % ),C0027362;C2348001
329,age cohort  no . ( % ),C2348001
329,acarbose 一 no . ( % ),C0050393
329,< $nmbr$ vr — no . ( % ),C3476815
329,$nmbr$ / $nmbr$ mga ( n = $nmbr$ ),C0065879
329,$nmbr$ - $nmbr$ vr — no . ( % ),C3476815
328,nfs > $nmbr$ . $nmbr$ ( high ),C1555018
328,nfs < - $nmbr$ . $nmbr$ ( low ),C1555018
328,low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
328,high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
327,vascular disease indicator no ( n = $nmbr$ ),C0021212;C0042373;C1235732;C1522602
327,patient ' s history of :,C0679831;C1369882
327,medical history  n ( % of patients ),C0679831;C1369882;C1609576
327,ischemic heart disease indicator no ( n = $nmbr$ l ),C0010054;C0021212;C0151744;C1235732;C1522602
327,bilateral disease ( % ) ' j ' ' j ',C1511113
326,umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
326,tio $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
326,sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$,C0021027;C0305052;C0360506;C4521536
326,qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
326,olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
326,olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
326,ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
326,ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0205999;C0305052;C0360506;C4554348
326,ff $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506;C4554348
325,proteinuria ( > $nmbr$ g / $nmbr$ h )  %,C0033687;C0560020;C1962972;C4554346
325,proteinuria $nmbr$ ( g / day ),C0033687;C0439417;C1962972;C4554346
325,protein in urine    ≥ $nmbr$ +,C0033687
325,greater than or equal to $nmbr$ mm hg,C0439093
325,greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439093
325,greater than or equal to $nmbr$ %,C0439093
324,total group ( n = $nmbr$ ),C0439175;C0439810;C0441848
324,rate - control group ( n = $nmbr$ ),C0441848;C0489879
324,no epa group n = $nmbr$,C0441848
324,no - diuretics group ( n = $nmbr$ ),C0012798;C0441848
324,nc group ( n = $nmbr$ ),C0027964;C0028407;C0067895;C0265987;C0441848
324,group c ( n = $nmbr$ ),C0441848
324,group b ( n = $nmbr$ ),C0441848
324,group a ( n = $nmbr$ ),C0441848
324,fatty acid group ( n = $nmbr$ ),C0015684;C0441848
324,epa group n = $nmbr$,C0441848
324,diuretics group ( n = $nmbr$ ),C0012798;C0441848
324,device group ( n = $nmbr$ ),C0025080;C0441848;C0699733
324,colesevelam hydrochloride group ( n = $nmbr$ ),C0441848;C0541154
324,c group ( n = $nmbr$ ),C0441848
324,benazepril - hydrochlorothiazide group ( n = $nmbr$ ),C0441848;C0717481
324,benazepril - amlodipine group ( n = $nmbr$ ),C0051696;C0053091;C0441848
324,aspirin group ( n = $nmbr$ ),C0004057;C0441848
324,antiplatelet - only group ( n = $nmbr$ ),C0205171;C0441848;C1720467
324,antiplatelet - onl group ( n = $nmbr$ ),C0441848
323,risedronate n / n ( % ),C0246719
323,risedronate ( n   =   $nmbr$ ),C0246719
323,risedronate ( n = $nmbr$ ),C0246719
323,nintedanib ( n   =   $nmbr$ ),C2930789
323,nintedanib ( n = $nmbr$ ),C2930789
323,drinker ( % ) a,C0556338
323,drinker ( % ),C0556338
323,drinker ( $nmbr$ to $nmbr$ drinks / week ),C0332174;C0439230;C0452428;C0556338
323,drinker ( $nmbr$ - $nmbr$ drinks / week ),C0556338
323,drinker  n ( % ),C0556338
323,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
323,dha ( n = $nmbr$ ),C0142831;C2348308
322,sr ii b $nmbr$ - cjl $nmbr$,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
322,s wave in v $nmbr$ ( mm ),C0456681;C4301968
322,s $nmbr$ gallop  n ( % ),C2986823
322,s $nmbr$ ( n = $nmbr$ ),C2986823
322,rerapamil - sr strategy ( n = $nmbr$ ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
322,$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ ),C2986823
321,psoriasis body surface area > $nmbr$ %,C0005902;C0033860
321,affected body - surface area > $nmbr$ % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
320,pre - bronchodilator fevi / fvc  %,C0802741;C2599602;C3815113
320,fevi / fvc ( % ),C0802741;C3815113
319,type b $nmbr$ / c lesions  n ( % ),C4264484
319,tachyarrhythmias  n ( % ),C0080203
319,smoking habit  n ( % ),C4505437
319,scalp psoriasis  n ( % ),C0406326
319,respiratory medication taken at baseline  n ( % ),C0418986
319,respiratory medication ( % ),C0418986
319,prothrombin mutation ( % ),C1610621
319,prior analgesic products  n ( % ),C0002771;C0332152;C2826257
319,pr / virgin islands  n ( % ),C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
319,paternal history  n ( % ),C0424909
319,nutraceuticals  n ( % ),C1518478
319,nos $nmbr$ glu $nmbr$ asp g . t  n ( % ),C0125690;C0326287;C0439267;C1518425
319,nos $nmbr$ $nmbr$ c . t  n ( % ),C0326287;C1518425
319,nos $nmbr$ $nmbr$ a . g  n ( % ),C0326287;C1518425
319,maternal history  n ( % ),C0559473
319,low - trauma fracture since age $nmbr$  n ( % ),C0521170
319,laba plus ics  n ( % ),C0332287;C0815320;C4551720
319,injectable anti ‐ hyperglycaemic  n ( % ),C0432633;C1272883
319,icsa plus laba  n ( % ),C0332287
319,freedom from gtc seizures  n ( % ),C1299590
319,facial psoriasis  n ( % ),C1276112
319,dose adjustment n ( % ),C2826232
319,digital clubbing  n ( % ),C0009080;C0149651
319,ca - channel blockers  n ( % ),C0870261;C3887642
319,bowel stricturing  ' n ( % ),C0267465
319,any llt other than nutraceuticals  n ( % ),C1518478;C2347090
319,anti ‐ tnf ‐ na ï ve    n   ( % ),C0042469;C0432633;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
319,anti ‐ hyperglycaemic agent  n ( % ),C0432633;C1321567
319,anti - tnf - naive  n ( % ),C0432633;C1448177
319,angioedema present  n ( % ) {,C0002994;C0150312;C0449450
319,angioedema present  n ( % ) $nmbr$,C0002994;C0150312;C0449450
319,angioedema ( adjudicated )  n ( % ),C0002994
319,analgesic medication  n ( % ),C0002771
319,> $nmbr$ y pathogenesis  n ( % ),C0543483;C0699748
319,( b ) concomitant respiratory medications [ n ( % ) ],C0418986;C0521115
318,mitral valve disease ( n = $nmbr$ $nmbr$ ),C0026265;C4553832
318,fistula at baseline  n ( % ),C0016169;C0168634;C1442488
318,fistula  ' n ( % ),C0016169
318,distal anastomosis ( % ),C0448964
318,chronic cardiovascular disease  no . ( % ),C1290380
318,aortic valve disease ( n = $nmbr$ $nmbr$ ),C1260873;C4553103
317,pm  n ( % ),C0030266;C4049155
317,lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients ),C0030266;C0523452;C2611142;C4049155
316,tah ( n = $nmbr$ ),C0404079
316,t ( n = $nmbr$  $nmbr$ ),C2986835
316,sun - $nmbr$ ( $nmbr$ ),C0038817;C0376223
316,ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
316,ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
316,sal ( n   = $nmbr$  $nmbr$ ),C0036140;C0037494;C0206136
316,sal ( n = $nmbr$ ),C0036140;C0037494;C0206136
316,phi ( n = $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
316,phi ( n - $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
316,pgi - s  n ( % ) y :,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
316,peace ( n = $nmbr$ ),C0680443
316,no mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
316,mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
316,li $nmbr$ ( $nmbr$ . $nmbr$ ),C0023617;C3495095
316,jvp $ $nmbr$ cm h $nmbr$ o,C0455483
316,jvd $ $nmbr$ cm h $nmbr$ o  %,C0425687;C0455483
316,ivc ( n = $nmbr$ ),C4085887
316,igm ( n = $nmbr$ ),C1706005
316,igl ( n = $nmbr$ ),C0021037;C0314619;C2247518
316,ifx ( n = $nmbr$ ),C0020823
316,ibs ( $nmbr$ . $nmbr$ ),C0022104;C0432306
316,europa ( n = $nmbr$ l $nmbr$ ),C0242751
316,dmab ( n = $nmbr$ ),C0012411
316,avm ( n = $nmbr$ ),C0003857;C0279476
316,avm % △ ( se ),C0003857;C0036919;C0279476
316,ama 士 s . e .,C0002461;C0279755;C2825862
316,am △ 士 s . e .,C3813124;C3890196;C4520798
316,alive ( n = $nmbr$ ),C2584946;C4551704
316,$nmbr$ % c . i .,C1547546
315,wc ( cm ),C0013123;C2825512
315,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
315,imt ( $nmbr$ ),C0334121;C1704614;C4318736
315,exact ( b ),C2828393;C4050514
314,normal weight ( bmi < $nmbr$ ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
314,normal ( bmi < $nmbr$ ),C4229017
314,bl alc < $nmbr$ . $nmbr$ %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
314,alc at weeko ( % ),C1424945;C3811058
314,alc at week $nmbr$ ( % ),C0332174;C0439230;C1424945;C3811058
314,alc > = $nmbr$ . $nmbr$ %,C1424945;C3811058
314,alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,C1424945;C3811058
314,alc < $nmbr$ . $nmbr$ %,C1424945;C3811058
314,alc ( % ),C1424945;C3811058
313,ib ( $nmbr$ . $nmbr$ ),C2744579;C3890035;C4283819
313,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
312,vilanterol  n = $nmbr$,C2935023
312,platelet  $nmbr$ / l,C0456525
312,plaque score ( $nmbr$ - $nmbr$ ),C0429153
312,plaque ( n  % ),C0011389;C0241148;C0332461;C0333463;C4316797
312,lce  n = $nmbr$,C1423759;C3273355
311,range iga modified $nmbr$ score  n ( % ),C1514721;C2348147;C2825347;C3542016
311,iga $nmbr$ / $nmbr$,C2825347
310,strain ( % ),C0080194;C0456178;C1518614;C2987481
310,racec  n ( % ),C4287599
310,origin [ n ( % ) ],C0079946;C0439659;C1550512
310,necrosis  n ( % ) a,C0027540;C1334928
310,kl $nmbr$ ( % ),C1366480;C1416656;C1704887
310,infected  n ( % ) a,C0439663
310,hla - b $nmbr$  n ( % ) ⁎ ⁎,C1426226
310,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
310,fraction ( % ),C1264633;C1554103
310,elms  n ( % ),C0330531;C2980688
310,el  n ( % ),C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
310,clean  n ( % ) a,C1947930
310,cgi - s  n ( % ) z :,C4526016
310,atv n ( % ),C0210243;C0674679;C1145759;C1334862
310,attack ( % ),C0277793;C1261512;C1304680
310,aicd  ( % ),C0972395;C2611803;C3537205;C3546309
309,alprostadil n / n %,C0002335
309,alprostadil n / n,C0002335
309,alprostadil ( n = $nmbr$ ),C0002335
309,aggressive ( n = $nmbr$ ),C0001807;C0580822
309,aggressive ( $nmbr$ ),C0001807;C0580822
308,vasp pri - defined hpr ( % patients ),C0034044;C0255567;C1421428;C1826843;C3539761;C3539762
308,low risk ( ri = $nmbr$ - $nmbr$ ),C0035487;C1826843;C3272281;C3538919
308,( ri = $nmbr$ ),C0035487;C1826843
307,£ $nmbr$ yo ( n = $nmbr$ ),C1413296
307,umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ ),C0439211;C3463985
307,ularitide n / n ( % ),C0077910
307,ularitide ( n = $nmbr$ ),C0077910
307,tirofiban ( n = $nmbr$ ),C0247025
307,tio i $nmbr$ mcg ( n = $nmbr$ ),C0021966;C0221138;C0439211;C3463985
307,teriparatide n / n ( % ),C0070093
307,teriparatide ( n   =   $nmbr$ ),C0070093
307,solifenacin ( n = $nmbr$ ),C1099677
307,sildenafil ( n = $nmbr$ ),C0529793
307,semuloparin ( n = $nmbr$ ),C2700104
307,roflumilast ( n = $nmbr$  $nmbr$ ),C0965618
307,readmission ( n = $nmbr$ ),C1548168;C4489276
307,r $nmbr$ + ezio ( n = $nmbr$ ),C0687673
307,r $nmbr$ ( n = $nmbr$ ),C0687673
307,post - fibrinolysis angioplasty ( n = $nmbr$ ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
307,oxypurinol ( n = $nmbr$ ),C0030086
307,normotensive ( n = $nmbr$ ),C2712122
307,non - carrier ( n = $nmbr$ ),C2986416
307,no readmission ( n = $nmbr$ ),C1548168;C4489276
307,no colchicine ( n = $nmbr$ ),C0009262
307,nebivolol ( n = $nmbr$ ),C0068475
307,montelukast ( n = $nmbr$ ),C0298130
307,monitoring group ( n = $nmbr$ ),C0150369;C0441848;C1283169
307,monitoring ( n = $nmbr$ ),C0150369;C1283169
307,metoprolol group ( n = $nmbr$ ),C0025859;C0441848
307,metoprolol ( n = $nmbr$ $nmbr$ ),C0025859
307,mar ( itt ) ( n = $nmbr$ ),C3829202;C4255469
307,levosimendan ( n   = $nmbr$ ),C0246904
307,ixekizumab every $nmbr$ weeks ( n = $nmbr$ ),C3489764
307,inconsistent fao ( n [ $nmbr$ ),C0016457;C0442809
307,hypertrophy per ecg ( n = $nmbr$ $nmbr$ ),C0020564;C1623258
307,hypertrophy  n ( % ),C0020564
307,heparin ± tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
307,heparin plus tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0332287;C0770546
307,heparin + tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
307,fibrinolysis ( n = $nmbr$ ),C0016017;C1305868
307,eplerenone ( n   = $nmbr$ ),C0961485
307,entocort ec ( n = $nmbr$ ),C1170256
307,dalteparin ( n = $nmbr$ ),C0206461
307,colesevelam ( n = $nmbr$ ),C0541155
307,colchicine ( n = $nmbr$ ),C0009262
307,cholecystectomy ( n = $nmbr$ ),C0008320
307,certolizumab pegol ( n = $nmbr$ ),C1872109
307,certolizumab group ( n = $nmbr$ ),C0441848;C1872109
307,canrenone ( n z $nmbr$ ),C0006882
307,blisibimod ( n = $nmbr$ ),C3713826
307,bempedoic acid ( n = $nmbr$ ),C3659310
307,> $nmbr$ days to $nmbr$ year ( n = $nmbr$ ),C0556972
307,< $nmbr$ yo ( n = $nmbr$ ),C1413296
307,$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ ),C1881833
307,$nmbr$ early intervention ( n = $nmbr$ ),C0242687;C1964029
306,unbound pcsk $nmbr$ ( nmol / l ),C0439282
306,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
306,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
306,testosterone ( nmol / l ),C0039601;C0439282
306,hscrp ( nmol / l ),C0439282
306,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
306,cholesterol ( nmol / l ),C0008377;C0439282
306,$nmbr$ - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
305,phosphorus  mmol $nmbr$ $nmbr$,C0031705;C0080014;C0439190;C3714498
305,homa - ir ( mu / l ^ mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
305,homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b,C0022065;C0022071;C0439190;C0439342;C0444504;C1448132;C2347634;C2348143;C2699239
305,glycemic variability  mmol / lc,C0005802;C0439190;C2827666
305,fpg ( mmol / $nmbr$ ),C0439190
305,fpg  mmol / lt,C0023376;C0230426;C0439190;C3887647;C4521399
305,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
305,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
305,> $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
305,> $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
305,< $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
305,< $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
305,( mu / l $ mmol / l ) b,C0439190;C0439342
304,troponin i ( pg / ml ),C0077401;C0439297
304,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
304,tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$,C0439297
304,tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$,C0439297
304,nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0439297;C1095989;C1317554;C1417808;C2825907;C2982014;C4284038
304,np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
304,np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
304,normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205307;C0231683;C0439166;C0439297;C1095989;C1417808;C2347086;C2982014;C4553972
304,n - terminal pro - brain natriuretic peptide  pg / ml,C0439297;C3272900
304,kim $nmbr$ ( pg / ml ),C0439297
304,interleukin - $nmbr$ ( ng / l ),C0021764;C0439297;C1527200
304,interleukin $nmbr$ ( pg / ml ),C0021764;C0439297;C1527200
304,il - $nmbr$ range  ng / l,C0020898;C0021764;C0022271;C0439297;C1514721;C2348147;C3542016
304,il - $nmbr$ ( pg / ml ),C0020898;C0021764;C0022271;C0439297
304,il - $nmbr$  ng / l,C0020898;C0021764;C0022271;C0439297
304,endothelin $nmbr$ ( pg / ml ),C0079284;C0439297
304,elevated bnp ( $nmbr$ pg / ml )  %,C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
304,elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
304,bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp > $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp > $nmbr$ pg / ml  n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
304,bnp < $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
304,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
304,avp pg / ml,C0439297;C1098706;C1568204;C1708407
304,> ulnand < $nmbr$ ng / l,C0439297
304,> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
304,> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
304,> = $nmbr$ ng / l ( n = $nmbr$ ),C0439297
304,> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
304,> $nmbr$ ng / l,C0439297
304,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
304,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ),C0439297
304,$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
304,$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
303,serum total ige  iu / ml,C0439458;C1441420
303,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
303,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
303,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
303,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
303,fasting serum glucose  mg / dl,C0015663;C0202041;C0439269;C3534430
303,fasting serum glucose  median ( sd )  mg / dl,C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3534430
303,fasting serum glucose  mean ( sd ) mg / dl,C0015663;C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
303,anti - dsdna ( > $nmbr$ iu / ml )  %,C0439458;C0741099
302,feno  $nmbr$ mg dn = $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
302,feno  $nmbr$ dn = $nmbr$ ),C1333964;C1707618
302,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) ',C1319635;C1333964;C1707618
302,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ),C1319635;C1333964;C1707618
301,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
301,plasma lipoproteins  mmol / l,C0023820;C0032105;C1532563;C1550098;C4521445
301,plasma creatine  mg / dl,C0010286;C0032105;C0439269;C1550098;C4521445
301,neutrophils  $nmbr$ / nl,C0027778;C0027950;C0560008;C3892223
301,monocytes  $nmbr$ / nl,C0026473;C0027778;C0560008;C3892223
301,leukocytes  $nmbr$ / nl,C0023516;C0027778;C0560008;C3892223
301,lansoprazole ( n = $nmbr$ ),C0050940
301,lansoprazole $nmbr$ mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
300,三 $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
300,≥ $nmbr$ to < $nmbr$ %,C0040363;C0041260;C1883351
300,study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental,C0031809;C0037712;C0040363;C0041260;C0205485;C0229992;C0348078;C0376315;C0449432;C0557651;C1282927;C1509143;C1522492;C1551338;C1705248;C1806781;C1883351;C2350002;C2603343;C3481509;C4255237;C4554251
300,naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes,C0040363;C0041260;C0199168;C0205476;C1274040;C1883351
300,> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
300,> $nmbr$ to s $nmbr$ yrs,C0040363;C0041260;C1883351
300,> $nmbr$ to < $nmbr$ uln,C0040363;C0041260;C1519815;C1883351
300,> $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
300,> $nmbr$ to $nmbr$,C0040363;C0041260;C1883351
300,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
300,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
300,> $nmbr$ % to < $nmbr$ %,C0040363;C0041260;C1883351
300,$nmbr$ to less than $nmbr$,C0040363;C0041260;C1883351
300,$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ ),C0040363;C0041260;C1883351
300,$nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
300,$nmbr$ to < $nmbr$ ( % ),C0040363;C0041260;C1883351
300,$nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
300,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % ),C0040363;C0041260;C1883351
300,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
300,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
300,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
300,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
300,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
300,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
299,• hemorrhagic stroke,C0553692
299,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
299,non ‐ haemorrhagic stroke — no . ( % ),C0333275;C1518422
299,hemorrhagic stroke ( n = $nmbr$ ),C0553692
299,hemorrhagic stroke,C0553692
299,hemorrhagic,C0333275
299,haemorrhagic stroke — no . ( % ),C0553692
299,haemorrhagic stroke,C0553692
299,haemorrhagic,C0333275
298,hematologic,C0018943;C0205488
298,hematocrit  %,C0018935;C0518014
298,haematological,C0018943;C0200627
297,fragile,C0302113
297,e major non - vertebral fragility fractures ( fas ),C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
297,d non - vertebral fragility fractures ( fas ),C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
296,verapamil ( n  % ),C0042523
296,use of verapamil or quinidine,C0042523;C1524063
295,number ( s ) of features present,C0237753;C0449788;C1521970;C1706388;C2346469;C2348519
295,infarct characteristics,C0021308;C1521970
295,glycemic characteristics,C0005802;C1521970
295,feature,C1521970;C1706388;C2346469;C2348519
295,ed characteristics,C1521970;C3538926
295,e ( characteristic n,C1521970
295,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
295,characteristics no . of participants,C1521970
295,characteristics *,C1521970
295,characteristics,C1521970
295,characteristic_name,C0027365;C1521970;C1547383;C4522128
295,characteristic †,C1521970
295,characteristic at baseline,C0168634;C1442488;C1521970
295,characteristic and treatment,C1521970
295,characteristic age — yr,C0001779;C0439234;C1521970
295,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
295,characteristic age,C0001779;C1521970
295,characteristic ^,C1521970
295,characteristic / outcome,C1274040;C1521970
295,characteristic *,C1521970
295,characteristic ( a ),C1521970
295,characteristic  no . ( % ),C1521970
295,characteristic,C1521970
295,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
295,arthritis characteristics,C0003864;C1521970;C4552845
295,anthropometric characteristics,C0003188;C1521970
295,angiographic characteristics  no . ( % ),C0002978;C1521970
294,secondary p,C0027627;C0175668;C0205436
294,secondary outcomes,C0027627;C0175668;C0205436;C1274040
294,secondary outcome,C0027627;C0175668;C0205436;C1274040
294,secondary nonresponse,C0027627;C0175668;C0205436
294,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
294,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
294,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
294,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
294,secondary end points $nmbr$,C0027627;C0175668;C0205436;C2349179
294,secondary end points,C0027627;C0175668;C0205436;C2349179
294,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
294,secondary *,C0027627;C0175668;C0205436
294,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
294,secondary # $nmbr$,C0027627;C0175668;C0205436
294,metastatic disease,C0027627;C2939419;C2939420
294,key secondary end points,C0027627;C0175668;C0205436;C2349179
293,recent use of allopurinol ( within $nmbr$ days of,C0002144;C0332185;C1524063
293,recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % ),C0013778;C0332185;C0439228
293,recent cardioversion ( within $nmbr$ days before randomization ) —,C0013778;C0332185;C0439228
293,recent,C0332185
292,oral contraceptives,C0009905
292,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151
291,relative risk ( $nmbr$ % confidence interval ),C0009667;C0242492
291,$nmbr$ % confidence interval,C0009667
290,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
290,select lipids and lipoproteins,C1707391
290,elective surgery,C0206058
290,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
289,percentages,C0439165;C1549488;C1561533
289,percentage with disease duration < $nmbr$ years,C0439165;C0439234;C0872146;C1549488;C1561533
289,percentage points,C0439165;C1549488;C1561533
289,percentage of time in therapeutic inr range  mean ( sd ),C0040223;C0439165;C1549488;C1561533;C3541383
289,percentage of p,C0439165;C1549488;C1561533
289,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
289,percentage of females,C0086287;C0439165;C1549488;C1561533
289,percentage of days without heartburn,C0439165;C0439228;C1549488;C1561533
289,percentage of bsa involved,C0439165;C1549488;C1561533
289,percentage,C0439165;C1549488;C1561533
289,percent work time missed due to asthma,C0040223;C0043227;C0439165;C3541383
289,percent overall work impairment due to asthma,C0439165
289,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C3541383
289,mean percentage of nights without heartburn,C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
289,between - treatment comparison of percentage change from baseline in total hip bmd,C0439165;C1299575;C1549488;C1561533;C1707455
288,pci indication,C0392360;C3146298;C4049621
288,indication for stent,C0038257;C0392360;C3146298
288,indication for pci,C0392360;C3146298;C4049621
288,indication,C0392360;C3146298
287,intermittent claudication,C0021775
287,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
287,claudication ( fontaine class > $nmbr$ ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
287,claudication,C0021775;C0311395;C1456822
286,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
286,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
286,inclusion criteria — no . ( % ),C1512693
286,inclusion criteria,C1512693
286,included in this study ( n = $nmbr$ ),C0332257;C0557651;C2603343
286,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C1512693;C3251812
286,( including hypertension ),C0332257
285,symptomatic localization - related,C0231220;C0475264;C1744691
285,infarct localization  n ( % ),C0021308;C0475264;C1744691
285,infarct localization,C0021308;C0475264;C1744691
285,infarct localisation,C0021308;C0475264;C1744691
285,disease localization ' ’  n ( % ),C0012634;C0475264;C1744691
285,disease localization  n ( % ),C0012634;C0475264;C1744691
285,cryptogenic localization - related,C0332240;C0475264;C1744691
284,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
284,bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
284,bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
284,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
284,bifurcation  n ( % ),C0184906;C3146289
284,bifurcation,C0184906;C3146289
283,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
283,qualifying symptomatic event  n ( % ) a,C1514624
283,qualifying peripheral arterial disease,C1514624
283,qualifying myocardial infarction,C1514624
283,qualifying mi < $nmbr$ yrs prior,C1514624;C3810814
283,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
283,qualifying mi $ $nmbr$ yrs prior,C1514624;C3810814
283,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
283,qualifying high - risk features — %,C1514624
283,qualifying hba $nmbr$ c ( % ),C0019016;C1514624;C1825777;C3538758
283,qualifying events,C0441471;C1514624;C3541888
283,qualifying event — no . ( % ),C0441471;C1514624;C4019010
283,qualifying event,C0441471;C1514624;C4019010
283,qualifying cv event  n ( % ),C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
283,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
283,pciperformed for qualifying event,C0441471;C1514624;C4019010
283,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
283,at qualifying event,C0441471;C1514624;C4019010
283,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C4019010
283,anatomic extent of qualifying event  n ( % . ) x,C0220784;C0439792;C0441471;C1514624;C4019010
282,s $nmbr$ exacerbations,C0565930;C2603362;C4086268
282,patients with > $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268
282,patients with > $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268
282,patients with > $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268
282,patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C1512346;C3810541;C3811131;C4086268
282,patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030673;C4086268
282,patients with > $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268
282,no . of exacerbations in past year,C4086268
282,hospitalized for an exacerbation,C0701159;C4086268
282,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
282,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C4086268
282,exacerbations requiring hospitalisation ( past year ) ( % ),C4086268
282,exacerbations in the year before study,C0439234;C0439508;C4086268
282,exacerbations in the prev . year : $nmbr$,C0439234;C0439508;C1552852;C4086268
282,exacerbations in the past $nmbr$ months n,C4086268;C4331910
282,exacerbations in previous $nmbr$ mo ( n )  mean ( sd ),C0026544;C0205156;C0332177;C0444504;C1552607;C2347634;C2348143;C2699239;C4086268
282,exacerbations in past $nmbr$ mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
282,exacerbations,C4086268
282,exacerbation within previous $nmbr$ mo  no . ( % ),C0026544;C0205156;C0332177;C1552607;C4086268
282,exacerbation within $nmbr$ mo  %,C0026544;C0332177;C4086268
282,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
282,exacerbation historyh  n ( % ),C4086268
282,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
282,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
282,> $nmbr$ exacerbations,C4086268
282,$nmbr$ exacerbations,C4086268
282,$nmbr$ exacerbation,C4086268
282,$ $nmbr$ exacerbations,C4086268
281,use of cgm interaction test p - value ^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
281,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
281,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
281,rvalue for interaction,C1704675
281,pvaluefor interaction $nmbr$ - $nmbr$,C1704675
281,pfor interaction,C1151635;C1704675
281,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C1704675;C1709380
281,p value for interaction by region,C1704675;C1709380
281,p value for interaction - dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
281,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
281,p value for interaction ( age continuous ),C0001779;C1704675;C1709380
281,p value for interaction  dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
281,p interaction = $nmbr$ . $nmbr$,C0369773;C1704675;C2603361
281,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
281,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
281,p - value for interaction *,C1704675;C1709380
281,p - value for interaction $nmbr$ :,C1704675;C1709380
281,p - value for interaction $nmbr$ . $nmbr$,C1704675;C1709380
281,lue for interaction,C1704675
281,interaction pf,C1704675;C3815179
281,interaction p value 中,C1704675;C1709380
281,interaction p value ∗,C1704675;C1709380
281,interaction p value §,C1704675;C1709380
281,interaction p value *,C1704675;C1709380
281,interaction p value $nmbr$ . $nmbr$,C1704675;C1709380
281,interaction p value !,C1704675;C1709380
281,interaction p value,C1704675;C1709380
281,interaction p vaiue,C1704675
281,interaction p = $nmbr$ . $nmbr$,C1704675
281,interaction p - valuef,C1704675
281,interaction p - value *,C1704675;C1709380
281,interaction p - value $nmbr$,C1704675;C1709380
281,interaction p - value,C1704675;C1709380
281,interaction p - vaiue,C1704675
281,interaction p,C1704675
281,interaction j $nmbr$ - valuet,C1704675
281,interaction : treatment by psoriasis p valueb,C1704675;C3258078
281,interaction : treatment by psoriasis p value $nmbr$,C1704675;C1709380;C3258078
281,interaction - p,C1704675
281,interaction $nmbr$,C1704675
281,interaction,C1704675
281,albuminuria_p_interaction,C0001925;C1704675
281,age - interaction,C0001779;C1704675
281,/ ’ interaction,C1704675
281,( $nmbr$ % cl ) interaction,C0596019;C1704675
280,insufficient,C0205412;C0231180;C0439856
280,influenza,C0021400;C0021403
280,inadequate,C0205412;C0439856
279,nnt,C1417750
279,ment,C0084844;C1538994
278,selena - sledai total score,C0451528;C2964552
278,selena - sledai > $nmbr$  %,C0451528
278,irregular or ulcerated ica plaquef,C0205271
278,irregular or ulcerated ica p ) laque : [ :,C0205271
277,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
277,sexually active $nmbr$ ( % ),C0241028
277,sexually active,C0241028
277,locally advanced,C1517927
276,delayed reaction,C0205421;C0443286;C1545665;C3272602
276,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
276,delayed - start group ( n = $nmbr$ ),C0205421;C0439659;C0441848;C1545665;C3272602
276,delayed - eptifibatide group ( n = $nmbr$ ),C0205421;C0253563;C0441848;C1545665;C3272602
276,delayed,C0205421;C1545665;C3272602
275,use of antihypertensive drugs,C0003364;C1524063
275,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
275,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
275,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
275,patients on antihypertensive medications  n ( % ) | |,C0003364;C0030705
275,other blood pressure - lowering drugs,C0003364
275,other blood - pressure drug,C0003364
275,other antihypertensive medications,C0003364
275,other antihypertensive drug,C0003364
275,other antihypertensive agents,C0003364
275,other antihypertensive,C0003364
275,other anti - hypertensives,C0003364
275,other anti - hypertensive,C0003364
275,one antihypertensive medication,C0003364;C0205447
275,no antihypertensive medication,C0003364
275,any blood - pressure - lowering drug 一 no . ( % ),C0003364
275,any antihypertensive drug,C0003364
275,any antihypertensive agent,C0003364
275,any anti - hypertensive agent,C0003364
275,antihypertensives ' *,C0003364
275,antihypertensives  n ( % ),C0003364
275,antihypertensives,C0003364
275,antihypertensive use,C0003364;C0042153;C0457083;C1947944
275,antihypertensive treatments,C0003364;C0087111
275,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
275,antihypertensive medication use  n ( % ),C0003364;C0042153;C0457083;C1947944
275,antihypertensive medication or,C0003364
275,antihypertensive medication ),C0003364
275,antihypertensive medication $nmbr$ ',C0003364
275,antihypertensive medication  open - label  no . ( % ),C0003364
275,antihypertensive medication,C0003364
275,antihypertensive drugs,C0003364
275,antihypertensive drug  %,C0003364
275,antihypertensive agents *,C0003364
275,antihypertensive agents ( n per patient ),C0003364;C0030705
275,antihypertensive agents  n ( % ),C0003364
275,antihypertensive agents,C0003364
275,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
275,antihypertensive,C0003364
275,anti - hypertensives,C0003364
275,anti - hypertensive,C0003364
275,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
275,> $nmbr$ antihypertensive medications,C0003364
275,> $nmbr$ antihypertensive medication  no . ( % ),C0003364
275,$nmbr$ antihypertensive medication,C0003364
274,untreated at baseline,C0168634;C0332155;C1442488
274,untreated,C0332155
274,new zealand,C0027978;C0324547
274,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
273,transaminases increased,C0002594;C0919834
273,pancreas,C0030274
273,osteoprotegerin decreased,C0538161;C1308614;C1336645
273,ggt increased,C1415053
272,q wave,C0429089;C1305738
272,non - q wave,C0429089;C1305738;C1518422
272,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
271,stable angina — no . ( % ),C0340288
271,stable angina ( n = $nmbr$  $nmbr$ ),C0340288
271,stable angina ( n - $nmbr$  $nmbr$ ),C0340288
271,stable angina  n ( % ),C0340288
271,stable angina,C0340288
271,histor y of stable angina,C0340288
271,chronic stable angina,C0340288
270,sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg,C0443318;C2732140
270,sustain $nmbr$ : semaglutide vs . placebo,C0443318;C2732140
270,sustain $nmbr$ : semaglutide vs . iglar,C0443318;C2732140
270,sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg,C0443318;C2732140
270,sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo,C0443318;C2732140
270,sustain $nmbr$,C0443318;C2732140
270,sustain,C0443318;C2732140
269,• unstable angina,C0002965
269,worsening angina,C0002965
269,unstable angina — no . ( % ),C0002965
269,unstable angina §,C0002965
269,unstable angina age,C0001779;C0002965
269,unstable angina > $nmbr$ mo ago,C0002965;C0026544;C0332177
269,unstable angina *,C0002965
269,unstable angina ( n = $nmbr$  $nmbr$ ),C0002965
269,unstable angina  n ( % ),C0002965
269,unstable angina,C0002965
269,rest angina past $nmbr$ h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
269,rest angina but not past $nmbr$ h,C0002965;C0152172
269,rest angina,C0002965;C0152172
269,no rest angina,C0002965;C0152172
269,histor y of unstable angina,C0002965
269,due worsening angina,C0002965;C0678226;C3146286
269,* * * unstable angina,C0002965
268,tnf antagonist - naive ®,C0231491;C1448177
268,tnf antagonist - naive subgroup ( n - $nmbr$ ),C0231491;C1079230;C1448177;C1515021
268,tnf antagonist - naive ' ’,C0231491;C1448177
268,tnf antagonist - exposed,C0231491;C1448177
268,tnf antagonist,C0231491;C1448177
268,ras antagonist  %,C0034678;C0231491;C0525678
268,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
268,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
268,prior tnf antagonist  n [ % ] ‘ *,C0231491;C0332152;C1448177;C2826257
268,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
268,miami k antagonist received,C0231491;C0597277;C1551421;C1708601
268,antagonist,C0231491
268,adp antagonist,C0231491;C0523452
267,vitamin k antagonist naive,C1096489;C2267235
267,vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ ),C1096489;C2267235
267,vitamin k antagonist experienced  n ( % ),C1096489;C2267235
267,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
267,vitamin k antagonist,C1096489;C2267235
267,previous use of vitamin k antagonist for > $nmbr$ days — no . ( % ),C0205156;C1096489;C1524063;C1552607;C2267235
267,long - term vitamin k antagonist,C0443252;C1096489;C2267235
266,unfractionated heparin — no . ( % ),C0019134;C2825026
266,unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % ),C0019134;C2825026
266,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0019134;C2825026
266,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
266,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
266,unfractionated heparin ( n = $nmbr$ ),C0019134;C2825026
266,unfractionated heparin ( n = $nmbr$  $nmbr$ ),C0019134;C2825026
266,unfractionated heparin,C0019134;C2825026
266,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
266,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C2825026
266,heparins and fondaparinux,C0019134
266,heparin only,C0019134;C0205171;C0770546;C1720467
266,heparin dose regimen,C0019134;C0770546;C2348331
266,heparin  ‘ ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546
266,heparin  fondaparinux or brvalirudin use between - oex event,C0019134;C0770546;C1098510
266,heparin,C0019134;C0770546
266,both unfractionated heparin and low - molecular - weight heparin,C0019134;C2825026
266,additional heparin,C0019134;C0770546;C1524062
265,favors dabigatran,C0309049;C2348066
265,factors dabigatran,C1521761;C2348066;C2827422
265,dabigatran ( n = $nmbr$ ),C2348066
265,dabigatran $nmbr$   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066
265,dabigatran $nmbr$ vs . warfarin p ( inter ),C2348066
265,dabigatran $nmbr$ mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
265,dabigatran $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran  $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran  $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,dabigatran,C2348066
265,$nmbr$ mg dabigatran ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
265,$nmbr$ mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
264,brazil,C0006137
264,brachial,C0445456
264,basal only,C0205112;C0205171;C1720467
264,basal,C0205112
263,rash,C0015230
263,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
262,ticlopidine ( n = $nmbr$ ),C0040207
262,ticlopidine,C0040207
262,cyclosporine ( n = $nmbr$ ),C0010592;C0010594
262,cyclosporin,C0010592;C0010594
261,diclofenac group ( n = $nmbr$ $nmbr$ ),C0012091;C0441848
261,diclofenac ( n = $nmbr$ ),C0012091
261,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091
261,diclofenac ( n = $nmbr$  $nmbr$ ),C0012091
261,diclofenac,C0012091
260,microalbuminuria — no . / total no . ( % ),C0730345
260,microalbuminuria — no . ( % ),C0730345
260,microalbuminuria or proteinuria,C0730345
260,microalbuminuria or macroalbuminuria §,C0730345
260,microalbuminuria or macroalbuminuria,C0730345
260,microalbuminuria ( uacr $nmbr$ – $nmbr$ ),C0730345
260,microalbuminuria  n ( % ),C0730345
260,microalbuminuria  mg / g cr,C0201975;C0730345;C1300563;C3539604;C3711669;C4084730;C4553336;C4553337
260,microalbuminuria,C0730345
260,high microalbuminuria to macroalbuminuria ( n = $nmbr$ ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
259,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
259,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
259,micro - or macroalbuminuria  no . ( % ),C0085672;C1553035;C3811161;C4049106
259,micro - or macroalbuminuria  n ( % ) §,C0085672;C1553035;C3811161;C4049106
259,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
259,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0085672;C1553035;C1561643;C2984010;C3811161;C4049106
259,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
258,native american or alaskan native,C0282204;C1515945
258,native american or alaska native,C0282204;C1515945
258,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
258,native american,C0282204;C1515945
258,latin american subgroup,C1079230;C1515021;C1553378
258,latin american,C1553378
258,latin america or south africa,C0023122
258,latin america hr ( $nmbr$ % cl ),C0023122;C0596019
258,latin america ( n = $nmbr$ ),C0023122
258,latin america,C0023122
257,inhaled anticholinergic §,C0004048;C0242896;C3537004
257,anticholinergics,C0242896;C3537307;C3540711
257,anticholinergic use  n ( % ),C0042153;C0242896;C0457083;C1947944;C3537004
257,anticholinergic drug,C0242896
257,anticholinergic,C0242896;C3537004
257,anti - cholinergics ( short - acting ) a,C0242896
257,anti - cholinergics ( long - acting ),C0242896
256,entry criteria ( % ),C0243161;C1705654
256,entry criteria,C0243161;C1705654
256,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
256,criterion reached first  n ( % ),C0243161
256,criterion,C0243161
256,criteria for subcortical vad ( by mri )  %,C0077973;C0243161;C0815275
256,clinical criteria $nmbr$,C0205210;C0243161
256,by who / simon broome criteria,C0243161;C0443058
255,measured at home with automated device,C0444706;C3541902
255,measured at clinic visit with usual device,C0008952;C0444706;C3541902
255,measured at clinic visit with automated device §,C0008952;C0444706;C3541902
255,acute infection without septic shock,C0036983;C0275518
254,less than high school,C0439092;C0599395;C0683862;C0870649
254,education  high school or higher,C0683862
253,no antianginal drug,C0013227;C1254351;C1874267;C3537168
253,new anti - anginal therapy,C1874267;C3242274;C3537168
253,intensification of antianginal therapy,C1511484;C1874267;C3537168
253,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
253,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C1874267;C3537168
253,$nmbr$ antianginal drugs,C0013227;C1874267;C3537168;C3687832
253,$nmbr$ antianginal drug,C0013227;C1254351;C1874267;C3537168
252,use of antiarrhythmic agent,C0003195;C0301380;C1524063
252,other antiarrhythmics ^,C0003195
252,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
252,antiarrhythmics,C0003195
252,antiarrhythmic drugs    n   ( % ),C0003195
252,antiarrhythmic drug,C0003195;C0301380
252,antiarrhythmic agent,C0003195;C0301380
252,antiarrhythmic,C0003195;C3537142
252,anti arrhythmic,C0003195;C3537142
251,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1709908
251,physician ' s judgment that vka inappropriate ],C0022423;C0031831;C0804815
251,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815
251,physician ' s judgment that vka,C0022423;C0031831;C0804815
251,physician ' s ga  $nmbr$ - $nmbr$ mmvas,C0016993;C0031831;C0804815
251,physician,C0031831;C0804815
251,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1511726;C1709908;C3245479;C3714741
250,upper limbs,C1140618
250,upper limb fractures,C1140618
250,upper limb fracture,C0178316
250,upper limb,C1140618
250,puerto rican,C0034043
250,puerperium,C0034042;C0086839;C1879329
249,inferior or posterior,C0542339;C0678975
249,inferior mi *  %,C0340305;C3542426
249,inferior / posterior,C0205095;C0542339;C0678975
249,inferior ( n  % ),C0542339;C0678975
249,inferior ( % ),C0542339;C0678975
249,inferior,C0542339;C0678975
249,anterior mi,C3536746
248,hyperkalemia * ’,C0020461;C4552983
248,hyperkalemia ( > $nmbr$ . $nmbr$ meq / l ),C0020461;C0439375;C4552983
248,hyperkalemia  n ( % ),C0020461;C4552983
248,hyperkalaemia ( investigator reported ),C0020461;C0035173;C4552983
248,hyperkalaemia,C0020461;C4552983
247,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C4555212
247,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
247,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
247,hyperlipidemia §,C0020473;C0428465;C4555212
247,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
247,hyperlipidemia | |,C0020473;C0428465;C4555212
247,hyperlipidemia ^,C0020473;C0428465;C4555212
247,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
247,hyperlipidemia ( % ),C0020473;C0428465;C4555212
247,hyperlipidemia  n / n ( % ),C0020473;C0428465;C4555212
247,hyperlipidemia  n ( % ),C0020473;C0428465;C4555212
247,hyperlipidemia  %,C0020473;C0428465;C4555212
247,hyperlipidemia,C0020473;C0428465;C4555212
247,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
247,hyperlipidaemia  n ( % ) yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
247,hyperlipidaemia,C0020473;C0428465;C4555212
246,interruption ( n = $nmbr$ ),C0332453;C1512900
246,interruption,C0332453;C1512900
246,interquartile range — yr,C0439234;C1711350
246,interquartile range — ml / min,C0439445;C1711350
246,interquartile range height — cm,C0489786;C1711350
246,interquartile range,C1711350
246,* interquartile range,C1711350
246,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
245,intermediate risk ( ri = $nmbr$ ),C0035487;C1826843;C3640764
245,intermediate risk,C3640764
245,interim analysis ( all patients ),C4684691
245,interim analysis,C4684691
244,intermediate - acting,C0205103;C1550465;C2827755;C3889971
244,intermediate ( $nmbr$ - $nmbr$ ),C0205103;C1550465;C2827755;C3889971
244,intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205103;C1550465;C2827755;C3889971
244,intermediate ( $nmbr$ )  %,C0205103;C1550465;C2827755;C3889971
244,intermediate,C0205103;C1550465;C2827755;C3889971
244,inter p - value,C0205103;C1548610
244,inter . p - value,C0205103;C1548610
244,inter .,C0205103;C1548610
243,unfractionated only,C0205171;C1720467
243,ufh only,C0205171;C1720467
243,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
243,st - depression only,C0205171;C0520887;C1720467
243,single vessel disease,C0037179;C0042373;C0087136;C0205171
243,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
243,single - vessel disease,C0037179;C0042373;C0087136;C0205171
243,single,C0037179;C0087136;C0205171
243,past only,C0205171;C1444637;C1720467;C4284302
243,oad only,C0205171;C1720467
243,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
243,lieum only  n ( % ),C0205171;C1720467
243,legs only,C0205171;C1140621;C1720467
243,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
243,laba ( only monotherapy ),C0205171;C1720467
243,jbs - $nmbr$ secondary prevention only $nmbr$,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
243,jbs - $nmbr$ primary prevention only $nmbr$,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
243,image only,C0205171;C1704254;C1704922;C1720467;C3542466
243,ileum only  n ( % ),C0020885;C0205171;C1720467
243,heparin alone ( n = $nmbr$ ),C0019134;C0205171;C0439044;C0679994;C0770546
243,handihaler only  n,C0205171;C1720467
243,fluticasone alone ( n = $nmbr$ ),C0082607;C0205171;C0439044;C0679994
243,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
243,diskus only  n,C0205171;C1553480;C1720467
243,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
243,class v only,C0205171;C0457166;C1720467;C1880098
243,basal alone,C0205112;C0205171;C0439044;C0679994
243,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
243,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
243,aspirin alone ( n = $nmbr$ ),C0004057;C0205171;C0439044;C0679994
243,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
243,antimalarials only,C0003374;C0205171;C1720467
243,alone,C0205171;C0439044;C0679994
243,( women only ),C0043210;C0205171;C1720467
243,$nmbr$ ( only $nmbr$ distal ),C0205108;C0205171;C1720467;C4522154
242,nc,C0027964;C0028407;C0067895;C0265987
242,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0023823;C0027964;C0028407;C0038257;C0067895;C0265987;C0717550;C1518422;C1739039;C2757044;C3811844;C3812682;C4551552
241,tjc ( / $nmbr$ joints ),C0022417;C0392905
241,tjc ( $nmbr$ joints ),C0022417;C0392905
241,sjc ( / $nmbr$ joints ),C0022417;C0392905
241,sjc ( $nmbr$ joints ),C0022417;C0392905
241,primary study joint  n ( % ),C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
241,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
240,heparin plus gpi ( n = $nmbr$  $nmbr$ ),C0019134;C0332287;C0770546;C1415351
240,heparin plus a gpi ( n = $nmbr$ ),C0019134;C0770546;C1415351
240,gpi used during pci,C1415351
239,electrocardiographic findings — no . ( % ),C0438154
239,electrocardiographic findings at randomization,C0034656;C0438154
239,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
239,ecg findings,C0438154
238,ugt induction status : per aeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
238,ugt induction status : as randomizeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
238,octave induction $nmbr$ and $nmbr$,C0205263;C0857127
238,octave induction $nmbr$,C0205263;C0857127
238,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
238,inducing,C0205263
238,baseline of induction )  n ( % ),C0168634;C0205263;C0857127;C1442488
238,baseline of induction,C0168634;C0205263;C0857127;C1442488
237,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178
237,dyspnea  frequent / continuous,C0013404;C0332183;C0549178;C1963100
237,dyspnea  % ( frequent / continuous ),C0013404;C0332183;C0549178;C1963100
237,continuous,C0549178
237,continued use of gpa,C0549178;C1524063;C3495801;C4553145
237,continued treatment study,C0549178;C3161471
237,continued thienopyridine n = $nmbr$ subjects,C0549178;C1120149
237,continued thienopyridine n ( % ),C0549178;C1120149
237,continued thienopyridine ( n = $nmbr$ ),C0549178;C1120149
237,continued thienopyridine ( n $nmbr$ $nmbr$ ),C0549178;C1120149
237,continued thienopyridine %,C0549178;C1120149
237,continue thienopyridine n = $nmbr$,C0549178
237,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
237,$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
236,clinical presentation of vte at initial diagnosis — no . ( % ),C0630906;C2708283
236,clinical presentation,C2708283
235,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
235,medically important infectionsa,C3898777;C4084912
234,previous hospitalization for heart failure,C0205156;C1552607;C3898876
234,hospitalization for heart failure within previous $nmbr$ mo — no . ( % ),C3898876
234,hospitalization for heart failure within $nmbr$ mo,C3898876
234,hospitalization for heart failure or cv death,C3898876
234,hospitalization for heart failure or cv,C3898876
234,hospitalization for heart failure n ( % ),C3898876
234,hospitalization for heart failure,C3898876
234,hospitalisation for heart failure,C3898876
234,heart failure hospitalizations,C3898876
234,heart failure hospitalisation or cv death,C3898876
233,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
233,no . of infusions,C0574032
233,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
233,infusion administered — no . / total no . ( % ),C0574032;C1827465
233,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
233,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
232,posterior circulation,C0005775;C0205095;C1516559
232,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
232,no regular consumption,C0009830;C0205272;C1947907
232,no hemoconcentration hemoconcentration,C0549409;C0854379
232,new - onset atrial fibrillation,C0741281
232,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
232,diagnostic catheterization,C0596429
231,thrombus aspiration done per lesion †,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
231,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
231,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
231,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
231,anti - thrombotics,C0087086
230,one tnfi and,C0205447
230,one tnfi *,C0205447
230,one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$,C0205447
230,one or more medications,C0205447
230,one or more exacerbations,C0205447
230,one or more copd exacerbations ( n / n [ % ] ),C0205447
230,one or more blood pressure medications  n ( % ),C0205447
230,one of the above,C0205447
230,one lesion,C0205447;C0221198;C1546698
230,one - third radius,C0034627;C0205437;C0205447;C1306504
230,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
230,at least one drug - eluting stent,C0205447;C1322815
229,tnfi - na ï ve  n ( % ),C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
229,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
229,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
229,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
229,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
229,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
229,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
229,n / a,C1272460
229,n . a .,C1272460
229,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
229,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C1272460;C1546968;C1879645;C3259781;C4049872;C4552882
229,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
229,a / v ( n = $nmbr$ ) v ( n = $nmbr$ ),C0560268;C1272460;C3887614
229,a / v ( n = $nmbr$ ),C1272460
229,a $nmbr$ c [ n ( % ) ],C1272460
229,a $nmbr$ + e $nmbr$ ( n = $nmbr$ ),C1272460
228,recent treatment ( < $nmbr$ months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
228,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
228,mycophenolate mofetil,C0209368
228,mmf ( n = $nmbr$ ),C0083765;C0209368;C3848524
228,inadequate response ( > $nmbr$ months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
227,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
227,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
227,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
227,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
227,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
227,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
227,managed medically — no . / total no . ( % ),C1273870
227,acs management  no . ( % ),C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
226,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
226,nstemi ( n = $nmbr$  $nmbr$ ),C3537184;C4255010
226,nstemi ( % ),C3537184;C4255010
226,nstemi,C3537184;C4255010
226,nste - mi,C3537184;C4255010
226,non - stemi,C3537184
226,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
225,in - stent restenosis of des,C0011702;C3272317;C4551552
225,in - stent restenosis,C3272317
225,any recurrent stroke,C2242682
225,all recurrent strokes,C1836785
224,standard treatment ( n - $nmbr$ ),C4684780
224,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
224,prestudy treatment status,C0749659
224,planned treatment duration  n ( % ),C4528394
224,past treatment for paod,C2945691
223,bare metal stent  n ( % ),C2825200
223,bare metal stent,C2825200
223,bare - metal stent — no . ( % ),C2825200
223,bare - metal stent,C2825200
223,all bare metal stents,C2825200
222,very elderly patients ( n - $nmbr$ ),C0442824;C0870602;C2984081
222,male patients *,C0150904
222,male patients  n ( % ),C0150904
222,female patients ^,C0150905
222,female patients  n ( % ),C0150905
222,elderly patients ( n — $nmbr$ ),C0870602
221,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
221,gamma glutamyltransferase  u / l,C0017040;C0439339
221,elevated creatine kinase mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
221,elevated creatine kinase - mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
220,mean score,C3533236
220,mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C3533236
220,mean mmse score,C0451306;C3533236
220,mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C1880389;C1883221;C3533236;C3541951;C3641331
220,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
220,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
219,mean systolic blood pressure ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
219,mean systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
219,mean diastolic blood pressure ( sd )  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
219,mean diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
219,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
219,mean blood pressure  mm hg,C0428886;C0439475;C0488053
219,mean arterial pressure  last,C0428886
219,mean arterial pressure  baseline,C0168634;C0428886;C1442488
219,mean ( s . d . ) systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
219,mean ( s . d . ) diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
218,number stent > $nmbr$,C0038257;C0237753;C0449788
218,number ste  t > $nmbr$,C0237753;C0449788;C1420459;C3811127
218,number resulting in hospital admission,C0237753;C0449788
218,number resulting in emergency department visit,C0237753;C0449788
218,number resulting in ed visit,C0237753;C0449788
218,number randomized,C0237753;C0449788
218,number of “ off ” periods,C0237753;C0449788
218,number of stents implanted,C0038257;C0237753;C0449788
218,number of stents ( per patient ),C0038257;C0237753;C0449788
218,number of stents,C0038257;C0237753;C0449788
218,number of stent = l or $nmbr$ or $nmbr$,C0038257;C0237753;C0449788
218,number of stent = $nmbr$,C0038257;C0237753;C0449788
218,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
218,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
218,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
218,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
218,number of previous anti - tnf treatments for psa  n ( % ),C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
218,number of people ( n ),C0027361;C0237753;C0449788
218,number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C4086268
218,number of exacerbations in the last $nmbr$ months  mean ± sd,C0237753;C0449788;C4086268
218,number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C4086268
218,number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C4086268
218,number of exacerbations in previous year  mean ( sd ),C0237753;C0449788;C4086268
218,number of exacerbations in previous $nmbr$   months,C0237753;C0449788;C4086268
218,number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C4086268
218,number of exacerbations in last $nmbr$ months,C0237753;C0449788;C4086268
218,number of exacerbations $nmbr$ months before randomisation,C0237753;C0439231;C0449788;C4086268
218,number of exacerbations,C0237753;C0449788;C4086268
218,number of exacerbation in the previous $nmbr$ months  n ( % ),C0237753;C0449788;C4086268
218,number of er visits in last year prior to baseline,C0237753;C0449788;C3810541;C3811131
218,number of e,C0237753;C0449788
218,number of copd exacerbations within $nmbr$ months  mean ( sd ),C0237753;C0449788;C0740304
218,number of copd exacerbations in the previous year    n   ( % ),C0237753;C0449788;C0740304
218,number of copd exacerbations in the previous year  n ( % ),C0237753;C0449788;C0740304
218,number of concomitant csdmards  n ( % ),C0237753;C0449788;C0521115
218,number of concomitant aedsc,C0237753;C0449788;C0521115
218,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
218,number of co - aeds  n ( % ),C0180309;C0237753;C0449788;C3245499
218,number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0237881;C0349790;C0449788;C0750502;C1546944
218,number of antihypertensive agent reported,C0003364;C0237753;C0449788
218,number of antidiabetes drugs at screening  n ( % ),C0013227;C0237753;C0449788;C3687832
218,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
218,number of ( % ) females,C0086287;C0237753;C0449788
218,number and % of participants with events  and incidence rate per $nmbr$ person - year,C0237753;C0449788
218,number ( % ) reporting migraine on $nmbr$ - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
218,number ( % ),C0237753;C0449788
218,number,C0237753;C0449788
218,non - epa number of <,C0237753;C0449788;C1518422
218,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
218,mean number of exacerbations in previous y ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
218,mean number of exacerbations in previous $nmbr$ months ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
218,mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
218,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
218,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
218,event number,C0237753;C0441471;C0449788;C4019010
218,> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,> q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,> median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,> median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,> median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,> $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
218,< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,< q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
218,< median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,< median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,< median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
218,< $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
217,rales  n ( % ),C0034642;C0240859
217,rales  ( % ),C0034642;C0240859
217,rales,C0034642;C0240859
217,pulmonary rales  n ( % ),C0034642
217,pulmonary rales,C0034642
216,radial access — no . / total no . ( % ),C0442038;C0920847
216,radial access,C0442038;C0444454;C0920847;C1554204
216,radial,C0442038;C0920847
215,shock risk indext,C0035647;C0036974;C4552904
215,risk stratum,C0035647;C4552904
215,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
215,risk category ( points ),C0035647;C0683312;C3889287;C4552904
215,risk categories,C0035647;C0683312;C4552904
215,risk at,C0035647;C4552904
215,risk *,C0035647;C4552904
215,risk,C0035647;C4552904
215,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
215,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
215,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
215,cardiovascular risk  n ( % ),C0007226;C0035647;C3887460;C4552904
215,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
215,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
215,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
215,$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ ),C0035647;C3538987;C4048877;C4318503;C4552904
215,$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ ),C0035647;C4552904
214,prior surgery for cd  n [ % ],C0007928;C0034283;C0455610;C4552032
214,prior surgery for cd  n ( % ),C0007928;C0034283;C0455610;C4552032
214,prior surgery : no,C0455610
214,prior oabg surgery,C0455610
214,prior cabg surgery,C0010055;C0455610
214,history of cabg surgery  n ( % ),C0010055;C0455610
214,history of cabg surgery,C0010055;C0455610
213,prasugrel or ticagrelor,C1620287
213,prasugrel,C1620287
212,timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci,C0005847;C0441800;C0919553;C3244287;C3272266;C3810814
212,timi flow grade $nmbr$ of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
212,rankin grade,C0441800;C0919553;C3244287
212,nerd grade,C0441800;C0919553;C3244287
212,mmrc grade  n ( % ),C0441800;C0919553;C3244287;C3826977
212,mmrc grade,C0441800;C0919553;C3244287;C3826977
212,mean mmrc grade  units ( sd ),C0439148;C0441800;C0444504;C0919553;C1519795;C2347634;C2348143;C2699239;C3244287;C3826977;C3853603
212,initial timi flow grade $nmbr$,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
212,grade > $nmbr$,C0441800;C0919553;C3244287
212,grade $nmbr$ ( severe copd )  n ( % ),C0441800;C0919553;C3244287
212,grade $nmbr$ ( moderate copd )  n ( % ),C0441800;C0919553;C3244287
212,grade $nmbr$,C0441800;C0919553;C3244287
212,gold grade $nmbr$,C0018026;C0441800;C0919553;C1304897;C3244287
212,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
212,final timi flow grade < $nmbr$,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
212,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
212,dyspnea – mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
211,right coronary artery  n ( % ),C1261316
211,right coronary artery,C1261316
211,right coronary,C0225808
211,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
211,acute coronary syndrome $nmbr$,C0948089
211,acute coronary syndrome,C0948089
210,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
210,current cigarette smoker  n ( % ),C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
210,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
210,current cigarette  n ( % ),C0521116;C0677453;C1704760;C1705970;C3890423
210,cigarette users,C0677453;C1704760;C1706077;C3890423
210,cigarette smoker *,C0337667
210,cigarette smoker  no . ( % ),C0337667
210,cigarette smoker,C0337667
209,smoking history ( pack - years ) ∗,C1277691;C1519384
209,smoking history ( pack - years ),C1277691;C1519384
209,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
209,smoking history  pack - years,C1277691;C1519384
209,smoking consumption pack - years,C0425291;C1277691
209,pack years,C1277691
209,pack - years smoked,C1277691
209,pack - years ( iqr ),C1277691
209,number of pack years,C0237753;C0449788;C1277691
209,number of pack - years,C0237753;C0449788;C1277691
209,nicotine pack - years,C0028040;C1277691
209,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
208,overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
208,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
208,not treated,C1518422
208,not tested,C1518422
208,not reported in ecrf,C1518422
208,not reported / unknown,C1518422
208,not reported,C1518422
208,not receiving,C1518422
208,not provided,C1518422
208,not present at screening  but within previous year,C1518422
208,not perfused,C1518422
208,not on an aha,C0050451;C0772110;C1518422
208,not localized,C1518422
208,not hospitalized for heart failure in the year prior to study enrollment,C1518422
208,not estimable,C1518422
208,not collected ^,C1518422
208,non - us ( n = $nmbr$ ),C1518422
208,non - us,C1518422
208,non - u . s .,C1518422
208,non - trial p blocker,C0008976;C1518422
208,non - trial antiplatelet,C0008976;C1518422
208,non - statin ( n = $nmbr$ ),C0360714;C1518422
208,non - st — elevation mi,C0520886;C1518422;C3810814
208,non - st - segment elevation mi,C0520886;C1518422;C3810814
208,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
208,non - st - segment elevation,C0520886;C1518422
208,non - st - elevation mi,C0520886;C1518422;C3810814
208,non - rollover,C0517067;C0543436;C1518422
208,non - rheumatic valvular heart disease,C0264757;C1518422
208,non - metsyn,C1518422
208,non - mets,C0812270;C1518422;C1705694;C2939420
208,non - lad,C1518422
208,non - ischemic,C0475224;C1518422
208,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
208,non - ischaemic ( n = $nmbr$ o $nmbr$ ),C0475224;C1518422
208,non - ischaemic ( n = $nmbr$ ),C0475224;C1518422
208,non - ischaemic,C0475224;C1518422
208,non - inhaled steroid use  n ( % ),C0586793;C1518422
208,non - ics +,C0815320;C1518422;C4551720
208,non - hispanicwhite,C1518422
208,non - hishnic,C1518422
208,non - hdlc,C1518422;C1704429
208,non - hdl - c / hdl - c,C1518422;C3715113
208,non - hdl - c *,C1518422;C3715113
208,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
208,non - hdl - c  mmol / l,C1518422;C1532563;C3715113
208,non - hdl - c,C1518422;C3715113
208,non - hdl,C1518422;C3715113
208,non - epa ( n = $nmbr$ ),C1518422
208,non - east asianf,C1518422;C1707877
208,non - east asian §,C0078988;C1518422;C1707877
208,non - dm,C0011816;C1518422;C3250443
208,non - diabetics ( n = $nmbr$ ),C0241863;C1518422
208,non - diabetics,C0241863;C1518422
208,non - diabetic ( n = $nmbr$ ),C0241863;C1518422
208,non - diabetic,C0241863;C1518422
208,non - cortical,C0001613;C0007776;C0022655;C1518422
208,non - cana ( n = $nmbr$ ),C1418845;C1518422
208,non - c,C1518422
208,non - / ex - tobacco user,C1518422;C3853727
208,no . of non - tnfi,C1518422
208,all non - mn,C0026327;C0026405;C1518422;C4285072
207,£ $nmbr$ ( men ) / £ $nmbr$ ( women ),C0025266;C0043210
207,women — no . ( % ),C0043210
207,women taking estrogen,C0043210
207,women t,C0043210
207,women men,C0025266;C0043210
207,women ethnic origin,C0015031;C0043210
207,women / men [ % ],C0025266;C0043210
207,women / men  %,C0025266;C0043210
207,women - no . ( % ),C0043210
207,women ( n = $nmbr$ vs $nmbr$ ),C0043210
207,women ( n = $nmbr$ ) events,C0043210;C0441471;C3541888
207,women ( n = $nmbr$ )  n / n ( % ),C0043210
207,women ( n = $nmbr$ ),C0043210
207,women ( n ( % ) ),C0043210
207,women ( % ),C0043210
207,women  no . ( % ),C0043210
207,women  n ( % ) *,C0043210
207,women  n ( % ),C0043210
207,women  > $nmbr$ cm,C0043210
207,women  < $nmbr$ cm,C0043210
207,women  %,C0043210
207,women,C0043210
207,woman,C0043210;C4281745
207,no . women,C0043210
207,men : women ( % ),C0025266;C0043210
207,men / women,C0025266;C0043210
207,hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women ),C0019046;C0025266;C0043210
207,hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
207,gmi ( women ),C0043210
207,all women,C0043210
207,< $nmbr$ ( men ) / < $nmbr$ ( women ),C0025266;C0043210
207,( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
207,$nmbr$ - $nmbr$ ( women ),C0043210
206,migraine without aura,C0338480
206,migraine with aura,C0154723
206,middle third,C0442050
205,spirometry,C0037981
205,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
205,baseline spirometry,C0037981;C0168634;C1442488
204,triglycerides $nmbr$ st third,C0036056;C0041004;C0205437;C3272372
204,triglycerides $nmbr$ nd third,C0041004;C0205437
204,triglycerides $nmbr$  d third,C0041004;C0205437
204,third yeart,C0205437
204,slowest third,C0205437;C0439834
204,omega - $nmbr$ fa intake $nmbr$ st third,C0036056;C0205437;C1512806;C1719844;C3272372
204,omega - $nmbr$ fa intake $nmbr$ nd third,C0205437;C1512806;C1719844
204,omega - $nmbr$ fa intake $nmbr$  d third,C0205437;C1512806;C1719844
203,within $nmbr$ h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
203,with dm ( n proactive intervention ( n = $nmbr$ a ),C0011816;C0184661;C0886296;C1273869;C3250443
203,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
203,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
203,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
203,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
203,procedure * *,C0184661;C2700391;C3274430;C3539779
203,procedure,C0184661;C2700391;C3274430;C3539779
203,proactive intervention ( n = $nmbr$ a ),C0184661;C0886296;C1273869
203,prior coronary intervention or coronary artery bypass grafting,C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
203,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
203,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
203,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
203,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
203,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
203,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
203,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
203,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
203,interventional or surgical procedures,C0184661;C3274035
203,intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869
203,intervention .,C0184661;C0886296;C1273869
203,intervention ( n = $nmbr$ ),C0184661;C0886296;C1273869
203,intervention,C0184661;C0886296;C1273869
203,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
203,experimental intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869;C1517586
203,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
203,coronary intervention,C0018787;C0184661;C0886296;C1273869
203,baseline procedure  n ( % ),C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
202,provoked,C1444748
202,pfor trend,C1151635;C1521798;C4554533
202,pfor,C1151635
202,improved,C0184511;C0332272;C1561611;C4084203
201,pnd,C1417807;C1956415;C4552608
201,paroxysmal nocturnal dyspnea,C1956415
200,esrd or death,C0022661;C0035078;C2316810
200,esrd or $nmbr$ % dedine in gfr,C0022661;C0035078;C2316810
200,esrd or $nmbr$ % decline in gfr,C0022661;C0035078;C2316810
200,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
200,esrd *,C0022661;C0035078;C2316810
200,esrd ',C0022661;C0035078;C2316810
200,esrd,C0022661;C0035078;C2316810
200,end - stage renal disease,C0022661;C2316810
199,esr ( mm / h ),C0456680;C3811131
199,esr,C3811131
198,west europe,C0015176;C1705493
198,w europe,C0015176
198,w est europe,C0015176;C3811127;C3890902
198,w . europe,C0015176
198,non europe,C0015176;C1518422
198,europe n z $nmbr$,C0015176
198,europe ii,C0015176;C1710602;C4082587
198,europe i,C0015176;C0021966;C0221138
198,europe and russia,C0015176
198,europe and canada,C0015176
198,europe and australia,C0015176
198,europe / lsrael,C0015176
198,europe ( zone $nmbr$ ),C0015176;C1710706
198,europe ( plus south africa ),C0015176;C0037712;C0332287
198,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
198,europe ( including south africa ),C0015176
198,europe ( eu ),C0015176;C0015179;C3665627
198,europe $nmbr$ ¶,C0015176
198,europe $nmbr$ +,C0015176
198,europe $nmbr$ ( n = $nmbr$ ),C0015176
198,europe $nmbr$ ( n = $nmbr$  $nmbr$ ),C0015176
198,europe $nmbr$,C0015176
198,europe,C0015176
198,e europe,C0015176
198,e . europe,C0015176
197,mildly impaired,C0750532;C2945599
197,mild teaes,C2945599
197,mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] ),C2945599
197,mild or moderate copd,C2945599
197,mild ed,C2945599;C3538926
197,mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0392756;C0439526;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
197,mild ( n = $nmbr$ ),C2945599
197,mild ( n $nmbr$ = $nmbr$ ) $nmbr$,C2945599
197,mild ( ipss < $nmbr$ ),C1019118;C1998280;C2827405;C2945599;C3811063
197,mild ( iief - ef $nmbr$ - $nmbr$ ),C2945599;C3641331
197,mild ( gold $nmbr$ ),C0018026;C1304897;C2945599
197,mild ( > $nmbr$ to < $nmbr$ ),C2945599
197,mild ( < $nmbr$ ),C2945599
197,mild ( $nmbr$ - $nmbr$ ),C2945599
197,mild,C2945599
197,< mild,C2945599
197,$nmbr$ - $nmbr$ ( mild ),C2945599
196,ind / gly n = $nmbr$,C0017890;C0523677;C4049864
196,ind / gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
196,ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$,C0017890;C0523677;C2827928;C4049864
196,ind / gly,C0017890;C0523677;C4049864
196,ind + gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
196,gly,C0017890;C0523677
196,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
196,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
195,insulin use at baseline,C0168634;C0240016;C1442488
195,insulin use    n   ( % ),C0240016
195,insulin use,C0240016
195,insulin treatment  n ( % ),C0745343
195,insulin treatment,C0745343
195,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
195,insulin dose ( u ),C0366513;C0439148
195,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
195,insulin dose  u,C0366513;C0439148
195,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
195,insulin aspart,C0123677;C1708521
195,insulin - dependent diabetes mellitus,C0011854
195,insulin - dependent diabetes,C0011854
195,inguinal hernia repair,C0021446
194,insulins and analogs,C0021641;C3537244;C4049919
194,insulins,C0021641;C3537244;C4049919
194,insulin sensitivity — % §,C0920563;C4049919
194,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
193,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
193,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
193,immunosuppressive use  n ( % ),C0021081;C0042153;C0457083;C1947944
193,immunosuppressive agents only,C0021081;C0205171;C1720467
193,immunosuppressants onlyff,C0021081
193,immunosuppressants only,C0021081;C0205171;C1720467
193,immunosuppressants and antimalarials only,C0021081
193,immunosuppressants,C0021081
193,immunosuppressant use  %,C0021081;C0042153;C0457083;C1947944
193,immunosuppressant ^ ^,C0021081
193,immunosuppressant ^,C0021081
193,immunosuppressant ( with or without corticosteroid ),C0021081
193,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
193,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
193,any immunosuppressive agent,C0021081
192,mild to moderate renal impairment *,C1299392;C1565489
192,mild to moderate,C1299392
192,mild / moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
192,mild - to - moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
192,mild - < moderate,C1299392
191,withdrew consent,C2349954
191,withdrawals  n / n ( % ),C1710677;C2349954;C2825032;C3812880;C4049634
190,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
190,amlodipine vs chlorthalidone overweight,C0051696
190,amlodipine vs chlorthalidone obese,C0051696
190,amlodipine vs chlorthalidone normal,C0051696
190,amlodipine and valsartan,C0051696
190,amlodipine / vaisartan ( n = $nmbr$ ),C0051696
190,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
190,amlodipine / lisinopril $nmbr$,C0051696;C0065374
190,amlodipine ( n = $nmbr$ ),C0051696
190,amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
190,amlodipine $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
190,amlodipine,C0051696
190,! amlodipine,C0051696
189,self - rated health status,C0018759;C0036588;C0871208;C1551994
189,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
189,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
189,rosuvastatin n ( rate ) $nmbr$,C0871208;C0965129;C1521828
189,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
189,rosuvastatin  n ( rate ),C0871208;C0965129;C1521828
189,rates,C0871208;C1521828
189,rate ‡,C0871208;C1521828
189,rate †,C0871208;C1521828
189,rate of sares,C0871208;C1521828
189,rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
189,rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
189,rate in all participants  % / y,C0679646;C0871208;C1521828
189,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
189,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
189,rate / $nmbr$ pyo,C0033809;C0871208;C1521828
189,rate * ( n ),C0871208;C1521828
189,rate *,C0871208;C1521828
189,rate  % / y,C0871208;C1521828
189,rate,C0871208;C1521828
189,proportion of > = $nmbr$ % responder rates,C0871208;C1521828;C1709707
189,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
189,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
189,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
189,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
189,km rates { % ) e / s,C0871208;C1521828;C3887676
189,km rate ( % ),C0871208;C1521828;C3887676
189,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
189,kaplan - meier rates  % i i,C0021966;C0221138;C0871208;C1521828
189,kaplan - meier rates  %,C0871208;C1521828
189,k ( rate ),C0597277;C0871208;C1521828;C1708601
189,health - care use rate ( peryear ),C0814514;C0871208;C1521828
189,filtration rate $nmbr$ - $nmbr$,C0016107;C0871208;C1521828
189,crude rate,C0871208;C1521828
189,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
189,> $nmbr$ % responder rate  n ( % ),C0871208;C1521828
189,$nmbr$ yr . km rate,C0439234;C0871208;C1521828;C3887676
189,$nmbr$ - yr rate / $nmbr$ participants,C0439234;C0679646;C0871208;C1521828
189,$nmbr$ - y rate per $nmbr$ persons ( se )  n,C0027361;C0036919;C0871208;C1521828
189,$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci ),C0008107;C0871208;C1521828;C3259781
189,$nmbr$ - wk kaplan - meier rate  %,C0332174;C0439230;C0871208;C1521828
188,pedal edema  slight / moderate / marked,C0205081;C0522501;C0574002;C1706089;C1881878;C2937276;C2945599;C4049705;C4049706;C4050469;C4085643;C4321335
188,patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
188,no . of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderately impaired,C0205081;C1881878;C4085643;C4321491
188,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate severe ( n = $nmbr$ ) ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate risk ( > $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
188,moderate risk ( $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
188,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
188,moderate renal impairment  n ( % ) *,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe renal disease  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe renal disease  b   n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate impairment ( $nmbr$ to < $nmbr$ ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate impairment ( $nmbr$ to $nmbr$ ml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate impairment  < $nmbr$ to < $nmbr$,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % ),C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
188,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate copdb [ n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
188,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate chronic kidney disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate / severe reduction in egfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate / severe exacerbations  patient subgroups  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate / severe exacerbation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate / low,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate - to -,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate - < severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( s $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( n $nmbr$ = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
188,moderate ( iief - ef $nmbr$ - $nmbr$ ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
188,moderate ( gold $nmbr$ ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( > $nmbr$ to < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( > $nmbr$ and < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( > $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ < ipss < $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ - $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ % < fev  < $nmbr$ % predicted ),C0205081;C1881878;C3714541;C4049705;C4049706;C4085643;C4321335
188,moderate ( $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate  n ( % ) a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate  gold $nmbr$,C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
188,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,> $nmbr$ - $nmbr$ ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
188,> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,$nmbr$ - $nmbr$ ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
188,$nmbr$ ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
187,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
187,severely impaired,C0205082
187,severe to end - stage impairment ( $nmbr$ ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
187,severe teaes,C0205082;C4050465;C4050466
187,severe renal impairment,C0205082;C1565489;C4050465;C4050466
187,severe or worse airflow limitation,C0205082;C4050465;C4050466
187,severe or very severe smoking status,C0205082;C4050465;C4050466
187,severe or very severe copd,C0205082;C4050465;C4050466
187,severe or very severe,C0205082;C4050465;C4050466
187,severe or moderate,C0205082;C4050465;C4050466
187,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
187,severe n z $nmbr$,C0205082;C4050465;C4050466
187,severe impairment ( egfr < $nmbr$ ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
187,severe impairment ( < $nmbr$ ),C0205082;C0221099;C0684336;C4050465;C4050466
187,severe hyperkalemiac,C0205082;C4050465;C4050466
187,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
187,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
187,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
187,severe exacerbations,C0205082;C4050465;C4050466;C4086268
187,severe ed,C0205082;C3538926;C4050465;C4050466
187,severe copdc [ n z $nmbr$ ],C0205082;C4050465;C4050466
187,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
187,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
187,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
187,severe / lite threatening,C0205082;C4050465;C4050466
187,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
187,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
187,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
187,severe ( n $nmbr$ = $nmbr$ ),C0205082;C4050465;C4050466
187,severe ( itt ) ( n = $nmbr$ ),C0205082;C4050465;C4050466
187,severe ( ipss > $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
187,severe ( iief - ef < $nmbr$ ),C0205082;C3641331;C4050465;C4050466
187,severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205082;C3641331;C4050465;C4050466
187,severe ( gold $nmbr$ ),C0018026;C0205082;C1304897;C4050465;C4050466
187,severe ( fev  < $nmbr$ % predicted ),C0205082;C3714541;C4050465;C4050466
187,severe ( > $nmbr$ ),C0205082;C4050465;C4050466
187,severe  n ( % ) b,C0205082;C4050465;C4050466
187,severe  gold $nmbr$,C0018026;C0205082;C1304897;C4050465;C4050466
187,severe,C0205082;C4050465;C4050466
187,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
187,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
187,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
187,more severe ^,C0205082;C0205172;C4050465;C4050466
187,more severe,C0205082;C0205172;C4050465;C4050466
187,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
187,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
187,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
187,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
187,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
187,major or clinically relevant non - major bleeding,C0205082;C0205164;C4318856;C4521762
187,major or clinically relevant non - major bleed,C0205082;C0205164;C4318856;C4521762
187,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
187,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
187,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
187,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
187,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
187,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
187,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
187,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
187,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
187,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
187,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
187,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
187,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
187,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
187,major bleeding $nmbr$ to $nmbr$,C0019080;C0205082;C0205164;C4318856;C4521762
187,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
187,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
187,major and crnm bleeds,C0205082;C0205164;C4318856;C4521762
187,major amputationsb,C0205082;C0205164;C4318856;C4521762
187,major amputations at week $nmbr$,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
187,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
187,major / crnm bleed,C0205082;C0205164;C4318856;C4521762
187,major,C0205082;C0205164;C4318856;C4521762
187,less severe $nmbr$,C0205082;C0439092;C0547044;C4050465;C4050466
187,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
187,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
187,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
187,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
187,history of major microvascular disease  n ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
187,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
187,history of major macrovascular disease  n ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
187,history of major cardiovascular disease  n ( % ),C0205082;C0205164;C0455539;C4318856;C4521762
187,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
187,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
187,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
187,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
187,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
187,combined major macrovascular events  neohrodathv . and all - cause mortalitv ■,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
187,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
187,at least $nmbr$ severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
187,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
187,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
187,> $nmbr$ % stenosis of major artery  n ( % ),C0038449;C0205082;C0205164;C4318856;C4521762
187,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
187,$nmbr$ - $nmbr$ ( severe ),C0205082;C4050465;C4050466
186,left atrial dimension  cm,C0018792;C0439534;C2950135
186,left anterior descending coronary artery,C0226032
186,left anterior descending artery  n ( % ),C0226032
186,left anterior descending artery,C0226032
186,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
185,life - threatening bleeding  disabling stroke  and death,C0019080;C0038454;C1546953;C2826244;C3537125;C4554100
185,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
185,life - threatening,C1546953;C2826244;C3537125
184,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
184,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
184,complete ulcer healing at week $nmbr$,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
184,complete healinga,C0205197;C0725685;C3853530;C4283785
184,complete clinical response at week $nmbr$,C0205197;C3853530;C4283785
184,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
183,type of insulin,C0457592
183,type of basal insulin  n ( % ),C0205112;C0332307;C0457592;C0650607;C1547052
183,insulin type  n ( % ),C0457592
182,non - enzyme inducing,C0014442;C1518422;C4521602
182,enzyme inducing,C0014442;C4521602
181,juvenile myoclonic epilepsy,C0270853
181,functional assessment of chronic illness,C0008679;C0278372
180,no . fingernails,C0222001
180,( incl . uncertain ),C0268281;C1418854
179,type of intervention,C3274412
179,time intervals  h,C0033727;C0369286;C0441932;C0564385;C0872291;C4528284
179,time intervals,C0872291
179,social interaction,C0037420
178,t wave inversion,C0520888
178,t - wave inversion only,C0205171;C0520888;C1720467
178,t - wave inversion,C0520888
178,symmetric t wave inversions,C0332516;C0520888;C2699744
178,symmetric t - wave inversions,C0332516;C0520888;C2699744
177,referent,C1706462
177,reference,C1514811;C1706462
177,no ( reference ),C1514811;C1706462
177,< $nmbr$ mg dl ( reference ),C0439269;C1514811;C1706462
177,$nmbr$ . $nmbr$ ( referent ),C1706462
177,$nmbr$ . $nmbr$ ( reference ),C1514811;C1706462
176,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
176,definite,C0439544;C1704787
176,$nmbr$ days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
175,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
175,proportion of predicted normal fev $nmbr$ value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
175,percentage of predicted pre - bronchodilator fev ^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
175,percent of predicted value before bronchodilation ^,C1882327
175,fevj % predicted !  t,C0681842;C1882327
175,fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C3714541
175,fev $nmbr$   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
175,fev $nmbr$ ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
175,> $nmbr$ % predicted to < $nmbr$ % predicted,C0681842;C1882327
175,> $nmbr$ % predicted arr ( n = $nmbr$ ),C0681842;C1882327;C2170357;C4084934
175,> $nmbr$ % predicted,C0681842;C1882327
175,< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),C0681842;C1882327;C2170357;C4084934
175,< $nmbr$ % predicted,C0681842;C1882327
175,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
175,% predicted prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541
175,% predicted pre - bronchodilator fev $nmbr$  % *,C0681842;C1882327;C2599602;C3714541
175,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
175,% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l,C0681842;C1882327
175,% predicted post - bronchodilator fev  ( sd ) ml,C0681842;C1882327
175,% predicted,C0681842;C1882327
175,% of predicted normal value *,C0086715;C0681842;C1882327
175,% of predicted,C0681842;C1882327
174,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
174,stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0441781;C1739039;C3811844;C3812682
174,severe impairment ( egfr < $nmbr$ ml / min / m ^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
174,severe impairment ( egfr < $nmbr$ )  n ( % ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
174,renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,renal function ( egfr ) according to mdrd  n ( % ),C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
174,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % ),C0232804;C0369637;C0439445;C0441923;C0680240;C1739039;C3811844;C3812682;C3839656
174,prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g ),C0022658;C0033105;C0220900;C0439445;C1739039;C3811844;C3812682
174,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C1739039;C3811844;C3812682
174,moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
174,moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
174,moderate impairment ( egfr $nmbr$ - $nmbr$ ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
174,mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
174,mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
174,mild impairment ( egfr $nmbr$ - $nmbr$ ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
174,mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
174,mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
174,mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
174,fgf - $nmbr$ low / egfr > $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
174,fgf - $nmbr$ low / egfr < $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
174,fgf - $nmbr$ high / egfr > $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
174,fgf - $nmbr$ high / egfr < $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
174,estimated glomerular filtration rate — no . ( % ),C3811844
174,estimated glomerular filtration rate §,C3811844
174,estimated glomerular filtration rate | |,C3811844
174,estimated glomerular filtration rate ^,C3811844
174,estimated glomerular filtration rate < $nmbr$,C3811844
174,estimated glomerular filtration rate - no . ( % ) : :,C3811844
174,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
174,estimated glomerular filtration rate  n ( % ),C3811844
174,estimated glomerular filtration rate,C3811844
174,established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease,C0022658;C0205156;C0369637;C0439445;C0441923;C0443211;C1272684;C1300563;C1552607;C1739039;C3811844;C3812682
174,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
174,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr using cg / mdrd formulae  % of patients,C1739039;C3811844;C3812682
174,egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
174,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
174,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
174,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
174,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
174,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
174,egfr at baseline  $nmbr$ ml / min ( % ) b,C0168634;C0439445;C1442488;C1739039;C3811844;C3812682
174,egfr and albuminuria,C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
174,egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr > $nmbr$  n ( % ),C1739039;C3811844;C3812682
174,egfr > $nmbr$,C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
174,egfr < $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
174,egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
174,egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$  n ( % ),C1739039;C3811844;C3812682
174,egfr < $nmbr$  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr < $nmbr$,C1739039;C3811844;C3812682
174,egfr -,C1739039;C3811844;C3812682
174,egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0441923;C1739039;C3811844;C3812682
174,egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
174,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr ( ml / min / $nmbr$ - $nmbr$ mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
174,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
174,egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
174,egfr ( mdrd )  n ( % ),C1739039;C3811844;C3812682;C3839656
174,egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0162734;C0369637;C0439445;C0441923;C1561643;C1739039;C3811844;C3812682;C4281721
174,egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0071744;C0162734;C0369637;C0439445;C0441923;C1413772;C1561643;C1739039;C3811844;C3812682;C4281721
174,egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
174,egfr $nmbr$ to < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
174,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
174,egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
174,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr $nmbr$ - $nmbr$,C1739039;C3811844;C3812682
174,egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ ),C0205307;C0231683;C0439166;C0439445;C1739039;C2347086;C3811844;C3812682;C4553972
174,egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$,C0026327;C0026405;C0369637;C0439526;C0441923;C1705224;C1739039;C3811844;C3812682;C3887665;C4285072
174,egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439232;C0439526;C0441923;C0700321;C0702093;C1282918;C1705224;C1739039;C2347166;C3811844;C3812682;C3887665
174,egfr  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr  ml / min / bsa,C0439445;C1739039;C3811844;C3812682
174,egfr  ml / min ( mdrd ),C0439445;C1739039;C3811844;C3812682;C3839656
174,egfr  ml / min,C0439445;C1739039;C3811844;C3812682
174,egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1300574;C1532718;C1705224;C1739039;C3811844;C3812682;C3887665
174,egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
174,egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
174,egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
174,egfr,C1739039;C3811844;C3812682
174,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .,C0005823;C1739039;C3811844;C3812682
174,baseline egfr ≥ $nmbr$ to < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
174,baseline egfr < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
174,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
173,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
173,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
173,serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C0302353;C0543465;C1532563
173,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
173,serum potassium  meq / l,C0302353;C0439375;C0543465
173,serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0302353;C0543465;C1532563
173,serum biochemistry potassium  mmol / l,C0005477;C0302353;C0543465;C1532563
173,hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
172,serum albumin concentration  g / l,C0001924;C0036773;C0086045;C0229671;C0439294;C0456615;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
172,serum albumin - adjusted calcium ( mg / dl ),C0036773;C0728877
172,serum albumin  g / l,C0036773;C0439294;C0456615;C0728877
172,serum albumin  g / dl,C0036773;C0439267;C0728877
172,serum albumin  g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
171,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
171,serum uric acid  n,C0455272;C0700634
171,serum uric acid  mg / dl,C0439269;C0455272;C0700634
171,serum urate ( mg / dl )  n ( % ),C0439269;C0455272
171,serum urate ( mg / dl ),C0439269;C0455272
171,serum sodium — mmol / liter,C0439190;C0475211;C0523891
171,serum sodium — meq / liter,C0439152;C0475211;C0523891
171,serum sodium . meq / l,C0439375;C0523891
171,serum sodium  meq / l,C0439375;C0523891
171,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
170,≤ $nmbr$ mg / l,C0439268
170,upadacitinib $nmbr$ mg ( n = l $nmbr$ ),C0439268
170,hscrp range  mg / l,C0439268;C1514721;C2348147;C3542016
170,hscrp > $nmbr$ to < $nmbr$ mg / l,C0439268
170,hscrp > $nmbr$ mg / l,C0439268
170,hscrp > $nmbr$ . $nmbr$ mg / l,C0439268
170,hscrp < $nmbr$ . $nmbr$ mg / l,C0439268
170,hscrp ( mg / l ) c,C0439268
170,hscrp ( mg / l ),C0439268
170,hscrp  mg / l,C0439268
170,hs - crp mg / l,C0439268;C3890735;C4048285
170,hs - crp j $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
170,hs - crp _ = $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
170,hs - crp > $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
170,hs - crp < $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
170,hs - crp ( mg / l ),C0439268;C3890735;C4048285
170,hs - crp  mg / l,C0439268;C3890735;C4048285
170,elevated hscrp > $nmbr$ mg / l  n ( % ),C0205250;C0439268;C3163633
170,crp — mg / l,C0439268;C3890735;C4048285
170,crp < $nmbr$ mg / l  n,C0439268;C3890735;C4048285
170,crp ( mg / l ) : < $nmbr$,C0439268;C3890735;C4048285
170,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
170,crp ( mg / l )  n,C0439268;C3890735;C4048285
170,crp ( mg / l ),C0439268;C3890735;C4048285
170,crp $ $nmbr$ mg / l  n,C0439268;C3890735;C4048285
170,crp  mg / l *,C0439268;C3890735;C4048285
170,crp  mg / l,C0439268;C3890735;C4048285
170,cld $nmbr$ mg ( n = l $nmbr$ ),C0439268
170,canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
170,canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
170,about $nmbr$ mg / l or more,C0439268
170,about $nmbr$ mg / l,C0439268
170,> $nmbr$ mg / l ( n = $nmbr$ ),C0439268
170,> $nmbr$ mg / l,C0439268
170,> $nmbr$ . $nmbr$ mg / l,C0439268
170,< $nmbr$ mg / l ( n = $nmbr$ ),C0439268
170,< $nmbr$ mg / l,C0439268
170,< $nmbr$ . $nmbr$ mg / l,C0439268
170,( ≥ $nmbr$ mg / l ),C0439268
170,( < $nmbr$ mg / l ),C0439268
170,$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ ),C0439268
170,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l,C0439268
169,≤ $nmbr$ u / kg / day,C1532634
169,uae ( p  g / min ),C0560021;C1519789
169,uacr  pg / mg,C1627892
169,> $nmbr$ u / kg / day,C1532634
169,( pg / mg ),C1627892
168,≥ $nmbr$ ng / ml,C0439275
168,wap $nmbr$ c ( ng / ml ),C0439275
168,vegfr ( ng / ml ),C0439275;C1568520
168,troy ( ng / ml ),C0439275;C1420811;C1883402
168,tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$,C0439275
168,t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C2603360
168,syndecan - $nmbr$ ( ng / ml ),C0075691;C0439275;C1419891
168,sdc ( ng / ml ),C0439275;C1419891;C3273112
168,sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C1419891;C3273112
168,sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml,C0439275;C1419891;C3273112
168,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
168,ptx $nmbr$ ( ng / ml ),C0030899;C0439275
168,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
168,psa level  ng / ml,C0439275;C4086720
168,procalcitonin ( ng / ml ),C0072027;C0439275
168,proadm ( ng / ml ),C0439275
168,pigr ( ng / ml ),C0439275;C1418569
168,pentraxin - $nmbr$ ( ng / ml ),C0439275
168,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
168,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
168,ntpro - cnp ( ng / ml ),C0439275;C3889729
168,nt probnp > $nmbr$ ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
168,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
168,neuropilin ( ng / ml ),C0287275;C0439275
168,mpo ( ng / ml ),C0439275
168,mmp - $nmbr$ ( ng / ml ) *,C0439275;C0623362;C0919336
168,mmp - $nmbr$ ( ng / ml ),C0439275;C0623362;C0919336
168,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
168,ltbr ( ng / ml ),C0439275;C1416931
168,gdf - $nmbr$ ( ng / ml ),C0439275;C1418244
168,galectin - $nmbr$ ( ng / ml ),C0439275;C0607430
168,esam ( ng / ml ),C0439275;C1424976
168,ctn - l  ng / ml,C0439275;C0917591
168,ctn - i  ng / ml,C0021966;C0221138;C0439275;C0917591
168,crp ( ng / ml ),C0439275;C3890735;C4048285
168,ck - mb  ng / ml,C0010290;C0439275
168,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
168,> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
168,> $nmbr$ . $nmbr$ ng / ml,C0439275
168,< $nmbr$ ng / ml,C0439275
168,< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
168,< $nmbr$ . $nmbr$ ng / ml,C0439275
167,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
167,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
167,uacr   ≥ $nmbr$   mg / mmol ∗,C0567349;C2348885
167,uacr   < $nmbr$   mg / mmol ∗,C0567349;C2348885
167,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
167,s $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
167,s $nmbr$ . $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
167,mg / mmol,C0567349;C2348885
167,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
167,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
167,> $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
167,< $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
167,. $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
167,$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
167,$nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
167,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
166,triglyceride ( mm,C0041004;C4330985;C4554674
166,subcortical wml load diameter  mm  mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
166,subcortical wml load diameter  mm   mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
166,stent diameter < $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
166,stent diameter $ $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
166,sokolow - lyon voltage  mm,C0598352;C4330985;C4554674
166,sokolow - lyon ( mm ) *,C4330985;C4554674
166,sokolow - lyon  mm,C4330985;C4554674
166,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
166,ptgada ( mm ),C4330985;C4554674
166,platelets xlooo / mm ^,C0005821;C0443116;C1963076;C4330985;C4554674
166,platelet count  x $nmbr$ mm $nmbr$,C0032181;C1287267;C4330985;C4554674
166,physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
166,physician global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
166,phgada ( mm ),C4330985;C4554674
166,patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm ),C0042815;C4054229;C4330985;C4554674
166,patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
166,patient global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
166,patient ' s ga  $nmbr$ - $nmbr$ mm vas,C0016993;C0030705;C0042815;C3536884;C3827561;C4330985;C4554674
166,pain vas  $nmbr$ - $nmbr$ mm,C0042815;C4330985;C4554674
166,pain ( $nmbr$ mm vas ),C0042815;C4330985;C4554674
166,pain ( $nmbr$ - $nmbr$ mm vas ),C0042815;C4330985;C4554674
166,pain  $nmbr$ - $nmbr$ mm vas,C0042815;C4330985;C4554674
166,mssbp  mm hga,C4330985;C4554674
166,msdbp  mm hga,C4330985;C4554674
166,lvdd ( mm ),C4330985;C4554674
166,long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
166,fibrous  mm ’,C0016059;C0439709;C4330985;C4554674
166,fibrofatty  mm ^,C4330985;C4554674
166,esr — mm / hr,C3811131;C4330985;C4554674
166,esr ( mm / hour ) git config - - global user . name  your name,C0205246;C0439227;C0564385;C1418224;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4554674
166,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
166,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
166,esr  mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
166,esr  $nmbr$ - $nmbr$ mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
166,blood pressure  mean ( sd )  mm hgt,C0428886;C2699239;C4330985;C4554674
166,> $nmbr$ to < $nmbr$ cells / mm ’,C0007584;C0007634;C4330985;C4554674
166,> $nmbr$ to < $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
166,> $nmbr$ mm ( n = $nmbr$ ),C4330985;C4554674
166,> $nmbr$ mm,C4330985;C4554674
166,> $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
166,> $nmbr$ . $nmbr$ mm,C4330985;C4554674
166,< = $nmbr$ . $nmbr$ mm,C4330985;C4554674
166,< $nmbr$ mm,C4330985;C4554674
166,< $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
166,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
166,$nmbr$ - $nmbr$ mm,C4330985;C4554674
166,$nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
165,systolic pressure — mm hg,C0439475;C0871470
165,systolic pressure  mm hg,C0439475;C0871470
165,systolic blood pressurea  mm hg,C0005767;C0005768;C0039155;C0229664;C0439475
165,sl $nmbr$ mm hg,C0439475
165,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
165,sitting blood pressure — mmhg,C0439475;C0580946
165,sbp ≥ $nmbr$ mmhg,C0085805;C0439475
165,sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg,C0085805;C0439475
165,sbp > $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
165,sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg,C0085805;C0439475
165,sbp > $nmbr$ mmhg,C0085805;C0439475
165,sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
165,sbp > $nmbr$ mm hg,C0085805;C0439475
165,sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
165,sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg,C0085805;C0439475
165,sbp < $nmbr$ mmhg,C0085805;C0439475
165,sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
165,sbp < $nmbr$ mm hg,C0085805;C0439475
165,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
165,sbp ( mmhg ) < $nmbr$,C0085805;C0439475
165,sbp ( mmhg ) *,C0085805;C0439475
165,sbp ( mmhg ),C0085805;C0439475
165,sbp ( mm hg ),C0085805;C0439475
165,sbp  mmhg,C0085805;C0439475
165,sbp  mm   hg,C0085805;C0439475
165,sbp  mm   hg,C0085805;C0439475
165,sbp  mm hg,C0085805;C0439475
165,s $nmbr$ mmhg,C0439475;C0565930;C2603362
165,mssbp > $nmbr$ mmhg,C0439475
165,mssbp < $nmbr$ mmhg,C0439475
165,mssbp ( mm hg ),C0439475
165,mssbp  mm hg,C0439475
165,msdbp ( mm hg ),C0439475
165,msdbp  mm hg,C0439475
165,mm hg,C0439475
165,mean pulmonary artery pressure  mm hg,C0439475;C3854605
165,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
165,iop  mm hg,C0439475;C0578862
165,diastolic pressure  mm hg,C0428883;C0439475
165,diastolic blood pressurea  mmhg,C0005767;C0005768;C0012000;C0229664;C0439475
165,dbp ≥ $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
165,dbp mm hg,C0439475;C0536221;C3813197;C4281799
165,dbp < $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
165,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
165,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
165,dbp  mmhg,C0439475;C0536221;C3813197;C4281799
165,dbp  mm   hg ( sd ),C0439475;C0536221;C2699239;C3813197;C4281799
165,dbp  mm   hg,C0439475;C0536221;C3813197;C4281799
165,dbp  mm hg,C0439475;C0536221;C3813197;C4281799
165,change in bp  mm hg,C0439475;C1268766
165,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
165,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
165,at home systolic pressure > $nmbr$ mm hg,C0439475;C0871470;C4534363
165,at home systolic pressure < $nmbr$ mm hg,C0439475;C0871470;C4534363
165,at home diastolic pressure > $nmbr$ mm hg,C0428883;C0439475;C4534363
165,at home diastolic pressure < $nmbr$ mm hg,C0428883;C0439475;C4534363
165,at clinic systolic pressure > $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
165,at clinic systolic pressure < $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
165,at clinic diastolic pressure > $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
165,at clinic diastolic pressure < $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
165,apasp ( per mmhg ),C0439475
165,^ $nmbr$ mm hg,C0439475
165,> = $nmbr$ mmhg,C0439475
165,> = $nmbr$ - < $nmbr$ mmhg,C0439475
165,> $nmbr$ to < $nmbr$ mm hg,C0439475
165,> $nmbr$ mmhg,C0439475
165,> $nmbr$ mm hg — no . ( % ),C0439475
165,> $nmbr$ mm hg,C0439475
165,> $nmbr$ / > $nmbr$ mm hg,C0439475
165,> $nmbr$ . $nmbr$ mm hg,C0439475
165,> $nmbr$ - < $nmbr$ mmhg,C0439475
165,< $nmbr$ mmhg,C0439475
165,< $nmbr$ mm hg — no . ( % ),C0439475
165,< $nmbr$ mm hg heart rate,C0018810;C0439475
165,< $nmbr$ mm hg,C0439475
165,< $nmbr$ / < $nmbr$ mm hg,C0439475
165,< $nmbr$ / $nmbr$ mm hg +,C0439475
165,< $nmbr$ / $nmbr$ mm hg,C0439475
165,< $nmbr$ . $nmbr$ mm hg,C0439475
165,$nmbr$ to < $nmbr$ mmhg,C0439475
165,$nmbr$ to < $nmbr$ mm hg — no . { % ),C0439475
165,$nmbr$ to < $nmbr$ mm hg,C0439475
165,$nmbr$ to $nmbr$ mm hg,C0439475
165,$nmbr$ o - i $nmbr$ mm hg,C0021966;C0221138;C0439475;C0483204
165,$nmbr$ mmhg,C0439475
165,$nmbr$ mm hg,C0439475
165,$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
165,$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
165,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg,C0439475
165,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg,C0439475
165,$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg,C0439475
164,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
164,within $nmbr$ h after,C0033727;C0369286;C0441932;C0564385;C4528284
164,within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
164,use of h $nmbr$ bloekers  n ( % ),C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
164,urgency episodes / $nmbr$ h,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
164,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
164,nocturia episodes / $nmbr$ h,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
164,micturitions / $nmbr$ h,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
164,mean $nmbr$ - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
164,mean $nmbr$ - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
164,interval from clopidogrel loading  h,C0033727;C0070166;C0369286;C0441932;C0564385;C1272706;C1552654;C1552713;C1708715;C4528284
164,incontinence episodes / $nmbr$ h,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
164,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
164,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
164,h $nmbr$ receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
164,h $nmbr$ - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
164,h,C0033727;C0369286;C0441932;C0564385;C4528284
164,first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
164,duration of symptoms  h,C0033727;C0369286;C0436359;C0441932;C0564385;C4528284
164,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .,C0018802;C0033727;C0034787;C0038894;C0038895;C0042153;C0369286;C0439228;C0441932;C0457083;C0543467;C0564385;C1274039;C1511726;C1622222;C1947944;C3245479;C3714741;C3888198;C4528284
164,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C0019588;C0030705;C0033727;C0062408;C0237753;C0369286;C0441932;C0449788;C0564385;C0871420;C1711350;C1739039;C2699239;C3538987;C3666909;C3811844;C3812682;C3887460;C4048877;C4318503;C4528284
164,baseline $nmbr$ - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
164,b + h ( n = $nmbr$ ),C0033727;C0369286;C0441932;C0564385;C4528284
164,after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
164,> = $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
164,> $nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
164,> $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
164,> $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
164,< $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
164,< $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
164,$nmbr$ — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
164,$nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
164,$nmbr$ - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
164,$nmbr$ - $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
163,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
163,om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ ),C0023465;C0023467;C0028971;C1319635;C1705272
163,olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0020261;C0386393;C1319635
163,feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ ),C1319635
163,$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg,C1319635;C4044947
162,vas ( $nmbr$ - $nmbr$ ),C0042815;C3536884;C3827561
162,ptga ( $nmbr$ - $nmbr$ cm vas ),C0042815;C3536884;C3827561
162,psa pain ( vas ),C0042815;C3810537;C3813209
162,physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4050369
162,physician ' s assessment of disease activity ( vas )  mm,C0031831;C0042815;C0456681;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
162,patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4054228
162,pain ( vas ),C0042815
162,( $nmbr$ - $nmbr$ - cm vas ),C0042815;C3536884;C3827561
161,ups score  mean ( sd ),C0334463;C3542434
161,hope patients with coronary - artery disease ( n = $nmbr$ ),C0010054;C0010068;C0030705;C0392347;C1956346
161,hope ( n = $nmbr$ ),C0392347
161,dpi ( other than diskus )  n,C1553480
160,quintile ( n ),C1508496
160,quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ ),C1508496
160,quintile  range  mg / dl,C0439269;C1508496;C1514721;C2348147;C3542016
159,door - to - balloon time — hr,C4296144
159,^ $nmbr$ - cell function — % §,C0007613
158,gaviscon da ( n = $nmbr$ ),C0011318;C0061146;C3668815
158,> $nmbr$ da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
157,watchman ( n = $nmbr$ ),C0335390
157,device = watchman filter,C0180860;C0335390
156,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
156,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
156,igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
156,igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0439340
156,igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
156,e $nmbr$ / s $nmbr$ vs s $nmbr$,C3846405
156,e $nmbr$ / s $nmbr$ vs e $nmbr$,C3846405
156,e $nmbr$ / s $nmbr$ ( n = $nmbr$ ),C3846405
156,ae ' ( per cm / s ),C0439392;C3887670
156,$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t,C0718146
155,( $nmbr$ % ell ' ll  * non - hdl - c,C1427925;C3273466
155,( $nmbr$ % ell ' ll,C1427925;C3273466
154,ssomgdayp . eq .,C0205163;C0439185
154,eq - $nmbr$ dprofile - mobility  n ( % ),C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
154,eq - $nmbr$ d mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
154,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf,C0205163;C0439185
154,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc,C0205163;C0439185
154,eq - $nmbr$ d ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
154,coronary heart disease risk equivalents  n ( % ) c,C0439185;C1277690;C4049980
154,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
154,< $nmbr$ mgday p . eq .,C0205163;C0439185
153,qrs width  ms,C0487742;C2349943;C3539704;C3713294
153,qrs duration > $nmbr$ ms  n ( % ),C0429025;C0488377;C2349943;C3539704;C3713294
153,qrs duration  ms,C0429025;C0488377;C2349943;C3539704;C3713294
153,qrs > $nmbr$ ms *,C2349943;C3539704;C3713294
153,qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients,C2349943;C3539704;C3713294
153,qrs > $nmbr$ ms  % ( n ),C2349943;C3539704;C3713294
153,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C1514463;C2349943;C3539704;C3713294
153,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
153,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
153,ms < $nmbr$  n [ % ],C2349943;C3539704;C3713294
153,ms $nmbr$ - $nmbr$  n [ % ],C2349943;C3539704;C3713294
153,corneii product  mm - ms,C1514468;C1704444;C2349943;C3539704;C3713294;C4330985;C4554674
152,total cholesterol > $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
152,total cholesterol > $nmbr$ ' $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
152,total cholesterol < $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
152,total cholesterol < $nmbr$ $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
152,total cholesterol  mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
152,scr  gmol / l,C1539487;C4050416
152,ldl cholesterol  mmol / lt,C0023376;C0023824;C0202117;C0230426;C0439190;C3887647;C4521399
152,hdl cholesterol  mmol / lt,C0023376;C0023822;C0230426;C0392885;C0439190;C3887647;C4521399
152,fpi  m - u / ml ( pmol / l ),C0369637;C0439192;C0439284;C0439340;C0441923;C0456616;C1880521;C2945590
152,fpi  gu / ml ( pmol / l ),C0120446;C0439192;C0439284;C0439526;C1635169;C1705224;C3887515;C3887665
152,estradiol ( pmol / l ),C0014912;C0439284
152,estradiol ( e $nmbr$ ) ( pmol / l ),C0014912;C0439284
152,$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284;C0694666;C4553350
152,$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284
152,$nmbr$ . $nmbr$ ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
152,$nmbr$ - h ppg ( mmol / l ) *,C1418888;C2827804
152,$nmbr$ - h ppg ( mmol / l ),C1418888;C2827804
152,$nmbr$ - h pmg ( mmol / l ),C2827804
152,$nmbr$ - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
151,£ $nmbr$ . $nmbr$ mmol / l,C1532563
151,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
151,serum phosphate  mmol / l,C0036820;C1532563
151,serum calcium  mmol / l,C0036785;C0728876;C1532563
151,ppg  mmol / l,C1418888;C1532563
151,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
151,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
151,mmol / l [ n ],C1532563
151,mmol / l ),C1532563
151,mmol / l,C1532563
151,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
151,ldl - c   *   ( mmol / l ),C1532563
151,ldl - c < $nmbr$ . $nmbr$ mmol / l,C1532563
151,ldl - c * ( mmol / l ),C1532563
151,ldl - c ( mmol / l ),C1532563
151,ldl - c  mmol / l ( sd ),C1532563;C2699239
151,ldl - c  mmol / l,C1532563
151,ldl ( mmol / l ),C1532563
151,k ( mmol / l ),C0597277;C1532563;C1708601
151,k  mmol / l,C0597277;C1532563;C1708601
151,hdl - c ( mmol / l ),C1532563;C3715113
151,hdl - c  mmol / l,C1532563;C3715113
151,hdl ( mmol / l ),C1532563;C3715113
151,glucose  mmol / l,C0017725;C1532563
151,free fatty acids ( mmol / l ),C0015688;C1532563
151,fpg ( mmol / l ),C1532563
151,fpg  mmol / l,C1532563
151,fpg  ( mmol / l ),C1532563
151,ffa ( mmol / l ),C0015688;C1532563
151,fbg ( mmol / l ),C1532563
151,fbg  mmol / l,C1532563
151,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
151,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
151,elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0553704;C1532563
151,bun  mmol / l,C1532563
151,[ $nmbr$ . $nmbr$ mmol / l ] ),C1532563
151,> $nmbr$ mmol / l,C1532563
151,> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C1532563
151,> $nmbr$ . $nmbr$ mmol / l,C1532563
151,> $nmbr$ - $nmbr$ mmol / l,C1532563
151,> $nmbr$ + $nmbr$ mmol / l,C1532563
151,> $nmbr$ ' $nmbr$ mmol / l,C1532563
151,< $nmbr$ mmol / l,C1532563
151,< $nmbr$ . $nmbr$ mmol / l,C1532563
151,< $nmbr$ - $nmbr$ mmol / l,C1532563
151,( mmol / l ],C1532563
151,( mmol / l ),C1532563
151,( < $nmbr$ . $nmbr$ mmol / l ),C1532563
151,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l,C1532563
151,$nmbr$ - hour ppg  mmol / l,C0439227;C0564385;C1418888;C1532563
151,$nmbr$ - $nmbr$ mmol / l,C1532563
150,≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
150,≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol ),C3829066
150,≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
150,mmol / mol,C3829066
150,mean hba $nmbr$ c  mmol / mol †,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
150,mean ( s . d . ) hbalc  mmol / mol,C0444504;C2347634;C2348143;C3829066
150,ls mean ( $nmbr$ % ci )  mmol / mol,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781;C3829066
150,hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$,C0332174;C0439230;C3829066
150,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
150,hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % ),C3829066
150,hbalc < $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
150,hbalc ( mmol / mol ),C3829066
150,hbalc  mmol / mol,C3829066
150,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
150,hbaj ( - ( %  mmol / mol ),C3829066
150,hba ] c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ ca  % ( mmol / mol ),C0019016;C1825777;C3538758;C3829066;C3887642
150,hba $nmbr$ c   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c ( sd )  mmol / mol,C0019016;C1825777;C2699239;C3538758;C3829066
150,hba $nmbr$ c ( mmol / mol [ se ] ),C0019016;C0036919;C1825777;C3538758;C3829066
150,hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c  mmol / mole,C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c  mmol / mol ( mean ),C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
150,hba $nmbr$ c  mmol / mol,C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c  mean ( sd )  % [ mmol / mol ],C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
150,hba $nmbr$ c  ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,hba $nmbr$ c  % [ mmol / mol ],C0019016;C1825777;C3538758;C3829066
150,baseline mean ( sd )  % [ mmol / mol ],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
150,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
150,alc ( mmol / mol ),C1424945;C3811058;C3829066
150,a $nmbr$ c ( mmol / mol ),C3829066
150,a $nmbr$ c  % ( mmol / mol ),C3829066
150,>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
150,> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol ),C3829066
150,> = $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
150,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
150,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
150,> $nmbr$ % ( > $nmbr$ mmol / mol ),C3829066
150,< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
150,< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
150,< $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
150,< $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
150,% hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
150,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
149,〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
149,≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,≥ $nmbr$ ml / min,C0439445
149,• ? sd ml / min,C0439445;C2699239
149,£ $nmbr$ ml / min,C0439445
149,stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
149,stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
149,stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
149,severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
149,s $nmbr$ ml / min,C0439445;C0565930;C2603362
149,rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C0871208;C1521828
149,mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C2945599
149,mean — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
149,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
149,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
149,mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439092;C0439445;C0441923
149,gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
149,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
149,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §,C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
149,estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
149,estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C3811844;C3839656
149,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
149,estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
149,estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
149,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143;C2699239;C3811844
149,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
149,egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$,C0369637;C0439445;C0441923
149,egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % ),C0369637;C0439445;C0441923
149,egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa,C0369637;C0439445;C0441923
149,egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$,C0369637;C0439445;C0441923
149,egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr — ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
149,egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
149,egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
149,egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ - $nmbr$ m ^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ - $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min per $nmbr$ + $nmbr$ m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
149,egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
149,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd ),C0369637;C0439445;C0441923;C1739039;C2699239;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682;C3839656
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
149,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,ecrcl < $nmbr$ ml / min,C0439445
149,ecrcl  ml / min,C0439445
149,ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923
149,ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,creat clearance > $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
149,creat clearance < $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
149,crcl > $nmbr$ ml / min,C0439445;C1846718
149,crcl > $nmbr$ - < $nmbr$ ml / min,C0439445;C1846718
149,crcl < $nmbr$ ml / min,C0439445;C1846718
149,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
149,crcl ( ml / min ),C0439445;C1846718
149,crcl  ml / min,C0439445;C1846718
149,chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
149,cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
149,^ $nmbr$ ml / min,C0439445
149,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,> $nmbr$ to < $nmbr$ ml / min,C0439445
149,> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0040363;C0041260;C0369637;C0439445;C0441923;C1739039;C1883351;C3811844;C3812682
149,> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
149,> $nmbr$ ml min ) $nmbr$,C0439445
149,> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
149,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,> $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445
149,> $nmbr$ ml / min ( n = $nmbr$ ),C0439445
149,> $nmbr$ ml / min,C0439445
149,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
149,< = $nmbr$ ml / min,C0439445
149,< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min — %,C0439445
149,< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
149,< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % ),C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,< $nmbr$ ml / min ( n = $nmbr$ ),C0439445
149,< $nmbr$ ml / min,C0439445
149,. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923
149,( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
149,( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
149,(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
149,$nmbr$ – ≤ $nmbr$ ml / min,C0439445
149,$nmbr$ – < $nmbr$ ml / min,C0439445
149,$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0483204
149,$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
149,$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
149,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$,C0439445
149,$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
149,$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ ),C0439445
149,$nmbr$ to < $nmbr$ ml / min,C0439445
149,$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
149,$nmbr$ ml / min,C0439445
149,$nmbr$ - < $nmbr$ ml / min,C0439445
149,$nmbr$ - $nmbr$ ml min ) $nmbr$,C0439445
149,$nmbr$ - $nmbr$ ml min  $nmbr$,C0439445
149,$nmbr$ - $nmbr$ ml / min,C0439445
149,$nmbr$ - $nmbr$ ( < $nmbr$ ml / min ),C0439445
149,$nmbr$ ( $nmbr$ to < $nmbr$ ml / min ),C0439445
149,$nmbr$ ( $ $nmbr$ ml / min ),C0439445
148,ors ( $nmbr$ % cis ) :,C0069590;C1963718
148,l . l ± $nmbr$ . $nmbr$,C3539687
148,l ( < l ),C3539687
148,< $nmbr$ . $nmbr$ l - g / l,C0439267;C3539687
148,$nmbr$ tq - fi ' i,C0021966;C0221138;C3555502;C4050619
148,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l ),C3539687
148,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ ),C3539687
148,$nmbr$ l ( l $nmbr$ ),C3539687
148,$nmbr$ . l ( $nmbr$ l . $nmbr$ ),C3539687
148,$nmbr$ . l ( $nmbr$ . l ),C3539687
148,$nmbr$ . $nmbr$ ± l . l,C3539687
148,$nmbr$ . $nmbr$ ( fi . $nmbr$ ),C4050619
148,$nmbr$ . $nmbr$ ( $nmbr$ l . l ),C3539687
148,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l ),C3539687
147,> l : $nmbr$ hrs : min ( n = $nmbr$ ),C0439393;C1568891
147,> = $nmbr$ l_ / min,C0439393
147,> = $nmbr$ l / min,C0439393
147,< $nmbr$ l / min,C0439393
146,s / se  mb or death,C0024853;C0036919;C0565930;C2603362
146,$nmbr$ mq / kq *,C0024853
145,ssed as ls means,C0023668;C1704970
145,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
145,ls / ul $nmbr$ $nmbr$,C0023668;C1300557
144,less than $nmbr$ y ears,C0013443;C0439092;C0521421
144,< $nmbr$ y ears,C0013443;C0521421
143,≥ $nmbr$ kg / m $nmbr$,C1532718
143,≥ $nmbr$  kg / m $nmbr$,C1532718
143,£ $nmbr$ kg / m $nmbr$,C1532718
143,s $nmbr$ kg / m ^,C0565930;C1532718;C2603362
143,s $nmbr$ kg / m $nmbr$,C0565930;C1532718;C2603362
143,overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ ),C0497406;C1532718
143,obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ ),C0006416;C0028754;C1532718;C1963185
143,obesity ( body mass index > $nmbr$ kg / m $nmbr$ ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
143,obesity ( bmi £ $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718;C1963185
143,obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %,C0028754;C0578022;C1532718;C1963185
143,obese ( bmi > $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718
143,obese ( > $nmbr$ kg / m ^ $nmbr$ ),C0028754;C1532718
143,obese ( > $nmbr$ kg / m $nmbr$ ) b,C0028754;C1532718
143,obese ( > $nmbr$ kg / m $nmbr$ ),C0028754;C1532718
143,lean ( < $nmbr$ kg / m $nmbr$ ),C1532718
143,kg / m $nmbr$ ),C1532718
143,kg / m $nmbr$,C1532718
143,bmp kg - m “ $nmbr$,C0053932;C0279266;C1532718;C4281808
143,bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ ),C0032659;C0578022;C1257890;C1532718
143,bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi ( kg / m $nmbr$ ) cardiovascular history,C0578022;C1532718;C1880008
143,bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
143,bmi  kg / m $nmbr$ cholesterol  mg / dl,C0008377;C0439269;C0578022;C1532718
143,bm $nmbr$ ( kg / m $nmbr$ ),C0006416;C1532718
143,a $nmbr$ kg / m $nmbr$,C1532718
143,[ kg / m ^ ],C1532718
143,> = $nmbr$ kg / m $nmbr$,C1532718
143,> $nmbr$ kg / m ’,C1532718
143,> $nmbr$ kg / m ^ ( obesity ),C0028754;C1532718;C1963185
143,> $nmbr$ kg / m ^,C1532718
143,> $nmbr$ kg / m $nmbr$ smokers,C0337664;C1532718
143,> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
143,> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
143,> $nmbr$ kg / m $nmbr$,C1532718
143,> $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
143,> $nmbr$ - s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
143,> $nmbr$ - ^ $nmbr$ kg / m ’,C1532718
143,> $nmbr$ - < s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
143,> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
143,< $nmbr$ kg / m ^,C1532718
143,< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
143,< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
143,< $nmbr$ kg / m $nmbr$,C1532718
143,< $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
143,< $nmbr$  kg / m $nmbr$,C1532718
143,$nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ kg / m ’,C1532718
143,$nmbr$ kg / m $nmbr$ or more,C1532718
143,$nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ - < $nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ - $nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
143,$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
142,( fxs ),C0016667
142,$nmbr$ ( mono ),C1551432;C1551969
142,$nmbr$ % ( ito $nmbr$ ),C0022283
142,$nmbr$ % ( - ito $nmbr$ ),C0022283
141,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
141,m / f,C1306057
141,gender ( m / f )  ( % ),C0079399;C1306057;C1522384
140,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
139,spondylitis with peripheral arthritis,C0038012;C0238694
139,asymmetric peripheral arthritis,C0238694;C0332514
138,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
138,glycoprotein llb / llla inhibitors,C0017968;C0243077
138,glycoprotein llb / llia inhibitor,C0017968;C1999216
138,glycoprotein llb / illa inhibitor,C0017968;C1999216
138,glycoprotein ilb / iiia inhibitor before pci ],C0017968;C1999216;C4049621;C4697913
138,glycoprotein iib / iiiareceptorinhibitor,C0017968
138,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0175673
137,α - glucosidase inhibitor,C1512211
137,sglt - $nmbr$ inhibitors ^,C3665045
137,renin inhibitors,C2917241;C3653375
137,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
137,p - gp inhibitor,C3898062
137,monoamine oxidase b inhibitors,C2917290;C3653412
137,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
137,factor xa inhibitor,C2825027;C4553708
137,converting enzyme inhibitor,C0014432;C0919438;C4521603
137,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
137,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
137,a - glucosidase inhibitors ' $nmbr$,C1512211
137,a - glucosidase inhibitors,C1512211
137,a - glucosidase inhibitor,C1512211
136,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
136,gpiib - iiia inhibitors,C0016011;C0243077
136,gp iib / iiia inhibitors,C0016011;C0243077
136,gp iib / iiia inhibitor used,C0016011;C1999216
136,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
136,glycoprotein iib / iiia inhibitort,C0016011
136,glycoprotein iib / iiia inhibitors,C0016011;C0243077
136,glycoprotein iib / iiia inhibitor,C0016011;C1999216
136,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0016011;C0168273;C0243077
136,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
135,tnf inhibitors,C0243077;C1448177
135,raas inhibitors,C0243077
135,non - tnf inhibitors,C0243077;C1448177;C1518422
135,no ilb / iiia inhibitors,C0243077;C4697913
135,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
135,inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^,C0243077
135,ilb / iiia inhibitors,C0243077;C4697913
135,gp llb / llla inhibitors,C0243077;C1705010;C3811116
134,tnf inhibitor,C1448177;C1999216
134,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
134,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
134,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
134,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
134,raas inhibitor,C1999216
134,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
134,p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
134,other sglt - $nmbr$ inhibitor,C1999216
134,inhibitor,C1999216
134,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
134,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
134,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
134,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
133,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
133,renin inhibitor,C1960108;C3537174;C4521920
132,previous pde $nmbr$ inhibitors,C0031638;C0205156;C1552607
132,platelet aggregation inhibitors excluding heparin,C0032177
132,platelet aggregation inhibitors  n ( % ),C0032177
132,pde $nmbr$ inhibitors,C0031638
132,pde $nmbr$ inhibitor monotherapy,C0031638
131,smoking classification  n ( % ),C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
131,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
131,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
131,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
131,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
131,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
131,classification of epilepsy type  n ( % ),C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
131,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
130,study protocol,C1507394;C2348563;C2599718
130,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
130,coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high,C0007226;C0442711;C1277690;C1507394;C1522729;C1698058;C2348563;C2599718;C3715209;C3887460;C4282383
130,atv $nmbr$ mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
130,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
129,time of symptom onset to randomization ( hrs ),C1320528
129,time of symptom onset to balloon inflation ( hrs ),C1320528
129,time from symptom onset of ra  years  median,C0439234;C1320528;C3538806;C4048756
129,time from sx onset to baseline ecg  min,C0449244;C1519428;C3539997;C3815196
129,time from onset to randomization  h  mean ± sd,C0449244
129,time from onset to medication  h  mean ± sd,C0449244
129,time from onset of symptoms to start of fibrinolytic therapy — hr,C1320528
129,time from onset of symptoms to randomization — days,C1320528
129,time from onset of symptoms to presentation — hr,C1320528
128,time since last dose of,C0946444
128,time from last dose of p $nmbr$ y $nmbr$ inhibitor  days,C0439228;C0946444;C1999216
127,mostly satisfied,C0205393;C0750554
127,mostly dissatisfied,C0205393;C0750554
127,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
127,most frequent infections,C0205393;C0239998
126,time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ ),C0019994;C0040223;C1510665;C1959907;C3541383
126,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1959907;C3541383
126,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
126,pci - hospital,C0019994;C1510665;C4049621
126,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
126,in - hospital,C0019994;C1510665
126,hospital factor # $nmbr$,C0019994;C1510665;C1521761;C2827422
126,duration from hospital admission to pci  h ( median  iqr ),C0019994;C0449238;C1510665;C1959907;C2926735
125,russia and georgia,C0035970
125,russia / ukraine / belarus,C0006539;C0035970;C0041580
125,russia / georgia ( n = $nmbr$ ),C0017452;C0017454;C0035970
125,russia / georgia,C0017452;C0017454;C0035970
125,russia,C0035970
125,rs - totala,C0035970;C3714753;C3813325
125,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
125,rs - breathlessnessb,C0035970;C3714753;C3813325
125,rs $nmbr$ ( cc ) & rs $nmbr$,C0008318;C0035970;C3538933;C3714753;C3813325
125,rs $nmbr$ ( ac ) & rs $nmbr$,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
125,rs $nmbr$ ( aa ) & rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
125,rs $nmbr$ & rs $nmbr$,C0035970;C3714753;C3813325
125,rs $nmbr$,C0035970;C3714753;C3813325
125,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
124,usa and canada,C0041703
124,usa / canada,C0006823;C0041703
124,usa ( n = $nmbr$ ),C0041703
124,usa ( n = $nmbr$  $nmbr$ ),C0041703
124,usa,C0041703
124,united states or canada,C0041703
124,united states and canada,C0041703
124,united states ( n   = $nmbr$  $nmbr$ ),C0041703
124,united states  canada,C0006823;C0041703
124,united states,C0041703
124,u . s . sites,C0041703;C0205145
124,u . s . site,C0041703;C0205145;C1515974;C2825164
124,non usa,C0041703;C1518422
124,non - united states,C0041703;C1518422
123,group c,C0441837
123,group b,C4522078
123,group a,C0441835;C4522145
123,gold group c,C0018026;C0441837;C1304897
123,gold group b,C0018026;C1304897;C4522078
123,gold group a,C0018026;C0441835;C1304897;C4522145
122,group d,C0441838
122,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
122,gold group d,C0018026;C0441838;C1304897
121,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
121,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
121,age groups,C0027362
121,age group 一 ％,C0027362;C2348001
121,age group $nmbr$,C0027362;C2348001
121,age group,C0027362;C2348001
120,hemoglobin ale *,C0019046;C0678386;C2632076
120,hemoglobin aj ^ ( % ),C0004486;C0019046;C0230613
120,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
120,hemoglobin  mg / dl,C0019046;C0439269
120,hemoglobin  g / l,C0019046;C0439267;C0439294;C0456615;C0635222
120,hemoglobin,C0019046
120,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
120,haemoglobin ( mg / dl ),C0019046;C0439269
120,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
120,haemoglobin  mg / dl,C0019046;C0439269
120,glyeated haemoglobin,C0019046
120,for combined hemoglobin groups,C0019046;C0205195
120,baseline hemoglobin aj ^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
119,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
119,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
119,previous warfarin use  no . ( % ),C0043031;C0205156;C1552607
119,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
119,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
119,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
119,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C1552607
119,previous use of systemic steroids  n ( % ),C0205156;C0205373;C0281991;C1552607
119,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607
119,previous use of nonbiologic systemic therapy  n ( % ),C0205156;C1515119;C1524063;C1552607
119,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1524063;C1552607
119,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
119,previous use of biologic systemic therapy  n ( % ),C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
119,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
119,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
119,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
119,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
119,previous treatment with a laba and / or lama  n ( % ) c,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
119,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
119,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
119,previous tnf antagonist exposure  n ( % ),C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
119,previous tnf - antagonist use  n ( % ),C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
119,previous tia or stroke,C0007787;C0205156;C0917805;C1054154;C1552607
119,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
119,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
119,previous therapies  n ( % ),C0087111;C0205156;C1552607
119,previous systemic treatment  n ( % ),C0205156;C0678812;C1552607
119,previous stroke 一 no . ( % ),C0205156;C1552607
119,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0205156;C1552607
119,previous stroke — no . ( % ),C0205156;C1552607
119,previous stroke yes ( n  % ) previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C3841753;C4552959
119,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
119,previous stroke ortia $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
119,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
119,previous stroke or transient ischemic attack — no . / total,C0038454;C0205156;C1552607;C4554100
119,previous stroke or transient ischemic attack  no . / total no . ( % ),C0038454;C0205156;C1552607;C4554100
119,previous stroke or tl a $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
119,previous stroke or tl a,C0038454;C0205156;C1552607;C4554100
119,previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
119,previous stroke or tia ( % ),C0038454;C0205156;C1552607;C4554100
119,previous stroke or tia  n ( % ),C0038454;C0205156;C1552607;C4554100
119,previous stroke or tia,C0038454;C0205156;C1552607;C4554100
119,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
119,previous stroke *,C0038454;C0205156;C1552607;C4554100
119,previous stroke  n ( % ),C0038454;C0205156;C1552607;C4554100
119,previous stroke,C0038454;C0205156;C1552607;C4554100
119,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
119,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
119,previous segments resection ( s ) *,C0205156;C1552607;C2987624
119,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
119,previous revascularization,C0205156;C0581603;C1552607
119,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
119,previous renal disease  n ( % ),C0022658;C0205156;C1552607
119,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1552607
119,previous ptca,C0205156;C1552607;C2936173
119,previous percutaneous coronary intervention  %,C0205156;C1532338;C1552607
119,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
119,previous pde $nmbr$ - i therapy  no . ( % ),C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
119,previous pci or cabg,C0205156;C1552607;C4049621
119,previous pci / cabg  n ( % ),C0010055;C0205156;C1552607;C4049621
119,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
119,previous pci  n ( % ),C0205156;C1552607;C4049621
119,previous pci,C0205156;C1552607;C4049621
119,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
119,previous oral antidiabetic medication use  n ( % ),C0205156;C0935929;C1527415;C1552607
119,previous or current use of im or cs : no,C0205156;C1552607
119,previous or current use of im and cs : no,C0205156;C1552607
119,previous or current im use : no,C0205156;C1552607
119,previous or current cs use : no,C0205156;C1552607
119,previous oad ( % ),C0205156;C1552607
119,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
119,previous myocardiaunfarction,C0205156;C1552607
119,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,previous myocardial infarction  no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,previous myocardial infarction  n ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
119,previous mi — no . ( % ),C0205156;C1552607;C3810814
119,previous mi and t $nmbr$ dm,C0205156;C1552607;C3810814
119,previous mi ( % ),C0205156;C1552607;C3810814
119,previous mi  n ( % ),C0205156;C1552607;C3810814
119,previous mi  %,C0205156;C1552607;C3810814
119,previous mi,C0205156;C1552607;C3810814
119,previous metformin use  %,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
119,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
119,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
119,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
119,previous labd alone,C0205156;C0396059;C1552607
119,previous ischemic stroke ortia,C0205156;C0948008;C1552607
119,previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
119,previous ischemic stroke  n ( % ),C0205156;C0948008;C1552607
119,previous infliximab therapy — no . of patients ( % ) * *,C0205156;C1552607;C4076075
119,previous infliximab therapy | |,C0205156;C1552607;C4076075
119,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
119,previous infarction,C0021308;C0205156;C1552607
119,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
119,previous ics alone,C0205156;C0815320;C1552607;C4551720
119,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
119,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
119,previous htn  n ( % ),C0020538;C0205156;C1552607
119,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
119,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
119,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
119,previous exposure to systemic psoriasis therapyb ( yes )  n ( % ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
119,previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
119,previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
119,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0597277;C1552607;C1708601;C2825076;C3714656
119,previous events  no . ( % ),C0205156;C0441471;C1552607;C3541888
119,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
119,previous dmards use  n ( % ),C0205156;C0242708;C1552607
119,previous dmards  mean ± sd,C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
119,previous dm  n ( % ),C0011816;C0205156;C1552607;C3250443
119,previous dm,C0011816;C0205156;C1552607;C3250443
119,previous disease — no . ( % ) f,C0012634;C0205156;C1552607
119,previous disease and drug use,C0012634;C0205156;C1552607
119,previous disease :,C0012634;C0205156;C1552607
119,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
119,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
119,previous diabetes mellitus,C0011849;C0205156;C1552607
119,previous diabetes,C0011847;C0011849;C0205156;C1552607
119,previous cvd ^,C0007222;C0205156;C1552607
119,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
119,previous coronary revascularization,C0205156;C0877341;C1552607
119,previous coronary revascularisation,C0205156;C0877341;C1552607
119,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
119,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
119,previous congestive heart failure,C0018802;C0205156;C1552607
119,previous clinical stroke or transient ischemic attack ( % ),C0038454;C0205156;C0205210;C1552607;C4554100
119,previous clinical stroke or tia,C0038454;C0205156;C0205210;C1552607;C4554100
119,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
119,previous chf — no . ( % ),C0018802;C0205156;C1552607
119,previous chf  n ( % ),C0018802;C0205156;C1552607
119,previous chf,C0018802;C0205156;C1552607
119,previous cardiovascular disease !,C0007222;C0205156;C1552607
119,previous cancerc,C0205156;C1552607
119,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
119,previous cancer  n ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
119,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
119,previous cad  n ( % ),C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
119,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
119,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
119,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
119,previous cabg  n ( % ),C0010055;C0205156;C1552607
119,previous cabg,C0010055;C0205156;C1552607
119,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
119,previous bdmard received,C0205156;C1552607
119,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
119,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
119,previous antiparkinson medication  no . ( % ),C0003405;C0205156;C1552607
119,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
119,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
119,previous anti - tnf therapy  n [ % ],C0205156;C0279936;C0432633;C1552607
119,previous angioplasty  n ( % ),C0162577;C0205156;C1548817;C1552607
119,previous angina pectoris,C0002962;C0205156;C1552607
119,previous angina  n ( % ),C0002962;C0205156;C1552607
119,previous analgesic products n ( % ),C0002771;C0205156;C1552607
119,previous ami  n ( % ),C0205156;C1552607;C4319936
119,previous ami,C0205156;C1552607;C4319936
119,previous af,C0205156;C0344434;C1552607;C4049859
119,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0205156;C0413234;C0666743;C1552607
119,previous a - blocker use,C0205156;C1552607
119,previous a - blocker,C0205156;C1552607
119,previous $nmbr$ ari use,C0205156;C1412533;C1552607;C4521376
119,previous $nmbr$ - ari use ( % ),C0205156;C1412533;C1552607;C4521376
119,previous,C0205156;C1552607
119,poor  tried previous glucocorticoid / non - laba,C0017710;C0032854;C0205156;C0542537;C1518422;C1552607;C2700379
119,poor  tried previous glucocorticoid + laba,C0017710;C0032854;C0205156;C0542537;C1552607;C2700379
119,phototherapy previous systemic treatment  n ( % ),C0031765;C0205156;C0678812;C1552607
119,participated in a previous febuxostat studyb  n ( % ),C0205156;C0249529;C1552607
119,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
119,no previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
119,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
119,no previous myocardial infarction $nmbr$ / $nmbr$,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
119,no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
119,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
119,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
119,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
119,no . of previous csdmards  n ( % ),C0205156;C1552607
119,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
119,good  tried previous glucocorticoid + laba,C0017710;C0205156;C0205170;C1552607
119,good  tried previous glucocorticoid,C0017710;C0205156;C0205170;C1552607
119,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
119,former or never diabetes,C0205156;C0750523
119,former or never,C0205156;C0750523
119,former or current smokers ( % ),C0205156;C0750523
119,former n z $nmbr$,C0205156;C0750523
119,former / current smoker ( n = $nmbr$ $nmbr$ ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
119,former / current smoker  n ( % ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
119,former ( n   = $nmbr$  $nmbr$ ),C0205156;C0750523
119,former  n ( % ),C0205156;C0750523
119,former,C0205156;C0750523
119,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
119,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
119,cardioversion in previous $nmbr$ wk,C0013778;C0205156;C0332174;C0439230;C1552607
119,> $nmbr$ previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
119,> $nmbr$ in previous,C0205156;C1552607
119,: mi  previous pci and chronic obstructive pulmonary disease .,C0205156;C1552607;C3810814;C4049621
118,≥ $nmbr$ to < $nmbr$ mg / dl,C0439269
118,≥ $nmbr$ mg / dl,C0439269
118,£ $nmbr$ mg / dl,C0439269
118,women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0043210;C0439269;C1532563
118,week $nmbr$ — mg / liter ^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,week $nmbr$ — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,vonoprazan $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
118,vildagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
118,viidagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
118,vi $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
118,uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
118,uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
118,uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
118,uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0015895;C0041980;C0439269
118,uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
118,uric acid ( mg / dl ),C0041980;C0439269
118,upa $nmbr$ mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
118,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
118,total cholesterol — mg / dl,C0201950;C0439269;C0543421
118,total cholesterol level  mg / dl,C0439269;C0878805;C1445957
118,total cholesterol > $nmbr$ mg / dl,C0201950;C0439269;C0543421
118,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
118,total cholesterol ( sd )  mg / dl,C0201950;C0439269;C0543421;C2699239
118,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
118,total cholesterol $nmbr$ > $nmbr$ mg / dl,C0201950;C0439269;C0543421
118,total cholesterol $nmbr$ < $nmbr$ mg / dl,C0201950;C0439269;C0543421
118,total cholesterol  mg / dl ^,C0201950;C0439269;C0543421
118,total cholesterol  mg / dl  ^,C0201950;C0439269;C0543421
118,total cholesterol  mg / dl,C0201950;C0439269;C0543421
118,toricoxib $nmbr$ mg n = $nmbr$ ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,toial cholcsierol ( mg / dl ),C0439269
118,tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib $nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib $nmbr$ mg bid [ n = $nmbr$ |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib $nmbr$ mg bid ( n   = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
118,tofacitinib  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
118,tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
118,tiotropium / olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
118,tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
118,tiotropium + olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
118,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
118,tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
118,tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
118,tiotropium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
118,tiotropium $nmbr$ mg ( n = $nmbr$,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
118,ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
118,ticagrelor $nmbr$ mg no diabetes n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
118,ticagrelor $nmbr$ mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
118,ticagrelor $nmbr$ mg diabetes n = $nmbr$,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
118,ticagrelor $nmbr$ mg $nmbr$ yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
118,ticagrelor $nmbr$ mg $nmbr$ year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
118,ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
118,ticagrelor  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
118,tgs ( mg / dl ),C0439269;C1156212;C1537574
118,tg > $nmbr$ mg / dl  n ( ° / o ),C0337445;C0439269
118,tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ ),C0337445;C0439269;C3715113
118,tg ( mg / dl ),C0337445;C0439269
118,tcz - sc $nmbr$ mg every other week ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1960952;C2346927;C4321396;C4521761
118,tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
118,tadalafil $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
118,tadalafil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
118,tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
118,tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
118,t $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
118,sotagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
118,sita $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
118,simvastatin $nmbr$ mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
118,silodosin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
118,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
118,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
118,serum triglycerides  mg / dle,C0024138;C0024671;C0026410;C0439269;C0542495;C1960952;C2346927;C3542918;C4321396;C4521761
118,semaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
118,secukinumab intravenous $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,secukinumab $nmbr$   mg no load ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,secukinumab $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,secukinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,secukinumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
118,sc belimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
118,saxa $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,saxa $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,sal $nmbr$ mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
118,rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
118,rosuva $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
118,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
118,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
118,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
118,r $nmbr$ mg + fa ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
118,r $nmbr$ mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
118,r $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
118,r $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
118,r $nmbr$ mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
118,pravastatin $nmbr$ mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
118,ppg  mg / dl,C0439269;C1418888
118,plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
118,plasma cholesterol — mg / dl,C0439269;C0858034
118,placebofigolimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,placebo → golimumab $nmbr$ mg / $nmbr$ mga  b,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
118,placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
118,pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
118,pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
118,p - value d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
118,omalizumab $nmbr$ mg ( n [ $nmbr$ ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
118,olodaterol $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
118,olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
118,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
118,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
118,non - hdl - c  mg / dl,C0439269;C1518422;C3715113
118,non - hdl ( mg / dl ) < $nmbr$,C0439269;C1518422;C3715113
118,no . of $nmbr$ - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
118,middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
118,mg / dl fpg ( mmol / l ),C0439269;C1532563
118,mg / dl,C0439269
118,metsyn with ldl > $nmbr$ . $nmbr$ mg / dl,C0439269
118,mepolizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
118,mepolizumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
118,men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0025266;C0439269;C1532563
118,mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
118,male acr definition  ^ . g / mg,C0024671;C0026410;C0086582;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
118,lpa  mg / dl,C0439269;C1096202;C1439335;C3539666;C4049711;C4553379
118,lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
118,lovastatin $nmbr$ mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,llraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,liraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
118,liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
118,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
118,lipid levels — mg / dl,C0428460;C0439269
118,ldl - c > $nmbr$ mg / dl,C0439269
118,ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
118,ldl - c < $nmbr$ mg / dl  no . ( % ),C0439269
118,ldl - c < $nmbr$ mg / dl,C0439269
118,ldl - c ( mg / dl ) < $nmbr$,C0439269
118,ldl - c ( mg / dl ) * *,C0439269
118,ldl - c ( mg / dl ),C0439269
118,ldl - c $nmbr$ - $nmbr$ mg / dl,C0439269
118,ldl - c  mg / dl *,C0439269
118,ldl - c  mg / dl,C0439269
118,iv - $nmbr$ mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
118,indacaterol $nmbr$ mg [ n z $nmbr$ ],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
118,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
118,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
118,i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
118,i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
118,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,hscrp  mg / dl,C0439269
118,highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
118,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
118,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
118,hdl < $nmbr$ mg / dl,C0439269;C3715113
118,hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563;C3715113
118,hdl - c < $nmbr$ mg / dl_,C0439269;C3715113
118,hdl - c < $nmbr$ mg / dl . n ( % ),C0439269;C3715113
118,hdl - c < $nmbr$ mg / dl  no . ( % ),C0439269;C3715113
118,hdl - c < $nmbr$ mg / dl,C0439269;C3715113
118,hdl - c ( mg / dl ) *,C0439269;C3715113
118,hdl - c ( mg / dl ),C0439269;C3715113
118,hdl - c  mg / dl,C0439269;C3715113
118,hdl - c  $nmbr$ mg / dl  n ( % ),C0439269;C3715113
118,hdl ( mg / dl ),C0439269;C3715113
118,hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl,C0019016;C0037623;C0439269;C0439475;C1415692;C1708288;C1825777;C3538758;C4318478
118,hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl ),C0024671;C0026410;C0439269;C0596019;C1960952;C2346927;C2348066;C2985465;C4321396;C4521761
118,h dl cholesterol < $nmbr$ mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
118,golimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
118,golimumab $nmbr$ mg ( n = $nmbr$ ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
118,golimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
118,golimumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
118,glycopyrronium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
118,glycemia  mg / dl,C0005802;C0439269
118,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
118,gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
118,glucose — mg / dl,C0017725;C0439269
118,glucose ( mg / dl ),C0017725;C0439269
118,glucose  mg / dl  mean,C0017725;C0439269;C0444504;C2347634;C2348143
118,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
118,fsg ( mg / dl ),C0439269
118,fpg ( mg / dl ) x,C0439269
118,fpg ( mg / dl ),C0439269
118,fpg  mg / dl ( mmol / l ),C0439269;C1532563
118,fpg  mg / dl,C0439269
118,fpg  ( mg / dl ),C0439269
118,fp $nmbr$ mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
118,fluvastatin $nmbr$ mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
118,feno $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,female acr definition  ^ g / mg,C0024671;C0026410;C0043210;C0086287;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
118,febuxostat $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
118,febuxostat $nmbr$ mg daily n = $nmbr$ n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
118,febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
118,febuxostat $nmbr$ mg daily n = $nmbr$,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
118,febuxostat $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
118,fc - ldl - c  mg / dl,C0439269;C2983605
118,fbs > = $nmbr$ mg / dl,C0439269;C3812213
118,fbs < $nmbr$ mg / dl,C0439269;C3812213
118,fbg ( mg / dl ),C0439269
118,fasting glucose level  mg / dl,C0202045;C0439269
118,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
118,famotidine $nmbr$ mg ( n = $nmbr$ ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,fa $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ ),C0013014;C0024671;C0026410;C0031831;C0439269;C1707664;C1960952;C2346927;C2348314;C3540849;C4321396;C4521761
118,eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
118,eze $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
118,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etoricoxib $nmbr$ mg  n = $nmbr$  n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
118,etn $nmbr$ mg + mtx n = $nmbr$,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
118,esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
118,ertuglrflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,ertugliflozin $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg vs placebo / glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg vs placebo / giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
118,ertuglifldzin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,erlugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,empagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
118,empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
118,empaglifiozin $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,eduglinozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,dupiiumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
118,dulaglutide $nmbr$ . $nmbr$ mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
118,dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
118,dulaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
118,dose equivalent  mg ( sd ) ),C0024671;C0026410;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C2699239;C4321396;C4521761
118,dose  mg,C0024671;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,diclofenac $nmbr$ mg  n = $nmbr$  n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ ),C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
118,dapagliflozin $nmbr$ mg group ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
118,dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
118,dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
118,dapagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
118,daily dose > $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
118,daily dose $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
118,daily dose $nmbr$ - $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
118,dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
118,dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
118,dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
118,dabigatran  $nmbr$ mg  vs . warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
118,czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg ( n $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg  % ( n / n ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,czp $nmbr$ mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
118,crp — mg / liter ^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
118,crp > $nmbr$ mg / $nmbr$  n [ % ],C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
118,crp > $nmbr$ . $nmbr$ mg / dl  n ( % ),C0439269;C3890735;C4048285
118,crp ( mg / dl ) < $nmbr$ . $nmbr$,C0439269;C3890735;C4048285
118,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
118,crp ( mg / dl ),C0439269;C3890735;C4048285
118,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
118,crp  mg / dl,C0439269;C3890735;C4048285
118,creatinine  mg / dl ( sd ),C0010294;C0439269;C1561535;C2699239
118,cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,cholesterol — mg / dl,C0008377;C0439269
118,cholesterol ( mg / dl ),C0008377;C0439269
118,cholesterol  mg / dl total,C0201950;C0439269;C0543421
118,cholesterol  mg / dl,C0008377;C0439269
118,change  mg / dl ( mmol / l ),C0392747;C0439269;C0443172;C1532563;C1705241;C4319952
118,carisbamate $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
118,carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
118,canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2974540;C4321396;C4521761
118,cana $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
118,cana $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
118,cana $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
118,cana $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
118,cana $nmbr$ mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
118,bun ( mg / dl ),C0439269
118,bun  mg / dl,C0439269
118,budesonide mmx $nmbr$ mg  ( n = $nmbr$ ),C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
118,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
118,blood urea nitrogen  mg / dl,C0005845;C0439269;C0600137
118,benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
118,belimumab $nmbr$ mg sc ( n $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
118,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
118,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
118,baseline fasting tgs  mg / dl,C0015663;C0168634;C0439269;C1156212;C1442488;C1537574
118,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
118,baseline aspirin dose < $nmbr$ mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
118,baricitinib $nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,baricitinib $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,baricitinib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,baricitinib $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,baricitinib  $nmbr$ mg daily ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
118,b . benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
118,azl - m $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
118,atv $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
118,atv $nmbr$ mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
118,atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ ),C0008107;C0023668;C0024671;C0026410;C0286651;C0439269;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
118,atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
118,ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,ato $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,aspirin $nmbr$ mg ( n = $nmbr$ ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,asa > $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
118,asa < $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
118,apolipoprotein b ( mg / dl ),C0003593;C0439269
118,apolipoprotein b $nmbr$  mg / dl,C0003593;C0439269
118,apolipoprotein b  mg / dl,C0003593;C0439269
118,apolipoprotein a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508
118,apob ( mg / dl ),C0003593;C0439269;C3252643
118,apob  mg / dl,C0003593;C0439269;C3252643
118,apoal ( mg / dl ) *,C0439269
118,apoal  mg / dl,C0439269
118,apoa $nmbr$  mg / dl,C0003592;C0439269;C0523508;C4553344;C4553379
118,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
118,apo b ( mg / dl ),C0003593;C0439269;C3252643
118,apo b  mg / dl,C0003593;C0439269;C3252643
118,aplxaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
118,apixaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
118,apixaban  $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
118,apixaban  $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
118,amlodipine / wlsartan i $nmbr$ / $nmbr$ mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
118,amlodipine / valsartan $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
118,aml / val $nmbr$ / $nmbr$ mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
118,aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761;C4554402
118,ami $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
118,ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
118,alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
118,alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
118,alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
118,albumin ( mg / dl ),C0001924;C0439269
118,> = $nmbr$ mg / dl,C0439269
118,> $nmbr$ to < $nmbr$ mg dl,C0439269
118,> $nmbr$ to < $nmbr$ mg / dl,C0439269
118,> $nmbr$ mg dl,C0439269
118,> $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,> $nmbr$ mg / dl — %,C0439269
118,> $nmbr$ mg / dl simva ( „ = $nmbr$ ),C0439269
118,> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ],C0439269
118,> $nmbr$ mg / dl simva,C0439269
118,> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ ),C0439269
118,> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ },C0439269
118,> $nmbr$ mg / dl eze / simva,C0439269
118,> $nmbr$ mg / dl chd status,C0280604;C0439269;C0449438;C3542407
118,> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +,C0439269;C1532563
118,> $nmbr$ mg / dl,C0439269
118,> $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,> $nmbr$ . $nmbr$ mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,> $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,> $nmbr$ . $nmbr$ mg / dl,C0439269
118,> $nmbr$ & < $nmbr$ mg / dl,C0439269
118,> $nmbr$  < $nmbr$ mg / dl,C0439269
118,< $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,< $nmbr$ mg / dl simva ( n = $nmbr$ ],C0439269
118,< $nmbr$ mg / dl simva ( n = $nmbr$ ),C0439269
118,< $nmbr$ mg / dl simva,C0439269
118,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ },C0439269
118,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ ),C0439269
118,< $nmbr$ mg / dl eze / simva,C0439269
118,< $nmbr$ mg / dl *,C0439269
118,< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
118,< $nmbr$ mg / dl,C0439269
118,< $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl,C0439269;C0439475
118,< $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
118,< $nmbr$ . $nmbr$ mg / dl,C0439269
118,* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023822;C0023824;C0024671;C0025266;C0026410;C0168634;C0202117;C0337445;C0368910;C0392885;C0439269;C1142985;C1305855;C1442160;C1442488;C1552663;C1960952;C2346927;C2360800;C2827109;C3642216;C3715113;C4321396;C4521761
118,* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .,C0010054;C0010068;C0012634;C0018787;C0024671;C0026410;C0027361;C0237753;C0333482;C0360714;C0439269;C0449788;C0948008;C1956346;C1960952;C2346927;C4081854;C4321396;C4521761
118,( sd )  mg / dl,C0439269;C2699239
118,( mg / dl ± sd ),C0439269;C2699239
118,( mg / dl ),C0439269
118,( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] ),C0439269;C1532563
118,$nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ to < $nmbr$ mg / dl,C0439269
118,$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b,C0036056;C0439269;C1532563;C3272372
118,$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d,C0439190;C0439269;C0567349;C0694666;C2348885;C3642216;C4553350
118,$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c,C0439269
118,$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
118,$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg ew n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg eow n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg / kgf ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg / dl,C0439269
118,$nmbr$ mg / $nmbr$ mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
118,$nmbr$ mg / $nmbr$ mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
118,$nmbr$ - $nmbr$ mg / dl *,C0439269
118,$nmbr$ - $nmbr$ mg / dl,C0439269
118,$nmbr$ $nmbr$ mg / dl,C0439269
117,rankin scale ≥ $nmbr$,C0451405
117,karnofsky score 竺 $nmbr$,C0206065
117,karnofsky score < $nmbr$,C0206065
117,bpearson ' s chi ‐ square test .,C0008041
116,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
116,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
116,abaloparatide - sc  n ( % ),C0282380;C4042342
115,carrier ( n = $nmbr$ ),C0007294;C0560175;C1325398;C1706209;C3273162
115,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
115,apoe   ε $nmbr$ carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
115,apoe e $nmbr$ carriers  no . ( % ),C0003595;C0007294;C0523511;C1412481
115,ala carriers,C0007294;C0523459;C3888236
114,adas — cog score,C0449820;C3539026;C4050231
114,adas - cog score *,C0449820;C3539026;C4050231
114,adas - cog,C3539026
114,ada $nmbr$ / $nmbr$ n [ $nmbr$,C1060325;C3811629
114,ada $nmbr$ / $nmbr$ ( n [ $nmbr$ ),C1060325;C3811629
114,ada  yes,C1060325;C1549445;C1705108;C1710701;C3811629
114,ada  no,C1060325;C3811629
113,advanced  n ( % ),C0205179
113,advanced,C0205179
112,without acei / arb,C3888198
112,with acei / arb,C3888198
112,previously on acei + arb,C3888198
112,peri - op ace - inhibitors / arbs : no ( n = $nmbr$ ),C0003015;C0347985;C3888198
112,baseiine acei / arb,C3888198
112,arbs or ace inhibitors,C3888198
112,arbs,C3888198
112,arb or ace inhibitor  n ( % ),C3888198
112,arb or ace inhibitor,C3888198
112,arb monotherapy,C3888198
112,arb / ace,C1452534;C3888198;C4284014
112,arb - arb / ccb,C0006684;C3888198
112,arb + ccb ( n = $nmbr$ ),C0006684;C3888198
112,arb ( n  % ),C3888198
112,arb  n ( % ),C3888198
112,arb  %,C3888198
112,arb,C3888198
112,aceis / arbs,C3888198
112,acei / arb therapy  n ( % ),C0039798;C0087111;C1363945;C3888198
112,acei / arb and bb after randomisation,C3888198
112,acei / arb,C3888198
112,ace inhibitor / arb therapy,C1444755;C3888198
112,ace / arb users,C1452534;C1706077;C3888198;C4284014
112,ace / arb use,C1452534;C3888198;C4284014
112,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
112,ace / arb,C1452534;C3888198;C4284014
111,stent plus abciximab,C0038257;C0288672;C0332287
111,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
111,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
111,abciximab vs . primary,C0288672
111,abciximab no . / total ( % ),C0288672
111,abciximab ( n = $nmbr$ ),C0288672
111,abciximab,C0288672
111,$nmbr$ abciximab ( n = $nmbr$ ),C0288672
110,baseline abi  affected limb,C0168634;C1328319;C1442488;C3888326
110,ankle / brachial index,C1328319;C3888326
110,ankle - brachial index £ $nmbr$ . $nmbr$,C1328319;C3888326
110,ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % ),C1328319;C3888326
110,ankle - brachial index < $nmbr$ . $nmbr$,C1328319;C3888326
110,abi > $nmbr$ . $nmbr$,C1328319;C3888326
110,abi < $nmbr$ . $nmbr$,C1328319;C3888326
110,abi # $nmbr$ . $nmbr$,C1328319;C3888326
110,abi,C1328319;C3888326
109,± standard deviation . triglyceride,C0041004;C0871420
109,sd = standard deviation  bmi = body mass index  ed = erectile,C0871420;C1305855;C2699239;C3538926
109,rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
108,western europe  australia  new zealand  middle east,C0026068;C0043129;C4289954
108,western europe  australia  new zealand  middle eai,C0043129;C0444598;C0549183;C1552826;C4289954
108,western europe  australia  new zealand  and middle east,C0043129;C4289954
108,western europe  australia  new zealand,C0043129;C4289954
108,the netherlands  australia  new zealand  and south africa,C0027778;C4289954
108,australia / new zealand,C4289954
108,asia / australia / new zealand,C0003980;C4289954
107,history of percutaneous coronary intervention,C1320647;C4554713
107,history of osteoporotic fracture  n ( % ) a,C4075937
107,history of microalbuminuria — no . ( % ),C3532606
107,history of gestational diabetes mellitus — no . ( % of women ),C2183115
107,history of diabetes mellitus ( n = $nmbr$ ),C0455488
107,history of diabetes mellitus  no . ( % ),C0455488
107,history of diabetes mellitus  n ( % ),C0455488
107,history of diabetes mellitus,C0455488
107,history of atrial fibrillation or flutter treatment at randomisation,C0729790
107,history of atrial fibrillation or flutter,C0729790
107,history of atrial fibrillation or fl utter,C0729790
107,history of atrial fibrillation and / or flutter,C0729790
107,history of atrial fibrillation / flutter  ( % ),C0016385;C0232197;C0729790;C1998417;C2242390
107,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
107,history of atrial fibrillation  type 一 no . ( % ),C0332307;C0729790;C1547052
107,history of atrial fibrillation  n ( % ),C0729790
107,history of atrial fibrillation,C0729790
107,history of asthma - related intubation — no . ( % ),C0455544
106,history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %,C0205267;C2315493
106,history of claudication,C2315493
105,unadjusted hazard ratio ( $nmbr$ % cl ),C0596019;C1439367;C2985465
105,unadjusted hazard ratio ( $nmbr$ % ci ),C0008107;C1439367;C2985465;C3259781
105,hazard ratio with low ( $nmbr$ % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
105,hazard ratio with high ( $nmbr$ % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
105,hazard ratio with,C2985465
105,hazard ratio vs . placebo,C2985465
105,hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value,C2985465
105,hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value,C2985465
105,hazard ratio for event ( $nmbr$ % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
105,hazard ratio and $nmbr$ % confidence interval,C2985465
105,hazard ratio [ $nmbr$ % cl ],C0596019;C2985465
105,hazard ratio [ $nmbr$ % ci ],C0008107;C2985465;C3259781
105,hazard ratio * ( and $nmbr$ % ci ),C2985465
105,hazard ratio * ( $nmbr$ % ci ),C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % confidence interval ) *,C0009667;C2985465
105,hazard ratio ( $nmbr$ % confidence interval ),C0009667;C2985465
105,hazard ratio ( $nmbr$ % confi dence interval ),C1272706;C1552654;C1552713;C2985465
105,hazard ratio ( $nmbr$ % cl ],C0596019;C2985465
105,hazard ratio ( $nmbr$ % cl ) *,C0596019;C2985465
105,hazard ratio ( $nmbr$ % cl ),C0596019;C2985465
105,hazard ratio ( $nmbr$ % ci ) vs . placebo,C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes,C0008107;C1320657;C2985465;C3259781
105,hazard ratio ( $nmbr$ % ci ) - j -,C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % ci ) *,C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis,C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % ci ),C0008107;C2985465;C3259781
105,hazard ratio ( $nmbr$ % c,C2985465
105,hazard ratio $nmbr$ ),C2985465
105,hazard ratio $nmbr$,C2985465
105,hazard ratio,C2985465
105,hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
105,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
105,adjusted hazard ratio *,C0456081;C2985465
105,adjusted hazard ratio ( $nmbr$ % cl ) *,C0456081;C0596019;C2985465
105,adiusted hazard ratio *,C2985465
104,risk factors — no . ( % ),C0035648;C1553898
104,risk factors specified as inclusion criteria — no . ( % ) f,C0035648;C1553898
104,risk factors only,C0035648;C0205171;C1553898;C1720467
104,risk factors for stroke  no . ( % ),C0035648;C1553898
104,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
104,risk factors for recurrent vte — no . ( % ) f,C0035648;C0630906;C1455761;C1553898;C2945760
104,risk factors and medical history,C0035648;C1553898
104,risk factors and immobility level  n ( % ),C0035648;C1553898
104,risk factors and diabetes status ( % ),C0035648;C1553898
104,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
104,risk factors ( % ),C0035648;C1553898
104,risk factors  no . ( % ),C0035648;C1553898
104,risk factors  %,C0035648;C1553898
104,risk factors,C0035648;C1553898
104,risk factor ( predefined ) for falling at screening  n ( % ),C0035648
104,risk factor,C0035648
104,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
104,qualifying risk factor — no . ( % ),C0035648;C1514624
104,qualifying risk factor  n ( % ),C0035648;C1514624
104,qualifying risk factor,C0035648;C1514624
104,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
104,other risk factors,C0035648;C1553898
104,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
104,non - transient risk factors for recurrent vte  n ( % ),C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
104,no . of risk factors for venous thromboembolism  no . ( % ),C0035648;C1553898
104,no . of risk factors ( % ) | |,C0035648;C1553898
104,multiple risk factors,C0035648;C0439064;C1553898
104,multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %,C0035648;C0280604;C0439064;C1553898;C3542407
104,diagnoses / risk factors  n ( % ],C0011900;C0035648;C1553898
104,diagnoses / risk factors  n ( % ),C0011900;C0035648;C1553898
104,cvd risk factors ( age > $nmbr$ ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
104,cvd risk factors ( age > $nmbr$ ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
104,cv risk factors and history,C0035648;C1553898;C3538987;C4048877;C4318503
104,chd risk factors #,C0035648;C0280604;C1553898;C3542407
104,chads $nmbr$ risk factors  n ( % ),C0007928;C0035648;C1413373;C1553898
104,> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
104,> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
104,> $nmbr$ chd risk factors,C0035648;C0280604;C1553898;C3542407
103,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
103,score on st . george ' s respiratory questionnaire ^ ^,C3472502
103,score on asthma control questionnaire * *,C4706265
103,health assessment questionnaire score,C2960025
102,table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0168634;C0370003;C0947343;C1315074;C1442488;C1706074;C2347026;C4684572
102,table $nmbr$ . selected baseline characteristics of the study patients . *,C0039224;C1706074
102,table $nmbr$ . characteristics of the patients at baseline . *,C0039224;C0815172;C1706074
102,table $nmbr$ . characteristics of patients treated with losartan and atenolol *,C0039224;C0815172;C1706074
101,aspartate aminotransferase increased,C0004002
101,aspartate aminotransferase  u / l,C0004002;C0439339
101,alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0001899;C0057041;C1415274;C3887708
101,alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708
101,alanine aminotransferase  u / l,C0001899;C0057041;C0439339;C1415274;C3887708
100,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C1532338;C2826257
100,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
100,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
100,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
100,percutaneous coronary revascularization,C1532338
100,percutaneous coronary intervention §,C1532338
100,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338
100,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C1532338
100,percutaneous coronary intervention n ( % ),C1532338
100,percutaneous coronary intervention done *,C1532338
100,percutaneous coronary intervention  n ( % ),C1532338
100,percutaneous coronary intervention,C1532338
100,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
100,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0181074;C0332835;C0917805;C1054154;C1532338;C1961139
99,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
99,toast classification of qualifying stroke  no . ( % ),C1514624;C1710306;C4521230
99,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
99,toast classification,C1710306;C4521230
98,angina class iii or iv — no . ( % ),C0264677
98,angina class iii or iv prior myocardial infarction,C0264677
98,angina class iii or iv prior,C0264677
97,radiographic progression based on change from baseline > sdc,C0242656;C0444708;C0449258
97,progression of albuminuria,C0001925;C0242656;C0449258
97,first disease - progression outcome to occur §,C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1947900;C3542417;C4552808
97,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
97,albuminuria progression,C0001925;C0242656;C0449258
97,% patients with no progression,C0030705;C0242656;C0449258
96,transfusions,C0005841;C0199960;C1879316
96,transfusion ≥ $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C0439148;C1519795;C1879316;C3853603
96,transfusion,C0005841;C0199960;C1879316
96,blood transfusion,C0005841;C0281867
96,any blood transfusion,C0005841;C0281867
96,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
95,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
95,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
95,qualifying type of atherosclerosis  n ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
95,qualifying atherosclerosis,C0003850;C0004153;C1514624
95,large - artery atherosclerosis,C0003850;C0004153;C0226003
95,atherosclerosis ^  n ( % ),C0003850;C0004153
95,atherosclerosis,C0003850;C0004153
95,arteriosclerosis,C0003850
94,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
94,blood glucose,C0005802
94,blood - glucose control,C3267174
94,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
93,fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0428568;C0439269;C1261430;C1532563
93,fasting blood glucose > $nmbr$ mg / dl,C0428568;C0439269;C1261430
93,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
93,fasting blood glucose,C0428568;C1261430
92,red blood cell counting  $nmbr$ / l,C0005767;C0005768;C0022827;C0229664;C0332575;C0750480;C1260956;C1705566;C4049926
92,blood bilirubin increased,C0005437;C0005767;C0005768;C0229664
92,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
92,any blood,C0005767;C0005768;C0229664
91,total study population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
91,total study population ( n = $nmbr$  $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
91,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
91,total study itt population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
91,total population n,C3258257
91,total population ( n = $nmbr$ ),C3258257
91,total population,C3258257
91,total ho population ( n = $nmbr$ ),C0019905;C1832110;C3258257;C3889614
91,total carmelina population,C3258257
91,study population,C2348561
90,vasodilator,C0042402;C3537240
90,other vasodilators §,C0042402
90,other vasodilator,C0042402;C3537240
90,iv vasodilator,C0022326;C0042402;C3537240;C4265176
90,both iv vasodilator and inotrope,C0022326;C0042402;C3537240;C4265176
89,with prior mi / stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C3810814;C4554100
89,st ‐ str ≥ $nmbr$ % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
89,prior years taking warfarin,C0332152;C0439234;C2826257
89,prior vka use for > $nmbr$ d  %,C0042153;C0332152;C0457083;C1947944;C2826257
89,prior use of systemic,C0205373;C0332152;C1524063;C2826257
89,prior use of synthetic dmards  n ( % ),C0242708;C0332152;C1524063;C1883254;C2826257
89,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
89,prior use of conventional dmards only ( biologic - nai ' ve )  n ( % ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
89,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
89,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
89,prior use of $ $nmbr$ systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
89,prior tnfi  n ( % ),C0332152;C2826257
89,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
89,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
89,prior tnf antagonist failure  n [ % ],C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
89,prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
89,prior thienopyridine ( - ),C0332152;C1120149;C2826257
89,prior thienopyridine ( + ),C0332152;C1120149;C2826257
89,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
89,prior stroke — no . ( % ),C0332152;C2826257
89,prior stroke or tza,C0038454;C0332152;C2826257;C4554100
89,prior stroke or tia  %,C0038454;C0332152;C2826257;C4554100
89,prior stroke or tia,C0038454;C0332152;C2826257;C4554100
89,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
89,prior stroke / mi  n ( % ),C0038454;C0332152;C2826257;C3810814;C4554100
89,prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
89,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
89,prior statin use ( n = $nmbr$ ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
89,prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
89,prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
89,prior revascularization ( % ),C0332152;C0581603;C2826257
89,prior revascularization,C0332152;C0581603;C2826257
89,prior peripheralarterialdisease,C0332152;C2826257
89,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
89,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
89,prior or new diabetes,C0332152;C2826257
89,prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
89,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
89,prior om,C0028971;C0332152;C1705272;C2826257
89,prior oad :,C0332152;C2826257
89,prior oac,C0332152;C2826257
89,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
89,prior nsaid  n ( % ) a,C0003211;C0332152;C2826257;C3536840
89,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
89,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
89,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
89,prior migraine *,C0149931;C0332152;C2826257
89,prior migraine,C0149931;C0332152;C2826257
89,prior mi within $nmbr$ y  no . ( % ),C0332152;C2826257;C3810814
89,prior mi n = $nmbr$,C0332152;C2826257;C3810814
89,prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
89,prior mi ( n - $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
89,prior mi  n / n ( % ),C0332152;C2826257;C3810814
89,prior mi  %,C0332152;C2826257;C3810814
89,prior mi,C0332152;C2826257;C3810814
89,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
89,prior lev use,C0023556;C0332152;C2826257
89,prior lev,C0023556;C0332152;C2826257
89,prior known stenosis > $nmbr$ %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
89,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
89,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
89,prior immunosuppressant failurec,C0021081;C0332152;C2826257
89,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
89,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
89,prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
89,prior gestational diabetes,C0085207;C0332152;C2826257
89,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
89,prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
89,prior dm,C0011816;C0332152;C2826257;C3250443
89,prior diabetes,C0011847;C0011849;C0332152;C2826257
89,prior cvd,C0007222;C0332152;C2826257
89,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
89,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
89,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
89,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
89,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
89,prior conventional synthetic dmards  n ( % ),C0242708;C0332152;C0439858;C1883254;C2826257
89,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
89,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
89,prior cardiovascular event  ',C0332152;C1320716;C2826257
89,prior cardiovascular event,C0332152;C1320716;C2826257
89,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
89,prior cabg  %,C0010055;C0332152;C2826257
89,prior cabg,C0010055;C0332152;C2826257
89,prior brachytherapy,C0006098;C0332152;C2826257
89,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
89,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
89,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
89,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
89,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
89,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
89,prior anti - tnf therapy,C0281481;C0332152;C2826257
89,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
89,prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0002978;C0332152;C2826257
89,prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °,C0002978;C0332152;C2826257
89,prior af ablation  n ( % ),C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
89,prior aeds  ≥ $nmbr$  n ( % ),C0180309;C0332152;C2826257
89,prior admb,C0332152;C2826257
89,prior acbi or arb use,C0332152;C2826257
89,prior a - blocker use,C0332152;C2826257
89,prior,C0332152;C2826257
89,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
89,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
89,pre fev $nmbr$,C0332152;C0740175;C2257086;C3669034;C3714541
89,pre - treatedforhypertension [ n ( % ) ],C0332152;C0740175;C2257086;C3669034
89,pre - mixed insulin,C0205430;C0332152;C0740175;C2257086;C3160715;C3669034
89,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
89,number of prior aeds    n   ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
89,number of prior aeds  n ( % ) b,C0180309;C0237753;C0332152;C0449788;C2826257
89,number of prior aeds  n ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
89,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
89,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
89,no prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
89,no prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
89,no prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
89,no prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
89,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
89,no prior mi n = $nmbr$,C0332152;C2826257;C3810814
89,no prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
89,no prior mi,C0332152;C2826257;C3810814
89,no prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
89,no prior dm,C0011816;C0332152;C2826257;C3250443
89,no prior cvd,C0007222;C0332152;C2826257
89,no prior cabg,C0010055;C0332152;C2826257
89,no prior admc,C0332152;C2826257
89,no . of prior tnfi,C0332152;C2826257
89,no . of prior bdmards,C0332152;C2826257
89,no . of prior aedsd,C0332152;C2826257
89,no . of prior aeds  n ( % ) $nmbr$ - $nmbr$,C0180309;C0332152;C2826257
89,no . of prior aeds  n ( % ),C0180309;C0332152;C2826257
89,no . of prior aeds  c n ( % ),C0180309;C0332152;C2826257
89,leading to study withdrawal,C0332152;C1522538
89,leading to study drug discontinuation,C0332152;C1522538
89,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
89,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
89,fev $nmbr$ reversibilityz ( pre / post salbutamol )  %,C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
89,fev $nmbr$ reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
89,fev $nmbr$ reversibility  pre - / post - albuterol  %,C0001927;C0332152;C0449261;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
89,fev $nmbr$ ( pre - albuterol )  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
89,fev $nmbr$  pre - albuterol  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
89,duration of prior statin therapy ^,C0332152;C0360714;C0444917;C2826257
89,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
89,dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
89,dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
89,$nmbr$ prior tnf antagonist failures  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
89,$nmbr$ prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
89,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
89,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
89,# of prior bdmards,C0332152;C2826257
88,yes vs . no,C1549445;C1705108;C1710701
88,yes *,C1549445;C1705108;C1710701
88,yes ( stopped for trial ),C1549445;C1705108;C1710701
88,yes ( n = $nmbr$ ),C1549445;C1705108;C1710701
88,yes ( n  % ),C1549445;C1705108;C1710701
88,yes ( any ),C1549445;C1705108;C1710701
88,yes ( % ),C1549445;C1705108;C1710701
88,yes ',C1549445;C1705108;C1710701
88,yes  z $nmbr$ cm,C1549445;C1705108;C1710701
88,yes  yes,C1549445;C1705108;C1710701
88,yes  unknown,C1549445;C1705108;C1710701
88,yes  r $nmbr$ y,C1549445;C1705108;C1710701
88,yes  proliferative,C1549445;C1705108;C1710701
88,yes  o $nmbr$ cm,C1549445;C1705108;C1710701
88,yes  non - proliferative,C1549445;C1705108;C1710701
88,yes  non - insulin - treated,C1549445;C1705108;C1710701
88,yes  n ( % ),C1549445;C1705108;C1710701
88,yes  insulin - treated,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
88,yes  $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
88,yes,C1549445;C1705108;C1710701
88,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
88,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
88,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
88,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
88,partner  n ( % yes ),C0682323;C1549445;C1705108;C1710701;C3887537
88,no  yes,C1549445;C1705108;C1710701
88,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
88,naive : yes,C1549445;C1705108;C1710701
88,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
88,etn  yes,C0014758;C0717758;C1549445;C1705108;C1710701
88,diabetic yes,C0241863;C1549445;C1705108;C1710701
88,diabetesh yes,C1549445;C1705108;C1710701
88,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
88,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
88,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
88,[ no / yes ] ( % ),C1549445;C1705108;C1710701
87,steroids § §,C0038317
87,steroids ( other ),C0038317
87,steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
87,steroids ( inhaled ) a,C0038317
87,steroids  n ( % ),C0038317
87,steroid - free cr - $nmbr$,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
87,other steroids,C0038317
87,no steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
87,baseline steroids,C0038317;C0168634;C1442488
86,sensitive responders ( n = $nmbr$ ),C0020517;C0332324;C1522640
86,sensitive responder ( n = $nmbr$ ),C0020517;C0332324;C1522640
86,sensitive,C0020517;C0332324;C1522640
86,hypersensitivity  n ( % ),C0020517;C0520946
86,allergic disease by historyb  n ( % ),C0020517;C0851444
85,traditional nsaid use,C0003211;C3536840;C3897349
85,traditional nsaid,C0003211;C0443324;C1548559;C3536840
85,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0032790;C3536840
85,postoperative nsaid or glucocorticoid use,C0003211;C0032790;C3536840
85,other nsaids,C0003211
85,nsaid   at   least   once,C0003211;C3536840
85,nsaid use — no . / total no . ( % ),C0003211;C3536840
85,nsaid,C0003211;C3536840
85,non - steroidal anti - inflammatory drugs,C0003211
85,never nsaid,C0003211;C2003901;C3536840
85,cox - $nmbr$ selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
85,cox - $nmbr$ selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
85,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
84,low - density lipoprotein choles -,C0023823
84,low - density lipoprotein ^,C0023823
84,low - density lipoprotein  mg / dl,C0023823;C0439269
84,low - density lipoprotein,C0023823
84,high density lipoprotein ( mg / dl ),C0023821;C0439269
84,high - density lipoprotein ],C0023821
84,high - density lipoprotein  mg / dl,C0023821;C0439269
84,high - density lipoprotein,C0023821
83,highly sensitive responders ( n = $nmbr$ ),C0439822
83,highly sensitive responder ( n = $nmbr$ ),C0439822
83,highly sensitive,C0439822
82,no high - intensity statin,C0360714;C4081854
82,high ‐ intensity statins ‡,C0360714;C4081854
82,high intensity,C4081854
82,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
82,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
82,high - intensity statin *,C0360714;C4081854
82,high - intensity statin,C0360714;C4081854
81,hypotension  n ( % ),C0020649;C3163620
81,hypotension,C0020649;C3163620
81,hypertensive  n ( % ),C0857121
81,hypertensive,C0857121
80,antihypertensive therapy — no . ( % ),C0585941
80,antihypertensive therapy  n ( % ),C0585941
80,antihypertensive therapy,C0585941
80,anti - hypertensive therapy - no . ( % ),C0585941
80,anti - hypertensive therapy,C0585941
79,underlying disease,C0012634;C4067746
79,uc disease durslion,C0012634
79,site of disease — no . ( % ),C0012634;C2945843
79,priorvascular disease  %,C0012634
79,priorbone disease,C0012634
79,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0332152;C0392747;C2826257;C3687832
79,prior disease,C0012634;C0332152;C2826257
79,prespecified medical conditions  n ( % ) f,C0012634;C0016327;C0199168;C0205476;C0348080;C1705253;C3864998
79,presenting condition  n ( % ),C0012634;C0348080;C0449450;C1705253;C3864998
79,polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
79,polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
79,polyvascular disease * and type $nmbr$ diabetes status,C0012634
79,polyvascular disease * ( n = $nmbr$ ),C0012634
79,polyvascular disease ( n = $nmbr$ ),C0012634
79,peripherai arteriai disease,C0012634
79,no polyvascular disease * ( n = $nmbr$ $nmbr$ ),C0012634
79,no polyvascular disease ( n = $nmbr$ $nmbr$ ),C0012634
79,no multivessel disease,C0012634
79,multivessel disease 一 no . ( % ),C0012634
79,multivessel disease — no . ( % ),C0012634
79,multivessel disease  no . ( % ),C0012634
79,multivessel disease  n ( % ),C0012634
79,multivessel disease,C0012634
79,microvascular disease *,C0012634;C0443258
79,microvascular disease  n ( % ),C0012634;C0443258
79,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
79,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
79,macrovascular disease  n ( % ),C0012634
79,left main disease  n ( % ),C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
79,history of other medical conditions  n ( % ),C0012634;C0262926;C0348080;C1705253;C3864998
79,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
79,established maerovaseular disease and albuminuria,C0012634;C0443211;C1272684
79,established disease,C0012634;C0443211;C1272684
79,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
79,disorders ( soc ),C0012634
79,disease site — no . of patients ( % ) |,C0012634;C0205145;C1515974;C2825164
79,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
79,disease site  n [ % ],C0012634;C0205145;C1515974;C2825164
79,disease hare . no . ( % ) i,C0012634
79,disease extent  n ( % ),C0012634;C0439792
79,disease and quality - of - life scores  mean ( sd ),C0012634
79,disease and quality - of - life scores,C0012634
79,disease,C0012634
79,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
79,coronarv arterv disease,C0012634
79,condition $nmbr$ ( $nmbr$ . $nmbr$ ),C0012634;C0348080;C1705253;C3864998
79,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
79,cerebrovascuiar disease,C0012634
79,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
79,any disease,C0012634
79,any condition,C0012634;C0348080;C1705253;C3864998
79,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .,C0012634;C0014442;C0018801;C0344434;C0348080;C0387288;C1705253;C3864998;C4049859;C4521602
78,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
78,type of reflux disease,C0232483;C0457464;C1882919;C4317146
78,rheumatic heart disease,C0035439
78,inflammatory disease,C1290884
78,inflammatory bowel disease,C0021390
78,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
78,gastrooesophageal reflux disease,C0017168;C4553201
78,gastroesophageal reflux disease,C0017168;C4553201
78,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
78,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
78,family history of coronary disease,C0018787;C0850707
78,family history of coronary artery disease,C2317524
78,connective tissue disease,C0009782
78,connective - tissue disease,C0009782
78,congenital heart disease,C0152021
78,chronic pulmonary disease,C0746102
78,chronic kidney diseased,C2364010
78,chronic inflammatory disease,C1290886
78,carotid artery disease,C0007273
78,associated with connective tissue disease,C0009782;C0332281
78,assoc  with connective tissue disease,C0009782
78,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
77,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
77,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
77,components,C0449432
77,component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called,C0205250;C0449432;C0449820;C1705248;C4551823
76,use of anti - hypertensive agents  n ( % ) *,C0432633;C0450442;C0857121;C1254351;C1521826;C1524063
76,two agents,C0205448;C0450442;C1254351;C1521826
76,treatment throughout study,C1521826;C3161471
76,study treatment — no . / total no . ( % ),C1521826
76,study treatment,C1521826
76,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
76,previous treatment in the healing study  n ( % ),C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
76,p - blocking agents  selective,C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C2603361
76,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
76,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
76,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
76,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
76,oral agent and / or insulin therapy,C0442027;C0450442;C1254351;C1521826;C4521986
76,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
76,no . of agents,C0450442;C1254351;C1521826
76,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
76,conventional agents *,C0439858;C0450442;C1254351;C1521826
76,anyantianginal agent,C0450442;C1254351;C1521826
76,any bp - lowering agents ^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
76,antialdosterone agents,C0450442;C1254351;C1521826
76,anti ‐ platelet agents  n ( % ),C0005821;C0432633;C0450442;C1254351;C1521826
76,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
76,> $nmbr$ oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
75,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
75,total cataract,C3665439
75,modmy al randcnxzaton,C0202311
74,clinically relevant non,C1518422;C2347946
74,any relevant infarct,C0021308;C2347946
73,oral medications,C0304289
73,oral anti - dm drug status  no . ( % ),C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
73,concomitant oral anti - dm drugs  no . ( % ) a,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
72,oral anticoagulants,C0354604
72,oral anticoagulant — no . / total no . ( % ),C0354604
72,oral anticoagulant n ( % ),C0354604
72,oral anticoagulant drugs  n ( % ),C0354604
72,oral anticoagulant drugs,C0354604
72,oral anticoagulant agent,C0354604
72,oral anticoagulant  n ( % ),C0354604
72,oral anticoagulant,C0354604
71,periprocedural anticoagulant,C0003280;C0848112;C3536711
71,other anticoagulant,C0003280;C0848112;C3536711
71,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
71,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
71,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
71,concomitant anticoagulant  antithrombotic or nsaid  n ( % ),C0003280;C0521115;C0848112;C3536711
71,any anticoagulant,C0003280;C0848112;C3536711
71,anticoagulants,C0003280
71,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
71,anticoagulant group ( n = $nmbr$ ),C0003280;C0441848;C0848112;C3536711
71,anticoagulant,C0003280;C0848112;C3536711
71,anti - coagulants - no . ( % ),C0848112
71,anti - coagulants,C0848112
70,postprandial indices,C0376674;C4033634
70,orthopaedic,C0029355
70,organic,C0747055
70,fasting indices,C0015663;C4033634
69,somnolence,C0013144;C2830004;C4553740
69,psycholeptics,C3653516
69,psychogenic,C0458006
68,progression to diabetes,C1735364
68,proctosigmoiditis,C0033252
68,pro / pro homozygotes,C0019904;C1120626
67,hormones,C0019932
67,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
66,primary composite endpoint ‡,C0205199;C1547335;C2986535
66,primary composite end point ‡,C0205199;C1547335;C2986535
66,primary composite end point,C0205199;C1547335;C2986535
66,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
66,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
66,composite ocular end point ^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
66,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
66,composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp,C0037623;C0205199;C1415692;C1547335;C1708288;C2349179;C2826544;C4318478
66,composite endpoint,C0205199;C1547335;C2349179;C2826544
66,composite,C0205199;C1547335
66,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
66,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
65,use $nmbr$ - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
65,no use of $nmbr$ - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
65,$nmbr$ - asa compounds  n ( % ),C0004057;C0205198;C1706082;C3853627
65,$nmbr$ - aminosalicylic compounds — no . ( % ),C0205198;C1706082
64,timi non - cabg major,C0010055;C1518422
64,safety : non - cabg - related bleeding,C0010055;C0036043;C1518422;C1705187
64,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
64,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
64,prior aortocoronary bypass surgery,C0010055;C0455610
64,non - cabg related bleeding at $nmbr$ h,C0010055;C1518422
64,non - cabg or combined,C0010055;C1518422
64,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
64,multivessel coronary - artery bypass grafting,C0010055
64,hx cabg,C0010055;C0262926;C3814444
64,coronary bypass surgery,C0010055
64,coronary bypass  n ( % ),C0010055
64,coronary artery bypass surgery,C0010055
64,coronary artery bypass grafting n ( % ),C0010055
64,coronary artery bypass grafting,C0010055
64,coronary artery bypass graft — no . ( % ),C0010055;C1260596
64,coronary artery bypass graft  n ( % ),C0010055;C1260596
64,coronary artery bypass graft,C0010055;C1260596
64,coronary artery bypass,C0010055
64,coronary - artery bypass grafting §,C0010055
64,coronary - artery bypass grafting,C0010055
64,cabg — no . { % ),C0010055
64,cabg — no . ( % ),C0010055
64,cabg surgery by no . of vessels $nmbr$,C0010055;C0042381;C3714645
64,cabg performed during index hospitalization,C0010055
64,cabg or valve,C0010055
64,cabg or ptca / pci,C0010055
64,cabg or ptca ( % ),C0010055
64,cabg or pci,C0010055
64,cabg or angioplasty,C0010055
64,cabg only,C0010055;C0205171;C1720467
64,cabg > $nmbr$ month ago,C0010055;C0332177;C0439231
64,cabg :,C0010055
64,cabg ( % ),C0010055
64,cabg  n ( % ),C0010055
64,cabg,C0010055
63,other oral hypoglycemic drug ( s ),C0359086
63,oral hypoglycemics,C0359086
63,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
63,oral hypoglycemic drug,C0359086
63,oral hypoglycemic agentsj,C0359086
63,oral hypoglycemic agents,C0359086
63,oral hypoglycemic agent,C0359086
63,oral hypoglycemic,C0359086
63,oral hypoglycaemics only,C0205171;C0359086;C1720467
63,oral antihyperglycaemic  n ( % ),C0359086
63,any oral hypoglycemic drug 一 no . ( % ),C0359086
63,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .,C0000723;C0003211;C0010055;C0033572;C0038952;C0042295;C0043210;C0205163;C0205166;C0205171;C0220921;C0237753;C0332490;C0359086;C0439165;C0444099;C0449788;C0600061;C0678226;C0679138;C0679199;C0679831;C1123023;C1305855;C1532338;C1549488;C1561533;C1706317;C1720467;C3146286;C4520765
62,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
62,neither ace - i nor arb use,C0021966;C0221138;C1452534;C4284014
62,ace ‐ i or arb,C0021966;C0221138;C1452534;C4284014
62,ace or arb,C1452534;C4284014
62,ace - lorarb,C1452534;C4284014
62,ace - l / arbs,C1452534;C3888198;C4284014
62,ace - i or arb use at baseline,C0021966;C0221138;C1452534;C4284014
62,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
62,ace - i or arb  % ( n ),C0021966;C0221138;C1452534;C4284014
62,ace - i or arb,C0021966;C0221138;C1452534;C4284014
62,ace - i or angiotensin receptor blocker,C0021966;C0221138;C1452534;C4284014
62,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
62,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
62,ace - i ( n  % ),C0021966;C0221138;C1452534;C4284014
62,ace,C1452534;C4284014
61,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
61,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
61,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
61,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
61,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
61,cancer — no . ( % ),C0006826;C0998265;C1306459
61,cancer §,C0006826;C0998265;C1306459
61,cancer n ( % ),C0006826;C0998265;C1306459
61,cancer * *,C0006826;C0998265;C1306459
61,cancer *,C0006826;C0998265;C1306459
61,cancer ( n = $nmbr$ ),C0006826;C0998265;C1306459
61,cancer  fatal and nonfatal,C0006826;C0998265;C1306459
61,cancer,C0006826;C0998265;C1306459
61,all cancer,C0006826;C0998265;C1306459
61,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
61,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
60,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
60,non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199;C1518422
60,ccbs  ( % ),C0006684
60,ccb,C0006684
60,caleium ehannel bloekers ( ccb ),C0006684
60,calcium channel blockers  n ( % ),C0006684;C2757014
60,calcium channel blockers,C0006684;C2757014
60,calcium channel blocker ( % ),C0006684;C3536851;C4521885
60,calcium channel blocker,C0006684;C3536851;C4521885
60,calcium channel antagonists  n ( % ),C0006684;C2757014
60,calcium antagonists  n ( % ),C0006684
60,calcium antagonists,C0006684
60,calcium antagonist — no . ( % ),C0006684
60,calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199
60,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
60,calcium antagonist,C0006684
60,calcium - channel blockers ( % ),C0006684;C2757014
60,calcium - channel blockers,C0006684;C2757014
60,calcium - channel blocker *,C0006684;C3536851;C4521885
60,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
60,calcium - channel blocker,C0006684;C3536851;C4521885
60,calcium - channel antagonists,C0006684;C2757014
60,baseiine ccb,C0006684
60,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
59,shared epitope  a % positive,C0003316;C0237876;C1522138
59,normal cognitive,C2712133
59,impaired cognitive,C0338656
59,fatty acid composition,C0015684;C0486616;C1555710
58,subject characteristics,C0681884;C1519021;C1706465
58,subgroup statistics,C0038215;C0600673;C1079230;C1515021
58,study eye characteristics,C0015392;C0700042;C1568011
58,statistics,C0038215;C0600673
58,parameter statistics,C0681933
58,lesion characteristics,C1286326
57,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
57,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
57,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
57,sgrq total score  units,C0439148;C1519795;C2964552;C3853603
57,or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
57,mtss units,C0439148;C1519795;C3853603
57,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
57,c $nmbr$ - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
57,% anti - ccp + ( > $nmbr$ units ),C0439148;C1519795;C3853603;C4318437
56,trial completers,C0008976
56,trial $nmbr$,C0008976
56,trial,C0008976
56,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
56,ended > $nmbr$ days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
56,end of trial,C0008976;C0444930;C2746065
56,dual iv - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
56,dual ii - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
56,dual i extension - end of trial hba $nmbr$ c,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
56,cure trial,C0008976;C1880198
56,completed trial,C0008976;C0205197;C3854010
56,combined trials,C0008976;C0205195
56,all trials,C0008976
55,tx $nmbr$,C0041403
55,tx,C0041403
55,triglycerides tx difference vs pbo  ls mean % change from baseline ( se ),C0041004;C0041403;C1705241;C1705242
55,low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023824;C0041403;C1705241;C1705242
55,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
55,insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0021641;C0041403;C1533581;C1579433;C1705241;C1705242;C3714501
55,homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters,C0041403;C1705241;C1705242
55,homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0022065;C0022071;C0041403;C1448132;C1705241;C1705242
55,homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
55,high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023822;C0041403;C1705241;C1705242
55,hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
55,hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0019016;C0041403;C1705241;C1705242;C1825777;C3538758
55,fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
55,c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0006558;C0041403;C1705241;C1705242
55,apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0041403;C1705241;C1705242
54,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
54,chlorthalidone vs lisinopril,C0008294
54,chlorthalidone vs doxazosin,C0008294
54,chlorthalidone vs amlodipine,C0008294
54,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
54,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
54,chlorthalidone ( n = $nmbr$ ),C0008294
54,chlorthalidone $nmbr$,C0008294
54,chlorthalidone,C0008294
54,amlodipione - chlorthalidone,C0008294
54,amlodipine / chlorthalidone,C0008294;C0051696
54,$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
54,$nmbr$ chlorthalidone ( n = $nmbr$ ),C0008294
54,$nmbr$ chlorthalidone,C0008294
54,$nmbr$ amlodipine - chlorthalidone,C0008294;C0051696
53,colon or rectum,C0009368;C3888384
53,colon only  n ( % ),C0009368;C0205171;C1720467;C3888384
53,colon only  ' n ( % ),C0009368;C0205171;C1720467;C3888384
53,colon only,C0009368;C0205171;C1720467;C3888384
53,colon,C0009368;C3888384
53,all of the colon,C0009368;C3888384
52,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
52,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
52,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
51,rotigotine n = $nmbr$,C1700683;C4318637
51,rotigotine ( n = $nmbr$ ),C1700683;C4318637
51,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
50,rosiglitazone versus metformin,C0289313
50,rosiglitazone versus glyburide,C0289313
50,rosiglitazone ( n = $nmbr$ ),C0289313
50,rosiglitazone $nmbr$ mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
50,rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
50,rosiglitazone,C0289313
50,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
50,pioglitazone only,C0071097;C0205171;C1720467
50,pioglitazone group ( n = $nmbr$ ),C0071097;C0441848
50,pioglitazone ( n = $nmbr$ ),C0071097
50,pioglitazone ( n = $nmbr$  $nmbr$ ),C0071097
50,pioglitazone,C0071097
49,zotarolimus - eluting,C1700035
49,zotarolimus,C1700035
49,arthritis mutilans,C0702102
48,sirolimus eluting stent,C0038257;C0072980
48,sirolimus - eluting,C0072980
48,sirolimus,C0072980
47,cross - clamp,C0175721;C1883710;C2828360;C3810601
47,cromoglicate,C0010347
46,first co - primary,C0205435;C1279901;C3245499
46,colombia,C3245499
45,diastolic bp ( mmhg ) *,C0428883;C0439475
45,diastolic bp ( mmhg ),C0428883;C0439475
45,diastolic bp ( mm hg ),C0428883;C0439475
45,diastolic bp  mmhg ( sd ),C0428883;C0439475;C2699239
45,diastolic bp  mmhg,C0428883;C0439475
45,diastolic bp  mm hg,C0428883;C0439475
45,diastolic bp,C0428883
45,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
45,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
45,diastolic blood pressure > $nmbr$ mm hg,C0428883;C0439475;C1305849
45,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
45,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
45,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
45,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
45,diastolic blood pressure  mmhg,C0428883;C0439475;C1305849
45,diastolic blood pressure  mm   hg,C0428883;C0439475;C1305849
45,diastolic blood pressure  mm hq,C0428883;C1305849;C4330985;C4554674
45,diastolic blood pressure  mm hg ^,C0428883;C0439475;C1305849
45,diastolic blood pressure  mm hg ( sd ),C0428883;C0439475;C1305849;C2699239
45,diastolic blood pressure  mm hg,C0428883;C0439475;C1305849
45,diastolic blood pressure  and lp ( a ),C0428883;C1305849
45,diastolic blood pressure  ( mm hg ),C0428883;C0439475;C1305849
45,diastolic blood pressure,C0428883;C1305849
45,< $nmbr$ . $nmbr$ mm hg diastolic blood pressure,C0428883;C0439475;C1305849
44,diastolic — mm hg,C0012000;C0439475
44,diastolic fmmhff ' ),C0012000
44,diastolic ( mmhg ),C0012000;C0439475
44,diastolic ( mm hg ),C0012000;C0439475
44,diastolic  treated at baseline,C0012000
44,diastolic  total,C0012000;C0439175;C0439810
44,diastolic,C0012000
43,systolic — mm hg,C0039155;C0439475
43,systolic ( mmhg ),C0039155;C0439475
43,systolic ( mm hg ),C0039155;C0439475
43,systolic  treated at baseline,C0039155
43,systolic  total,C0039155;C0439175;C0439810
43,systolic,C0039155
43,peak systolic pressure gradient,C0039155;C4687747
43,mean systolic pressure gradient,C0039155;C4687744
43,left ventricular systolic or diastolic dysfunction,C0039155;C0225897
42,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
42,loading dose of clopidogrel or ticlopidine,C0070166;C3714444
42,intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
42,clopidogrel plus aspirin ( n = $nmbr$ ),C0004057;C0070166;C0332287
42,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
42,clopidogrel plus aspirin,C0004057;C0070166;C0332287
42,clopidogrel or ticlopidine,C0070166
42,clopidogrel no . of patients % ),C0070166
42,clopidogrel n / n { % ),C0070166
42,clopidogrel n / n ( % ),C0070166
42,clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
42,clopidogrel given before procedure,C0070166
42,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
42,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
42,clopidogrel / total no . of patients % %,C0070166;C0439175;C0439810
42,clopidogrel / ticlopidine,C0040207;C0070166
42,clopidogrel + aspirin ( n = $nmbr$ ),C0004057;C0070166
42,clopidogrel ( n = $nmbr$ ) n / n ( % ),C0070166
42,clopidogrel ( n = $nmbr$ ),C0070166
42,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166
42,clopidogrel ( n = $nmbr$  $nmbr$ ),C0070166
42,clopidogrel %,C0070166
42,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166
42,clopidogrel  %,C0070166
42,clopidogrel  $nmbr$ mg loading doset,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C4321396;C4521761
42,clopidogrel  $nmbr$ mg loading dose !,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
42,clopidogrel  $nmbr$ mg *,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C4321396;C4521761
42,clopidogrel  $nmbr$ - mg loading dose,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
42,clopidogrel,C0070166
42,aspirin plus clopidogrel ( n = $nmbr$ ),C0004057;C0070166;C0332287
42,aspirin i clopidogrel ( n = $nmbr$  $nmbr$ ),C0004057;C0021966;C0070166;C0221138
42,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0070166
42,aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0070166
42,aspirin $nmbr$ clopidogrel,C0004057;C0070166
42,$nmbr$ mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
41,no digoxin scd  no . ( % / y ),C0012265
41,no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % ),C0012265
41,digoxin scd  no . ( % / y ),C0012265
41,digoxin or digitalis preparations,C0012265
41,digoxin or digitalis preparation,C0012265
41,digoxin or digitalis glycoside,C0012265
41,digoxin n = $nmbr$ ( $nmbr$ % ),C0012265
41,digoxin n ( % ),C0012265
41,digoxin / digitalis glycoside,C0012253;C0012265
41,digoxin  n ( % ),C0012265
41,digoxin  ( % ),C0012265
41,digoxin  % ( n ),C0012265
41,digoxin  %,C0012265
41,digoxin,C0012265
40,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
40,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
40,local eosinophil count,C0200638;C0205276;C0750879
40,eosinophil count,C0200638;C0750879
40,central eosinophil count,C0200638;C0205099;C0750879;C1879652
40,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
40,blood eosinophil count cells / mm $nmbr$ no .,C0005773;C0200638;C0750879;C4330985;C4554674
40,blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0229664;C0439231;C0750480;C0750879;C1705566;C4330985;C4554674
40,blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
40,blood eosinophil count ( $nmbr$ cells per l ),C0200638
39,eosinophils £ $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils $nmbr$ % ( n - $nmbr$ ),C0014467;C0200638
39,eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
39,eosinophils,C0014467;C0200638
39,eosinophil low,C0014467
39,eosinophil high,C0014467
39,blood eosinophils count,C0014467
39,blood eosinophils  mean ( range )  cells / mlb,C0005773;C0007584;C0007634;C0014467;C0200638;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
39,blood eosinophils  mean ( range )  cells / ml,C0014467;C0444504;C1514721;C2347634;C2348143;C2348147;C2699156;C3542016
39,blood eosinophils  cells / ml,C0014467;C2699156
39,blood eosinophil count  geometric mean ( sd loge scale ) cells / ll,C0014467
39,blood eosinophil,C0014467
38,lisinopril vs chlorthalidone overweight,C0065374
38,lisinopril vs chlorthalidone obese,C0065374
38,lisinopril vs chlorthalidone normal,C0065374
38,lisinopril vs chlorthalidone,C0065374
38,lisinopril vs amlodipineb,C0065374
38,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
38,lisinopril / chlorthalidone,C0008294;C0065374
38,lisinopril - chlorthalidone,C0008294;C0065374
38,lisinopril ( n = $nmbr$ ),C0065374
38,lisinopril,C0065374
38,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
38,ii lisinopril,C0065374;C1710602;C4082587
38,ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
38,i lisinopril ( n = $nmbr$ ),C0021966;C0065374;C0221138
38,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
38,$nmbr$ lisinopril - chlorthalidone,C0008294;C0065374
38,$nmbr$ lisinopril,C0065374
37,type of end point,C0332307;C1547052;C2349179;C2826544
37,primary end points,C0205225;C0439612;C0439631;C2349179
37,other prespecified end points,C2349179
37,other end points,C2349179
37,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
37,endpoints,C2349179
37,endpoint week $nmbr$,C0332174;C0439230;C2349179;C2826544
37,endpoint rate,C0871208;C1521828;C2349179;C2826544
37,endpoint / baselinec,C2349179;C2826544
37,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
37,endpoint *,C2349179;C2826544
37,endpoint,C2349179;C2826544
37,end points,C2349179
37,end point,C2349179;C2826544
37,end - point ( sd ),C2349179;C2699239;C2826544
37,coronary endpoint,C0018787;C2349179;C2826544
37,coronary end point,C0018787;C2349179;C2826544
37,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
37,additional endpoints,C1524062;C2349179
36,tender and swollen joints — mean no . : :,C0234234
36,tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .,C0234234
36,tender,C0234234
36,number of tender joints ( $nmbr$ assessed ),C0234234;C0449813
36,number of tender joints ( $nmbr$ - $nmbr$ ),C0234234;C0449813
35,weight at baseline,C1303013
35,baseline body weight quartile,C1303013;C2828255
34,placebo - famotidine $nmbr$ - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
34,placebo - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
34,famotidine $nmbr$ - famotidine $nmbr$,C0015620
33,non - / ex - drinker,C0457801
33,former / non - drinker,C0205156;C0457801;C0750523
33,ex - drinker,C0337679
32,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
32,suit index  nmol / mmol,C0600653;C0918012;C1532564;C1533073;C1552854;C1637833;C2986546
32,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
32,revascularization during index hospitalization  %,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
32,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
32,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
32,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
32,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
32,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
32,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
32,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
32,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
32,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
32,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
32,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
32,no revascularization for index acs event  no . ( % ),C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
32,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
32,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
32,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
32,mass index,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
32,lv mass index ( mg / m $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
32,lv mass index ( g / m $nmbr$ - $nmbr$ ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
32,lower - target group ( n = $nmbr$ ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
32,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
32,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
32,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
32,insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
32,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
32,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
32,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
32,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
32,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
32,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
32,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event not confirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
32,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event  n / n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event  n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
32,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
32,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
32,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
32,higher - target group ( n = $nmbr$ ),C0205250;C0441848;C1521840;C2986546
32,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
32,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
32,extent of index pe ' ( n  % of pe patients ),C0030705;C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
32,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,extent of index dvt ' ( n  % of dvt patients ' ),C0030705;C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
32,eq $nmbr$ da health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
32,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
32,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
32,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
32,cu index test  n ( % ) $nmbr$,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
32,cornell index  pv,C0030840;C0032463;C0600653;C0918012;C1552854;C1637833;C2986546
32,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
32,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
32,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
32,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
32,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
32,body weight index ( kg / m $nmbr$ ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
32,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
32,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
32,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
32,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
32,( % of target ) ∗,C1521840;C2986546
31,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
31,angiotensin receptor blockers,C0521942;C0815017
31,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
31,angiotensin receptor blocker and / or ace,C0034787;C1622222
31,angiotensin receptor blocker,C0034787;C1622222
31,angiotensin receptor,C0034787;C1622222
31,angiotensin receptive blocker,C0003018;C0544683;C4521302
31,angiotensin ll - receptor blocker,C0003018;C4521302
31,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302
31,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
31,angiotensin ii receptor blockers,C0521942;C2757003
31,angiotensin ii receptor blocker,C0521942;C3536793
31,angiotensin - receptor blocker,C0034787;C1622222
31,angiotensin - receptor,C0034787;C1622222
31,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
31,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
31,angiotensin -,C0003018;C4521302
30,no incident dm or change in fg > $nmbr$,C0011816;C1551358;C3250443
30,incident or worsening nephropathy,C1551358
30,incident dm or change in,C0011816;C1551358;C3250443
30,incidence rate per $nmbr$ person years,C0027361;C0439234;C1708485;C2347489
30,incidence rate per $nmbr$ person - years,C0027361;C0439234;C1708485;C2347489
30,incidence rate of cv events  n ( % ),C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
30,incidence rate no . ( / $nmbr$ person - years ),C1708485
30,incidence rate *,C1708485
30,incidence rate ( per $nmbr$ person - yr ),C0027361;C0439234;C1708485;C2347489
30,incidence rate ( n ) a,C1708485
30,incidence rate ( n ),C1708485
30,incidence rate,C1708485
30,incidence [ n / n ( rate per $nmbr$ person - years ) ],C0027361;C0439234;C1708485;C2347489
30,$nmbr$ - y incidence rate ( se ) per $nmbr$ participants,C0036919;C0679646;C1708485
29,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
29,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
29,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
29,air + ig ( n = $nmbr$ ),C0001861;C0021027;C0305052;C0360506;C3536832
29,air ( n = $nmbr$ ),C0001861;C3536832
28,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
28,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
28,allergic rhinitis,C1334103;C2607914;C4552864
27,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
27,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
27,modified rankin scale — no . ( % ) |,C2984908;C3854213
27,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
27,modified rankin scale at screening  $nmbr$ - $nmbr$,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
26,enrolled into osler,C4684790
26,enrolled in the americas,C0002454;C0596070;C4684790
26,enrolled in russia or georgia,C0035970;C4684790
26,enrolled from re - cover study — no . ( % ),C4684790
26,enrolled from re - cover ii study — no . ( % ),C4684790
25,no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C1960636
25,no dysglycaemia or mets,C1960636
25,dysglycemic categories  n ( % ),C0683312;C1960636
25,dysglycaemia or mets,C1960636
24,tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$,C0439278;C1540071
24,initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l ),C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0589507;C1059964;C1158830;C1704686;C4551529
23,insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro,C0293359
23,all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
22,beta - blockers through hospital discharge or day $nmbr$ — %,C0001645;C0586003
22,antidiabetes drug usage [ % ( n ) ],C0242510
22,antibodies to infliximab  n ( % ) * *,C3533054
22,ace inhibitors through hospital discharge or day $nmbr$ — %,C0003015;C0586003
21,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
21,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
21,erythrocyte sedimentation rate  mm / hour,C0439227;C0564385;C1176468;C1619634;C4330985;C4554674
21,elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl,C0020649;C0231220;C0439269;C0700225;C3163620
21,elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ ),C0439269;C0700225
21,elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl,C0439269;C0700225
21,elevated creatinine ( > $nmbr$ pmol / l ),C0151578;C0439284;C0700225
20,mild dysfunction or normal,C3274775
20,mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274775
19,study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ ),C0013175;C0237400;C0439228;C1708715
19,actual or estimated weight  kg,C0237400
19,actual ( l ),C0237400
18,ecg abnormality at entry,C0522055;C1705654
18,any electrocardiographic abnormality — no . ( % ),C0522055
17,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
17,treatment with antiplatelet drugs,C3469597
17,on drug treatment ( % ),C0150270;C3469597
17,days of study - drug administration ( % ) * * $nmbr$ day,C0150270;C2826182;C3469597
16,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
16,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
16,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
16,mri substudy ( n = $nmbr$ ),C0024485;C1824234;C3890166
16,dexlansoprazole mr ( n = $nmbr$ ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
16,dexlansoprazole mr $nmbr$ mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
16,dexlansoprazole mr $nmbr$ mg  n = $nmbr$,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
16,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
15,t - score at femoral neck,C0015815;C3854607
15,mean femoral neck t score,C0015815;C3533236
15,femoral neck bmd ( g / cm $nmbr$ ),C0015815;C0439267
15,femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0015815;C0439267;C2699239
15,femoral neck,C0015815
14,tanezumab ( all doses combined ) + nsaida,C2346819
14,tanezumab ( all doses combined ),C2346819
14,tanezumab $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
14,tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
14,tanezumab $nmbr$ . $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
14,tanezumab $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
13,cyclo,C1172566
12,acm,C0001143;C1549040
12,acid,C0001128;C0202406
12,acd,C4554601
11,locf ),C2825507
11,lcl,C3658298
11,focal,C0205234
11,$nmbr$ locf ),C2825507
10,ocn,C1412791;C2347392
10,concern,C2699424
9,with placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
9,with placebo,C0032042;C1696465;C1706408
9,vorapaxar placebo $nmbr$ - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
9,vorapaxar placebo $nmbr$ - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
9,vorapaxar placebo $nmbr$ - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
9,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
9,statin + placebo ( n = $nmbr$ ),C0032042;C0360714;C1696465;C1706408
9,rerandomization to placebo ( n = $nmbr$ ) f,C0016327;C0032042;C1696465;C1706408
9,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
9,placebo §,C0032042;C1696465;C1706408
9,placebo |,C0032042;C1696465;C1706408
9,placebo to ustekinumab $nmbr$ mgt,C0032042;C1608841;C1696465;C1706408
9,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
9,placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
9,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
9,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
9,placebo plus statin ( n = $nmbr$ ),C0032042;C0332287;C0360714;C1696465;C1706408
9,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
9,placebo patients with events / total,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo no diabetes n = $nmbr$,C0032042;C1696465;C1706408
9,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
9,placebo no . of events / no .,C0032042;C1696465;C1706408
9,placebo no . / total no .,C0032042;C1696465;C1706408
9,placebo no . / total ( % ),C0032042;C1696465;C1706408
9,placebo no . ( $nmbr$ - y km % ),C0032042;C1696465;C1706408
9,placebo n [ $nmbr$,C0032042;C1696465;C1706408
9,placebo n = $nmbr$ subjects,C0032042;C1696465;C1706408
9,placebo n = $nmbr$ n ( % ),C0032042;C1696465;C1706408
9,placebo n = $nmbr$,C0032042;C1696465;C1706408
9,placebo n / n ( % ),C0032042;C1696465;C1706408
9,placebo n / n,C0032042;C1696465;C1706408
9,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
9,placebo n ( rate ) $nmbr$,C0032042;C0871208;C1521828;C1696465;C1706408
9,placebo n ( % ),C0032042;C1696465;C1706408
9,placebo n,C0032042;C1696465;C1706408
9,placebo mortality rate  events per $nmbr$ person - y,C0026565;C0027361;C0032042;C0205848;C0441471;C1696465;C1706408;C2347489;C3541888
9,placebo monthly ( n = $nmbr$ ),C0032042;C0332177;C1696465;C1706408
9,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
9,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
9,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
9,placebo km %,C0032042;C1696465;C1706408;C3887676
9,placebo group ( n = $nmbr$ ) ’ j ',C0032042;C0441844;C1696465;C1706408
9,placebo group ( n = $nmbr$ ) f,C0016327;C0032042;C0441848;C1696465;C1706408
9,placebo group ( n = $nmbr$ ),C0032042;C0441848;C1696465;C1706408
9,placebo every $nmbr$ weeks ( n = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo estimated mean,C0032042;C1696465;C1706408
9,placebo dr = $nmbr$ ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
9,placebo dn = $nmbr$ ),C0032042;C1333964;C1696465;C1706408;C1707618
9,placebo diabetes n = $nmbr$,C0011847;C0011849;C0032042;C1696465;C1706408
9,placebo croup  n / n ( % ),C0010380;C0032042;C1696465;C1706408
9,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
9,placebo analysed ( % ),C0032042;C1696465;C1706408
9,placebo allocation,C0032042;C1696465;C1706408;C1706778
9,placebo [ n z $nmbr$ ],C0032042;C1696465;C1706408
9,placebo [ n = $nmbr$ |,C0032042;C1696465;C1706408
9,placebo [ n = $nmbr$ ],C0032042;C1696465;C1706408
9,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
9,placebo / simva,C0032042;C1696465;C1706408
9,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
9,placebo /,C0032042;C1696465;C1706408
9,placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
9,placebo - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
9,placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$,C0032042;C0033228;C1532737;C1696465;C1706408
9,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
9,placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg,C0032042;C1319635;C1696465;C1706408;C1871983
9,placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] ),C0032042;C1696465;C1706408
9,placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$,C0032042;C1619966;C1696465;C1706408
9,placebo + statin ( n = $nmbr$  $nmbr$ ),C0032042;C0360714;C1696465;C1706408
9,placebo + statin,C0032042;C0360714;C1696465;C1706408
9,placebo + pioglitazone ( n = $nmbr$ ),C0032042;C0071097;C1696465;C1706408
9,placebo + mtx ( n = $nmbr$ ),C0025677;C0032042;C1417487;C1696465;C1706408
9,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
9,placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ ),C0004446;C0032042;C0907402;C1696465;C1706408
9,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
9,placebo ( » = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( « = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( w = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n — $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n   =   $nmbr$ ) b,C0032042;C1696465;C1706408
9,placebo ( n   =   $nmbr$ ) a,C0032042;C1696465;C1706408
9,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n   =   $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n   = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n   = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n z $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n [ $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = l $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ o ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ l ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ i $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ * ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ) †,C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ) n ( % ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ) i -,C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ) ',C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ )  n ( % ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n = $nmbr$,C0032042;C1696465;C1706408
9,placebo ( n : $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n - $nmbr$ . $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n - $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( n $nmbr$ $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( lsm ),C0032042;C1696465;C1706408
9,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
9,placebo ( % ),C0032042;C1696465;C1706408
9,placebo ( $nmbr$ = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo ( $nmbr$  $nmbr$ . $nmbr$ % ),C0032042;C1696465;C1706408
9,placebo %,C0032042;C1696465;C1706408
9,placebo $nmbr$ yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
9,placebo $nmbr$ year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
9,placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
9,placebo $nmbr$ / $nmbr$,C0032042;C1696465;C1706408
9,placebo $nmbr$ . $nmbr$ pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
9,placebo $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
9,placebo $nmbr$  $nmbr$,C0032042;C1696465;C1706408
9,placebo $nmbr$,C0032042;C1696465;C1706408
9,placebo  n   =   $nmbr$,C0032042;C1696465;C1706408
9,placebo  n = l $nmbr$,C0032042;C1696465;C1706408
9,placebo  n = i $nmbr$,C0032042;C1696465;C1706408
9,placebo  n = $nmbr$,C0032042;C1696465;C1706408
9,placebo  n / n ( % ),C0032042;C1696465;C1706408
9,placebo  n *,C0032042;C1696465;C1706408
9,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
9,placebo  n ( % ),C0032042;C1696465;C1706408
9,placebo  n,C0032042;C1696465;C1706408
9,placebo  events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
9,placebo  ( n = $nmbr$ ),C0032042;C1696465;C1706408
9,placebo  % > ( n / n ),C0032042;C1696465;C1706408
9,placebo  % ( n / n ),C0032042;C1696465;C1706408
9,placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ ),C0032042;C0439526;C1696465;C1705224;C1706408;C3887665
9,placebo,C0032042;C1696465;C1706408
9,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
9,n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
9,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
9,losartan plus placebo ( n = $nmbr$ ),C0032042;C0126174;C0332287;C1696465;C1706408
9,i placebo ( n = $nmbr$ ),C0021966;C0032042;C0221138;C1696465;C1706408
9,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
9,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3259781;C3538758;C3829066;C4319952;C4553351
9,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
9,hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1532563;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
9,feno placebo ( lsm ),C0032042;C1696465;C1706408
9,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
9,duration from clopidogrel / placebo to pci  min ( median  iqr ),C0032042;C0070166;C0449238;C1696465;C1706408;C2926735
9,dapagliflozin placebo no . of events / no . of patients,C0032042;C1696465;C1706408;C2353951
9,copd - placebo ( n = $nmbr$ ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
9,copd - placebo ( $nmbr$ pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
9,comparison with placebo,C0032042;C1696465;C1706408;C1707455
9,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
9,canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
9,baseline to eom placebo ( n = $nmbr$ ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
9,aspirin plus placebo ( n = $nmbr$ ),C0004057;C0032042;C0332287;C1696465;C1706408
9,any placebo,C0032042;C1696465;C1706408
9,> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
9,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0524620;C1142985;C1696465;C1706408
9,= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
9,< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
9,- $nmbr$ placebo,C0032042;C1696465;C1706408
9,$nmbr$ placebo n = $nmbr$,C0032042;C1696465;C1706408
9,$nmbr$ placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
9,$nmbr$ placebo,C0032042;C1696465;C1706408
8,mras,C1335594;C1367476
8,mca,C0149566
8,impacts,C1825598;C4049986
8,empa,C2699863
7,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
7,demography,C0011298
7,demographics and clinical characteristics,C0011298;C1704791
7,demographics age ( years ),C0011298;C1510829;C1704791
7,demographics age  years  mean ( sd ),C0011298;C0444504;C1510829;C1704791;C2347634;C2348143;C2699239
7,demographics,C0011298;C1704791
7,demographic variable,C0011298;C0439828;C4553760
7,demographic factors,C0011292;C0011298
7,demographic characteristic,C0011298;C1521970
7,demographic and medical variables,C0011298
7,demographic and clinical characteristics,C0011298
7,demographic and clinical,C0011298
7,demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0011298
7,demographic,C0011298
7,baseline demographics,C0011298;C0168634;C1442488;C1704791
7,( a ) demographics,C0011298;C1704791
6,musculoskeletal stiffness,C0427008;C0497254;C2707260
6,musculoskeletal,C0497254;C2707260
6,muscle twitching,C0015644;C0231530
6,muscle spasms,C0037763
5,febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$,C0249529;C3886073
5,febuxostat - febuxostat / lesinurad $nmbr$,C0249529;C3886073
5,febuxostat $nmbr$ mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
5,febuxostat,C0249529
5,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
4,with rehospitalization  urgent coronary revascularization,C0439609;C0877341;C3272275
4,urgent coronary revascularization,C0439609;C0877341;C3272275
4,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
4,prior coronary revascularization ( pci or cabg ),C0332152;C0877341;C2826257;C4049621
4,prior coronary revascularization  no . ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization  n / n ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
4,prior coronary revascularization,C0332152;C0877341;C2826257
4,coronary revascularization procedure,C0877341
4,coronary revascularization,C0877341
4,coronary revascularisation §,C0877341
4,coronary revascularisation,C0877341
4,any coronary revascularization,C0877341
3,• urgent coronaiy revascularization > $nmbr$ days,C0439228;C0439609;C0581603;C3272275
3,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
3,urgent revascularizati on,C0439609;C3272275
3,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
3,$nmbr$ days urgent revascularization,C0439228;C0439609;C0581603;C3272275
2,with revascularisation,C0581603
2,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
2,target - vessel revascularization,C0449618;C0581603
2,revascularization in $nmbr$ days,C0439228;C0581603
2,revascularization,C0581603
2,revascularisation but no antiplatelets  lipid - lowering agents  or p blockers,C0581603
2,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
2,revascularisation  n ( % ),C0581603
2,peripheral revascularization ( n = $nmbr$ ),C0205100;C0581603
2,peripheral revascularization,C0205100;C0581603
2,peripheral revascularisation,C0205100;C0581603
2,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
2,pci revascularization,C0581603;C4049621
2,no revascularisation,C0581603
2,no peripheral revascularization ( n = $nmbr$  $nmbr$ ),C0205100;C0581603
2,carotid revascularization,C0581603;C0741968
2,arterial revascularization,C0003842;C0221464;C0581603
2,any revascularization,C0581603
2,any peripheral revascularization,C0205100;C0581603
1,之 $nmbr$,
1,≥ $nmbr$ yearsa,
1,≥ $nmbr$ teae,
1,≥ $nmbr$ bpm ( n = $nmbr$ ),
1,≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
1,≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %,
1,≥ $nmbr$ %,
1,≥ $nmbr$,
1,≤ $nmbr$ . $nmbr$ %,
1,≤ $nmbr$ %,
1,≤ $nmbr$,
1,• j . the body - mass index is the weight in kilograms divided by the square of the,
1,“ off ”,
1,— no . ( % ),
1,β ‐ blocker,
1,β blockers,
1,β blocker,
1,β - blockers,
1,β - blocker,
1,» $nmbr$ y,
1,« = $nmbr$,
1,« $nmbr$ - $nmbr$,
1,£ $nmbr$ . $nmbr$ yrs,
1,£ $nmbr$ . $nmbr$ % * *,
1,£ $nmbr$ %,
1,£ $nmbr$,
1,| interactior $nmbr$ p,
1,| ? > - blocker ( n  % ),
1,| ? ) - blocker  %,
1,zt = $nmbr$,
1,zotarolimust,
1,z\tonastaiin,
1,yearl,
1,yaa,
1,y $nmbr$,
1,xanthinesg,
1,x ? = l - $nmbr$  p = $nmbr$ - $nmbr$,
1,x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$,
1,x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
1,x / n *,
1,x / n,
1,x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$,
1,x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
1,x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$,
1,x $nmbr$  n ( % ),
1,wssng,
1,woscops,
1,womens,
1,without revascularsation,
1,without antiplatelets,
1,without an sfua,
1,with antiplatelets,
1,with an sfua,
1,whiteb,
1,while ethnic origin,
1,while,
1,wegu,
1,wafarin,
1,w hite,
1,w,
1,vs . warfarin,
1,vs . placebo,
1,vora,
1,vldm n = $nmbr$,
1,vka naxve,
1,vka naive  n ( % ),
1,vka naive,
1,vka experienced,
1,vka ( n   = $nmbr$ ),
1,vka  only reason,
1,vka,
1,vhd,
1,versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg,
1,versus tiotropium $nmbr$ pg,
1,versus tiotropium $nmbr$ . $nmbr$ pg,
1,versus olodaterol $nmbr$ pg,
1,veflonzumao,
1,vdz n = \ $nmbr$,
1,vdz n = $nmbr$,
1,vdz / vdz [ n = $nmbr$ ],
1,vdhmtss,
1,vadas score *,
1,v ( n = $nmbr$ ),
1,v $nmbr$ ( n = $nmbr$,
1,ustekinu,
1,usteki,
1,useofmedical therapyathospitaldischarge,
1,us w = $nmbr$,
1,us,
1,urti,
1,ure,
1,upcr  n ( % ),
1,unstableangina,
1,unprovoked,
1,univariable or ( $nmbr$ % ci )  p value *,
1,univariable,
1,uniti - $nmbr$ and uniti - $nmbr$ im - uniti,
1,uniti - $nmbr$,
1,unfractionated,
1,undeterminedc,
1,undergoing major vascular surgery,
1,uncover - $nmbr$,
1,uncodable,
1,uncerlain,
1,umied,
1,ulpasi $nmbr$,
1,uistekinumab,
1,ufh,
1,ucr,
1,ucl,
1,uc [ gemini $nmbr$ ] ‘,
1,uc ( n   =   $nmbr$ ),
1,uc,
1,uas $nmbr$ {,
1,uas $nmbr$,
1,uacr not available,
1,uacr ( mgg - $nmbr$ ),
1,uacr  n ( % ) †,
1,uacr,
1,uac =,
1,tzd,
1,tvr,
1,transradial,
1,transfemoral,
1,tpasi $nmbr$,
1,toward,
1,totai mortaiity,
1,tolal choleslerol,
1,tnt and ideal ( pooled ),
1,tngtycerides a median,
1,tngtycerides < median,
1,tngtycendes a median,
1,tnglycendes < median,
1,tnfi naive,
1,tnfi exposed,
1,tnfi and other bdmardst  n ( % ),
1,tnfi - naive,
1,tnfi - exposed †,
1,tnfi ( no other bdmard taken ) t  n ( % ),
1,tjc  $nmbr$ - $nmbr$,
1,tjc,
1,tiotropiumc,
1,tion — no . ( % ),
1,tio ( n $nmbr$ $nmbr$ ),
1,tio,
1,timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h,
1,timi ≥ $nmbr$ and spoke,
1,timi ≥ $nmbr$,
1,timi score,
1,timi risk scoret,
1,timi minor,
1,timi major or minor bleeding,
1,timi major or,
1,timi major,
1,timi clinically significant,
1,timi - defined bleeding,
1,timi - bleeding major / minor,
1,ticlopidin,
1,thromboaspiration — no . ( % ),
1,thromboaspiration,
1,thiazolidinedionesc,
1,thiazolidinedioneb,
1,texcaps,
1,tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
1,tertile $nmbr$ ( n = $nmbr$ ),
1,tertile $nmbr$,
1,terlile $nmbr$,
1,teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % ),
1,teaes leading to discontinuation of study drug,
1,teaes,
1,tbp,
1,tamong those enrolling via bnp stratum . the study - qualifying bnp or,
1,symptomaticb,
1,sulfonylureasb,
1,sulfonylureaa,
1,subtrochanteric,
1,subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -,
1,subgroupt,
1,sua < $nmbr$ . $nmbr$,
1,strokezsee,
1,stratum *,
1,stratum  n ( % ),
1,stratum,
1,still taking alendronate at study entry  n ( % ),
1,std n ( n / loopy ),
1,statisticd,
1,statini,
1,stalin,
1,sso - $nmbr$,
1,ssi - $nmbr$,
1,spoke,
1,spirono ( n = $nmbr$ ),
1,spiralcomputedtomographyangiography,
1,spga > $nmbr$,
1,sonti amenca,
1,some walking,
1,some,
1,soe or sue,
1,socalone ( n = $nmbr$ ),
1,soc,
1,smokingb,
1,smmse < $nmbr$,
1,smmse,
1,smi :,
1,sk . $nmbr$,
1,sjc  $nmbr$ - $nmbr$,
1,sjc,
1,sita $nmbr$,
1,sirius,
1,since onset,
1,since diagnosis,
1,simva n = $nmbr$ n ( % ),
1,simva ( „ = $nmbr$ },
1,simva ( n = $nmbr$ ),
1,simva ( % ),
1,simva,
1,sgrq scores  mean ( sd ),
1,sgrq responder ( % ),
1,severitya,
1,sesbp,
1,sedbp,
1,scd ( % ),
1,saxagiiptin,
1,saxa + met n = $nmbr$,
1,saxa + dapa + met n = $nmbr$,
1,samac,
1,sack,
1,sabae,
1,sabaa,
1,saba §,
1,saba ( inhaled )  c   n ( % ),
1,saba,
1,saaca,
1,rvw,
1,rvfac ( % ),
1,rvalue,
1,rrr,
1,rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
1,rr *,
1,rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ },
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *,
1,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ ),
1,rr $nmbr$ . $nmbr$,
1,rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’,
1,rr,
1,rosigiitazone ± oad,
1,revive ii,
1,revive i,
1,resllzumab,
1,reqion,
1,remodeling,
1,reinfarction,
1,regiont,
1,redon,
1,recervng,
1,recervini },
1,rca  n ( % ),
1,rca,
1,ratet n ( % ),
1,ratet,
1,rarertd antocagibtcn before andorrtzafon,
1,ranozaline,
1,ranotazine vs . placebo km failure rate,
1,randomly assigned to diuretic,
1,randomly assigned to calcium channel blocker,
1,randomly assigned to ace,
1,randomize,
1,randomised to canakinumab $nmbr$ mg,
1,raee,
1,racey  z,
1,racea,
1,qveral,
1,quicki,
1,qtc > $nmbr$ n = $nmbr$,
1,qtc < $nmbr$ n = $nmbr$,
1,qmi,
1,q ( q $nmbr$ \,
1,q $nmbr$ w ( n = $nmbr$ ),
1,q $nmbr$ w ( n $nmbr$ $nmbr$ ),
1,q $nmbr$ - q $nmbr$,
1,q $nmbr$ ( n   = $nmbr$ ),
1,pvaluefor any mi versus no mi,
1,pvalue ∗,
1,pvalue,
1,ptga ⁎ ⁎ ⁎,
1,ptga  $nmbr$ - $nmbr$,
1,psychoactivesd,
1,psaqol,
1,prosthetic,
1,prosper,
1,priorother ( predefined ) medical conditions,
1,priorother ( not predefined ) medical conditions,
1,priorheartfailure  %,
1,previously taken tnfi  %,
1,previously taken methotrexate  %,
1,previously taken dmards other than methotrexate  %,
1,previously taken any other dmards  n ( % ),
1,previously failed anti - tnf treatment  no . ( % ),
1,previously,
1,prediabeticb,
1,prediabetese,
1,ppci in - $nmbr$,
1,ppci ( n = $nmbr$ ),
1,ppci,
1,postamendment,
1,poslmenopausal  no ht,
1,pollent s $nmbr$,
1,pollent < $nmbr$,
1,poci ( n = $nmbr$ ),
1,poci,
1,poba  n ( % ),
1,pnorpci,
1,pnorcabg,
1,plaeebo,
1,placeboa,
1,pinteraction = $nmbr$ . $nmbr$,
1,pinteraction,
1,piacebo ( n = $nmbr$ ) no . of participants with events ( % ),
1,piacebo,
1,phakic,
1,persisent,
1,pdq - $nmbr$,
1,pasia,
1,paod,
1,pacific,
1,overally,
1,overallb,
1,overaii ( n = $nmbr$ ),
1,overaii,
1,otherz,
1,otherx,
1,othert,
1,othersc,
1,otherj ^ :,
1,otherf,
1,otherd,
1,otherc,
1,otherb,
1,othera,
1,other †,
1,other — no . ( % ),
1,other vasculars,
1,other uc - related gi surgical procedure,
1,other teaes,
1,other or missing data,
1,other bdmards ( no tnfi taken ) t  n ( % ),
1,other bdmard §,
1,other antiplatelet,
1,other ^,
1,other : :,
1,other * ’,
1,other *,
1,other ',
1,other $nmbr$,
1,other !,
1,other  no . ( % ),
1,other,
1,oretal,
1,oralb,
1,or_value,
1,or 、 ( $nmbr$ % ci ),
1,or ulcerations  ® n ( % ),
1,or taking antihypertensive medication,
1,or severe,
1,or raloxifene,
1,or primary outcome,
1,or placebo treatment,
1,or no microalbuminuria or macroalbuminuria,
1,or morbidity and mortality,
1,or esrd,
1,or death,
1,or [ $nmbr$ % cl ],
1,or [ $nmbr$ % ci ],
1,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$,
1,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,
1,or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$,
1,or ( unadjusted ),
1,or ( itt ) ( n = $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ ),
1,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),
1,or ( $nmbr$ % cl ),
1,or ( $nmbr$ % ci ) a,
1,or ( $nmbr$ % ci ),
1,or $nmbr$ _value,
1,or $nmbr$ % ci,
1,or $nmbr$,
1,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ ),
1,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
1,or,
1,op  vfx,
1,op  no vfx,
1,onsetofaf  no . ( % ),
1,on or after e ^ andomization,
1,on omt ( n = $nmbr$ ),
1,on omt,
1,on $nmbr$,
1,olaemia  n ( % ),
1,ol / l ),
1,off omt ( n = $nmbr$ ),
1,off omt,
1,octi,
1,octave sustain,
1,ocs use,
1,ocs reduced / stopped,
1,ocs maintained / increased,
1,ocs  n ( % ),
1,ocs,
1,obesityj,
1,oascvd,
1,oam,
1,oads  n ( % ),
1,oad,
1,oac experienced  bn   ( % ),
1,nyhaiiioriv,
1,nyhaii,
1,numbera,
1,numab,
1,ntbnp ( n = $nmbr$ ),
1,nsteacs,
1,nothfref,
1,northamerica,
1,normoalbuminuria — no . / total no . ( % ),
1,normoalbuminuria — no . ( % ),
1,normoalbuminuria §,
1,normoalbuminuria or microalbuminuria,
1,normoalbuminuria  no . ( % ),
1,normoalbuminuria,
1,normalfunction or mild impairment,
1,normai fasting giucose levei ( n = $nmbr$ ),
1,noppi,
1,nonwhite race — no . ( % ) ejection fraction,
1,nonwhite,
1,nonvertebral,
1,nonuser,
1,nonreversible,
1,nonischemic,
1,noninducing,
1,nonfatal,
1,noneh,
1,none 一 no . ( % ),
1,none or seldom,
1,none or diet,
1,none ( cdmard - naive or past use at baseline ),
1,none,
1,nondiabetic,
1,nondiabetes,
1,noncaucasian,
1,noncardiovascular,
1,nonblack race — no . ( % ) f,
1,nonblack race — no . ( % ) - j -,
1,nonblack ( n = $nmbr$ ),
1,nonblack,
1,nonanterior,
1,nominal p vs placebo,
1,noliecervrig,
1,noirecerving,
1,no vhd,
1,no ststm,
1,no or unknown,
1,no op  vfx,
1,no op  no vfx,
1,no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years,
1,no ocs,
1,no oam,
1,no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),
1,no laba  no ics  n ( % ),
1,no ipst ( n = $nmbr$  $nmbr$ ),
1,no ipst,
1,no immomtedion,
1,no ?,
1,no . of tnfi among non - tnfi naive,
1,no . of panents . total no . $nmbr$ % ),
1,no . of,
1,no . needed to treat ( $nmbr$ % cl ) *,
1,no . evenls,
1,no . a,
1,no . *,
1,no . ( % ) *,
1,no . ( % ) ',
1,no . ( % ) $nmbr$ ( $nmbr$ ),
1,no . ( % ),
1,no .,
1,no *,
1,no ( % ),
1,no ( $nmbr$ . $nmbr$ ),
1,no $nmbr$  $nmbr$,
1,no  no,
1,no,
1,nkf stage,
1,nitratesf,
1,niacini,
1,nerd,
1,neohrodathv . and all - cause mortalitv,
1,neither uh or lmw heparin,
1,neither,
1,nd not due to swelling or ich,
1,nd,
1,nct $nmbr$,
1,nbp,
1,napsit,
1,napsi score ( $nmbr$ - $nmbr$ ) of target fingernail,
1,naive : no,
1,naive ( no treatment for current flare ),
1,naive ( n = $nmbr$ ),
1,naive,
1,myopathyt,
1,myoclonic,
1,multivariable or ( $nmbr$ % ci )  p value *,
1,multivariable,
1,mucocutaneous,
1,mtss at,
1,mtss ( $nmbr$ - $nmbr$ ),
1,mtss,
1,mssbp / msdbp,
1,mssbp,
1,msfc timed $nmbr$ - foot walk test .,
1,msfc timed $nmbr$ - foot walk test  median seconds,
1,msdbp,
1,monteiukast vs placebo,
1,monteiukast ( n = $nmbr$ ),
1,monteiukast,
1,monotherapy $nmbr$,
1,monotherapy,
1,moderatez,
1,moderatey,
1,moderatex,
1,mnapsi,
1,mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ],
1,mhi,
1,mfns ( n = $nmbr$ ),
1,metsyn,
1,metrex modified intention - to - treat population with an eosinophilic phenotypey,
1,metforminmonotherapy,
1,merformin,
1,mepo ( n = $nmbr$ ),
1,mensa,
1,mellitus,
1,mcs score ( $nmbr$ – $nmbr$ scale ),
1,mcs score,
1,mbesc  n / n ( % ),
1,mbesb  n / n ( % ),
1,mbes / crbesc,
1,mbes / crbesb  n / n ( % ),
1,mafcaiancy at randorrtzaton,
1,maf,
1,macroalbuminuriaf,
1,macroalbuminuria — no . / total no . ( % ),
1,macroalbuminuria — no . ( % ) drug therapy — no . ( % ),
1,macroalbuminuria ( uacr > $nmbr$ ),
1,macroalbuminuria  n ( % ),
1,macroalbuminuria,
1,macce ( % ),
1,macce,
1,lvmi ( $nmbr$,
1,lunchb,
1,lntensityd,
1,llpasi $nmbr$,
1,lleocolon,
1,ll ( $nmbr$ ),
1,ll $nmbr$ ( $nmbr$ ),
1,ll  n ( % ),
1,lixi,
1,lithe,
1,lisrs,
1,lgm ( n = $nmbr$ ),
1,leader,
1,ldu - c,
1,ldl cholesterolt,
1,ldl choleslerol,
1,ldl cholesicrol ( minol / l ),
1,ldl - csmedian,
1,ldl - c ( measured ) *,
1,ldl - c ( measured )  mean ( sd ),
1,ldl - c ( calculated ) *,
1,ldl - c ( calculated )  mg / dl  mean ( sd ),
1,ldl - c ( calculated )  mean ( sd ),
1,ldl - c,
1,ldl *,
1,ldl $nmbr$ - c,
1,ldl  - c,
1,ldl,
1,ldi - b > $nmbr$ ( n = $nmbr$ ),
1,ldi $nmbr$,
1,lcz $nmbr$ ( n = $nmbr$ ),
1,lcz $nmbr$,
1,lc  n = $nmbr$,
1,lb,
1,lavolta $nmbr$,
1,latin and north america,
1,latin ameriea,
1,latin,
1,lamad,
1,lad,
1,labaa,
1,laba or lamab n = $nmbr$,
1,laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl ),
1,laba or lama ’,
1,laba or lama,
1,laba alone,
1,laba - inhaled glucocorticoid use at screening,
1,laba ( inhaled )  d   n ( % ),
1,laba ',
1,laba  no ics  n ( % ),
1,laba  n ( % ),
1,laba,
1,laaca,
1,laa,
1,killip ciass,
1,kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % ),
1,jvp > $nmbr$ cm,
1,jvp ( 〉 $nmbr$ cm ),
1,jvp  ( % ),
1,j $nmbr$ - blocker  % ( n ),
1,j $nmbr$ - blocker,
1,ization — no . ( % ),
1,ixeq $nmbr$ w  n = $nmbr$,
1,itt,
1,itherchdt,
1,ith vs . without ),
1,it $nmbr$ . $nmbr$,
1,islander,
1,ish,
1,is only,
1,is domain luts severity ( % ),
1,irofiban,
1,iqr,
1,ipst ( n = $nmbr$ ),
1,ipst,
1,iorii ( n z $nmbr$ ),
1,interact !,
1,intensified ( n 二 $nmbr$ ),
1,insulina  n ( % ),
1,insulina,
1,insuiin giargine ± oad,
1,inhixanab $nmbr$ mgikg versus piacom,
1,inhaledb,
1,indzgly,
1,incidencea,
1,in thirds,
1,in,
1,immobazaton,
1,im use : no,
1,im or cs use : no,
1,im on ] y,
1,im and cs use : no,
1,im - uniti,
1,ileocolonic ( both ileum and colon ),
1,ileocolon,
1,ijb ^,
1,iiiv,
1,ii or iii,
1,ii = $nmbr$,
1,ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$,
1,ii ( $nmbr$ ),
1,ii $nmbr$ ± $nmbr$,
1,ii,
1,igt or ifg,
1,igm,
1,iglarlixi ( n   =   $nmbr$ ),
1,iglarlixi,
1,iglar ( n   =   $nmbr$ ),
1,iglar,
1,igelow ( n = $nmbr$  $nmbr$ ),
1,idr,
1,idiopathica,
1,idegasp – biasp $nmbr$,
1,idegasp bid,
1,ideg,
1,icsusers atbaseline  n ( % ),
1,icsf,
1,icsa,
1,ibdq score |,
1,hypoglycemiat,
1,hypoglycaemiad  %,
1,hypertensiont,
1,hyperlipidmemia,
1,hyperlension,
1,hyperkalemiab,
1,hypercholesterolemiat,
1,hydochlorothiazide ( n = $nmbr$ ),
1,hvpertension,
1,hvpercholesterolemia,
1,hvookalemia,
1,hscrp §,
1,hscrp,
1,hr ‡,
1,hr vs placebo ( $nmbr$ % ci ),
1,hr vs control ( $nmbr$ % cl ) *,
1,hr vs . warfarin ( $nmbr$ % ci ),
1,hr is < $nmbr$ if pravastatin is better than diet alone,
1,hr and $nmbr$ % ci *,
1,hr * or rr † ( $nmbr$ % ci ),
1,hr * or rr †,
1,hr ( enl vs lcz ) ( $nmbr$ % cl ),
1,hr ( bpm ),
1,hr ( adjusteda ),
1,hr ( $nmbr$ s % a ),
1,hr ( $nmbr$ % c ! ),
1,hr $nmbr$ and $nmbr$ % cl,
1,hr $nmbr$ . $nmbr$,
1,hr  bpm,
1,hr,
1,hosji fcrhypoglycemia,
1,hordic,
1,homa - p,
1,homa - b,
1,homa,
1,highjj,
1,hhf ( n = $nmbr$ ),
1,hfref ( n = $nmbr$ ),
1,hfref,
1,hfpef ( ef n $nmbr$ )  ( % ),
1,hdm n = $nmbr$,
1,hdlcholesterol,
1,hd ( n = $nmbr$ ),
1,hcru ( a ),
1,hbau  %,
1,hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),
1,hbalc > = $nmbr$ % ( n - $nmbr$ ),
1,hbalc > $nmbr$ %,
1,hbalc < medan,
1,hbalc < $nmbr$ %,
1,hbalc ( % ),
1,hbalc  %,
1,hbalc,
1,hbaie ( % ),
1,hbaie  %,
1,hbaic — %,
1,hbaic ( % ),
1,hbai,
1,has - bledo,
1,has - bled score ’,
1,has - bled score > $nmbr$,
1,has - bled score,
1,has - bled > $nmbr$,
1,has - bled $nmbr$ - $nmbr$,
1,handihaler and diskus  n,
1,hale,
1,gusto severe or,
1,gusto severe,
1,gusto moderate or severe bleeding,
1,gusto moderate or severe,
1,gusto moderate / severe bleeding,
1,gusto moderate / severe bleed,
1,gusto moderate / severe,
1,gusto moderate,
1,gusto - defined bleeding,
1,gusto - bleeding severe / moderate,
1,granulating  n ( % ) a,
1,golden - $nmbr$ and - $nmbr$,
1,golden - $nmbr$,
1,glulisine monotherapy,
1,glulisine + oad,
1,glacial $nmbr$,
1,giimepiride ± oad,
1,giargine,
1,getgoal - s,
1,gertder,
1,gentype,
1,gendar,
1,fpg,
1,fpci vs . ppci in women,
1,fpci vs . ppci in men,
1,fibrofatty,
1,fibrinolysist,
1,fibrate or other lipid - lowering agent,
1,fibrate,
1,fh $nmbr$,
1,fenofibric,
1,feno + eze,
1,feno,
1,femoralneck t - scorebybaselinevfxstatus,
1,femalesex,
1,femaleb,
1,femaie,
1,fas,
1,eze / simva ( „ = $nmbr$ },
1,eze / simva ( n = $nmbr$ ),
1,eze / simva,
1,eze,
1,extenswe,
1,evomab + soc,
1,evomab ( n = $nmbr$ ),
1,evomab,
1,ever smoked ( current / former ),
1,ever been on a vka,
1,ever,
1,ethnieity,
1,erd *  n ( % ),
1,epa ( n = $nmbr$ ),
1,epa,
1,enrope + sonth afriea,
1,endpointc,
1,enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ ),
1,enact - $nmbr$ trial,
1,empagllflozln,
1,empagllflozin,
1,ef b $nmbr$ %,
1,ef > $nmbr$ % n = $nmbr$,
1,ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % ),
1,ef > $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1,ef > $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef > $nmbr$ %,
1,ef < $nmbr$ % n = $nmbr$,
1,ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % ),
1,ef < $nmbr$ % ( n = $nmbr$  $nmbr$ ),
1,ef < $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef < $nmbr$ %,
1,ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ ),
1,ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % ),
1,ef $nmbr$ - $nmbr$ %,
1,ef  %,
1,educ ssy,
1,educ > $nmbr$ y,
1,educ $nmbr$ - $nmbr$ y,
1,edo,
1,e / e ' ( septal ),
1,e $nmbr$ + a $nmbr$ -,
1,e $nmbr$ + a $nmbr$,
1,e $nmbr$ ( n = $nmbr$ ),
1,e,
1,dyslipidaemiat,
1,dyslipidaemiaj,
1,dosing,
1,diureties,
1,diureticff,
1,diurciic,
1,discontinu - ation,
1,disabling or fatal stroke,
1,disabling or fatal,
1,differencevs . pbof,
1,diff_measure,
1,did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ ),
1,did not enrol into osler,
1,diabeticb,
1,diabetesz,
1,diabetesf,
1,diabetese,
1,diabetesc,
1,denotes angiotensin - converting enzyme .,
1,deathsb,
1,dcct a $nmbr$ c,
1,dapagliflozint,
1,dapaglifloz . in  n,
1,dapaglifloiin  n *,
1,dapa + met n = $nmbr$,
1,dabetes,
1,currentd,
1,csii,
1,cse ] +,
1,crude,
1,crt - p + d  n ( % ),
1,crt - p,
1,crt - d,
1,crt,
1,crpnonr ?,
1,crj,
1,crci > $nmbr$ - < $nmbr$,
1,crci > $nmbr$,
1,covariates,
1,covariate,
1,corticosteroidsa,
1,controlld,
1,continuation ( n = $nmbr$ ),
1,continuation,
1,conservative,
1,conieosieroids and / or $nmbr$ - mp,
1,comorbidites  n ( % ),
1,combo vs . primary,
1,combinationf,
1,coexisting conditions — no . ( % ),
1,cm,
1,clopiodogrel,
1,clonic,
1,ckdc  n ( % ),
1,cigarettesmoking  %,
1,ciass ll - iv,
1,chda,
1,charlson,
1,characteristicsa,
1,characteristica,
1,chajdsrvasc $nmbr$ - $nmbr$,
1,chajdsj - vasc > $nmbr$,
1,chajdsj - vasc $nmbr$ - $nmbr$,
1,chajdsa - vasc $nmbr$ - $nmbr$,
1,chadsj > $nmbr$,
1,chadsj < $nmbr$,
1,chadsa < $nmbr$,
1,cerebral,
1,cdmard,
1,ccq score § §,
1,cclear < $nmbr$,
1,cclear $nmbr$ - $nmbr$,
1,cclear $nmbr$ +,
1,causaslan,
1,caucasiana ( % ),
1,catscorecategory  n ( % ),
1,cardiovasculardeath,
1,cardiovascuiar mortaiity,
1,cardioembolism,
1,cardioembolic,
1,cancert,
1,canagiiflozin,
1,cabgorptca,
1,c,
1,bsa involved  % $nmbr$,
1,bsa affected  mean ± sd  %,
1,bsa affected  %,
1,bsa > $nmbr$ %  n ( % ) t,
1,bsa ( % ),
1,bsa  % *,
1,breakfastb,
1,brandomization was stratified by diabetic status .,
1,both ( % ),
1,both,
1,bms,
1,bmit,
1,bmij,
1,bmia,
1,blockers,
1,blocker,
1,blaic > $nmbr$ . $nmbr$ %,
1,blaic < $nmbr$ . $nmbr$ %,
1,blaek / afriean - ameriean,
1,blaek,
1,biolimus a $nmbr$ - eluting stent ¶,
1,bilag a  b or c domain score  n ( % ),
1,bid,
1,biasp $nmbr$ bid,
1,biasp $nmbr$,
1,biack non - hispanic,
1,biack,
1,bi ( $nmbr$ . $nmbr$ ),
1,bempedoic,
1,bdmard - naive,
1,basfi *,
1,baselinec,
1,baselineb,
1,baseiine diuretic,
1,barc $nmbr$ - $nmbr$,
1,b pooled new and worsened vertebral fractures ( mfas ),
1,b includes both ex - smokers and nonsmokers .,
1,b - blockers  n ( % ),
1,b - blockers,
1,b - blocker,
1,b + a ( n = $nmbr$ ),
1,b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .,
1,b  vhd ( n = $nmbr$ ),
1,b,
1,austrafca and new zealand,
1,attain,
1,atorvastatinb,
1,atenoioi ( n = $nmbr$ ),
1,at or above the median,
1,at or above median,
1,at least $nmbr$ flare,
1,at,
1,asui score  mean ( sd ),
1,asui score  mean,
1,associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % ),
1,aslan,
1,as,
1,arvfac ( per $nmbr$ % ),
1,arteriai access,
1,aqe ^ $nmbr$,
1,aqe < $nmbr$,
1,aqc < $nmbr$,
1,apolipoproiein b ( mij / $nmbr$ ),
1,apolipoproiein a $nmbr$ ( tng / $nmbr$ ),
1,apobe,
1,apoal,
1,apo bt,
1,any timi bleeding,
1,any teaes,
1,any teae,
1,any other llts ( other than statin ),
1,any other lipid ‐ lowering therapy  n ( % ),
1,any other antihyperglycaemic drugs,
1,any bleeding,
1,any ( including corticosteroid ),
1,any,
1,antithrombotic and anticoagulant medications,
1,antithrombotic,
1,antiplateletsa,
1,antiplatelets or anticoagulants,
1,antiplatelets  any,
1,antiplatelets,
1,antiplatelet — no . / total no . ( % ),
1,antiplatelet — no . ( % ),
1,antiplatelet or anticoagulant therapy,
1,antiplatelet or anticoagulant,
1,antiplatelet or anti - inflammatory drugs,
1,antiplatelet,
1,antihyperglycemictherapies  %,
1,anti - p $nmbr$,
1,annt or bnnh ( $nmbr$ % ci ),
1,aniagonisi,
1,anesthesiad  n ( % ),
1,and vfx status,
1,and physical examination,
1,and microalbuminuria or macroalbuminuria,
1,and infusion,
1,and either an ace inhibitor or angiotension receptor blocker,
1,and / or discharge,
1,and / or aza at baseline,
1,amputationsa,
1,ampd $nmbr$,
1,am_delta,
1,am_ % delta,
1,am pef ( sd )  l / min,
1,alvef ( per $nmbr$ % ),
1,allopurinolt,
1,allogliptin,
1,all teaes *,
1,all teaes,
1,all subjects - n,
1,all subjects,
1,all strokes *,
1,all strokes  n ( % ),
1,all strokes,
1,all rosuva,
1,all responders  ( n = $nmbr$ ),
1,all randomly assigned,
1,all randomized all - cause mortality or hospitalization for worsening hf ^,
1,all randomized all - cause mortality,
1,all randomized,
1,all patientsb,
1,all participantst ( n = $nmbr$ / $nmbr$ ),
1,all participantsa,
1,all other,
1,all noncompleters,
1,all itt sutajects,
1,all grafts,
1,all diabetesd,
1,all completers ( n $nmbr$ $nmbr$ ),
1,all completers,
1,all bleeding,
1,all bleed,
1,all,
1,ali,
1,alathosterol ( % ),
1,aiorvasiaiin,
1,aiirocumab ( n = $nmbr$ ),
1,aiirocumab,
1,aget  y,
1,ageadj,
1,agea,
1,afcaps /,
1,adverse eventy,
1,adjustedaor,
1,adjustedahr,
1,acholesterol ( % ),
1,acenocoumaroi,
1,aceis  n ( % ),
1,aceis,
1,acei vs . non - acei,
1,acei use,
1,acei or arb pre - randomisation,
1,acei or arb post - randomisation,
1,acei or arb,
1,acei and / or arb,
1,acei  n ( % ),
1,acei,
1,acecoumarol  no . ( % ),
1,absolutedifferenceestimate vs placebo ( $nmbr$ % ci ),
1,aab $nmbr$ ( % ),
1,a vs . c,
1,a from baselineb,
1,a excludes two randomized patients with unknown diabetes status at baseline .,
1,a a ( $nmbr$ ( % ),
1,a / c,
1,a . beuralizuinab $nmbr$ ing q $nmbr$ w,
1,a - blockers,
1,a - blocker,
1,a ) those receiving no inhaled pre - treatment maintenance medication,
1,a $nmbr$ vs placebo,
1,a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %,
1,a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,
1,a $nmbr$ c > $nmbr$ . $nmbr$ %,
1,a $nmbr$ c < $nmbr$ . $nmbr$ %,
1,a $nmbr$ c ( % ),
1,a $nmbr$ c  %,
1,a $nmbr$ c,
1,a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$,
1,a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),
1,a $nmbr$,
1,a  no vhd ( n = $nmbr$ $nmbr$ ),
1,a,
1,^ - blockers,
1,^ - blocker,
1,^ $nmbr$ y  n ( % ),
1,^ $nmbr$ - $nmbr$,
1,^ $nmbr$,
1,\ $nmbr$ %,
1,\ $nmbr$,
1,[ } ifrerence vs . placebo  % ( $nmbr$ % cl ),
1,> lto < $nmbr$ ( n = $nmbr$ ),
1,> is years,
1,> ii,
1,> = $nmbr$ yea ' s,
1,> = $nmbr$ y,
1,> = $nmbr$ mmhq,
1,> = $nmbr$ . $nmbr$,
1,> = $nmbr$ * ( % ),
1,> = $nmbr$ ( % ),
1,> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol ),
1,> = $nmbr$,
1,> - $nmbr$ cm,
1,> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$,
1,> - $nmbr$ . $nmbr$ - vfx,
1,> - $nmbr$ . $nmbr$ + vfx,
1,> - $nmbr$ . $nmbr$,
1,> $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ — no . { % ),
1,> $nmbr$ yrs,
1,> $nmbr$ yearstos is years,
1,> $nmbr$ y . n ( % ),
1,> $nmbr$ y ( n = $nmbr$ ),
1,> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,> $nmbr$ y  no . ( % ),
1,> $nmbr$ y  n ( % ),
1,> $nmbr$ y,
1,> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ or incident vitrectomy or photocoagulation,
1,> $nmbr$ oads,
1,> $nmbr$ nd and < $nmbr$ rd quartile,
1,> $nmbr$ mon ( n = $nmbr$ ),
1,> $nmbr$ mlymin,
1,> $nmbr$ microg / l,
1,> $nmbr$ lb,
1,> $nmbr$ ky / nr,
1,> $nmbr$ hr,
1,> $nmbr$ enroll,
1,> $nmbr$ cm,
1,> $nmbr$ but < $nmbr$ mg / dl,
1,> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ ),
1,> $nmbr$ bpm ( n = $nmbr$ ),
1,> $nmbr$ beats / min,
1,> $nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1,> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$,
1,> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$,
1,> $nmbr$ and < $nmbr$ years,
1,> $nmbr$ and < $nmbr$ mg / dl,
1,> $nmbr$ and < $nmbr$ %,
1,> $nmbr$ and < $nmbr$,
1,> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ ),
1,> $nmbr$ < $nmbr$,
1,> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$ yrs,
1,> $nmbr$ . $nmbr$ bpm,
1,> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
1,> $nmbr$ . $nmbr$ ( % ),
1,> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
1,> $nmbr$ . $nmbr$ %,
1,> $nmbr$ . $nmbr$,
1,> $nmbr$ - < $nmbr$,
1,> $nmbr$ - $nmbr$ cm,
1,> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
1,> $nmbr$ - $nmbr$ - $nmbr$,
1,> $nmbr$ - $nmbr$,
1,> $nmbr$ ( % ),
1,> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),
1,> $nmbr$ % and < $nmbr$ %,
1,> $nmbr$ % $nmbr$,
1,> $nmbr$ %,
1,> $nmbr$ $nmbr$,
1,> $nmbr$  no . ( % ),
1,> $nmbr$  < = $nmbr$,
1,> $nmbr$  < $nmbr$,
1,> $nmbr$,
1,= $nmbr$ ’ ),
1,= $nmbr$,
1,< = $nmbr$ . $nmbr$ %,
1,< = $nmbr$ %,
1,< = $nmbr$,
1,< - $nmbr$ . $nmbr$ cm,
1,< - $nmbr$ . $nmbr$ - vfx,
1,< - $nmbr$ . $nmbr$ + vfx,
1,< - $nmbr$ . $nmbr$,
1,< $nmbr$ — no . { % ),
1,< $nmbr$ — no . ( % ),
1,< $nmbr$ » < $nmbr$ y,
1,< $nmbr$ { % ),
1,< $nmbr$ yrs,
1,< $nmbr$ yea ' s,
1,< $nmbr$ y ( n = $nmbr$ ),
1,< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,< $nmbr$ y  n ( % ),
1,< $nmbr$ y,
1,< $nmbr$ xuln,
1,< $nmbr$ nwrrtn,
1,< $nmbr$ no . ( % ),
1,< $nmbr$ mon ( n = $nmbr$ ),
1,< $nmbr$ mlymin,
1,< $nmbr$ mlmin ) $nmbr$,
1,< $nmbr$ microg / l,
1,< $nmbr$ lb,
1,< $nmbr$ ky / nr,
1,< $nmbr$ hr,
1,< $nmbr$ enroll,
1,< $nmbr$ cm,
1,< $nmbr$ bpm ( n = $nmbr$ ),
1,< $nmbr$ beats / min,
1,< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ ),
1,< $nmbr$ . $nmbr$ yrs,
1,< $nmbr$ . $nmbr$ bpm,
1,< $nmbr$ . $nmbr$ ( % ),
1,< $nmbr$ . $nmbr$ %,
1,< $nmbr$ . $nmbr$,
1,< $nmbr$ - $nmbr$,
1,< $nmbr$ ( % ),
1,< $nmbr$ %,
1,< $nmbr$,
1,/ j - valuc ! l,
1,/ $nmbr$ - blockers,
1,/ $nmbr$ - blocker,
1,. $nmbr$,
1,- ° - $nmbr$  wom -,
1,- bi -,
1,- $nmbr$ . $nmbr$ ± lno ^,
1,- $nmbr$ . $nmbr$ to - $nmbr$ cm,
1,- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll,
1,- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ ),
1,* $nmbr$ to < $nmbr$ y,
1,( sem ),
1,( ofl ),
1,( iqr ),
1,( e - blocker,
1,( cm ),
1,( a blocker,
1,( : > blockers,
1,( % ) ( $nmbr$ . $nmbr$ ),
1,( % ) ( $nmbr$ - $nmbr$ ),
1,( % ) $nmbr$ - $nmbr$,
1,( $nmbr$ blocker,
1,( $nmbr$ - blockers,
1,( $nmbr$ - blocker,
1,% phg,
1,% fhg,
1,% $nmbr$ - $nmbr$,
1,%,
1,$nmbr$ — em,
1,$nmbr$ — < $nmbr$,
1,$nmbr$ — $nmbr$ nlmw,
1,$nmbr$ ± ll,
1,$nmbr$ §,
1,$nmbr$ yrs or more,
1,$nmbr$ yrs l,
1,$nmbr$ yrs,
1,$nmbr$ y,
1,$nmbr$ tol ( n = $nmbr$ ),
1,$nmbr$ to < $nmbr$ — no . { % ),
1,$nmbr$ to < $nmbr$ mumin,
1,$nmbr$ to < $nmbr$ hr,
1,$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
1,$nmbr$ to $nmbr$ y  n ( % ),
1,$nmbr$ tcz,
1,$nmbr$ rrmnl ),
1,$nmbr$ q $nmbr$ w ( n = $nmbr$ ),
1,$nmbr$ or more,
1,$nmbr$ or greater,
1,$nmbr$ or $nmbr$ — no . / total no . ( % ),
1,$nmbr$ or $nmbr$ step,
1,$nmbr$ or $nmbr$ high cardiovascular risk categories,
1,$nmbr$ or $nmbr$ high - risk categories,
1,$nmbr$ or $nmbr$ days,
1,$nmbr$ or $nmbr$ d / wk,
1,$nmbr$ or $nmbr$ d / mo,
1,$nmbr$ or $nmbr$  no . / total no . ( % ),
1,$nmbr$ or $nmbr$  n ( % ),
1,$nmbr$ or $nmbr$,
1,$nmbr$ oam,
1,$nmbr$ oads,
1,$nmbr$ oad,
1,$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$,
1,$nmbr$ mortis,
1,$nmbr$ montlts,
1,$nmbr$ mgrdl,
1,$nmbr$ mentis,
1,$nmbr$ is ( $nmbr$ . $nmbr$ ),
1,$nmbr$ ii ( $nmbr$ . $nmbr$ ),
1,$nmbr$ e < $nmbr$ %  n ( % ),
1,$nmbr$ e < $nmbr$ %,
1,$nmbr$ e $nmbr$,
1,$nmbr$ c . t,
1,$nmbr$ blockers,
1,$nmbr$ blocker,
1,$nmbr$ b ( $nmbr$ b to > $nmbr$ a ),
1,$nmbr$ b ( $nmbr$ b to $nmbr$ a ),
1,$nmbr$ < - $nmbr$,
1,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ / $nmbr$ ( $nmbr$ ),
1,$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ / $nmbr$,
1,$nmbr$ . $nmbr$ ± ii . $nmbr$,
1,$nmbr$ . $nmbr$ ± b . b,
1,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$,
1,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1,$nmbr$ . $nmbr$ yrs,
1,$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ per $nmbr$ pyr,
1,$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr,
1,$nmbr$ . $nmbr$ or more,
1,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ - < $nmbr$,
1,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$,
1,$nmbr$ . $nmbr$ ( ll . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
1,$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ ),
1,$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ % or more,
1,$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$ % ( $nmbr$ ),
1,$nmbr$ . $nmbr$ %,
1,$nmbr$ . $nmbr$,
1,$nmbr$ - up and / or aza at baseline,
1,$nmbr$ - blockers,
1,$nmbr$ - blocker,
1,$nmbr$ - < $nmbr$ yrs,
1,$nmbr$ - < $nmbr$ y,
1,$nmbr$ - < $nmbr$ mvmin,
1,$nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$ - < $nmbr$ ( % ),
1,$nmbr$ - < $nmbr$ %,
1,$nmbr$ - < $nmbr$,
1,$nmbr$ - $nmbr$ — no . ( % ),
1,$nmbr$ - $nmbr$ yrs,
1,$nmbr$ - $nmbr$ y  n ( % ),
1,$nmbr$ - $nmbr$ hr,
1,$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^,
1,$nmbr$ - $nmbr$ . $nmbr$,
1,$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
1,$nmbr$ - $nmbr$  no . / totalno . ( % ),
1,$nmbr$ - $nmbr$,
1,$nmbr$ +  no . ( % ),
1,$nmbr$ +,
1,$nmbr$ ( or $nmbr$  if female only ),
1,$nmbr$ ( oo $nmbr$ - o . $nmbr$ ),
1,$nmbr$ ( > $nmbr$ % ),
1,$nmbr$ ( < $nmbr$ % ),
1,$nmbr$ ( $nmbr$ si,
1,$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e,
1,$nmbr$ ( $nmbr$ e < $nmbr$ % ),
1,$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze ),
1,$nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr,
1,$nmbr$ ( $nmbr$ . $nmbr$ % ),
1,$nmbr$ ( $nmbr$ % ),
1,$nmbr$ ( $nmbr$  $nmbr$ ),
1,$nmbr$ % - $nmbr$ %,
1,$nmbr$ % ( oto $nmbr$ ),
1,$nmbr$ % $nmbr$,
1,$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ ),
1,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$ $nmbr$,
1,$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$,
1,$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
1,$nmbr$,
1,$ $nmbr$ and  $nmbr$ years,
1,$ $nmbr$ %,
1,$ $nmbr$,
